
A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic  Androgen-Independent Prostate Cancer(https://clinicaltrials.gov/show/NCT00090545)
 ,First Stage - Disease Progression,Second Stage - Increased Accrual
 ,The first stage was to rule out the probability of 4 month progression free survival. Patients were given 400 mg BAY 43-9006 orally twice daily in 28 day cycles.,Due to prostatic specific antigen and radiographic discordance during the first stage the protocol was amended to allow accrual to a second stage. 400 mg BAY 43-9006 orally twice daily in 28 day cycles.
Total all-cause mortality,0/22 %0.0,1/24 %4.17
Total serious adverse events,2/22 %9.09,6/24 %25.0
Constipation,0/22 %0.0,1/24 %4.17
Dehydration,0/22 %0.0,1/24 %4.17
Death not associated with CTCAE term::Death NOS,0/22 %0.0,1/24 %4.17
Infection with normal ANC or Grade 1 or 2 neutrophils::Bladder (urinary),0/22 %0.0,1/24 %4.17
Infection with normal ANC or Grade 1 or 2 neutrophils::Lung (pneumonia),0/22 %0.0,1/24 %4.17
Hemoglobin,0/22 %0.0,2/24 %8.33
Pain::Back,0/22 %0.0,1/24 %4.17
Pain::Bone,0/22 %0.0,1/24 %4.17
Pain::Joint,0/22 %0.0,1/24 %4.17
Pain::Muscle,0/22 %0.0,1/24 %4.17
CNS cerebrovascular ischemia,0/22 %0.0,1/24 %4.17
Pain::Head/headache,0/22 %0.0,1/24 %4.17
Hypertension,1/22 %4.55,0/24 %0.0
Hypotension,1/22 %4.55,0/24 %0.0

BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer(https://clinicaltrials.gov/show/NCT00098254)
 ,BAY 43-9006 (Sorafenib)
 ,Self administered oral doses at 400 mg twice a day with 250 ml (8 oz.) of water each morning and evening (i.e. 12-hourly) continuously in a 28 day cycle. Tablets may be taken with or without food.
Total serious adverse events,11/37 %29.73
Anemia,1/37 %2.7
Death NOS,1/37 %2.7
Fatigue,1/37 %2.7
Lung infection,2/37 %5.41
Alanine aminotransferase increased,1/37 %2.7
Alkaline phosphatase increased,1/37 %2.7
Aspartate aminotransferase increased,1/37 %2.7
Platelet count decreased,1/37 %2.7
Hypermagnesemia,1/37 %2.7
Hypoalbuminemia,1/37 %2.7
Hypomagnesemia,1/37 %2.7
Hyponatremia,1/37 %2.7
Confusion,1/37 %2.7
Bronchopulmonary hemorrhage,1/37 %2.7
Bronchospasm,1/37 %2.7
Cough,1/37 %2.7
Dyspnea,4/37 %10.81
Hypoxia,2/37 %5.41
Palmar-plantar erythrodysesthesia syndrome,1/37 %2.7
Hypertension,1/37 %2.7
Vasculitis,1/37 %2.7

Sorafenib in Treating Patients With Advanced or Metastatic Cancer of the Urinary Tract(https://clinicaltrials.gov/show/NCT00112671)
 ,Treatment (Sorafenib Tosylate)
 ,Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. sorafenib tosylate: Given orally laboratory biomarker analysis: Correlative studies
Total serious adverse events,2/17 %11.76
Multi-organ failure,1/17 %5.88
Death NOS,1/17 %5.88

Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer(https://clinicaltrials.gov/show/NCT00126568)
 ,BAY 43-9006
 ,BAY 43-9006 (sorafenib) will be administered on a fixed daily oral dosing schedule of 400 mg twice daily. A cycle of therapy will be considered 28 days (4 weeks / 1 month).
Total serious adverse events,8/20 %40.0
Edema: limb,1/20 %5.0
Lymphopenia,1/20 %5.0
Pain - Eye,1/20 %5.0
Ileus GI (functional obstruction of bowel i.e. neuroconstipation),1/20 %5.0
Pain - Abdomen NOS(not otherwise specified),1/20 %5.0
Perforation GI - Appendix,1/20 %5.0
Death not associated with CTCAE term - Death NOS(not otherwise specified),1/20 %5.0
Death not associated with CTCAE term - Disease progression NOS(not otherwise specified),3/20 %15.0
Death not associated with CTCAE term - Sudden death,1/20 %5.0
Infection with unknown ANC(Absolute neutrophil count) - Lung (pneumonia),1/20 %5.0
Speech impairment (e.g. dysphasia or aphasia),1/20 %5.0
Dyspnea (shortness of breath),2/20 %10.0
Pneumothorax,1/20 %5.0
Pulmonary/Upper Respiratory,1/20 %5.0
Thrombosis/thrombus/embolism,1/20 %5.0

Sorafenib Tosylate With or Without Recombinant Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer(https://clinicaltrials.gov/show/NCT00126594)
 ,Sorafenib Tosylate,Sorafenib Tosylate Recombinant Interferon Alfa-2b
 ,Arm I: Oral Sorafenib 400 mg twice daily on days 1-28.,Arm II: Sorafenib as in Arm I and low-dose Interferon alfa-2b 0.5 million units subcutaneously twice daily on days 1-28.
Total serious adverse events,29/40 %72.5,30/40 %75.0
Death,27/40 %67.5,29/40 %72.5
Pancreatitis,1/40 %2.5,0/40 %0.0
Appendicitis,1/40 %2.5,0/40 %0.0
Hyperuricemia,6/40 %15.0,2/40 %5.0
Serum amylase increased,1/40 %2.5,0/40 %0.0
Lipase Increased,0/40 %0.0,1/40 %2.5

Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors(https://clinicaltrials.gov/show/NCT00131911)
 ,All Patients
 ,Patients receive 400 mg oral sorafenib twice daily on days 1-28.
Total serious adverse events,52/93 %55.91
Hemoglobin decreased,3/93 %3.23
Hypothyroidism,1/93 %1.08
Abdominal distension,1/93 %1.08
Abdominal pain,18/93 %19.35
Ascites,3/93 %3.23
Constipation,3/93 %3.23
Diarrhea,5/93 %5.38
Dry mouth,1/93 %1.08
Duodenal hemorrhage,1/93 %1.08
Duodenal perforation,1/93 %1.08
Duodenal ulcer,1/93 %1.08
Ear nose and throat examination abnormal,4/93 %4.3
Gastrointestinal disorder,2/93 %2.15
Intra-abdominal hemorrhage,1/93 %1.08
Lower gastrointestinal hemorrhage,1/93 %1.08
Mucositis oral,1/93 %1.08
Nausea,13/93 %13.98
Rectal fistula,1/93 %1.08
Small intestinal obstruction,3/93 %3.23
Small intestinal perforation,1/93 %1.08
Vomiting,8/93 %8.6
Chills,1/93 %1.08
Disease progression,1/93 %1.08
Edema limbs,3/93 %3.23
Fatigue,15/93 %16.13
Fever,4/93 %4.3
Localized edema,1/93 %1.08
Cholecystitis,1/93 %1.08
Gallbladder pain,1/93 %1.08
Hepatobiliary disease,1/93 %1.08
Hypersensitivity,1/93 %1.08
Bladder infection,1/93 %1.08
Pleural infection,1/93 %1.08
Pneumonia,1/93 %1.08
Sepsis,1/93 %1.08
Skin infection,1/93 %1.08
Alanine aminotransferase increased,1/93 %1.08
Alkaline phosphatase increased,3/93 %3.23
Aspartate aminotransferase increased,4/93 %4.3
Blood bilirubin increased,2/93 %2.15
Creatinine increased,1/93 %1.08
Leukocyte count decreased,1/93 %1.08
Lymphocyte count decreased,1/93 %1.08
Neutrophil count decreased,1/93 %1.08
Weight gain,1/93 %1.08
Weight loss,1/93 %1.08
Alkalosis,1/93 %1.08
Anorexia,10/93 %10.75
Blood glucose increased,2/93 %2.15
Dehydration,6/93 %6.45
Serum albumin decreased,3/93 %3.23
Serum calcium decreased,2/93 %2.15
Serum phosphate decreased,1/93 %1.08
Serum potassium decreased,3/93 %3.23
Serum potassium increased,3/93 %3.23
Serum sodium decreased,3/93 %3.23
Serum sodium increased,1/93 %1.08
Serum triglycerides increased,1/93 %1.08
Arthralgia,2/93 %2.15
Back pain,3/93 %3.23
Bone pain,1/93 %1.08
Myalgia,6/93 %6.45
Neck pain,1/93 %1.08
Pain in extremity,1/93 %1.08
Dizziness,2/93 %2.15
Headache,2/93 %2.15
Confusion,1/93 %1.08
Insomnia,1/93 %1.08
Dyspnea,6/93 %6.45
Pneumonitis,1/93 %1.08
Respiratory tract hemorrhage,1/93 %1.08
Voice alteration,2/93 %2.15
Alopecia,2/93 %2.15
Hand-and-foot syndrome,4/93 %4.3
Rash acneiform,4/93 %4.3
Rash desquamating,2/93 %2.15
Skin disorder,1/93 %1.08
Skin ulceration,1/93 %1.08
Sweating,3/93 %3.23
Flushing,1/93 %1.08
Hemorrhage,1/93 %1.08
Hot flashes,1/93 %1.08
Hypotension,2/93 %2.15
Thrombosis,2/93 %2.15

Sorafenib in Treating Patients With Extensive Stage Small Cell Lung Cancer(https://clinicaltrials.gov/show/NCT00182689)
 ,Platinum Sensitive,Platinum Refractory
 
Total serious adverse events,6/38 %15.79,7/44 %15.91
Diarrhea,0/38 %0.0,1/44 %2.27
Heartburn/dyspepsia,1/38 %2.63,0/44 %0.0
Nausea,1/38 %2.63,0/44 %0.0
Pain - Abdomen NOS,0/38 %0.0,1/44 %2.27
Pancreatitis,0/38 %0.0,1/44 %2.27
Fatigue (asthenia lethargy malaise),1/38 %2.63,0/44 %0.0
Infection with normal ANC or Grade 1 or 2 neutrophils - Urinary tract NOS,0/38 %0.0,1/44 %2.27
AST SGOT (serum glutamic oxaloacetic transaminase),1/38 %2.63,0/44 %0.0
Lipase,0/38 %0.0,1/44 %2.27
Dehydration,0/38 %0.0,1/44 %2.27
Sodium serum-low (hyponatremia),1/38 %2.63,2/44 %4.55
Muscle weakness generalized or specific area (not due to neuropathy) - Whole body/generalized,0/38 %0.0,1/44 %2.27
Pain - Joint,1/38 %2.63,0/44 %0.0
Ataxia (incoordination),0/38 %0.0,1/44 %2.27
Dizziness,1/38 %2.63,0/44 %0.0
Neuropathy: motor,1/38 %2.63,0/44 %0.0
Neuropathy: sensory,1/38 %2.63,0/44 %0.0
Pain - Head/headache,1/38 %2.63,0/44 %0.0
Speech impairment (e.g. dysphasia or aphasia),0/38 %0.0,1/44 %2.27
Syncope (fainting),1/38 %2.63,0/44 %0.0
Tremor,1/38 %2.63,0/44 %0.0
Confusion,1/38 %2.63,2/44 %4.55
Dyspnea (shortness of breath),1/38 %2.63,0/44 %0.0
Pleural effusion (non-malignant),0/38 %0.0,1/44 %2.27
Hypertension,1/38 %2.63,0/44 %0.0

Sorafenib and Anastrozole in Treating Postmenopausal Women With Metastatic Breast Cancer(https://clinicaltrials.gov/show/NCT00217399)
 ,Sorafenib and Anastrozole
 ,A single arm of 35 patients with advanced or metastatic breast cancer receiving a combination of sorafenib and anastrozole.
Total serious adverse events,12/35 %34.29
hand-foot syndome,12/35 %34.29

S0505 Sorafenib in Treating Patients With Advanced Soft Tissue Sarcomas(https://clinicaltrials.gov/show/NCT00217620)
 ,Sorafenib (BAY 43-9006)
 ,Sorafenib (BAY 43-9006) 800 mg per day divided into two equal doses of 400 mg by mouth (PO). Patients received the drug continuously on a daily basis until progression; each cycle is 28 days. All eligible patients who received treatment were included in baseline measures.
Total serious adverse events,10/37 %27.03
Hemoglobin,1/37 %2.7
Constipation,1/37 %2.7
Hemorrhage GI - Colon,1/37 %2.7
Nausea,1/37 %2.7
Pain - Abdomen NOS,3/37 %8.11
Pancreatitis,1/37 %2.7
Pain - Chest/thorax NOS,1/37 %2.7
AST SGOT,1/37 %2.7
Amylase,1/37 %2.7
Lipase,2/37 %5.41
Platelets,1/37 %2.7
Anorexia,1/37 %2.7
Calcium serum-low (hypocalcemia),1/37 %2.7
Potassium serum-low (hypokalemia),1/37 %2.7
Sodium serum-low (hyponatremia),1/37 %2.7
Death - Disease progression NOS,2/37 %5.41
Mental status,1/37 %2.7
Neuropathy: motor,1/37 %2.7
Syncope (fainting),1/37 %2.7
Obstruction GU - Ureter,1/37 %2.7
Dyspnea (shortness of breath),1/37 %2.7
Hypotension,1/37 %2.7

Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery(https://clinicaltrials.gov/show/NCT00281957)
 ,Arm I,Arm II
 ,Sorafenib and Temsirolimu,Sorafenib and Tipifarnib
Total serious adverse events,13/63 %20.63,6/39 %15.38
Hemoglobin,1/63 %1.59,0/39 %0.0
Left ventricular systolic dysfunction,1/63 %1.59,0/39 %0.0
Ileus GI (functional obstruction of bowel i.e. neuroconstipation),1/63 %1.59,0/39 %0.0
Nausea,1/63 %1.59,0/39 %0.0
Pain - Abdomen NOS,1/63 %1.59,0/39 %0.0
Pancreatitis,1/63 %1.59,1/39 %2.56
Vomiting,2/63 %3.17,0/39 %0.0
Fatigue (asthenia lethargy malaise),1/63 %1.59,0/39 %0.0
Infection with normal ANC or Grade 1 or 2 neutrophils - Nose,1/63 %1.59,0/39 %0.0
Infection with normal ANC or Grade 1 or 2 neutrophils - Skin (cellulitis),1/63 %1.59,0/39 %0.0
Amylase,0/63 %0.0,1/39 %2.56
Lipase,0/63 %0.0,1/39 %2.56
Albumin serum-low (hypoalbuminemia),1/63 %1.59,0/39 %0.0
Calcium serum-low (hypocalcemia),1/63 %1.59,0/39 %0.0
Dehydration,2/63 %3.17,0/39 %0.0
Glucose serum-high (hyperglycemia),1/63 %1.59,0/39 %0.0
Phosphate serum-low (hypophosphatemia),2/63 %3.17,0/39 %0.0
Potassium serum-low (hypokalemia),2/63 %3.17,0/39 %0.0
Muscle weakness generalized or specific area (not due to neuropathy) - Whole body/generalized,2/63 %3.17,1/39 %2.56
Pain - Back,0/63 %0.0,1/39 %2.56
Pain - Joint,1/63 %1.59,0/39 %0.0
Neurology-Other (Specify),1/63 %1.59,0/39 %0.0
Neuropathy: motor,0/63 %0.0,1/39 %2.56
Pain - Head/headache,1/63 %1.59,0/39 %0.0
Confusion,1/63 %1.59,0/39 %0.0
Renal failure,1/63 %1.59,0/39 %0.0
Pneumonitis/pulmonary infiltrates,2/63 %3.17,0/39 %0.0
Pulmonary/Upper Respiratory-Other (Specify),1/63 %1.59,0/39 %0.0
Pruritus/itching,1/63 %1.59,0/39 %0.0
Rash/desquamation,1/63 %1.59,0/39 %0.0
Flushing,1/63 %1.59,0/39 %0.0
Hypertension,1/63 %1.59,1/39 %2.56
Thrombosis/thrombus/embolism,0/63 %0.0,1/39 %2.56

BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer(https://clinicaltrials.gov/show/NCT00326495)
 ,BAY 43-9006 & Cetuximab
 ,BAY 43-9006: Administered orally at a dose of 400 mg twice a day (BID) BAY 43-9006: is a potent inhibitor of proto-oncogene c-Raf (c-raf) and wild-type and mutant proto-oncogene b-Raf (b-raf) in vitro. Cetuximab will be given intravenously (IV) at a dose of 400 mg/m^2 initially as a loading dose on week 2 followed by 250 mg/m^2 weekly starting on week 3. Cetuximab is a recombinant human/mouse chimeric monoclonal antibody which binds specifically to the extracellular domain of the epidermal growth factor receptor (epidermal growth factor receptor (EGFR) human epidermal growth factor receptor 1 (HER1) c-ErbB) in normal and tumor cells and competitively inhibits the binding of epidermal growth factor (EGF) and other ligands such as transforming growth factor-alpha.
Total all-cause mortality,2/50 %4.0
Total serious adverse events,22/50 %44.0
Anemia,2/50 %4.0
Abdominal distension,2/50 %4.0
Dehydration,1/50 %2.0
Diarrhea,1/50 %2.0
Duodenal obstruction,1/50 %2.0
Ileus,1/50 %2.0
Nausea,1/50 %2.0
Rectal hemorrhage,1/50 %2.0
Small intestinal obstruction,6/50 %12.0
Vomiting,2/50 %4.0
Chills,1/50 %2.0
Death NOS,2/50 %4.0
Fever,5/50 %10.0
Pain,1/50 %2.0
Anaphylaxis,1/50 %2.0
Bladder infection,2/50 %4.0
Catheter related infection,1/50 %2.0
Tooth infection,1/50 %2.0
Urinary tract infection,1/50 %2.0
Wound infection,1/50 %2.0
Blood bilirubin increased,1/50 %2.0
Lipase increased,1/50 %2.0
Hypokalemia,1/50 %2.0
Hyponatremia,1/50 %2.0
Back pain,1/50 %2.0
Headache,2/50 %4.0
Ischemia cerebrovascular,1/50 %2.0
Movements involuntary,1/50 %2.0
Hematuria,1/50 %2.0
Urinary tract obstruction,1/50 %2.0
Vaginal hemorrhage,1/50 %2.0

Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery(https://clinicaltrials.gov/show/NCT00326898)
 ,Arm A (Sunitinib + Sorafenib Placebo),Arm B (Sorafenib + Sunitinib Placebo),Arm C (Sunitinib Placebo + Sorafenib Placebo)
 ,Beginning 4-12 weeks following radical or partial nephrectomy patients receive sunitinib malate 37.5mg PO QD for 4 weeks and placebo sorafenib tosylate 400mg PO QD or BID for 6 weeks.,Beginning 4-12 weeks following radical or partial nephrectomy patients receive sorafenib tosylate 400mg PO QD or BID for 6 weeks and placebo sunitinib malate 37.5mg PO QD for 4 weeks followed.,Beginning 4-12 weeks following radical or partial nephrectomy patients receive placebo sorafenib tosylate 400mg as in Arm A and placebo sunitinib malate 37.5mg as in Arm B.
Total serious adverse events,368/625 %58.88,424/628 %67.52,81/626 %12.94
Anemia,2/625 %0.32,1/628 %0.16,0/626 %0.0
Thrombotic microangiopathy,1/625 %0.16,0/628 %0.0,0/626 %0.0
Febrile neutropenia,2/625 %0.32,0/628 %0.0,0/626 %0.0
Heart block abnormality NOS,0/625 %0.0,0/628 %0.0,1/626 %0.16
Atrial fibrillation,1/625 %0.16,0/628 %0.0,2/626 %0.32
Atrial flutter,0/625 %0.0,0/628 %0.0,2/626 %0.32
Sinus bradycardia,1/625 %0.16,0/628 %0.0,0/626 %0.0
Supraventricular tachycardia,1/625 %0.16,0/628 %0.0,0/626 %0.0
Bigeminy,1/625 %0.16,0/628 %0.0,0/626 %0.0
Cardiac-ischemia,1/625 %0.16,3/628 %0.48,4/626 %0.64
Left ventricular systolic dysfunction,4/625 %0.64,4/628 %0.64,2/626 %0.32
Cor Pulmonale,0/625 %0.0,1/628 %0.16,0/626 %0.0
cardiac-other,0/625 %0.0,1/628 %0.16,0/626 %0.0
Cardiac/heart pain,2/625 %0.32,3/628 %0.48,0/626 %0.0
Hearing w/o audiogr not in monitor prg,1/625 %0.16,0/628 %0.0,0/626 %0.0
Adrenal insufficiency,0/625 %0.0,1/628 %0.16,0/626 %0.0
Hyopthyroidism,2/625 %0.32,0/628 %0.0,0/626 %0.0
Cataract,0/625 %0.0,0/628 %0.0,1/626 %0.16
Double vision,0/625 %0.0,0/628 %0.0,1/626 %0.16
Retinal detachment,1/625 %0.16,0/628 %0.0,0/626 %0.0
Ocular-other,0/625 %0.0,1/628 %0.16,0/626 %0.0
Colitis,0/625 %0.0,3/628 %0.48,0/626 %0.0
Constipation,1/625 %0.16,0/628 %0.0,0/626 %0.0
Diarrhea w/o prior colostomy,57/625 %9.12,55/628 %8.76,2/626 %0.32
Distention/bloating abdominal,0/625 %0.0,1/628 %0.16,0/626 %0.0
Esophagitis,0/625 %0.0,1/628 %0.16,0/626 %0.0
Gastritis,1/625 %0.16,1/628 %0.16,0/626 %0.0
Dyspepsia,14/625 %2.24,4/628 %0.64,1/626 %0.16
Ileus,0/625 %0.0,0/628 %0.0,1/626 %0.16
Muco/stomatitis by exam oral cavity,2/625 %0.32,0/628 %0.0,0/626 %0.0
Muco/stomatitis (symptom) oral cavity,3/625 %0.48,1/628 %0.16,0/626 %0.0
Nausea,22/625 %3.52,5/628 %0.8,0/626 %0.0
Perforation colon,0/625 %0.0,1/628 %0.16,0/626 %0.0
Vomiting,11/625 %1.76,3/628 %0.48,1/626 %0.16
Colon hemorrhage,2/625 %0.32,0/628 %0.0,0/626 %0.0
Lower GI hemorrhage NOS,0/625 %0.0,1/628 %0.16,0/626 %0.0
Stomach hemorrhage,1/625 %0.16,0/628 %0.0,0/626 %0.0
Pancreatitis,3/625 %0.48,1/628 %0.16,0/626 %0.0
Abdomen pain,4/625 %0.64,8/628 %1.27,2/626 %0.32
Esophagus pain,1/625 %0.16,0/628 %0.0,0/626 %0.0
Oral cavity pain,1/625 %0.16,1/628 %0.16,0/626 %0.0
Stomach pain,0/625 %0.0,1/628 %0.16,0/626 %0.0
Fatigue,108/625 %17.28,41/628 %6.53,15/626 %2.4
Fever w/o neutropenia,1/625 %0.16,2/628 %0.32,0/626 %0.0
Edema head and neck,3/625 %0.48,1/628 %0.16,0/626 %0.0
Edema limb,2/625 %0.32,0/628 %0.0,0/626 %0.0
Chest/thoracic pain NOS,4/625 %0.64,4/628 %0.64,0/626 %0.0
Pain-other,0/625 %0.0,1/628 %0.16,0/626 %0.0
Flu-like syndrome,3/625 %0.48,0/628 %0.0,0/626 %0.0
Cholecystitis,1/625 %0.16,0/628 %0.0,0/626 %0.0
Liver dysfunction/failure,1/625 %0.16,0/628 %0.0,0/626 %0.0
Hepatic-other,1/625 %0.16,0/628 %0.0,0/626 %0.0
Allergic reaction,1/625 %0.16,0/628 %0.0,0/626 %0.0
Infection w/ gr3-4 neut ileum,1/625 %0.16,0/628 %0.0,0/626 %0.0
Infection Gr0-2 neut appendix,0/625 %0.0,0/628 %0.0,1/626 %0.16
Infection Gr0-2 neut colon,0/625 %0.0,2/628 %0.32,0/626 %0.0
Infection Gr0-2 neut kidney,1/625 %0.16,1/628 %0.16,0/626 %0.0
Infection Gr0-2 neut lung,2/625 %0.32,3/628 %0.48,2/626 %0.32
Infection Gr0-2 neut mediastinm,0/625 %0.0,0/628 %0.0,1/626 %0.16
Infection Gr0-2 neut mucosa,0/625 %0.0,1/628 %0.16,0/626 %0.0
Infection Gr0-2 neut muscle,0/625 %0.0,1/628 %0.16,0/626 %0.0
Infection Gr0-2 neut nerve-cranial,1/625 %0.16,0/628 %0.0,0/626 %0.0
Infection Gr0-2 neut skin,0/625 %0.0,1/628 %0.16,0/626 %0.0
Infection Gr0-2 neut urinary tract,1/625 %0.16,0/628 %0.0,1/626 %0.16
Infection Gr0-2 neut vagina,1/625 %0.16,0/628 %0.0,0/626 %0.0
Infection Gr0-2 neut wound,0/625 %0.0,1/628 %0.16,0/626 %0.0
Infection w/ unk ANC skin (cellulitis),0/625 %0.0,2/628 %0.32,0/626 %0.0
Infection w/ unk ANC urinary tract NOS,0/625 %0.0,1/628 %0.16,0/626 %0.0
Infection Gr0-2 neut blood,1/625 %0.16,0/628 %0.0,0/626 %0.0
Infection-other,1/625 %0.16,1/628 %0.16,0/626 %0.0
Wound - non-infectious,0/625 %0.0,1/628 %0.16,0/626 %0.0
Vascular accessThrombosis/embolism,0/625 %0.0,1/628 %0.16,0/626 %0.0
Leukocytes decreased,3/625 %0.48,0/628 %0.0,0/626 %0.0
Neutrophils decreased,7/625 %1.12,2/628 %0.32,0/626 %0.0
Platelets decreased,13/625 %2.08,2/628 %0.32,1/626 %0.16
Weight gain,0/625 %0.0,0/628 %0.0,2/626 %0.32
Alanine aminotransferase increased,4/625 %0.64,4/628 %0.64,0/626 %0.0
Serum amylase increased,0/625 %0.0,1/628 %0.16,0/626 %0.0
Aspartate aminotransferase increased,6/625 %0.96,4/628 %0.64,0/626 %0.0
Blood bilirubin increased,1/625 %0.16,1/628 %0.16,1/626 %0.16
Hypercholesterolemia,1/625 %0.16,0/628 %0.0,0/626 %0.0
CPK increased,1/625 %0.16,1/628 %0.16,0/626 %0.0
Creatinine increased,1/625 %0.16,3/628 %0.48,0/626 %0.0
Lipase increased,4/625 %0.64,3/628 %0.48,1/626 %0.16
Anorexia,11/625 %1.76,5/628 %0.8,0/626 %0.0
Dehydration,10/625 %1.6,3/628 %0.48,0/626 %0.0
Hypoalbuminemia,1/625 %0.16,0/628 %0.0,0/626 %0.0
Hypocalcemia,1/625 %0.16,1/628 %0.16,0/626 %0.0
Hyperglycemia,0/625 %0.0,1/628 %0.16,1/626 %0.16
Hypophosphatemia,1/625 %0.16,1/628 %0.16,0/626 %0.0
Hyperkalemia,3/625 %0.48,1/628 %0.16,0/626 %0.0
Hypokalemia,2/625 %0.32,1/628 %0.16,0/626 %0.0
Hypernatremia,1/625 %0.16,0/628 %0.0,0/626 %0.0
Hyponatremia,1/625 %0.16,5/628 %0.8,4/626 %0.64
Hypertriglyceridemia,2/625 %0.32,0/628 %0.0,0/626 %0.0
Hyperuricemia,0/625 %0.0,1/628 %0.16,3/626 %0.48
Nonneuropathic upper extr muscle weak,1/625 %0.16,0/628 %0.0,0/626 %0.0
Nonneuropathic left-side muscle weak,0/625 %0.0,1/628 %0.16,0/626 %0.0
Nonneuropathic right-side muscle weak,0/625 %0.0,0/628 %0.0,1/626 %0.16
Nonneuropathic generalized weakness,1/625 %0.16,1/628 %0.16,1/626 %0.16
Myositis,1/625 %0.16,0/628 %0.0,0/626 %0.0
Musculoskeletal/soft tissue-other,0/625 %0.0,2/628 %0.32,0/626 %0.0
Back pain,1/625 %0.16,3/628 %0.48,0/626 %0.0
Bone pain,2/625 %0.32,1/628 %0.16,0/626 %0.0
Extremity-limb pain,4/625 %0.64,3/628 %0.48,0/626 %0.0
Joint pain,8/625 %1.28,8/628 %1.27,3/626 %0.48
Muscle pain,2/625 %0.32,8/628 %1.27,1/626 %0.16
Secondary malignancy,0/625 %0.0,1/628 %0.16,1/626 %0.16
Vasovagal episode,1/625 %0.16,0/628 %0.0,0/626 %0.0
Ataxia,0/625 %0.0,0/628 %0.0,1/626 %0.16
CNS cerebrovascular ischemia,4/625 %0.64,0/628 %0.0,1/626 %0.16
Cognitive disturbance,0/625 %0.0,1/628 %0.16,0/626 %0.0
Dizziness,4/625 %0.64,2/628 %0.32,2/626 %0.32
Memory impairment,1/625 %0.16,0/628 %0.0,1/626 %0.16
Neuropathy-motor,3/625 %0.48,1/628 %0.16,0/626 %0.0
Neuropathy-sensory,3/625 %0.48,12/628 %1.91,3/626 %0.48
Syncope,4/625 %0.64,2/628 %0.32,0/626 %0.0
Head/headache,6/625 %0.96,4/628 %0.64,0/626 %0.0
Insomnia,0/625 %0.0,4/628 %0.64,0/626 %0.0
Confusion,2/625 %0.32,0/628 %0.0,1/626 %0.16
Anxiety,0/625 %0.0,1/628 %0.16,0/626 %0.0
Depression,1/625 %0.16,2/628 %0.32,2/626 %0.32
Kidney hemorrhage,1/625 %0.16,0/628 %0.0,0/626 %0.0
Proteinuria,2/625 %0.32,2/628 %0.32,0/626 %0.0
Renal failure,6/625 %0.96,4/628 %0.64,0/626 %0.0
Renal/GU-other,0/625 %0.0,1/628 %0.16,0/626 %0.0
Sexual/Reproductive function-Other,0/625 %0.0,1/628 %0.16,0/626 %0.0
Pulmonary hypertension,0/625 %0.0,0/628 %0.0,1/626 %0.16
Muco/stomatitis (symptom) pharynx,24/625 %3.84,14/628 %2.23,0/626 %0.0
Nose hemorrhage,3/625 %0.48,0/628 %0.0,0/626 %0.0
Dyspnea,4/625 %0.64,4/628 %0.64,2/626 %0.32
Pleural effusion (non-malignant),1/625 %0.16,1/628 %0.16,0/626 %0.0
Voice changes/dysarthria,0/625 %0.0,1/628 %0.16,0/626 %0.0
Dry skin,0/625 %0.0,1/628 %0.16,0/626 %0.0
Nail changes,1/625 %0.16,0/628 %0.0,0/626 %0.0
Pruritus/itching,1/625 %0.16,11/628 %1.75,1/626 %0.16
Rash/desquamation,15/625 %2.4,93/628 %14.81,3/626 %0.48
Rash: acne/acneiform,0/625 %0.0,2/628 %0.32,0/626 %0.0
Erythema multiforme,0/625 %0.0,1/628 %0.16,0/626 %0.0
Hand-foot reaction,94/625 %15.04,208/628 %33.12,7/626 %1.12
Urticaria,0/625 %0.0,1/628 %0.16,0/626 %0.0
Scalp pain,0/625 %0.0,2/628 %0.32,0/626 %0.0
Skin pain,0/625 %0.0,1/628 %0.16,0/626 %0.0
Hypertension,104/625 %16.64,96/628 %15.29,15/626 %2.4
Hypotension,1/625 %0.16,0/628 %0.0,0/626 %0.0
Thrombosis/thrombus/embolism,3/625 %0.48,5/628 %0.8,1/626 %0.16
Vascular-Other (Specify),0/625 %0.0,1/628 %0.16,0/626 %0.0

Sorafenib  Carboplatin  and Paclitaxel in Treating Patients With Stage IV Melanoma of the Eye(https://clinicaltrials.gov/show/NCT00329641)
 ,Intervention
 ,Sorafenib Carboplatin Paclitaxel
Total serious adverse events,2/24 %8.33
Neutrophils/granulocytes (ANC/AGC),1/24 %4.17
Rash/desquamation,1/24 %4.17

Sorafenib in Treating Patients With Soft Tissue Sarcomas (Extremity Sarcoma Closed to Entry as of 5/30/07)(https://clinicaltrials.gov/show/NCT00330421)
 ,Group II (Metastatic or Inoperable Sarcomas)
 ,Patients receive oral sorafenib twice daily on days 1-28. Treatment repeats every 28 days for 2 courses. Patients with responding or stable disease may continue sorafenib in the absence of disease progression or unacceptable toxicity. Biopsy tissue and blood samples are examined for biomarkers and IFP is measured at baseline and on days 28 and 56. laboratory biomarker analysis : Correlative studies sorafenib tosylate : Given PO pharmacological study : Correlative studies computed tomography : Correlative studies dynamic contrast-enhanced magnetic resonance imaging : Correlative studies
Total serious adverse events,11/15 %73.33
Hemoglobin,8/15 %53.33
Hematologic - other,6/15 %40.0
Diarrhea,6/15 %40.0
Abdominal pain,5/15 %33.33
Fatigue,11/15 %73.33
Anorexia,5/15 %33.33
Alkaline phosphatase,7/15 %46.67
AST,7/15 %46.67

Sorafenib Combined With Erlotinib  Tipifarnib  or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma(https://clinicaltrials.gov/show/NCT00335764)
 ,Group 1 Phase I Sorafenib and Erlotinib,Group 2 Phase I Sorafenib and Temsirolimus,Group 3 Phase I Sorafenib and Tipifarnib,Group 1 Phase II Sorafenib and Erlotinib,Group 2 Phase II Sorafenib and Temsirolimus
 ,Patients receive oral sorafenib tosylate twice daily and oral erlotinib hydrochloride once daily on days 1-28. sorafenib tosylate: given orally erlotinib hydrochloride: given orally,Patients receive sorafenib tosylate as in group 2. Patients also receive temsirolimus IV over 30 minutes on days 1 8 15 and 22. sorafenib tosylate: given orally temsirolimus: IV administration,Patients receive sorafenib tosylate as in group 3. Patients also receive oral tipifarnib twice daily on days 1-21. sorafenib tosylate: given orally tipifarnib: given orally,Patients receive oral sorafenib tosylate twice daily and oral erlotinib hydrochloride once daily on days 1-28. sorafenib tosylate: given orally erlotinib hydrochloride: given orally,Patients receive sorafenib tosylate 400 mg BID as in group 2. Patients also receive temsirolimus IV 25 mg over 30 minutes on days 1 8 15 and 22. sorafenib tosylate: given orally temsirolimus: IV administration
Total all-cause mortality,15/16 %93.75,13/13 %100.0,24/24 %100.0,19/19 %100.0,18/18 %100.0
Total serious adverse events,0/16 %0.0,0/13 %0.0,4/24 %16.67,1/19 %5.26,2/18 %11.11
Abdominal pain,0/16 %0.0,0/13 %0.0,1/24 %4.17,0/19 %0.0,0/18 %0.0
Diarrhea,0/16 %0.0,0/13 %0.0,0/24 %0.0,1/19 %5.26,1/18 %5.56
Pancrease infection,0/16 %0.0,0/13 %0.0,1/24 %4.17,0/19 %0.0,0/18 %0.0
Lipase increased,0/16 %0.0,0/13 %0.0,1/24 %4.17,0/19 %0.0,0/18 %0.0
Serum amylase increased,0/16 %0.0,0/13 %0.0,1/24 %4.17,0/19 %0.0,0/18 %0.0
Hypertriglyceridemia,0/16 %0.0,0/13 %0.0,0/24 %0.0,0/19 %0.0,1/18 %5.56
Encephalopathy,0/16 %0.0,0/13 %0.0,1/24 %4.17,0/19 %0.0,0/18 %0.0
Headache,0/16 %0.0,0/13 %0.0,1/24 %4.17,0/19 %0.0,0/18 %0.0
Seizure,0/16 %0.0,0/13 %0.0,0/24 %0.0,0/19 %0.0,1/18 %5.56
Confusion,0/16 %0.0,0/13 %0.0,1/24 %4.17,1/19 %5.26,0/18 %0.0
Rash acneiform,0/16 %0.0,0/13 %0.0,1/24 %4.17,0/19 %0.0,0/18 %0.0
Hypertension,0/16 %0.0,0/13 %0.0,1/24 %4.17,0/19 %0.0,0/18 %0.0
Thromboembolic event,0/16 %0.0,0/13 %0.0,1/24 %4.17,0/19 %0.0,0/18 %0.0

Sorafenib Tosylate in Treating Patients With Metastatic  Locally Advanced  or Recurrent Medullary Thyroid Cancer(https://clinicaltrials.gov/show/NCT00390325)
 ,Arm A (Hereditary MTC) and Arm B (Sporadic MTC)
 ,Arm A: Sorafenib (BAY 43-9006) was administered at the dose of 400 mg orally twice a day on a continuous basis. Arm B: Sorafenib (BAY 43-9006) was administered at the dose of 400 mg orally twice a day on a continuous basis.
Total all-cause mortality,1/21 %4.76
Total serious adverse events,5/21 %23.81
Cardiac ischemia/infarction,1/21 %4.76
Perforation GI-small bowel,1/21 %4.76
Infection,1/21 %4.76
Hypokalemia,1/21 %4.76
Renal Failure,1/21 %4.76
Thrombosis/Thrombus/embois,1/21 %4.76

Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer(https://clinicaltrials.gov/show/NCT00390611)
 ,Paclitaxel/Carboplatin/Sorafenib,Paclitaxel/Carboplatin
 ,Paclitaxel 175 mg/m2 1-3 hour IV infusion Day 1 Carboplatin AUC 6 infused over 20 minutes IV Day 1 Sorafenib 400mg PO bid Sorafenib Paclitaxel: Paclitaxel Carboplatin: Carboplatin,Paclitaxel 175 mg/m2 1-3 hour IV infusion Day 1 Carboplatin AUC 6 infused over 20 minutes IV Paclitaxel: Paclitaxel Carboplatin: Carboplatin
Total serious adverse events,12/43 %27.91,10/42 %23.81
Anemia,0/43 %0.0,1/42 %2.38
Febrile neutropenia,1/43 %2.33,0/42 %0.0
Atrial fibrillation,1/43 %2.33,0/42 %0.0
Abdominal pain,3/43 %6.98,2/42 %4.76
Nausea,1/43 %2.33,3/42 %7.14
Vomiting,1/43 %2.33,3/42 %7.14
Gastrointestinal disorders - Other small bowel obstruction,1/43 %2.33,1/42 %2.38
Colitis,0/43 %0.0,1/42 %2.38
Constipation,0/43 %0.0,1/42 %2.38
Diarrhea,0/43 %0.0,1/42 %2.38
Gastrointestinal disorders - Other hemorrhage,0/43 %0.0,1/42 %2.38
Lower gastrointestinal hemorrhage,1/43 %2.33,0/42 %0.0
Upper gastrointestinal hemorrhage,1/43 %2.33,0/42 %0.0
General disorders and administration site conditions - Other disease progression,1/43 %2.33,0/42 %0.0
General disorders and administration site conditions - Other failure to thrive,0/43 %0.0,1/42 %2.38
Infusion related reaction,1/43 %2.33,0/42 %0.0
Cholecystitis,1/43 %2.33,0/42 %0.0
Allergic reaction,4/43 %9.3,1/42 %2.38
Investigations - Other pancytopenia,0/43 %0.0,1/42 %2.38
Dehydration,0/43 %0.0,3/42 %7.14
Hypokalemia,0/43 %0.0,1/42 %2.38
Metabolism and nutrition disorders - Other electrolyte imbalance,0/43 %0.0,1/42 %2.38
Dyspnea,1/43 %2.33,0/42 %0.0
Pleural effusion,1/43 %2.33,0/42 %0.0
Rash,1/43 %2.33,0/42 %0.0
Thromboembolic event,1/43 %2.33,1/42 %2.38
Hypotension,0/43 %0.0,1/42 %2.38

Sorafenib and Bevacizumab to Treat Ovarian  Fallopian and Peritoneal Cancer(https://clinicaltrials.gov/show/NCT00436215)
 ,BAY 43-9006 + Bevacizumab
 ,BAY 43-9006 (sorafenib) + Bevacizumab Bevacizumab: bevacizumab 5 mg/kg intravenous (IV) every two weeks BAY 43-9006: BAY 43-9006 200 mg po (by mouth) twice daily 5 out of 7 days each week (Mon-Fri)
Total all-cause mortality,1/55 %1.82
Total serious adverse events,25/55 %45.45
Pericardial effusion,1/55 %1.82
Abdominal pain,5/55 %9.09
Diarrhea,1/55 %1.82
Gastrointestinal disorders - Other specify,1/55 %1.82
Nausea,2/55 %3.64
Obstruction gastric,1/55 %1.82
Small intestinal obstruction,7/55 %12.73
Vomiting,1/55 %1.82
Fever,2/55 %3.64
Hepatobiliary disorders - Other specify (bile duct obstruction),1/55 %1.82
Allergic reaction,1/55 %1.82
Catheter related infection,1/55 %1.82
Cecal infection,1/55 %1.82
Wound infection,1/55 %1.82
Vascular access complication,1/55 %1.82
Dehydration,1/55 %1.82
Hyponatremia,1/55 %1.82
Headache,1/55 %1.82
Urinary tract obstruction,1/55 %1.82
Pleural effusion,2/55 %3.64
Pneumonitis,1/55 %1.82
Hypertension,1/55 %1.82
Thromboembolic event,4/55 %7.27
Vascular disorders - Other specify,1/55 %1.82

Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer(https://clinicaltrials.gov/show/NCT00454194)
 ,Arm I (Pemetrexed + Sorafenib),Arm II (Pemetrexed)
 ,Patients receive oral sorafenib tosylate twice daily on days 1-21 and pemetrexed disodium IV over 10 minutes on day 1.,Patients receive pemetrexed disodium IV over 10 minutes on day 1.
Total serious adverse events,13/47 %27.66,7/51 %13.73
Febrile neutropenia,1/47 %2.13,0/51 %0.0
Hemoglobin decreased,1/47 %2.13,2/51 %3.92
Abdominal pain,2/47 %4.26,0/51 %0.0
Dry mouth,1/47 %2.13,0/51 %0.0
Small intestinal perforation,1/47 %2.13,0/51 %0.0
Vomiting,0/47 %0.0,1/51 %1.96
Fatigue,1/47 %2.13,0/51 %0.0
Sudden death,1/47 %2.13,0/51 %0.0
Aspartate aminotransferase increased,1/47 %2.13,0/51 %0.0
Bilirubin increased,0/47 %0.0,1/51 %1.96
Leukocyte count decreased,1/47 %2.13,1/51 %1.96
Lipase increased,0/47 %0.0,1/51 %1.96
Neutrophil count decreased,4/47 %8.51,1/51 %1.96
Platelet count decreased,3/47 %6.38,2/51 %3.92
Weight loss,1/47 %2.13,0/51 %0.0
Anorexia,1/47 %2.13,0/51 %0.0
Chest wall pain,0/47 %0.0,1/51 %1.96
Headache,0/47 %0.0,1/51 %1.96
Ischemia cerebrovascular,1/47 %2.13,0/51 %0.0
Bronchial hemorrhage,1/47 %2.13,1/51 %1.96
Dyspnea,0/47 %0.0,2/51 %3.92
Thrombosis,0/47 %0.0,1/51 %1.96

Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib(https://clinicaltrials.gov/show/NCT00474786)
 ,Temsirolimus,Sorafenib
 ,Temsirolimus 25 milligrams (mg) once weekly by intravenous (IV) infusion administered in 6 week cycles for up to 24 months participants were premedicated with 25-50 mg IV diphenydramine 30 minutes before temsirolimus infusion. In event of toxicity dose could be modified or held according to the protocol or at the discretion of the investigator.,Sorafenib 400 mg (two 200 mg tablets) by mouth (PO) twice daily (BID) administered in 6 week cycles for up to 24 months. In event of toxicity dose could be modified or held according to the protocol or at the discretion of the investigator.
Total serious adverse events,104/249 %41.77,87/252 %34.52
Anaemia,5/249 %2.01,4/252 %1.59
Febrile neutropenia,1/249 %0.4,0/252 %0.0
Lymphopenia,1/249 %0.4,0/252 %0.0
Thrombocytopenia,1/249 %0.4,0/252 %0.0
Acute myocardial infarction,1/249 %0.4,0/252 %0.0
Atrial fibrillation,0/249 %0.0,3/252 %1.19
Atrial flutter,0/249 %0.0,1/252 %0.4
Cardiac arrest,1/249 %0.4,0/252 %0.0
Cardiac tamponade,1/249 %0.4,0/252 %0.0
Cardio-respiratory arrest,1/249 %0.4,1/252 %0.4
Cardiopulmonary failure,2/249 %0.8,0/252 %0.0
Myocardial infarction,1/249 %0.4,4/252 %1.59
Myocardial ischaemia,0/249 %0.0,1/252 %0.4
Palpitations,0/249 %0.0,1/252 %0.4
Pericardial effusion,1/249 %0.4,0/252 %0.0
Prinzmetal angina,1/249 %0.4,0/252 %0.0
Hyperthyroidism,0/249 %0.0,1/252 %0.4
Toxic nodular goitre,0/249 %0.0,1/252 %0.4
Retinal artery occlusion,0/249 %0.0,1/252 %0.4
Abdominal distension,1/249 %0.4,1/252 %0.4
Abdominal pain,7/249 %2.81,1/252 %0.4
Ascites,3/249 %1.2,1/252 %0.4
Constipation,1/249 %0.4,1/252 %0.4
Diarrhoea,3/249 %1.2,1/252 %0.4
Duodenal perforation,1/249 %0.4,0/252 %0.0
Dysphagia,0/249 %0.0,1/252 %0.4
Gastrointestinal haemorrhage,0/249 %0.0,1/252 %0.4
Gastrointestinal obstruction,2/249 %0.8,0/252 %0.0
Hernial eventration,1/249 %0.4,0/252 %0.0
Hiatus hernia,0/249 %0.0,1/252 %0.4
Intestinal obstruction,1/249 %0.4,0/252 %0.0
Intestinal ulcer perforation,1/249 %0.4,0/252 %0.0
Large intestine perforation,0/249 %0.0,1/252 %0.4
Nausea,1/249 %0.4,0/252 %0.0
Obstruction gastric,0/249 %0.0,1/252 %0.4
Oesophageal hypomotility,1/249 %0.4,0/252 %0.0
Rectal haemorrhage,1/249 %0.4,0/252 %0.0
Salivary hypersecretion,1/249 %0.4,0/252 %0.0
Stomatitis,1/249 %0.4,0/252 %0.0
Vomiting,6/249 %2.41,4/252 %1.59
Asthenia,3/249 %1.2,1/252 %0.4
Chest pain,1/249 %0.4,3/252 %1.19
Fatigue,2/249 %0.8,4/252 %1.59
General physical health deterioration,8/249 %3.21,9/252 %3.57
Multi-organ failure,0/249 %0.0,1/252 %0.4
Oedema peripheral,2/249 %0.8,0/252 %0.0
Pain,1/249 %0.4,2/252 %0.79
Performance status decreased,1/249 %0.4,0/252 %0.0
Pyrexia,7/249 %2.81,4/252 %1.59
Sudden death,1/249 %0.4,1/252 %0.4
Systemic inflammatory response syndrome,0/249 %0.0,1/252 %0.4
Cholecystitis acute,1/249 %0.4,0/252 %0.0
Bile duct stone,1/249 %0.4,0/252 %0.0
Cholecystitis,1/249 %0.4,0/252 %0.0
Cholestasis,1/249 %0.4,0/252 %0.0
Gallbladder obstruction,0/249 %0.0,1/252 %0.4
Hepatobiliary disease,0/249 %0.0,1/252 %0.4
Anaphylactic reaction,1/249 %0.4,0/252 %0.0
Drug hypersensitivity,0/249 %0.0,1/252 %0.4
Abdominal infection,1/249 %0.4,0/252 %0.0
Abscess intestinal,0/249 %0.0,1/252 %0.4
Anal abscess,0/249 %0.0,1/252 %0.4
Bronchitis,1/249 %0.4,0/252 %0.0
Chest wall abscess,0/249 %0.0,1/252 %0.4
Cholangitis suppurative,0/249 %0.0,1/252 %0.4
Device related infection,2/249 %0.8,0/252 %0.0
Enterococcal bacteraemia,0/249 %0.0,1/252 %0.4
Hepatitis B,1/249 %0.4,0/252 %0.0
Herpes zoster,1/249 %0.4,0/252 %0.0
Infection,0/249 %0.0,1/252 %0.4
Infectious pleural effusion,0/249 %0.0,1/252 %0.4
Lobar pneumonia,1/249 %0.4,0/252 %0.0
Lower respiratory tract infection,2/249 %0.8,0/252 %0.0
Lung infection,1/249 %0.4,0/252 %0.0
Perirectal abscess,1/249 %0.4,0/252 %0.0
Pharyngitis,1/249 %0.4,0/252 %0.0
Pneumocystis jiroveci pneumonia,1/249 %0.4,0/252 %0.0
Pneumonia,7/249 %2.81,7/252 %2.78
Pneumonia influenzal,1/249 %0.4,0/252 %0.0
Pneumonia legionella,1/249 %0.4,0/252 %0.0
Pulmonary tuberculosis,0/249 %0.0,1/252 %0.4
Respiratory tract infection,1/249 %0.4,0/252 %0.0
Sepsis,2/249 %0.8,2/252 %0.79
Septic shock,1/249 %0.4,0/252 %0.0
Subcutaneous abscess,1/249 %0.4,0/252 %0.0
Tooth abscess,0/249 %0.0,1/252 %0.4
Urosepsis,0/249 %0.0,1/252 %0.4
Wound infection,0/249 %0.0,1/252 %0.4
Compression fracture,1/249 %0.4,0/252 %0.0
Hip fracture,0/249 %0.0,1/252 %0.4
Humerus fracture,0/249 %0.0,1/252 %0.4
Infusion related reaction,1/249 %0.4,0/252 %0.0
Ligament sprain,0/249 %0.0,1/252 %0.4
Lumbar vertebral fracture,1/249 %0.4,0/252 %0.0
Overdose,0/249 %0.0,1/252 %0.4
Pelvic fracture,1/249 %0.4,0/252 %0.0
Radiation mucositis,0/249 %0.0,1/252 %0.4
Alanine aminotransferase increased,0/249 %0.0,2/252 %0.79
Aspartate aminotransferase increased,0/249 %0.0,3/252 %1.19
Blood potassium increased,0/249 %0.0,1/252 %0.4
Prostatic specific antigen increased,0/249 %0.0,1/252 %0.4
Weight decreased,0/249 %0.0,1/252 %0.4
Cachexia,1/249 %0.4,0/252 %0.0
Decreased appetite,0/249 %0.0,2/252 %0.79
Dehydration,7/249 %2.81,6/252 %2.38
Diabetes mellitus inadequate control,1/249 %0.4,0/252 %0.0
Hypercalcaemia,1/249 %0.4,3/252 %1.19
Hypercholesterolaemia,1/249 %0.4,0/252 %0.0
Hyperglycaemia,2/249 %0.8,1/252 %0.4
Hyperkalaemia,0/249 %0.0,1/252 %0.4
Hypertriglyceridaemia,1/249 %0.4,0/252 %0.0
Hyponatraemia,0/249 %0.0,3/252 %1.19
Malnutrition,0/249 %0.0,1/252 %0.4
Arthralgia,2/249 %0.8,0/252 %0.0
Back pain,0/249 %0.0,3/252 %1.19
Bone lesion,1/249 %0.4,0/252 %0.0
Bone pain,1/249 %0.4,0/252 %0.0
Costochondritis,0/249 %0.0,1/252 %0.4
Flank pain,1/249 %0.4,0/252 %0.0
Intervertebral disc protrusion,0/249 %0.0,1/252 %0.4
Musculoskeletal chest pain,0/249 %0.0,1/252 %0.4
Musculoskeletal pain,1/249 %0.4,0/252 %0.0
Neck pain,0/249 %0.0,1/252 %0.4
Osteolysis,1/249 %0.4,1/252 %0.4
Pain in extremity,2/249 %0.8,3/252 %1.19
Pathological fracture,1/249 %0.4,0/252 %0.0
Spinal disorder,0/249 %0.0,1/252 %0.4
Malignant pleural effusion,1/249 %0.4,0/252 %0.0
Squamous cell carcinoma,0/249 %0.0,2/252 %0.79
Cerebral infarction,0/249 %0.0,1/252 %0.4
Cerebral ischaemia,0/249 %0.0,1/252 %0.4
Cerebrovascular accident,2/249 %0.8,0/252 %0.0
Cognitive disorder,0/249 %0.0,1/252 %0.4
Convulsion,0/249 %0.0,1/252 %0.4
Headache,1/249 %0.4,1/252 %0.4
Hypoaesthesia,0/249 %0.0,1/252 %0.4
Paraesthesia,1/249 %0.4,0/252 %0.0
Peripheral motor neuropathy,0/249 %0.0,1/252 %0.4
Spinal cord compression,1/249 %0.4,2/252 %0.79
Syncope,0/249 %0.0,1/252 %0.4
Unresponsive to stimuli,0/249 %0.0,1/252 %0.4
Completed suicide,1/249 %0.4,1/252 %0.4
Confusional state,0/249 %0.0,3/252 %1.19
Haematuria,1/249 %0.4,0/252 %0.0
Nephrotic syndrome,0/249 %0.0,1/252 %0.4
Renal failure,4/249 %1.61,1/252 %0.4
Renal failure acute,1/249 %0.4,1/252 %0.4
Renal tubular necrosis,1/249 %0.4,0/252 %0.0
Urinary retention,2/249 %0.8,0/252 %0.0
Prostatic haemorrhage,0/249 %0.0,1/252 %0.4
Asthmatic crisis,0/249 %0.0,1/252 %0.4
Dyspnoea,7/249 %2.81,8/252 %3.17
Epistaxis,1/249 %0.4,0/252 %0.0
Haemoptysis,0/249 %0.0,1/252 %0.4
Interstitial lung disease,2/249 %0.8,0/252 %0.0
Lung disorder,2/249 %0.8,0/252 %0.0
Pleural effusion,7/249 %2.81,5/252 %1.98
Pleuritic pain,1/249 %0.4,0/252 %0.0
Pneumonitis,7/249 %2.81,0/252 %0.0
Pneumothorax,3/249 %1.2,0/252 %0.0
Pulmonary embolism,1/249 %0.4,0/252 %0.0
Respiratory arrest,0/249 %0.0,1/252 %0.4
Respiratory distress,1/249 %0.4,0/252 %0.0
Respiratory failure,2/249 %0.8,2/252 %0.79
Palmar-plantar erythrodysaesthesia syndrome,0/249 %0.0,1/252 %0.4
Rash,1/249 %0.4,2/252 %0.79
Rash papular,0/249 %0.0,1/252 %0.4
Lung operation,1/249 %0.4,0/252 %0.0
Medical device implantation,1/249 %0.4,0/252 %0.0
Haematoma,0/249 %0.0,1/252 %0.4
Haemorrhage,1/249 %0.4,0/252 %0.0
Hypertension,1/249 %0.4,0/252 %0.0
Hypotension,1/249 %0.4,0/252 %0.0
Thrombosis,1/249 %0.4,0/252 %0.0

Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma(https://clinicaltrials.gov/show/NCT00474929)
 ,Phase I Dose Level 0,Phase I Dose Level 1,Phase I Dose Level 2,Phase I Dose Level 3,Phase II
 ,Phase I: Dose level 0: Sorafenib 200 mg twice daily RAD001 5mg every other day,Phase I: Dose level 1: Sorafenib 200 mg twice daily RAD001 5mg every day,Phase I: Dose level 2: Sorafenib 400 mg twice daily RAD001 5mg every day,Phase I: Dose level 3: Sorafenib 400 mg twice daily RAD001 10mg every day,Phase II: Sorafenib 200 mg twice daily RAD001 5mg every day;
Total serious adverse events,2/6 %33.33,1/5 %20.0,2/5 %40.0,1/5 %20.0,22/77 %28.57
Hemoglobin decreased,0/6 %0.0,0/5 %0.0,0/5 %0.0,0/5 %0.0,3/77 %3.9
Cardiac valve disease,0/6 %0.0,0/5 %0.0,0/5 %0.0,0/5 %0.0,1/77 %1.3
Sinus bradycardia,0/6 %0.0,0/5 %0.0,0/5 %0.0,0/5 %0.0,1/77 %1.3
Diarrhea,0/6 %0.0,0/5 %0.0,0/5 %0.0,0/5 %0.0,1/77 %1.3
Ear nose and throat examination abnormal,0/6 %0.0,0/5 %0.0,0/5 %0.0,0/5 %0.0,2/77 %2.6
Nausea,0/6 %0.0,0/5 %0.0,0/5 %0.0,0/5 %0.0,1/77 %1.3
Death,0/6 %0.0,0/5 %0.0,0/5 %0.0,0/5 %0.0,1/77 %1.3
Disease progression,0/6 %0.0,0/5 %0.0,0/5 %0.0,0/5 %0.0,1/77 %1.3
Fatigue,0/6 %0.0,0/5 %0.0,0/5 %0.0,0/5 %0.0,2/77 %2.6
Fever,0/6 %0.0,0/5 %0.0,0/5 %0.0,0/5 %0.0,1/77 %1.3
Sudden death,0/6 %0.0,0/5 %0.0,0/5 %0.0,0/5 %0.0,1/77 %1.3
Hypersensitivity,0/6 %0.0,0/5 %0.0,0/5 %0.0,0/5 %0.0,1/77 %1.3
Infectious colitis,0/6 %0.0,0/5 %0.0,0/5 %0.0,0/5 %0.0,1/77 %1.3
Sepsis,0/6 %0.0,0/5 %0.0,0/5 %0.0,0/5 %0.0,1/77 %1.3
Bilirubin increased,0/6 %0.0,0/5 %0.0,0/5 %0.0,0/5 %0.0,1/77 %1.3
Leukocyte count decreased,0/6 %0.0,0/5 %0.0,0/5 %0.0,0/5 %0.0,2/77 %2.6
Lymphocyte count decreased,0/6 %0.0,0/5 %0.0,0/5 %0.0,0/5 %0.0,1/77 %1.3
Neutrophil count decreased,1/6 %16.67,0/5 %0.0,1/5 %20.0,0/5 %0.0,2/77 %2.6
Platelet count decreased,1/6 %16.67,1/5 %20.0,1/5 %20.0,1/5 %20.0,2/77 %2.6
Anorexia,0/6 %0.0,0/5 %0.0,0/5 %0.0,0/5 %0.0,1/77 %1.3
Myalgia,0/6 %0.0,0/5 %0.0,0/5 %0.0,0/5 %0.0,1/77 %1.3
Tumor pain,0/6 %0.0,0/5 %0.0,1/5 %20.0,0/5 %0.0,0/77 %0.0
Ataxia,0/6 %0.0,0/5 %0.0,0/5 %0.0,0/5 %0.0,1/77 %1.3
Hand-and-foot syndrome,0/6 %0.0,0/5 %0.0,0/5 %0.0,0/5 %0.0,1/77 %1.3
Rash desquamating,0/6 %0.0,0/5 %0.0,1/5 %20.0,0/5 %0.0,2/77 %2.6
Urticaria,0/6 %0.0,0/5 %0.0,0/5 %0.0,0/5 %0.0,1/77 %1.3
Hypotension,0/6 %0.0,0/5 %0.0,0/5 %0.0,0/5 %0.0,1/77 %1.3
Thrombosis,0/6 %0.0,0/5 %0.0,1/5 %20.0,0/5 %0.0,0/77 %0.0

Capecitabine and Cisplatin (XP)+Sorafenib in Advanced Gastric Cancer (AGC): Sorafenib+XP(https://clinicaltrials.gov/show/NCT00565370)
 ,XP Plus Sorafenib
 ,Capecitabine and cisplatin plus sorafenib
Total serious adverse events,4/21 %19.05
Febrile neutropenia,1/21 %4.76
Deep vein thrombosis,2/21 %9.52
Diarrhea,1/21 %4.76
Gastric perforation,1/21 %4.76

Sorafenib and Letrozole  Anastrozole  or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast Cancer(https://clinicaltrials.gov/show/NCT00573755)
 ,Sorafenib Plus Aromatase Inhibitor,Placebo Plus Aromatase Inhibitor
 ,Patients receive oral sorafenib tosylate twice daily and oral letrozole anastrozole or exemestane once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.,Patients receive oral placebo twice daily and oral letrozole anastrozole or exemestane once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
Total serious adverse events,1/2 %50.0,0/2 %0.0
Hemoglobin decreased,1/2 %50.0,0/2 %0.0
Thrombotic microangiopathy,1/2 %50.0,0/2 %0.0
Ear nose and throat examination abnormal,1/2 %50.0,0/2 %0.0
Mucositis oral,1/2 %50.0,0/2 %0.0
Fatigue,1/2 %50.0,0/2 %0.0
Platelet count decreased,1/2 %50.0,0/2 %0.0
Serum potassium increased,1/2 %50.0,0/2 %0.0
Serum sodium decreased,1/2 %50.0,0/2 %0.0
Muscle weakness,1/2 %50.0,0/2 %0.0

Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib(https://clinicaltrials.gov/show/NCT00609804)
 ,Sorafenib+Erlotinib,Sorafenib
 ,Sorafenib and Erlotinib: Sorafenib 400 mg twice daily by mouth Erlotinib 150 mg once daily by mouth Study treatment will be given in cycles of 28 days. Patients will be re-staged every 2 treatment cycles (every 8 weeks). Patients with an objective response or stable disease will continue study treatment. Patients will continue until disease progression or intolerable toxicity occurs.,Sorafenib: Sorafenib 400 mg twice daily by mouth. Study treatment will be given in cycles of 28 days. Patients will be re-staged every 2 treatment cycles (every 8 weeks). Patients with an objective response or stable disease will continue study treatment. Patients will continue until disease progression or intolerable toxicity occurs.
Total serious adverse events,11/25 %44.0,5/28 %17.86
Cardiac disorders - Other unspecified,1/25 %4.0,0/28 %0.0
Heart Failure,1/25 %4.0,0/28 %0.0
Constipation,1/25 %4.0,1/28 %3.57
Diarrhea,3/25 %12.0,0/28 %0.0
Dysphagia,1/25 %4.0,0/28 %0.0
Gastric perforation,1/25 %4.0,0/28 %0.0
Ileus,1/25 %4.0,0/28 %0.0
Nausea,1/25 %4.0,0/28 %0.0
Obstruction gastric,1/25 %4.0,0/28 %0.0
Abdominal pain,1/25 %4.0,0/28 %0.0
Vomiting,1/25 %4.0,0/28 %0.0
Fatigue,2/25 %8.0,0/28 %0.0
Non-cardiac chest pain,0/25 %0.0,1/28 %3.57
Anorexia,1/25 %4.0,0/28 %0.0
Dehydration,3/25 %12.0,0/28 %0.0
Hyperglycemia,1/25 %4.0,0/28 %0.0
Hypokalemia,0/25 %0.0,1/28 %3.57
Hyponatremia,1/25 %4.0,0/28 %0.0
Dizziness,0/25 %0.0,1/28 %3.57
Intracranial hemorrhage,1/25 %4.0,0/28 %0.0
Peripheral motor neuropathy,1/25 %4.0,0/28 %0.0
Cognitive disturbance,1/25 %4.0,0/28 %0.0
Confusion,0/25 %0.0,1/28 %3.57
Personality change,1/25 %4.0,0/28 %0.0
Respiratory thoracic and mediastinal disorders - Other COPD exacerbation,0/25 %0.0,1/28 %3.57
Cough,1/25 %4.0,0/28 %0.0
Respiratory failure,1/25 %4.0,0/28 %0.0
Rash,0/25 %0.0,1/28 %3.57
Hypertension,1/25 %4.0,1/28 %3.57
Thromboembolic event,0/25 %0.0,1/28 %3.57

A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer(https://clinicaltrials.gov/show/NCT00632541)
 ,Single Arm A
 ,Sorafenib 200mg po daily Bevacizumab 5mg/kg every other week 1 Cycle = 4 weeks. Imaging every third cycle
Total serious adverse events,4/18 %22.22
ASCITES (NON-MALIGNANT),1/18 %5.56
DEATH NOT ASSOCIATED WITH CTCAE TERM / DISEASE PROGRESSION NOS,1/18 %5.56
NEUROPATHY: SENSORY,1/18 %5.56
PAIN / CHEST WALL,1/18 %5.56

Phase II Study of Sorafenib + Carboplatin and Docetaxel in First Line Treatment of Stage IIIB/IV NSCLC(https://clinicaltrials.gov/show/NCT00647426)
 ,Sorafenib + Docetaxel
 ,400 mg po BID Sorafenib + 75 mg/m2 IV Docetaxel on day 1 plus AUC 6 on Carboplatin on day 1 of each 21 day cycle Sorafenib + Docetaxel/Carboplatin: 400 mg po BID Sorafenib + 75 mg/m2 IV Docetaxel on day 1 plus AUC 6 on Carboplatin on day 1 of each 21 day cycle
Total serious adverse events,0/7 %0.0

Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer(https://clinicaltrials.gov/show/NCT00678392)
 ,Axitinib 5 mg,Sorafenib 400 mg
 ,Axitinib (AG-013736) 5 milligram (mg) tablet administered orally twice daily in cycles of 4 weeks.,Sorafenib 400 mg tablet administered orally twice daily in cycles of 4 weeks.
Total serious adverse events,146/359 %40.67,127/355 %35.77
Anaemia,0/359 %0.0,8/355 %2.25
Splenic infarction,0/359 %0.0,1/355 %0.28
Acute coronary syndrome,0/359 %0.0,2/355 %0.56
Acute myocardial infarction,2/359 %0.56,0/355 %0.0
Angina pectoris,0/359 %0.0,2/355 %0.56
Arrhythmia supraventricular,1/359 %0.28,0/355 %0.0
Arteriosclerosis coronary artery,1/359 %0.28,0/355 %0.0
Atrial fibrillation,2/359 %0.56,0/355 %0.0
Atrial flutter,1/359 %0.28,0/355 %0.0
Atrioventricular block,0/359 %0.0,1/355 %0.28
Bradycardia,1/359 %0.28,0/355 %0.0
Cardiac arrest,1/359 %0.28,0/355 %0.0
Cardiac failure,2/359 %0.56,1/355 %0.28
Cardiopulmonary failure,2/359 %0.56,1/355 %0.28
Congestive cardiomyopathy,0/359 %0.0,1/355 %0.28
Coronary artery insufficiency,1/359 %0.28,0/355 %0.0
Haemorrhage coronary artery,1/359 %0.28,0/355 %0.0
Mitral valve incompetence,1/359 %0.28,0/355 %0.0
Myocardial infarction,6/359 %1.67,4/355 %1.13
Myocardial ischaemia,1/359 %0.28,0/355 %0.0
Prinzmetal angina,1/359 %0.28,0/355 %0.0
Supraventricular tachycardia,1/359 %0.28,0/355 %0.0
Tachycardia,0/359 %0.0,1/355 %0.28
Adrenal insufficiency,0/359 %0.0,1/355 %0.28
Hypothyroidism,1/359 %0.28,0/355 %0.0
Secondary hypothyroidism,1/359 %0.28,0/355 %0.0
Thyroiditis,0/359 %0.0,1/355 %0.28
Diplopia,1/359 %0.28,0/355 %0.0
Retinal artery embolism,0/359 %0.0,1/355 %0.28
Retinal artery occlusion,1/359 %0.28,0/355 %0.0
Retinal vein occlusion,1/359 %0.28,0/355 %0.0
Retinal vein thrombosis,1/359 %0.28,0/355 %0.0
Abdominal pain,1/359 %0.28,2/355 %0.56
Anal fistula,1/359 %0.28,0/355 %0.0
Ascites,0/359 %0.0,1/355 %0.28
Colitis ulcerative,0/359 %0.0,1/355 %0.28
Constipation,2/359 %0.56,1/355 %0.28
Diarrhoea,8/359 %2.23,5/355 %1.41
Duodenal ulcer haemorrhage,0/359 %0.0,1/355 %0.28
Enterocolitis,0/359 %0.0,1/355 %0.28
Gastric haemorrhage,2/359 %0.56,0/355 %0.0
Gastric ulcer,1/359 %0.28,0/355 %0.0
Gastritis,0/359 %0.0,1/355 %0.28
Gastrointestinal haemorrhage,0/359 %0.0,5/355 %1.41
Gastrointestinal perforation,1/359 %0.28,0/355 %0.0
Haematemesis,0/359 %0.0,1/355 %0.28
Inguinal hernia,3/359 %0.84,0/355 %0.0
Intestinal obstruction,4/359 %1.11,1/355 %0.28
Lower gastrointestinal haemorrhage,1/359 %0.28,1/355 %0.28
Melaena,1/359 %0.28,0/355 %0.0
Nausea,1/359 %0.28,1/355 %0.28
Pancreatitis,0/359 %0.0,1/355 %0.28
Rectal haemorrhage,0/359 %0.0,1/355 %0.28
Retroperitoneal haemorrhage,0/359 %0.0,1/355 %0.28
Small intestinal obstruction,1/359 %0.28,0/355 %0.0
Subileus,0/359 %0.0,1/355 %0.28
Upper gastrointestinal haemorrhage,0/359 %0.0,1/355 %0.28
Vomiting,5/359 %1.39,2/355 %0.56
Asthenia,2/359 %0.56,1/355 %0.28
Chest pain,2/359 %0.56,2/355 %0.56
Chills,1/359 %0.28,0/355 %0.0
Death,3/359 %0.84,6/355 %1.69
Device dislocation,0/359 %0.0,1/355 %0.28
Disease progression,32/359 %8.91,18/355 %5.07
Fatigue,4/359 %1.11,0/355 %0.0
General physical health deterioration,3/359 %0.84,5/355 %1.41
Hernia,1/359 %0.28,0/355 %0.0
Impaired healing,0/359 %0.0,1/355 %0.28
Inflammation,0/359 %0.0,1/355 %0.28
Malaise,1/359 %0.28,0/355 %0.0
Mucosal inflammation,1/359 %0.28,0/355 %0.0
Oedema,1/359 %0.28,0/355 %0.0
Pain,2/359 %0.56,3/355 %0.85
Pyrexia,7/359 %1.95,5/355 %1.41
Biliary dilatation,0/359 %0.0,1/355 %0.28
Budd-Chiari syndrome,1/359 %0.28,0/355 %0.0
Cholangitis,1/359 %0.28,1/355 %0.28
Cholecystitis,1/359 %0.28,1/355 %0.28
Cholelithiasis,0/359 %0.0,1/355 %0.28
Hepatic function abnormal,0/359 %0.0,1/355 %0.28
Hypersensitivity,1/359 %0.28,0/355 %0.0
Abdominal abscess,1/359 %0.28,0/355 %0.0
Appendicitis,1/359 %0.28,2/355 %0.56
Aspergillus infection,0/359 %0.0,1/355 %0.28
Bacterial diarrhoea,1/359 %0.28,0/355 %0.0
Cellulitis,0/359 %0.0,1/355 %0.28
Diverticulitis,0/359 %0.0,1/355 %0.28
Erysipelas,1/359 %0.28,0/355 %0.0
Gastroenteritis,1/359 %0.28,0/355 %0.0
Gastroenteritis viral,1/359 %0.28,0/355 %0.0
Herpes zoster,0/359 %0.0,1/355 %0.28
Infection,3/359 %0.84,0/355 %0.0
Intervertebral discitis,0/359 %0.0,1/355 %0.28
Lower respiratory tract infection,0/359 %0.0,4/355 %1.13
Lower respiratory tract infection bacterial,1/359 %0.28,0/355 %0.0
Lung infection,0/359 %0.0,1/355 %0.28
Muscle abscess,0/359 %0.0,1/355 %0.28
Pneumonia,5/359 %1.39,4/355 %1.13
Pneumonia streptococcal,1/359 %0.28,0/355 %0.0
Pneumonia viral,1/359 %0.28,0/355 %0.0
Pulmonary tuberculosis,0/359 %0.0,1/355 %0.28
Pyelonephritis,0/359 %0.0,1/355 %0.28
Respiratory tract infection,1/359 %0.28,1/355 %0.28
Sepsis,1/359 %0.28,2/355 %0.56
Septic shock,0/359 %0.0,1/355 %0.28
Urinary tract infection,2/359 %0.56,2/355 %0.56
Fall,1/359 %0.28,2/355 %0.56
Femoral neck fracture,1/359 %0.28,0/355 %0.0
Gastrointestinal anastomotic leak,1/359 %0.28,0/355 %0.0
Humerus fracture,1/359 %0.28,0/355 %0.0
Laceration,1/359 %0.28,0/355 %0.0
Lumbar vertebral fracture,2/359 %0.56,0/355 %0.0
Procedural pain,1/359 %0.28,0/355 %0.0
Radiation pneumonitis,1/359 %0.28,0/355 %0.0
Rib fracture,0/359 %0.0,1/355 %0.28
Soft tissue injury,0/359 %0.0,1/355 %0.28
Spinal compression fracture,1/359 %0.28,0/355 %0.0
Neutrophil count abnormal,1/359 %0.28,0/355 %0.0
Alanine aminotransferase increased,0/359 %0.0,1/355 %0.28
Aspartate aminotransferase increased,0/359 %0.0,1/355 %0.28
Blood alkaline phosphatase increased,0/359 %0.0,1/355 %0.28
Blood creatinine increased,2/359 %0.56,1/355 %0.28
Blood lactate dehydrogenase increased,0/359 %0.0,1/355 %0.28
C-reactive protein increased,0/359 %0.0,1/355 %0.28
Gamma-glutamyltransferase increased,0/359 %0.0,1/355 %0.28
Hepatic enzyme increased,0/359 %0.0,1/355 %0.28
Decreased appetite,3/359 %0.84,0/355 %0.0
Dehydration,10/359 %2.79,1/355 %0.28
Hypercalcaemia,1/359 %0.28,2/355 %0.56
Hyperkalaemia,2/359 %0.56,1/355 %0.28
Hypocalcaemia,0/359 %0.0,1/355 %0.28
Hypoglycaemia,1/359 %0.28,0/355 %0.0
Hypokalaemia,2/359 %0.56,0/355 %0.0
Hyponatraemia,1/359 %0.28,3/355 %0.85
Hypovolaemia,1/359 %0.28,0/355 %0.0
Arthralgia,1/359 %0.28,1/355 %0.28
Back pain,3/359 %0.84,2/355 %0.56
Flank pain,0/359 %0.0,1/355 %0.28
Musculoskeletal chest pain,0/359 %0.0,1/355 %0.28
Pain in extremity,2/359 %0.56,0/355 %0.0
Polyarthritis,0/359 %0.0,1/355 %0.28
Spinal column stenosis,0/359 %0.0,1/355 %0.28
Spondylolisthesis,0/359 %0.0,1/355 %0.28
Metastasis,1/359 %0.28,0/355 %0.0
Metastatic pain,0/359 %0.0,1/355 %0.28
Neoplasm progression,1/359 %0.28,0/355 %0.0
Renal cell carcinoma,1/359 %0.28,1/355 %0.28
Squamous cell carcinoma,0/359 %0.0,1/355 %0.28
Tumour associated fever,1/359 %0.28,0/355 %0.0
Aphasia,1/359 %0.28,0/355 %0.0
Balance disorder,0/359 %0.0,1/355 %0.28
Central nervous system haemorrhage,1/359 %0.28,0/355 %0.0
Cerebral infarction,0/359 %0.0,1/355 %0.28
Cerebral ischaemia,0/359 %0.0,1/355 %0.28
Cerebrovascular accident,2/359 %0.56,1/355 %0.28
Dizziness,3/359 %0.84,0/355 %0.0
Headache,1/359 %0.28,0/355 %0.0
Hemiparesis,0/359 %0.0,1/355 %0.28
Ischaemic stroke,0/359 %0.0,1/355 %0.28
Leukoencephalopathy,1/359 %0.28,0/355 %0.0
Loss of consciousness,2/359 %0.56,0/355 %0.0
Meningeal disorder,1/359 %0.28,0/355 %0.0
Monoplegia,0/359 %0.0,1/355 %0.28
Presyncope,1/359 %0.28,0/355 %0.0
Seizure,1/359 %0.28,0/355 %0.0
Spinal cord compression,2/359 %0.56,0/355 %0.0
Syncope,2/359 %0.56,0/355 %0.0
Transient ischaemic attack,3/359 %0.84,0/355 %0.0
Anxiety,0/359 %0.0,1/355 %0.28
Confusional state,1/359 %0.28,0/355 %0.0
Disorientation,1/359 %0.28,0/355 %0.0
Mental status changes,1/359 %0.28,1/355 %0.28
Acute kidney injury,4/359 %1.11,2/355 %0.56
Acute prerenal failure,1/359 %0.28,0/355 %0.0
Haematuria,1/359 %0.28,0/355 %0.0
Nephropathy,0/359 %0.0,1/355 %0.28
Oliguria,0/359 %0.0,1/355 %0.28
Renal failure,1/359 %0.28,0/355 %0.0
Urinary retention,1/359 %0.28,0/355 %0.0
Benign prostatic hyperplasia,1/265 %0.38,0/258 %0.0
Menometrorrhagia,0/96 %0.0,1/104 %0.96
Vaginal polyp,1/96 %1.04,0/104 %0.0
Chronic obstructive pulmonary disease,0/359 %0.0,1/355 %0.28
Cough,0/359 %0.0,1/355 %0.28
Dyspnoea,7/359 %1.95,3/355 %0.85
Dyspnoea exertional,1/359 %0.28,0/355 %0.0
Epistaxis,1/359 %0.28,1/355 %0.28
Haemoptysis,1/359 %0.28,2/355 %0.56
Haemothorax,0/359 %0.0,1/355 %0.28
Interstitial lung disease,1/359 %0.28,0/355 %0.0
Lung disorder,1/359 %0.28,0/355 %0.0
Pleural effusion,3/359 %0.84,5/355 %1.41
Pleurisy,0/359 %0.0,1/355 %0.28
Pneumothorax,4/359 %1.11,1/355 %0.28
Pneumothorax spontaneous,1/359 %0.28,0/355 %0.0
Pulmonary embolism,7/359 %1.95,1/355 %0.28
Pulmonary haemorrhage,0/359 %0.0,2/355 %0.56
Respiratory distress,1/359 %0.28,0/355 %0.0
Erythema multiforme,0/359 %0.0,3/355 %0.85
Hyperhidrosis,1/359 %0.28,0/355 %0.0
Palmar-plantar erythrodysaesthesia syndrome,0/359 %0.0,1/355 %0.28
Pustular psoriasis,0/359 %0.0,1/355 %0.28
Rash,0/359 %0.0,2/355 %0.56
Urticaria,1/359 %0.28,0/355 %0.0
Pain management,0/359 %0.0,1/355 %0.28
Vertebroplasty,0/359 %0.0,1/355 %0.28
Accelerated hypertension,1/359 %0.28,0/355 %0.0
Deep vein thrombosis,1/359 %0.28,1/355 %0.28
Hypertension,1/359 %0.28,2/355 %0.56
Hypertensive crisis,1/359 %0.28,0/355 %0.0
Hypotension,1/359 %0.28,4/355 %1.13
Infarction,0/359 %0.0,1/355 %0.28
Jugular vein thrombosis,1/359 %0.28,0/355 %0.0
Subclavian vein thrombosis,1/359 %0.28,0/355 %0.0

Sorafenib  Lenalidomide  and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma(https://clinicaltrials.gov/show/NCT00687674)
 ,Sorafenib + Lenalidomide + Dexamethasone
 
Total serious adverse events,3/13 %23.08
Pneumonia,1/13 %7.69
Leukopenia,1/13 %7.69
Rash,1/13 %7.69

Sorafenib in Treating Non-Smokers or Former Light Smokers With Relapsed or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer(https://clinicaltrials.gov/show/NCT00754923)
 ,Treatment: Sorafenib
 ,Sorafenib will be administered at a dose of 400 mg taken twice daily continuously on a 28 day cycle. sorafenib: administered orally at 400 mg taken twice daily  continuously on a 28 day cycle as an outpatient.
Total serious adverse events,1/11 %9.09
Fatigue,1/11 %9.09

Sorafenib Therapy Prior to Radiofrequency Ablation for Intermediate Sized Hepatocellular Cancer(https://clinicaltrials.gov/show/NCT00813293)
 ,Sorafenib,Placebo
 ,Participants received a nine-day course of oral sorafenib 400 mg twice a day and radiofrequency ablation (RFA) on Day 10. Tumors in each group underwent RFA using a standard regimen (1 cm tip 70  2 C 5 min). Sorafenib radiofrequency ablation,Participants received a nine-day course of placebo pills twice a day and radiofrequency ablation (RFA) on Day 10. Tumors in each group underwent RFA using a standard regimen (1 cm tip 70  2 C 5 min). radiofrequency ablation
Total all-cause mortality,0/9 %0.0,0/10 %0.0
Total serious adverse events,1/9 %11.11,1/10 %10.0
Liver hemorrhage,0/9 %0.0,1/10 %10.0
Leukocytes,1/9 %11.11,0/10 %0.0
Lymphopenia,1/9 %11.11,0/10 %0.0
AST SGOT,1/9 %11.11,0/10 %0.0
Bilirubin,1/9 %11.11,0/10 %0.0

Study of Sorafenib/Cetuximab in Head and Neck Cancer(https://clinicaltrials.gov/show/NCT00815295)
 ,Phase 1 - Dose Level 1,Phase 1 - Dose Level 2,Phase 2
 ,Cetuximab was administered at the standard approved dose: 400 mg/m2 loading dose followed by 250 mg/m2 weekly. Sorafenib 200 mg/m2 was administered orally twice daily.,Cetuximab was administered at the standard approved dose: 400 mg/m2 loading dose followed by 250 mg/m2 weekly. Sorafenib 400 mg/m2 was administered orally twice daily.,Cetuximab was administered at the standard approved dose: 400 mg/m2 loading dose followed by 250 mg/m2 weekly. Sorafenib was administered orally twice daily at the MTD from Phase I.
Total serious adverse events,1/8 %12.5,1/8 %12.5,5/12 %41.67
Myocardial infarction,1/8 %12.5,0/8 %0.0,0/12 %0.0
Nausea,0/8 %0.0,1/8 %12.5,0/12 %0.0
Vomiting,0/8 %0.0,1/8 %12.5,0/12 %0.0
Death NOS,0/8 %0.0,0/8 %0.0,2/12 %16.67
General disorders and administration site conditions - Other specify,0/8 %0.0,0/8 %0.0,1/12 %8.33
Cytokine release syndrome,0/8 %0.0,0/8 %0.0,1/12 %8.33
Dehydration,0/8 %0.0,1/8 %12.5,0/12 %0.0
Respiratory thoracic and mediastinal disorders - Other specify,0/8 %0.0,0/8 %0.0,1/12 %8.33

Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast Cancer(https://clinicaltrials.gov/show/NCT00825734)
 ,Dose Level 1a
 ,Includes patients treated at the Phase II dose - Sorafenib PO BID (400mg) Ixabepilone IV every 21 days (32mg/m^2)
Total serious adverse events,6/76 %7.89
ANEMIA,1/76 %1.32
DEATH,1/76 %1.32
INFECTION,1/76 %1.32
WEIGHT LOSS,1/76 %1.32
BACK PAIN,1/76 %1.32
ACUTE RENAL FAILURE,1/76 %1.32
DYSPNEA,2/76 %2.63
PNEUMONIA,1/76 %1.32
PALMAR-PLANTAR ERYTHRODYSESTHESIA SYNDROME,1/76 %1.32
RASH,1/76 %1.32

Study of Sorafenib and Transarterial Chemoembolization (TACE) to Treat Hepatocellular Carcinoma(https://clinicaltrials.gov/show/NCT00844883)
 ,Sorafenib and Drug Eluting Beads
 ,single arm sorafenib: sorafenib: given 400 mg twice per day for as long as it is beneficial LC Bead-TACE: LC Beads loaded with doxorubicin Doxorubicin loaded LC Beads: given intra-arterially into the liver up to fours times in a 6 month period
Total all-cause mortality,3/50 %6.0
Total serious adverse events,8/50 %16.0
Abdominal pain,1/50 %2.0
Non-cardiac chest pain,2/50 %4.0
Overdose on pain medication,1/50 %2.0
Cholangitis,1/50 %2.0
Elevated creatinine,1/50 %2.0
Tumor rupture,1/50 %2.0
Encephalopathy,1/50 %2.0

Randomized Phase 1/2 Open-Label Trial of PR104 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)(https://clinicaltrials.gov/show/NCT00862082)
 ,PR104 550 mg/m^2 + Sorafenib,PR104 770 mg/m^2 + Sorafenib
 ,550 mg/m^2 PR104 administered IV every 4 weeks + Standard dose sorafenib (400 mg PO twice daily),770 mg/m^2 PR104 administered IV every 4 weeks + Standard dose sorafenib (400 mg PO twice daily)
Total serious adverse events,5/8 %62.5,2/6 %33.33
Febrile neutropenia,1/8 %12.5,0/6 %0.0
Abdominal Pain,2/8 %25.0,0/6 %0.0
Decrease in general condition,1/8 %12.5,0/6 %0.0
Fatigue,0/8 %0.0,1/6 %16.67
Fever in absence of neutropenia,2/8 %25.0,0/6 %0.0
Cellulitis,1/8 %12.5,0/6 %0.0
Sepsis,0/8 %0.0,1/6 %16.67
Thrombocytopenia,1/8 %12.5,0/6 %0.0

Trial of Neoadjuvant Conformal Radiotherapy Plus Sorafenib for Patients With Soft Tissue Sarcoma of the Extremity and Body Wall(https://clinicaltrials.gov/show/NCT00864032)
 ,Sorafenib 200/200,Sorafenib 200/400
 ,Dose level 1. Sorafenib 200 mg PO BID,Dose level 2. Sorafenib 200 mg PO Q AM and 400 mg PO Q PM
Total serious adverse events,0/3 %0.0,2/5 %40.0
rash,0/3 %0.0,2/5 %40.0

Cisplatin or Carboplatin and Sorafenib in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery(https://clinicaltrials.gov/show/NCT00875615)
 ,Cisplatin or Carboplatin + Sorafenib
 ,Cisplatin : Cisplatin 60 m/m via percutaneous intrahepatic (IA) artery infusion at the investigator's discretion. Treatment is given every 6 weeks for up to 12 Cycles. Sorafenib : Sorafenib 400 mg po bid daily starting on Day 1 ( up to 3 days) continuously. Carboplatin : Carboplatin AUC =6 at the investigator's discretion. Treatment is given every 6 weeks for up to 12 Cycles.
Total serious adverse events,0/10 %0.0

A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver(https://clinicaltrials.gov/show/NCT00906373)
 ,Cohort 1 - 10 mg/kg Cixutumumab,Cohort 2 - 20 mg/kg Cixutumumab
 ,Cixutumumab: 10 mg/kg administered by IV infusion on Day 1 of each 3-week cycle. Sorafenib: 400 mg administered orally twice per day on Days 1 through 21 of each 3-week cycle. Treatment cycles were repeated until there was evidence of PD toxicity or participant withdrawal.,Cixutumumab: 20 mg/kg administered by IV infusions on Day 1 of each 3-week cycle. Sorafenib: 400 mg administered orally twice per day on Days 1 through 21 of each 3-week cycle. Treatment cycles were repeated until there was evidence of PD toxicity or participant withdrawal.
Total serious adverse events,4/6 %66.67,15/41 %36.59
Retinal tear,0/6 %0.0,1/41 %2.44
Abdominal pain,0/6 %0.0,1/41 %2.44
Colitis,0/6 %0.0,1/41 %2.44
Diarrhoea,1/6 %16.67,0/41 %0.0
Gastrointestinal haemorrhage,2/6 %33.33,2/41 %4.88
Pancreatitis,1/6 %16.67,0/41 %0.0
Small intestinal perforation,0/6 %0.0,1/41 %2.44
Asthenia,0/6 %0.0,1/41 %2.44
Chest pain,0/6 %0.0,1/41 %2.44
Pyrexia,0/6 %0.0,2/41 %4.88
Bile duct stenosis,0/6 %0.0,1/41 %2.44
Cholangitis,1/6 %16.67,0/41 %0.0
Hepatic haemorrhage,0/6 %0.0,1/41 %2.44
Peritonitis,0/6 %0.0,1/41 %2.44
Peritonitis bacterial,0/6 %0.0,1/41 %2.44
Septic shock,1/6 %16.67,1/41 %2.44
Infusion related reaction,1/6 %16.67,0/41 %0.0
Spinal compression fracture,0/6 %0.0,1/41 %2.44
Blood bilirubin increased,0/6 %0.0,1/41 %2.44
Lipase increased,0/6 %0.0,1/41 %2.44
Liver function test abnormal,0/6 %0.0,1/41 %2.44
Dehydration,1/6 %16.67,0/41 %0.0
Hyperglycaemia,0/6 %0.0,2/41 %4.88
Neoplasm malignant,1/6 %16.67,2/41 %4.88
Neoplasm progression,0/6 %0.0,1/41 %2.44
Headache,0/6 %0.0,1/41 %2.44
Renal failure acute,1/6 %16.67,1/41 %2.44
Pleural effusion,0/6 %0.0,1/41 %2.44
Respiratory failure,0/6 %0.0,1/41 %2.44

Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer(https://clinicaltrials.gov/show/NCT00917462)
 ,Sorafenib
 ,Sorafenib for patients with metastatic or recurrent esophageal and gastroesophageal junction cancer. Sorafenib administered orally: Sorafenib 400 mg twice daily administered continuously. Patients will continue on treatment until progression of disease. Each cycle consists of 28 days. The cycle start date will coincide with the physician visit date. Because of the potential need for physician visit scheduling to vary (due to both physician and patient issues) to avoid violation of and deviation from the protocol these visits may vary by up to one to fourteen (1-14) days. A study diary will be completed by patients to ensure compliance with the study drug.
Total all-cause mortality,35/35 %100.0
Total serious adverse events,15/35 %42.86
Sinus Tachycardia,1/35 %2.86
Constipation,1/35 %2.86
Dry Mouth,1/35 %2.86
Dysphagia,1/35 %2.86
Fistula - GI Esophagus,2/35 %5.71
Vomiting,1/35 %2.86
Constitutional Symptoms Other,1/35 %2.86
Edema: viscera,1/35 %2.86
Fatigue,2/35 %5.71
Fever,1/35 %2.86
Pain - Other,1/35 %2.86
Rigors/Chills,1/35 %2.86
Pleural Infection,1/35 %2.86
Hyperbilirubinemia,1/35 %2.86
Hypercalcemia,1/35 %2.86
Dehydration,4/35 %11.43
Pain - Chest Wall,1/35 %2.86
Pain in extremity,1/35 %2.86
Secondary malignancy,1/35 %2.86
Motor neuropathy,2/35 %5.71
Confusion,2/35 %5.71
Renal/Genitourinary - Other,1/35 %2.86
Cough,1/35 %2.86
Dyspnea,1/35 %2.86
Pleural effusion,1/35 %2.86
Pneumonitis,1/35 %2.86
Hypertension,1/35 %2.86
Thrombosis/Thrombus/Embolism,1/35 %2.86

Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer(https://clinicaltrials.gov/show/NCT00920816)
 ,Axitinib (First-line Participants),Sorafenib (First-line Participants),Axitinib (Second-line Participants),Sorafenib (Second-line Participants)
 ,Participants with no prior systemic first-line therapy received axitinib (AG-013736) tablet at a starting dose of 5 mg orally twice daily dose adjustment was done based on the tolerability as per investigators discretion. Study medication was administered in cycles of 4 weeks.,Participants with no prior systemic first-line therapy received sorafenib tablet at a starting dose of 400 mg orally twice daily dose adjustment was done based on the tolerability as per investigators discretion. Study medication was administered in cycles of 4 weeks.,Asian participants with prior systemic first-line therapy containing sunitinib or cytokine received axitinib (AG-013736) tablet at a starting dose of 5 mg orally twice daily dose adjustment was done based on the tolerability as per investigators discretion. Study medication was administered in cycles of 4 weeks.,Asian participants with prior systemic first-line therapy containing sunitinib or cytokine received sorafenib tablet at a starting dose of 400 mg orally twice daily dose adjustment was done based on the tolerability as per investigators discretion. Study medication was administered in cycles of 4 weeks.
Total serious adverse events,64/189 %33.86,24/96 %25.0,40/135 %29.63,14/69 %20.29
Anaemia,0/189 %0.0,0/96 %0.0,1/135 %0.74,0/69 %0.0
Thrombocytopenia,1/189 %0.53,0/96 %0.0,0/135 %0.0,0/69 %0.0
Cardiac failure,0/189 %0.0,0/96 %0.0,1/135 %0.74,1/69 %1.45
Myocardial infarction,1/189 %0.53,0/96 %0.0,2/135 %1.48,0/69 %0.0
Myocardial ischaemia,1/189 %0.53,0/96 %0.0,1/135 %0.74,0/69 %0.0
Acute myocardial infarction,0/189 %0.0,2/96 %2.08,0/135 %0.0,0/69 %0.0
Atrial flutter,1/189 %0.53,0/96 %0.0,0/135 %0.0,0/69 %0.0
Cardiac arrest,3/189 %1.59,0/96 %0.0,0/135 %0.0,0/69 %0.0
Cardio-respiratory arrest,2/189 %1.06,0/96 %0.0,0/135 %0.0,0/69 %0.0
Abdominal pain,1/189 %0.53,3/96 %3.12,1/135 %0.74,0/69 %0.0
Anal fistula,1/189 %0.53,0/96 %0.0,0/135 %0.0,1/69 %1.45
Diarrhoea,5/189 %2.65,2/96 %2.08,2/135 %1.48,0/69 %0.0
Gastritis,0/189 %0.0,0/96 %0.0,1/135 %0.74,0/69 %0.0
Intestinal obstruction,0/189 %0.0,0/96 %0.0,0/135 %0.0,1/69 %1.45
Oesophagitis,0/189 %0.0,0/96 %0.0,1/135 %0.74,0/69 %0.0
Upper gastrointestinal haemorrhage,0/189 %0.0,0/96 %0.0,1/135 %0.74,0/69 %0.0
Abdominal distension,1/189 %0.53,0/96 %0.0,0/135 %0.0,0/69 %0.0
Gastric haemorrhage,0/189 %0.0,1/96 %1.04,0/135 %0.0,0/69 %0.0
Gastric ulcer,1/189 %0.53,0/96 %0.0,0/135 %0.0,0/69 %0.0
Gastrointestinal haemorrhage,1/189 %0.53,0/96 %0.0,0/135 %0.0,0/69 %0.0
Impaired gastric emptying,1/189 %0.53,0/96 %0.0,0/135 %0.0,0/69 %0.0
Melaena,1/189 %0.53,0/96 %0.0,0/135 %0.0,0/69 %0.0
Nausea,1/189 %0.53,1/96 %1.04,0/135 %0.0,0/69 %0.0
Oesophageal varices haemorrhage,1/189 %0.53,0/96 %0.0,0/135 %0.0,0/69 %0.0
Peptic ulcer,1/189 %0.53,0/96 %0.0,0/135 %0.0,0/69 %0.0
Periproctitis,0/189 %0.0,1/96 %1.04,0/135 %0.0,0/69 %0.0
Rectal haemorrhage,2/189 %1.06,0/96 %0.0,0/135 %0.0,0/69 %0.0
Retroperitoneal haematoma,1/189 %0.53,0/96 %0.0,0/135 %0.0,0/69 %0.0
Vomiting,1/189 %0.53,0/96 %0.0,0/135 %0.0,0/69 %0.0
Death,1/189 %0.53,0/96 %0.0,2/135 %1.48,0/69 %0.0
Multi-organ failure,0/189 %0.0,0/96 %0.0,0/135 %0.0,1/69 %1.45
Oedema peripheral,0/189 %0.0,0/96 %0.0,1/135 %0.74,0/69 %0.0
Disease progression,20/189 %10.58,7/96 %7.29,12/135 %8.89,5/69 %7.25
Asthenia,2/189 %1.06,0/96 %0.0,0/135 %0.0,0/69 %0.0
Chest pain,2/189 %1.06,1/96 %1.04,0/135 %0.0,0/69 %0.0
General physical health deterioration,1/189 %0.53,0/96 %0.0,0/135 %0.0,0/69 %0.0
Impaired healing,0/189 %0.0,1/96 %1.04,0/135 %0.0,0/69 %0.0
Mucosal inflammation,1/189 %0.53,0/96 %0.0,0/135 %0.0,0/69 %0.0
Pyrexia,1/189 %0.53,0/96 %0.0,0/135 %0.0,0/69 %0.0
Sudden death,1/189 %0.53,0/96 %0.0,0/135 %0.0,0/69 %0.0
Bile duct stone,0/189 %0.0,0/96 %0.0,1/135 %0.74,0/69 %0.0
Cholangitis acute,0/189 %0.0,0/96 %0.0,1/135 %0.74,0/69 %0.0
Cholecystitis acute,1/189 %0.53,0/96 %0.0,2/135 %1.48,0/69 %0.0
Hepatic failure,0/189 %0.0,0/96 %0.0,0/135 %0.0,1/69 %1.45
Bile duct stenosis,0/189 %0.0,0/96 %0.0,1/135 %0.74,0/69 %0.0
Bronchopulmonary aspergillosis,0/189 %0.0,0/96 %0.0,1/135 %0.74,0/69 %0.0
Gastroenteritis,1/189 %0.53,0/96 %0.0,1/135 %0.74,0/69 %0.0
Upper respiratory tract infection,0/189 %0.0,0/96 %0.0,1/135 %0.74,0/69 %0.0
Anal abscess,0/189 %0.0,0/96 %0.0,0/135 %0.0,1/69 %1.45
Pyopneumothorax,0/189 %0.0,0/96 %0.0,1/135 %0.74,0/69 %0.0
Lung infection,1/189 %0.53,0/96 %0.0,2/135 %1.48,0/69 %0.0
Abscess,1/189 %0.53,0/96 %0.0,0/135 %0.0,0/69 %0.0
Cholecystitis infective,1/189 %0.53,0/96 %0.0,0/135 %0.0,0/69 %0.0
Infection,1/189 %0.53,0/96 %0.0,0/135 %0.0,0/69 %0.0
Osteomyelitis,1/189 %0.53,0/96 %0.0,0/135 %0.0,0/69 %0.0
Pericoronitis,1/189 %0.53,0/96 %0.0,0/135 %0.0,0/69 %0.0
Pneumonia,2/189 %1.06,1/96 %1.04,0/135 %0.0,0/69 %0.0
Pyelonephritis,1/189 %0.53,0/96 %0.0,0/135 %0.0,0/69 %0.0
Sepsis,1/189 %0.53,0/96 %0.0,0/135 %0.0,0/69 %0.0
Skin bacterial infection,0/189 %0.0,1/96 %1.04,0/135 %0.0,0/69 %0.0
Tonsillitis,1/189 %0.53,0/96 %0.0,0/135 %0.0,0/69 %0.0
Urinary tract infection,2/189 %1.06,0/96 %0.0,0/135 %0.0,0/69 %0.0
Wound infection,1/189 %0.53,0/96 %0.0,0/135 %0.0,0/69 %0.0
Ankle fracture,0/189 %0.0,1/96 %1.04,0/135 %0.0,0/69 %0.0
Facial bones fracture,0/189 %0.0,1/96 %1.04,0/135 %0.0,0/69 %0.0
Humerus fracture,1/189 %0.53,0/96 %0.0,0/135 %0.0,0/69 %0.0
Multiple injuries,0/189 %0.0,1/96 %1.04,0/135 %0.0,0/69 %0.0
Patella fracture,0/189 %0.0,1/96 %1.04,0/135 %0.0,0/69 %0.0
Upper limb fracture,0/189 %0.0,1/96 %1.04,0/135 %0.0,0/69 %0.0
Wound dehiscence,1/189 %0.53,0/96 %0.0,0/135 %0.0,0/69 %0.0
Haemoglobin decreased,0/189 %0.0,0/96 %0.0,1/135 %0.74,0/69 %0.0
Decreased appetite,1/189 %0.53,0/96 %0.0,0/135 %0.0,1/69 %1.45
Dehydration,1/189 %0.53,1/96 %1.04,0/135 %0.0,0/69 %0.0
Hyperkalaemia,0/189 %0.0,1/96 %1.04,0/135 %0.0,0/69 %0.0
Back pain,1/189 %0.53,0/96 %0.0,1/135 %0.74,0/69 %0.0
Muscular weakness,1/189 %0.53,0/96 %0.0,0/135 %0.0,0/69 %0.0
Pathological fracture,1/189 %0.53,1/96 %1.04,0/135 %0.0,0/69 %0.0
Cardiac neoplasm unspecified,1/189 %0.53,0/96 %0.0,0/135 %0.0,0/69 %0.0
Renal cancer,1/189 %0.53,0/96 %0.0,0/135 %0.0,0/69 %0.0
Renal cancer metastatic,2/189 %1.06,0/96 %0.0,0/135 %0.0,0/69 %0.0
Renal cell carcinoma,0/189 %0.0,1/96 %1.04,0/135 %0.0,0/69 %0.0
Tumour haemorrhage,1/189 %0.53,0/96 %0.0,0/135 %0.0,0/69 %0.0
Brain stem haemorrhage,0/189 %0.0,0/96 %0.0,0/135 %0.0,1/69 %1.45
Cerebral infarction,0/189 %0.0,0/96 %0.0,2/135 %1.48,1/69 %1.45
Cerebrovascular accident,0/189 %0.0,0/96 %0.0,1/135 %0.74,0/69 %0.0
Hemiplegia,0/189 %0.0,0/96 %0.0,0/135 %0.0,1/69 %1.45
Loss of consciousness,0/189 %0.0,0/96 %0.0,1/135 %0.74,0/69 %0.0
Paralysis,0/189 %0.0,0/96 %0.0,0/135 %0.0,1/69 %1.45
Transient ischaemic attack,0/189 %0.0,0/96 %0.0,1/135 %0.74,0/69 %0.0
Cerebral haemorrhage,1/189 %0.53,0/96 %0.0,0/135 %0.0,0/69 %0.0
Cerebral ischaemia,2/189 %1.06,0/96 %0.0,0/135 %0.0,0/69 %0.0
Demyelinating polyneuropathy,0/189 %0.0,1/96 %1.04,0/135 %0.0,0/69 %0.0
Paraparesis,0/189 %0.0,1/96 %1.04,0/135 %0.0,0/69 %0.0
Paraplegia,0/189 %0.0,1/96 %1.04,0/135 %0.0,0/69 %0.0
Spinal cord compression,0/189 %0.0,1/96 %1.04,0/135 %0.0,0/69 %0.0
Syncope,0/189 %0.0,1/96 %1.04,0/135 %0.0,0/69 %0.0
Renal failure,0/189 %0.0,0/96 %0.0,0/135 %0.0,1/69 %1.45
Renal failure acute,0/189 %0.0,0/96 %0.0,2/135 %1.48,0/69 %0.0
Ureteric obstruction,0/189 %0.0,0/96 %0.0,1/135 %0.74,0/69 %0.0
Dysuria,1/189 %0.53,0/96 %0.0,0/135 %0.0,0/69 %0.0
Haematuria,1/189 %0.53,0/96 %0.0,0/135 %0.0,0/69 %0.0
Urinary retention,0/189 %0.0,1/96 %1.04,0/135 %0.0,0/69 %0.0
Acute respiratory failure,0/189 %0.0,0/96 %0.0,1/135 %0.74,0/69 %0.0
Chronic obstructive pulmonary disease,0/189 %0.0,0/96 %0.0,1/135 %0.74,0/69 %0.0
Epistaxis,0/189 %0.0,0/96 %0.0,1/135 %0.74,0/69 %0.0
Pleural effusion,3/189 %1.59,3/96 %3.12,1/135 %0.74,0/69 %0.0
Pneumothorax,0/189 %0.0,0/96 %0.0,1/135 %0.74,0/69 %0.0
Atelectasis,1/189 %0.53,0/96 %0.0,0/135 %0.0,0/69 %0.0
Dyspnoea,1/189 %0.53,0/96 %0.0,0/135 %0.0,0/69 %0.0
Haemoptysis,1/189 %0.53,1/96 %1.04,0/135 %0.0,0/69 %0.0
Pleurisy,0/189 %0.0,1/96 %1.04,0/135 %0.0,0/69 %0.0
Pulmonary oedema,1/189 %0.53,0/96 %0.0,0/135 %0.0,0/69 %0.0
Respiratory distress,1/189 %0.53,0/96 %0.0,0/135 %0.0,0/69 %0.0
Respiratory failure,0/189 %0.0,1/96 %1.04,0/135 %0.0,0/69 %0.0
Rash,0/189 %0.0,0/96 %0.0,0/135 %0.0,1/69 %1.45
Erythema multiforme,0/189 %0.0,1/96 %1.04,0/135 %0.0,0/69 %0.0
Palmar-plantar erythrodysaesthesia syndrome,0/189 %0.0,1/96 %1.04,0/135 %0.0,0/69 %0.0
Hypotension,0/189 %0.0,0/96 %0.0,1/135 %0.74,0/69 %0.0
Orthostatic hypotension,0/189 %0.0,0/96 %0.0,1/135 %0.74,0/69 %0.0
Deep vein thrombosis,0/189 %0.0,0/96 %0.0,1/135 %0.74,0/69 %0.0
Arterial haemorrhage,0/189 %0.0,0/96 %0.0,1/135 %0.74,0/69 %0.0
Aorto-duodenal fistula,1/189 %0.53,0/96 %0.0,0/135 %0.0,0/69 %0.0
Circulatory collapse,0/189 %0.0,1/96 %1.04,0/135 %0.0,0/69 %0.0
Hypertensive crisis,1/189 %0.53,0/96 %0.0,0/135 %0.0,0/69 %0.0

Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006)(https://clinicaltrials.gov/show/NCT00941863)
 ,Sorafenib 100 mg (50-mg Tablet),Sorafenib 200 mg (50-mg Tablet),Sorafenib 400 mg (50-mg Tablet),Sorafenib 400 mg (200-mg Tablet),Sorafenib 400 mg (Expansion)
 ,Dose-escalation cohort 1: Sorafenib (Nexavar BAY43-9006) 100 mg twice daily (50-mg tablet),Dose-escalation cohort 2: Sorafenib (Nexavar BAY43-9006) 200 mg twice daily (50-mg tablet),Dose-escalation cohort 3: Sorafenib (Nexavar BAY43-9006) 400 mg twice daily (50-mg tablet),Dose-escalation cohort 4: Sorafenib (Nexavar BAY43-9006) 400 mg twice daily (200-mg tablet),Dose-expansion cohort: Sorafenib (Nexavar BAY43-9006) 400 mg twice daily (200-mg tablet) expansion
Total serious adverse events,5/7 %71.43,1/3 %33.33,8/12 %66.67,9/17 %52.94,76/119 %63.87
Neutrophils/granulocytes (ANC/AGC),0/7 %0.0,0/3 %0.0,2/12 %16.67,0/17 %0.0,4/119 %3.36
Platelets,0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,6/119 %5.04
Hemoglobin (HGB),0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,3/119 %2.52
Leukocytes (total WBC),0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,1/119 %0.84
Coagulation - other,0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,1/119 %0.84
Supraventricular arrhythmias (SVT/A FIB/FLUTT),0/7 %0.0,0/3 %0.0,0/12 %0.0,1/17 %5.88,4/119 %3.36
Cardiovascular/arrhythmias - other,0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,1/119 %0.84
Thrombosis/embolism,0/7 %0.0,0/3 %0.0,1/12 %8.33,3/17 %17.65,8/119 %6.72
Cardiac - ischemia/infarction,0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,3/119 %2.52
Hypotension,0/7 %0.0,0/3 %0.0,0/12 %0.0,1/17 %5.88,2/119 %1.68
Pericardial effusion/pericarditis,0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,3/119 %2.52
Phlebitis (superficial),0/7 %0.0,0/3 %0.0,0/12 %0.0,1/17 %5.88,1/119 %0.84
Edema,0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,1/119 %0.84
Cardiovascular/general - other,0/7 %0.0,0/3 %0.0,0/12 %0.0,1/17 %5.88,0/119 %0.0
Vomiting,0/7 %0.0,0/3 %0.0,1/12 %8.33,2/17 %11.76,8/119 %6.72
Dehydration,0/7 %0.0,0/3 %0.0,1/12 %8.33,0/17 %0.0,8/119 %6.72
Nausea,0/7 %0.0,0/3 %0.0,1/12 %8.33,1/17 %5.88,6/119 %5.04
Diarrhea patients without colostomy,0/7 %0.0,0/3 %0.0,0/12 %0.0,1/17 %5.88,2/119 %1.68
Gastrointestinal - other,0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,3/119 %2.52
Anorexia,0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,2/119 %1.68
Colitis,0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,1/119 %0.84
Constipation,0/7 %0.0,0/3 %0.0,0/12 %0.0,1/17 %5.88,0/119 %0.0
Dysphagia esophagitis odynophagia (painfull swallowing),0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,1/119 %0.84
Ileus (or neuroconstipation),0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,1/119 %0.84
Pancreatitis,0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,1/119 %0.84
Duodenal ulcer (radiographic or endoscopic),0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,1/119 %0.84
Fever (in absence of neutropenia),0/7 %0.0,0/3 %0.0,0/12 %0.0,1/17 %5.88,7/119 %5.88
Fatigue (Lethargy Malaise Asthenia),0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,5/119 %4.2
Constitutional symptoms - other,0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,3/119 %2.52
Pain - other,0/7 %0.0,0/3 %0.0,0/12 %0.0,1/17 %5.88,10/119 %8.4
Abdominal pain or cramping,1/7 %14.29,0/3 %0.0,1/12 %8.33,1/17 %5.88,4/119 %3.36
Chest pain (non-cardiac and nonpleuritic),1/7 %14.29,0/3 %0.0,0/12 %0.0,0/17 %0.0,3/119 %2.52
Headache,1/7 %14.29,0/3 %0.0,1/12 %8.33,0/17 %0.0,2/119 %1.68
Tumor pain (onset/exacerb. tumor pain),0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,1/119 %0.84
SGPT (ALT),0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,1/119 %0.84
SGOT (AST),0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,1/119 %0.84
Allergic reaction/hypersensitivity,0/7 %0.0,0/3 %0.0,0/12 %0.0,1/17 %5.88,0/119 %0.0
Febrile neutropenia (fever w/ unknow origin),0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,12/119 %10.08
Infection without neutropenia,0/7 %0.0,0/3 %0.0,0/12 %0.0,1/17 %5.88,5/119 %4.2
Infection (doc clinic or microbio) w/ GR 3 or 4 Neu,0/7 %0.0,0/3 %0.0,1/12 %8.33,0/17 %0.0,3/119 %2.52
Infection with unknown ANC,0/7 %0.0,0/3 %0.0,0/12 %0.0,1/17 %5.88,2/119 %1.68
Infection/febrile neutropenia - other,0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,2/119 %1.68
Hyperglycemia,0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,2/119 %1.68
Hypokalemia,0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,2/119 %1.68
Hypomagnesemia,0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,2/119 %1.68
Amylase,0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,1/119 %0.84
Hypercalcemia,0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,1/119 %0.84
Hypoglycemia,0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,1/119 %0.84
Lipase,0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,1/119 %0.84
Musculoskeletal - other,0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,3/119 %2.52
Neurology - other,0/7 %0.0,0/3 %0.0,1/12 %8.33,1/17 %5.88,9/119 %7.56
Syncope (fainting),0/7 %0.0,0/3 %0.0,0/12 %0.0,1/17 %5.88,3/119 %2.52
CNS cerebrovascular ischemia,0/7 %0.0,1/3 %33.33,1/12 %8.33,0/17 %0.0,1/119 %0.84
Confusion,0/7 %0.0,0/3 %0.0,0/12 %0.0,1/17 %5.88,1/119 %0.84
Seizure(s),0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,2/119 %1.68
Depressed level of consciousness,0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,2/119 %1.68
Ataxia (incoordination),0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,1/119 %0.84
Speech impairment (dysphasia or aphasia),1/7 %14.29,0/3 %0.0,0/12 %0.0,0/17 %0.0,0/119 %0.0
Neuropathy - motor,1/7 %14.29,0/3 %0.0,0/12 %0.0,0/17 %0.0,0/119 %0.0
Neuropathy - sensory,0/7 %0.0,0/3 %0.0,1/12 %8.33,0/17 %0.0,0/119 %0.0
Renal/genitourinary - other,0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,4/119 %3.36
Creatinine,0/7 %0.0,0/3 %0.0,1/12 %8.33,1/17 %5.88,0/119 %0.0
Ureteral obstruction,0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,1/119 %0.84
Pleural effusion (non-malignant),0/7 %0.0,0/3 %0.0,0/12 %0.0,1/17 %5.88,7/119 %5.88
Dyspnea (shortness of breath),0/7 %0.0,0/3 %0.0,2/12 %16.67,0/17 %0.0,3/119 %2.52
Pulmonary - other,1/7 %14.29,0/3 %0.0,0/12 %0.0,0/17 %0.0,2/119 %1.68
Pneumonitis/pulmonary infiltrates,0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,1/119 %0.84
Dermatology/skin - other,1/7 %14.29,0/3 %0.0,1/12 %8.33,0/17 %0.0,10/119 %8.4
Wound - infectious,0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,1/119 %0.84
Wound - non-infectious,0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,1/119 %0.84
Rash/desquamation,1/7 %14.29,0/3 %0.0,0/12 %0.0,0/17 %0.0,0/119 %0.0
CNS Hemorrhage/belleding,0/7 %0.0,0/3 %0.0,2/12 %16.67,0/17 %0.0,1/119 %0.84
Hemorrhage - other,0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,3/119 %2.52
Melena/GI bleeding,0/7 %0.0,0/3 %0.0,0/12 %0.0,1/17 %5.88,1/119 %0.84
Hemoptysis,0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,1/119 %0.84
Rectal bleeding/hematochezia,0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,1/119 %0.84
Hemorrhage/bleeding with grade 3 or 4 thrombo,0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,1/119 %0.84
Hematuria (in absence of vaginal bleeding),0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,1/119 %0.84
Vaginal bleeding,0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,1/119 %0.84

Depocyt With Sorafenib in Neoplastic Meningitis(https://clinicaltrials.gov/show/NCT00964743)
 ,Intrathecal DepoCyt and Oral Sorafenib
 ,This is a single arm pilot study. Investigators planned to enroll approximately 10 patients to receive concurrent intrathecal DepoCyt and oral Sorafenib. DepoCyt: through a reservoir every 2 weeks for 5 doses then every 4 weeks for an additional 5 doses (a total of 10 DepoCyt treatments). Oral Sorafenib: at 400 mg twice a day throughout the treatment course until disease progression or death.
Total serious adverse events,2/2 %100.0
Death not associated with CTCAE term - Death not otherwise specified (NOS),1/2 %50.0
Death not associated with CTCAE term - Disease progression not otherwise specified (NOS),1/2 %50.0

A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients(https://clinicaltrials.gov/show/NCT00987935)
 ,Phase I Group I Nintedanib 100 mg Bid,Phase I Group I Nintedanib 150 mg Bid,Phase I Group I Nintedanib 200 mg Bid,Phase I Group II Nintedanib 50 mg Bid,Phase I Group II Nintedanib 100 mg Bid,Phase I Group II Nintedanib 150 mg Bid,Phase I Group II Nintedanib 200 mg Bid,Phase II Nintedanib 200 mg Bid,Phase II Sorafenib 400 mg Bid
 ,Oral administration of Nintedanib (BIBF 1120) 100 mg soft gelatine capsules twice daily (bid) for the Group I patients during Phase I,Oral administration of Nintedanib (BIBF 1120) 150 mg soft gelatine capsules twice daily (bid) for the Group I patients during Phase I,Oral administration of Nintedanib (BIBF 1120) 200 mg soft gelatine capsules twice daily (bid) for the Group I patients during Phase I,Oral administration of Nintedanib (BIBF 1120) 50 mg soft gelatine capsules twice daily (bid) for the Group II patients during Phase I,Oral administration of Nintedanib (BIBF 1120) 100 mg soft gelatine capsules twice daily (bid) for the Group II patients during Phase I,Oral administration of Nintedanib (BIBF 1120) 150 mg soft gelatine capsules twice daily (bid) for the Group II patients during Phase I,Oral administration of Nintedanib (BIBF 1120) 200 mg soft gelatine capsules twice daily (bid) for the Group II patients during Phase I,Oral administration of Nintedanib (BIBF 1120) 200 mg soft gelatine capsules twice daily (bid) during Phase II,Oral administration of Sorafenib 400 mg film coated tablets twice daily (bid) during Phase II
Total serious adverse events,2/4 %50.0,1/3 %33.33,0/3 %0.0,3/3 %100.0,4/7 %57.14,1/3 %33.33,10/16 %62.5,29/63 %46.03,18/32 %56.25
Haemorrhagic anaemia,0/4 %0.0,0/3 %0.0,0/3 %0.0,1/3 %33.33,0/7 %0.0,0/3 %0.0,0/16 %0.0,0/63 %0.0,0/32 %0.0
Thrombocytopenia,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,1/63 %1.59,0/32 %0.0
Acute coronary syndrome,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,0/63 %0.0,1/32 %3.12
Acute myocardial infarction,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,1/63 %1.59,0/32 %0.0
Abdominal distension,0/4 %0.0,1/3 %33.33,0/3 %0.0,0/3 %0.0,1/7 %14.29,0/3 %0.0,0/16 %0.0,0/63 %0.0,1/32 %3.12
Abdominal pain,0/4 %0.0,0/3 %0.0,0/3 %0.0,1/3 %33.33,0/7 %0.0,0/3 %0.0,1/16 %6.25,1/63 %1.59,1/32 %3.12
Anal fistula,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,0/63 %0.0,1/32 %3.12
Ascites,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,2/63 %3.17,0/32 %0.0
Diarrhoea,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,2/63 %3.17,0/32 %0.0
Food poisoning,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,1/63 %1.59,0/32 %0.0
Gastric haemorrhage,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,1/16 %6.25,0/63 %0.0,0/32 %0.0
Gastric perforation,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,1/16 %6.25,0/63 %0.0,0/32 %0.0
Gastric ulcer,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,1/16 %6.25,1/63 %1.59,0/32 %0.0
Gastroduodenitis,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,1/63 %1.59,0/32 %0.0
Gastrointestinal haemorrhage,0/4 %0.0,0/3 %0.0,0/3 %0.0,1/3 %33.33,0/7 %0.0,0/3 %0.0,0/16 %0.0,1/63 %1.59,0/32 %0.0
Haematochezia,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,0/63 %0.0,1/32 %3.12
Haemorrhoids,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,1/63 %1.59,0/32 %0.0
Nausea,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,0/63 %0.0,1/32 %3.12
Oesophageal varices haemorrhage,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,1/63 %1.59,0/32 %0.0
Pancreatitis acute,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,0/63 %0.0,1/32 %3.12
Upper gastrointestinal haemorrhage,0/4 %0.0,0/3 %0.0,0/3 %0.0,1/3 %33.33,0/7 %0.0,1/3 %33.33,0/16 %0.0,3/63 %4.76,1/32 %3.12
Vomiting,1/4 %25.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,1/7 %14.29,0/3 %0.0,1/16 %6.25,0/63 %0.0,0/32 %0.0
Asthenia,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,1/7 %14.29,0/3 %0.0,0/16 %0.0,0/63 %0.0,2/32 %6.25
Chest pain,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,1/63 %1.59,0/32 %0.0
Disease progression,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,1/7 %14.29,0/3 %0.0,0/16 %0.0,0/63 %0.0,0/32 %0.0
Fatigue,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,1/63 %1.59,0/32 %0.0
Malaise,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,1/16 %6.25,0/63 %0.0,0/32 %0.0
Pyrexia,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,1/7 %14.29,0/3 %0.0,0/16 %0.0,4/63 %6.35,3/32 %9.38
Cholecystitis acute,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,1/63 %1.59,0/32 %0.0
Hepatic failure,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,1/63 %1.59,2/32 %6.25
Hepatic function abnormal,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,2/16 %12.5,0/63 %0.0,2/32 %6.25
Hepatitis,0/4 %0.0,0/3 %0.0,0/3 %0.0,1/3 %33.33,0/7 %0.0,0/3 %0.0,0/16 %0.0,0/63 %0.0,0/32 %0.0
Hyperbilirubinaemia,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,1/63 %1.59,0/32 %0.0
Biliary tract infection,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,1/63 %1.59,0/32 %0.0
Cellulitis,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,1/63 %1.59,0/32 %0.0
Peritonitis bacterial,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,1/63 %1.59,0/32 %0.0
Pneumonia,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,0/63 %0.0,1/32 %3.12
Sepsis,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,2/63 %3.17,0/32 %0.0
Septic shock,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,1/16 %6.25,0/63 %0.0,0/32 %0.0
Upper respiratory tract infection,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,1/16 %6.25,0/63 %0.0,0/32 %0.0
Eye injury,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,1/63 %1.59,0/32 %0.0
Aspartate aminotransferase increased,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,1/63 %1.59,1/32 %3.12
Blood bilirubin increased,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,2/16 %12.5,1/63 %1.59,1/32 %3.12
Blood creatinine increased,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,0/63 %0.0,1/32 %3.12
Blood urea increased,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,1/63 %1.59,0/32 %0.0
Decreased appetite,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,1/7 %14.29,0/3 %0.0,0/16 %0.0,0/63 %0.0,0/32 %0.0
Hyperkalaemia,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,1/63 %1.59,0/32 %0.0
Hypoglycaemia,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,2/63 %3.17,0/32 %0.0
Hyponatraemia,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,1/63 %1.59,0/32 %0.0
Back pain,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,1/16 %6.25,0/63 %0.0,0/32 %0.0
Musculoskeletal chest pain,0/4 %0.0,0/3 %0.0,0/3 %0.0,1/3 %33.33,0/7 %0.0,0/3 %0.0,0/16 %0.0,0/63 %0.0,0/32 %0.0
Pathological fracture,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,1/16 %6.25,1/63 %1.59,0/32 %0.0
Hepatic cancer metastatic,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,1/16 %6.25,0/63 %0.0,0/32 %0.0
Hepatocellular carcinoma,1/4 %25.0,0/3 %0.0,0/3 %0.0,1/3 %33.33,2/7 %28.57,0/3 %0.0,1/16 %6.25,0/63 %0.0,0/32 %0.0
Malignant neoplasm progression,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,1/16 %6.25,6/63 %9.52,2/32 %6.25
Metastases to central nervous system,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,1/63 %1.59,1/32 %3.12
Metastatic pain,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,1/7 %14.29,0/3 %0.0,0/16 %0.0,0/63 %0.0,0/32 %0.0
Nasal sinus cancer,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,1/63 %1.59,0/32 %0.0
Tumour associated fever,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,1/63 %1.59,0/32 %0.0
Tumour haemorrhage,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,0/63 %0.0,1/32 %3.12
Tumour rupture,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,1/7 %14.29,0/3 %0.0,0/16 %0.0,1/63 %1.59,0/32 %0.0
Cognitive disorder,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,1/63 %1.59,0/32 %0.0
Headache,1/4 %25.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,0/63 %0.0,0/32 %0.0
Hemiparesis,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,1/63 %1.59,0/32 %0.0
Hepatic encephalopathy,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,0/63 %0.0,1/32 %3.12
Sciatica,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,1/63 %1.59,0/32 %0.0
Anxiety,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,1/63 %1.59,0/32 %0.0
Renal failure,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,1/63 %1.59,0/32 %0.0
Renal failure chronic,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,1/63 %1.59,0/32 %0.0
Dyspnoea,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,2/63 %3.17,0/32 %0.0
Pleural effusion,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,1/63 %1.59,0/32 %0.0
Pneumonia aspiration,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,1/63 %1.59,0/32 %0.0
Pneumonitis,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,1/16 %6.25,0/63 %0.0,0/32 %0.0
Pulmonary embolism,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,0/63 %0.0,1/32 %3.12
Respiratory failure,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,1/63 %1.59,0/32 %0.0
Visceral arterial ischaemia,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,1/63 %1.59,0/32 %0.0

Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer(https://clinicaltrials.gov/show/NCT01015833)
 ,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),Arm II (Sorafenib Tosylate)
 ,Patients receive 60 mg/m2 doxorubicin hydrochloride IV on day 1 and 400 mg sorafenib tosylate PO QD or BID on days 1-21. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After 6 courses patients may continue to receive sorafenib tosylate PO QD or BID in the absence of disease progression or unacceptable toxicity.,Patients receive 400 mg sorafenib tosylate PO QD or BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Total all-cause mortality,12/167 %7.19,16/171 %9.36
Total serious adverse events,71/167 %42.51,57/171 %33.33
Anemia,9/167 %5.39,4/171 %2.34
Febrile neutropenia,7/167 %4.19,0/171 %0.0
Leukocytosis,1/167 %0.6,0/171 %0.0
Spleen disorder,0/167 %0.0,1/171 %0.58
Thrombotic thrombocytopenic purpura,0/167 %0.0,1/171 %0.58
Atrial fibrillation,3/167 %1.8,1/171 %0.58
Cardiac disorder,1/167 %0.6,0/171 %0.0
Chest pain - cardiac,0/167 %0.0,1/171 %0.58
Left ventricular systolic dysfunction,3/167 %1.8,0/171 %0.0
Myocardial infarction,1/167 %0.6,0/171 %0.0
Palpitations,1/167 %0.6,0/171 %0.0
Sinus bradycardia,0/167 %0.0,1/171 %0.58
Sinus tachycardia,1/167 %0.6,1/171 %0.58
Hypothyroidism,1/167 %0.6,1/171 %0.58
Conjunctivitis,1/167 %0.6,0/171 %0.0
Abdominal distension,0/167 %0.0,1/171 %0.58
Abdominal pain,22/167 %13.17,28/171 %16.37
Anal mucositis,1/167 %0.6,0/171 %0.0
Ascites,3/167 %1.8,2/171 %1.17
Colitis,2/167 %1.2,0/171 %0.0
Constipation,1/167 %0.6,0/171 %0.0
Diarrhea,27/167 %16.17,13/171 %7.6
Dyspepsia,1/167 %0.6,0/171 %0.0
Dysphagia,3/167 %1.8,0/171 %0.0
Esophageal ulcer,1/167 %0.6,0/171 %0.0
Esophageal varices hemorrhage,1/167 %0.6,4/171 %2.34
Esophagitis,2/167 %1.2,0/171 %0.0
Gastric hemorrhage,0/167 %0.0,2/171 %1.17
Gastrointestinal disorders - Other specify,0/167 %0.0,1/171 %0.58
Hemorrhoidal hemorrhage,0/167 %0.0,1/171 %0.58
Lower gastrointestinal hemorrhage,1/167 %0.6,0/171 %0.0
Mucositis oral,17/167 %10.18,4/171 %2.34
Nausea,34/167 %20.36,24/171 %14.04
Pancreatitis,2/167 %1.2,0/171 %0.0
Rectal hemorrhage,1/167 %0.6,0/171 %0.0
Rectal mucositis,1/167 %0.6,0/171 %0.0
Upper gastrointestinal hemorrhage,1/167 %0.6,3/171 %1.75
Vomiting,4/167 %2.4,6/171 %3.51
Death NOS,4/167 %2.4,7/171 %4.09
Edema limbs,1/167 %0.6,0/171 %0.0
Edema trunk,0/167 %0.0,1/171 %0.58
Fatigue,49/167 %29.34,32/171 %18.71
Fever,2/167 %1.2,1/171 %0.58
Localized edema,0/167 %0.0,1/171 %0.58
Multi-organ failure,1/167 %0.6,0/171 %0.0
Non-cardiac chest pain,0/167 %0.0,2/171 %1.17
Pain,1/167 %0.6,0/171 %0.0
Sudden death NOS,1/167 %0.6,2/171 %1.17
Cholecystitis,0/167 %0.0,1/171 %0.58
Gallbladder obstruction,1/167 %0.6,1/171 %0.58
Hepatic failure,3/167 %1.8,1/171 %0.58
Hepatic hemorrhage,0/167 %0.0,2/171 %1.17
Hepatobiliary disorders - Other specify,0/167 %0.0,1/171 %0.58
Anaphylaxis,1/167 %0.6,0/171 %0.0
Abdominal infection,0/167 %0.0,1/171 %0.58
Bone infection,1/167 %0.6,1/171 %0.58
Infections and infestations - Other specify,3/167 %1.8,1/171 %0.58
Lung infection,6/167 %3.59,0/171 %0.0
Peritoneal infection,1/167 %0.6,1/171 %0.58
Rash pustular,1/167 %0.6,0/171 %0.0
Sepsis,5/167 %2.99,2/171 %1.17
Skin infection,2/167 %1.2,2/171 %1.17
Urinary tract infection,1/167 %0.6,0/171 %0.0
Wound infection,0/167 %0.0,1/171 %0.58
Fall,0/167 %0.0,2/171 %1.17
Fracture,0/167 %0.0,1/171 %0.58
Wound complication,1/167 %0.6,0/171 %0.0
Activated partial thromboplastin time prolonged,0/167 %0.0,1/171 %0.58
Alanine aminotransferase increased,3/167 %1.8,3/171 %1.75
Alkaline phosphatase increased,3/167 %1.8,4/171 %2.34
Aspartate aminotransferase increased,4/167 %2.4,6/171 %3.51
Blood bilirubin increased,8/167 %4.79,7/171 %4.09
Creatinine increased,3/167 %1.8,0/171 %0.0
Ejection fraction decreased,3/167 %1.8,1/171 %0.58
Haptoglobin decreased,1/167 %0.6,0/171 %0.0
INR increased,2/167 %1.2,1/171 %0.58
Leukocyte count decreased,1/167 %0.6,0/171 %0.0
Lipase increased,1/167 %0.6,0/171 %0.0
Lymphocyte count decreased,6/167 %3.59,2/171 %1.17
Neutrophil count decreased,31/167 %18.56,0/171 %0.0
Platelet count decreased,35/167 %20.96,20/171 %11.7
Weight loss,2/167 %1.2,1/171 %0.58
White blood cell decreased,10/167 %5.99,0/171 %0.0
Anorexia,5/167 %2.99,4/171 %2.34
Dehydration,14/167 %8.38,5/171 %2.92
Hyperglycemia,2/167 %1.2,2/171 %1.17
Hyperkalemia,4/167 %2.4,1/171 %0.58
Hypernatremia,0/167 %0.0,1/171 %0.58
Hypoalbuminemia,4/167 %2.4,1/171 %0.58
Hypokalemia,2/167 %1.2,0/171 %0.0
Hypomagnesemia,0/167 %0.0,1/171 %0.58
Hyponatremia,10/167 %5.99,4/171 %2.34
Hypophosphatemia,4/167 %2.4,1/171 %0.58
Metabolism and nutrition disorders - Other specify,0/167 %0.0,1/171 %0.58
Serum phosphate decreased,1/167 %0.6,0/171 %0.0
Back pain,1/167 %0.6,1/171 %0.58
Bone pain,0/167 %0.0,1/171 %0.58
Generalized muscle weakness,1/167 %0.6,1/171 %0.58
Myalgia,1/167 %0.6,0/171 %0.0
Neoplasms benign malignant and unspecified (incl cysts and polyps) - Other specify,1/167 %0.6,3/171 %1.75
Treatment related secondary malignancy,2/167 %1.2,0/171 %0.0
Amnesia,1/167 %0.6,0/171 %0.0
Headache,0/167 %0.0,1/171 %0.58
Intracranial hemorrhage,0/167 %0.0,1/171 %0.58
Nervous system disorders - Other specify,1/167 %0.6,0/171 %0.0
Seizure,0/167 %0.0,1/171 %0.58
Syncope vasovagal,1/167 %0.6,0/171 %0.0
Anxiety,1/167 %0.6,1/171 %0.58
Confusion,1/167 %0.6,2/171 %1.17
Acute kidney injury,1/167 %0.6,0/171 %0.0
Hematuria,2/167 %1.2,1/171 %0.58
Urogenital disorder,1/167 %0.6,0/171 %0.0
Dyspnea,4/167 %2.4,4/171 %2.34
Epistaxis,1/167 %0.6,3/171 %1.75
Hypoxia,1/167 %0.6,1/171 %0.58
Pulmonary edema,0/167 %0.0,1/171 %0.58
Sore throat,1/167 %0.6,0/171 %0.0
Alopecia,2/167 %1.2,0/171 %0.0
Erythema multiforme,1/167 %0.6,0/171 %0.0
Palmar-plantar erythrodysesthesia syndrome,13/167 %7.78,10/171 %5.85
Pruritus,1/167 %0.6,0/171 %0.0
Rash maculo-papular,1/167 %0.6,2/171 %1.17
Scalp pain,0/167 %0.0,1/171 %0.58
Skin ulceration,3/167 %1.8,3/171 %1.75
Stevens-Johnson syndrome,1/167 %0.6,0/171 %0.0
Hypertension,21/167 %12.57,16/171 %9.36
Hypotension,2/167 %1.2,1/171 %0.58
Thromboembolic event,0/167 %0.0,3/171 %1.75

Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma(https://clinicaltrials.gov/show/NCT01032850)
 ,Arm 1: Sorafenib & Capecitabine
 ,Intervention: Sorafenib & Capecitabine: Sorafenib twice a day by mouth (400 mg) Capecitabine twice a day by mouth (850 mg) Sorafenib & Capecitabine: Intervention: Sorafenib twice a day by mouth (400 mg) Capecitabine twice a day by mouth (850 mg). One cycle of treatment will consist of capecitabine on days 1-7 and 15-22 while sorafenib will be given daily continuously. Cycles will be repeated every 28 days.
Total serious adverse events,2/13 %15.38
Nausea,1/13 %7.69
Vomiting,1/13 %7.69
Fatigue,1/13 %7.69
Fever,1/13 %7.69
Death,1/13 %7.69
Hyponatremia (Low sodium levels),1/13 %7.69
Anorexia (lack of appetite),1/13 %7.69
Dehydration,1/13 %7.69
Weakness,1/13 %7.69

Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced  Unresectable  or Metastatic Gallbladder Cancer or Cholangiocarcinoma(https://clinicaltrials.gov/show/NCT01093222)
 ,Sorafenib and Erlotinib
 ,Patients receive sorafenib tosylate 400 mg PO twice daily and erlotinib hydrochloride 100 mg PO once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
Total serious adverse events,17/34 %50.0
Cardiac arrest,1/34 %2.94
Abdominal pain,4/34 %11.76
Ascites,1/34 %2.94
Diarrhea,1/34 %2.94
Duodenal ulcer,1/34 %2.94
Gastric perforation,1/34 %2.94
Gastritis,1/34 %2.94
Gastrointestinal disorders - Other specify,1/34 %2.94
Nausea,3/34 %8.82
Small intestinal obstruction,1/34 %2.94
Vomiting,2/34 %5.88
Death NOS,6/34 %17.65
Multi-organ failure,1/34 %2.94
Bile duct stenosis,1/34 %2.94
Gallbladder obstruction,1/34 %2.94
Hepatic necrosis,1/34 %2.94
Hepatobiliary disorders - Other specify,1/34 %2.94
Allergic reaction,1/34 %2.94
Device related infection,1/34 %2.94
Hepatic infection,1/34 %2.94
Lung infection,1/34 %2.94
Sepsis,3/34 %8.82
Alanine aminotransferase increased,1/34 %2.94
Alkaline phosphatase increased,2/34 %5.88
Aspartate aminotransferase increased,2/34 %5.88
Blood bilirubin increased,4/34 %11.76
Dehydration,2/34 %5.88
Hypoalbuminemia,2/34 %5.88
Generalized muscle weakness,1/34 %2.94
Neoplasms benign malignant and unspecified - Other,1/34 %2.94
Dizziness,1/34 %2.94
Lethargy,1/34 %2.94
Dyspnea,1/34 %2.94
Erythema multiforme,1/34 %2.94
Hypertension,1/34 %2.94

Velcade and Sorafenib in Unresected or Metastatic Renal Cell Carcinoma(https://clinicaltrials.gov/show/NCT01100242)
 ,VELCADE and Sorafenib
 ,VELCADE (bortezomib) 1mg/m2 intravenously on days 148 & 11 and sorafenib at 200 mg orally twice per day. One full course is comprised of 21 days.
Total serious adverse events,6/17 %35.29
Chest pain,1/17 %5.88
Pain - other,1/17 %5.88
Pancreatitis,1/17 %5.88
Infection - Other,1/17 %5.88
Seizure,1/17 %5.88
Urinary retention,1/17 %5.88
Dyspnea (Shortness of breath),1/17 %5.88

A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib(https://clinicaltrials.gov/show/NCT01140347)
 ,Ramucirumab (IMC-1121B) + BSC,Placebo + BSC
 ,Ramucirumab 8 mg/kg IV infusion every 2 weeks. BSC: Palliative and supportive care for disease-related symptoms and toxicity associated with treatment as deemed medically necessary and appropriate in the opinion of the investigator.,Placebo: 8 mg/kg IV infusion every 2 weeks. BSC: Palliative and supportive care for disease-related symptoms and toxicity associated with treatment as deemed medically necessary and appropriate in the opinion of the investigator.
Total serious adverse events,124/277 %44.77,92/276 %33.33
Anaemia,0/277 %0.0,2/276 %0.72
Disseminated intravascular coagulation,1/277 %0.36,0/276 %0.0
Neutropenia,1/277 %0.36,0/276 %0.0
Thrombocytopenia,1/277 %0.36,0/276 %0.0
Cardiac failure,0/277 %0.0,1/276 %0.36
Pericardial effusion,1/277 %0.36,0/276 %0.0
Supraventricular tachycardia,1/277 %0.36,0/276 %0.0
Retinal detachment,1/277 %0.36,0/276 %0.0
Abdominal distension,1/277 %0.36,1/276 %0.36
Abdominal pain,6/277 %2.17,9/276 %3.26
Abdominal pain upper,0/277 %0.0,1/276 %0.36
Ascites,8/277 %2.89,3/276 %1.09
Colitis,0/277 %0.0,1/276 %0.36
Diarrhoea,1/277 %0.36,0/276 %0.0
Duodenal ulcer,1/277 %0.36,0/276 %0.0
Dysphagia,1/277 %0.36,0/276 %0.0
Food poisoning,1/277 %0.36,0/276 %0.0
Gastric antral vascular ectasia,1/277 %0.36,0/276 %0.0
Gastric haemorrhage,1/277 %0.36,1/276 %0.36
Gastric varices haemorrhage,1/277 %0.36,0/276 %0.0
Gastroduodenitis,1/277 %0.36,0/276 %0.0
Gastrointestinal haemorrhage,7/277 %2.53,0/276 %0.0
Haemorrhoids,0/277 %0.0,1/276 %0.36
Ileus,0/277 %0.0,1/276 %0.36
Inguinal hernia,0/277 %0.0,1/276 %0.36
Intestinal obstruction,0/277 %0.0,1/276 %0.36
Irritable bowel syndrome,1/277 %0.36,0/276 %0.0
Large intestine perforation,1/277 %0.36,0/276 %0.0
Melaena,0/277 %0.0,1/276 %0.36
Nausea,2/277 %0.72,1/276 %0.36
Oesophageal haemorrhage,1/277 %0.36,1/276 %0.36
Oesophageal varices haemorrhage,4/277 %1.44,10/276 %3.62
Pancreatitis,0/277 %0.0,1/276 %0.36
Peritoneal haemorrhage,1/277 %0.36,0/276 %0.0
Small intestinal obstruction,0/277 %0.0,1/276 %0.36
Umbilical hernia,1/277 %0.36,0/276 %0.0
Upper gastrointestinal haemorrhage,2/277 %0.72,1/276 %0.36
Varices oesophageal,1/277 %0.36,0/276 %0.0
Vomiting,1/277 %0.36,1/276 %0.36
Asthenia,4/277 %1.44,1/276 %0.36
Chills,1/277 %0.36,0/276 %0.0
Death,1/277 %0.36,0/276 %0.0
Extravasation,0/277 %0.0,1/276 %0.36
Fatigue,1/277 %0.36,2/276 %0.72
General physical health deterioration,9/277 %3.25,3/276 %1.09
Generalised oedema,1/277 %0.36,0/276 %0.0
Hernia obstructive,1/277 %0.36,0/276 %0.0
Hyperthermia,1/277 %0.36,0/276 %0.0
Malaise,0/277 %0.0,1/276 %0.36
Multi-organ failure,2/277 %0.72,1/276 %0.36
Non-cardiac chest pain,1/277 %0.36,1/276 %0.36
Oedema,0/277 %0.0,2/276 %0.72
Oedema peripheral,2/277 %0.72,1/276 %0.36
Pyrexia,7/277 %2.53,3/276 %1.09
Sudden death,1/277 %0.36,0/276 %0.0
Acute hepatic failure,1/277 %0.36,0/276 %0.0
Bile duct stone,1/277 %0.36,1/276 %0.36
Cholangitis,5/277 %1.81,1/276 %0.36
Cholangitis acute,1/277 %0.36,1/276 %0.36
Hepatic cirrhosis,1/277 %0.36,1/276 %0.36
Hepatic failure,6/277 %2.17,5/276 %1.81
Hepatic function abnormal,0/277 %0.0,1/276 %0.36
Hepatorenal syndrome,4/277 %1.44,1/276 %0.36
Hyperbilirubinaemia,1/277 %0.36,3/276 %1.09
Hypertransaminasaemia,1/277 %0.36,0/276 %0.0
Jaundice,1/277 %0.36,1/276 %0.36
Jaundice cholestatic,0/277 %0.0,2/276 %0.72
Liver disorder,1/277 %0.36,0/276 %0.0
Portal vein thrombosis,1/277 %0.36,1/276 %0.36
Anaphylactic reaction,2/277 %0.72,0/276 %0.0
Anal abscess,2/277 %0.72,0/276 %0.0
Bacteraemia,1/277 %0.36,0/276 %0.0
Campylobacter infection,1/277 %0.36,0/276 %0.0
Candida sepsis,1/277 %0.36,0/276 %0.0
Device related infection,1/277 %0.36,0/276 %0.0
Device related sepsis,1/277 %0.36,0/276 %0.0
Infection,1/277 %0.36,0/276 %0.0
Influenza,0/277 %0.0,1/276 %0.36
Liver abscess,1/277 %0.36,0/276 %0.0
Lobar pneumonia,1/277 %0.36,0/276 %0.0
Lung infection,2/277 %0.72,0/276 %0.0
Peritonitis,1/277 %0.36,1/276 %0.36
Peritonitis bacterial,1/277 %0.36,0/276 %0.0
Pneumonia,3/277 %1.08,3/276 %1.09
Pneumonia bacterial,1/277 %0.36,0/276 %0.0
Pneumonia klebsiella,0/277 %0.0,1/276 %0.36
Pulmonary sepsis,1/277 %0.36,0/276 %0.0
Sepsis,3/277 %1.08,2/276 %0.72
Septic shock,0/277 %0.0,1/276 %0.36
Upper respiratory tract infection,1/277 %0.36,1/276 %0.36
Urinary tract infection,3/277 %1.08,0/276 %0.0
Fall,0/277 %0.0,1/276 %0.36
Femur fracture,0/277 %0.0,1/276 %0.36
Infusion related reaction,1/277 %0.36,0/276 %0.0
Aspartate aminotransferase increased,0/277 %0.0,1/276 %0.36
Blood bilirubin increased,2/277 %0.72,0/276 %0.0
Blood creatinine increased,1/277 %0.36,0/276 %0.0
General physical condition abnormal,1/277 %0.36,0/276 %0.0
Liver function test abnormal,1/277 %0.36,0/276 %0.0
Cachexia,1/277 %0.36,1/276 %0.36
Decreased appetite,3/277 %1.08,0/276 %0.0
Dehydration,2/277 %0.72,1/276 %0.36
Diabetes mellitus,1/277 %0.36,0/276 %0.0
Hypercalcaemia,1/277 %0.36,1/276 %0.36
Hyperglycaemia,0/277 %0.0,2/276 %0.72
Hyperkalaemia,1/277 %0.36,0/276 %0.0
Hypertriglyceridaemia,1/277 %0.36,0/276 %0.0
Hypocalcaemia,1/277 %0.36,0/276 %0.0
Hypoglycaemia,0/277 %0.0,1/276 %0.36
Hyponatraemia,1/277 %0.36,1/276 %0.36
Arthritis,1/277 %0.36,0/276 %0.0
Back pain,0/277 %0.0,4/276 %1.45
Flank pain,0/277 %0.0,1/276 %0.36
Musculoskeletal chest pain,0/277 %0.0,1/276 %0.36
Neck pain,1/277 %0.36,0/276 %0.0
Pathological fracture,1/277 %0.36,0/276 %0.0
Spinal pain,0/277 %0.0,1/276 %0.36
Liver carcinoma ruptured,2/277 %0.72,2/276 %0.72
Malignant neoplasm progression,23/277 %8.3,16/276 %5.8
Metastases to bone,1/277 %0.36,1/276 %0.36
Metastases to central nervous system,1/277 %0.36,0/276 %0.0
Metastases to lung,1/277 %0.36,0/276 %0.0
Small intestine adenocarcinoma,0/277 %0.0,1/276 %0.36
Tumour associated fever,1/277 %0.36,0/276 %0.0
Tumour pain,0/277 %0.0,4/276 %1.45
Central nervous system lesion,1/277 %0.36,0/276 %0.0
Cerebral infarction,0/277 %0.0,1/276 %0.36
Coma hepatic,1/277 %0.36,0/276 %0.0
Convulsion,2/277 %0.72,0/276 %0.0
Diplegia,1/277 %0.36,0/276 %0.0
Dizziness,1/277 %0.36,1/276 %0.36
Encephalopathy,1/277 %0.36,0/276 %0.0
Hepatic encephalopathy,12/277 %4.33,1/276 %0.36
Mental impairment,1/277 %0.36,0/276 %0.0
Peripheral motor neuropathy,0/277 %0.0,1/276 %0.36
Somnolence,1/277 %0.36,0/276 %0.0
Spinal cord compression,1/277 %0.36,0/276 %0.0
Subarachnoid haemorrhage,0/277 %0.0,1/276 %0.36
Tongue biting,0/277 %0.0,1/276 %0.36
Mental status changes,0/277 %0.0,1/276 %0.36
Renal failure,2/277 %0.72,0/276 %0.0
Renal failure acute,3/277 %1.08,1/276 %0.36
Renal impairment,1/277 %0.36,0/276 %0.0
Acute respiratory distress syndrome,0/277 %0.0,1/276 %0.36
Dyspnoea,1/277 %0.36,2/276 %0.72
Haemoptysis,2/277 %0.72,1/276 %0.36
Hypoxia,1/277 %0.36,0/276 %0.0
Pleural effusion,2/277 %0.72,3/276 %1.09
Pneumonitis,0/277 %0.0,1/276 %0.36
Pulmonary embolism,1/277 %0.36,2/276 %0.72
Pulmonary haemorrhage,0/277 %0.0,1/276 %0.36
Dermatitis allergic,1/277 %0.36,0/276 %0.0
Skin lesion,1/277 %0.36,0/276 %0.0
Skin ulcer,1/277 %0.36,0/276 %0.0
Deep vein thrombosis,2/277 %0.72,0/276 %0.0
Haemorrhage,0/277 %0.0,1/276 %0.36
Hypertension,1/277 %0.36,0/276 %0.0
Shock haemorrhagic,1/277 %0.36,0/276 %0.0

Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC)(https://clinicaltrials.gov/show/NCT01203787)
 ,Sorafenib Standard Dosing Regimen,Sorafenib Ramp-Up Regimen
 ,Sorafenib 400 mg (2 tablets of 200 mg) twice daily until end of treatment or week 24,200 mg daily from Day 0-Day 13 200 mg twice daily from Day 14-Day 20 600 mg daily from Day 21-Day 27 400 mg twice daily beginning Day 28 until end of treatment or Week 24
Total serious adverse events,16/63 %25.4,13/57 %22.81
Anemia,2/63 %3.17,0/57 %0.0
Thrombocytopenia,1/63 %1.59,0/57 %0.0
Acute congestive heart failure,1/63 %1.59,0/57 %0.0
Chest pain,1/63 %1.59,0/57 %0.0
Cardiac arrest,1/63 %1.59,0/57 %0.0
Hypertension,0/63 %0.0,1/57 %1.75
Hypotension,3/63 %4.76,0/57 %0.0
Blurred vision,0/63 %0.0,1/57 %1.75
Abdominal pain,1/63 %1.59,0/57 %0.0
Nausea,1/63 %1.59,0/57 %0.0
Upper gastrointestinal bleed,1/63 %1.59,2/57 %3.51
Vomiting,1/63 %1.59,0/57 %0.0
Deterioration of condition,0/63 %0.0,1/57 %1.75
Hypothermia,1/63 %1.59,0/57 %0.0
Syncopal episode,1/63 %1.59,0/57 %0.0
Ascites,1/63 %1.59,1/57 %1.75
Biliary obstruction,1/63 %1.59,0/57 %0.0
Decompensated liver failure,1/63 %1.59,0/57 %0.0
Encephalopathy,6/63 %9.52,1/57 %1.75
Liver failure,0/63 %0.0,4/57 %7.02
Cellulitis,1/63 %1.59,0/57 %0.0
Influenza,1/63 %1.59,0/57 %0.0
Meningitis,1/63 %1.59,0/57 %0.0
Pneumonia,1/63 %1.59,1/57 %1.75
Sepsis,2/63 %3.17,1/57 %1.75
Spontaneous bacterial perotinitis,1/63 %1.59,0/57 %0.0
Urinary tract infection,0/63 %0.0,1/57 %1.75
Drug toxicity,1/63 %1.59,0/57 %0.0
Post-embolization syndrome,3/63 %4.76,0/57 %0.0
Dehydration,2/63 %3.17,1/57 %1.75
Failure to thrive,1/63 %1.59,0/57 %0.0
Rib fracture,1/63 %1.59,0/57 %0.0
Dizziness,1/63 %1.59,0/57 %0.0
Vertigo,0/63 %0.0,1/57 %1.75
Unsteady gait,0/63 %0.0,1/57 %1.75
Acute renal failure,3/63 %4.76,0/57 %0.0
Pleural effusion,1/63 %1.59,1/57 %1.75
Pulmonary embolism,1/63 %1.59,0/57 %0.0
Respiratory failure,2/63 %3.17,1/57 %1.75
Abrasion,1/63 %1.59,0/57 %0.0

ABT-888 and Temozolomide for Liver Cancer(https://clinicaltrials.gov/show/NCT01205828)
 ,Temozolomide + ABT-888
 ,Temozolomide and ABT-888 temozolomide + ABT-888: Temozolomide 150 mg/m2/day PO Days 1-5 every 28 days ABT-888 40 mg BID PO Days 1-7 every 28 days Patents with stable disease or continued response to therapy will be treated and followed for a total of 6 cycles (6 months).
Total serious adverse events,6/16 %37.5
nausea vomit,3/16 %18.75
bleeding,1/16 %6.25
fatigue,1/16 %6.25
multiorgan failure,1/16 %6.25

Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer(https://clinicaltrials.gov/show/NCT01234337)
 ,Sorafenib (Nexavar BAY43-9006) + Capecitabine,Placebo + Capecitabine
 ,Sorafenib tablets were administered orally continuously at a total daily dose of 600 mg (200 mg in the morning 400 mg in the evening) in a 3-week cycle. Capecitabine was administered orally at a total daily dose of 2000 mg/m^2 (1000 mg/m^2 twice daily 12 hours apart). If tolerability criteria were met for a subject capecitabine dose was escalated to 2500 mg/m^2 total daily dose (1250 mg/m^2 twice daily) and sorafenib dose to a total daily dose of 800 mg for that subject.,Placebo tablets matching with sorafenib were administered orally continuously (1 tablet in the morning 2 tablets in the evening) in a 3-week cycle. Capecitabine was administered orally at a total daily dose of 2000 mg/m^2 (1000 mg/m^2 twice daily 12 hours apart). If tolerability criteria were met for a subject capecitabine dose was escalated to 2500 mg/m^2 total daily dose (1250 mg/m^2 twice daily) and placebo dose to a total daily dose of 4 tablets (2 tablets twice daily) for that subject.
Total serious adverse events,80/260 %30.77,71/267 %26.59
Anaemia,2/260 %0.77,2/267 %0.75
Febrile neutropenia,0/260 %0.0,1/267 %0.37
Neutropenia,2/260 %0.77,0/267 %0.0
Thrombocytopenia,0/260 %0.0,1/267 %0.37
Bundle branch block right,0/260 %0.0,1/267 %0.37
Pericardial effusion,0/260 %0.0,5/267 %1.87
Cardiopulmonary failure,0/260 %0.0,1/267 %0.37
Aplasia,0/260 %0.0,1/267 %0.37
Eye symptom,1/260 %0.38,0/267 %0.0
Abdominal discomfort,0/260 %0.0,1/267 %0.37
Abdominal pain,2/260 %0.77,1/267 %0.37
Acute abdomen,1/260 %0.38,0/267 %0.0
Ascites,1/260 %0.38,2/267 %0.75
Colitis,1/260 %0.38,2/267 %0.75
Constipation,1/260 %0.38,0/267 %0.0
Diarrhoea,3/260 %1.15,8/267 %3.0
Enteritis,0/260 %0.0,1/267 %0.37
Melaena,1/260 %0.38,0/267 %0.0
Nausea,3/260 %1.15,2/267 %0.75
Oesophageal stenosis,1/260 %0.38,0/267 %0.0
Pancreatitis,1/260 %0.38,0/267 %0.0
Swollen tongue,1/260 %0.38,0/267 %0.0
Vomiting,7/260 %2.69,1/267 %0.37
Duodenal stenosis,1/260 %0.38,0/267 %0.0
Subileus,0/260 %0.0,1/267 %0.37
Neutropenic colitis,0/260 %0.0,3/267 %1.12
Death,2/260 %0.77,1/267 %0.37
Fatigue,2/260 %0.77,2/267 %0.75
Mucosal inflammation,1/260 %0.38,0/267 %0.0
Pain,2/260 %0.77,0/267 %0.0
Pyrexia,0/260 %0.0,3/267 %1.12
General physical health deterioration,3/260 %1.15,3/267 %1.12
Gallbladder pain,1/260 %0.38,0/267 %0.0
Hepatic failure,2/260 %0.77,1/267 %0.37
Hyperbilirubinaemia,1/260 %0.38,0/267 %0.0
Jaundice cholestatic,1/260 %0.38,0/267 %0.0
Bronchitis,1/260 %0.38,0/267 %0.0
Gastroenteritis viral,1/260 %0.38,0/267 %0.0
Pneumonia,2/260 %0.77,0/267 %0.0
Sepsis,2/260 %0.77,0/267 %0.0
Urinary tract infection,2/260 %0.77,1/267 %0.37
Cytomegalovirus enterocolitis,1/260 %0.38,0/267 %0.0
Lung infection,2/260 %0.77,0/267 %0.0
Femoral neck fracture,1/260 %0.38,0/267 %0.0
Femur fracture,1/260 %0.38,1/267 %0.37
Hip fracture,0/260 %0.0,1/267 %0.37
Humerus fracture,0/260 %0.0,1/267 %0.37
Tendon rupture,0/260 %0.0,1/267 %0.37
Wrist fracture,1/260 %0.38,0/267 %0.0
Biopsy lung,1/260 %0.38,0/267 %0.0
Blood bilirubin increased,0/260 %0.0,1/267 %0.37
White blood cell count decreased,1/260 %0.38,0/267 %0.0
Dehydration,2/260 %0.77,0/267 %0.0
Hypercalcaemia,0/260 %0.0,2/267 %0.75
Hyperglycaemia,0/260 %0.0,1/267 %0.37
Hypoglycaemia,0/260 %0.0,1/267 %0.37
Hypokalaemia,1/260 %0.38,4/267 %1.5
Hyponatraemia,1/260 %0.38,0/267 %0.0
Hypophosphataemia,0/260 %0.0,1/267 %0.37
Arthralgia,3/260 %1.15,1/267 %0.37
Back pain,2/260 %0.77,0/267 %0.0
Bone pain,0/260 %0.0,1/267 %0.37
Musculoskeletal pain,0/260 %0.0,1/267 %0.37
Myopathy,1/260 %0.38,0/267 %0.0
Mobility decreased,0/260 %0.0,1/267 %0.37
Musculoskeletal chest pain,1/260 %0.38,0/267 %0.0
Breast cancer,0/260 %0.0,1/267 %0.37
Malignant pleural effusion,1/260 %0.38,0/267 %0.0
Metastases to liver,0/260 %0.0,1/267 %0.37
Metastases to spine,0/260 %0.0,1/267 %0.37
Metastases to meninges,0/260 %0.0,1/267 %0.37
Tumour associated fever,1/260 %0.38,0/267 %0.0
Breast cancer metastatic,1/260 %0.38,2/267 %0.75
Cancer pain,1/260 %0.38,0/267 %0.0
Metastases to central nervous system,1/260 %0.38,0/267 %0.0
Disturbance in attention,1/260 %0.38,0/267 %0.0
Dizziness,0/260 %0.0,1/267 %0.37
Epilepsy,1/260 %0.38,0/267 %0.0
Facial paralysis,0/260 %0.0,1/267 %0.37
Headache,2/260 %0.77,1/267 %0.37
Hepatic encephalopathy,1/260 %0.38,1/267 %0.37
Lethargy,0/260 %0.0,1/267 %0.37
Neuralgia,1/260 %0.38,0/267 %0.0
Presyncope,1/260 %0.38,0/267 %0.0
Sciatica,1/260 %0.38,0/267 %0.0
Spinal cord compression,0/260 %0.0,1/267 %0.37
Brain oedema,0/260 %0.0,1/267 %0.37
Central nervous system mass,0/260 %0.0,1/267 %0.37
Cytotoxic oedema,1/260 %0.38,0/267 %0.0
Confusional state,1/260 %0.38,0/267 %0.0
Hydronephrosis,1/260 %0.38,1/267 %0.37
Renal colic,1/260 %0.38,0/267 %0.0
Acute kidney injury,1/260 %0.38,0/267 %0.0
Menorrhagia,1/260 %0.38,0/267 %0.0
Asphyxia,1/260 %0.38,0/267 %0.0
Bronchospasm,1/260 %0.38,0/267 %0.0
Dyspnoea,8/260 %3.08,3/267 %1.12
Haemoptysis,0/260 %0.0,1/267 %0.37
Pleural effusion,6/260 %2.31,11/267 %4.12
Pneumonitis,1/260 %0.38,0/267 %0.0
Pneumothorax,1/260 %0.38,3/267 %1.12
Pulmonary embolism,3/260 %1.15,4/267 %1.5
Pulmonary microemboli,1/260 %0.38,0/267 %0.0
Respiratory failure,3/260 %1.15,0/267 %0.0
Tracheal obstruction extrinsic,1/260 %0.38,0/267 %0.0
Erythema multiforme,1/260 %0.38,0/267 %0.0
Palmar-plantar erythrodysaesthesia syndrome,0/260 %0.0,1/267 %0.37
Rash,1/260 %0.38,0/267 %0.0
Cholecystectomy,0/260 %0.0,1/267 %0.37
Hysterectomy,1/260 %0.38,0/267 %0.0
Pleurodesis,2/260 %0.77,0/267 %0.0
Central venous catheterisation,1/260 %0.38,0/267 %0.0
Hepatectomy,1/260 %0.38,0/267 %0.0
Axillary lymphadenectomy,1/260 %0.38,0/267 %0.0
Cancer surgery,0/260 %0.0,1/267 %0.37
Lymphoedema,1/260 %0.38,0/267 %0.0
Superior vena cava syndrome,1/260 %0.38,0/267 %0.0
Deep vein thrombosis,1/260 %0.38,3/267 %1.12
Peripheral artery occlusion,1/260 %0.38,0/267 %0.0
Venous thrombosis limb,0/260 %0.0,1/267 %0.37

Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma(https://clinicaltrials.gov/show/NCT01258608)
 ,Sorafenib+Placebo,Sorafenib+Mapatumumab 30 mg/kg
 ,Participants received sorafenib 400 milligrams (mg) orally twice daily continuously in each 21-day cycle. Placebo was administered via the intravenous route on Day 1 of each 21-day cycle. The treatments were administered until radiologic disease progression or unacceptable toxicity.,Participants received sorafenib 400 mg orally twice daily continuously in each 21-day cycle. Mapatumumab 30 milligrams per kilogram (mg/kg) was administered via the intravenous route on Day 1 of each 21-day cycle. The treatments were administered until radiologic disease progression or unacceptable toxicity.
Total all-cause mortality,40/51 %78.43,39/50 %78.0
Total serious adverse events,27/51 %52.94,21/50 %42.0
Disseminated intravascular coagulation,0/51 %0.0,1/50 %2.0
Acute myocardial infarction,0/51 %0.0,2/50 %4.0
Cardio-respiratory arrest,0/51 %0.0,1/50 %2.0
Myocardial ischaemia,0/51 %0.0,1/50 %2.0
Atrial fibrillation,1/51 %1.96,0/50 %0.0
Atrial flutter,1/51 %1.96,0/50 %0.0
Atrioventricular block,1/51 %1.96,0/50 %0.0
Oesophageal varices haemorrhage,0/51 %0.0,3/50 %6.0
Gastric haemorrhage,2/51 %3.92,1/50 %2.0
Upper gastrointestinal haemorrhage,2/51 %3.92,1/50 %2.0
Food poisoning,0/51 %0.0,1/50 %2.0
Ascites,1/51 %1.96,0/50 %0.0
Gastric ulcer,1/51 %1.96,0/50 %0.0
Gastric ulcer haemorrhage,1/51 %1.96,0/50 %0.0
General physical health deterioration,2/51 %3.92,1/50 %2.0
Disease progression,1/51 %1.96,0/50 %0.0
Fatigue,1/51 %1.96,0/50 %0.0
Hepatic failure,0/51 %0.0,3/50 %6.0
Hyperbilirubinaemia,1/51 %1.96,0/50 %0.0
Appendicitis,0/51 %0.0,1/50 %2.0
Gangrene,0/51 %0.0,1/50 %2.0
Oesophageal candidiasis,0/51 %0.0,1/50 %2.0
Device related infection,1/51 %1.96,0/50 %0.0
Craniocerebral injury,1/51 %1.96,1/50 %2.0
Road traffic accident,0/51 %0.0,1/50 %2.0
Gamma-glutamyltransferase increased,3/51 %5.88,0/50 %0.0
Blood bilirubin increased,1/51 %1.96,2/50 %4.0
Alanine aminotransferase increased,0/51 %0.0,1/50 %2.0
Lipase increased,1/51 %1.96,0/50 %0.0
Hyperkalaemia,1/51 %1.96,2/50 %4.0
Dehydration,0/51 %0.0,1/50 %2.0
Malnutrition,0/51 %0.0,1/50 %2.0
Cachexia,1/51 %1.96,0/50 %0.0
Hyponatraemia,1/51 %1.96,0/50 %0.0
Arthritis,1/51 %1.96,0/50 %0.0
Hepatocellular carcinoma,9/51 %17.65,4/50 %8.0
Hepatic cancer metastatic,1/51 %1.96,0/50 %0.0
Hepatic encephalopathy,0/51 %0.0,1/50 %2.0
Haemorrhagic stroke,1/51 %1.96,0/50 %0.0
Renal failure,0/51 %0.0,1/50 %2.0
Pulmonary embolism,2/51 %3.92,0/50 %0.0
Bronchitis chronic,0/51 %0.0,1/50 %2.0
Skin ulcer,1/51 %1.96,0/50 %0.0

Sorafenib and TRC105 in Hepatocellular Cancer(https://clinicaltrials.gov/show/NCT01306058)
 ,Sorafenib & TRC105 in Hepatocellular CA
 ,CA (cancer); 15 mg/kg TRC105 intravenous (IV) every 2 weeks and 400 mg sorafenib by mouth (PO) twice per day TRC 105: 15 mg/kg IV every 2 weeks Sorafenib: 400 mg twice a day (bid) continuously in a 28 days cycle
Total all-cause mortality,16/27 %59.26
Total serious adverse events,11/27 %40.74
Left ventricular systolic dysfunction,1/27 %3.7
Myocardial infarction,1/27 %3.7
Diarrhea,1/27 %3.7
Gastrointestinal pain,1/27 %3.7
Mucositis oral,1/27 %3.7
Pancreatitis,1/27 %3.7
Fever,1/27 %3.7
Infusion related reaction,1/27 %3.7
Hepatic failure,1/27 %3.7
Lung infection,1/27 %3.7
Sepsis,1/27 %3.7
Aspartate aminotransferase increased,1/27 %3.7
Blood bilirubin increased,1/27 %3.7
Lipase increased,1/27 %3.7
Serum amylase increased,1/27 %3.7
Intracranial hemorrhage,1/27 %3.7
Stroke,1/27 %3.7
Epistaxis,1/27 %3.7
Rash maculo-papular,2/27 %7.41
Flushing,1/27 %3.7
Hypotension,1/27 %3.7

A Phase II Trial of OSI-906 and Sorafenib in Advanced Hepatocellular Cancer(https://clinicaltrials.gov/show/NCT01334710)
 ,Sorafenib and OSI-906
 ,This is a single arm phase II trial designed to evaluate the effect of adding OSI-906 to sorafenib in patients with hepatocellular cancer. The study is designed to evaluate the safety of the regimen in the first six patients. Sorafenib and OSI-906 : Sorafenib - 400 mg twice daily OSI-906 - 150 mg twice daily
Total serious adverse events,0/3 %0.0

Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia(https://clinicaltrials.gov/show/NCT01371981)
 ,Arm A,Arm B,Arm C (Cohort 1),Arm C (Cohort 2),Arm C (Cohort 3),Arm D
 ,INDUCTION (IND) 1Pts receive intrathecal (IT) cytarabine on day 1 and ADE with IV cytarabine over 1-30 minutes on days 1-10; daunorubicin hydrochloride IV over 1-15 minutes days1 3 5; etoposide IV 1-2 hours days1-5. IND IILow risk (LR) pts receive cytarabine IT and ADE chemotherapy as in INDI. High risk (HR) cytarabine IT day 1 MA chemo comprising high-dose cytarabine IV over 1-3 hours days1-4 mitoxantrone IV over 15-30 minutes days 3-6. INTENSIFICATION (INT) I: cytarabine IT day 1 AE chemo with high-dose cytarabine IV over 1-3 hours etoposide IV over 1-2 hours days 1-5. INT II: LR-cytarabine IT day 1; Induction II MA chemo. HR and no SCT donor - high-dose cytarabine IV over 3 hours days1 2 8 9; asparaginase intramuscularly (IM) days29. SCT: : pts receive fludarabine phosphate IV over 30 minutes once daily days -5 to -2 busulfan IV over 2 hours 4 times daily days -5 to -2. Allogeneic SCT within 36 to 48 hours after last busulfan dose. Pts receive GVHD prophylaxis.,IND I: Pts receive cytarabine IT and ADE chemotherapy as in Induction I Arm A. Patients also receive bortezomib IV over 3-5 seconds on days 1 4 8. IND II: LR pts receive cytarabine IT ADE chemotherapy bortezomib as in IND I. HR pts receive cytarabine IT MA as in IND II Arm A (HR patients) and bortezomib IV on days 1 4 8. INT I: Pts receive cytarabine IT and AE in Arm A Intensification II and bortezomib IV on days 1 4 8. INT II: LR pts receive cytarabine IT on day 1 MA as in Arm A IND II (HR patients) and bortezomib IV on days 1 4 8. HR pts with no donor for SCT receive high-dose cytarabine IV over 3 hours on days 1 2 8 9 and asparaginase intramuscularly (IM) on days 2 and 9. SCT - Pts receive fludarabine phosphate IV over 30 minutes once daily on days -5 to -2 and busulfan IV over 2 hours 4 times daily on days -5 to -2.Pts undergo allogeneic SCT within 36 to 48 hours after the last dose of busulfan. Pts receive GVHD prophylaxis.,IND II: Pts receive cytarabine IT on day 1 cytarabine IV over 1-30 minutes on days 1-8 daunorubicin hydrochloride IV over 1-15 minutes on days 1 3 and 5 etoposide IV over 1-2 hours on days 1-5 sorafenib tosylate PO on days 9-36. INT I: Pts receive cytarabine IT and AE chemotherapy in Arm A Intensification II and sorafenib tosylate PO on daily on days 6-28. INT II: Pts receive cytarabine IT on day 1 MA chemotherapy as in Arm A Induction II (HR patients) sorafenib tosylate PO on days 7-34. SCT (HR patients with matched family [MFD] or unrelated donor): Pts receive fludarabine phosphate IV over 30 minutes once daily on days -5 to -2 busulfan IV over 2 hours 4 times daily on days -5 to -2. Patients undergo allogeneic SCT within 36 to 48 hours after the last dose of busulfan. Pts receive GVHD prophylaxis. MAINTENANCE: Pts receive sorafenib tosylate PO starting day 40-100 after INT II or SCT for one year.,IND I: Pts receive cytarabine IT & ADE as in Arm A IND I & sorafenib tosylate PO at the time of known HR FLT3/ITD+ (including IND I & concurrently with chemo). IND II: Pts receive cytarabine IT day (d) 1 cytarabine IV over 1-30 minutes on d 1-8 daunorubicin hydrochloride IV over 1-15 minutes days 1 3 5 etoposide IV over 1-2 hours d 1-5 sorafenib tosylate PO d 9-36. INTE I: Pts receive cytarabine IT and AE in Arm A INT II and sorafenib tosylate PO on daily d 6-28. INT II: Pts receive cytarabine IT on d 1 MA as in Arm A IND II (HR pts) sorafenib tosylate PO d 7-34. SCT (HR patients with matched family [MFD] or unrelated donor): Pts receive fludarabine phosphate IV over 30 minutes once daily on d -5 to -2 busulfan IV over 2 hours 4 times daily d -5 to -2. Pts undergo allogeneic SCT within 36-48 hours after last busulfan dose. Pts receive GVHD prophylaxis. MAINTENANCE: Pts receive sorafenib tosylate PO starting d 40-100 after INT II or SCT for 1 year.,IND I: Pts receive cytarabine IT & ADE as in Arm A IND I & sorafenib tosylate PO days 11-28. IND II: Pts receive cytarabine IT day 1 cytarabine IV over 1-30 minutes on days 1-8 daunorubicin hydrochloride IV over 1-15 minutes days 1 3 5 etoposide IV over 1-2 hours days 1-5 sorafenib tosylate PO days 9-36. INT I: Pts receive cytarabine IT & AE cin Arm A INT II & sorafenib tosylate PO daily days 6-28. INT II: Pts receive cytarabine IT day 1 MA as in Arm A IND II (HR patients) & sorafenib tosylate PO days 7-34. SCT (HR patients with matched family [MFD] or unrelated donor): Pts receive fludarabine phosphate IV over 30 minutes once daily on days -5 to -2 and busulfan IV over 2 hours 4 times daily days -5 to -2. Pts undergo allogeneic SCT within 36 to 48 hours after last busulfan dose. Pts receive GVHD prophylaxis. MAINTENANCE: Pts receive sorafenib tosylate PO starting day 40-100 after INT II or SCT for 1 year.,INDUCTION I: Patients with unknown FLT3/ITD status prior to study enrollment receive cytarabine IT and ADE chemotherapy as in Arm A Induction I. If patients are determined to be HR FLT3/ITD+ no later than the end of Induction I they will be eligible to participate in Arm C.
Total all-cause mortality,198/559 %35.42,189/575 %32.87,7/12 %58.33,11/33 %33.33,16/47 %34.04,2/376 %0.53
Total serious adverse events,82/559 %14.67,305/575 %53.04,6/12 %50.0,16/33 %48.48,30/47 %63.83,2/376 %0.53
Anemia,0/559 %0.0,3/575 %0.52,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Blood and lymphatic system disorders - Other specify,1/559 %0.18,4/575 %0.7,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Bone marrow hypocellular,0/559 %0.0,2/575 %0.35,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Disseminated intravascular coagulation,3/559 %0.54,3/575 %0.52,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Febrile neutropenia,0/559 %0.0,21/575 %3.65,0/12 %0.0,1/33 %3.03,0/47 %0.0,0/376 %0.0
Hemolysis,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Hemolytic uremic syndrome,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Leukocytosis,0/559 %0.0,3/575 %0.52,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Asystole,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Atrial fibrillation,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Atrial flutter,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Cardiac arrest,3/559 %0.54,4/575 %0.7,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Cardiac disorders - Other specify,0/559 %0.0,7/575 %1.22,0/12 %0.0,1/33 %3.03,2/47 %4.26,0/376 %0.0
Chest pain - cardiac,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Heart failure,4/559 %0.72,15/575 %2.61,0/12 %0.0,1/33 %3.03,2/47 %4.26,0/376 %0.0
Left ventricular systolic dysfunction,3/559 %0.54,23/575 %4.0,0/12 %0.0,2/33 %6.06,4/47 %8.51,0/376 %0.0
Myocardial infarction,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Pericardial effusion,0/559 %0.0,2/575 %0.35,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Pericarditis,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Restrictive cardiomyopathy,0/559 %0.0,4/575 %0.7,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Right ventricular dysfunction,2/559 %0.36,2/575 %0.35,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Sinus bradycardia,1/559 %0.18,0/575 %0.0,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Sinus tachycardia,0/559 %0.0,10/575 %1.74,0/12 %0.0,0/33 %0.0,1/47 %2.13,0/376 %0.0
Supraventricular tachycardia,0/559 %0.0,2/575 %0.35,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Ventricular arrhythmia,0/559 %0.0,3/575 %0.52,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Ventricular fibrillation,1/559 %0.18,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Ventricular tachycardia,0/559 %0.0,2/575 %0.35,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Adrenal insufficiency,0/559 %0.0,3/575 %0.52,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Endocrine disorders - Other specify,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Hypothyroidism,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Eye disorders - Other specify,1/559 %0.18,2/575 %0.35,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Optic nerve disorder,0/559 %0.0,0/575 %0.0,0/12 %0.0,0/33 %0.0,1/47 %2.13,0/376 %0.0
Papilledema,0/559 %0.0,0/575 %0.0,0/12 %0.0,0/33 %0.0,1/47 %2.13,0/376 %0.0
Abdominal distension,0/559 %0.0,2/575 %0.35,0/12 %0.0,1/33 %3.03,0/47 %0.0,0/376 %0.0
Abdominal pain,0/559 %0.0,2/575 %0.35,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Anal pain,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Ascites,1/559 %0.18,0/575 %0.0,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Colitis,0/559 %0.0,9/575 %1.57,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Colonic perforation,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Diarrhea,0/559 %0.0,9/575 %1.57,0/12 %0.0,1/33 %3.03,0/47 %0.0,0/376 %0.0
Enterocolitis,0/559 %0.0,2/575 %0.35,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Esophagitis,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Gastric hemorrhage,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Gastritis,0/559 %0.0,2/575 %0.35,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Gastrointestinal disorders - Other specify,0/559 %0.0,3/575 %0.52,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Ileus,0/559 %0.0,1/575 %0.17,0/12 %0.0,1/33 %3.03,1/47 %2.13,0/376 %0.0
Lower gastrointestinal hemorrhage,0/559 %0.0,0/575 %0.0,0/12 %0.0,0/33 %0.0,1/47 %2.13,0/376 %0.0
Mucositis oral,0/559 %0.0,3/575 %0.52,1/12 %8.33,0/33 %0.0,0/47 %0.0,0/376 %0.0
Nausea,0/559 %0.0,1/575 %0.17,0/12 %0.0,1/33 %3.03,0/47 %0.0,0/376 %0.0
Oral pain,0/559 %0.0,2/575 %0.35,0/12 %0.0,1/33 %3.03,0/47 %0.0,0/376 %0.0
Pancreatitis,0/559 %0.0,8/575 %1.39,0/12 %0.0,0/33 %0.0,1/47 %2.13,0/376 %0.0
Small intestinal obstruction,0/559 %0.0,2/575 %0.35,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Typhlitis,2/559 %0.36,24/575 %4.17,0/12 %0.0,1/33 %3.03,1/47 %2.13,0/376 %0.0
Upper gastrointestinal hemorrhage,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Vomiting,0/559 %0.0,1/575 %0.17,0/12 %0.0,1/33 %3.03,0/47 %0.0,0/376 %0.0
Chills,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Death NOS,38/559 %6.8,35/575 %6.09,1/12 %8.33,5/33 %15.15,6/47 %12.77,0/376 %0.0
Edema face,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Fever,0/559 %0.0,13/575 %2.26,0/12 %0.0,0/33 %0.0,3/47 %6.38,0/376 %0.0
Gait disturbance,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Hypothermia,1/559 %0.18,0/575 %0.0,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Multi-organ failure,1/559 %0.18,8/575 %1.39,0/12 %0.0,0/33 %0.0,2/47 %4.26,0/376 %0.0
Non-cardiac chest pain,0/559 %0.0,2/575 %0.35,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Pain,0/559 %0.0,2/575 %0.35,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Bile duct stenosis,1/559 %0.18,0/575 %0.0,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Cholecystitis,0/559 %0.0,2/575 %0.35,0/12 %0.0,0/33 %0.0,1/47 %2.13,0/376 %0.0
Hepatic failure,2/559 %0.36,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Hepatobiliary disorders - Other specify,0/559 %0.0,4/575 %0.7,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Allergic reaction,1/559 %0.18,2/575 %0.35,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Anaphylaxis,0/559 %0.0,5/575 %0.87,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Immune system disorders - Other specify,1/559 %0.18,0/575 %0.0,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Anorectal infection,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Appendicitis,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Bladder infection,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Bronchial infection,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Catheter related infection,0/559 %0.0,5/575 %0.87,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Cecal infection,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Duodenal infection,1/559 %0.18,0/575 %0.0,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Encephalitis infection,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Enterocolitis infectious,1/559 %0.18,2/575 %0.35,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Esophageal infection,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,1/47 %2.13,0/376 %0.0
Infections and infestations - Other specify,2/559 %0.36,13/575 %2.26,0/12 %0.0,2/33 %6.06,0/47 %0.0,0/376 %0.0
Lung infection,1/559 %0.18,13/575 %2.26,1/12 %8.33,2/33 %6.06,0/47 %0.0,0/376 %0.0
Lymph gland infection,1/559 %0.18,0/575 %0.0,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Meningitis,1/559 %0.18,0/575 %0.0,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Mucosal infection,0/559 %0.0,3/575 %0.52,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Periorbital infection,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Sepsis,17/559 %3.04,50/575 %8.7,0/12 %0.0,1/33 %3.03,4/47 %8.51,0/376 %0.0
Skin infection,0/559 %0.0,3/575 %0.52,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Soft tissue infection,1/559 %0.18,0/575 %0.0,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Tracheitis,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Upper respiratory infection,1/559 %0.18,3/575 %0.52,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Urinary tract infection,1/559 %0.18,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Infusion related reaction,0/559 %0.0,2/575 %0.35,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Postoperative hemorrhage,1/559 %0.18,0/575 %0.0,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Vascular access complication,0/559 %0.0,3/575 %0.52,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Activated partial thromboplastin time prolonged,0/559 %0.0,4/575 %0.7,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Alanine aminotransferase increased,0/559 %0.0,16/575 %2.78,0/12 %0.0,0/33 %0.0,2/47 %4.26,0/376 %0.0
Aspartate aminotransferase increased,1/559 %0.18,10/575 %1.74,0/12 %0.0,0/33 %0.0,1/47 %2.13,0/376 %0.0
Blood bilirubin increased,2/559 %0.36,16/575 %2.78,0/12 %0.0,1/33 %3.03,1/47 %2.13,0/376 %0.0
Carbon monoxide diffusing capacity decreased,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Creatinine increased,0/559 %0.0,8/575 %1.39,0/12 %0.0,1/33 %3.03,0/47 %0.0,0/376 %0.0
Ejection fraction decreased,2/559 %0.36,18/575 %3.13,0/12 %0.0,2/33 %6.06,4/47 %8.51,0/376 %0.0
Electrocardiogram QT corrected interval prolonged,1/559 %0.18,3/575 %0.52,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Fibrinogen decreased,1/559 %0.18,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
GGT increased,0/559 %0.0,4/575 %0.7,0/12 %0.0,1/33 %3.03,0/47 %0.0,0/376 %0.0
Investigations - Other specify,0/559 %0.0,2/575 %0.35,0/12 %0.0,0/33 %0.0,1/47 %2.13,0/376 %0.0
Lipase increased,0/559 %0.0,4/575 %0.7,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Lymphocyte count decreased,0/559 %0.0,5/575 %0.87,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Neutrophil count decreased,0/559 %0.0,8/575 %1.39,0/12 %0.0,1/33 %3.03,0/47 %0.0,0/376 %0.0
Platelet count decreased,0/559 %0.0,7/575 %1.22,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Serum amylase increased,0/559 %0.0,3/575 %0.52,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Urine output decreased,1/559 %0.18,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Weight loss,0/559 %0.0,0/575 %0.0,0/12 %0.0,1/33 %3.03,1/47 %2.13,0/376 %0.0
White blood cell decreased,0/559 %0.0,5/575 %0.87,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Acidosis,0/559 %0.0,4/575 %0.7,0/12 %0.0,1/33 %3.03,0/47 %0.0,0/376 %0.0
Alkalosis,0/559 %0.0,1/575 %0.17,0/12 %0.0,1/33 %3.03,0/47 %0.0,0/376 %0.0
Anorexia,0/559 %0.0,1/575 %0.17,0/12 %0.0,1/33 %3.03,0/47 %0.0,0/376 %0.0
Dehydration,0/559 %0.0,3/575 %0.52,0/12 %0.0,1/33 %3.03,0/47 %0.0,0/376 %0.0
Hypercalcemia,0/559 %0.0,2/575 %0.35,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Hyperglycemia,1/559 %0.18,2/575 %0.35,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Hyperkalemia,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,1/47 %2.13,0/376 %0.0
Hypernatremia,2/559 %0.36,3/575 %0.52,0/12 %0.0,0/33 %0.0,1/47 %2.13,0/376 %0.0
Hypertriglyceridemia,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Hypoalbuminemia,0/559 %0.0,6/575 %1.04,0/12 %0.0,1/33 %3.03,0/47 %0.0,0/376 %0.0
Hypocalcemia,0/559 %0.0,8/575 %1.39,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Hypokalemia,1/559 %0.18,27/575 %4.7,0/12 %0.0,2/33 %6.06,1/47 %2.13,0/376 %0.0
Hypomagnesemia,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Hyponatremia,0/559 %0.0,10/575 %1.74,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Hypophosphatemia,1/559 %0.18,3/575 %0.52,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Metabolism and nutrition disorders - Other specify,2/559 %0.36,0/575 %0.0,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Tumor lysis syndrome,1/559 %0.18,3/575 %0.52,0/12 %0.0,1/33 %3.03,0/47 %0.0,0/376 %0.0
Arthralgia,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Back pain,0/559 %0.0,4/575 %0.7,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Neck pain,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Pain in extremity,0/559 %0.0,2/575 %0.35,0/12 %0.0,1/33 %3.03,0/47 %0.0,0/376 %0.0
Neoplasms benign malignant and unspecified (incl cysts and polyps) - Other specify,2/559 %0.36,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,1/376 %0.27
Ataxia,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Central nervous system necrosis,1/559 %0.18,0/575 %0.0,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Cerebrospinal fluid leakage,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Cognitive disturbance,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Depressed level of consciousness,0/559 %0.0,2/575 %0.35,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Dizziness,0/559 %0.0,2/575 %0.35,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Dysesthesia,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Edema cerebral,1/559 %0.18,4/575 %0.7,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Encephalopathy,1/559 %0.18,5/575 %0.87,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Headache,0/559 %0.0,4/575 %0.7,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Hydrocephalus,1/559 %0.18,0/575 %0.0,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Hypersomnia,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Intracranial hemorrhage,2/559 %0.36,3/575 %0.52,0/12 %0.0,0/33 %0.0,0/47 %0.0,1/376 %0.27
Leukoencephalopathy,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Nervous system disorders - Other specify,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Neuralgia,0/559 %0.0,1/575 %0.17,0/12 %0.0,1/33 %3.03,0/47 %0.0,0/376 %0.0
Paresthesia,0/559 %0.0,2/575 %0.35,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Peripheral sensory neuropathy,0/559 %0.0,14/575 %2.43,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Reversible posterior leukoencephalopathy syndrome,0/559 %0.0,4/575 %0.7,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Seizure,1/559 %0.18,3/575 %0.52,0/12 %0.0,0/33 %0.0,1/47 %2.13,0/376 %0.0
Somnolence,0/559 %0.0,4/575 %0.7,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Syncope,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Agitation,0/559 %0.0,2/575 %0.35,1/12 %8.33,0/33 %0.0,0/47 %0.0,0/376 %0.0
Anxiety,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Delirium,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Acute kidney injury,5/559 %0.89,15/575 %2.61,0/12 %0.0,3/33 %9.09,3/47 %6.38,0/376 %0.0
Cystitis noninfective,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Hematuria,0/559 %0.0,3/575 %0.52,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Proteinuria,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Renal and urinary disorders - Other specify,1/559 %0.18,3/575 %0.52,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Adult respiratory distress syndrome,3/559 %0.54,15/575 %2.61,0/12 %0.0,2/33 %6.06,0/47 %0.0,0/376 %0.0
Apnea,1/559 %0.18,0/575 %0.0,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Aspiration,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Atelectasis,0/559 %0.0,2/575 %0.35,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Bronchopulmonary hemorrhage,3/559 %0.54,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Bronchospasm,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Cough,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Dyspnea,1/559 %0.18,12/575 %2.09,0/12 %0.0,1/33 %3.03,0/47 %0.0,0/376 %0.0
Epistaxis,0/559 %0.0,7/575 %1.22,0/12 %0.0,1/33 %3.03,0/47 %0.0,0/376 %0.0
Hypoxia,3/559 %0.54,55/575 %9.57,1/12 %8.33,3/33 %9.09,3/47 %6.38,0/376 %0.0
Laryngeal edema,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Laryngeal mucositis,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Mediastinal hemorrhage,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Pharyngeal mucositis,0/559 %0.0,2/575 %0.35,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Pleural effusion,0/559 %0.0,8/575 %1.39,0/12 %0.0,1/33 %3.03,0/47 %0.0,0/376 %0.0
Pneumonitis,0/559 %0.0,9/575 %1.57,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Productive cough,0/559 %0.0,0/575 %0.0,0/12 %0.0,0/33 %0.0,1/47 %2.13,0/376 %0.0
Pulmonary edema,3/559 %0.54,12/575 %2.09,0/12 %0.0,0/33 %0.0,2/47 %4.26,0/376 %0.0
Pulmonary hypertension,1/559 %0.18,2/575 %0.35,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Respiratory failure,10/559 %1.79,22/575 %3.83,0/12 %0.0,2/33 %6.06,2/47 %4.26,0/376 %0.0
Respiratory thoracic and mediastinal disorders - Other specify,1/559 %0.18,6/575 %1.04,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Sore throat,0/559 %0.0,1/575 %0.17,1/12 %8.33,0/33 %0.0,0/47 %0.0,0/376 %0.0
Stridor,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Tracheal mucositis,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Wheezing,0/559 %0.0,3/575 %0.52,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Erythroderma,0/559 %0.0,0/575 %0.0,1/12 %8.33,0/33 %0.0,0/47 %0.0,0/376 %0.0
Pain of skin,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,1/47 %2.13,0/376 %0.0
Palmar-plantar erythrodysesthesia syndrome,0/559 %0.0,1/575 %0.17,1/12 %8.33,1/33 %3.03,1/47 %2.13,0/376 %0.0
Pruritus,0/559 %0.0,1/575 %0.17,1/12 %8.33,0/33 %0.0,0/47 %0.0,0/376 %0.0
Rash maculo-papular,0/559 %0.0,10/575 %1.74,1/12 %8.33,2/33 %6.06,3/47 %6.38,0/376 %0.0
Skin and subcutaneous tissue disorders - Other specify,0/559 %0.0,2/575 %0.35,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Toxic epidermal necrolysis,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Urticaria,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Capillary leak syndrome,0/559 %0.0,5/575 %0.87,0/12 %0.0,0/33 %0.0,1/47 %2.13,0/376 %0.0
Flushing,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Hypertension,0/559 %0.0,10/575 %1.74,0/12 %0.0,1/33 %3.03,1/47 %2.13,0/376 %0.0
Hypotension,7/559 %1.25,47/575 %8.17,1/12 %8.33,3/33 %9.09,3/47 %6.38,0/376 %0.0
Peripheral ischemia,1/559 %0.18,0/575 %0.0,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Thromboembolic event,3/559 %0.54,3/575 %0.52,0/12 %0.0,0/33 %0.0,1/47 %2.13,0/376 %0.0

TRC105 for Liver Cancer That Has Not Responded to Sorafenib(https://clinicaltrials.gov/show/NCT01375569)
 ,TRC105 in Liver Cancer
 ,TRC105 is an experimental cancer drug designed to slow or stop the growth of tumors. It does this by preventing the growth of new blood vessels that feed these tumors. This drug is being used to test the safety and effectiveness to treat liver cancer that has not responded to standard therapy. TRC105 will be given as an intravenous infusion every two weeks.
Total all-cause mortality,0/11 %0.0
Total serious adverse events,5/11 %45.45
Myocardial infarction,1/11 %9.09
Hepatic failure,1/11 %9.09
Lung infection,1/11 %9.09
Aspartate aminotransferase increased,1/11 %9.09
Neoplasms benign malignant and unspecified (incl cysts and polyps) - Other specify,1/11 %9.09
Encephalopathy,1/11 %9.09

Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer(https://clinicaltrials.gov/show/NCT01471353)
 ,Sorafenib Plus Capecitabine (SorCape)
 ,Sorafenib 200-400 mg PO twice daily on days 1-21 (dose escalation schema) plus Capecitabine 1000 mg/m2 PO twice daily on days 1-14 repeated every 21 days. Single arm study. Sorafenib Plus Capecitabine (SorCape): Sorafenib 200-400 mg PO twice daily on days 1-21 (dose escalation schema) plus Capecitabine 1000 mg/m2 PO twice daily on days 1-14 repeated every 21 days
Total serious adverse events,13/42 %30.95
Anemia,1/42 %2.38
Spleen Disorder,1/42 %2.38
Sinus Tachycardia,1/42 %2.38
Abdominal Pain,2/42 %4.76
Colonic Obstruction,1/42 %2.38
Gastrointestinal Disorders - Other Bowel Perforation,1/42 %2.38
Fatigue,1/42 %2.38
General Disorders and Administration Site Conditions - Other Anasarca,1/42 %2.38
Non-Cardiac Chest Pain,2/42 %4.76
Pain,1/42 %2.38
Hepatobiliary Disorders - Other Cirrhosis,1/42 %2.38
Sepsis,1/42 %2.38
Creatinine Increased,1/42 %2.38
Hyponatremia,1/42 %2.38
Dehydration,2/42 %4.76
Generalized Muscle Weakness,1/42 %2.38
Syncope,1/42 %2.38
Agitation,1/42 %2.38
Confusion,1/42 %2.38
Delirium,2/42 %4.76
Pneumothorax,1/42 %2.38

MEDI-573 in Combination With SOC in Unresectable or Metastatic HCC.(https://clinicaltrials.gov/show/NCT01498952)
 ,Phase 1b Cohort A,Phase 1b Cohort B
 ,Participants received MEDI-573 10 mg/kg IV on Day 1 of each 21-day cycle and sorafenib 400 mg orally twice daily as background therapy until unacceptable toxicity documentation of disease progression initiation of alternative anticancer treatment or withdrawal for other reasons.,Participants received MEDI-573 45 mg/kg IV on Day 1 of each 21-day cycle and sorafenib 400 mg orally twice daily as background therapy until unacceptable toxicity documentation of disease progression initiation of alternative anticancer treatment or withdrawal for other reasons.
Total all-cause mortality,2/3 %66.67,2/3 %66.67
Total serious adverse events,1/3 %33.33,1/3 %33.33
Abdominal pain,1/3 %33.33,0/3 %0.0
Asthenia,1/3 %33.33,0/3 %0.0
Non-cardiac chest pain,1/3 %33.33,0/3 %0.0
Hepatic failure,0/3 %0.0,1/3 %33.33
Lipase increased,0/3 %0.0,1/3 %33.33
Hepatic encephalopathy,0/3 %0.0,1/3 %33.33
Pneumothorax,1/3 %33.33,0/3 %0.0

Sorafenib for the Treatment of Chronic Lymphocytic Leukemia (CLL)(https://clinicaltrials.gov/show/NCT01510756)
 ,Sorafenib
 ,Sorafenib 400mg orally twice daily will be administered for three cycles (1 cycle = 28 days). Sorafenib: Sorafenib 400mg orally twice daily will be administered for three cycles (1 cycle = 28 days). Subjects without significant toxicity or progressive disease may elect to continue treatment for a total of twelve cycles.
Total serious adverse events,1/4 %25.0
Brain abscess (aspergillus),1/4 %25.0

Phase I/II Study of Combination of Sorafenib  Vorinostat  and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype(https://clinicaltrials.gov/show/NCT01534260)
 ,Phase I Dose Escalating,Phase II at MTD
 ,escalating dose cohorts of sorafenib vorinostat and bortezomib. All cohorts will receive sorafenib from day 1 to 14 and vorinostat from day 1 to 4 and day 8 to 12. Bortezomib will be given on days 1 and 8 for all cohorts with cohorts 4 and 5 also receiving bortezomib on days 4 and 11 for cycles 1 through 4. This will be followed by 7 days of rest. Therefore each cycle will be 21 days.,patients received sorafenib at 400 mg bid from day 1 to 14 and vorinostat 200 mg bid from day 1 to 14. Bortezomib will be given at 1.3 mg/m2 on days 1 4 8 and 11 for cycles 1-4 and then on days 1 and 8 for cycle 5 and beyond. Bortezomib will be given on days 1 and 8 beyond 4 cycles to reduce the risk of neurotoxicity.
Total serious adverse events,7/17 %41.18,11/20 %55.0
Febrile neutropenia,2/17 %11.76,1/20 %5.0
Myocardial infarction,0/17 %0.0,1/20 %5.0
Eye disorders  Other,0/17 %0.0,1/20 %5.0
Diarrhea,0/17 %0.0,2/20 %10.0
Nausea,1/17 %5.88,0/20 %0.0
Rectal hemorrhage,1/17 %5.88,0/20 %0.0
Fever,3/17 %17.65,2/20 %10.0
Lung infection,1/17 %5.88,1/20 %5.0
Sepsis,1/17 %5.88,2/20 %10.0
Neutrophil count decreased,0/17 %0.0,1/20 %5.0
Generalized muscle weakness,0/17 %0.0,1/20 %5.0
Myositis,0/17 %0.0,1/20 %5.0
Syncope,0/17 %0.0,1/20 %5.0
Epistaxis,1/17 %5.88,0/20 %0.0
Respiratory failure,0/17 %0.0,2/20 %10.0

Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate(https://clinicaltrials.gov/show/NCT01582009)
 ,Arm I: Oral Panobinostat and Oral Everolimus
 ,Patients receive oral panobinostat once daily on days 1 3 4 8 10 and 12 and oral everolimus once daily on days 1-21. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. panobinostat: Given orally everolimus: Given orally laboratory biomarker analysis: Correlative studies pharmacological study: Correlative studies liquid chromatography: Correlative studies mass spectrometry: Correlative studies enzyme-linked immunosorbent assay: Correlative studies immunohistochemistry staining method: Correlative studies
Total serious adverse events,9/26 %34.62
Thrombocytopenia,1/26 %3.85
Atrial fibrillation,1/26 %3.85
Supraventricular tachycardia,1/26 %3.85
Abdominal hernia,1/26 %3.85
Abdominal pain lower,1/26 %3.85
Disease progression,1/26 %3.85
Pneumocystis jiroveci pneumonia,1/26 %3.85
Pneumonia,1/26 %3.85
Contusion,1/26 %3.85
Dehydration,1/26 %3.85
Muscular weakness,1/26 %3.85
Confusional state,1/26 %3.85
Dyspnoea,1/26 %3.85

SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)(https://clinicaltrials.gov/show/NCT01752933)
 ,Guadecitabine 60 mg/m^2,Guadecitabine 45 mg/m^2
 ,Guadecitabine (SGI-110) 60 mg/m^2 SC on Days 1 - 5 of each 28-day cycle,Guadecitabine (SGI-110) 45 mg/m^2 SC on Days 1 - 5 of each 28-day cycle
Total all-cause mortality,4/4 %100.0,34/46 %73.91
Total serious adverse events,1/4 %25.0,21/46 %45.65
Anaemia,0/4 %0.0,1/46 %2.17
Febrile neutropenia,1/4 %25.0,5/46 %10.87
Atrial fibrillation,0/4 %0.0,1/46 %2.17
Adrenal haemorrhage,0/4 %0.0,1/46 %2.17
Abdominal pain,0/4 %0.0,2/46 %4.35
Ascites,0/4 %0.0,1/46 %2.17
Diarrhoea,0/4 %0.0,1/46 %2.17
Gastrointestinal haemorrhage,0/4 %0.0,1/46 %2.17
Nausea,0/4 %0.0,1/46 %2.17
Oesophagitis,0/4 %0.0,1/46 %2.17
Upper gastrointestinal haemorrhage,0/4 %0.0,1/46 %2.17
Vomiting,0/4 %0.0,1/46 %2.17
Hyperbilirubinaemia,0/4 %0.0,1/46 %2.17
Portal vein thrombosis,0/4 %0.0,1/46 %2.17
Pneumonia,0/4 %0.0,1/46 %2.17
Staphylococcal sepsis,0/4 %0.0,1/46 %2.17
Road traffic accident,0/4 %0.0,2/46 %4.35
Blood creatinine increased,0/4 %0.0,1/46 %2.17
Hyponatremia,0/4 %0.0,1/46 %2.17
Pain in extremity,0/4 %0.0,2/46 %4.35
Hepatic encephalopathy,0/4 %0.0,1/46 %2.17
Nephrolithiasis,0/4 %0.0,1/46 %2.17
Renal failure acute,0/4 %0.0,1/46 %2.17
Scrotal pain,0/4 %0.0,1/46 %2.17
Hypoxia,0/4 %0.0,1/46 %2.17
Respiratory failure,0/4 %0.0,1/46 %2.17
Hypotension,0/4 %0.0,1/46 %2.17

A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective(https://clinicaltrials.gov/show/NCT01754987)
 ,Ascorbic Acid + Sorafenib,Sorafenib Alone
 ,Drug: Vitamin C Other Names: Ascorbic Acid Ascorbate Dosage: Vitamin C : 100 grams (infusion) Phase I: 3x a week for 8 weeks Phase II: 3x a week for 16 weeks Sorafenib: taken daily (oral) Ascorbic Acid + Sorafenib,Sorafenib: taken daily (oral) Sorafenib
Total serious adverse events,1/5 %20.0,0/0 %0.0
Dehydration,1/5 %20.0,0/0 %0.0

Sorafenib + mFOLFOX for Hepatocellular Carcinoma(https://clinicaltrials.gov/show/NCT01775501)
 ,FOLFOX + Sorafenib
 ,FOLFOX (Leucovorin Fluorouracil and Oxaliplatin) + Sorafenib Sorafenib: orally twice daily FOLFOX: injected via portacath once every two weeks Leucovorin: 200mg/m2 administered IV on Days 1 and 15 of a 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops. Fluorouracil: 5-FU continuous infusion: 2400mg/m2 total (1200mg/m2/d on day 1 and 2) to start on Day 1 and Day 15 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops. Oxaliplatin: 85 mg/m2 IV on Days 1 and 15 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops. Sorafenib: 400mg po BID continuously for a 2 week lead-in phase and then Days 1-28 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
Total all-cause mortality,2/40 %5.0
Total serious adverse events,32/40 %80.0
Anemia,3/40 %7.5
Bleeding (Epistaxis Hematuria Hematoma Hemorrhoidal hemorrhage Rectal hemorrhage),1/40 %2.5
Diarrhea,4/40 %10.0
Mouth Sores,1/40 %2.5
Pancreatitis,1/40 %2.5
Fatigue,3/40 %7.5
Fever,1/40 %2.5
Vascular access complication,1/40 %2.5
Alanine aminotransferase increased,6/40 %15.0
Alkaline phosphatase increased,2/40 %5.0
Aspartate aminotransferase increased,9/40 %22.5
Blood bilirubin increased,4/40 %10.0
Lipase increased,9/40 %22.5
Lymphocyte count decreased,7/40 %17.5
Neutrophil count decreased,3/40 %7.5
Platelet count decreased,2/40 %5.0
Serum amylase increased,2/40 %5.0
Hyperglycemia,1/40 %2.5
Hypernatremia,1/40 %2.5
Hyponatremia,2/40 %5.0
Hypophosphatemia,13/40 %32.5
Pneumonitis,1/40 %2.5
Diaphoresis,1/40 %2.5
Palmar-plantar erythrodysesthesia syndrome,3/40 %7.5
Rash,1/40 %2.5
Flushing,1/40 %2.5
Hypertension,2/40 %5.0

Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein(https://clinicaltrials.gov/show/NCT01887717)
 ,TheraSphere,Sorafenib
 ,Participants received TheraSphere at a dose consistent with the approved package insert to the treated lobe of the liver. TheraSphere was administered through the hepatic artery. The targeted dose was 120 Gy + 10%. Dose reduction to a minimum dose of 80 Gy + 10% was permitted to manage radiation exposure to the lungs. Re-treatment of the same participant/lobe with further cycles of TheraSphere was permitted if a treatable progression was detected during follow-up evaluations. Any re-treatment took place at least 28 days after the previous TheraSphere treatment administered to that lobe. Participants could receive a subsequent TheraSphere administration in the absence of radiological progression criteria at the Investigator's discretion. A maximum of 3 TheraSphere administrations was permitted.,Participants received sorafenib oral tablets 400 milligrams (mg) twice daily in accordance with the package insert. Treatment was to continue until the participant was no longer clinically benefiting from therapy or until unacceptable toxicity occurred. Medically appropriate dose adjustments and drug holidays due to adverse events (AEs) and toxicity were allowed.
Total all-cause mortality,15/15 %100.0,16/16 %100.0
Total serious adverse events,0/15 %0.0,12/16 %75.0
Diarrhoea,0/15 %0.0,1/16 %6.25
Gastrointestinal haemorrhage,0/15 %0.0,1/16 %6.25
Gastrointestinal vascular malformation,0/15 %0.0,1/16 %6.25
Haematemesis,0/15 %0.0,1/16 %6.25
Nausea,0/15 %0.0,1/16 %6.25
Vomiting,0/15 %0.0,1/16 %6.25
General Physical Health Deterioration,0/15 %0.0,1/16 %6.25
Influenza like illness,0/15 %0.0,1/16 %6.25
Hepatic encephalopathy,0/15 %0.0,2/16 %12.5
Dyspnoea,0/15 %0.0,1/16 %6.25
Respiratory Failure,0/15 %0.0,1/16 %6.25

A Study To Evaluate The Efficacy And Safety of The Investigational Drug PF-03446962 (A Monoclonal Antibody With Antiangiogenic Features) In Combination With Best Supportive Care Versus Placebo Plus Best Supportive Care In Patients Affected By Recurrent Liver Cancer(https://clinicaltrials.gov/show/NCT01911273)
 ,PF-03446962 Plus BSC,BSC Alone
 ,PF-03446962 7 mg/kg was administered IV as 1-hour infusion q2w plus BSC,BSC might vary depending on the participant's signs and symptoms site current practice and country practice and might include medications and supportive measures deemed necessary to palliate disease-related symptoms and improve quality of life.
Total serious adverse events,0/1 %0.0,0/2 %0.0

Efficacy  Safety  and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma(https://clinicaltrials.gov/show/NCT01988493)
 ,Phase 1b: Tepotinib 300 mg,Phase 1b: Tepotinib 500 mg,Phase 1b: Tepotinib 1000 mg,Phase 2: Tepotinib,Phase 2 Sorafenib
 ,Participants received Tepotinib 300 milligram (mg) orally once daily over a 21-day cycle until disease progression intolerable toxicity or participant withdrawal.,Participants received Tepotinib 500 mg orally once daily over a 21-day cycle until disease progression intolerable toxicity or participant withdrawal.,Participants received Tepotinib 1000 mg orally once daily over a 21-day cycle until disease progression intolerable toxicity or participant withdrawal.,Participants randomized to receive Tepotinib recommended Phase 2 dose (RP2D) determined from Phase 1b over a 21-day cycle until disease progression intolerable toxicity or participant withdrawal.,Participants randomized to receive Sorafenib 400 mg orally twice daily over a 21-day cycle until disease progression intolerable toxicity or participant withdrawal.
Total all-cause mortality,7/7 %100.0,11/14 %78.57,3/6 %50.0,24/45 %53.33,30/44 %68.18
Total serious adverse events,2/7 %28.57,9/14 %64.29,4/6 %66.67,23/45 %51.11,12/44 %27.27
Thrombocytopenia,0/7 %0.0,0/14 %0.0,0/6 %0.0,1/45 %2.22,0/44 %0.0
Supraventricular tachycardia,0/7 %0.0,0/14 %0.0,0/6 %0.0,1/45 %2.22,0/44 %0.0
Abdominal pain,0/7 %0.0,1/14 %7.14,1/6 %16.67,2/45 %4.44,2/44 %4.55
Ascites,0/7 %0.0,1/14 %7.14,0/6 %0.0,2/45 %4.44,0/44 %0.0
Diarrhoea,0/7 %0.0,1/14 %7.14,0/6 %0.0,1/45 %2.22,1/44 %2.27
Duodenal ulcer,0/7 %0.0,1/14 %7.14,0/6 %0.0,0/45 %0.0,0/44 %0.0
Encapsulating peritoneal sclerosis,0/7 %0.0,1/14 %7.14,0/6 %0.0,0/45 %0.0,0/44 %0.0
Ileus,0/7 %0.0,1/14 %7.14,0/6 %0.0,1/45 %2.22,0/44 %0.0
Melaena,0/7 %0.0,1/14 %7.14,0/6 %0.0,0/45 %0.0,0/44 %0.0
Upper gastrointestinal haemorrhage,0/7 %0.0,1/14 %7.14,0/6 %0.0,1/45 %2.22,1/44 %2.27
Duodenal ulcer haemorrhage,0/7 %0.0,0/14 %0.0,0/6 %0.0,1/45 %2.22,0/44 %0.0
Peritoneal haemorrhage,0/7 %0.0,0/14 %0.0,0/6 %0.0,1/45 %2.22,0/44 %0.0
Disease progression,1/7 %14.29,0/14 %0.0,0/6 %0.0,7/45 %15.56,2/44 %4.55
Asthenia,0/7 %0.0,0/14 %0.0,0/6 %0.0,0/45 %0.0,1/44 %2.27
Hernia,0/7 %0.0,0/14 %0.0,0/6 %0.0,1/45 %2.22,0/44 %0.0
Oedema peripheral,0/7 %0.0,0/14 %0.0,0/6 %0.0,2/45 %4.44,0/44 %0.0
Cholecystitis acute,0/7 %0.0,0/14 %0.0,0/6 %0.0,0/45 %0.0,1/44 %2.27
Hepatic failure,0/7 %0.0,0/14 %0.0,0/6 %0.0,1/45 %2.22,1/44 %2.27
Hepatic function abnormal,0/7 %0.0,0/14 %0.0,0/6 %0.0,1/45 %2.22,0/44 %0.0
Candida infection,0/7 %0.0,0/14 %0.0,1/6 %16.67,0/45 %0.0,0/44 %0.0
Cellulitis,0/7 %0.0,0/14 %0.0,0/6 %0.0,1/45 %2.22,0/44 %0.0
Enteritis infectious,0/7 %0.0,0/14 %0.0,0/6 %0.0,1/45 %2.22,0/44 %0.0
Pneumonia,0/7 %0.0,1/14 %7.14,0/6 %0.0,0/45 %0.0,0/44 %0.0
Alanine aminotransferase increased,1/7 %14.29,0/14 %0.0,0/6 %0.0,0/45 %0.0,0/44 %0.0
Aspartate aminotransferase increased,1/7 %14.29,0/14 %0.0,0/6 %0.0,0/45 %0.0,0/44 %0.0
Blood bilirubin increased,0/7 %0.0,1/14 %7.14,0/6 %0.0,0/45 %0.0,1/44 %2.27
Lipase increased,0/7 %0.0,0/14 %0.0,0/6 %0.0,0/45 %0.0,1/44 %2.27
Decreased appetite,0/7 %0.0,0/14 %0.0,1/6 %16.67,1/45 %2.22,0/44 %0.0
Hyperglycaemia,0/7 %0.0,0/14 %0.0,0/6 %0.0,1/45 %2.22,0/44 %0.0
Muscular weakness,0/7 %0.0,0/14 %0.0,1/6 %16.67,0/45 %0.0,0/44 %0.0
Musculoskeletal pain,0/7 %0.0,0/14 %0.0,0/6 %0.0,1/45 %2.22,0/44 %0.0
Gouty arthritis,0/7 %0.0,0/14 %0.0,0/6 %0.0,1/45 %2.22,0/44 %0.0
Metastases to central nervous system,0/7 %0.0,0/14 %0.0,0/6 %0.0,0/45 %0.0,1/44 %2.27
Bladder cancer,0/7 %0.0,1/14 %7.14,0/6 %0.0,0/45 %0.0,0/44 %0.0
Cerebrovascular accident,0/7 %0.0,1/14 %7.14,0/6 %0.0,0/45 %0.0,0/44 %0.0
Haemorrhage intracranial,0/7 %0.0,1/14 %7.14,0/6 %0.0,0/45 %0.0,1/44 %2.27
Hepatic encephalopathy,0/7 %0.0,0/14 %0.0,0/6 %0.0,2/45 %4.44,1/44 %2.27
Paraesthesia,0/7 %0.0,0/14 %0.0,0/6 %0.0,2/45 %4.44,0/44 %0.0
Seizure,0/7 %0.0,0/14 %0.0,1/6 %16.67,0/45 %0.0,0/44 %0.0
Dyspnoea exertional,1/7 %14.29,0/14 %0.0,0/6 %0.0,0/45 %0.0,0/44 %0.0
Haemoptysis,1/7 %14.29,0/14 %0.0,0/6 %0.0,0/45 %0.0,0/44 %0.0
Pleural effusion,1/7 %14.29,0/14 %0.0,0/6 %0.0,0/45 %0.0,0/44 %0.0
Rash maculo-papular,0/7 %0.0,1/14 %7.14,0/6 %0.0,0/45 %0.0,0/44 %0.0
Deep vein thrombosis,0/7 %0.0,0/14 %0.0,0/6 %0.0,0/45 %0.0,1/44 %2.27
Hypertension,1/7 %14.29,0/14 %0.0,0/6 %0.0,0/45 %0.0,0/44 %0.0
Lymphoedema,0/7 %0.0,0/14 %0.0,0/6 %0.0,1/45 %2.22,0/44 %0.0

Sorafenib Tosylate  Combination Chemotherapy  Radiation Therapy  and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma(https://clinicaltrials.gov/show/NCT02050919)
 ,Treatment (Sorafenib Chemotherapy Radiation Surgery)
 ,Patients receive sorafenib tosylate PO QD on days 1-71 and 85-155 epirubicin hydrochloride IV over 3-5 minutes and ifosfamide IV over 90 minutes on days 15-17 36-38 (ifosfamide only) 57-59 99-101 120-122 and 141-143. Patients undergo EBRT on days 36-45 and surgical resection on day 78. Patients with positive margins undergo EBRT boost on days 91-98. Epirubicin Hydrochloride: Given IV External Beam Radiation Therapy: Undergo EBRT Ifosfamide: Given IV Laboratory Biomarker Analysis: Correlative studies Sorafenib Tosylate: Given PO Therapeutic Conventional Surgery: Undergo surgical resection
Total all-cause mortality,5/20 %25.0
Total serious adverse events,18/20 %90.0
Febrile Neutropenia,12/20 %60.0
Constipation,1/20 %5.0
Diarrhea,1/20 %5.0
Catheter Related infection,1/20 %5.0
enterocolitis infectious,1/20 %5.0
Sepsis,3/20 %15.0
Soft tissue infection,1/20 %5.0
wound infection,7/20 %35.0
wound dehiscence,1/20 %5.0
Lymphocyte count decreased,1/20 %5.0
Neutrophil Count decreased,1/20 %5.0
Platelet Count Decreased,2/20 %10.0
Hypokalemia,1/20 %5.0
Encephalopathy,3/20 %15.0
syncope,1/20 %5.0
Delirium,1/20 %5.0
Palmar-plantar erythrodysesthesia syndrome,1/20 %5.0

Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis(https://clinicaltrials.gov/show/NCT02066181)
 ,Arm I (Sorafenib Tosylate),Arm II (Placebo),Crossover Group
 ,Patients receive sorafenib tosylate PO QD on days 1-28.,Patients receive placebo PO QD on days 1-28. Patients may crossover to Arm I upon disease progression.,Upon disease progression patients treated with placebo will be allowed to crossover to the open label sorafenib arm.
Total all-cause mortality,1/49 %2.04,0/36 %0.0,0/28 %0.0
Total serious adverse events,11/49 %22.45,6/36 %16.67,5/28 %17.86
Anemia,1/49 %2.04,0/36 %0.0,0/28 %0.0
Blood and lymphatic system disorders - Other specify,1/49 %2.04,0/36 %0.0,0/28 %0.0
Chest pain - cardiac,1/49 %2.04,0/36 %0.0,0/28 %0.0
Heart failure,1/49 %2.04,0/36 %0.0,0/28 %0.0
Palpitations,1/49 %2.04,0/36 %0.0,0/28 %0.0
Abdominal pain,0/49 %0.0,1/36 %2.78,0/28 %0.0
Diarrhea,2/49 %4.08,0/36 %0.0,0/28 %0.0
Gastric perforation,1/49 %2.04,0/36 %0.0,0/28 %0.0
Malabsorption,0/49 %0.0,0/36 %0.0,1/28 %3.57
Nausea,1/49 %2.04,1/36 %2.78,0/28 %0.0
Pancreatitis,1/49 %2.04,0/36 %0.0,0/28 %0.0
Small intestinal obstruction,0/49 %0.0,2/36 %5.56,0/28 %0.0
Vomiting,0/49 %0.0,1/36 %2.78,0/28 %0.0
Fatigue,2/49 %4.08,0/36 %0.0,0/28 %0.0
Fever,0/49 %0.0,1/36 %2.78,0/28 %0.0
General disorders and administration site conditions - Other specify,0/49 %0.0,1/36 %2.78,0/28 %0.0
Appendicitis,0/49 %0.0,0/36 %0.0,1/28 %3.57
Sepsis,0/49 %0.0,0/36 %0.0,1/28 %3.57
Injury poisoning and procedural complications - Other specify,0/49 %0.0,0/36 %0.0,1/28 %3.57
Alanine aminotransferase increased,0/49 %0.0,0/36 %0.0,1/28 %3.57
Hypertriglyceridemia,1/49 %2.04,1/36 %2.78,0/28 %0.0
Arthralgia,1/49 %2.04,0/36 %0.0,0/28 %0.0
Flank pain,0/49 %0.0,1/36 %2.78,0/28 %0.0
Pregnancy puerperium and perinatal conditions - Other specify,1/49 %2.04,0/36 %0.0,0/28 %0.0
Unintended pregnancy,1/49 %2.04,0/36 %0.0,0/28 %0.0
Acute kidney injury,1/49 %2.04,0/36 %0.0,0/28 %0.0
Dyspnea,1/49 %2.04,0/36 %0.0,0/28 %0.0
Palmar-plantar erythrodysesthesia syndrome,2/49 %4.08,0/36 %0.0,0/28 %0.0
Skin and subcutaneous tissue disorders - Other specify,1/49 %2.04,0/36 %0.0,0/28 %0.0
Hypertension,1/49 %2.04,1/36 %2.78,1/28 %3.57

c-Met Second-Line Hepatocellular Carcinoma(https://clinicaltrials.gov/show/NCT02115373)
 ,Phase 1b: Tepotinib 300 mg,Phase 1b: Tepotinib 500 mg,Phase 2: Tepotinib 500 mg
 ,Participants received a single oral dose of Tepotinib 300 milligram (mg) daily in each 21 days treatment cycle until progressive disease intolerable toxicity death or withdrawal from treatment.,Participants received a single oral dose of Tepotinib 500 mg daily in each 21 days treatment cycle until progressive disease intolerable toxicity death or withdrawal from treatment.,Participants received a single oral dose of Tepotinib 500 mg daily in each 21 days treatment cycle until progressive disease intolerable toxicity death or withdrawal from treatment.
Total all-cause mortality,3/4 %75.0,11/13 %84.62,40/49 %81.63
Total serious adverse events,2/4 %50.0,5/13 %38.46,21/49 %42.86
Abdominal pain,1/4 %25.0,0/13 %0.0,0/49 %0.0
Ascites,0/4 %0.0,2/13 %15.38,3/49 %6.12
Gastrointestinal haemorrhage,0/4 %0.0,0/13 %0.0,1/49 %2.04
Disease progression,1/4 %25.0,1/13 %7.69,7/49 %14.29
Localised oedema,0/4 %0.0,1/13 %7.69,0/49 %0.0
Oedema peripheral,0/4 %0.0,2/13 %15.38,1/49 %2.04
Discomfort,0/4 %0.0,0/13 %0.0,1/49 %2.04
General physical health deterioration,0/4 %0.0,0/13 %0.0,1/49 %2.04
Pyrexia,0/4 %0.0,0/13 %0.0,1/49 %2.04
Vascular stent stenosis,0/4 %0.0,0/13 %0.0,1/49 %2.04
Cholangitis,0/4 %0.0,0/13 %0.0,1/49 %2.04
Hepatic failure,0/4 %0.0,0/13 %0.0,1/49 %2.04
Jaundice,0/4 %0.0,0/13 %0.0,1/49 %2.04
Hepatorenal syndrome,0/4 %0.0,1/13 %7.69,0/49 %0.0
Device related infection,0/4 %0.0,0/13 %0.0,1/49 %2.04
Peritonitis bacterial,0/4 %0.0,0/13 %0.0,1/49 %2.04
Sepsis,0/4 %0.0,1/13 %7.69,1/49 %2.04
Peritonitis,0/4 %0.0,1/13 %7.69,0/49 %0.0
Post procedural infection,1/4 %25.0,0/13 %0.0,0/49 %0.0
Blood bilirubin increased,1/4 %25.0,0/13 %0.0,0/49 %0.0
Hypercalcaemia,0/4 %0.0,0/13 %0.0,1/49 %2.04
Hypercreatininaemia,0/4 %0.0,0/13 %0.0,1/49 %2.04
Hyponatraemia,0/4 %0.0,0/13 %0.0,1/49 %2.04
Decreased appetite,1/4 %25.0,0/13 %0.0,0/49 %0.0
Rhabdomyolysis,0/4 %0.0,0/13 %0.0,1/49 %2.04
Cancer pain,0/4 %0.0,0/13 %0.0,1/49 %2.04
Tumour pain,0/4 %0.0,0/13 %0.0,1/49 %2.04
Coma,0/4 %0.0,1/13 %7.69,0/49 %0.0
Hepatic encephalopathy,0/4 %0.0,1/13 %7.69,0/49 %0.0
Cerebral thrombosis,0/4 %0.0,0/13 %0.0,1/49 %2.04
Hypoglycaemic coma,0/4 %0.0,0/13 %0.0,1/49 %2.04
Acute kidney injury,1/4 %25.0,1/13 %7.69,3/49 %6.12
Chronic kidney disease,0/4 %0.0,0/13 %0.0,1/49 %2.04
Prostatitis,0/4 %0.0,1/13 %7.69,0/49 %0.0
Pneumonia aspiration,0/4 %0.0,0/13 %0.0,1/49 %2.04

Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation(https://clinicaltrials.gov/show/NCT02196857)
 ,Azacytidine + Sorafenib
 ,Azacitidine 75 mg/m2 administered subcutaneously (SQ) or intravenously (IV) daily for 7 days per 28 day cycle. Sorafenib administered orally at a dose of 400 mg twice daily every day continuously. Azacytidine: 75 mg/m2 administered subcutaneously (SQ) or intravenously (IV) on Days 1 - 7 for a 28 day cycle. Sorafenib: 400 mg by mouth twice daily about 12 hours apart every day for a 28 day cycle.
Total all-cause mortality,0/16 %0.0
Total serious adverse events,14/16 %87.5
Cardiac Triponin Increase,1/16 %6.25
Intracranial Hemorrhage,1/16 %6.25
Thrombocytopenia,1/16 %6.25
Acute Heart Failure,1/16 %6.25
Colitis,2/16 %12.5
Dehydration,1/16 %6.25
Intestine Obstruction,1/16 %6.25
Facial Pain/Dental,1/16 %6.25
Fatigue,1/16 %6.25
Fever,1/16 %6.25
Cellulitis,1/16 %6.25
Febrile Neutropenia,5/16 %31.25
Urinary Tract Infection,2/16 %12.5
Infection,1/16 %6.25
Lung Infection,5/16 %31.25
Sepsis,1/16 %6.25
Skin Infection,1/16 %6.25
Arthritis,1/16 %6.25
Seizure,1/16 %6.25
Stroke,1/16 %6.25
Syncope,1/16 %6.25
Tremor,1/16 %6.25
Acute Kidney failure,1/16 %6.25
generalized edema,1/16 %6.25
Acute Respiratory Failure,1/16 %6.25
Dyspnea,2/16 %12.5
Laryngeal Hemorrhage,1/16 %6.25
Laryngeal Inflammation,2/16 %12.5
Hypotnesion,4/16 %25.0

A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma(https://clinicaltrials.gov/show/NCT02460991)
 ,DEB-TACE,Sorafenib
 ,ONCO-DOX (Doxorubicin loaded Microspheres) up to 150 mg per treatment; treatments could be repeated every 4-8 weeks until complete tumor response was achieved,200 mg of Sorafenib twice daily; continue until unacceptable toxicity or unequivocal tumor progression
Total all-cause mortality,0/0 %0.0,0/2 %0.0
Total serious adverse events,0/0 %0.0,1/2 %50.0
Hypertensive Emergency,0/0 %0.0,1/2 %50.0

S9912 Combination Chemo in Stage III Ovarian Cancer (https://clinicaltrials.gov/show/NCT00003896)
 ,Paclitaxel/CDDP/Liposomal Doxorubicin
 
Total serious adverse events,2/61 %3.28
GI Mucositis NOS,1/61 %1.64
Infection with 3-4 neutropenia,1/61 %1.64
Infection unk ANC,1/61 %1.64
Leukopenia,1/61 %1.64
Dehydration,1/61 %1.64

Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer(https://clinicaltrials.gov/show/NCT00005908)
 ,Docetaxel/Capecitabine - A & B
 ,Docetaxel/Capecitabine - A- Docetaxel 75 mg/m^2 intravenous day 1capecitabine 1000 mg/m^2 orally twice daily day 2-15 for 4 cycles. Docetaxel/Capecitabine - B- Docetaxel 60 mg/m2 intravenous day 1 capecitabine 937.5 mg/m2 orally twice daily day 2-15
Total serious adverse events,29/30 %96.67
Febrile neutropenia,3/30 %10.0
Lymphatics,1/30 %3.33
Diarrhea (without colostomy),5/30 %16.67
Abdominal pain or cramping,2/30 %6.67
Colitis,1/30 %3.33
Dehydration,1/30 %3.33
Nausea,1/30 %3.33
Stomatitis/pharyngitis (oral/pharyngeal/mucositis),1/30 %3.33
Vomiting,1/30 %3.33
Fatigue (lethargy malaise asthenia),3/30 %10.0
Allergic reaction/hypersensitivity (including drug fever),2/30 %6.67
Infection Other,5/30 %16.67
Infection (documented clinically or microbiologically) with grade 3 or 4 neutropenia,4/30 %13.33
Infection without neutropenia,2/30 %6.67
Injection site reaction,1/30 %3.33
Wound-infectious,1/30 %3.33
Wound-non-infectious,1/30 %3.33
Leukocytes (total WBC),12/30 %40.0
Neutrophils/granulocytes (ANC/AGC),26/30 %86.67
SGOT (AST),1/30 %3.33
SGPT (ALT),1/30 %3.33
Hyperglycemia,5/30 %16.67
Hypokalemia,1/30 %3.33
Hyponatremia,1/30 %3.33
Hypophosphatemia,1/30 %3.33
Myalgia (muscle ache),2/30 %6.67
Arthralgia (joint pain),1/30 %3.33
Bone pain,1/30 %3.33
Neuropathy-sensory,1/30 %3.33
Headache,1/30 %3.33
Syncope,1/30 %3.33
Mood alteration-depression,1/30 %3.33
Urinary frequency/urgency,1/30 %3.33
Pleural effusion (non-malignant),1/30 %3.33
Hand/foot skin reaction,13/30 %43.33
Urticaria (hives welts wheals),1/30 %3.33
Anorexia,1/30 %3.33
Thrombosis/embolism,2/30 %6.67

Chemotherapy  Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma(https://clinicaltrials.gov/show/NCT00006184)
 ,Recipient - Chemotherapy Group,Donor - Vaccination Generation Group
 ,Induction chemotherapy with fludarabine etoposide doxorubicin vincristine cyclophosphamide prednisone and GCSF followed by transplant preparative regimen chemotherapy with fludarabine cyclophosphamide mesna cyclosporine and methotrexate followed by stem cell infusion and immunization.,3 subcutaneous injections of myeloma protein within 10 weeks before stem cell collection. The first (week 0) second (week 2) and third injection (week 6) with Id-KLH (0.5 mg subcutaneous day 1) and Granulocyte macrophage-colony stimulating factor (GM-CSF) (250 mcg/m^2 subcutaneous on days 1-4). Stem cell collection is 4 weeks after the third vaccination
Total all-cause mortality,0/10 %0.0,0/10 %0.0
Total serious adverse events,10/10 %100.0,0/10 %0.0
Febrile neutropenia,1/10 %10.0,0/10 %0.0
Abdominal pain or cramping,1/10 %10.0,0/10 %0.0
Diarrhea (without colostomy),1/10 %10.0,0/10 %0.0
Nausea and vomiting,1/10 %10.0,0/10 %0.0
Infection without neutropenia,2/10 %20.0,0/10 %0.0
Leukocytes (total WBC),6/10 %60.0,0/10 %0.0
Leukocytes (total WBC) for BMT,4/10 %40.0,0/10 %0.0
Neutrophils/granulocytes (ANC/AGC),7/10 %70.0,0/10 %0.0
Neutrophils/granulocytes (ANC/AGC) for BMT,8/10 %80.0,0/10 %0.0
Platelets,2/10 %20.0,0/10 %0.0
Platelets for BMT,2/10 %20.0,0/10 %0.0
SGOT (AST),1/10 %10.0,0/10 %0.0
SGPT (ALT),2/10 %20.0,0/10 %0.0
Transfusion: Platelets,1/10 %10.0,0/10 %0.0
Anorexia,3/10 %30.0,0/10 %0.0
Hyperglycemia,1/10 %10.0,0/10 %0.0
Metabolic-Other (GGT),1/10 %10.0,0/10 %0.0
Neurologic-Other (Neuropathy),1/10 %10.0,0/10 %0.0
Mood alteration::Depression,1/10 %10.0,0/10 %0.0
Hypoxia,2/10 %20.0,0/10 %0.0

S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma(https://clinicaltrials.gov/show/NCT00006721)
 ,CHOP Only,CHOP + Rituximab,CHOP + Tositumomab
 ,Patients receive cyclophosphamide IV over 15 minutes doxorubicin IV over 5-20 minutes and vincristine IV over 5-15 minutes on day 1. Patients also receive oral prednisone daily on days 1-5. Treatment continues every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. (Arm I closed to accrual as of 12/15/02),Patients receive cyclophosphamide IV over 15 minutes doxorubicin IV over 5-20 minutes and vincristine IV over 5-15 minutes on days 8 29 50 71 92 and 113. Patients also receive oral prednisone daily on days 8-12 29-33 50-54 71-75 92-96 and 113-117 and rituximab IV over 4-6 hours on days 1 6 48 90 134 and 141,Patients receive cyclophosphamide IV over 15 minutes doxorubicin IV over 5-20 minutes and vincristine IV over 5-15 minutes on days 1 22 43 64 85 and 106. Patients also receive oral prednisone daily on days 1-5 22-26 43-47 64-68 85-89 and 106-120 and tositumomab (monoclonal antibody anti-B1) IV over 1 hour followed by iodine I 131 tositumomab IV over 20 minutes on days 134 and 141
Total serious adverse events,0/13 %0.0,3/263 %1.14,16/263 %6.08
Febrile neutropenia,0/13 %0.0,0/263 %0.0,2/263 %0.76
Hematologic-other,0/13 %0.0,0/263 %0.0,3/263 %1.14
Platelet transfusion,0/13 %0.0,0/263 %0.0,1/263 %0.38
LVEF decrease/CHF,0/13 %0.0,0/263 %0.0,1/263 %0.38
Pancreatitis,0/13 %0.0,1/263 %0.38,0/263 %0.0
Infection w/o 3-4 neutropenia,0/13 %0.0,0/263 %0.0,2/263 %0.76
Respiratory infect w/ neutrop,0/13 %0.0,0/263 %0.0,1/263 %0.38
Neutropenia/granulocytopenia,0/13 %0.0,0/263 %0.0,1/263 %0.38
Second primary,0/13 %0.0,0/263 %0.0,6/263 %2.28
Cerebrovascular ischemia,0/13 %0.0,1/263 %0.38,0/263 %0.0
ARDS,0/13 %0.0,0/263 %0.0,1/263 %0.38
Thrombosis/embolism,0/13 %0.0,1/263 %0.38,0/263 %0.0

Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer(https://clinicaltrials.gov/show/NCT00011986)
 ,Carbo/Taxol,Carbo/Taxol/Gemcitabine,Carbo/Taxol/Doxil,Carbo/Topotecan - Carbo/Taxol,Carbo/Gemcitabine - Carbo/Taxol
 ,Carboplatin AUC 6 IV on day 1 plus Paclitaxel 175 mg/m2 IV on day 1 x 8 cycles,Carboplatin AUC 5 IV on day 1 plus Paclitaxel 175 mg/m2 IV on day 1 x 8 cycles plus Gemcitabine 800 mg/m2/dIV on days 1 and 8 x 8 cycles,Carboplatin AUC 5 IV on day 1 plus Paclitaxel 175 mg/m2 IV on day 1 x 8 cycles plus Doxil 30 mg/m2 IV every other cycle on day 1 x 8 cycles,Topotecan 1.25 mg/m2/dIV days 1-3 plus Carboplatin AUC 5 IV on day 3 plus x 4 cycles followed by Carboplatin AUC 6 IV on day 1 plus Paclitaxel 175 mg/m2 IV on day 1 x 4 cycles,Gemcitabine 1000 mg/m2/dIV on days 1 and 8 plus Carboplatin AUC 6 IV on day 8 plus x 4 cycles followed by Carboplatin AUC 6 IV on day 1 plus Paclitaxel 175 mg/m2 IV on day 1 x 4 cycles
Total serious adverse events,86/777 %11.07,107/774 %13.82,115/767 %14.99,77/766 %10.05,100/767 %13.04
Hemoglobin,2/777 %0.26,2/774 %0.26,1/767 %0.13,0/766 %0.0,3/767 %0.39
Platelets,1/777 %0.13,12/774 %1.55,2/767 %0.26,0/766 %0.0,8/767 %1.04
Neutrophils/Granulocytes,1/777 %0.13,3/774 %0.39,3/767 %0.39,3/766 %0.39,1/767 %0.13
Leukocytes,0/777 %0.0,0/774 %0.0,0/767 %0.0,1/766 %0.13,0/767 %0.0
Hypertension,1/777 %0.13,0/774 %0.0,0/767 %0.0,1/766 %0.13,1/767 %0.13
Circulatory Or Cardiac-Other,0/777 %0.0,0/774 %0.0,1/767 %0.13,0/766 %0.0,1/767 %0.13
Cardiac Left Ventricular Function,0/777 %0.0,1/774 %0.13,1/767 %0.13,0/766 %0.0,1/767 %0.13
Cardiac Troponin I,0/777 %0.0,0/774 %0.0,1/767 %0.13,0/766 %0.0,0/767 %0.0
Hypotension,1/777 %0.13,0/774 %0.0,0/767 %0.0,0/766 %0.0,0/767 %0.0
Sinus Tachycardia,0/777 %0.0,1/774 %0.13,2/767 %0.26,0/766 %0.0,0/767 %0.0
Phlebitis,0/777 %0.0,1/774 %0.13,0/767 %0.0,0/766 %0.0,1/767 %0.13
Vasovagal Episode,0/777 %0.0,1/774 %0.13,0/767 %0.0,0/766 %0.0,0/767 %0.0
Supraventricular Arrhythmias,1/777 %0.13,1/774 %0.13,1/767 %0.13,0/766 %0.0,1/767 %0.13
Thrombosis/Embolism,10/777 %1.29,9/774 %1.16,13/767 %1.69,13/766 %1.7,16/767 %2.09
Nodal/Junctional Arrhythmia/Dysrhythmia,0/777 %0.0,0/774 %0.0,1/767 %0.13,0/766 %0.0,0/767 %0.0
Arrhythmia- Other,0/777 %0.0,0/774 %0.0,1/767 %0.13,0/766 %0.0,2/767 %0.26
Cardiac-Ischemia/Infarction,1/777 %0.13,1/774 %0.13,2/767 %0.26,1/766 %0.13,0/767 %0.0
Sinus Bradycardia,0/777 %0.0,1/774 %0.13,0/767 %0.0,0/766 %0.0,0/767 %0.0
Edema,0/777 %0.0,1/774 %0.13,0/767 %0.0,1/766 %0.13,1/767 %0.13
Inner Ear/Hearing,0/777 %0.0,0/774 %0.0,0/767 %0.0,0/766 %0.0,1/767 %0.13
Hearing-Other,0/777 %0.0,1/774 %0.13,0/767 %0.0,0/766 %0.0,0/767 %0.0
Glaucoma,0/777 %0.0,1/774 %0.13,0/767 %0.0,0/766 %0.0,0/767 %0.0
Stomatitis/Pharyngitis,0/777 %0.0,0/774 %0.0,1/767 %0.13,0/766 %0.0,1/767 %0.13
Pancreatitis,0/777 %0.0,0/774 %0.0,0/767 %0.0,1/766 %0.13,0/767 %0.0
Gi-Other,1/777 %0.13,1/774 %0.13,0/767 %0.0,1/766 %0.13,0/767 %0.0
Ileus,5/777 %0.64,4/774 %0.52,2/767 %0.26,4/766 %0.52,5/767 %0.65
Gastritis,0/777 %0.0,0/774 %0.0,0/767 %0.0,2/766 %0.26,0/767 %0.0
Anorexia,0/777 %0.0,0/774 %0.0,0/767 %0.0,0/766 %0.0,1/767 %0.13
Dyspepsia/Heartburn,0/777 %0.0,0/774 %0.0,1/767 %0.13,1/766 %0.13,0/767 %0.0
Gastric Ulcer,1/777 %0.13,0/774 %0.0,1/767 %0.13,0/766 %0.0,0/767 %0.0
Colitis,0/777 %0.0,1/774 %0.13,1/767 %0.13,0/766 %0.0,0/767 %0.0
Ascites (Non-Malignant),0/777 %0.0,1/774 %0.13,1/767 %0.13,1/766 %0.13,1/767 %0.13
Fistula-Rectal/Anal,0/777 %0.0,0/774 %0.0,0/767 %0.0,1/766 %0.13,0/767 %0.0
Dehydration,2/777 %0.26,3/774 %0.39,2/767 %0.26,2/766 %0.26,1/767 %0.13
Constipation,6/777 %0.77,7/774 %0.9,3/767 %0.39,5/766 %0.65,3/767 %0.39
Diarrhea (Without Colostomy),1/777 %0.13,4/774 %0.52,3/767 %0.39,1/766 %0.13,2/767 %0.26
Vomiting,7/777 %0.9,8/774 %1.03,11/767 %1.43,7/766 %0.91,1/767 %0.13
Nausea,0/777 %0.0,0/774 %0.0,2/767 %0.26,1/766 %0.13,1/767 %0.13
Constitutional Symptoms-Other,1/777 %0.13,0/774 %0.0,0/767 %0.0,0/766 %0.0,0/767 %0.0
Fever In The Absence Of Neutropenia,0/777 %0.0,0/774 %0.0,0/767 %0.0,1/766 %0.13,0/767 %0.0
Fatigue,0/777 %0.0,3/774 %0.39,1/767 %0.13,1/766 %0.13,0/767 %0.0
Chest Pain Non-Cardiac Or Non-Pleuritic,0/777 %0.0,0/774 %0.0,1/767 %0.13,1/766 %0.13,0/767 %0.0
Headache,0/777 %0.0,0/774 %0.0,1/767 %0.13,0/766 %0.0,0/767 %0.0
Abdominal Pain Or Cramping,4/777 %0.51,3/774 %0.39,4/767 %0.52,1/766 %0.13,1/767 %0.13
Bone Pain,1/777 %0.13,0/774 %0.0,0/767 %0.0,0/766 %0.0,0/767 %0.0
Arthralgia,0/777 %0.0,0/774 %0.0,1/767 %0.13,0/766 %0.0,0/767 %0.0
Myalgia,1/777 %0.13,0/774 %0.0,0/767 %0.0,0/766 %0.0,0/767 %0.0
Pain-Other,0/777 %0.0,1/774 %0.13,1/767 %0.13,0/766 %0.0,1/767 %0.13
Hepatic-Other,0/777 %0.0,0/774 %0.0,0/767 %0.0,1/766 %0.13,1/767 %0.13
Sgpt,0/777 %0.0,0/774 %0.0,0/767 %0.0,0/766 %0.0,1/767 %0.13
Sgot,0/777 %0.0,2/774 %0.26,0/767 %0.0,1/766 %0.13,1/767 %0.13
Bilirubin,0/777 %0.0,0/774 %0.0,1/767 %0.13,0/766 %0.0,0/767 %0.0
Allergy-Other,4/777 %0.51,0/774 %0.0,2/767 %0.26,1/766 %0.13,0/767 %0.0
Allergic Reaction/Hypersensitivity,9/777 %1.16,6/774 %0.78,6/767 %0.78,3/766 %0.39,6/767 %0.78
Infection Other,1/777 %0.13,1/774 %0.13,0/767 %0.0,0/766 %0.0,2/767 %0.26
Catheter-Related Infection,0/777 %0.0,1/774 %0.13,1/767 %0.13,0/766 %0.0,0/767 %0.0
Infection With Unknown Anc,0/777 %0.0,1/774 %0.13,1/767 %0.13,1/766 %0.13,2/767 %0.26
Infection Documented W Grd 3/4 Neutropn.,5/777 %0.64,9/774 %1.16,15/767 %1.96,7/766 %0.91,4/767 %0.52
Infection Without Neutropenia,7/777 %0.9,8/774 %1.03,5/767 %0.65,6/766 %0.78,6/767 %0.78
Febrile Neutropenia-Fuo Infect Not Docum,8/777 %1.03,12/774 %1.55,15/767 %1.96,10/766 %1.31,7/767 %0.91
Metabolic-Other,0/777 %0.0,1/774 %0.13,0/767 %0.0,1/766 %0.13,0/767 %0.0
Hyponatremia,0/777 %0.0,1/774 %0.13,0/767 %0.0,1/766 %0.13,1/767 %0.13
Hyperkalemia,0/777 %0.0,0/774 %0.0,0/767 %0.0,0/766 %0.0,1/767 %0.13
Hyperglycemia,0/777 %0.0,0/774 %0.0,0/767 %0.0,1/766 %0.13,0/767 %0.0
Hypokalemia,0/777 %0.0,0/774 %0.0,0/767 %0.0,0/766 %0.0,2/767 %0.26
Hypomagnesmia,0/777 %0.0,1/774 %0.13,0/767 %0.0,0/766 %0.0,0/767 %0.0
Joint Muscle Or Bone-Other,0/777 %0.0,0/774 %0.0,1/767 %0.13,0/766 %0.0,0/767 %0.0
Tremor,0/777 %0.0,2/774 %0.26,0/767 %0.0,0/766 %0.0,0/767 %0.0
Speech Impairment- Dysphasia/Aphasia,0/777 %0.0,0/774 %0.0,1/767 %0.13,0/766 %0.0,0/767 %0.0
Seizure(S),1/777 %0.13,0/774 %0.0,0/767 %0.0,0/766 %0.0,2/767 %0.26
Hallucinations,0/777 %0.0,0/774 %0.0,0/767 %0.0,0/766 %0.0,1/767 %0.13
Cns Cerebrovascular Ischemia,0/777 %0.0,0/774 %0.0,4/767 %0.52,0/766 %0.0,2/767 %0.26
Confusion,0/777 %0.0,0/774 %0.0,1/767 %0.13,1/766 %0.13,1/767 %0.13
Syncope,6/777 %0.77,2/774 %0.26,5/767 %0.65,0/766 %0.0,3/767 %0.39
Mood Alteration-Anxiety Agitation,0/777 %0.0,1/774 %0.13,0/767 %0.0,1/766 %0.13,0/767 %0.0
Dizziness/Lightheadedness,0/777 %0.0,0/774 %0.0,0/767 %0.0,1/766 %0.13,1/767 %0.13
Neuropathy-Sensory,1/777 %0.13,0/774 %0.0,1/767 %0.13,0/766 %0.0,0/767 %0.0
Neuropathy Motor,1/777 %0.13,1/774 %0.13,1/767 %0.13,0/766 %0.0,1/767 %0.13
Operative Injury To Bladder/Ureter,0/777 %0.0,0/774 %0.0,0/767 %0.0,0/766 %0.0,1/767 %0.13
Fistula Or Gu Fistula,0/777 %0.0,0/774 %0.0,2/767 %0.26,0/766 %0.0,0/767 %0.0
Renal Failure,0/777 %0.0,0/774 %0.0,2/767 %0.26,1/766 %0.13,1/767 %0.13
Creatinine,1/777 %0.13,0/774 %0.0,0/767 %0.0,0/766 %0.0,1/767 %0.13
Renal/Gu-Other,0/777 %0.0,0/774 %0.0,0/767 %0.0,0/766 %0.0,1/767 %0.13
Pleural Effusion (Non-Malignant),1/777 %0.13,2/774 %0.26,2/767 %0.26,1/766 %0.13,3/767 %0.39
Dyspnea,1/777 %0.13,3/774 %0.39,4/767 %0.52,3/766 %0.39,0/767 %0.0
Pneumothorax,0/777 %0.0,0/774 %0.0,0/767 %0.0,0/766 %0.0,1/767 %0.13
Hypoxia,0/777 %0.0,2/774 %0.26,0/767 %0.0,0/766 %0.0,0/767 %0.0
Adult Respiratory Distress Syndrome,0/777 %0.0,1/774 %0.13,1/767 %0.13,0/766 %0.0,1/767 %0.13
Pruritus,1/777 %0.13,0/774 %0.0,0/767 %0.0,0/766 %0.0,0/767 %0.0
Urticaria,0/777 %0.0,0/774 %0.0,1/767 %0.13,1/766 %0.13,1/767 %0.13
Wound-Infectious,1/777 %0.13,1/774 %0.13,0/767 %0.0,1/766 %0.13,2/767 %0.26
Rash/Desquamation,0/777 %0.0,1/774 %0.13,0/767 %0.0,0/766 %0.0,2/767 %0.26
Skin-Other,0/777 %0.0,0/774 %0.0,0/767 %0.0,0/766 %0.0,1/767 %0.13
Wound-Non-Infectious,0/777 %0.0,0/774 %0.0,1/767 %0.13,0/766 %0.0,0/767 %0.0
Erythema Multiforme,0/777 %0.0,1/774 %0.13,0/767 %0.0,0/766 %0.0,0/767 %0.0
Hemorrhage-Other,0/777 %0.0,0/774 %0.0,0/767 %0.0,0/766 %0.0,1/767 %0.13
Rectal Bleeding/Hematochezia,0/777 %0.0,1/774 %0.13,0/767 %0.0,0/766 %0.0,1/767 %0.13
Hemorrhage/Bleeding Associated With Surgery,0/777 %0.0,0/774 %0.0,0/767 %0.0,0/766 %0.0,1/767 %0.13
Epistaxis,0/777 %0.0,0/774 %0.0,0/767 %0.0,1/766 %0.13,1/767 %0.13
Hemorrhage/Bleeding With Grade 3 Or 4 Th,0/777 %0.0,0/774 %0.0,1/767 %0.13,0/766 %0.0,0/767 %0.0
Hematuria (In The Absence Of Vaginal Bleeding,1/777 %0.13,0/774 %0.0,0/767 %0.0,0/766 %0.0,0/767 %0.0

Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer(https://clinicaltrials.gov/show/NCT00024102)
 ,Standard Chemotherapy (CMF),Standard Chemotherapy (AC),Capecitabine
 ,CMF: cyclophosphamide (100 mg/m^2 orally days 1-14)+ MTX (40 mg/m^2 by IV days 1 and 8) + 5-FU (600 mg/m^2 by IV days 1 and 8) repeated every 28 days for 6 cycles,AC: Cyclophosphamide (600 mg/m^2 by IV on day 1)+ doxorubicin (60 mg/m^2 by IV on day 1) repeated every 21 days for 4 cycles,Capecitabine (2000 mg/m^2 in 2 doses days 1-14) repeated every 21 days for 6 cycles
Total serious adverse events,15/131 %11.45,17/181 %9.39,26/299 %8.7
Disseminated intravascular coagulation,1/131 %0.76,0/181 %0.0,0/299 %0.0
Febrile neutropenia,5/131 %3.82,1/181 %0.55,2/299 %0.67
Hemoglobin decreased,7/131 %5.34,13/181 %7.18,8/299 %2.68
Lymphatics,1/131 %0.76,0/181 %0.0,0/299 %0.0
Transfusion: pRBCs,0/131 %0.0,1/181 %0.55,0/299 %0.0
Arrhythmia supraventricular,0/131 %0.0,1/181 %0.55,0/299 %0.0
Cardiac disorder,1/131 %0.76,0/181 %0.0,0/299 %0.0
Edema,0/131 %0.0,0/181 %0.0,1/299 %0.33
Left ventricular failure,0/131 %0.0,1/181 %0.55,1/299 %0.33
Myocardial ischemia,1/131 %0.76,0/181 %0.0,0/299 %0.0
Abdominal pain,0/131 %0.0,0/181 %0.0,3/299 %1.0
Colitis,0/131 %0.0,0/181 %0.0,1/299 %0.33
Diarrhea,5/131 %3.82,5/181 %2.76,18/299 %6.02
Esophagitis,0/131 %0.0,1/181 %0.55,0/299 %0.0
Gastritis,0/131 %0.0,1/181 %0.55,0/299 %0.0
Mucositis oral,0/131 %0.0,5/181 %2.76,2/299 %0.67
Nausea,5/131 %3.82,4/181 %2.21,10/299 %3.34
Typhlitis,0/131 %0.0,0/181 %0.0,2/299 %0.67
Vomiting,1/131 %0.76,2/181 %1.1,6/299 %2.01
Chest pain,1/131 %0.76,0/181 %0.0,1/299 %0.33
Fatigue,8/131 %6.11,9/181 %4.97,16/299 %5.35
Anorectal infection,1/131 %0.76,0/181 %0.0,0/299 %0.0
Infection,0/131 %0.0,1/181 %0.55,1/299 %0.33
Infection with grade 3 or 4 neutropenia,1/131 %0.76,1/181 %0.55,0/299 %0.0
Infection without neutropenia,1/131 %0.76,0/181 %0.0,5/299 %1.67
Infectious colitis,0/131 %0.0,0/181 %0.0,1/299 %0.33
Upper respiratory infection,0/131 %0.0,0/181 %0.0,1/299 %0.33
Aspartate aminotransferase increased,1/131 %0.76,0/181 %0.0,0/299 %0.0
Coagulopathy,1/131 %0.76,0/181 %0.0,0/299 %0.0
Creatinine increased,1/131 %0.76,1/181 %0.55,4/299 %1.34
INR increased,1/131 %0.76,0/181 %0.0,1/299 %0.33
Leukocyte count decreased,12/131 %9.16,13/181 %7.18,2/299 %0.67
Lymphocyte count decreased,2/131 %1.53,0/181 %0.0,0/299 %0.0
Neutrophil count decreased,7/131 %5.34,10/181 %5.52,2/299 %0.67
Platelet count decreased,4/131 %3.05,8/181 %4.42,1/299 %0.33
Anorexia,3/131 %2.29,3/181 %1.66,10/299 %3.34
Blood glucose increased,3/131 %2.29,0/181 %0.0,1/299 %0.33
Blood uric acid increased,0/131 %0.0,0/181 %0.0,1/299 %0.33
Dehydration,1/131 %0.76,1/181 %0.55,7/299 %2.34
Serum albumin decreased,0/131 %0.0,0/181 %0.0,1/299 %0.33
Serum calcium decreased,0/131 %0.0,0/181 %0.0,2/299 %0.67
Serum glucose decreased,0/131 %0.0,0/181 %0.0,1/299 %0.33
Serum magnesium decreased,0/131 %0.0,0/181 %0.0,1/299 %0.33
Serum potassium decreased,1/131 %0.76,0/181 %0.0,3/299 %1.0
Serum sodium decreased,0/131 %0.0,0/181 %0.0,1/299 %0.33
Bone pain,0/131 %0.0,0/181 %0.0,1/299 %0.33
Ataxia,0/131 %0.0,0/181 %0.0,2/299 %0.67
Dizziness,0/131 %0.0,0/181 %0.0,1/299 %0.33
Ischemia cerebrovascular,0/131 %0.0,0/181 %0.0,1/299 %0.33
Peripheral motor neuropathy,0/131 %0.0,0/181 %0.0,1/299 %0.33
Speech disorder,0/131 %0.0,0/181 %0.0,2/299 %0.67
Syncope,1/131 %0.76,0/181 %0.0,0/299 %0.0
Vaginal hemorrhage,1/131 %0.76,0/181 %0.0,0/299 %0.0
Adult respiratory distress syndrome,1/131 %0.76,0/181 %0.0,0/299 %0.0
Bronchospasm,0/131 %0.0,1/181 %0.55,0/299 %0.0
Cough,0/131 %0.0,1/181 %0.55,1/299 %0.33
Dyspnea,1/131 %0.76,0/181 %0.0,0/299 %0.0
Dyspnea (shortness of breath),0/131 %0.0,0/181 %0.0,3/299 %1.0
Hypoxia,0/131 %0.0,0/181 %0.0,1/299 %0.33
Pleural effusion,0/131 %0.0,0/181 %0.0,1/299 %0.33
Pneumonitis,1/131 %0.76,0/181 %0.0,0/299 %0.0
Rash/Dermatitis BMT,0/131 %0.0,0/181 %0.0,1/299 %0.33
Hand-and-foot syndrome,0/131 %0.0,0/181 %0.0,8/299 %2.68
Rash desquamating,0/131 %0.0,0/181 %0.0,2/299 %0.67
Hypertension,0/131 %0.0,0/181 %0.0,1/299 %0.33
Hypotension,1/131 %0.76,1/181 %0.55,3/299 %1.0
Peripheral arterial ischemia,0/131 %0.0,0/181 %0.0,1/299 %0.33
Phlebitis,1/131 %0.76,0/181 %0.0,0/299 %0.0
Thrombosis,3/131 %2.29,3/181 %1.66,2/299 %0.67

Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma(https://clinicaltrials.gov/show/NCT00026208)
 ,Stanford V-C + Low-dose Radiotherapy,Stanford V-C Only
 ,"Stanford V-C" = Vinblastine cyclophosphamide doxorubicin prednisone bleomycin + etoposide.  Vincristine: 1.4 mg/m intravenously (IV) on week 2 4 6 8  Cyclophosphamide: 650 mg/m on week 1 and 5  Doxorubicin: 25 mg/m on week 1 3 5 7  Prednisone: 40 mg/m oral every other day. Taper-reduction 10 mg/m mg every other day during last 2 weeks of chemotherapy  Bleomycin: 5 u/m intravenously (IV) on week 2 4 6 8  Etoposide: 60 mg/m x 2 intravenously (IV) on week 3 7 (d 15 16 43 44)  "Low-dose radiotherapy (RT)" = 20 Grey (Gy) modified involved field radiotherapy administered as consolidative irradiation will beginning between 2 and 12 weeks after the completion of Stanford V-C chemotherapy regimen.,"Stanford V-C" = Vinblastine cyclophosphamide doxorubicin prednisone bleomycin + etoposide.  Vincristine: 1.4 mg/m intravenously (IV) on week 2 4 6 8  Cyclophosphamide: 650 mg/m on week 1 and 5  Doxorubicin: 25 mg/m on week 1 3 5 7  Prednisone: 40 mg/m oral every other day. Taper-reduction 10 mg/m mg every other day during last 2 weeks of chemotherapy  Bleomycin: 5 u/m intravenously (IV) on week 2 4 6 8  Etoposide: 60 mg/m x 2 intravenously (IV) on week 3 7 (d 15 16 43 44)
Total all-cause mortality,7/72 %9.72,0/4 %0.0
Total serious adverse events,25/72 %34.72,2/4 %50.0
Atrial fibrillation,1/72 %1.39,0/4 %0.0
Hypothyroidism,17/72 %23.61,2/4 %50.0
Fever,5/72 %6.94,1/4 %25.0
Crush injury automobile accident,1/72 %1.39,0/4 %0.0
Second cancer,2/72 %2.78,0/4 %0.0
Rash,1/72 %1.39,0/4 %0.0

Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer(https://clinicaltrials.gov/show/NCT00041119)
 ,Arm I (CA for 4 Courses),Arm II (CA for 6 Courses [Closed to Accrual 12/15/2007]),Arm III (Paclitaxel for 4 Courses),Arm IV (Paclitaxel for 6 Courses [Closed 12/15/2007])
 ,Patients receive cyclophosphamide IV and doxorubicin hydrochloride IV on day 1. Treatment repeats every 14 days for 4 courses in the absence of disease progression or unacceptable toxicity.,Patients receive cyclophosphamide IV and doxorubicin hydrochloride IV on day 1. Treatment repeats every 14 days for 6 courses in the absence of disease progression or unacceptable toxicity.,Patients receive paclitaxel IV over 3 hours on day 1. Treatment repeats every 14 days for 4 courses in the absence of disease progression or unacceptable toxicity.,Patients receive paclitaxel IV over 3 hours on day 1. Treatment repeats every 14 days for 6 courses in the absence of disease progression or unacceptable toxicity.
Total serious adverse events,113/1142 %9.89,104/789 %13.18,59/1151 %5.13,53/789 %6.72
Blood disorder,0/1110 %0.0,1/765 %0.13,0/1118 %0.0,0/762 %0.0
Febrile neutropenia,30/1110 %2.7,29/765 %3.79,1/1118 %0.09,0/762 %0.0
Hemoglobin decreased,81/1110 %7.3,64/765 %8.37,29/1118 %2.59,19/762 %2.49
Transfusion: pRBCs,3/1110 %0.27,5/765 %0.65,2/1118 %0.18,1/762 %0.13
Arrhythmia,6/1110 %0.54,5/765 %0.65,7/1118 %0.63,2/762 %0.26
Atrial fibrillation,1/1110 %0.09,0/765 %0.0,0/1118 %0.0,0/762 %0.0
Cardiac disorder,1/1110 %0.09,0/765 %0.0,1/1118 %0.09,1/762 %0.13
Cardiac pain,1/1110 %0.09,0/765 %0.0,0/1118 %0.0,0/762 %0.0
Edema,0/1110 %0.0,0/765 %0.0,0/1118 %0.0,1/762 %0.13
Left ventricular failure,1/1110 %0.09,5/765 %0.65,1/1118 %0.09,0/762 %0.0
Myocardial ischemia,2/1110 %0.18,1/765 %0.13,0/1118 %0.0,0/762 %0.0
Vertigo,0/1110 %0.0,1/765 %0.13,0/1118 %0.0,0/762 %0.0
Photophobia,0/1110 %0.0,1/765 %0.13,0/1118 %0.0,0/762 %0.0
Vision blurred,1/1110 %0.09,0/765 %0.0,0/1118 %0.0,0/762 %0.0
Abdominal pain,1/1110 %0.09,0/765 %0.0,4/1118 %0.36,1/762 %0.13
Colitis,2/1110 %0.18,2/765 %0.26,1/1118 %0.09,0/762 %0.0
Constipation,1/1110 %0.09,0/765 %0.0,0/1118 %0.0,0/762 %0.0
Diarrhea,27/1110 %2.43,24/765 %3.14,11/1118 %0.98,5/762 %0.66
Dyspepsia,1/1110 %0.09,0/765 %0.0,0/1118 %0.0,0/762 %0.0
Dysphagia,0/1110 %0.0,2/765 %0.26,0/1118 %0.0,0/762 %0.0
Esophagitis,4/1110 %0.36,0/765 %0.0,0/1118 %0.0,0/762 %0.0
Gastric hemorrhage,0/1110 %0.0,0/765 %0.0,1/1118 %0.09,0/762 %0.0
Gastric ulcer,0/1110 %0.0,0/765 %0.0,0/1118 %0.0,1/762 %0.13
Gastrointestinal disorder,0/1110 %0.0,1/765 %0.13,0/1118 %0.0,2/762 %0.26
Melena/GI bleeding,0/1110 %0.0,1/765 %0.13,0/1118 %0.0,0/762 %0.0
Mucositis oral,39/1110 %3.51,30/765 %3.92,7/1118 %0.63,4/762 %0.52
Nausea,12/1110 %1.08,8/765 %1.05,7/1118 %0.63,3/762 %0.39
Pancreatitis,0/1110 %0.0,2/765 %0.26,0/1118 %0.0,0/762 %0.0
Rectal bleeding/hematochezia,0/1110 %0.0,1/765 %0.13,0/1118 %0.0,0/762 %0.0
Rectal hemorrhage,1/1110 %0.09,0/765 %0.0,0/1118 %0.0,0/762 %0.0
Rectal pain,2/1110 %0.18,0/765 %0.0,0/1118 %0.0,0/762 %0.0
Typhlitis,0/1110 %0.0,1/765 %0.13,0/1118 %0.0,0/762 %0.0
Vomiting,7/1110 %0.63,9/765 %1.18,5/1118 %0.45,1/762 %0.13
Chest pain,3/1110 %0.27,2/765 %0.26,1/1118 %0.09,3/762 %0.39
Chills,0/1110 %0.0,0/765 %0.0,0/1118 %0.0,1/762 %0.13
Fatigue,14/1110 %1.26,12/765 %1.57,4/1118 %0.36,6/762 %0.79
Fever,0/1110 %0.0,1/765 %0.13,0/1118 %0.0,2/762 %0.26
Gait abnormal,0/1110 %0.0,0/765 %0.0,0/1118 %0.0,1/762 %0.13
Pain,3/1110 %0.27,2/765 %0.26,0/1118 %0.0,4/762 %0.52
Hypersensitivity,1/1110 %0.09,2/765 %0.26,4/1118 %0.36,6/762 %0.79
Catheter related infection,1/1110 %0.09,1/765 %0.13,2/1118 %0.18,1/762 %0.13
Eye infection intraocular,1/1110 %0.09,0/765 %0.0,0/1118 %0.0,0/762 %0.0
Infection,1/1110 %0.09,0/765 %0.0,0/1118 %0.0,0/762 %0.0
Infection with grade 3 or 4 neutropenia,10/1110 %0.9,8/765 %1.05,0/1118 %0.0,0/762 %0.0
Infection with unknown ANC,0/1110 %0.0,0/765 %0.0,0/1118 %0.0,1/762 %0.13
Infection without neutropenia,7/1110 %0.63,5/765 %0.65,7/1118 %0.63,3/762 %0.39
Infectious colitis,1/1110 %0.09,0/765 %0.0,0/1118 %0.0,0/762 %0.0
Peripheral nerve infection,1/1110 %0.09,0/765 %0.0,0/1118 %0.0,0/762 %0.0
Skin infection,2/1110 %0.18,1/765 %0.13,0/1118 %0.0,0/762 %0.0
Soft tissue infection,1/1110 %0.09,0/765 %0.0,0/1118 %0.0,0/762 %0.0
Tooth infection,1/1110 %0.09,0/765 %0.0,0/1118 %0.0,0/762 %0.0
Urinary tract infection,0/1110 %0.0,0/765 %0.0,0/1118 %0.0,1/762 %0.13
Wound infection,1/1110 %0.09,0/765 %0.0,1/1118 %0.09,0/762 %0.0
Wound-infectious,2/1110 %0.18,3/765 %0.39,0/1118 %0.0,0/762 %0.0
Vascular access complication,0/1110 %0.0,0/765 %0.0,1/1118 %0.09,0/762 %0.0
Wound dehiscence,1/1110 %0.09,0/765 %0.0,0/1118 %0.0,0/762 %0.0
Activated partial thromboplastin time prolonged,0/1110 %0.0,1/765 %0.13,1/1118 %0.09,1/762 %0.13
Alanine aminotransferase increased,0/1110 %0.0,1/765 %0.13,1/1118 %0.09,4/762 %0.52
Alkaline phosphatase,0/1110 %0.0,0/765 %0.0,0/1118 %0.0,1/762 %0.13
Amylase increased,0/1110 %0.0,1/765 %0.13,0/1118 %0.0,0/762 %0.0
Aspartate aminotransferase increased,0/1110 %0.0,0/765 %0.0,0/1118 %0.0,2/762 %0.26
Blood bilirubin increased,0/1110 %0.0,0/765 %0.0,0/1118 %0.0,1/762 %0.13
Cardiac troponin T increased,0/1110 %0.0,1/765 %0.13,0/1118 %0.0,0/762 %0.0
Creatinine increased,1/1110 %0.09,1/765 %0.13,1/1118 %0.09,0/762 %0.0
Fibrinogen for leukemia studies,0/1110 %0.0,0/765 %0.0,0/1118 %0.0,1/762 %0.13
INR increased,1/1110 %0.09,0/765 %0.0,0/1118 %0.0,1/762 %0.13
Laboratory test abnormal,1/1110 %0.09,0/765 %0.0,0/1118 %0.0,0/762 %0.0
Leukocyte count decreased,67/1110 %6.04,66/765 %8.63,8/1118 %0.72,2/762 %0.26
Lipase increased,0/1110 %0.0,1/765 %0.13,0/1118 %0.0,0/762 %0.0
Lymphocyte count decreased,4/1110 %0.36,4/765 %0.52,1/1118 %0.09,1/762 %0.13
Neutrophil count decreased,66/1110 %5.95,61/765 %7.97,10/1118 %0.89,4/762 %0.52
Platelet count decreased,40/1110 %3.6,36/765 %4.71,3/1118 %0.27,5/762 %0.66
Anorexia,5/1110 %0.45,3/765 %0.39,1/1118 %0.09,0/762 %0.0
Blood glucose increased,4/1110 %0.36,2/765 %0.26,4/1118 %0.36,5/762 %0.66
Dehydration,12/1110 %1.08,8/765 %1.05,3/1118 %0.27,2/762 %0.26
Serum albumin decreased,0/1110 %0.0,1/765 %0.13,0/1118 %0.0,0/762 %0.0
Serum calcium decreased,0/1110 %0.0,1/765 %0.13,1/1118 %0.09,0/762 %0.0
Serum glucose decreased,0/1110 %0.0,0/765 %0.0,0/1118 %0.0,1/762 %0.13
Serum potassium decreased,8/1110 %0.72,2/765 %0.26,1/1118 %0.09,0/762 %0.0
Serum potassium increased,0/1110 %0.0,0/765 %0.0,0/1118 %0.0,1/762 %0.13
Serum sodium decreased,1/1110 %0.09,0/765 %0.0,0/1118 %0.0,1/762 %0.13
Arthralgia,1/1110 %0.09,0/765 %0.0,1/1118 %0.09,5/762 %0.66
Arthritis,0/1110 %0.0,1/765 %0.13,0/1118 %0.0,0/762 %0.0
Bone pain,0/1110 %0.0,1/765 %0.13,3/1118 %0.27,0/762 %0.0
Muscle weakness,0/1110 %0.0,1/765 %0.13,0/1118 %0.0,0/762 %0.0
Myalgia,0/1110 %0.0,1/765 %0.13,4/1118 %0.36,5/762 %0.66
Pain in extremity,0/1110 %0.0,0/765 %0.0,1/1118 %0.09,0/762 %0.0
Arachnoiditis,1/1110 %0.09,0/765 %0.0,0/1118 %0.0,0/762 %0.0
Ataxia,0/1110 %0.0,0/765 %0.0,1/1118 %0.09,0/762 %0.0
Depressed level of consciousness,0/1110 %0.0,0/765 %0.0,0/1118 %0.0,1/762 %0.13
Dizziness,1/1110 %0.09,1/765 %0.13,0/1118 %0.0,1/762 %0.13
Dysgeusia,2/1110 %0.18,1/765 %0.13,0/1118 %0.0,0/762 %0.0
Headache,4/1110 %0.36,1/765 %0.13,0/1118 %0.0,4/762 %0.52
Ischemia cerebrovascular,0/1110 %0.0,0/765 %0.0,0/1118 %0.0,1/762 %0.13
Memory impairment,0/1110 %0.0,0/765 %0.0,0/1118 %0.0,1/762 %0.13
Neuralgia,1/1110 %0.09,0/765 %0.0,1/1118 %0.09,0/762 %0.0
Peripheral motor neuropathy,3/1110 %0.27,0/765 %0.0,4/1118 %0.36,7/762 %0.92
Peripheral sensory neuropathy,9/1110 %0.81,6/765 %0.78,23/1118 %2.06,25/762 %3.28
Syncope,3/1110 %0.27,2/765 %0.26,0/1118 %0.0,4/762 %0.52
Tremor,0/1110 %0.0,0/765 %0.0,0/1118 %0.0,1/762 %0.13
Vasovagal episode,0/1110 %0.0,0/765 %0.0,0/1118 %0.0,2/762 %0.26
Anxiety,0/1110 %0.0,1/765 %0.13,0/1118 %0.0,0/762 %0.0
Confusion,1/1110 %0.09,1/765 %0.13,0/1118 %0.0,1/762 %0.13
Depression,1/1110 %0.09,1/765 %0.13,1/1118 %0.09,1/762 %0.13
Hallucinations,1/1110 %0.09,1/765 %0.13,0/1118 %0.0,0/762 %0.0
Insomnia,1/1110 %0.09,0/765 %0.0,0/1118 %0.0,0/762 %0.0
Personality change,0/1110 %0.0,1/765 %0.13,1/1118 %0.09,0/762 %0.0
Dysuria (painful urination),0/1110 %0.0,1/765 %0.13,1/1118 %0.09,0/762 %0.0
Renal failure,0/1110 %0.0,0/765 %0.0,1/1118 %0.09,0/762 %0.0
Urogenital disorder,1/1110 %0.09,0/765 %0.0,0/1118 %0.0,1/762 %0.13
Reproductive tract disorder,0/1110 %0.0,0/765 %0.0,1/1118 %0.09,0/762 %0.0
Vaginal hemorrhage,1/1110 %0.09,0/765 %0.0,1/1118 %0.09,1/762 %0.13
Adult respiratory distress syndrome,0/1110 %0.0,1/765 %0.13,0/1118 %0.0,0/762 %0.0
Apnea,0/1110 %0.0,0/765 %0.0,1/1118 %0.09,1/762 %0.13
Cough,2/1110 %0.18,2/765 %0.26,0/1118 %0.0,0/762 %0.0
Dyspnea,3/1110 %0.27,1/765 %0.13,1/1118 %0.09,0/762 %0.0
Dyspnea (shortness of breath),5/1110 %0.45,5/765 %0.65,1/1118 %0.09,3/762 %0.39
Epistaxis,0/1110 %0.0,1/765 %0.13,0/1118 %0.0,0/762 %0.0
Hemoptysis,0/1110 %0.0,1/765 %0.13,0/1118 %0.0,0/762 %0.0
Hypoxia,1/1110 %0.09,2/765 %0.26,1/1118 %0.09,3/762 %0.39
Pharyngeal examination abnormal,0/1110 %0.0,1/765 %0.13,0/1118 %0.0,0/762 %0.0
Pneumonitis,2/1110 %0.18,7/765 %0.92,0/1118 %0.0,1/762 %0.13
Respiratory disorder,1/1110 %0.09,2/765 %0.26,0/1118 %0.0,0/762 %0.0
Alopecia,3/1110 %0.27,1/765 %0.13,3/1118 %0.27,1/762 %0.13
Hand-and-foot syndrome,2/1110 %0.18,3/765 %0.39,0/1118 %0.0,0/762 %0.0
Nail disorder,0/1110 %0.0,0/765 %0.0,1/1118 %0.09,0/762 %0.0
Pruritus,0/1110 %0.0,0/765 %0.0,1/1118 %0.09,0/762 %0.0
Skin disorder,2/1110 %0.18,0/765 %0.0,1/1118 %0.09,0/762 %0.0
Sweating,0/1110 %0.0,1/765 %0.13,0/1118 %0.0,0/762 %0.0
Capillary leak syndrome,0/1110 %0.0,0/765 %0.0,1/1118 %0.09,0/762 %0.0
Hematoma,0/1110 %0.0,0/765 %0.0,1/1118 %0.09,0/762 %0.0
Hemorrhage,0/1110 %0.0,0/765 %0.0,0/1118 %0.0,1/762 %0.13
Hemorrhage/bleeding without grade 3 or 4 thrombocytopenia,0/1110 %0.0,0/765 %0.0,0/1118 %0.0,1/762 %0.13
Hypertension,0/1110 %0.0,0/765 %0.0,3/1118 %0.27,1/762 %0.13
Hypotension,3/1110 %0.27,3/765 %0.39,0/1118 %0.0,2/762 %0.26
Thrombosis,8/1110 %0.72,7/765 %0.92,6/1118 %0.54,4/762 %0.52

Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas(https://clinicaltrials.gov/show/NCT00043979)
 ,Arm 2-Recipients
 ,Recipients (n=30) were enrolled to receive peripheral blood stem cells (PBSC) and receive either cyclosporine or tacrolimus and sirolimus for graft versus host disease (GVHD) prophylaxis.
Total all-cause mortality,29/30 %96.67
Total serious adverse events,29/30 %96.67
Cardiac General: Hypotension,1/30 %3.33
Pericardial effusion,1/30 %3.33
Thrombosis,2/30 %6.67
Supraventricular arrhythmias (SVT/atrial fibrillation/flutter),1/30 %3.33
Gastrointestinal: Diarrhea,2/30 %6.67
Gastrointestinal:Mucositis/stomatitis (clinical exam)::oral cavity,1/30 %3.33
GI other,1/30 %3.33
Intussception,1/30 %3.33
Stomatitis,1/30 %3.33
Constitutional Symptoms: Fever,1/30 %3.33
Death: Death not associated with CTCAE term: Disease progression NOS,29/30 %96.67
Pain - right chest wall,1/30 %3.33
Infection with neutropenia,1/30 %3.33
Infection without neutropenia,1/30 %3.33
Infection: Febrile neutropenia,1/30 %3.33
Metabolic/Laboratory: Bilirubin serum-high (hyperbilirubinemia),1/30 %3.33
Metabolic/Laboratory: ALT SGPT (serum glutamic pyruvic transaminase),1/30 %3.33
Metabolic/Laboratory: AST SGOT (serum glutamic oxaloacetic transaminase),1/30 %3.33
AST high,1/30 %3.33
Mood alteration; suicide gesture,1/30 %3.33
Neurology: Mood alteration: anxiety,1/30 %3.33
Neurology: Seizure,2/30 %6.67
Creatinine,1/30 %3.33
Vaginitis,1/30 %3.33
Pulmonary/Upper Respiratory: Pneumonitis/pulmonary infiltrates,1/30 %3.33
Pulmonary - Other (pulmonary edema w/normal 02 sat),1/30 %3.33
Pulmonary/Upper Respiratory: Dyspnea (shortness of breath),2/30 %6.67
Pulmonary/Upper Respiratory: Hypoxia,2/30 %6.67
Respiratory failure,1/30 %3.33
Pneumonitits/Pulmonary infiltrates,1/30 %3.33
Radiation Recall Reaction (anterior chest),1/30 %3.33

Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer(https://clinicaltrials.gov/show/NCT00048893)
 ,Carcinoembryonic Antigen (CEA)-Tricom Vaccines
 ,(fV-CEA (6D)/Tricom with sargramostim (rGM-CSF) 1.5 x 10^8 plaque-forming unit (pfu) x 1 dose subcutaneously
Total serious adverse events,11/37 %29.73
Leukocytes (total WBC),1/37 %2.7
Neutrophils/granulocytes (ANC/AGC),5/37 %13.51
Platelets,1/37 %2.7
DIC (disseminated intravascular coagulation),1/37 %2.7
Partial thromboplastin time (PTT),1/37 %2.7
Prothrombin time (PT),2/37 %5.41
Hypotension,2/37 %5.41
Thrombosis/embolism,1/37 %2.7
Diarrhea patients without colostomy,1/37 %2.7
Fatigue (lethargy malaise asthenia),1/37 %2.7
Fever (in the absence of neutropenia where neutropenia is defined as AGC<1.0x10e9/L),5/37 %13.51
Alkaline phosphatase,1/37 %2.7
Bilirubin,2/37 %5.41
Hypoalbuminemia,1/37 %2.7
Liver dysfunction/failure (clinical),1/37 %2.7
SGOT (AST) (serum glutamic oxaloacetic transaminase),1/37 %2.7
SGPT (ALT) (serum glutamic pyruvic transaminase),1/37 %2.7
Catheter-related infection,5/37 %13.51
Febrile neutropenia,8/37 %21.62
Infection (documented clinically or microbiologically) with grade 3 or 4 neutropenia (ANC <1.0 x 10e,2/37 %5.41
Infection without neutropenia,2/37 %5.41
Infection/Febrile Neutropenia-Other (Specify infection:catheter-related infection),1/37 %2.7
Acidosis (metabolic or respiratory),1/37 %2.7
Hyponatremia,2/37 %5.41
Confusion,1/37 %2.7
Dizziness/lightheadedness,1/37 %2.7
Creatinine,1/37 %2.7
Dyspnea (shortness of breath),1/37 %2.7
Hypoxia,2/37 %5.41

PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma(https://clinicaltrials.gov/show/NCT00054665)
 ,Part A: PS-341 Alone,Part B: PS-341 & EPOCH
 ,PS-341 1.3 mg/m^2 intravenous injection days 1 4 8 11 every 3 weeks,PS-341: level 1: 0.5 mg/m^2 intravenous (IV) days 1 4; level 2: 1.0 mg/m^2 IV days 1 4; level 3: 1.5 mg/m^2 IV days 1 4; level 4: 1.7 mg/m^2 IV days 1 4.  EPOCH: Etoposide: 50 mg/m^2 day continuous intravenous infusion (CIV) days 1-4 96 hour infusion; Doxorubicin: 10 mg/m^2 day CIV days 1-4 96 hour infusion; Vincristine: 0.4 mg/m^2 day CIV days 1-4 96 hour infusion; Cyclophosphamide: 750 mg/m^2 day IV day 5 bolus; Prednisone: 60 mg/m^2 by mouth twice a day days 1-5; Filgrastim: 300 micrograms subcutaneously days 6 to absolute neutrophil count recovery greater than or equal to 5000/mm^3. Repeat cycles every 21 days.
Total serious adverse events,21/24 %87.5,40/44 %90.91
Hemoglobin,6/24 %25.0,17/44 %38.64
Leukocytes (total WBC),7/24 %29.17,17/44 %38.64
Leukocytes (total WBC) for BMT studies if specified in the protocol.,1/24 %4.17,0/44 %0.0
Lymphopenia,5/24 %20.83,13/44 %29.55
Neutrophils/granulocytes (ANC/AGC),5/24 %20.83,21/44 %47.73
Platelets,12/24 %50.0,33/44 %75.0
Transfusion: Platelets,1/24 %4.17,12/44 %27.27
Transfusion: pRBCs,1/24 %4.17,13/44 %29.55
Vasovagal episode,1/24 %4.17,0/44 %0.0
Hypotension,4/24 %16.67,11/44 %25.0
Prolonged QTc interval (QTc > 0.48 seconds),0/24 %0.0,1/44 %2.27
Ventricular arrhythmia (PVCs/bigeminy/trigeminy/ventricular tachycardia),0/24 %0.0,1/44 %2.27
Inner ear/hearing,0/24 %0.0,1/44 %2.27
Ocular/Visual-Other (Specify periorbital edema),1/24 %4.17,0/44 %0.0
Anorexia,4/24 %16.67,8/44 %18.18
Constipation,1/24 %4.17,6/44 %13.64
Diarrhea patients without colostomy,7/24 %29.17,11/44 %25.0
Nausea,7/24 %29.17,12/44 %27.27
Stomatitis/pharyngitis (oral/pharyngeal mucositis),2/24 %8.33,8/44 %18.18
Taste disturbance (dysgeusia),3/24 %12.5,6/44 %13.64
Vomiting,1/24 %4.17,5/44 %11.36
Abdominal pain or cramping,3/24 %12.5,5/44 %11.36
Dehydration,0/24 %0.0,1/44 %2.27
Dysphagia esophagitis odynophagia (painful swallowing),0/24 %0.0,1/44 %2.27
Flatulence,0/24 %0.0,1/44 %2.27
Gastrointestinal-Other,0/24 %0.0,2/44 %4.55
Ileus (or neuroconstipation),0/24 %0.0,1/44 %2.27
Rectal bleeding/hematochezia,0/24 %0.0,2/44 %4.55
Edema,1/24 %4.17,5/44 %11.36
Fatigue (lethargy malaise asthenia),8/24 %33.33,10/44 %22.73
Fever (in the absence of neutropenia where neutropenia is defined as AGC<,3/24 %12.5,3/44 %6.82
Rigors chills,1/24 %4.17,0/44 %0.0
Sweating (diaphoresis),1/24 %4.17,0/44 %0.0
Weight loss,0/24 %0.0,2/44 %4.55
Pain-Other (Specify testicular),0/24 %0.0,1/44 %2.27
Constitutional Symptoms-Other (Specify generalized weakness),0/24 %0.0,1/44 %2.27
Alkaline phosphatase,1/24 %4.17,3/44 %6.82
Hypoalbuminemia,1/24 %4.17,9/44 %20.45
SGOT (AST) (serum glutamic oxaloacetic transaminase),2/24 %8.33,4/44 %9.09
SGPT (ALT) (serum glutamic pyruvic transaminase),3/24 %12.5,3/44 %6.82
Bilirubin,0/24 %0.0,3/44 %6.82
Allergic rhinitis (including sneezing nasal stuffiness postnasal drip),1/24 %4.17,0/44 %0.0
Febrile neutropenia,0/24 %0.0,5/44 %11.36
Infection,0/24 %0.0,9/44 %20.45
Infection with unknown ANC,0/24 %0.0,1/44 %2.27
Infection without neutropenia,0/24 %0.0,7/44 %15.91
Partial thromboplastin time (PTT),3/24 %12.5,4/44 %9.09
Prothrombin time (PT),1/24 %4.17,1/44 %2.27
Bicarbonate,0/24 %0.0,1/44 %2.27
Hypocalcemia,1/24 %4.17,4/44 %9.09
Hypoglycemia,1/24 %4.17,0/44 %0.0
Hypokalemia,1/24 %4.17,5/44 %11.36
Hypomagnesemia,2/24 %8.33,4/44 %9.09
Hyponatremia,1/24 %4.17,4/44 %9.09
Hyperglycemia,0/24 %0.0,10/44 %22.73
Hypermagnesemia,0/24 %0.0,1/44 %2.27
Hyperuricemia,0/24 %0.0,3/44 %6.82
Hypophosphatemia,0/24 %0.0,2/44 %4.55
Arthralgia (joint pain),1/24 %4.17,1/44 %2.27
Myalgia (muscle pain),3/24 %12.5,1/44 %2.27
Muscle weakness (not due to neuropathy),0/24 %0.0,7/44 %15.91
Bone pain,0/24 %0.0,3/44 %6.82
Chest pain (non-cardiac and non-pleuritic),0/24 %0.0,1/44 %2.27
Ataxia (incoordination),1/24 %4.17,1/44 %2.27
Dizziness/lightheadedness,2/24 %8.33,4/44 %9.09
Neuropathy - motor,1/24 %4.17,2/44 %4.55
Neuropathy-sensory,5/24 %20.83,8/44 %18.18
Syncope (fainting),1/24 %4.17,1/44 %2.27
Headache,1/24 %4.17,1/44 %2.27
Neuropathic pain,1/24 %4.17,1/44 %2.27
Neurology-Other (Specify),0/24 %0.0,4/44 %9.09
Insomnia,0/24 %0.0,3/44 %6.82
Mood alteration-anxiety agitation,0/24 %0.0,1/44 %2.27
Creatinine,0/24 %0.0,1/44 %2.27
Epistaxis,0/24 %0.0,1/44 %2.27
Dyspnea (shortness of breath),0/24 %0.0,4/44 %9.09
Hiccoughs (hiccups singultus),0/24 %0.0,1/44 %2.27
Voice changes/stridor/larynx (e.g. hoarseness loss of voice laryngitis),0/24 %0.0,1/44 %2.27
Hypoxia,0/24 %0.0,1/44 %2.27
Pulmonary-Other (Specify wheezing),0/24 %0.0,2/44 %4.55
Bruising (in absence of grade 3 or 4 thrombocytopenia),1/24 %4.17,0/44 %0.0
Rash/desquamation,3/24 %12.5,0/44 %0.0
Urticaria (hives welts wheals),1/24 %4.17,0/44 %0.0
Nail changes,0/24 %0.0,1/44 %2.27
Pruritus,0/24 %0.0,1/44 %2.27

Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas(https://clinicaltrials.gov/show/NCT00069238)
 ,All Participants
 ,All participants who received at least one dose of Alemtuzumab (Campath) 30mg 60mg or 90mg on day 1 of therapy followed by etoposide prednisone vincristine cyclophosphamide doxorubicin (EPOCH) chemotherapy intravenously every 3 weeks for up to 6 cycles.  The adverse events are not reported per dose level because we normally look at all adverse events together irrespective of the dose level.
Total all-cause mortality,23/31 %74.19
Total serious adverse events,23/31 %74.19
HEMORRHAGE/BLEEDING:: Hemorrhage GI:: Upper GI Not otherwise specified (NOS),1/31 %3.23
DEATH:: Death related to the study,7/31 %22.58
DEATH:: Death due to progression,16/31 %51.61
INFECTION:: Febrile neutropenia,1/31 %3.23
INFECTION:: Infection,1/31 %3.23
INFECTION:: Infection (documented clinically or microbiologically),1/31 %3.23
INFECTION:: Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils,1/31 %3.23
INFECTION:: Infection with unknown ANC:: Blood,1/31 %3.23
RENAL/GENITOURINARY:: Cystitis,1/31 %3.23
RENAL/GENITOURINARY:: Urinary frequency/urgency,1/31 %3.23

S0221 Adjuvant Doxorubicin  Cyclophosphamide  and Paclitaxel in Treating Patients With Breast Cancer(https://clinicaltrials.gov/show/NCT00070564)
 ,ARM I,ARM II,ARM III,ARM IV,ARM V,ARM VI
 ,(closed 11/10/10) Patients receive doxorubicin IV and cyclophosphamide IV on day 1 and pegfilgrastim subcutaneously (SC) on day 2 or filgrastim (G-CSF) SC on days 3-10. Treatment repeats every 14 days for 6 courses. Beginning 2 weeks after completion of doxorubicin and cyclophosphamide patients receive paclitaxel IV over 3 hours on day 1 and pegfilgrastim SC on day 2. Treatment repeats every 14 days for 6 courses.,(closed 11/10/10) Patients receive doxorubicin IV on day 1 oral cyclophosphamide on days 1-7 and G-CSF SC on days 2-7. Treatment repeats every 7 days for 15 courses. Beginning 2 weeks after completion of cyclophosphamide patients receive paclitaxel and pegfilgrastim as in arm I.,(closed 11/10/10) Patients receive doxorubicin cyclophosphamide and pegfilgrastim or G-CSF as in arm I. Beginning 2 weeks after completion of doxorubicin and cyclophosphamide patients receive paclitaxel IV over 1 hour on day 1. Treatment repeats every 7 days for 12 courses.,(closed 11/10/10) Patients receive doxorubicin cyclophosphamide and G-CSF as in arm II. Beginning 2 weeks after completion of cyclophosphamide patients receive paclitaxel as in arm III.,Patients receive doxorubicin IV and cyclophosphamide IV on day 1 and pegfilgrastim SC on day 2. Treatment repeats every 14 days for 4 courses. Patients receive doxorubicin IV and cyclophosphamide IV on day 1 and pegfilgrastim SC on day 2. Treatment repeats every 14 days for 6 courses.  Beginning 2 weeks after completion of doxorubicin and cyclophosphamide patients receive paclitaxel IV over 3 hours on day 1 and pegfilgrastim SC on day 2. Treatment repeats every 14 days for 6 courses.,(reopened in 12/2010) Patients receive doxorubicin IV and cyclophosphamide IV on day 1 and pegfilgrastim SC on day 2. Treatment repeats every 14 days for 4 courses. Patients receive doxorubicin IV and cyclophosphamide IV on day 1 and pegfilgrastim SC on day 2. Treatment repeats every 14 days for 6 courses.  Beginning 2 weeks after completion of doxorubicin and cyclophosphamide patients receive paclitaxel IV over 1 hour on day 1. Treatment repeats every 7 days for 12 courses.
Total serious adverse events,10/654 %1.53,8/663 %1.21,17/674 %2.52,9/624 %1.44,5/275 %1.82,8/291 %2.75
Blood/Bone Marrow-Other,1/654 %0.15,0/663 %0.0,0/674 %0.0,0/624 %0.0,0/275 %0.0,0/291 %0.0
DIC (disseminated intravascular coagulation),1/654 %0.15,0/663 %0.0,0/674 %0.0,0/624 %0.0,0/275 %0.0,0/291 %0.0
Febrile neutropenia,0/654 %0.0,0/663 %0.0,0/674 %0.0,0/624 %0.0,1/275 %0.36,2/291 %0.69
Cardiac-ischemia/infarction,0/654 %0.0,0/663 %0.0,1/674 %0.15,0/624 %0.0,0/275 %0.0,0/291 %0.0
Conduction abnormality - Asystole,0/654 %0.0,0/663 %0.0,1/674 %0.15,0/624 %0.0,0/275 %0.0,0/291 %0.0
Left ventricular diastolic dysfunction,1/654 %0.15,0/663 %0.0,1/674 %0.15,0/624 %0.0,0/275 %0.0,0/291 %0.0
Left ventricular systolic dysfunction,1/654 %0.15,0/663 %0.0,0/674 %0.0,0/624 %0.0,1/275 %0.36,0/291 %0.0
Myocarditis,0/654 %0.0,0/663 %0.0,1/674 %0.15,0/624 %0.0,0/275 %0.0,0/291 %0.0
Pericardial effusion (non-malignant),0/654 %0.0,0/663 %0.0,0/674 %0.0,0/624 %0.0,0/275 %0.0,1/291 %0.34
Ventricular arrhythmia - PVCs,1/654 %0.15,0/663 %0.0,0/674 %0.0,0/624 %0.0,0/275 %0.0,0/291 %0.0
Constitutional Symptoms-Other,0/654 %0.0,1/663 %0.15,0/674 %0.0,0/624 %0.0,0/275 %0.0,0/291 %0.0
Death - Multi-organ failure,1/654 %0.15,0/663 %0.0,1/674 %0.15,0/624 %0.0,0/275 %0.0,0/291 %0.0
Death not associated with CTCAE term - Death NOS,0/654 %0.0,0/663 %0.0,0/674 %0.0,1/624 %0.16,0/275 %0.0,1/291 %0.34
Liver dysfunction/failure (clinical),1/654 %0.15,0/663 %0.0,1/674 %0.15,0/624 %0.0,0/275 %0.0,0/291 %0.0
Inf (clin/microbio) w/Gr 3-4 neuts - Lung,1/654 %0.15,1/663 %0.15,0/674 %0.0,2/624 %0.32,0/275 %0.0,0/291 %0.0
Inf w/normal ANC or Gr 1-2 neutrophils - Blood,1/654 %0.15,0/663 %0.0,0/674 %0.0,0/624 %0.0,0/275 %0.0,0/291 %0.0
Inf w/normal ANC or Gr 1-2 neutrophils - Lung,0/654 %0.0,0/663 %0.0,0/674 %0.0,1/624 %0.16,0/275 %0.0,0/291 %0.0
Inf w/normal ANC or Gr 1-2 neutrophils - Soft tiss,0/654 %0.0,0/663 %0.0,1/674 %0.15,0/624 %0.0,0/275 %0.0,0/291 %0.0
Infection with unknown ANC - Blood,0/654 %0.0,0/663 %0.0,0/674 %0.0,0/624 %0.0,0/275 %0.0,1/291 %0.34
Infection with unknown ANC - Skin (cellulitis),0/654 %0.0,0/663 %0.0,0/674 %0.0,0/624 %0.0,0/275 %0.0,1/291 %0.34
Thrombosis/embolism (vascular access-related),0/654 %0.0,1/663 %0.15,0/674 %0.0,0/624 %0.0,0/275 %0.0,0/291 %0.0
ALT SGPT (serum glutamic pyruvic transaminase),0/654 %0.0,0/663 %0.0,2/674 %0.3,0/624 %0.0,0/275 %0.0,0/291 %0.0
AST SGOT,0/654 %0.0,0/663 %0.0,1/674 %0.15,0/624 %0.0,0/275 %0.0,0/291 %0.0
Bilirubin (hyperbilirubinemia),0/654 %0.0,0/663 %0.0,1/674 %0.15,0/624 %0.0,0/275 %0.0,0/291 %0.0
Cardiac troponin I (cTnI),0/654 %0.0,0/663 %0.0,1/674 %0.15,0/624 %0.0,0/275 %0.0,0/291 %0.0
Neutrophils/granulocytes (ANC/AGC),0/654 %0.0,0/663 %0.0,1/674 %0.15,0/624 %0.0,3/275 %1.09,0/291 %0.0
Potassium serum-low (hypokalemia),0/654 %0.0,0/663 %0.0,0/674 %0.0,0/624 %0.0,0/275 %0.0,1/291 %0.34
Myelodysplasia,0/654 %0.0,1/663 %0.15,1/674 %0.15,0/624 %0.0,0/275 %0.0,0/291 %0.0
Secondary Malignancy-poss rel to cancer Tx,2/654 %0.31,1/663 %0.15,4/674 %0.59,3/624 %0.48,1/275 %0.36,0/291 %0.0
CNS cerebrovascular ischemia,0/654 %0.0,0/663 %0.0,0/674 %0.0,1/624 %0.16,0/275 %0.0,0/291 %0.0
Seizure,0/654 %0.0,0/663 %0.0,0/674 %0.0,0/624 %0.0,0/275 %0.0,1/291 %0.34
Somnolence/depressed level of consciousness,0/654 %0.0,0/663 %0.0,0/674 %0.0,0/624 %0.0,0/275 %0.0,1/291 %0.34
Confusion,0/654 %0.0,1/663 %0.15,0/674 %0.0,0/624 %0.0,0/275 %0.0,0/291 %0.0
Adult respiratory distress syndrome (ARDS),1/654 %0.15,0/663 %0.0,0/674 %0.0,0/624 %0.0,0/275 %0.0,0/291 %0.0
Dyspnea (shortness of breath),0/654 %0.0,0/663 %0.0,1/674 %0.15,0/624 %0.0,0/275 %0.0,0/291 %0.0
Pleural effusion (non-malignant),0/654 %0.0,1/663 %0.15,0/674 %0.0,0/624 %0.0,0/275 %0.0,0/291 %0.0
Pneumonitis/pulmonary infiltrates,0/654 %0.0,0/663 %0.0,1/674 %0.15,0/624 %0.0,0/275 %0.0,0/291 %0.0
Pulmonary/Upper Respiratory-Other,1/654 %0.15,1/663 %0.15,1/674 %0.15,0/624 %0.0,0/275 %0.0,0/291 %0.0
Hypotension,0/654 %0.0,0/663 %0.0,1/674 %0.15,0/624 %0.0,0/275 %0.0,0/291 %0.0
Thrombosis/thrombus/embolism,1/654 %0.15,2/663 %0.3,2/674 %0.3,1/624 %0.16,0/275 %0.0,0/291 %0.0

Surgery Plus Chemotherapy (Doxorubicin  Vincristine and Etoposide)  Mitotane  and Tariquidar to Treat Adrenocortical Cancer(https://clinicaltrials.gov/show/NCT00071058)
 ,Surgery Plus Chemothrapy
 ,Surgical resection can be performed at the time of study entry when patients have a mixed response or if their tumors respond to chemotherapy.  Surgical resection will be followed by chemotherapy with 2 grams oral dose daily of mitotane on cycle 1 day 1 6 mg/m^2 continuous intravenous infusion doxorubicin over 96 hours days 1-4 0.18 mg/m2 continuous intravenous infusion vincristine over 96 hours days 1-4 and 36 mg/m^2 continuous intravenous infusion etoposide over 96 hours days 1-4 and 150 mg tariquidar through central venous catheter over 30 minutes on days 1 and 3.
Total serious adverse events,13/50 %26.0
Leukocytes (total WBC),1/50 %2.0
Neutrophils/granulocytes (ANC/AGC),3/50 %6.0
Cardiac left ventricular function,1/50 %2.0
Cardiac-ischemia/infarction,1/50 %2.0
Thrombosis/embolism,2/50 %4.0
Anorexia,1/50 %2.0
Constipation,3/50 %6.0
Dehydration,1/50 %2.0
Diarrhea patients without colostomy,1/50 %2.0
Dysphagia esophagitis odynophagia (painful swallowing),1/50 %2.0
Ileus (or neuroconstipation),1/50 %2.0
Nausea,5/50 %10.0
Vomiting,3/50 %6.0
Abdominal pain or cramping,2/50 %4.0
Fatigue (lethargy malaise asthenia),1/50 %2.0
Fever (in the absence of neutropenia where neutropenia is defined as ANC <1.0 x 10e9/L),5/50 %10.0
Rigors/chills,1/50 %2.0
Allergic reaction/hypersensitivity (including drug fever),1/50 %2.0
Febrile Neutropenia,2/50 %4.0
Infection,1/50 %2.0
Infection without neutropenia,1/50 %2.0
Hyponatremia,1/50 %2.0
Dyspnea (shortness of breath),1/50 %2.0

Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers(https://clinicaltrials.gov/show/NCT00074490)
 ,Arm IVD Cohort 1 (Th2 DLI),Arm IVD Cohort 3 (Multiple Th2 DLI),Arm IVA (12-day Expanded Th2 DLI),Arm IVB (6-day Expanded Th2 DLI),Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus)
 ,Patients receive low intensity fludarabine phosphate intravenous (IV) and cyclophosphamide IV on days -6 to -3. Patients undergo donor lymphocyte infusion (DLI) with sirolimus generated donor T-helper 2 (Th2) cells on day 14 (single T-Rapa cell DLI in patients with cluster of differentiation 4 (CD4) count between 100 and 200 inclusive).,Patients with nonlymphoma diagnosis or rapidly progressive lymphoma undergo DLI with multiple infusions of sirolimus generated donor Th2 cells beginning on day 14 (multiple T-Rapa cell DLI in patients with CD4 count lower than 100 or ALC lower than 300).,Patients receive low-intensity preparative chemotherapy with fludarabine phosphate IV and cyclophosphamide IV on days -6 to -3 cyclosporine by mouth twice a day (PO BID) on days -4 to 100 and standard dose sirolimus PO on days -2 to 14. Patients undergo mobilized allogeneic peripheral blood stem cells (PBSC) on day 0. Patients undergo DLI with 12-day expanded sirolimus-generated donor Th2 cells on day 14.,Patients receive low-intensity preparative chemotherapy with fludarabine phosphate IV and cyclophosphamide IV on days -6 to -3 cyclosporine PO BID on days -4 to 100 and standard dose sirolimus PO on days -2 to 14. Patients undergo mobilized allogeneic PBSC or bone marrow transplant on day 0. Patients undergo DLI with 6-day expanded sirolimus-generated donor Th2 cells on day 14.,Patients receive low-intensity preparative chemotherapy with fludarabine phosphate IV and cyclophosphamide IV on days -6 to -3 cyclosporine PO BID on days -7 to 100 and high dose sirolimus PO on days -4 to 7 Patients undergo mobilized allogeneic PBSC on day 0. Patients undergo DLI with 6-day expanded sirolimus-generated donor Th2 cells on day 14.
Total all-cause mortality,0/1 %0.0,14/34 %41.18,22/40 %55.0,24/44 %54.55,22/45 %48.89
Total serious adverse events,1/1 %100.0,22/34 %64.71,37/40 %92.5,35/44 %79.55,31/45 %68.89
Blood/Bone Marrow - Other (engraftment syndrome),0/1 %0.0,0/34 %0.0,0/40 %0.0,0/44 %0.0,1/45 %2.22
Febrile neutropenia,0/1 %0.0,2/34 %5.88,10/40 %25.0,25/44 %56.82,5/45 %11.11
Hemoglobin,0/1 %0.0,2/34 %5.88,8/40 %20.0,10/44 %22.73,3/45 %6.67
Hemolysis (e.g. immune hemolytic anemia drug-related hemolysis),0/1 %0.0,0/34 %0.0,1/40 %2.5,0/44 %0.0,0/45 %0.0
Thrombotic microangiopathy,0/1 %0.0,0/34 %0.0,0/40 %0.0,1/44 %2.27,0/45 %0.0
Cardiac Arrhythmia - Other (atrial fibrillation),0/1 %0.0,0/34 %0.0,1/40 %2.5,0/44 %0.0,0/45 %0.0
Cardiac General - Other (congestive heart failure),0/1 %0.0,0/34 %0.0,0/40 %0.0,1/44 %2.27,0/45 %0.0
Cardiac ischemia/infarction,0/1 %0.0,0/34 %0.0,0/40 %0.0,1/44 %2.27,0/45 %0.0
Conduction abnormality/atrioventricular heart block::AV Block-First degree,0/1 %0.0,0/34 %0.0,0/40 %0.0,1/44 %2.27,0/45 %0.0
Conduction abnormality/atrioventricular heart block::AV Block-Second degree Mobitz Type II,0/1 %0.0,0/34 %0.0,1/40 %2.5,0/44 %0.0,0/45 %0.0
Left ventricular diastolic dysfunction,0/1 %0.0,0/34 %0.0,0/40 %0.0,0/44 %0.0,1/45 %2.22
Left ventricular systolic dysfunction,0/1 %0.0,0/34 %0.0,2/40 %5.0,1/44 %2.27,2/45 %4.44
Pericardial effusion (non-malignant),0/1 %0.0,1/34 %2.94,0/40 %0.0,0/44 %0.0,1/45 %2.22
Restrictive cardiomyopathy,0/1 %0.0,1/34 %2.94,0/40 %0.0,0/44 %0.0,0/45 %0.0
Supraventricular and nodal arrhythmia::Atrial fibrillation,0/1 %0.0,0/34 %0.0,1/40 %2.5,0/44 %0.0,0/45 %0.0
Supraventricular and nodal arrhythmia::Atrial flutter,0/1 %0.0,0/34 %0.0,1/40 %2.5,0/44 %0.0,0/45 %0.0
Supraventricular and nodal arrhythmia::Sinus tachycardia,0/1 %0.0,0/34 %0.0,1/40 %2.5,0/44 %0.0,0/45 %0.0
Supraventricular and nodal arrhythmia::Supraventricular tachycardia,0/1 %0.0,0/34 %0.0,1/40 %2.5,2/44 %4.55,0/45 %0.0
Pancreatic endocrine: glucose intolerance,0/1 %0.0,0/34 %0.0,2/40 %5.0,5/44 %11.36,0/45 %0.0
Thyroid function high (hyperthyroidism thyrotoxicosis),0/1 %0.0,0/34 %0.0,1/40 %2.5,0/44 %0.0,0/45 %0.0
Thyroid function low (hypothyroidism),0/1 %0.0,0/34 %0.0,1/40 %2.5,1/44 %2.27,0/45 %0.0
Dry eye syndrome,0/1 %0.0,0/34 %0.0,1/40 %2.5,0/44 %0.0,0/45 %0.0
Ocular/Visual - Other (GVHD),0/1 %0.0,0/34 %0.0,1/40 %2.5,0/44 %0.0,0/45 %0.0
Ocular/Visual - Other (ocular GVHD restasis started; EXTENSIVE CGVHD),0/1 %0.0,0/34 %0.0,1/40 %2.5,0/44 %0.0,0/45 %0.0
Ophthalmoplegia/diplopia (double vision),0/1 %0.0,0/34 %0.0,0/40 %0.0,1/44 %2.27,0/45 %0.0
Colitis,0/1 %0.0,2/34 %5.88,1/40 %2.5,3/44 %6.82,0/45 %0.0
Colitis infectious (e.g. Clostridium difficile),0/1 %0.0,1/34 %2.94,2/40 %5.0,7/44 %15.91,7/45 %15.56
Diarrhea,1/1 %100.0,4/34 %11.76,10/40 %25.0,16/44 %36.36,11/45 %24.44
Dry mouth/salivary gland (xerostomia),0/1 %0.0,1/34 %2.94,0/40 %0.0,1/44 %2.27,0/45 %0.0
Dysphagia (difficulty swallowing),0/1 %0.0,0/34 %0.0,1/40 %2.5,2/44 %4.55,1/45 %2.22
Esophagitis,0/1 %0.0,0/34 %0.0,3/40 %7.5,1/44 %2.27,0/45 %0.0
Gastritis (including bile reflux gastritis),0/1 %0.0,0/34 %0.0,0/40 %0.0,1/44 %2.27,0/45 %0.0
Gastrointestinal - Other (Abdominal pain (GVHD of the gut),0/1 %0.0,0/34 %0.0,1/40 %2.5,0/44 %0.0,0/45 %0.0
Gastrointestinal - Other (abdominal pain nausea and diarrhea c/w GVHD),0/1 %0.0,1/34 %2.94,0/40 %0.0,0/44 %0.0,0/45 %0.0
Hemorrhage GI::Lower GI NOS,0/1 %0.0,2/34 %5.88,0/40 %0.0,0/44 %0.0,1/45 %2.22
Hemorrhage GI::Rectum,0/1 %0.0,0/34 %0.0,1/40 %2.5,1/44 %2.27,0/45 %0.0
Hemorrhage GI::Upper GI NOS,0/1 %0.0,1/34 %2.94,2/40 %5.0,0/44 %0.0,3/45 %6.67
Ileus GI (functional obstruction of bowel i.e. neuroconstipation),0/1 %0.0,1/34 %2.94,3/40 %7.5,1/44 %2.27,0/45 %0.0
Mucositis/stomatitis (clinical exam)::Oral cavity,0/1 %0.0,1/34 %2.94,3/40 %7.5,2/44 %4.55,0/45 %0.0
Mucositis/stomatitis (functional/symptomatic)::Oral cavity,0/1 %0.0,0/34 %0.0,1/40 %2.5,0/44 %0.0,0/45 %0.0
Nausea,0/1 %0.0,2/34 %5.88,3/40 %7.5,5/44 %11.36,1/45 %2.22
Obstruction GI::Gallbladder,0/1 %0.0,0/34 %0.0,0/40 %0.0,1/44 %2.27,0/45 %0.0
Obstruction GI::Small bowel NOS,0/1 %0.0,0/34 %0.0,0/40 %0.0,0/44 %0.0,1/45 %2.22
Pain::Abdomen NOS,0/1 %0.0,2/34 %5.88,2/40 %5.0,2/44 %4.55,3/45 %6.67
Pain::Oral cavity,0/1 %0.0,0/34 %0.0,0/40 %0.0,1/44 %2.27,1/45 %2.22
Perforation GI::Small bowel NOS,0/1 %0.0,1/34 %2.94,0/40 %0.0,1/44 %2.27,0/45 %0.0
Typhlitis (cecal inflammation),0/1 %0.0,1/34 %2.94,0/40 %0.0,0/44 %0.0,0/45 %0.0
Ulcer GI::Stomach,0/1 %0.0,0/34 %0.0,1/40 %2.5,0/44 %0.0,0/45 %0.0
Vomiting,0/1 %0.0,1/34 %2.94,3/40 %7.5,1/44 %2.27,1/45 %2.22
Death not associated with CTCAE term::Death NOS,0/1 %0.0,1/34 %2.94,3/40 %7.5,2/44 %4.55,5/45 %11.11
Death not associated with CTCAE term::Disease progression NOS,0/1 %0.0,7/34 %20.59,9/40 %22.5,12/44 %27.27,11/45 %24.44
Death not associated with CTCAE term::Multi-organ failure,0/1 %0.0,2/34 %5.88,0/40 %0.0,0/44 %0.0,0/45 %0.0
Death not associated with CTCAE term::Sudden death,0/1 %0.0,0/34 %0.0,0/40 %0.0,2/44 %4.55,0/45 %0.0
Fever (in the absence of neutropenia where neutropenia is defined as ANC <1.0 x 10e9/L),0/1 %0.0,1/34 %2.94,14/40 %35.0,10/44 %22.73,0/45 %0.0
Hemorrhage/Bleeding - Other (Conjunctival low platelet ct),0/1 %0.0,0/34 %0.0,1/40 %2.5,0/44 %0.0,0/45 %0.0
Allergic reaction/hypersensitivity (including drug fever),0/1 %0.0,0/34 %0.0,0/40 %0.0,1/44 %2.27,0/45 %0.0
Infection (documented clinically or microbiologically),0/1 %0.0,2/34 %5.88,0/40 %0.0,0/44 %0.0,0/45 %0.0
Infection (documented clinically,0/1 %0.0,0/34 %0.0,0/40 %0.0,1/44 %2.27,0/45 %0.0
Infection,0/1 %0.0,8/34 %23.53,5/40 %12.5,13/44 %29.55,1/45 %2.22
Infection,0/1 %0.0,0/34 %0.0,0/40 %0.0,1/44 %2.27,0/45 %0.0
Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils,0/1 %0.0,0/34 %0.0,7/40 %17.5,0/44 %0.0,0/45 %0.0
Infection,0/1 %0.0,0/34 %0.0,3/40 %7.5,3/44 %6.82,0/45 %0.0
Infection,0/1 %0.0,1/34 %2.94,1/40 %2.5,12/44 %27.27,2/45 %4.44
Infection,0/1 %0.0,0/34 %0.0,1/40 %2.5,0/44 %0.0,0/45 %0.0
Infection,0/1 %0.0,0/34 %0.0,0/40 %0.0,1/44 %2.27,0/45 %0.0
Infection,0/1 %0.0,0/34 %0.0,2/40 %5.0,0/44 %0.0,0/45 %0.0
Infection,0/1 %0.0,0/34 %0.0,3/40 %7.5,1/44 %2.27,0/45 %0.0
Infection,0/1 %0.0,0/34 %0.0,1/40 %2.5,2/44 %4.55,0/45 %0.0
Infection,0/1 %0.0,1/34 %2.94,1/40 %2.5,0/44 %0.0,1/45 %2.22
Infection,0/1 %0.0,1/34 %2.94,0/40 %0.0,1/44 %2.27,0/45 %0.0
Infection,0/1 %0.0,0/34 %0.0,1/40 %2.5,0/44 %0.0,0/45 %0.0
Infection,0/1 %0.0,1/34 %2.94,0/40 %0.0,0/44 %0.0,0/45 %0.0
Infection,0/1 %0.0,0/34 %0.0,0/40 %0.0,3/44 %6.82,0/45 %0.0
Infection,0/1 %0.0,1/34 %2.94,1/40 %2.5,2/44 %4.55,1/45 %2.22
Infection - Other (C.Diff: PCR +),0/1 %0.0,0/34 %0.0,0/40 %0.0,0/44 %0.0,1/45 %2.22
Infection - Other (HHV6 reactivation; admitted for anemia & leukocytosis),0/1 %0.0,0/34 %0.0,1/40 %2.5,0/44 %0.0,0/45 %0.0
Infection - Other (Influenza A +),0/1 %0.0,0/34 %0.0,0/40 %0.0,0/44 %0.0,1/45 %2.22
Infection - Other (R. wrist septic arthritis),0/1 %0.0,0/34 %0.0,0/40 %0.0,1/44 %2.27,0/45 %0.0
Infection - Other (pseudomonas bacteremia/sepsis.),0/1 %0.0,1/34 %2.94,0/40 %0.0,0/44 %0.0,0/45 %0.0
Infection - Other (worsening right great toe pain with drainage and now neutropenic),0/1 %0.0,0/34 %0.0,0/40 %0.0,1/44 %2.27,0/45 %0.0
Infection with normal ANC or Grade 1 or 2 neutrophils::Appendix,0/1 %0.0,0/34 %0.0,0/40 %0.0,1/44 %2.27,0/45 %0.0
Infection with normal ANC or Grade 1 or 2 neutrophils::Blood,1/1 %100.0,13/34 %38.24,10/40 %25.0,18/44 %40.91,13/45 %28.89
Infection with normal ANC or Grade 1 or 2 neutrophils::Bone (osteomyelitis),0/1 %0.0,0/34 %0.0,0/40 %0.0,1/44 %2.27,0/45 %0.0
Infection with normal ANC or Grade 1 or 2 neutrophils::Brain (encephalitis infectious),0/1 %0.0,0/34 %0.0,0/40 %0.0,4/44 %9.09,0/45 %0.0
Infection with normal ANC or Grade 1 or 2 neutrophils::Brain + Spinal cord (encephalomyelitis),0/1 %0.0,0/34 %0.0,0/40 %0.0,0/44 %0.0,1/45 %2.22
Infection with normal ANC or Grade 1 or 2 neutrophils::Bronchus,0/1 %0.0,0/34 %0.0,0/40 %0.0,1/44 %2.27,1/45 %2.22
Infection with normal ANC or Grade 1 or 2 neutrophils::Catheter-related,0/1 %0.0,0/34 %0.0,6/40 %15.0,4/44 %9.09,0/45 %0.0
Infection with normal ANC or Grade 1 or 2 neutrophils::Colon,1/1 %100.0,1/34 %2.94,7/40 %17.5,8/44 %18.18,6/45 %13.33
Infection with normal ANC or Grade 1 or 2 neutrophils::External ear (otitis externa),0/1 %0.0,0/34 %0.0,1/40 %2.5,0/44 %0.0,0/45 %0.0
Infection with normal ANC or Grade 1 or 2 neutrophils::Lung (pneumonia),0/1 %0.0,4/34 %11.76,12/40 %30.0,24/44 %54.55,11/45 %24.44
Infection with normal ANC or Grade 1 or 2 neutrophils::Lymphatic,0/1 %0.0,0/34 %0.0,0/40 %0.0,0/44 %0.0,2/45 %4.44
Infection with normal ANC or Grade 1 or 2 neutrophils::Oral cavity-gums (gingivitis),0/1 %0.0,0/34 %0.0,0/40 %0.0,0/44 %0.0,1/45 %2.22
Infection with normal ANC or Grade 1 or 2 neutrophils::Peritoneal cavity,0/1 %0.0,0/34 %0.0,0/40 %0.0,1/44 %2.27,0/45 %0.0
Infection with normal ANC or Grade 1 or 2 neutrophils::Pharynx,0/1 %0.0,0/34 %0.0,1/40 %2.5,0/44 %0.0,0/45 %0.0
Infection with normal ANC or Grade 1 or 2 neutrophils::Pleura (empyema),0/1 %0.0,0/34 %0.0,1/40 %2.5,0/44 %0.0,0/45 %0.0
Infection with normal ANC or Grade 1 or 2 neutrophils::Rectum,0/1 %0.0,0/34 %0.0,2/40 %5.0,0/44 %0.0,0/45 %0.0
Infection with normal ANC or Grade 1 or 2 neutrophils::Sinus,0/1 %0.0,0/34 %0.0,4/40 %10.0,4/44 %9.09,2/45 %4.44
Infection with normal ANC or Grade 1 or 2 neutrophils::Skin (cellulitis),0/1 %0.0,0/34 %0.0,3/40 %7.5,3/44 %6.82,4/45 %8.89
Infection with normal ANC or Grade 1 or 2 neutrophils::Stomach,0/1 %0.0,0/34 %0.0,1/40 %2.5,1/44 %2.27,1/45 %2.22
Infection with normal ANC or Grade 1 or 2 neutrophils::Upper airway NOS,0/1 %0.0,0/34 %0.0,6/40 %15.0,4/44 %9.09,6/45 %13.33
Infection with normal ANC or Grade 1 or 2 neutrophils::Urinary tract NOS,0/1 %0.0,1/34 %2.94,4/40 %10.0,4/44 %9.09,1/45 %2.22
Infection with normal ANC or Grade 1 or 2 neutrophils::Wound,0/1 %0.0,0/34 %0.0,1/40 %2.5,0/44 %0.0,0/45 %0.0
Infection with unknown ANC::Abdomen NOS,0/1 %0.0,1/34 %2.94,0/40 %0.0,0/44 %0.0,0/45 %0.0
Infection with unknown ANC::Blood,0/1 %0.0,0/34 %0.0,1/40 %2.5,1/44 %2.27,2/45 %4.44
Infection with unknown ANC::Lung (pneumonia),0/1 %0.0,0/34 %0.0,2/40 %5.0,3/44 %6.82,1/45 %2.22
Infection with unknown ANC::Meninges (meningitis),0/1 %0.0,0/34 %0.0,0/40 %0.0,0/44 %0.0,1/45 %2.22
Infection with unknown ANC::Sinus,0/1 %0.0,0/34 %0.0,0/40 %0.0,1/44 %2.27,1/45 %2.22
Infection with unknown ANC::Upper aerodigestive NOS,0/1 %0.0,0/34 %0.0,0/40 %0.0,1/44 %2.27,0/45 %0.0
Infection with unknown ANC::Upper airway NOS,0/1 %0.0,0/34 %0.0,0/40 %0.0,0/44 %0.0,1/45 %2.22
Infection with unknown ANC::Urinary tract NOS,0/1 %0.0,0/34 %0.0,0/40 %0.0,1/44 %2.27,0/45 %0.0
Viral hepatitis,0/1 %0.0,0/34 %0.0,0/40 %0.0,1/44 %2.27,0/45 %0.0
Fracture,0/1 %0.0,0/34 %0.0,0/40 %0.0,3/44 %6.82,0/45 %0.0
ALT SGPT (serum glutamic pyruvic transaminase),0/1 %0.0,5/34 %14.71,4/40 %10.0,16/44 %36.36,5/45 %11.11
AST SGOT(serum glutamic oxaloacetic transaminase),0/1 %0.0,1/34 %2.94,4/40 %10.0,12/44 %27.27,1/45 %2.22
Alkaline phosphatase,0/1 %0.0,0/34 %0.0,1/40 %2.5,1/44 %2.27,0/45 %0.0
Amylase,0/1 %0.0,0/34 %0.0,0/40 %0.0,0/44 %0.0,1/45 %2.22
Carbon monoxide diffusion capacity (DL(co)),0/1 %0.0,1/34 %2.94,0/40 %0.0,0/44 %0.0,0/45 %0.0
Cardiac troponin I (cTnI),0/1 %0.0,0/34 %0.0,1/40 %2.5,1/44 %2.27,0/45 %0.0
Creatinine,0/1 %0.0,0/34 %0.0,3/40 %7.5,4/44 %9.09,0/45 %0.0
Leukocytes (total WBC),0/1 %0.0,0/34 %0.0,2/40 %5.0,0/44 %0.0,0/45 %0.0
Lipase,0/1 %0.0,0/34 %0.0,0/40 %0.0,0/44 %0.0,1/45 %2.22
Neutrophils/granulocytes (ANC/AGC),0/1 %0.0,3/34 %8.82,15/40 %37.5,13/44 %29.55,7/45 %15.56
PTT (Partial Thromboplastin Time),0/1 %0.0,1/34 %2.94,1/40 %2.5,0/44 %0.0,0/45 %0.0
Platelets,0/1 %0.0,2/34 %5.88,7/40 %17.5,7/44 %15.91,3/45 %6.67
Prolonged QTc interval,0/1 %0.0,0/34 %0.0,1/40 %2.5,1/44 %2.27,0/45 %0.0
Weight loss,0/1 %0.0,0/34 %0.0,0/40 %0.0,1/44 %2.27,0/45 %0.0
Acidosis (metabolic or respiratory),0/1 %0.0,0/34 %0.0,0/40 %0.0,2/44 %4.55,0/45 %0.0
Albumin serum-low (hypoalbuminemia),0/1 %0.0,1/34 %2.94,0/40 %0.0,1/44 %2.27,0/45 %0.0
Alkalosis (metabolic or respiratory),0/1 %0.0,1/34 %2.94,0/40 %0.0,0/44 %0.0,0/45 %0.0
Anorexia,0/1 %0.0,1/34 %2.94,1/40 %2.5,2/44 %4.55,0/45 %0.0
Calcium serum-low (hypocalcemia),0/1 %0.0,0/34 %0.0,1/40 %2.5,0/44 %0.0,0/45 %0.0
Dehydration,0/1 %0.0,0/34 %0.0,2/40 %5.0,0/44 %0.0,0/45 %0.0
Glucose serum-high (hyperglycemia),0/1 %0.0,0/34 %0.0,1/40 %2.5,2/44 %4.55,0/45 %0.0
Glucose serum-low (hypoglycemia),0/1 %0.0,0/34 %0.0,1/40 %2.5,0/44 %0.0,0/45 %0.0
Metabolic/Laboratory - Other (ph>7.5 with life threating consequences ALKALOSIS),0/1 %0.0,0/34 %0.0,0/40 %0.0,0/44 %0.0,1/45 %2.22
Metabolic/Laboratory - Other (steroid induced hyperglycemia),0/1 %0.0,0/34 %0.0,1/40 %2.5,0/44 %0.0,0/45 %0.0
Phosphate serum-low (hypophosphatemia),0/1 %0.0,0/34 %0.0,0/40 %0.0,5/44 %11.36,1/45 %2.22
Potassium serum-high (hyperkalemia),0/1 %0.0,0/34 %0.0,1/40 %2.5,0/44 %0.0,0/45 %0.0
Potassium serum-low (hypokalemia),0/1 %0.0,0/34 %0.0,2/40 %5.0,5/44 %11.36,0/45 %0.0
Sodium serum-low (hyponatremia),0/1 %0.0,2/34 %5.88,2/40 %5.0,3/44 %6.82,0/45 %0.0
Triglyceride serum-high (hypertriglyceridemia),0/1 %0.0,0/34 %0.0,0/40 %0.0,1/44 %2.27,0/45 %0.0
Tumor lysis syndrome,0/1 %0.0,0/34 %0.0,0/40 %0.0,1/44 %2.27,0/45 %0.0
Uric acid serum-high (hyperuricemia),0/1 %0.0,0/34 %0.0,0/40 %0.0,1/44 %2.27,1/45 %2.22
Arthritis (non-septic),0/1 %0.0,0/34 %0.0,1/40 %2.5,2/44 %4.55,0/45 %0.0
Muscle weakness generalized or specific area (not due to neuropathy)::Whole body/generalized,0/1 %0.0,0/34 %0.0,0/40 %0.0,3/44 %6.82,1/45 %2.22
Osteonecrosis (avascular necrosis),0/1 %0.0,0/34 %0.0,1/40 %2.5,0/44 %0.0,0/45 %0.0
Pain::Back,0/1 %0.0,1/34 %2.94,0/40 %0.0,0/44 %0.0,0/45 %0.0
Pain::Bone,0/1 %0.0,0/34 %0.0,1/40 %2.5,0/44 %0.0,0/45 %0.0
Pain::Chest wall,0/1 %0.0,0/34 %0.0,0/40 %0.0,2/44 %4.55,0/45 %0.0
Pain::Neck,0/1 %0.0,0/34 %0.0,1/40 %2.5,0/44 %0.0,0/45 %0.0
Secondary Malignancy -,0/1 %0.0,0/34 %0.0,0/40 %0.0,0/44 %0.0,1/45 %2.22
Secondary Malignancy - possibly related to cancer treatment (squamous cell carcinoma),0/1 %0.0,1/34 %2.94,0/40 %0.0,0/44 %0.0,0/45 %0.0
Secondary Malignancy - possibly related to cancer treatment,0/1 %0.0,0/34 %0.0,0/40 %0.0,0/44 %0.0,1/45 %2.22
Bilirubin (hyperbilirubinemia),0/1 %0.0,3/34 %8.82,6/40 %15.0,7/44 %15.91,0/45 %0.0
CNS cerebrovascular ischemia,0/1 %0.0,0/34 %0.0,2/40 %5.0,0/44 %0.0,0/45 %0.0
Cognitive disturbance,0/1 %0.0,0/34 %0.0,1/40 %2.5,0/44 %0.0,0/45 %0.0
Dizziness,0/1 %0.0,0/34 %0.0,1/40 %2.5,0/44 %0.0,0/45 %0.0
Edema: head and neck,0/1 %0.0,0/34 %0.0,1/40 %2.5,0/44 %0.0,0/45 %0.0
Encephalopathy,0/1 %0.0,0/34 %0.0,3/40 %7.5,0/44 %0.0,0/45 %0.0
Hemorrhage/Bleeding - Other (Massive Intracranial hemorrhage of left frontal lobe mass),0/1 %0.0,0/34 %0.0,0/40 %0.0,0/44 %0.0,1/45 %2.22
Leukoencephalopathy (radiographic findings),0/1 %0.0,0/34 %0.0,1/40 %2.5,0/44 %0.0,0/45 %0.0
Neuropathy: cranial::CN III Pupil upper eyelid extra ocular movements,0/1 %0.0,0/34 %0.0,2/40 %5.0,0/44 %0.0,0/45 %0.0
Neuropathy: cranial::CN VI Lateral deviation of eye,0/1 %0.0,0/34 %0.0,1/40 %2.5,0/44 %0.0,0/45 %0.0
Neuropathy: motor,0/1 %0.0,0/34 %0.0,1/40 %2.5,3/44 %6.82,0/45 %0.0
Neuropathy: sensory,0/1 %0.0,0/34 %0.0,1/40 %2.5,2/44 %4.55,0/45 %0.0
Pain::Head/headache,0/1 %0.0,0/34 %0.0,0/40 %0.0,1/44 %2.27,1/45 %2.22
Seizure,0/1 %0.0,2/34 %5.88,1/40 %2.5,0/44 %0.0,0/45 %0.0
Somnolence/depressed level of consciousness,0/1 %0.0,0/34 %0.0,1/40 %2.5,1/44 %2.27,0/45 %0.0
Syncope (fainting),0/1 %0.0,0/34 %0.0,0/40 %0.0,0/44 %0.0,1/45 %2.22
Confusion,0/1 %0.0,0/34 %0.0,2/40 %5.0,1/44 %2.27,1/45 %2.22
Mental status,0/1 %0.0,0/34 %0.0,0/40 %0.0,1/44 %2.27,0/45 %0.0
Psychosis (hallucinations/delusions),0/1 %0.0,0/34 %0.0,0/40 %0.0,1/44 %2.27,1/45 %2.22
Cystitis,0/1 %0.0,1/34 %2.94,1/40 %2.5,1/44 %2.27,0/45 %0.0
Hemorrhage GU::Urinary NOS,0/1 %0.0,0/34 %0.0,1/40 %2.5,0/44 %0.0,0/45 %0.0
Renal failure,0/1 %0.0,1/34 %2.94,4/40 %10.0,5/44 %11.36,2/45 %4.44
Stricture/stenosis (including anastomotic) GU::Urethra,0/1 %0.0,0/34 %0.0,1/40 %2.5,0/44 %0.0,0/45 %0.0
Adult Respiratory Distress Syndrome (ARDS),0/1 %0.0,1/34 %2.94,0/40 %0.0,0/44 %0.0,0/45 %0.0
Apnea,0/1 %0.0,0/34 %0.0,1/40 %2.5,0/44 %0.0,0/45 %0.0
Cough,0/1 %0.0,1/34 %2.94,0/40 %0.0,0/44 %0.0,0/45 %0.0
Dyspnea (shortness of breath),0/1 %0.0,1/34 %2.94,5/40 %12.5,3/44 %6.82,1/45 %2.22
Edema larynx,0/1 %0.0,0/34 %0.0,0/40 %0.0,0/44 %0.0,1/45 %2.22
Hemorrhage pulmonary/upper respiratory::Bronchopulmonary NOS,0/1 %0.0,0/34 %0.0,0/40 %0.0,1/44 %2.27,1/45 %2.22
Hemorrhage pulmonary/upper respiratory::Lung,0/1 %0.0,1/34 %2.94,1/40 %2.5,0/44 %0.0,1/45 %2.22
Hemorrhage pulmonary/upper respiratory::Nose,0/1 %0.0,0/34 %0.0,0/40 %0.0,1/44 %2.27,1/45 %2.22
Hemorrhage/Bleeding - Other (diffuse alveolar hemorrhage),0/1 %0.0,0/34 %0.0,0/40 %0.0,0/44 %0.0,1/45 %2.22
Hypoxia,0/1 %0.0,1/34 %2.94,12/40 %30.0,11/44 %25.0,3/45 %6.67
Obstruction/stenosis of airway::Bronchus,0/1 %0.0,0/34 %0.0,1/40 %2.5,0/44 %0.0,0/45 %0.0
Obstruction/stenosis of airway::Trachea,0/1 %0.0,0/34 %0.0,0/40 %0.0,1/44 %2.27,0/45 %0.0
Pain::Throat/pharynx/larynx,0/1 %0.0,0/34 %0.0,0/40 %0.0,1/44 %2.27,0/45 %0.0
Pleural effusion (non-malignant),0/1 %0.0,0/34 %0.0,1/40 %2.5,5/44 %11.36,1/45 %2.22
Pneumonitis/pulmonary infiltrates,0/1 %0.0,1/34 %2.94,6/40 %15.0,5/44 %11.36,0/45 %0.0
Dermatology/Skin - Other,0/1 %0.0,0/34 %0.0,1/40 %2.5,0/44 %0.0,0/45 %0.0
Pruritus/itching,0/1 %0.0,1/34 %2.94,0/40 %0.0,0/44 %0.0,0/45 %0.0
Rash/desquamation,0/1 %0.0,1/34 %2.94,11/40 %27.5,9/44 %20.45,4/45 %8.89
Rash: acne/acneiform,0/1 %0.0,2/34 %5.88,0/40 %0.0,0/44 %0.0,1/45 %2.22
Acute vascular leak syndrome,0/1 %0.0,0/34 %0.0,1/40 %2.5,0/44 %0.0,0/45 %0.0
Hypertension,0/1 %0.0,1/34 %2.94,6/40 %15.0,3/44 %6.82,0/45 %0.0
Hypotension,0/1 %0.0,1/34 %2.94,6/40 %15.0,2/44 %4.55,1/45 %2.22
Thrombosis/embolism (vascular access-related),0/1 %0.0,0/34 %0.0,2/40 %5.0,4/44 %9.09,1/45 %2.22
Thrombosis/thrombus/embolism,0/1 %0.0,0/34 %0.0,1/40 %2.5,3/44 %6.82,1/45 %2.22
Vasculitis,0/1 %0.0,0/34 %0.0,1/40 %2.5,0/44 %0.0,0/45 %0.0

Universal Granulocyte Macrophage-colony Stimulating Factor (GM-CSF)-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell Lymphoma(https://clinicaltrials.gov/show/NCT00101101)
 ,Vaccine and Conventional Therapy
 ,Patients were treated with 3-6 cycles of chemotherapy +/- rituximab with type and duration at the discretion of the individual clinician.  Chemotherapy: 6 courses of cyclophosphamide doxorubicin vincristine and prednisone (CHOP) OR 3 courses of hyperfractionated cyclophosphamide vincristine doxorubicin and dexamethasone alternating with high-dose methotrexate and cytarabine (hyper-CVAD) for patients who have relapsed after CHOP.  Patients who achieve a partial or complete response after completion of chemotherapy proceed to autologous tumor cell-based vaccine therapy.  Patients who have stable or responding disease at 12 months receive 4 additional courses of booster vaccine and low-dose IL-2.  Treatment continues in the absence of disease progression or unacceptable toxicity.
Total serious adverse events,2/43 %4.65
Leukocyte,1/43 %2.33
Granulocyte,1/43 %2.33
Cough,1/43 %2.33

Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma(https://clinicaltrials.gov/show/NCT00103506)
 ,Velcade (Bortezomib) Monotherapy,Doxil/Caelyx Plus Velcade (Bortezomib)
 ,Velcade (bortezomib) 1.3 milligram/meter per square (mg/m^2) by rapid (bolus) intravenous (IV) administration given on Day 1 4 8 and 11 of each 21-day cycle for up to 8 cycles.,Velcade (bortezomib) 1.3 mg/m^2 by rapid (bolus) IV administration given on Day 1 4 8 and 11 of each 21-day cycle for up to 8 cycles. Doxorubicin hydrochloride (DOXIL/CAELYX) 30 mg/m^2 by IV infusion will be given on Day 4 of every 21-day cycle after the administration of VELCADE (bortezomib) up to 8 cycles.
Total serious adverse events,105/318 %33.02,120/318 %37.74
Anaemia,4/318 %1.26,3/318 %0.94
Febrile Neutropenia,2/318 %0.63,5/318 %1.57
Leukopenia,0/318 %0.0,1/318 %0.31
Neutropenia,0/318 %0.0,2/318 %0.63
Pancytopenia,0/318 %0.0,2/318 %0.63
Thrombocytopenia,0/318 %0.0,9/318 %2.83
Acute Myocardial Infarction,0/318 %0.0,1/318 %0.31
Angina Pectoris,1/318 %0.31,0/318 %0.0
Angina Unstable,1/318 %0.31,0/318 %0.0
Arrhythmia,1/318 %0.31,0/318 %0.0
Atrial Fibrillation,2/318 %0.63,0/318 %0.0
Atrial Flutter,0/318 %0.0,1/318 %0.31
Cardiac Arrest,0/318 %0.0,1/318 %0.31
Cardiac Failure,2/318 %0.63,0/318 %0.0
Cardiac Failure Chronic,0/318 %0.0,1/318 %0.31
Cardiac Failure Congestive,2/318 %0.63,2/318 %0.63
Cardio-Respiratory Arrest,1/318 %0.31,0/318 %0.0
Myocardial Infarction,1/318 %0.31,2/318 %0.63
Nodal Arrhythmia,0/318 %0.0,1/318 %0.31
Right Ventricular Failure,1/318 %0.31,1/318 %0.31
Tachyarrhythmia,0/318 %0.0,1/318 %0.31
Deafness,0/318 %0.0,1/318 %0.31
Vertigo,3/318 %0.94,0/318 %0.0
Adrenal Insufficiency,0/318 %0.0,1/318 %0.31
Hypercorticoidism,0/318 %0.0,1/318 %0.31
Inappropriate Antidiuretic Hormone Secretion,1/318 %0.31,0/318 %0.0
Cataract,0/318 %0.0,1/318 %0.31
Corneal Erosion,0/318 %0.0,1/318 %0.31
Diplopia,1/318 %0.31,0/318 %0.0
Retinal Vein Thrombosis,1/318 %0.31,0/318 %0.0
Abdominal Pain,2/318 %0.63,2/318 %0.63
Diarrhoea,6/318 %1.89,7/318 %2.2
Dyspepsia,0/318 %0.0,1/318 %0.31
Dysphagia,0/318 %0.0,2/318 %0.63
Faecaloma,0/318 %0.0,1/318 %0.31
Flatulence,1/318 %0.31,0/318 %0.0
Gastric Ulcer,0/318 %0.0,2/318 %0.63
Gastroduodenal Haemorrhage,0/318 %0.0,1/318 %0.31
Gastrointestinal Haemorrhage,1/318 %0.31,3/318 %0.94
Gastrooesophageal Reflux Disease,0/318 %0.0,1/318 %0.31
Haematemesis,2/318 %0.63,2/318 %0.63
Ileus,0/318 %0.0,1/318 %0.31
Ileus Paralytic,1/318 %0.31,1/318 %0.31
Large Intestine Perforation,0/318 %0.0,1/318 %0.31
Mallory-Weiss Syndrome,0/318 %0.0,2/318 %0.63
Nausea,3/318 %0.94,7/318 %2.2
Rectal Haemorrhage,0/318 %0.0,1/318 %0.31
Rectal Prolapse,1/318 %0.31,0/318 %0.0
Small Intestinal Obstruction,1/318 %0.31,1/318 %0.31
Stomatitis,0/318 %0.0,1/318 %0.31
Upper Gastrointestinal Haemorrhage,0/318 %0.0,2/318 %0.63
Vomiting,2/318 %0.63,13/318 %4.09
Asthenia,1/318 %0.31,2/318 %0.63
Catheter Related Complication,1/318 %0.31,0/318 %0.0
Chest Pain,3/318 %0.94,0/318 %0.0
Chills,1/318 %0.31,0/318 %0.0
Death,1/318 %0.31,0/318 %0.0
Fatigue,0/318 %0.0,3/318 %0.94
General Physical Health Deterioration,0/318 %0.0,1/318 %0.31
Hyperthermia,1/318 %0.31,0/318 %0.0
Influenza Like Illness,0/318 %0.0,1/318 %0.31
Multi-Organ Failure,0/318 %0.0,1/318 %0.31
Oedema Peripheral,1/318 %0.31,0/318 %0.0
Pain,0/318 %0.0,1/318 %0.31
Pyrexia,8/318 %2.52,15/318 %4.72
Sudden Cardiac Death,1/318 %0.31,0/318 %0.0
Sudden Death,0/318 %0.0,1/318 %0.31
Hypersensitivity,0/318 %0.0,1/318 %0.31
Abdominal Infection,0/318 %0.0,1/318 %0.31
Bacterial Sepsis,1/318 %0.31,0/318 %0.0
Bronchitis,1/318 %0.31,0/318 %0.0
Bronchitis Acute,2/318 %0.63,0/318 %0.0
Bronchitis Chronic,2/318 %0.63,0/318 %0.0
Bronchopneumonia,1/318 %0.31,3/318 %0.94
Candidiasis,0/318 %0.0,1/318 %0.31
Catheter Related Infection,0/318 %0.0,2/318 %0.63
Cellulitis,1/318 %0.31,1/318 %0.31
Diarrhoea Infectious,1/318 %0.31,0/318 %0.0
Ear Infection,0/318 %0.0,1/318 %0.31
Furuncle,0/318 %0.0,1/318 %0.31
Gastroenteritis,3/318 %0.94,1/318 %0.31
Genitourinary Tract Infection,1/318 %0.31,0/318 %0.0
Herpes Zoster,3/318 %0.94,5/318 %1.57
Herpes Zoster Disseminated,1/318 %0.31,1/318 %0.31
Infection,1/318 %0.31,1/318 %0.31
Klebsiella Sepsis,1/318 %0.31,0/318 %0.0
Laryngitis,1/318 %0.31,0/318 %0.0
Lobar Pneumonia,1/318 %0.31,0/318 %0.0
Lower Respiratory Tract Infection,3/318 %0.94,3/318 %0.94
Meningitis Bacterial,1/318 %0.31,0/318 %0.0
Neutropenic Sepsis,0/318 %0.0,1/318 %0.31
Opportunistic Infection,0/318 %0.0,1/318 %0.31
Orchitis,0/318 %0.0,1/318 %0.31
Osteomyelitis,0/318 %0.0,1/318 %0.31
Pneumococcal Bacteraemia,0/318 %0.0,1/318 %0.31
Pneumococcal Sepsis,1/318 %0.31,2/318 %0.63
Pneumocystis JiroveCI Pneumonia,0/318 %0.0,1/318 %0.31
Pneumonia,20/318 %6.29,16/318 %5.03
Pneumonia Aspergillus,1/318 %0.31,0/318 %0.0
Pneumonia Legionella,0/318 %0.0,1/318 %0.31
Pneumonia Pneumococcal,0/318 %0.0,1/318 %0.31
Pseudomonas Infection,0/318 %0.0,2/318 %0.63
Respiratory Tract Infection,2/318 %0.63,3/318 %0.94
Respiratory Tract Infection Bacterial,0/318 %0.0,1/318 %0.31
Sepsis,0/318 %0.0,1/318 %0.31
Septic Embolus,0/318 %0.0,1/318 %0.31
Septic Shock,1/318 %0.31,3/318 %0.94
Sinusitis,1/318 %0.31,0/318 %0.0
Skin Infection,1/318 %0.31,0/318 %0.0
Staphylococcal Sepsis,0/318 %0.0,2/318 %0.63
Upper Respiratory Tract Infection,2/318 %0.63,4/318 %1.26
Urinary Tract Infection,2/318 %0.63,0/318 %0.0
Urosepsis,1/318 %0.31,0/318 %0.0
Drug Toxicity,0/318 %0.0,1/318 %0.31
Fall,1/318 %0.31,1/318 %0.31
Skeletal Injury,0/318 %0.0,1/318 %0.31
Spinal Compression Fracture,0/318 %0.0,1/318 %0.31
Thoracic Vertebral Fracture,1/318 %0.31,0/318 %0.0
Blood Creatinine Increased,2/318 %0.63,3/318 %0.94
Blood Glucose Increased,0/318 %0.0,1/318 %0.31
Ejection Fraction Decreased,0/318 %0.0,2/318 %0.63
Troponin I Increased,1/318 %0.31,0/318 %0.0
Anorexia,0/318 %0.0,2/318 %0.63
Dehydration,6/318 %1.89,6/318 %1.89
Gout,0/318 %0.0,1/318 %0.31
Hypercalcaemia,1/318 %0.31,1/318 %0.31
Hyperkalaemia,1/318 %0.31,0/318 %0.0
Hypoalbuminaemia,1/318 %0.31,1/318 %0.31
Hypoglycaemia,1/318 %0.31,0/318 %0.0
Hypokalaemia,1/318 %0.31,3/318 %0.94
Hyponatraemia,1/318 %0.31,1/318 %0.31
Arthralgia,2/318 %0.63,0/318 %0.0
Back Pain,3/318 %0.94,0/318 %0.0
Bone Lesion,1/318 %0.31,1/318 %0.31
Bone Pain,1/318 %0.31,1/318 %0.31
Bursitis,0/318 %0.0,1/318 %0.31
Joint Instability,0/318 %0.0,1/318 %0.31
Musculoskeletal Chest Pain,0/318 %0.0,1/318 %0.31
Myalgia,1/318 %0.31,0/318 %0.0
Osteonecrosis,0/318 %0.0,1/318 %0.31
Pain in Extremity,2/318 %0.63,0/318 %0.0
Pathological Fracture,0/318 %0.0,2/318 %0.63
Cancer Pain,1/318 %0.31,0/318 %0.0
Colon Cancer,0/318 %0.0,1/318 %0.31
Tumour Lysis Syndrome,1/318 %0.31,2/318 %0.63
Autonomic Neuropathy,1/318 %0.31,0/318 %0.0
Balance Disorder,1/318 %0.31,0/318 %0.0
Cauda Equina Syndrome,2/318 %0.63,1/318 %0.31
Cerebral Haemorrhage,0/318 %0.0,1/318 %0.31
Cerebral Infarction,0/318 %0.0,1/318 %0.31
Cerebral Ischaemia,0/318 %0.0,1/318 %0.31
Coordination Abnormal,0/318 %0.0,1/318 %0.31
Dizziness,1/318 %0.31,2/318 %0.63
Lumbar Radiculopathy,1/318 %0.31,0/318 %0.0
Neuralgia,1/318 %0.31,0/318 %0.0
Neuropathy,1/318 %0.31,0/318 %0.0
Neuropathy Peripheral,1/318 %0.31,2/318 %0.63
Paralysis,1/318 %0.31,0/318 %0.0
Paraparesis,1/318 %0.31,0/318 %0.0
Paraplegia,1/318 %0.31,0/318 %0.0
Polyneuropathy,1/318 %0.31,1/318 %0.31
Polyneuropathy in Malignant Disease,1/318 %0.31,0/318 %0.0
Quadriparesis,1/318 %0.31,0/318 %0.0
Spinal Cord Compression,0/318 %0.0,3/318 %0.94
Syncope,4/318 %1.26,4/318 %1.26
Tremor,0/318 %0.0,1/318 %0.31
Agitation,1/318 %0.31,0/318 %0.0
Anxiety,1/318 %0.31,0/318 %0.0
Completed Suicide,1/318 %0.31,0/318 %0.0
Nervousness,1/318 %0.31,0/318 %0.0
Suicidal Ideation,1/318 %0.31,0/318 %0.0
Calculus Bladder,0/318 %0.0,1/318 %0.31
Haematuria,0/318 %0.0,1/318 %0.31
Nephritis Interstitial,1/318 %0.31,0/318 %0.0
Renal Colic,0/318 %0.0,1/318 %0.31
Renal Failure,2/318 %0.63,3/318 %0.94
Renal Failure Acute,5/318 %1.57,4/318 %1.26
Renal Failure Chronic,1/318 %0.31,0/318 %0.0
Renal Impairment,2/318 %0.63,0/318 %0.0
Urinary Bladder Haemorrhage,0/318 %0.0,1/318 %0.31
Urinary Retention,2/318 %0.63,1/318 %0.31
Benign Prostatic Hyperplasia,0/318 %0.0,1/318 %0.31
Epididymitis,1/318 %0.31,0/318 %0.0
Acute Pulmonary Oedema,1/318 %0.31,2/318 %0.63
Chronic Obstructive Pulmonary Disease,1/318 %0.31,0/318 %0.0
Dyspnoea,6/318 %1.89,2/318 %0.63
Dyspnoea Exertional,0/318 %0.0,1/318 %0.31
Interstitial Lung Disease,1/318 %0.31,0/318 %0.0
Pneumonitis,0/318 %0.0,2/318 %0.63
Pulmonary Embolism,2/318 %0.63,2/318 %0.63
Pulmonary Fibrosis,1/318 %0.31,0/318 %0.0
Pulmonary Hypertension,0/318 %0.0,2/318 %0.63
Pulmonary Oedema,0/318 %0.0,1/318 %0.31
Respiratory Failure,1/318 %0.31,1/318 %0.31
Epidermal Necrosis,0/318 %0.0,1/318 %0.31
Jessner's Lymphocytic Infiltration,1/318 %0.31,0/318 %0.0
Palmar-Plantar Erythrodysaesthesia Syndrome,0/318 %0.0,1/318 %0.31
Rash,0/318 %0.0,1/318 %0.31
Swelling Face,1/318 %0.31,0/318 %0.0
Deep Vein Thrombosis,1/318 %0.31,0/318 %0.0
Hypotension,2/318 %0.63,4/318 %1.26
Orthostatic Hypotension,2/318 %0.63,2/318 %0.63
Phlebitis,0/318 %0.0,1/318 %0.31
Thrombophlebitis,0/318 %0.0,1/318 %0.31

S0433 Iodine I 131 Tositumomab  Rituximab  and Combination Chemotherapy in Treating Older Patients With Stage II  Stage III  or Stage IV Non-Hodgkin's Lymphoma(https://clinicaltrials.gov/show/NCT00107380)
 ,R-CHOP + I-131-tositumomab
 ,Patients receive cyclophosphamide 750 mg/m^2 IV over 15 minutes doxorubicin 50 mg/m^2 IV and vincristine IV on days 1 22 43 64 85 106 127 and 148. Patients also receive oral prednisone 100 mg daily on days 1-5 22-26 43-47 64-68 85-89 106-110 127-131 and 148-152; rituximab 375 mg/m^2 IV on days 1 22 43 64 85 and 106; unlabeled anti-B1 antibody 450 mg/m^2 IV and dosimetric dose 35 mg IV over 20 minutes on day 170 and unlabeled anti-B1 antibody 450 mg IV and therapeutic dose 35mg IV over 20 minutes on day 177
Total serious adverse events,8/84 %9.52
Febrile neutropenia,1/84 %1.19
Cardiac-ischemia/infarction,2/84 %2.38
Hemorrhage GI - Rectum,1/84 %1.19
Hemorrhage GI - Upper GI NOS,1/84 %1.19
Inf w/normal ANC or Gr 1-2 neutrophils - Lung,1/84 %1.19
Platelets,1/84 %1.19
Secondary Malignancy-poss rel to cancer Tx,2/84 %2.38
Renal failure,1/84 %1.19

S0333 Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia(https://clinicaltrials.gov/show/NCT00109837)
 ,First Induction,Second Induction,Consolidation,Maintenance
 ,One induction cycle with allopurinol daunorubicin vincristine prednisone amd PEG- L-asparaginase.,A second induction cycle with allopurinol  dexamergasone G-CSF high-dose ara-C and mitoxantrone,Patients who had a CR after induction could receive one course of consolidation therapy consisting of cyclophosphamide ara-C 6-mercaptopurine G-CSF and methotrexate,Patient with a CR after consolidation could receive up to four courses of maintenance. Course 1 included 6-mercaptopurine and methotrexate. course 2 included vincristine adriamycin and dexamethasone. course 3 included cyclophosphamide 6-thioguanine and ara-C. course 4 included 6-mercaptopurine and methotrexate
Total serious adverse events,2/75 %2.67,2/56 %3.57,1/33 %3.03,0/12 %0.0
Pancreatitis,1/75 %1.33,0/56 %0.0,0/33 %0.0,0/12 %0.0
Death not associated with CTCAE term - Multi-organ failure,1/75 %1.33,0/56 %0.0,0/33 %0.0,0/12 %0.0
Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Blood,0/75 %0.0,1/56 %1.79,0/33 %0.0,0/12 %0.0
Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Lung (pneumon,0/75 %0.0,1/56 %1.79,0/33 %0.0,0/12 %0.0
Hemorrhage/bleeding associated with surgery intra-operative or post-operative,0/75 %0.0,1/56 %1.79,0/33 %0.0,0/12 %0.0
Leukocytes (total WBC),0/75 %0.0,0/56 %0.0,1/33 %3.03,0/12 %0.0
Platelets,0/75 %0.0,0/56 %0.0,1/33 %3.03,0/12 %0.0
Triglyceride serum-high (hypertriglyceridemia),1/75 %1.33,0/56 %0.0,0/33 %0.0,0/12 %0.0

EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma(https://clinicaltrials.gov/show/NCT00114738)
 ,EPOCH-R+Bortezomib
 ,Combo chemo etoposide prednisone vincristine cyclophosphamide doxorubicin (EPOCH)-Rituxan (R) + Bortezomib (B)  Rituximab (R): Rituximab is given with etoposide prednisone vincristine cyclophosphamide doxorubicin (EPOCH) and bortezomib every 3 weeks for 6 cycles.  EPOCH: EPOCH is given with Rituximab and bortezomib every 3 weeks for 6 cycles.  Bortezomib (B): Bortezomib is given alone for one cycle.
Total all-cause mortality,1/53 %1.89
Total serious adverse events,21/53 %39.62
Hemoglobin,1/53 %1.89
Platelets,1/53 %1.89
Constipation,1/53 %1.89
Diarrhea,1/53 %1.89
Esophagitis,1/53 %1.89
Hemorrhage GI::Peritoneal cavity,1/53 %1.89
Obstruction GI::Colon,1/53 %1.89
Obstruction GI::Small bowel NOS,1/53 %1.89
Pain::Abdomen NOS,1/53 %1.89
Perforation GI::Colon,1/53 %1.89
Death not associated with CTCAE term::Disease progression NOS,1/53 %1.89
Allergic reaction/hypersensitivity (including drug fever),1/53 %1.89
Febrile neutropenia,9/53 %16.98
Infection with normal ANC or Grade 1 or 2 neutrophils::Lung (pneumonia),1/53 %1.89
Infection with normal ANC or Grade 1 or 2 neutrophils::Skin (cellulitis),1/53 %1.89
Infection with unknown ANC::Lung (pneumonia),1/53 %1.89
Creatinine,1/53 %1.89
Fracture,1/53 %1.89
Pain::Bone,1/53 %1.89
Dizziness,1/53 %1.89
Hemorrhage CNS,1/53 %1.89
Dyspnea (shortness of breath),1/53 %1.89

Combination Chemo  Rituximab  and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma(https://clinicaltrials.gov/show/NCT00121199)
 ,CHOP + Rituximab + Bevacizumab
 ,Treatment with CHOP rituximab and bevacizumab will be administered every 21 days for a maximum of 8 cycles (one cycle is defined as a single 21 day course of treatment). Bevacizumab and rituximab will be given before chemotherapy.
Total serious adverse events,27/63 %42.86
Febrile neutropenia,3/63 %4.76
Hemoglobin,3/63 %4.76
Left ventricular systolic dysfunction,2/63 %3.17
Constipation,2/63 %3.17
Diarrhea,1/63 %1.59
Distention/bloating abdominal,1/63 %1.59
Hemorrhage GI - Colon,1/63 %1.59
Mucositis/stomatitis (clinical exam) - Esophagus,1/63 %1.59
Nausea,2/63 %3.17
Pain - Abdomen NOS,2/63 %3.17
Perforation GI - Jejunum,2/63 %3.17
Perforation GI - Small bowel NOS,1/63 %1.59
Perforation GI - Stomach,1/63 %1.59
Vomiting,1/63 %1.59
Fatigue (asthenia lethargy malaise),3/63 %4.76
Pain-Other (Specify),1/63 %1.59
Sudden death,2/63 %3.17
Inf (clin/microbio) w/Gr 3-4 neuts - Lung,1/63 %1.59
Inf (clin/microbio) w/Gr 3-4 neuts - Skin,1/63 %1.59
Inf w/normal ANC or Gr 1-2 neutrophils - Blood,1/63 %1.59
Inf w/normal ANC or Gr 1-2 neutrophils - Lung,2/63 %3.17
Inf w/normal ANC or Gr 1-2 neutrophils - Lymphatic,1/63 %1.59
Inf w/normal ANC or Gr 1-2 neutrophils - Perit cav,1/63 %1.59
Inf w/normal ANC or Gr 1-2 neutrophils - UTI,1/63 %1.59
Fracture,1/63 %1.59
Leukocytes (total WBC),4/63 %6.35
Lymphopenia,2/63 %3.17
Neutrophils/granulocytes (ANC/AGC),7/63 %11.11
Platelets,3/63 %4.76
Anorexia,2/63 %3.17
Dehydration,1/63 %1.59
Potassium serum-low (hypokalemia),1/63 %1.59
Sodium serum-low (hyponatremia),2/63 %3.17
Muscle weakness not d/t neuropathy - body/general,1/63 %1.59
Pain - Bone,1/63 %1.59
Death - Disease progression NOS,1/63 %1.59
Neuropathy: motor,1/63 %1.59
Pain - Head/headache,1/63 %1.59
Adult respiratory distress syndrome (ARDS),1/63 %1.59
Hemorrhage pulmonary/upper respiratory - Nose,1/63 %1.59
Pneumonitis/pulmonary infiltrates,2/63 %3.17
Pneumothorax,1/63 %1.59
Hypertension,1/63 %1.59
Hypotension,1/63 %1.59
Thrombosis/thrombus/embolism,3/63 %4.76

AMG 531 in Patients With Advanced Malignancy Receiving Treatment With Carboplatin(https://clinicaltrials.gov/show/NCT00147225)
 ,1 mcg/kg AMG 531 Post Chemotherapy,3 mcg/kg AMG 531 Post Chemotherapy,10 mcg/kg AMG 531 Post Chemotherapy,10 mcg/kg Pre/Post Chemotherapy,5 mcg/kg AMG 531 Pre/Pre/Post/Post Chemotherapy,10 mcg/kg AMG 531 Pre/Pre/Post/Post Chemotherapy
 ,Cycle 1: Chemotherapy  Cycle 2: Chemotherapy 1 mcg/kg AMG 531 subcutaneously on day after chemotherapy and 2 days later,Cycle 1: Chemotherapy  Cycle 2: Chemotherapy 3 mcg/kg AMG 531 subcutaneously on day after chemotherapy and 2 days later,Cycle 1: Chemotherapy  Cycle 2: Chemotherapy 10 mcg/kg AMG 531 subcutaneously on day after chemotherapy and 2 days later,Cycle 1: Chemotherapy  Cycle 2: Chemotherapy 10 mcg/kg AMG 531 subcutaneously on Day -5 (pre dose) and on day after chemotherapy,Cycle 1: Chemotherapy  Cycle 2: Chemotherapy 5 mcg/kg AMG 531 for 2 doses on Days -5 and -3 (pre doses) and on day after chemotherapy and 2 days later (post doses),Cycle 1: Chemotherapy  Cycle 2: Chemotherapy 10 mcg/kg AMG 531 for 2 doses on Days -5 and -3 (pre doses) and on day after chemotherapy and 2 days later (post doses)
Total serious adverse events,0/6 %0.0,0/6 %0.0,1/6 %16.67,0/11 %0.0,2/10 %20.0,0/12 %0.0
Deep Vein Thrombosis,0/6 %0.0,0/6 %0.0,0/6 %0.0,0/11 %0.0,1/10 %10.0,0/12 %0.0
Pulmonary Embolism,0/6 %0.0,0/6 %0.0,1/6 %16.67,0/11 %0.0,1/10 %10.0,0/12 %0.0

Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer(https://clinicaltrials.gov/show/NCT00182767)
 ,Ixabepilone 24mg/m2 and Doxorubicin 30mg/m2: Level 1,Ixabepilone 32mg/m2 and Doxorubicin 30mg/m2: Level 2,Ixabepilone 40mg/m2 and Doxorubicin 30mg/m2: Level 3,Ixabepilone 13mg/m2 and Doxorubicin 30mg/m2: Level 4,Ixabepilone 16mg/m2 and Doxorubicin 30mg/m2: Level 5
 ,Ixabepilone IV over 3 hours and pegylated liposomal doxorubicin hydrochloride IV over 30-60 minutes on day 1.  ixabepilone: Given IV  pegylated liposomal doxorubicin hydrochloride: Given IV,Ixabepilone IV over 3 hours and pegylated liposomal doxorubicin hydrochloride IV over 30-60 minutes on day 1.  ixabepilone: Given IV  pegylated liposomal doxorubicin hydrochloride: Given IV,Ixabepilone IV over 3 hours and pegylated liposomal doxorubicin hydrochloride IV over 30-60 minutes on day 1.  ixabepilone: Given IV  pegylated liposomal doxorubicin hydrochloride: Given IV,Ixabepilone IV over 3 hours on days 1 8 and 15 and pegylated liposomal doxorubicin hydrochloride IV over 30-60 minutes on day 1  ixabepilone: Given IV  pegylated liposomal doxorubicin hydrochloride: Given IV,Ixabepilone IV over 3 hours on days 1 8 and 15 and pegylated liposomal doxorubicin hydrochloride IV over 30-60 minutes on day 1  ixabepilone: Given IV  pegylated liposomal doxorubicin hydrochloride: Given IV
Total serious adverse events,6/6 %100.0,6/6 %100.0,6/6 %100.0,3/3 %100.0,24/24 %100.0
Anemia,1/6 %16.67,0/6 %0.0,0/6 %0.0,0/3 %0.0,4/24 %16.67
Constipation,1/6 %16.67,0/6 %0.0,0/6 %0.0,0/3 %0.0,0/24 %0.0
Mucositis,1/6 %16.67,2/6 %33.33,1/6 %16.67,0/3 %0.0,2/24 %8.33
Vomiting,0/6 %0.0,1/6 %16.67,0/6 %0.0,0/3 %0.0,0/24 %0.0
Dehydration,0/6 %0.0,1/6 %16.67,0/6 %0.0,0/3 %0.0,0/24 %0.0
Abdominal pain,0/6 %0.0,0/6 %0.0,0/6 %0.0,0/3 %0.0,1/24 %4.17
Small intestinal obstruction,0/6 %0.0,0/6 %0.0,0/6 %0.0,0/3 %0.0,2/24 %8.33
Nausea,0/6 %0.0,0/6 %0.0,0/6 %0.0,0/3 %0.0,1/24 %4.17
Ascites,0/6 %0.0,0/6 %0.0,0/6 %0.0,0/3 %0.0,1/24 %4.17
Diarrhea,0/6 %0.0,0/6 %0.0,0/6 %0.0,0/3 %0.0,1/24 %4.17
Fatigue,0/6 %0.0,0/6 %0.0,2/6 %33.33,0/3 %0.0,2/24 %8.33
Death NOS,1/6 %16.67,0/6 %0.0,0/6 %0.0,0/3 %0.0,1/24 %4.17
Infection with grade 3 or 4 neutrophils,0/6 %0.0,1/6 %16.67,0/6 %0.0,0/3 %0.0,0/24 %0.0
Lung infections,1/6 %16.67,0/6 %0.0,0/6 %0.0,0/3 %0.0,0/24 %0.0
Catheter related infection,0/6 %0.0,0/6 %0.0,0/6 %0.0,1/3 %33.33,0/24 %0.0
Blood Bilirubin increased,1/6 %16.67,0/6 %0.0,0/6 %0.0,0/3 %0.0,0/24 %0.0
White blood cell count decreased,1/6 %16.67,1/6 %16.67,1/6 %16.67,2/3 %66.67,1/24 %4.17
Neutrophils count decreased,1/6 %16.67,1/6 %16.67,1/6 %16.67,1/3 %33.33,5/24 %20.83
Platelet count decreased,0/6 %0.0,0/6 %0.0,0/6 %0.0,0/3 %0.0,2/24 %8.33
Hypokalemia,1/6 %16.67,0/6 %0.0,0/6 %0.0,0/3 %0.0,0/24 %0.0
Hypophosphatemia,0/6 %0.0,0/6 %0.0,0/6 %0.0,0/3 %0.0,1/24 %4.17
Hypercalcemia,0/6 %0.0,0/6 %0.0,0/6 %0.0,0/3 %0.0,1/24 %4.17
Bone pain,0/6 %0.0,1/6 %16.67,0/6 %0.0,0/3 %0.0,0/24 %0.0
Chest Wall Pain,0/6 %0.0,1/6 %16.67,0/6 %0.0,0/3 %0.0,0/24 %0.0
CNS cerebrovascular ischemia,0/6 %0.0,0/6 %0.0,0/6 %0.0,0/3 %0.0,0/24 %0.0
Neuropathy: Sensory,1/6 %16.67,0/6 %0.0,0/6 %0.0,0/3 %0.0,0/24 %0.0
Headache,1/6 %16.67,0/6 %0.0,0/6 %0.0,0/3 %0.0,0/24 %0.0
Ataxia,0/6 %0.0,0/6 %0.0,0/6 %0.0,0/3 %0.0,1/24 %4.17
Anxiety,0/6 %0.0,0/6 %0.0,0/6 %0.0,0/3 %0.0,1/24 %4.17
Hemorrhage pulmonary/upper respiratory,1/6 %16.67,0/6 %0.0,0/6 %0.0,0/3 %0.0,0/24 %0.0
Dyspnea,0/6 %0.0,1/6 %16.67,1/6 %16.67,0/3 %0.0,1/24 %4.17
Pleural Effusion,0/6 %0.0,0/6 %0.0,0/6 %0.0,0/3 %0.0,1/24 %4.17
Rash: desquamation,0/6 %0.0,0/6 %0.0,3/6 %50.0,0/3 %0.0,1/24 %4.17
Hand-foot skin reaction,1/6 %16.67,1/6 %16.67,0/6 %0.0,0/3 %0.0,0/24 %0.0
Thromboembolic event,0/6 %0.0,0/6 %0.0,1/6 %16.67,1/3 %33.33,2/24 %8.33
Hot flashes,0/6 %0.0,0/6 %0.0,0/6 %0.0,0/3 %0.0,1/24 %4.17

Doxorubicin (Doxil) Combined With Rituxan  Cyclophosphamide  Vincristine and Prednisone in Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas(https://clinicaltrials.gov/show/NCT00184002)
 ,DR-COP
 ,On cycle 1 patients receive Doxil 40 mg/m2 iv day 1 over a minimum of 60 min. Cyclophosphamide 750 mg/m2 iv day 1 over a minimum of 60 min. Vincristine 1.4 mg/m2 iv bolus day 1 (2.0 mg maximum) and Prednisone 100 mg po days 1-5.  On cycle 2 until study completion patients receive Doxil 40 mg/m2 iv day 1 Rituxan 375 mg/m2 iv day 1 Cyclophosphamide 750 mg/m2 iv day 1 Vincristine 1.4 mg/m2 iv bolus day 1 (2.0 mg maximum) and Prednisone 100 mg po days 1-5  1 cycle = 21 days.  Continue treatment until 2 cycles beyond documentation of CR for a maximum of 8 cycles.  Doxorubicin Rituxan Cyclophosphamide Vincristine and Prednisone: Cycle 1 Doxil 40 mg/m2 iv day 1 over a minimum of 60 min. Cyclophosphamide 750 mg/m2 iv day 1 over a minimum of 60 min. Vincristine 1.4 mg/m2 iv bolus day 1 (2.0 mg maximum). Prednisone 100 mg po days 1-5.  Cycle 2 until study completion Doxil 40 mg/m2 iv day 1 Rituxan 375 mg/m2 iv day 1 Cyclophosphamide 750 mg/m2 iv day 1
Total all-cause mortality,3/68 %4.41
Total serious adverse events,35/68 %51.47
Neutrophils/granulocytes (ANC/AGC),35/68 %51.47
Hemoglobin,11/68 %16.18
Leukocytes (total WBC),1/68 %1.47
Platelets,5/68 %7.35
Cardiac left ventricular function,1/68 %1.47
Hypertension,2/68 %2.94
Hypotension,2/68 %2.94
Abdominal pain or cramping,2/68 %2.94
Diarrhea patients without colostomy,1/68 %1.47
Ileus (or neuroconstipation),2/68 %2.94
Melena/GI bleeding,1/68 %1.47
Nausea,2/68 %2.94
Stomatitis/pharingitis (oral/pharyngeal mucositis),2/68 %2.94
Vomiting,2/68 %2.94
Fatigue (lethargy malaise asthenia),1/68 %1.47
Weight loss,1/68 %1.47
Bilirubin,1/68 %1.47
SGOT (AST) (serum glutamic oxaloacetic transaminase),3/68 %4.41
SGPT (ALT) (serum glutamic pyruvic transaminase),3/68 %4.41
Febrile neutropenia,8/68 %11.76
Infection,8/68 %11.76
Infection without neutropenia,6/68 %8.82
Cardiac troponin I (cTnl),1/68 %1.47
Anorexia,1/68 %1.47
Dehydration,1/68 %1.47
Hyperglycemia,2/68 %2.94
Hypocalcemia,1/68 %1.47
Hypokalemia,3/68 %4.41
Hyponatremia,1/68 %1.47
Hypophosphatemia,1/68 %1.47
Tumor lysis syndrome,1/68 %1.47
Myalgia (muscle pain),1/68 %1.47
Neuropathy-sensory,2/68 %2.94
Incontinence,1/68 %1.47
Ureteral obstruction,1/68 %1.47
Dyspnea (shortness of breath),6/68 %8.82
Hypoxia,2/68 %2.94
Pleural effusion (non-malignant),1/68 %1.47
Pneumonitis/pulmonary infiltrates,1/68 %1.47
Voice changes/stridor/larynx (e.g. hoarseness loss of voice laryngitis),1/68 %1.47
Hand-foot skin reaction,10/68 %14.71

Primary Systemic Therapy in Operable/Locally Advanced Breast Cancer(https://clinicaltrials.gov/show/NCT00203502)
 ,Intervention: Drug:Docetaxel + Cyclophosphamide + Avastin
 ,Docetaxel 75mg/m2 + Cyclophosphamide 500 mg/m2  + Avastin 15 mg/kg  Q 3 weeks X 4 cycles  Bevacizumab/Avastin: IV 15mg/kg 21 days  Cyclophosphamide: 500mg per meter squared IV every 21 days  Doxorubicin: 60 mg per meter squared IV every 21 days
Total serious adverse events,39/39 %100.0
Febrile Neutropenia,1/39 %2.56
Heart failure,1/39 %2.56
Diarrhea,3/39 %7.69
Nausea/vomiting,4/39 %10.26
Mucositis,3/39 %7.69
Fatigue,4/39 %10.26
infection,3/39 %7.69
Urinary tract infection,2/39 %5.13
Musculoskeletal pain,6/39 %15.38
Syncope,1/39 %2.56
Insomnia,3/39 %7.69
Anxiety,2/39 %5.13
Depression,2/39 %5.13
pulmonary embolism,1/39 %2.56
Hypertension,3/39 %7.69

A Study of ONTAK and CHOP in Newly Diagnosed  Peripheral T-Cell Lymphoma(https://clinicaltrials.gov/show/NCT00211185)
 ,Denileukin Diftitox in Combination With CHOP
 ,Unblinded denileukin diftitox at 18 micrograms/kilogram/day (ug/kg/d) was administered intravenously (IV) on Days 1 and 2 of each 21-day cycle. Cyclophosphamide doxorubicin vincristine and prednisone (CHOP) was administered on Day 3 of each 21-day cycle. On Day 4 of each 21-day cycle pegfilgrastim (a granulocyte colony-stimulating factor (G-CSF)) was started as a prophylaxis to prevent neutropenia. After completion of two 21-day cycles participants were evaluated for clinical response. Two 21-day cycles with denileukin and CHOP were repeated followed by response evaluations after each set of two 21-day cycles with intent to treat for 6 cycles with a maximum of 8 cycles.
Total all-cause mortality,18/49 %36.73
Total serious adverse events,25/49 %51.02
Leukocytes,3/49 %6.12
Lymphopenia,2/49 %4.08
Neutrophils,4/49 %8.16
Platelets,3/49 %6.12
Supra Arrhyth: Sinus Tachy,1/49 %2.04
Cardiac ischemia/infarction,2/49 %4.08
Cardiopulmonary arrest,1/49 %2.04
Hypotension,1/49 %2.04
Left vent. diastolic dysfunct.,1/49 %2.04
Neurop. lat dev. of eye,1/49 %2.04
GI obstruction small bowel,1/49 %2.04
Fever,6/49 %12.24
Death NOS,1/49 %2.04
Disease progression NOS,2/49 %4.08
Lung hemorrhage lung,1/49 %2.04
Edema-limb,1/49 %2.04
Cardio. pain cardiac/heart,1/49 %2.04
GI pain abdomen,1/49 %2.04
Pain-other,1/49 %2.04
Pain NOS,1/49 %2.04
Tumor lysis syndrome,1/49 %2.04
Allergic reaction,1/49 %2.04
Allergy-other,1/49 %2.04
Febrile Neutropenia,6/49 %12.24
Inf. 0-2 ANC: cath-related,1/49 %2.04
Inf 3-4 ANC: blood,1/49 %2.04
Inf 3-4 ANC: cath-related,1/49 %2.04
Infection-other,1/49 %2.04
Lung inf 0-2 ANC: lung,1/49 %2.04
Skin Inf 0-2 ANC: skin,1/49 %2.04
Alanine transaminase (AST),1/49 %2.04
Creatinine phosphokinase (CPK),1/49 %2.04
Cerebral spinal fluid (CSF) leak,1/49 %2.04
Renal failure,1/49 %2.04
Dyspnea,1/49 %2.04
Hypoxia,1/49 %2.04
Pneumonitis,2/49 %4.08
Thrombosis/embolism,1/49 %2.04

Phase III Randomized Trial of Thalidomide/Dexamethasone Versus Vincristine+Adriamycin+Dexamethasone (VAD)(https://clinicaltrials.gov/show/NCT00215943)
 ,Active Comparator: VAD Treatment,Active Comparator: Thalidomide and Dexamethasone Treatment
 ,VAD (vincristine adriamycin dexamethasone). Vincristine and adriamycin was administered by continuous infusion via a venous catheter for 96 hours every 28 days. Each 28 days is considered one "cycle" of therapy. Patients were to receive 4 to 6 cycles of therapy. Dexamethasone was taken in pill form. During the first 2 cycles it was taken on days 1-4 9-12 17-20. For all other cycles dexamethasone was taken only on days 1-4. Patients were randomized to receive zoledronic acid IV on either Day 1 or 15 of each cycle.,Thalidomide was taken orally once every day in the evening for four to six months. The dexamethasone was taken in a pill form. During the first 2 cycles it was taken on days 1-4 9-12 17-20. For all other cycles dexamethasone was taken only on days 1-4.
Total serious adverse events,0/36 %0.0,1/37 %2.7
Pneumonitis/pulmonary infiltrates - Grade 4,0/36 %0.0,1/37 %2.7
Pulmonary/Upper Respiratory - Other - Grade 3,0/36 %0.0,1/37 %2.7

A Study Evaluating Efficacy  Toxicity  Harvest Yield and Quality of Life(https://clinicaltrials.gov/show/NCT00222105)
 ,Arm 1
 ,Doxil Thalidomide Dexamethasone  Doxil: Doxil 40 mg/m2 IV day 1  Thalidomide: 50-100 mg day 1-28  Dexamethasone: Dexamethasone 40 mg day 1-4 and 15-18
Total all-cause mortality,2/25 %8.0
Total serious adverse events,8/25 %32.0
Arrhythmia,1/25 %4.0
Infection,5/25 %20.0
Dehydration,1/25 %4.0
Acute Renal Failure,1/25 %4.0

Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer(https://clinicaltrials.gov/show/NCT00245050)
 ,Pyridoxine,Placebo
 ,Arm I: Patients receive doxorubicin HCl liposome IV 40mg/m2 over 1 hour on day 1 and oral pyridoxine 100 mg twice daily on days 1-28.,Arm II: Patients receive doxorubicin HCl liposome IV 40mg/m2 over 1 hour on day 1 and oral placebo 100 mg twice daily on days 1-28.
Total serious adverse events,8/15 %53.33,6/14 %42.86
Blood/bone marrow,1/15 %6.67,2/14 %14.29
Hemorrhage/bleeding,1/15 %6.67,0/14 %0.0
Lymphatics,0/15 %0.0,0/14 %0.0
Gastrointestinal,2/15 %13.33,0/14 %0.0
Constitutional symptoms,0/15 %0.0,1/14 %7.14
Pain,0/15 %0.0,0/14 %0.0
Allergy/immunologic,0/15 %0.0,1/14 %7.14
Infection,1/15 %6.67,0/14 %0.0
Metabolic/laboratory,0/15 %0.0,1/14 %7.14
Neurology,1/15 %6.67,0/14 %0.0
Renal/genitourinary,0/15 %0.0,0/14 %0.0
Pulmonary/upper respiratory,1/15 %6.67,0/14 %0.0
Vascular,1/15 %6.67,1/14 %7.14

Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell Lymphoma(https://clinicaltrials.gov/show/NCT00290433)
 ,HCVIDDOXIL Regimen
 ,Cycle 1: Cyclophosphamide 300 mg/m^2 intravenous (IV) twice a day on Days 1-3. Mesna 600 mg/m^2 continuous IV Days 1-3. Doxil 25 mg/m^2 IV over 1 hour on Day 2. Vincristine 1.4 mg/m^2 IV on Days 4 and 11. Dexamethasone 40 mg Iv or oral on Days 1 - 4 and 11 - 14.  Cycle 2: Methotrexate 200 mg/m^2 over 2 hours on Day 1 and 800 mg/m^2 over 22 hours on day 1. Cytarabine 3 Gm/m^2 IV twice a day on Days 2 and 3.
Total serious adverse events,1/53 %1.89
massive cytomegalovirus infection,1/53 %1.89

Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger(https://clinicaltrials.gov/show/NCT00290498)
 ,RHCVAD,RCHOP
 ,Rituximab 375mg/m2 intravenously on day 1cyclophosphamide 300mg/m2 intravenously every 12 h for six doses on days 13doxorubicin 50mg/m2 intravenously on day 5vincristine 1.4mg/m2 or maximum 2mg intravenously on days 5 and 12and dexamethasone 40mg intravenously or orally on days 25alternating with RMA(cycles 246)rituximab 375mg/2 intravenously on day 1methotrexate 200mg/m2 over 2 h followed by 800mg/m2 over 22 h on day 1 and cytarabine 3g/m2 every 12 h for four doses on days 3 and 4 with a 21 day cycle.,RCHOP consisted of rituximab 375mg/m2 intravenously on day 1cyclophosphamide 750mg/m2 intravenously on day 1doxorubicin 50mg/m2 intravenously on day 1 either over 15min or 48 h  vincristine 1.4mg/m2 or maximum 2mg intravenouslyand prednisone 100mg orally on days 15with a 21d cycle.
Total all-cause mortality,4/49 %8.16,0/10 %0.0
Total serious adverse events,49/49 %100.0,7/10 %70.0
BLOOD BONE MARROW (OTHER),1/49 %2.04,0/10 %0.0
FEBRILE NEUTROPENIA,27/49 %55.1,2/10 %20.0
HEMORRHAGE,8/49 %16.33,1/10 %10.0
PETECHIAE,6/49 %12.24,0/10 %0.0
PHLEBITIS,1/49 %2.04,0/10 %0.0
ATRIAL FIBRILLATION,1/49 %2.04,0/10 %0.0
ATRIAL FLUTTER,2/49 %4.08,0/10 %0.0
HYPERTENSION,9/49 %18.37,0/10 %0.0
HYPOTENSION,13/49 %26.53,0/10 %0.0
PALPITATIONS,1/49 %2.04,1/10 %10.0
PERICARDIAL EFFUSION,1/49 %2.04,1/10 %10.0
SINUS BRADYCARDIA,3/49 %6.12,0/10 %0.0
SINUS TACHYCARDIA,9/49 %18.37,0/10 %0.0
TACHYCARDIA,2/49 %4.08,1/10 %10.0
AUDITORY/EAR (OTHER),1/49 %2.04,0/10 %0.0
TINNITUS,4/49 %8.16,0/10 %0.0
ENDOCRINE (OTHER),1/49 %2.04,0/10 %0.0
HYPERTHYROIDISM,1/49 %2.04,0/10 %0.0
HYPOTHYROIDISM,1/49 %2.04,0/10 %0.0
BLURRED VISION,0/49 %0.0,2/10 %20.0
DRY EYE,2/49 %4.08,0/10 %0.0
OCULAR/VISUAL(OTHER),1/49 %2.04,0/10 %0.0
PAIN (EYE),1/49 %2.04,0/10 %0.0
WATERY EYE,4/49 %8.16,2/10 %20.0
ABDOMINAL CRAMPING,1/49 %2.04,1/10 %10.0
CONSTIPATION,16/49 %32.65,0/10 %0.0
DIARRHEA,11/49 %22.45,2/10 %20.0
DISTENSION/BLOATING,1/49 %2.04,0/10 %0.0
DRY MOUTH,2/49 %4.08,1/10 %10.0
DYSPHAGIA,2/49 %4.08,0/10 %0.0
GASTRITIS,7/49 %14.29,0/10 %0.0
GERD,2/49 %4.08,0/10 %0.0
GASTROINTESTINAL (OTHER),2/49 %4.08,1/10 %10.0
HEARTBURN,5/49 %10.2,0/10 %0.0
HEMORRHOIDS,6/49 %12.24,0/10 %0.0
NAUSEA,30/49 %61.22,6/10 %60.0
OBSTRUCTIONGI,2/49 %4.08,0/10 %0.0
PAIN (ABDOMEN NOS),6/49 %12.24,2/10 %20.0
PAIN (ANUS),0/49 %0.0,1/10 %10.0
PAIN( ORALCAVITY),1/49 %2.04,0/10 %0.0
PAIN( STOMACH),1/49 %2.04,0/10 %0.0
STOMATITIS,3/49 %6.12,2/10 %20.0
TASTE ALTERATION,2/49 %4.08,0/10 %0.0
TEETH,2/49 %4.08,0/10 %0.0
VOMITING,24/49 %48.98,5/10 %50.0
DEATH NOS,2/49 %4.08,0/10 %0.0
DRUG FEVER,1/49 %2.04,0/10 %0.0
EDEMA,8/49 %16.33,3/10 %30.0
EDEMA:HEAD AND NECK,2/49 %4.08,0/10 %0.0
EDEMA:LIMB,13/49 %26.53,3/10 %30.0
EDEMA:TRUNK/GENITAL,2/49 %4.08,0/10 %0.0
EDEMA (LARYNX),1/49 %2.04,0/10 %0.0
FATIGUE,31/49 %63.27,2/10 %20.0
FEVER UNKNOWN ORIGIN,2/49 %4.08,1/10 %10.0
FEVER WITHOUT NEUTROPENI,14/49 %28.57,3/10 %30.0
FLU-LIKE SYNDROME,1/49 %2.04,1/10 %10.0
GAIT/WALKING,1/49 %2.04,0/10 %0.0
PAIN (DENTAL/TEETH/PERID,2/49 %4.08,1/10 %10.0
PAIN (NOS),4/49 %8.16,2/10 %20.0
RIGORS/CHILLS,18/49 %36.73,1/10 %10.0
ALLERGIC REACTION DRUG,10/49 %20.41,1/10 %10.0
ALLERGY (OTHER),1/49 %2.04,1/10 %10.0
AUTOIMMUNE REACTION,1/49 %2.04,0/10 %0.0
CANDIDIASIS,3/49 %6.12,0/10 %0.0
INFECTION(S),47/49 %95.92,6/10 %60.0
BRUISING (NON-THROMBOPENIA),1/49 %2.04,0/10 %0.0
ALKALINE PHOSPHATASE INCR,4/49 %8.16,1/10 %10.0
ALTSGPT INCR,17/49 %34.69,3/10 %30.0
ASTSGOT INCR,17/49 %34.69,1/10 %10.0
BILIRUBIN INCREASE,9/49 %18.37,0/10 %0.0
CHOLESTEROLSERUM-HIGH,1/49 %2.04,0/10 %0.0
CREATININE INCREASE,7/49 %14.29,2/10 %20.0
ELEV LDH (OTHER),6/49 %12.24,3/10 %30.0
GRANULOCYTOPENIA,0/49 %0.0,1/10 %10.0
HEMOGLOBIN DECREASE,48/49 %97.96,7/10 %70.0
HYPERGLYCEMIA,25/49 %51.02,6/10 %60.0
HYPERKALEMIA,2/49 %4.08,0/10 %0.0
HYPERURICEMIA,4/49 %8.16,5/10 %50.0
HYPOALBUMINEMIA,27/49 %55.1,4/10 %40.0
HYPOCALCEMIA,15/49 %30.61,4/10 %40.0
HYPOGLYCEMIA,1/49 %2.04,1/10 %10.0
HYPOKALEMIA,15/49 %30.61,4/10 %40.0
HYPOMAGNESEMIA,14/49 %28.57,6/10 %60.0
HYPONATREMIA,7/49 %14.29,2/10 %20.0
HYPOPHOSPHATEMIA,2/49 %4.08,0/10 %0.0
LEUKOPENIA,48/49 %97.96,7/10 %70.0
NEUTROPENIA,46/49 %93.88,4/10 %40.0
OLIGURIA,1/49 %2.04,0/10 %0.0
PLATELETS DECREASED,39/49 %79.59,3/10 %30.0
THROMBOCYTOPENIA,7/49 %14.29,1/10 %10.0
ANOREXIA,1/49 %2.04,1/10 %10.0
DEHYDRATION,2/49 %4.08,0/10 %0.0
DIABETES,3/49 %6.12,0/10 %0.0
METABOLIC/LABORATORY (OTHER),1/49 %2.04,1/10 %10.0
OBESITY,2/49 %4.08,0/10 %0.0
WEIGHT GAIN,1/49 %2.04,1/10 %10.0
WEIGHT LOSS,1/49 %2.04,1/10 %10.0
MUSCLE WEAKNESS,8/49 %16.33,1/10 %10.0
MYALGIA,3/49 %6.12,0/10 %0.0
MYOSITIS,1/49 %2.04,0/10 %0.0
PAIN (BACK),10/49 %20.41,1/10 %10.0
PAIN (BONE),5/49 %10.2,1/10 %10.0
PAIN (EXTREMITY-LIMB),6/49 %12.24,0/10 %0.0
PAIN (JOINT),3/49 %6.12,0/10 %0.0
PAIN (MUSCLE),7/49 %14.29,2/10 %20.0
PAIN (NECK),5/49 %10.2,0/10 %0.0
PAIN (PELVIS),1/49 %2.04,0/10 %0.0
COGNITIVE DISTURBANCE,1/49 %2.04,0/10 %0.0
DIZZINESS,14/49 %28.57,3/10 %30.0
HEADACHE,1/49 %2.04,0/10 %0.0
MEMORY IMPAIRMENT,1/49 %2.04,0/10 %0.0
NEUROPATHY:MOTOR,1/49 %2.04,3/10 %30.0
NEUROPATHY:SENSORY,20/49 %40.82,4/10 %40.0
PAIN( HEAD/HEADACHE),22/49 %44.9,3/10 %30.0
PAIN (NEURALGIA/PERIPHERALNER,1/49 %2.04,0/10 %0.0
SENSORY,2/49 %4.08,1/10 %10.0
SYNCOPE (FAINTING),7/49 %14.29,0/10 %0.0
CONFUSION,1/49 %2.04,0/10 %0.0
INSOMNIA,12/49 %24.49,2/10 %20.0
MOOD ALTERATION,16/49 %32.65,2/10 %20.0
DYSURIA,1/49 %2.04,1/10 %10.0
HEMATURIA,1/49 %2.04,0/10 %0.0
POLYURIA,1/49 %2.04,0/10 %0.0
RENAL FAILURE,4/49 %8.16,0/10 %0.0
URINARY FREQUENCY,1/49 %2.04,1/10 %10.0
HOT FLASHES,1/49 %2.04,0/10 %0.0
MENORRHAGIA,1/49 %2.04,0/10 %0.0
PAIN (BREAST),1/49 %2.04,0/10 %0.0
PAIN (TESTICLE),2/49 %4.08,0/10 %0.0
PAIN (VAGINA),1/49 %2.04,0/10 %0.0
VAGINAL DRYNESS,1/49 %2.04,0/10 %0.0
ALLERGIC RHINITIS,9/49 %18.37,3/10 %30.0
COUGH,17/49 %34.69,4/10 %40.0
DYSPNEA,22/49 %44.9,3/10 %30.0
HEMOPTYSIS,1/49 %2.04,1/10 %10.0
HORSENESS,0/49 %0.0,1/10 %10.0
HYPOXIA,1/49 %2.04,1/10 %10.0
MUCOSITIS,20/49 %40.82,3/10 %30.0
PAIN (CHEST/THORAX),7/49 %14.29,0/10 %0.0
PAIN (PLEURITIC),0/49 %0.0,1/10 %10.0
PAIN (THROAT/PHARYNX/LARYNX),3/49 %6.12,0/10 %0.0
PLEURAL EFFUSION,8/49 %16.33,0/10 %0.0
PNEUMONITIS,1/49 %2.04,0/10 %0.0
PNEUMOTHORAX,1/49 %2.04,0/10 %0.0
PULMONARY(OTHER),1/49 %2.04,1/10 %10.0
RESPIRATORY FAILURE,1/49 %2.04,0/10 %0.0
RHINORRHEA,6/49 %12.24,0/10 %0.0
SORE THROAT,1/49 %2.04,0/10 %0.0
UPPER RESPIRATORY INFECT,1/49 %2.04,0/10 %0.0
VOICE CHANGES,3/49 %6.12,1/10 %10.0
ALOPECIA,20/49 %40.82,5/10 %50.0
DERMATOLOGY/SKIN (OTHER),1/49 %2.04,0/10 %0.0
DRY SKIN,3/49 %6.12,0/10 %0.0
ERYTHEMA MULTIFORME,5/49 %10.2,0/10 %0.0
HAND-FOOT SYNDROME,4/49 %8.16,0/10 %0.0
HYPERPIGMENTATION,1/49 %2.04,0/10 %0.0
PRURITUS,4/49 %8.16,0/10 %0.0
PRURITUS/ITCHING,1/49 %2.04,0/10 %0.0
PULMONARY EMBOLISM,1/49 %2.04,0/10 %0.0
RASH/DESQUAMATION,14/49 %28.57,2/10 %20.0
SWEATING,7/49 %14.29,1/10 %10.0
ULCERATION,1/49 %2.04,0/10 %0.0
FLUSHING,4/49 %8.16,0/10 %0.0
HEMATOMA,0/49 %0.0,1/10 %10.0
SYNDROMES (OTHER),1/49 %2.04,0/10 %0.0
THROMBOSIS/THROMBUS/EMBOLISM,12/49 %24.49,1/10 %10.0
VASCULAR (OTHER),1/49 %2.04,1/10 %10.0

Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor(https://clinicaltrials.gov/show/NCT00304070)
 ,Stratum 3
 ,Stage III OR IV Disease (chemotherapy)
Total serious adverse events,1/39 %2.56
Pneumonitis,1/39 %2.56

Study of NGR-hTNF in Combination With Doxorubicin in Solid Tumors(https://clinicaltrials.gov/show/NCT00305084)
 ,Cohort 1: NGRhTNF 0.2 g/m^2+ Doxorubicin 60 mg/m^2,Cohort 2: NGRhTNF 0.2 g/m^2+ Doxorubicin 75 mg/m^2,Cohort 3: NGR-hTNF 0.4 g/m^2+ Doxorubicin 75 mg/m^2,Cohort 4: NGR-hTNF 0.8 g/m^2+ Doxorubicin 75 mg/m^2,Cohort 5: NGR-hTNF: 1.6 g/m^2 + Doxorubicin 75 mg/m^2
 ,NGR-hTNF: 0.2 g/m^2 as 60-minute intravenous infusion every 3 weeks  Doxorubicin: 60 mg/m intravenous infusion over 15 minutes (starting 1 hour after the end of NGR-hTNF infusion),NGR-hTNF: 0.2 g/m^2 as 60-minute intravenous infusion every 3 weeks  Doxorubicin: 75 mg/m intravenous infusion over 15 minutes (starting 1 hour after the end of NGR-hTNF infusion),NGR-hTNF: 0.4 g/m^2 as 60-minute intravenous infusion every 3 weeks  Doxorubicin: 75 mg/m intravenous infusion over 15 minutes (starting 1 hour after the end of NGR-hTNF infusion),NGR-hTNF: 0.8 g/m^2 as 60-minute intravenous infusion every 3 weeks  Doxorubicin: 75 mg/m intravenous infusion over 15 minutes (starting 1 hour after the end of NGR-hTNF infusion),NGR-hTNF: 1.6 g/m^2 as 60-minute intravenous infusion every 3 weeks  Doxorubicin: 75 mg/m intravenous infusion over 15 minutes (starting 1 hour after the end of NGR-hTNF infusion)
Total all-cause mortality,2/3 %66.67,1/3 %33.33,2/3 %66.67,0/3 %0.0,2/3 %66.67
Total serious adverse events,2/3 %66.67,1/3 %33.33,2/3 %66.67,3/3 %100.0,1/3 %33.33
Febrile neutropenia,0/3 %0.0,1/3 %33.33,0/3 %0.0,0/3 %0.0,0/3 %0.0
Leukopenia,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,1/3 %33.33
Anaemia,1/3 %33.33,0/3 %0.0,0/3 %0.0,0/3 %0.0,1/3 %33.33
Acute myocardial infarction,0/3 %0.0,0/3 %0.0,1/3 %33.33,0/3 %0.0,0/3 %0.0
Vomiting,0/3 %0.0,0/3 %0.0,0/3 %0.0,1/3 %33.33,0/3 %0.0
Diarrhoea,0/3 %0.0,0/3 %0.0,0/3 %0.0,1/3 %33.33,0/3 %0.0
Abdominal pain,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,1/3 %33.33
Constipation,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,1/3 %33.33
Sacral pain,0/3 %0.0,0/3 %0.0,0/3 %0.0,1/3 %33.33,0/3 %0.0
Deep vein thrombosis,1/3 %33.33,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0
Pulmonary embolism,0/3 %0.0,0/3 %0.0,1/3 %33.33,0/3 %0.0,0/3 %0.0

Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer(https://clinicaltrials.gov/show/NCT00327171)
 ,Aflibercept 2.0 mg/kg,Aflibercept 4.0 mg/kg
 ,Participants with advanced ovarian epithelial adenocarcinoma administered 2.0 mg/kg Aflibercept intravenously every two weeks,Participants with advanced ovarian epithelial adenocarcinoma administered 4.0 mg/kg Aflibercept intravenously every two weeks
Total serious adverse events,51/106 %48.11,56/109 %51.38
Anaemia,2/106 %1.89,1/109 %0.92
Thrombocytopenia,1/106 %0.94,0/109 %0.0
Thrombotic thrombocytopenic purpura,0/106 %0.0,1/109 %0.92
Angina pectoris,1/106 %0.94,0/109 %0.0
Cardio-respiratory arrest,1/106 %0.94,0/109 %0.0
Congestive cardiomyopathy,1/106 %0.94,0/109 %0.0
Left ventricular dysfunction,0/106 %0.0,1/109 %0.92
Vertigo,0/106 %0.0,1/109 %0.92
Blindness transient,0/106 %0.0,1/109 %0.92
Abdominal pain,4/106 %3.77,6/109 %5.5
Ascites,1/106 %0.94,0/109 %0.0
Colonic obstruction,1/106 %0.94,0/109 %0.0
Crohn's disease,1/106 %0.94,0/109 %0.0
Diarrhoea,1/106 %0.94,1/109 %0.92
Gastrointestinal haemorrhage,0/106 %0.0,1/109 %0.92
Gastrointestinal necrosis,1/106 %0.94,0/109 %0.0
Gastrointestinal obstruction,2/106 %1.89,1/109 %0.92
Intestinal obstruction,10/106 %9.43,6/109 %5.5
Intestinal perforation,1/106 %0.94,2/109 %1.83
Melaena,1/106 %0.94,0/109 %0.0
Nausea,3/106 %2.83,0/109 %0.0
Small intestinal obstruction,0/106 %0.0,2/109 %1.83
Subileus,0/106 %0.0,2/109 %1.83
Vomiting,2/106 %1.89,2/109 %1.83
Asthenia,1/106 %0.94,2/109 %1.83
Disease progression,3/106 %2.83,7/109 %6.42
Fatigue,0/106 %0.0,1/109 %0.92
General physical health deterioration,0/106 %0.0,2/109 %1.83
Pyrexia,2/106 %1.89,2/109 %1.83
Sudden death,0/106 %0.0,1/109 %0.92
Jaundice cholestatic,1/106 %0.94,0/109 %0.0
Abscess intestinal,0/106 %0.0,1/109 %0.92
Appendicitis,0/106 %0.0,1/109 %0.92
Catheter site infection,0/106 %0.0,1/109 %0.92
Clostridial infection,0/106 %0.0,1/109 %0.92
Clostridium difficile colitis,0/106 %0.0,1/109 %0.92
Device related infection,1/106 %0.94,0/109 %0.0
Febrile infection,1/106 %0.94,1/109 %0.92
Gastroenteritis salmonella,1/106 %0.94,0/109 %0.0
Hepatitis a,0/106 %0.0,1/109 %0.92
Peritonitis bacterial,0/106 %0.0,1/109 %0.92
Pneumonia,2/106 %1.89,2/109 %1.83
Pneumonia streptococcal,1/106 %0.94,0/109 %0.0
Pyelonephritis,0/106 %0.0,1/109 %0.92
Sepsis,1/106 %0.94,0/109 %0.0
Septic shock,1/106 %0.94,0/109 %0.0
Urinary tract infection,1/106 %0.94,0/109 %0.0
Ankle fracture,0/106 %0.0,1/109 %0.92
Narcotic intoxication,0/106 %0.0,1/109 %0.92
Wound dehiscence,0/106 %0.0,1/109 %0.92
Blood alkaline phosphatase increased,1/106 %0.94,0/109 %0.0
Blood creatinine increased,1/106 %0.94,0/109 %0.0
Gamma-glutamyltransferase increased,1/106 %0.94,0/109 %0.0
Hepatic enzyme increased,1/106 %0.94,0/109 %0.0
International normalised ratio increased,0/106 %0.0,1/109 %0.92
Decreased appetite,2/106 %1.89,0/109 %0.0
Dehydration,4/106 %3.77,2/109 %1.83
Hypoalbuminaemia,1/106 %0.94,0/109 %0.0
Hyponatraemia,1/106 %0.94,1/109 %0.92
Type 1 diabetes mellitus,0/106 %0.0,1/109 %0.92
Arthralgia,0/106 %0.0,1/109 %0.92
Musculoskeletal chest pain,0/106 %0.0,1/109 %0.92
Cardiac myxoma,1/106 %0.94,0/109 %0.0
Malignant pleural effusion,1/106 %0.94,0/109 %0.0
Metastases to central nervous system,0/106 %0.0,2/109 %1.83
Metastases to lymph nodes,1/106 %0.94,0/109 %0.0
Metastases to small intestine,0/106 %0.0,1/109 %0.92
Grand mal convulsion,0/106 %0.0,1/109 %0.92
Headache,1/106 %0.94,2/109 %1.83
Hypertensive encephalopathy,0/106 %0.0,1/109 %0.92
Polyneuropathy,0/106 %0.0,1/109 %0.92
Syncope,1/106 %0.94,0/109 %0.0
Transient ischaemic attack,1/106 %0.94,0/109 %0.0
Hydronephrosis,1/106 %0.94,0/109 %0.0
Nephrotic syndrome,1/106 %0.94,0/109 %0.0
Proteinuria,1/106 %0.94,1/109 %0.92
Renal failure,3/106 %2.83,3/109 %2.75
Renal failure acute,0/106 %0.0,1/109 %0.92
Urinary retention,1/106 %0.94,0/109 %0.0
Acute respiratory distress syndrome,1/106 %0.94,0/109 %0.0
Chronic obstructive pulmonary disease,0/106 %0.0,1/109 %0.92
Dyspnoea,2/106 %1.89,4/109 %3.67
Hypoxia,1/106 %0.94,0/109 %0.0
Pleural effusion,3/106 %2.83,1/109 %0.92
Pneumonia aspiration,0/106 %0.0,1/109 %0.92
Pulmonary embolism,1/106 %0.94,2/109 %1.83
Pulmonary oedema,0/106 %0.0,1/109 %0.92
Respiratory failure,1/106 %0.94,0/109 %0.0
Erythema,0/106 %0.0,1/109 %0.92
Deep vein thrombosis,0/106 %0.0,1/109 %0.92
Hypertension,4/106 %3.77,6/109 %5.5
Phlebitis,0/106 %0.0,1/109 %0.92

Observation  Radiation Therapy  Combination Chemotherapy  and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma(https://clinicaltrials.gov/show/NCT00346164)
 ,Arm A: No Adjuvant Treatment,Arm B: Low Risk; Adjuvant Radiotherapy,Arm C: Intermediate & High Risk; Adjuvant Chemoradiotherapy,Arm D: Intermediate & High Risk; Neoadjuvant Chemoradiotherapy
 ,Patients with low-grade tumor with either negative or positive microscopic margins or high-grade tumor  5 cm (in maximum diameter) with negative microscopic margins are assigned to arm A: (observation only).  clinical observation: Patients undergo observation  therapeutic conventional surgery: Patients undergo surgery,Patients with high-grade tumor  5 cm (in maximum diameter) with positive microscopic margins are assigned to arm B: (adjuvant radiotherapy). Beginning between 6-42 days after surgical resection patients undergo a total of 31 fractions of adjuvant radiotherapy.  clinical observation: Patients undergo observation  therapeutic conventional surgery: Patients undergo surgery  3-dimensional conformal radiation therapy: Patients undergo radiotherapy,High risk [metastatic resected incompletely resected or unresected disease] patients with high-grade grossly resected primary tumor with metastases are assigned to receive arm C: (adjuvant chemoradiotherapy). Patients receive ifosfamide IV; doxorubicin hydrochloride IV; beginning in week 4 patients also undergo a total of 31 fractions of radiotherapy.  doxorubicin hydrochloride: Given IV  clinical observation: Patients undergo observation  3-dimensional conformal radiation therapy: Patients undergo radiotherapy  ifosfamide: Given IV,High risk [metastatic resected incompletely resected or unresected disease] patients with unresected high-grade metastatic tumor are assigned to receive treatment as in arm D: (neoadjuvant chemoradiotherapy surgery and adjuvant chemotherapy with or without radiotherapy): Patients receive ifosfamide IV; doxorubicin hydrochloride IV. Beginning in week 4 patients also undergo a total of 31 fractions of radiotherapy. Patients undergo surgical resection in week 13.  doxorubicin hydrochloride: Given IV  clinical observation: Patients undergo observation  therapeutic conventional surgery: Patients undergo surgery  3-dimensional conformal radiation therapy: Patients undergo radiotherapy  ifosfamide: Given IV
Total serious adverse events,0/205 %0.0,1/17 %5.88,1/110 %0.91,3/196 %1.53
Upper gastrointestinal hemorrhage,0/205 %0.0,0/17 %0.0,1/110 %0.91,0/196 %0.0
Death NOS,0/205 %0.0,0/17 %0.0,0/110 %0.0,1/196 %0.51
Infections and infestations - Other specify,0/205 %0.0,0/17 %0.0,0/110 %0.0,1/196 %0.51
Neoplasms benign malignant and unspecified (incl cysts and polyps) - Other specify,0/205 %0.0,0/17 %0.0,0/110 %0.0,1/196 %0.51
Treatment related secondary malignancy,0/205 %0.0,1/17 %5.88,0/110 %0.0,0/196 %0.0

Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma(https://clinicaltrials.gov/show/NCT00352027)
 ,Stanford V Chemotherapy
 ,Intermediate risk single arm study defined as  EITHER Ann Arbor stage IB and IIIA  OR Ann Arbor stage IA or IIA with ANY of the following features: (1) extranodal extension of disease lesion(s) (2) 3 or more nodal sites involved (3) Bulky mediastinal adenopathy (mediastinal mass to thoracic cavity ratio 33% or greater by chest radiograph).  Participants receive 12 weeks of Stanford V chemotherapy:  Adriamycin IV Day 1 of weeks 1 3 5 7 9 and 11 Vinblastine IV Day 1 of weeks 1 3 5 7 9 11 Nitrogen Mustard (or Cyclophosphamide) IV Day 1 of weeks 1 5 9 Vincristine IV Day 1 of weeks 2 4 6 8 10 12 Bleomycin IV Day 1 of weeks 2 4 6 8 10 12 Etoposide IV Days 1 2 of weeks 1-10 Prednisone PO every other day of weeks 1-12 G-CSF SC days 3-13 16-26 29-39 42-52 55-65 68-78 (as clinically indicated)  After completion of 12 weeks of Stanford V chemotherapy participants receive radiotherapy.
Total serious adverse events,1/80 %1.25
Thrombosis/thrombus/embolism,1/80 %1.25

High-Dose Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Metastatic Rhabdomyosarcoma or Ectomesenchymoma(https://clinicaltrials.gov/show/NCT00354744)
 ,High_Risk_Rhabdomyosarcoma
 ,Parameningeal (without intracranial extension) and paraspinal tumors receive chemotherapy starting Week 1 and begin radiation therapy at Week 20. Weeks 1-6: vincristine sulfate and irinotecan hydrochloride. Weeks 7-34: vincristine sulfate and irinotecan hydrochloride Cyclophosphamide with MESNA Doxorubicin hydrochloride Etoposide Ifosfamide with MESNA. Weeks 35-54: vincristine sulfate Dactinomycin irinotecan hydrochloride and Cyclophosphamide with MESNA and Filgrastim. Radiation therapy beginning at Week 20. Second look conventional surgery: Surgical resection other than biopsy will be applicable for the majority of patients.
Total serious adverse events,4/108 %3.7
Anorectal infection,1/108 %0.93
Infections and infestations - Other,1/108 %0.93
Sepsis,1/108 %0.93
Radiation recall reaction (dermatologic),1/108 %0.93

Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer(https://clinicaltrials.gov/show/NCT00365365)
 ,AC->T + Bevacizumab,TAC + Bevacizumab,TCH + Bevacizumab
 ,HER2-negative participants administered  doxorubicin and cyclophosphamide (AC) + bevacizumab for 4 cycles followed by  docetaxel (T) + bevacizumab for 4 cycles followed by  bevacizumab maintenance therapy for total of 52 weeks from date of first dose regardless of number of doses received or missed,HER2-negative participants administered  docetaxel doxorubicin cyclophosphamide (TAC) + bevacizumab for 6 cycles followed by  bevacizumab maintenance therapy for total of 52 weeks from date of first dose regardless of number of doses received or missed,All HER2-positive participants administered  docetaxel carboplatin trastuzumab (TCH) + bevacizumab for 6 cycles followed by  bevacizumab and trastuzumab maintenance therapy for total of 52 weeks from date of first dose regardless of number of doses received or missed
Total serious adverse events,23/78 %29.49,24/75 %32.0,12/59 %20.34
Febrile neutropenia,4/78 %5.13,8/75 %10.67,0/59 %0.0
Neutropenia,1/78 %1.28,3/75 %4.0,0/59 %0.0
Thrombocytopenia,0/78 %0.0,2/75 %2.67,0/59 %0.0
Acute coronary syndrome,1/78 %1.28,0/75 %0.0,0/59 %0.0
Cardiac failure congestive,1/78 %1.28,2/75 %2.67,0/59 %0.0
Myocardial infarction,1/78 %1.28,0/75 %0.0,0/59 %0.0
Cardiomyopathy,0/78 %0.0,1/75 %1.33,0/59 %0.0
Abdominal pain,1/78 %1.28,0/75 %0.0,0/59 %0.0
Diarrhoea,1/78 %1.28,1/75 %1.33,1/59 %1.69
Upper gastrointestinal haemorrhage,1/78 %1.28,0/75 %0.0,0/59 %0.0
Caecitis,0/78 %0.0,1/75 %1.33,0/59 %0.0
Colitis,0/78 %0.0,2/75 %2.67,0/59 %0.0
Gastrointestinal haemorrhage,0/78 %0.0,0/75 %0.0,1/59 %1.69
Intestinal ulcer,0/78 %0.0,1/75 %1.33,0/59 %0.0
Irritable bowel syndrome,0/78 %0.0,0/75 %0.0,1/59 %1.69
Oesophagitis,0/78 %0.0,1/75 %1.33,0/59 %0.0
Oesophagitis ulcerative,0/78 %0.0,0/75 %0.0,1/59 %1.69
Stomatitis,0/78 %0.0,1/75 %1.33,0/59 %0.0
Mucosal inflammation,1/78 %1.28,0/75 %0.0,0/59 %0.0
Chest pain,0/78 %0.0,0/75 %0.0,1/59 %1.69
Non-cardiac chest pain,0/78 %0.0,1/75 %1.33,1/59 %1.69
Pyrexia,0/78 %0.0,1/75 %1.33,0/59 %0.0
Cholelithiasis,0/78 %0.0,1/75 %1.33,0/59 %0.0
Appendicitis,1/78 %1.28,1/75 %1.33,0/59 %0.0
Bronchitis,1/78 %1.28,0/75 %0.0,0/59 %0.0
Diverticulitis,1/78 %1.28,1/75 %1.33,0/59 %0.0
Hand-foot-and-mouth disease,1/78 %1.28,0/75 %0.0,0/59 %0.0
Influenza,1/78 %1.28,0/75 %0.0,0/59 %0.0
Neutropenic infection,1/78 %1.28,1/75 %1.33,0/59 %0.0
Device related infection,0/78 %0.0,0/75 %0.0,1/59 %1.69
Herpes zoster,0/78 %0.0,1/75 %1.33,0/59 %0.0
Incision site abscess,0/78 %0.0,0/75 %0.0,1/59 %1.69
Lung infection pseudomonal,0/78 %0.0,1/75 %1.33,0/59 %0.0
Neutropenic sepsis,0/78 %0.0,1/75 %1.33,0/59 %0.0
Pseudomonal sepsis,0/78 %0.0,1/75 %1.33,0/59 %0.0
Sepsis,0/78 %0.0,1/75 %1.33,0/59 %0.0
Septic shock,0/78 %0.0,1/75 %1.33,0/59 %0.0
Urinary tract infection,0/78 %0.0,0/75 %0.0,1/59 %1.69
Ejection fraction decreased,0/78 %0.0,0/75 %0.0,1/59 %1.69
Dehydration,1/78 %1.28,4/75 %5.33,0/59 %0.0
Hypokalaemia,0/78 %0.0,1/75 %1.33,0/59 %0.0
Hyponatraemia,0/78 %0.0,0/75 %0.0,1/59 %1.69
Hypovolaemia,0/78 %0.0,1/75 %1.33,0/59 %0.0
Rotator cuff syndrome,1/78 %1.28,0/75 %0.0,0/59 %0.0
Musculoskeletal pain,0/78 %0.0,0/75 %0.0,1/59 %1.69
Metastases to meninges,1/78 %1.28,0/75 %0.0,0/59 %0.0
Headache,1/78 %1.28,0/75 %0.0,0/59 %0.0
Lacunar infarction,1/78 %1.28,0/75 %0.0,0/59 %0.0
Neuropathy peripheral,1/78 %1.28,0/75 %0.0,0/59 %0.0
Subarachnoid haemorrhage,0/78 %0.0,1/75 %1.33,0/59 %0.0
Renal failure acute,0/78 %0.0,1/75 %1.33,0/59 %0.0
Female genital tract fistula,0/78 %0.0,1/75 %1.33,0/59 %0.0
Pulmonary embolism,1/78 %1.28,0/75 %0.0,1/59 %1.69
Acute respiratory distress syndrome,0/78 %0.0,1/75 %1.33,0/59 %0.0
Exfoliative rash,1/78 %1.28,0/75 %0.0,0/59 %0.0
Palmar-plantar erythrodysaesthesia syndrome,1/78 %1.28,0/75 %0.0,0/59 %0.0
Deep vein thrombosis,2/78 %2.56,1/75 %1.33,0/59 %0.0
Hypertension,1/78 %1.28,0/75 %0.0,1/59 %1.69
Hypertensive crisis,0/78 %0.0,0/75 %0.0,1/59 %1.69
Hypotension,0/78 %0.0,1/75 %1.33,0/59 %0.0
Superior vena cava syndrome,0/78 %0.0,1/75 %1.33,0/59 %0.0

Therapy With Bevacizumab (BEV)  Doxorubicin  and Cyclophosphamide Followed by BEV  Docetaxel  and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer(https://clinicaltrials.gov/show/NCT00365417)
 ,Chemo Plus Bevacizumab
 ,Bevacizumab beginning concurrently with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy followed by postoperative bevacizumab alone for women with HER2 negative locally advanced breast cancer
Total serious adverse events,14/45 %31.11
Hemoglobin,1/45 %2.22
Diarrhea,1/45 %2.22
Esophagitis,1/45 %2.22
Mucositis (clinical exam) - oral cavity,1/45 %2.22
Mucositis (functional/symptomatic) - esophagus,1/45 %2.22
Mucositis (functional/symptomatic) - oral cavity,2/45 %4.44
Insomnia,1/45 %2.22
Pain - abdominal NOS,2/45 %4.44
Pain - back,1/45 %2.22
Pain - musculoskeletal (hip),1/45 %2.22
Syncope (fainting),1/45 %2.22
Infection - blood,1/45 %2.22
Infection - catheter related,1/45 %2.22
Infection - lung (pneumonia),2/45 %4.44
Infection - skin (cellulites),3/45 %6.67
Infection - ungual (nails),1/45 %2.22
Infection - urinary tract NOS,1/45 %2.22
Infection with normal ANC - sinus,1/45 %2.22
Infection with normal ANC - skin (cellulites),2/45 %4.44
Infection with normal ANC - upper airway NOS,1/45 %2.22
Infection with normal ANC - urinary tract NOS,1/45 %2.22
Infection with normal ANC - wound,1/45 %2.22
Hypokalemia,1/45 %2.22
Dyspnea,1/45 %2.22
Hand-foot,1/45 %2.22
Thrombosis/thrombus/embolism,2/45 %4.44

S0601 Rituximab  Combination Chemotherapy  and Bortezomib Followed by Bortezomib Alone in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma(https://clinicaltrials.gov/show/NCT00376961)
 ,Rituximab-CHOP-Bortezomib (R-CHOP-V) Induction,Bortezomib Maintenance (VM)
 ,Rituximab-CHOP-Bortezomib (R-CHOP-V) induction is administered every 21 days for 6 cycles (1 cycle= 21 days),Bortezomib maintenance (VM) therapy is given 3 months after the completion of R-CHOP-V induction therapy. Treatment with VM is administered once every 3 month for 8 cycles Cycle 7-14 ( 1 cycle = 3 months)
Total serious adverse events,1/65 %1.54,0/47 %0.0
Sudden death,1/65 %1.54,0/47 %0.0

Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL(https://clinicaltrials.gov/show/NCT00379574)
 ,Bortezomib + CHOP Every 2 Weeks
 ,CHOP; cyclophosphamide doxorubicin vincristine and prednisone
Total serious adverse events,22/49 %44.9
anemia,22/40 %55.0
neutropenia,14/40 %35.0
feberile neutropenia,7/40 %17.5
thrombocytopenia,13/40 %32.5
hyperglycemia,4/40 %10.0
abdominal pain,4/40 %10.0
constipation,0/40 %0.0
diarrhea,4/40 %10.0
vomiting,4/40 %10.0
fatigue,2/40 %5.0
sensory neuropathy,11/40 %27.5
motor neuropathy,3/40 %7.5

Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia(https://clinicaltrials.gov/show/NCT00381680)
 ,Regimen A: Standard Vincristine Dosing,Arm B: Randomized High Dose Vincristine Regimen
 ,See detailed description.  vincristine sulfate: Given IV  prednisone: Given PO  doxorubicin hydrochloride: Given IV  pegaspargase: Given IM  cytarabine: Given IT or IV  methotrexate: Given IT or IV  dexamethasone: Given PO  etoposide: Given IV  cyclophosphamide: Given IV  leucovorin calcium: Given IV or PO  filgrastim: Given IV or SC  asparaginase: Given IM  mercaptopurine: Given PO,See detailed description. Closed to accrual as of 09/2010).  vincristine sulfate: Given IV  prednisone: Given PO  doxorubicin hydrochloride: Given IV  pegaspargase: Given IM  cytarabine: Given IT or IV  methotrexate: Given IT or IV  dexamethasone: Given PO  etoposide: Given IV  cyclophosphamide: Given IV  leucovorin calcium: Given IV or PO  filgrastim: Given IV or SC  asparaginase: Given IM  mercaptopurine: Given PO
Total serious adverse events,40/203 %19.7,11/68 %16.18
Disseminated intravascular coagulation,1/203 %0.49,1/68 %1.47
Febrile neutropenia,4/203 %1.97,0/68 %0.0
Sinus tachycardia,2/203 %0.99,0/68 %0.0
Ventricular arrhythmia,1/203 %0.49,0/68 %0.0
Abdominal pain,1/203 %0.49,0/68 %0.0
Anal necrosis,1/203 %0.49,0/68 %0.0
Anal ulcer,1/203 %0.49,0/68 %0.0
Death NOS,15/203 %7.39,1/68 %1.47
Edema face,1/203 %0.49,0/68 %0.0
Fever,1/203 %0.49,0/68 %0.0
Multi-organ failure,2/203 %0.99,1/68 %1.47
Hepatic failure,0/203 %0.0,1/68 %1.47
Appendicitis,1/203 %0.49,0/68 %0.0
Catheter related infection,2/203 %0.99,0/68 %0.0
Infections and infestations - Other specify,7/203 %3.45,6/68 %8.82
Lung infection,2/203 %0.99,1/68 %1.47
Meningitis,1/203 %0.49,0/68 %0.0
Mucosal infection,1/203 %0.49,0/68 %0.0
Sepsis,8/203 %3.94,1/68 %1.47
Upper respiratory infection,1/203 %0.49,0/68 %0.0
Alanine aminotransferase increased,1/203 %0.49,0/68 %0.0
Aspartate aminotransferase increased,1/203 %0.49,0/68 %0.0
Blood bilirubin increased,2/203 %0.99,0/68 %0.0
Neutrophil count decreased,3/203 %1.48,1/68 %1.47
Platelet count decreased,3/203 %1.48,2/68 %2.94
White blood cell decreased,1/203 %0.49,0/68 %0.0
Acidosis,1/203 %0.49,0/68 %0.0
Dehydration,1/203 %0.49,0/68 %0.0
Hypernatremia,1/203 %0.49,0/68 %0.0
Hyponatremia,1/203 %0.49,0/68 %0.0
Leukemia secondary to oncology chemotherapy,2/203 %0.99,0/68 %0.0
Myelodysplastic syndrome,1/203 %0.49,1/68 %1.47
Treatment related secondary malignancy,1/203 %0.49,0/68 %0.0
Intracranial hemorrhage,0/203 %0.0,2/68 %2.94
Myelitis,1/203 %0.49,0/68 %0.0
Seizure,0/203 %0.0,1/68 %1.47
Stroke,1/203 %0.49,0/68 %0.0
Adult respiratory distress syndrome,1/203 %0.49,0/68 %0.0
Bronchopulmonary hemorrhage,2/203 %0.99,0/68 %0.0
Hypoxia,1/203 %0.49,0/68 %0.0
Pleural effusion,1/203 %0.49,0/68 %0.0
Pneumonitis,1/203 %0.49,0/68 %0.0
Pneumothorax,1/203 %0.49,0/68 %0.0
Respiratory failure,1/203 %0.49,0/68 %0.0
Skin and subcutaneous tissue disorders - Other specify,1/203 %0.49,0/68 %0.0
Hypotension,4/203 %1.97,1/68 %1.47
Thromboembolic event,2/203 %0.99,0/68 %0.0

Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma(https://clinicaltrials.gov/show/NCT00392990)
 ,High Risk - Treated With Alternating R-CODOX-M/R-IVAC Cycles,Low Risk - Treatment With 3 Cycles of R-CODOX-M
 ,Patients are stratified between high risk and low risk disease status.  High risk patients receive 1 cycle of R-CODOX-M chemotherapy IV followed by R-IVAC chemotherapy over 30 minutes(Regimen B); regimens A and B are then repeated.  Regimen A: Cyclophosphamide (800 mg/m2 IV over 1 hour)+ vincristine (1.5 mg/m2 IV PUSH)+ doxorubicin (40 mg/m2 IV)+ high-dose methotrexate (2700 mg/m2 IV over 23 hours)+ rituximab (500 mg/m2 IV)(R-CODOX-M) regimen  Regimen B: Rituximab (500 mg/m2 IV once)+ Ifosfamide (1500 mg/m2 IV daily over 3 hours)+ Etoposide (60 mg/m2 IV daily over 1 hour) and Cytarabine (2 grams/m2 IV over 3 hours for 4 doses),Patients are stratified between high risk and low risk disease status. Low risk patients receive 3 cycles of rituximab (500 mg/m2) R-CODOX-M chemotherapy IV over 2-4 hours with intrathecal chemotherapy (Regimen A).  Regimen A: Cyclophosphamide (800 mg/m2 IV over 1 hour)+ vincristine (1.5 mg/m2 IV PUSH)+ doxorubicin (40 mg/m2 IV)+ high-dose methotrexate (2700 mg/m2 IV over 23 hours)+ rituximab (500 mg/m2 IV)(R-CODOX-M) regimen  Regimen B: Rituximab (500 mg/m2 IV once)+ Ifosfamide (1500 mg/m2 IV daily over 3 hours)+ Etoposide (60 mg/m2 IV daily over 1 hour) and Cytarabine (2 grams/m2 IV over 3 hours for 4 doses)
Total all-cause mortality,4/20 %20.0,0/5 %0.0
Total serious adverse events,20/20 %100.0,2/5 %40.0
myelodysplastic syndrome,1/20 %5.0,0/5 %0.0
Cardiac dysfunction,1/20 %5.0,0/5 %0.0
Pleuritic chest pain,1/20 %5.0,0/5 %0.0
Mucositis,1/20 %5.0,0/5 %0.0
GI bleed,1/20 %5.0,0/5 %0.0
Fever,1/20 %5.0,0/5 %0.0
Cerebritis,1/20 %5.0,0/5 %0.0
Febrile neutropnia,5/20 %25.0,1/5 %20.0
Infection,2/20 %10.0,0/5 %0.0
Bloodinfection,1/20 %5.0,0/5 %0.0
Pancytopenia,3/20 %15.0,1/5 %20.0
Neuro symptoms - Seizure,1/20 %5.0,0/5 %0.0
Renal failuretumor lysis syndrome,1/20 %5.0,0/5 %0.0
Hematoma,0/20 %0.0,1/5 %20.0

Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer(https://clinicaltrials.gov/show/NCT00394251)
 ,AC --> ABI-007,AC --> Taxol
 ,Adriamycin and Cytoxan plus Bevacizumab for four cycles (weeks 1-8); 260 mg/m^2 ABI-007 (Abraxane) plus Bevacizumab for four cycles (weeks 9-16); Bevacizumab (weeks 17-46).,Adriamycin and Cytoxan plus Bevacizumab for four cycles (weeks 1-8); 175 mg/m^2 Taxol plus Bevacizumab for four cycles (weeks 9-16); Bevacizumab (weeks 17-46).
Total serious adverse events,30/98 %30.61,21/99 %21.21
Coagulopathy,1/98 %1.02,0/99 %0.0
Febrile neutropenia,7/98 %7.14,5/99 %5.05
Pancytopenia,2/98 %2.04,0/99 %0.0
Cardiac failure,0/98 %0.0,1/99 %1.01
Cardiac failure congestive,0/98 %0.0,4/99 %4.04
Pericardial effusion,0/98 %0.0,1/99 %1.01
Appendicitis perforated,1/98 %1.02,0/99 %0.0
Colitis,1/98 %1.02,0/99 %0.0
Ileus,1/98 %1.02,0/99 %0.0
Abdominal pain upper,1/98 %1.02,0/99 %0.0
Gastrointestinal haemorrhage,0/98 %0.0,1/99 %1.01
Oesophagitis ulcerative,0/98 %0.0,1/99 %1.01
Chest pain,1/98 %1.02,2/99 %2.02
Pyrexia,2/98 %2.04,0/99 %0.0
Non-cardiac chest pain,1/98 %1.02,0/99 %0.0
Diverticulitis,1/98 %1.02,1/99 %1.01
Perirectal abscess,1/98 %1.02,0/99 %0.0
Pneumonia,1/98 %1.02,1/99 %1.01
Sepsis,2/98 %2.04,0/99 %0.0
Sinusitis,1/98 %1.02,0/99 %0.0
Wound infection,1/98 %1.02,0/99 %0.0
Cellulitis,1/98 %1.02,1/99 %1.01
Appendicitis,1/98 %1.02,0/99 %0.0
Breast cellulitis,0/98 %0.0,1/99 %1.01
Catheter related infection,0/98 %0.0,1/99 %1.01
Catheter site cellulitis,1/98 %1.02,0/99 %0.0
Gastroenteritis,0/98 %0.0,1/99 %1.01
Postoperative wound infection,0/98 %0.0,1/99 %1.01
Staphylococcal sepsis,1/98 %1.02,0/99 %0.0
Urinary tract infection,0/98 %0.0,1/99 %1.01
Wound dehiscence,1/98 %1.02,1/99 %1.01
Hepatic enzyme increased,0/98 %0.0,1/99 %1.01
Hyponatraemia,1/98 %1.02,0/99 %0.0
Hypovolaemia,1/98 %1.02,0/99 %0.0
Dehydration,0/98 %0.0,1/99 %1.01
Arthralgia,1/98 %1.02,1/99 %1.01
Myalgia,0/98 %0.0,1/99 %1.01
Bone pain,1/98 %1.02,0/99 %0.0
Syncope,1/98 %1.02,2/99 %2.02
Cerebrovascular accident,1/98 %1.02,0/99 %0.0
Encephalopathy,0/98 %0.0,1/99 %1.01
Dyspnoea,1/98 %1.02,0/99 %0.0
Pulmonary embolism,1/98 %1.02,1/99 %1.01
Chronic obstructive pulmonary disease,1/98 %1.02,1/99 %1.01
Acute respiratory distress syndrome,1/98 %1.02,0/99 %0.0
Skin reaction,1/98 %1.02,0/99 %0.0
Hypertension,1/98 %1.02,1/99 %1.01
Hypotension,1/98 %1.02,0/99 %0.0
Deep vein thrombosis,2/98 %2.04,0/99 %0.0

Bevacizumab + CHOP-Rituximab in Untreated Mantle Cell Lymphoma(https://clinicaltrials.gov/show/NCT00401817)
 ,Study Treatment Arm
 ,Bevacizumab-R-CHOP therapy included bevacizumab administered at 15 mg/kg on day 1 and standard dose R-CHOP on day 3 for six 21-day cycles  Bevacizumab: 15 mg/kg on day 1 of each of 6 cycles
Total serious adverse events,1/11 %9.09
Prostate Cancer,1/11 %9.09

Chemotherapy With or Without Bevacizumab in Treating Women With Stage I  Stage II  or Stage IIIA Breast Cancer That Can Be Removed By Surgery(https://clinicaltrials.gov/show/NCT00408408)
 ,Docetaxel Then AC,Docetaxel + Bev Then AC + Bev,Docetaxel + Capecitabine Then AC,Docetaxel + Cape + Bev Then AC + Bev,Docetaxel + Gem Then AC,Docetaxel + Gem + Bev Then AC + Bev
 ,Docetaxel then AC,Docetaxel + Bev then AC + Bev,Docetaxel + Capecitabine then AC,Docetaxel + Cape + Bev then AC + Bev,Docetaxel + Gem then AC,Docetaxel + Gem + Bev then AC + Bev
Total serious adverse events,4/199 %2.01,15/196 %7.65,8/203 %3.94,30/196 %15.31,2/194 %1.03,15/202 %7.43
Anemia,0/199 %0.0,0/196 %0.0,0/203 %0.0,1/196 %0.51,0/194 %0.0,0/202 %0.0
Blood and lymphatic system disorders - Other specify,0/199 %0.0,1/196 %0.51,0/203 %0.0,0/196 %0.0,0/194 %0.0,0/202 %0.0
Cardiac arrest,0/199 %0.0,0/196 %0.0,0/203 %0.0,0/196 %0.0,0/194 %0.0,1/202 %0.5
Heart failure,0/199 %0.0,1/196 %0.51,0/203 %0.0,1/196 %0.51,0/194 %0.0,1/202 %0.5
Myocardial infarction,0/199 %0.0,0/196 %0.0,0/203 %0.0,1/196 %0.51,0/194 %0.0,1/202 %0.5
Pericardial effusion,0/199 %0.0,0/196 %0.0,0/203 %0.0,1/196 %0.51,0/194 %0.0,0/202 %0.0
Left ventricular systolic dysfunction,0/199 %0.0,1/196 %0.51,1/203 %0.49,5/196 %2.55,0/194 %0.0,2/202 %0.99
Abdominal pain,0/199 %0.0,0/196 %0.0,0/203 %0.0,1/196 %0.51,0/194 %0.0,0/202 %0.0
Colonic hemorrhage,0/199 %0.0,0/196 %0.0,0/203 %0.0,1/196 %0.51,0/194 %0.0,0/202 %0.0
Colonic perforation,0/199 %0.0,0/196 %0.0,0/203 %0.0,0/196 %0.0,0/194 %0.0,1/202 %0.5
Small intestinal perforation,0/199 %0.0,0/196 %0.0,0/203 %0.0,0/196 %0.0,0/194 %0.0,1/202 %0.5
Lower gastrointestinal hemorrhage,0/199 %0.0,0/196 %0.0,0/203 %0.0,1/196 %0.51,0/194 %0.0,0/202 %0.0
Anal hemorrhage,0/199 %0.0,0/196 %0.0,0/203 %0.0,0/196 %0.0,0/194 %0.0,1/202 %0.5
Upper gastrointestinal hemorrhage,0/199 %0.0,0/196 %0.0,0/203 %0.0,1/196 %0.51,0/194 %0.0,0/202 %0.0
Sudden death NOS,0/199 %0.0,0/196 %0.0,1/203 %0.49,0/196 %0.0,0/194 %0.0,0/202 %0.0
Anaphylaxis,0/199 %0.0,0/196 %0.0,0/203 %0.0,1/196 %0.51,0/194 %0.0,0/202 %0.0
Endocarditis infective,0/199 %0.0,1/196 %0.51,0/203 %0.0,0/196 %0.0,0/194 %0.0,0/202 %0.0
Infections and infestations - Other specify,0/199 %0.0,0/196 %0.0,0/203 %0.0,0/196 %0.0,1/194 %0.52,0/202 %0.0
Sepsis,0/199 %0.0,1/196 %0.51,0/203 %0.0,0/196 %0.0,0/194 %0.0,0/202 %0.0
Abdominal infection,0/199 %0.0,0/196 %0.0,0/203 %0.0,1/196 %0.51,0/194 %0.0,0/202 %0.0
Lung infection,0/199 %0.0,0/196 %0.0,0/203 %0.0,0/196 %0.0,0/194 %0.0,1/202 %0.5
Wound dehiscence,0/199 %0.0,2/196 %1.02,0/203 %0.0,3/196 %1.53,0/194 %0.0,2/202 %0.99
Cardiac troponin I increased,0/199 %0.0,0/196 %0.0,1/203 %0.49,1/196 %0.51,0/194 %0.0,1/202 %0.5
Creatinine increased,0/199 %0.0,0/196 %0.0,0/203 %0.0,0/196 %0.0,1/194 %0.52,0/202 %0.0
Investigations - Other specify,0/199 %0.0,0/196 %0.0,1/203 %0.49,0/196 %0.0,0/194 %0.0,0/202 %0.0
Dehydration,0/199 %0.0,0/196 %0.0,0/203 %0.0,0/196 %0.0,0/194 %0.0,2/202 %0.99
Hyperkalemia,1/199 %0.5,0/196 %0.0,0/203 %0.0,0/196 %0.0,0/194 %0.0,0/202 %0.0
Hypokalemia,2/199 %1.01,0/196 %0.0,0/203 %0.0,2/196 %1.02,1/194 %0.52,1/202 %0.5
Hyponatremia,0/199 %0.0,0/196 %0.0,0/203 %0.0,0/196 %0.0,0/194 %0.0,1/202 %0.5
Hypophosphatemia,0/199 %0.0,0/196 %0.0,0/203 %0.0,1/196 %0.51,0/194 %0.0,0/202 %0.0
Myositis,0/199 %0.0,0/196 %0.0,1/203 %0.49,0/196 %0.0,0/194 %0.0,0/202 %0.0
Leukemia secondary to oncology chemotherapy,0/199 %0.0,0/196 %0.0,0/203 %0.0,1/196 %0.51,0/194 %0.0,0/202 %0.0
Treatment related secondary malignancy,0/199 %0.0,0/196 %0.0,0/203 %0.0,1/196 %0.51,0/194 %0.0,0/202 %0.0
Headache,0/199 %0.0,1/196 %0.51,0/203 %0.0,1/196 %0.51,0/194 %0.0,0/202 %0.0
Nervous system disorders - Other specify,0/199 %0.0,0/196 %0.0,0/203 %0.0,1/196 %0.51,0/194 %0.0,2/202 %0.99
Anxiety,0/199 %0.0,0/196 %0.0,1/203 %0.49,0/196 %0.0,0/194 %0.0,1/202 %0.5
Depression,0/199 %0.0,1/196 %0.51,1/203 %0.49,1/196 %0.51,0/194 %0.0,0/202 %0.0
Proteinuria,0/199 %0.0,4/196 %2.04,0/203 %0.0,0/196 %0.0,0/194 %0.0,1/202 %0.5
Uterine hemorrhage,0/199 %0.0,1/196 %0.51,0/203 %0.0,0/196 %0.0,0/194 %0.0,0/202 %0.0
Dyspnea,0/199 %0.0,0/196 %0.0,0/203 %0.0,2/196 %1.02,0/194 %0.0,1/202 %0.5
Epistaxis,0/199 %0.0,1/196 %0.51,0/203 %0.0,1/196 %0.51,0/194 %0.0,1/202 %0.5
Pneumothorax,0/199 %0.0,0/196 %0.0,0/203 %0.0,1/196 %0.51,0/194 %0.0,0/202 %0.0
Pleural hemorrhage,0/199 %0.0,0/196 %0.0,0/203 %0.0,1/196 %0.51,0/194 %0.0,0/202 %0.0
Stevens-Johnson syndrome,0/199 %0.0,1/196 %0.51,1/203 %0.49,0/196 %0.0,0/194 %0.0,0/202 %0.0
Hypertension,0/199 %0.0,1/196 %0.51,0/203 %0.0,1/196 %0.51,0/194 %0.0,0/202 %0.0
Thromboembolic event,1/199 %0.5,1/196 %0.51,2/203 %0.99,4/196 %2.04,0/194 %0.0,1/202 %0.5
Vascular disorders - Other specify,0/199 %0.0,0/196 %0.0,1/203 %0.49,0/196 %0.0,0/194 %0.0,0/202 %0.0
Visceral arterial ischemia,1/199 %0.5,0/196 %0.0,0/203 %0.0,0/196 %0.0,0/194 %0.0,0/202 %0.0

Doxorubicin and Cyclophosphamide Followed By Trastuzumab  Paclitaxel  and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery(https://clinicaltrials.gov/show/NCT00436566)
 ,AC/PTL
 ,Standard doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (80 mg/m^2) x 12 with concurrent standard dose trastuzumab (weekly x 12 then repeat 3 weeks for an additional 9 months) plus daily lapatinib (modified to 750 mg during Paclitaxel + Trastuzumab + Lapatinib (PTL) and 1000 mg during trastuzumab + lapatinib (TL)) for a total of 12 months.
Total serious adverse events,17/108 %15.74
Febrile neutropenia,1/108 %0.93
Left ventricular failure,1/108 %0.93
Diarrhea,6/108 %5.56
Fatigue,1/108 %0.93
Pneumonia,1/108 %0.93
Skin infection,1/108 %0.93
Urinary tract infection,1/108 %0.93
Alanine aminotransferase increased,1/108 %0.93
Aspartate aminotransferase increased,1/108 %0.93
Leukopenia,2/108 %1.85
Neutrophil count decreased,4/108 %3.7
Hypokalemia,1/108 %0.93
Peripheral sensory neuropathy,1/108 %0.93
Cough,1/108 %0.93
Pulmonary,1/108 %0.93
Thrombosis,1/108 %0.93

R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma(https://clinicaltrials.gov/show/NCT00450801)
 ,R-MACLO Cycles,R-IVAM Cycles,Thalidomide Therapy
 ,Adverse Events occurring during the combination Rituximab Methotrexate Doxorubicin Cyclophosphamide and Vincristine (R-MACLO) treatment cycles.,Adverse Events occurring during the Rituximab Ifosfamide (and Mesna) Etoposide and Cytarabine (R-IVAM) treatment cycles.,Adverse Events occurring during Thalidomide maintenance therapy.
Total serious adverse events,21/22 %95.45,21/22 %95.45,19/20 %95.0
Thrombocytopenia (Grade 3-4),8/22 %36.36,21/22 %95.45,0/20 %0.0
Diarrhea (Grade 3-4),2/22 %9.09,1/22 %4.55,1/20 %5.0
Dizziness (Grade 3-4),0/22 %0.0,0/22 %0.0,1/20 %5.0
Neutropenia (Grade 3-4),12/22 %54.55,13/22 %59.09,7/20 %35.0
Febrile neutropenia (Grade 3-4),9/22 %40.91,20/22 %90.91,0/20 %0.0
Infection (Grade 3-4),5/22 %22.73,11/22 %50.0,2/20 %10.0
Bacteremia (Grade 3-4),2/22 %9.09,12/22 %54.55,0/20 %0.0
Mucositis (Grade 3-4),1/22 %4.55,0/22 %0.0,0/20 %0.0
Anemia (Grade 3-4),7/22 %31.82,19/22 %86.36,0/20 %0.0
Peripheral Neuropathy (Grade 3-4),0/22 %0.0,0/22 %0.0,8/20 %40.0
Dyspnea (Grade 3-4),1/22 %4.55,1/22 %4.55,0/20 %0.0
Pleural effusion (Grade 3-4),1/22 %4.55,1/22 %4.55,0/20 %0.0
Erectile Dysfunction (Grade 3-4),0/22 %0.0,0/22 %0.0,2/20 %10.0

A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only(https://clinicaltrials.gov/show/NCT00451178)
 ,R-CHOP and Enzastaurin,R-CHOP
 ,Chemotherapy for up to 6 cycles 21 days/cycle with R-CHOP and 500 mg Enzastaurin administered QD as four 125-mg tablets with 1125-mg loading dose (3 tablets TID) on Day 2.  R-CHOP included:  Rituximab: 375 mg/m^2 IV administration on Day 1  Cyclophosphamide: 750 mg/m^2 IV administration on Day 1  Doxorubicin: 50 mg/m^2 IV administration on Day 1  Vincristine: 1.4 mg/m^2 (maximum 2 mg) IV administration on Day 1  Prednisone: 100 mg administered orally on Days 1 through 5  Only this arm eligible for maintenance therapy (500 mg enzastaurin QD up to 3 years). This included pts who had CR CRu and/or were PET-negative. Maintenance therapy allowed at investigator's discretion if pts had PR and/or were PET-positive/equivocal or pts who discontinued therapy before 6 cycles otherwise met response criteria.,Chemotherapy for up to 6 cycles 21 days/cycle with R-CHOP.  For each cycle R-CHOP therapy included:  Rituximab: 375 mg/m^2 IV administration on Day 1  Cyclophosphamide: 750 mg/m^2 IV administration on Day 1  Doxorubicin: 50 mg/m^2 IV administration on Day 1  Vincristine: 1.4 mg/m^2 (maximum 2 mg) IV administration on Day 1  Prednisone: 100 mg administered orally on Days 1 through 5
Total serious adverse events,35/57 %61.4,18/43 %41.86
Anaemia,4/57 %7.02,1/43 %2.33
Febrile neutropenia,9/57 %15.79,3/43 %6.98
Leukopenia,0/57 %0.0,1/43 %2.33
Neutropenia,2/57 %3.51,3/43 %6.98
Thrombocytopenia,1/57 %1.75,2/43 %4.65
Angina unstable,0/57 %0.0,1/43 %2.33
Atrial fibrillation,1/57 %1.75,2/43 %4.65
Atrioventricular block,1/57 %1.75,1/43 %2.33
Cardio-respiratory arrest,1/57 %1.75,0/43 %0.0
Abdominal pain,2/57 %3.51,0/43 %0.0
Anal fistula,1/57 %1.75,0/43 %0.0
Constipation,2/57 %3.51,0/43 %0.0
Diarrhoea,1/57 %1.75,0/43 %0.0
Diverticular perforation,1/57 %1.75,0/43 %0.0
Dysphagia,1/57 %1.75,0/43 %0.0
Gastrointestinal haemorrhage,2/57 %3.51,0/43 %0.0
Nausea,1/57 %1.75,1/43 %2.33
Oesophageal disorder,0/57 %0.0,1/43 %2.33
Oesophageal ulcer haemorrhage,1/57 %1.75,0/43 %0.0
Small intestinal obstruction,0/57 %0.0,1/43 %2.33
Vomiting,0/57 %0.0,1/43 %2.33
Asthenia,1/57 %1.75,0/43 %0.0
Fatigue,1/57 %1.75,1/43 %2.33
Multi-organ failure,1/57 %1.75,0/43 %0.0
Pain,1/57 %1.75,0/43 %0.0
Pyrexia,3/57 %5.26,4/43 %9.3
Hypersensitivity,0/57 %0.0,1/43 %2.33
Alpha haemolytic streptococcal infection,1/57 %1.75,0/43 %0.0
Bacteraemia,2/57 %3.51,1/43 %2.33
Cellulitis,1/57 %1.75,0/43 %0.0
Cellulitis orbital,1/57 %1.75,0/43 %0.0
Infection,1/57 %1.75,1/43 %2.33
Neutropenic sepsis,1/57 %1.75,0/43 %0.0
Pneumonia,5/57 %8.77,2/43 %4.65
Pneumonia streptococcal,1/57 %1.75,0/43 %0.0
Sepsis,2/57 %3.51,4/43 %9.3
Septic shock,1/57 %1.75,1/43 %2.33
Tooth abscess,1/57 %1.75,0/43 %0.0
Urinary tract infection,2/57 %3.51,2/43 %4.65
Urosepsis,0/57 %0.0,1/43 %2.33
Viral upper respiratory tract infection,1/57 %1.75,0/43 %0.0
Fall,1/57 %1.75,0/43 %0.0
Femoral neck fracture,1/57 %1.75,0/43 %0.0
Fibula fracture,1/57 %1.75,0/43 %0.0
Tibia fracture,1/57 %1.75,0/43 %0.0
Alanine aminotransferase increased,0/57 %0.0,1/43 %2.33
Aspartate aminotransferase increased,0/57 %0.0,1/43 %2.33
Blood alkaline phosphatase increased,0/57 %0.0,1/43 %2.33
Haemoglobin decreased,1/57 %1.75,1/43 %2.33
Weight decreased,1/57 %1.75,0/43 %0.0
Dehydration,2/57 %3.51,0/43 %0.0
Hyperkalaemia,1/57 %1.75,0/43 %0.0
Muscular weakness,1/57 %1.75,0/43 %0.0
Pathological fracture,1/57 %1.75,0/43 %0.0
Metastases to meninges,1/57 %1.75,0/43 %0.0
Thyroid cancer,1/57 %1.75,0/43 %0.0
Hypoaesthesia,1/57 %1.75,0/43 %0.0
Neuropathy peripheral,1/57 %1.75,0/43 %0.0
Syncope,2/57 %3.51,0/43 %0.0
Depression,0/57 %0.0,1/43 %2.33
Mental status changes,1/57 %1.75,0/43 %0.0
Renal failure,0/57 %0.0,1/43 %2.33
Renal failure acute,1/57 %1.75,0/43 %0.0
Acute respiratory distress syndrome,1/57 %1.75,0/43 %0.0
Epistaxis,1/57 %1.75,0/43 %0.0
Pleural effusion,1/57 %1.75,0/43 %0.0
Pulmonary embolism,2/57 %3.51,1/43 %2.33
Decubitus ulcer,0/57 %0.0,1/43 %2.33
Deep vein thrombosis,2/57 %3.51,1/43 %2.33
Hypertension,1/57 %1.75,0/43 %0.0
Hypotension,3/57 %5.26,0/43 %0.0
Orthostatic hypotension,0/57 %0.0,1/43 %2.33

Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer(https://clinicaltrials.gov/show/NCT00455533)
 ,Ixabepilone,Paclitaxel
 ,ixabepilone 40 mg/m^2 administered intravenously (IV) over 3 hours every 3 weeks for 4 cycles (12 weeks),paclitaxel 80 mg/m^2 administered IV every week for 12 weeks
Total serious adverse events,17/145 %11.72,11/144 %7.64
ANAEMIA,0/145 %0.0,1/144 %0.69
LEUKOPENIA,2/145 %1.38,0/144 %0.0
NEUTROPENIA,1/145 %0.69,0/144 %0.0
LEUKOCYTOSIS,1/145 %0.69,0/144 %0.0
THROMBOCYTOPENIA,1/145 %0.69,0/144 %0.0
FEBRILE NEUTROPENIA,1/145 %0.69,1/144 %0.69
THROMBOTIC THROMBOCYTOPENIC PURPURA,0/145 %0.0,1/144 %0.69
DISSEMINATED INTRAVASCULAR COAGULATION,0/145 %0.0,1/144 %0.69
CARDIAC FAILURE,1/145 %0.69,0/144 %0.0
ATRIAL FIBRILLATION,1/145 %0.69,0/144 %0.0
CARDIO-RESPIRATORY ARREST,0/145 %0.0,1/144 %0.69
VOMITING,2/145 %1.38,0/144 %0.0
DIARRHOEA,4/145 %2.76,0/144 %0.0
ABDOMINAL PAIN,1/145 %0.69,0/144 %0.0
GALLSTONE ILEUS,0/145 %0.0,1/144 %0.69
FATIGUE,2/145 %1.38,1/144 %0.69
PYREXIA,0/145 %0.0,3/144 %2.08
SUDDEN DEATH,0/145 %0.0,1/144 %0.69
OEDEMA PERIPHERAL,0/145 %0.0,1/144 %0.69
HYPERBILIRUBINAEMIA,0/145 %0.0,1/144 %0.69
ANAPHYLACTIC SHOCK,1/145 %0.69,0/144 %0.0
ANAPHYLACTIC REACTION,1/145 %0.69,0/144 %0.0
SEPSIS,0/145 %0.0,1/144 %0.69
PNEUMONIA,1/145 %0.69,1/144 %0.69
URINARY TRACT INFECTION,0/145 %0.0,1/144 %0.69
RESPIRATORY TRACT INFECTION,0/145 %0.0,1/144 %0.69
OVERDOSE,3/145 %2.07,0/144 %0.0
MEDICATION ERROR,0/145 %0.0,1/144 %0.69
LOWER LIMB FRACTURE,1/145 %0.69,0/144 %0.0
HAEMOGLOBIN DECREASED,0/145 %0.0,1/144 %0.69
HYPOALBUMINAEMIA,0/145 %0.0,1/144 %0.69
MYALGIA,1/145 %0.69,1/144 %0.69
HEADACHE,0/145 %0.0,1/144 %0.69
SOMNOLENCE,1/145 %0.69,0/144 %0.0
ENCEPHALOPATHY,1/145 %0.69,0/144 %0.0
CRANIAL NEUROPATHY,0/145 %0.0,1/144 %0.69
NEUROPATHY PERIPHERAL,1/145 %0.69,0/144 %0.0
CEREBRAL VENOUS THROMBOSIS,0/145 %0.0,1/144 %0.69
PERIPHERAL SENSORY NEUROPATHY,2/145 %1.38,1/144 %0.69
DEPRESSED LEVEL OF CONSCIOUSNESS,1/145 %0.69,0/144 %0.0
COUGH,1/145 %0.69,0/144 %0.0
ASTHMA,0/145 %0.0,1/144 %0.69
HYPOXIA,0/145 %0.0,1/144 %0.69
DYSPNOEA,0/145 %0.0,3/144 %2.08
PNEUMONITIS,0/145 %0.0,1/144 %0.69
OROPHARYNGEAL PAIN,0/145 %0.0,1/144 %0.69
PULMONARY EMBOLISM,1/145 %0.69,1/144 %0.69
NON-CARDIOGENIC PULMONARY OEDEMA,0/145 %0.0,1/144 %0.69
ACUTE RESPIRATORY DISTRESS SYNDROME,0/145 %0.0,1/144 %0.69
RASH,1/145 %0.69,0/144 %0.0
URTICARIA,1/145 %0.69,0/144 %0.0
EXFOLIATIVE RASH,0/145 %0.0,1/144 %0.69
HYPOTENSION,1/145 %0.69,1/144 %0.69
PERIPHERAL ISCHAEMIA,0/145 %0.0,1/144 %0.69

Doxorubicin and Cyclophosphamide Followed by Paclitaxel  Trastuzumab  and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer(https://clinicaltrials.gov/show/NCT00482391)
 ,AC PACLITAXEL  TRASTUZUMAB & LAPATINIB
 ,The regimen consists of AC (doxorubicin 60 mg/m2 cyclophosphamide 600 mg/m2) q 14 days x 4 with pegfilgrastim followed by weekly paclitaxel (80 mg/m2) x 12 + trastuzumab (H) + lapatinib (L). Pegfilgrastim 6mg is given subcutaneously (SQ) on day # 2 of each AC. Filgrastim may be used in lieu of pegfilgrastim at the physician's discretion. Trastuzumab will be administered weekly starting with paclitaxel treatment # 1. Near the completion of all chemotherapy patients may receive trastuzumab on a q 3-weekly schedule starting as early as with paclitaxel cycle # 12. The total duration of trastuzumab from beginning to end is 52 weeks. Lapatinib will be given orally at 1000 mg daily starting with trastuzumab for a total duration of 52 weeks. Hormonal therapy such as tamoxifen or an aromatase inhibitor will be given to patients with hormone receptor positive disease at the physician's discretion. Radiation therapy to the breast or chest is recommended to patients as appropriate.
Total serious adverse events,23/95 %24.21
Edema: limb,1/95 %1.05
Hematoma,1/95 %1.05
Hemoglobin,2/95 %2.11
Leukocytes (total WBC),1/95 %1.05
Hypertension,1/95 %1.05
Hypotension,2/95 %2.11
Left ventricular diastolic dysfunction,1/95 %1.05
Prolonged QTc interval,1/95 %1.05
Sinus tachycardia,1/95 %1.05
Ocular/Visual - Other (specify),1/95 %1.05
Dehydration,1/95 %1.05
Diarrhea,3/95 %3.16
Gastrointestinal other,1/95 %1.05
Nausea,1/95 %1.05
Fatigue (asthenia lethargy malaise),1/95 %1.05
Fever,4/95 %4.21
Flu-like syndrome,1/95 %1.05
Pain - Head/headache,1/95 %1.05
Pain - Muscle,1/95 %1.05
Pain - Other (specify),1/95 %1.05
Rigors/chills,1/95 %1.05
Liver dysfunction/failure,1/95 %1.05
Inf norm ANC/gr1/2 neut-Cellulitis(skin),2/95 %2.11
Inf norm ANC/gr1/2 neut-Gingivitis(oral-gums),1/95 %1.05
Inf unknown ANC-Cellulitis(skin),1/95 %1.05
Inf unknown ANC-Pneumonia(lung),1/95 %1.05
Infection w/ Gr 3/4 neut Catheter-related,1/95 %1.05
Infection w/ Gr 3/4 neut Skin (cellulites),1/95 %1.05
Infection other,2/95 %2.11
Neutrophils/granulocytes (ANC/AGC),1/95 %1.05
Cholesterolhigh(hypercholestremia),1/95 %1.05
Cough,1/95 %1.05
Dyspnea (shortness of breath),6/95 %6.32
Pleural effusion (non-malig),1/95 %1.05
Pneumonitis/pulm infiltrates,1/95 %1.05
Thrombosis/embolism (vascular access-related),1/95 %1.05

Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Metastatic Small Cell Lung Carcinoma(https://clinicaltrials.gov/show/NCT00483509)
 ,A: NGR-hTNF + Doxorubicin
 ,NGR-hTNF plus doxorubicin  NGR-hTNF: iv q3W 0.8 mcg/sqm NGR-hTNF  Doxorubicin: iv q3W 75 mg/sqm doxorubicin 60 minutes after NGR-hTNF infusion
Total all-cause mortality,28/28 %100.0
Total serious adverse events,7/28 %25.0
Febrile neutropenia,1/28 %3.57
Neutopenia,1/28 %3.57
Anaemia,1/28 %3.57
Enteritis,1/28 %3.57
Stomatitis,1/28 %3.57
Infectious Fever,1/28 %3.57
Mucosal Inflammation,1/28 %3.57
Wound infection,1/28 %3.57
Pneumonia,1/28 %3.57
Muscular weakness,1/28 %3.57
Seizure,1/28 %3.57
Pulmonary embolism,1/28 %3.57

Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide Doxorubicin  Vincristine  Predisolone) in Follicular Lymphoma (FL) Patients(https://clinicaltrials.gov/show/NCT00494780)
 ,500 mg Ofatumumab + CHOP,1000 mg Ofatumumab + CHOP,500 mg Ofatumumab + CHOP: Extended Follow-up,1000 mg Ofatumumab + CHOP: Extended Follow-up
 ,Ofatumumab was given on Day 1 and CHOP on Day 3 of each 21-day cycle with 300 mg in Cycle 1 and 500 mg in Cycles 2 to 6. Participants were followed up for 15 weeks during the Treatment period; then every 3 months for 24 months in the Follow-up period; then every 6 months until Month 60 or withdrawal from the study.,Ofatumumab was given on Day 1 and CHOP on Day 3 of each 21-day cycle with 300 mg in Cycle 1 and 1000 mg in Cycles 2 to 6. Participants were followed up for 15 weeks during the Treatment period; then every 3 months for 24 months in the Follow-up period; then every 6 months until Month 60 or withdrawal from the study.,Ofatumumab was given on Day 1 and CHOP on Day 3 of each 21-day cycle with 300 mg in Cycle 1 and 500 mg in Cycles 2 to 6. Participants were followed up for 15 weeks during the Treatment period; then every 3 months for 24 months in the Follow-up period; then every 6 months until Month 60 or withdrawal from the study.,Ofatumumab was given on Day 1 and CHOP on Day 3 of each 21-day cycle with 300 mg in Cycle 1 and 1000 mg in Cycles 2 to 6. Participants were followed up for 15 weeks during the Treatment period; then every 3 months for 24 months in the Follow-up period; then every 6 months until Month 60 or withdrawal from the study.
Total serious adverse events,13/29 %44.83,11/29 %37.93,1/29 %3.45,6/29 %20.69
Leukopenia,5/29 %17.24,3/29 %10.34,0/29 %0.0,0/29 %0.0
Neutropenia,4/29 %13.79,3/29 %10.34,0/29 %0.0,0/29 %0.0
Febrile neutropenia,2/29 %6.9,2/29 %6.9,0/29 %0.0,0/29 %0.0
Ascites,0/29 %0.0,1/29 %3.45,0/29 %0.0,0/29 %0.0
Ileus,0/29 %0.0,1/29 %3.45,0/29 %0.0,0/29 %0.0
Nausea,0/29 %0.0,1/29 %3.45,0/29 %0.0,0/29 %0.0
Peritonitis,0/29 %0.0,1/29 %3.45,0/29 %0.0,0/29 %0.0
Small intestinal perforation,0/29 %0.0,1/29 %3.45,0/29 %0.0,0/29 %0.0
Pyrexia,2/29 %6.9,0/29 %0.0,0/29 %0.0,0/29 %0.0
Injection site extravasation,1/29 %3.45,0/29 %0.0,0/29 %0.0,0/29 %0.0
Disease progression,1/29 %3.45,0/29 %0.0,0/29 %0.0,0/29 %0.0
Abnorminal hernia,0/29 %0.0,0/29 %0.0,0/29 %0.0,2/29 %6.9
Cytokine release syndrome,1/29 %3.45,0/29 %0.0,0/29 %0.0,0/29 %0.0
Hypersensitivity,1/29 %3.45,1/29 %3.45,0/29 %0.0,0/29 %0.0
Lung infection,1/29 %3.45,0/29 %0.0,0/29 %0.0,0/29 %0.0
Candidiasis,1/29 %3.45,0/29 %0.0,0/29 %0.0,0/29 %0.0
Erysipelas,0/29 %0.0,0/29 %0.0,0/29 %0.0,1/29 %3.45
Fibula Fracture,0/29 %0.0,0/29 %0.0,1/29 %3.45,0/29 %0.0
Meniscus injury,0/29 %0.0,0/29 %0.0,0/29 %0.0,1/29 %3.45
Weight decreased,0/29 %0.0,1/29 %3.45,0/29 %0.0,0/29 %0.0
Alanine aminotransferase increased,1/29 %3.45,0/29 %0.0,0/29 %0.0,0/29 %0.0
Hyperglycemia,0/29 %0.0,1/29 %3.45,0/29 %0.0,0/29 %0.0
Periostitis,0/29 %0.0,1/29 %3.45,0/29 %0.0,0/29 %0.0
Intervertebral disc protrusion,0/29 %0.0,0/29 %0.0,0/29 %0.0,1/29 %3.45
Ovarian cancer,0/29 %0.0,1/29 %3.45,0/29 %0.0,0/29 %0.0
Prostate cancer,0/29 %0.0,1/29 %3.45,0/29 %0.0,0/29 %0.0
Basal cell carcinoma,0/29 %0.0,1/29 %3.45,0/29 %0.0,0/29 %0.0
Vulval Cancer,0/29 %0.0,0/29 %0.0,0/29 %0.0,1/29 %3.45
Migraine,0/29 %0.0,1/29 %3.45,0/29 %0.0,0/29 %0.0
Presyncope,0/29 %0.0,1/29 %3.45,0/29 %0.0,0/29 %0.0
Ovarian cyst,0/29 %0.0,1/29 %3.45,0/29 %0.0,0/29 %0.0
Precancerous skin lesion,0/29 %0.0,1/29 %3.45,0/29 %0.0,0/29 %0.0
Rosacea,0/29 %0.0,1/29 %3.45,0/29 %0.0,0/29 %0.0
Iliostomy,0/29 %0.0,1/29 %3.45,0/29 %0.0,0/29 %0.0
Infarction (CNS),0/29 %0.0,0/29 %0.0,0/29 %0.0,1/29 %3.45

NOV-002  Doxorubicin  Cyclophosphamide  and Docetaxel in Women With Newly Diagnosed Stage II or IIIC Breast Cancer(https://clinicaltrials.gov/show/NCT00499122)
 ,NOV-002 and Chemotherapy
 ,NOV-002:  Cycle 1 Day -1 only: 60 mg intravenously (IV) x 2 3 hours (+/- 30 minutes) apart  Cycles 1 - 8 Day 1: 60 mg IV 1 hour (+/- 30 minutes) prior to chemotherapy administration  Cycle 1 - 8 Days 2 - 21: 60 mg subcutaneous injections  Cyclophosphamide: 600 mg/m2 IV Cycles 1 - 4 Day 1  Doxorubicin: 60 mg/m2 IV Cycles 1 - 4 Day 1  Docetaxel: 100 mg/m2 IV Cycles 5 - 8 Day 1
Total serious adverse events,27/41 %65.85
Febrile Neutropenia,4/41 %9.76
Neutropenia,1/41 %2.44
Deep Vein Thrombosis,1/41 %2.44
Pulmonary embolism,1/41 %2.44
Femoral Artery occlusion,1/41 %2.44
Abdominal Pain,2/41 %4.88
Constipation,1/41 %2.44
Fatigue,2/41 %4.88
Headache,1/41 %2.44
Nausea,1/41 %2.44
Cellulitis,1/41 %2.44
Muscular Weakness,1/41 %2.44
Palmar-plantar erythroysaesthesia,6/41 %14.63
Sensory Neuropathy,4/41 %9.76

Sunitinib Malate  Paclitaxel  Doxorubicin Hydrochloride  and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer(https://clinicaltrials.gov/show/NCT00513695)
 ,Treatment (Neoadjuvant Chemotherapy Before Surgery)
 ,Patients receive neoadjuvant chemotherapy comprising sunitinib malate PO once daily and paclitaxel IV over 1 hour once weekly for 8-12 weeks in the absence of disease progression or unacceptable toxicity. Beginning within 3 weeks of completion of sunitinib malate and paclitaxel patients receive doxorubicin IV once weekly for 15 weeks cyclophosphamide PO once daily for 15 weeks and filgrastim SC on days 2-7 for 16 weeks in the absence of disease progression or unacceptable toxicity. Beginning 3-6 weeks after completion of chemotherapy patients undergo surgery.  sunitinib malate: Given PO  paclitaxel: Given IV  doxorubicin hydrochloride: Given IV  cyclophosphamide: Given PO  filgrastim: Given SC  therapeutic conventional surgery: Undergo surgery  laboratory biomarker analysis: Correlative studies  flow cytometry: Correlative studies
Total serious adverse events,47/68 %69.12
Neutropenia (ANC),47/68 %69.12
Leucopenia,23/68 %33.82
Anemia,15/68 %22.06
Diarrhea,3/68 %4.41
Nausea,1/68 %1.47
Fatigue,3/68 %4.41
Pain,2/68 %2.94
ALT elevation,4/68 %5.88
Sensory Neuropathy,3/68 %4.41
Mucositis,7/68 %10.29
Rash,1/68 %1.47
Nail changes,2/68 %2.94

Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System(https://clinicaltrials.gov/show/NCT00520130)
 ,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,B - Cyclosporine (AC) Arm
 ,TMS Arm  Rituximab: Rituximab: 375 mg/m2 IV day 1 for patients with CD20-positive disease  Allogenic stem cell transplant (ASCT): Allogenic stem cell transplant  Conditioning Chemotherapy: Fludarabine:30 mg/m2 per day IV infusion over 30 minutes daily On days -6 -5 -4 and -3 Cyclophosphamide:1200 mg/m2 per day IV infusion over 2 hours on Days 6 -5 -4 -3 Mesna: 1200 mg/m2 per day IV infusion Daily on days 6 -5-4 and -3  TMS: Tacrolimus: 0.02 mg/kg  start day 3. Continue IV or PO. Taper will begin at day +63 if no acute GVHD then at day +119 and discontinue at day +180 as tolerated Methotrexate: 5 mg/m2 IV over 15 minutes on days 1 3 6 and 11. Sirolimus: 12 mg PO on days -3 to 63 followed by a taper if GVHD does not develop.  FLAG: Fludarabine:25 mg/m2 per day IV over 30 minutes Daily on days 1-5 Cytarabine: 2000 mg/m2 IV over 4 hourson Days 1 2 3 4 5 Filgrastim: 5 mcg/kg per day SC beginning 24 hours PRIOR to initiation of chemotherapy,AC Arm  Rituximab: Rituximab: 375 mg/m2 IV day 1 for patients with CD20-positive disease  Cyclosporine: Cyclosporine: IV over 2 hours or orally every 12 hours on days -1 to 100 followed by a taper if GVHD does not develop.  Allogenic stem cell transplant (ASCT): Allogenic stem cell transplant  Conditioning Chemotherapy: Fludarabine:30 mg/m2 per day IV infusion over 30 minutes daily On days -6 -5 -4 and -3 Cyclophosphamide:1200 mg/m2 per day IV infusion over 2 hours on Days 6 -5 -4 -3 Mesna: 1200 mg/m2 per day IV infusion Daily on days 6 -5-4 and -3  FLAG: Fludarabine:25 mg/m2 per day IV over 30 minutes Daily on days 1-5 Cytarabine: 2000 mg/m2 IV over 4 hourson Days 1 2 3 4 5 Filgrastim: 5 mcg/kg per day SC beginning 24 hours PRIOR to initiation of chemotherapy EPOCH-F: Fludarabine:25 mg/m2 per day IV infusion over 30 minutes daily on days 1-4 Etoposide :50 mg/m2 per day continuous IV infusion over 24 hours on days 1-4 Doxorubicin:10 mg/m2/d
Total all-cause mortality,8/44 %18.18,19/45 %42.22
Total serious adverse events,36/44 %81.82,41/45 %91.11
Edema: limb,1/44 %2.27,0/45 %0.0
Edema: viscera,1/44 %2.27,0/45 %0.0
Hemoglobin,3/44 %6.82,2/45 %4.44
Hemolysis (e.g. immune hemolytic anemia drug-related hemolysis),0/44 %0.0,1/45 %2.22
Iron overload,0/44 %0.0,1/45 %2.22
Leukocytes (total WBC),0/44 %0.0,2/45 %4.44
Lymphopenia,1/44 %2.27,2/45 %4.44
Neutrophils/granulocytes (ANC/AGC),3/44 %6.82,1/45 %2.22
PTT (Partial Thromboplastin Time),1/44 %2.27,0/45 %0.0
Platelets,1/44 %2.27,2/45 %4.44
Thrombotic microangiopathy,2/44 %4.55,1/45 %2.22
Cardiac ischemia/infarction,1/44 %2.27,0/45 %0.0
Cardiopulmonary arrest cause unknown (non-fatal),1/44 %2.27,0/45 %0.0
Hypertension,0/44 %0.0,5/45 %11.11
Hypotension,3/44 %6.82,5/45 %11.11
Left ventricular diastolic dysfunction,1/44 %2.27,1/45 %2.22
Left ventricular systolic dysfunction,2/44 %4.55,4/45 %8.89
Right ventricular dysfunction (cor pulmonale),0/44 %0.0,1/45 %2.22
Supraventricular and nodal arrhythmia::Atrial fibrillation,3/44 %6.82,0/45 %0.0
Supraventricular and nodal arrhythmia::Sinus tachycardia,0/44 %0.0,2/45 %4.44
Supraventricular and nodal arrhythmia::Supraventricular tachycardia,0/44 %0.0,1/45 %2.22
Ventricular arrhythmia::Ventricular tachycardia,0/44 %0.0,1/45 %2.22
Adrenal insufficiency,0/44 %0.0,1/45 %2.22
Pancreatic endocrine: glucose intolerance,2/44 %4.55,1/45 %2.22
Dry eye syndrome,3/44 %6.82,0/45 %0.0
Ocular/Visual - Other,0/44 %0.0,1/45 %2.22
Colitis,0/44 %0.0,1/45 %2.22
Colitis infectious (e.g. Clostridium difficile),5/44 %11.36,7/45 %15.56
Diarrhea,8/44 %18.18,8/45 %17.78
Dysphagia (difficulty swallowing),1/44 %2.27,2/45 %4.44
Esophagitis,0/44 %0.0,1/45 %2.22
Gastritis (including bile reflux gastritis),2/44 %4.55,0/45 %0.0
Heartburn/dyspepsia,0/44 %0.0,1/45 %2.22
Hemorrhage GI::Abdomen NOS,0/44 %0.0,1/45 %2.22
Hemorrhage GI::Duodenum,0/44 %0.0,1/45 %2.22
Hemorrhage GI::Lower GI NOS,0/44 %0.0,3/45 %6.67
Hemorrhage GI::Rectum,0/44 %0.0,1/45 %2.22
Hemorrhage GI::Upper GI NOS,0/44 %0.0,1/45 %2.22
Ileus GI (functional obstruction of bowel i.e. neuroconstipation),1/44 %2.27,1/45 %2.22
Mucositis/stomatitis (clinical exam)::Oral cavity,3/44 %6.82,0/45 %0.0
Mucositis/stomatitis (functional/symptomatic)::Oral cavity,1/44 %2.27,0/45 %0.0
Nausea,1/44 %2.27,2/45 %4.44
Pain::Abdomen NOS,1/44 %2.27,0/45 %0.0
Perforation GI::Small bowel NOS,1/44 %2.27,0/45 %0.0
Stricture/stenosis (including anastomotic) GI::Esophagus,1/44 %2.27,0/45 %0.0
Ulcer GI::Duodenum,1/44 %2.27,0/45 %0.0
Death not associated with CTCAE term::Death NOS,4/44 %9.09,7/45 %15.56
Death not associated with CTCAE term::Disease progression NOS,3/44 %6.82,10/45 %22.22
Death not associated with CTCAE term::Multi-organ failure,1/44 %2.27,2/45 %4.44
Fatigue (asthenia lethargy malaise),0/44 %0.0,1/45 %2.22
Fever (in the absence of neutropenia where neutropenia is defined as ANC <1.0 x 10e9/L),2/44 %4.55,1/45 %2.22
Tumor lysis syndrome,0/44 %0.0,1/45 %2.22
Weight gain,0/44 %0.0,1/45 %2.22
Cholecystitis,1/44 %2.27,1/45 %2.22
Liver dysfunction/failure (clinical),1/44 %2.27,0/45 %0.0
Allergic reaction/hypersensitivity (including drug fever),2/44 %4.55,0/45 %0.0
Cytokine release syndrome/acute infusion reaction,0/44 %0.0,1/45 %2.22
Febrile neutropenia,6/44 %13.64,6/45 %13.33
Infection:: Abdomen NOS,0/44 %0.0,1/45 %2.22
Infection ::Bladder (urinary),0/44 %0.0,1/45 %2.22
Infection ::Blood,3/44 %6.82,8/45 %17.78
Infection::Catheter-related,1/44 %2.27,4/45 %8.89
Infection ::Lip/perioral,0/44 %0.0,1/45 %2.22
Infection ::Lung (pneumonia),4/44 %9.09,3/45 %6.67
Infection::Meninges (meningitis),1/44 %2.27,0/45 %0.0
Infection ::Muscle (infection myositis),0/44 %0.0,1/45 %2.22
Infection::Nose,0/44 %0.0,1/45 %2.22
Infection::Rectum,1/44 %2.27,0/45 %0.0
Infection::Sinus,2/44 %4.55,2/45 %4.44
Infection ::Trachea,1/44 %2.27,0/45 %0.0
Infection::Upper airway NOS,0/44 %0.0,1/45 %2.22
Infection ::Urinary tract NOS,2/44 %4.55,1/45 %2.22
Infection - Other,1/44 %2.27,2/45 %4.44
Infection with normal ANC or Grade 1 or 2 neutrophils::Bladder (urinary),1/44 %2.27,1/45 %2.22
Infection with normal ANC or Grade 1 or 2 neutrophils::Blood,9/44 %20.45,21/45 %46.67
Infection with normal ANC or Grade 1 or 2 neutrophils::Brain (encephalitis infectious),3/44 %6.82,0/45 %0.0
Infection with normal ANC or Grade 1 or 2 neutrophils::Bronchus,2/44 %4.55,1/45 %2.22
Infection with normal ANC or Grade 1 or 2 neutrophils::Catheter-related,4/44 %9.09,12/45 %26.67
Infection with normal ANC or Grade 1 or 2 neutrophils::Colon,0/44 %0.0,1/45 %2.22
Infection with normal ANC or Grade 1 or 2 neutrophils::Esophagus,1/44 %2.27,0/45 %0.0
Infection with normal ANC or Grade 1 or 2 neutrophils::Heart (endocarditis),1/44 %2.27,0/45 %0.0
Infection with normal ANC or Grade 1 or 2 neutrophils::Liver,1/44 %2.27,1/45 %2.22
Infection with normal ANC or Grade 1 or 2 neutrophils::Lung (pneumonia),10/44 %22.73,13/45 %28.89
Infection with normal ANC or Grade 1 or 2 neutrophils::Meninges (meningitis),1/44 %2.27,0/45 %0.0
Infection with normal ANC or Grade 1 or 2 neutrophils::Paranasal,1/44 %2.27,0/45 %0.0
Infection with normal ANC or Grade 1 or 2 neutrophils::Pharynx,2/44 %4.55,1/45 %2.22
Infection with normal ANC or Grade 1 or 2 neutrophils::Sinus,4/44 %9.09,6/45 %13.33
Infection with normal ANC or Grade 1 or 2 neutrophils::Skin (cellulitis),2/44 %4.55,4/45 %8.89
Infection with normal ANC or Grade 1 or 2 neutrophils::Stomach,0/44 %0.0,1/45 %2.22
Infection with normal ANC or Grade 1 or 2 neutrophils::Upper airway NOS,0/44 %0.0,1/45 %2.22
Infection with normal ANC or Grade 1 or 2 neutrophils::Urinary tract NOS,1/44 %2.27,3/45 %6.67
Infection with normal ANC or Grade 1 or 2 neutrophils::Wound,1/44 %2.27,1/45 %2.22
Infection with unknown ANC::Blood,2/44 %4.55,2/45 %4.44
Infection with unknown ANC::Catheter-related,1/44 %2.27,0/45 %0.0
Infection with unknown ANC::Colon,1/44 %2.27,0/45 %0.0
Infection with unknown ANC::Lung (pneumonia),2/44 %4.55,1/45 %2.22
ALT SGPT (serum glutamic pyruvic transaminase),4/44 %9.09,1/45 %2.22
AST SGOT(serum glutamic oxaloacetic transaminase),4/44 %9.09,1/45 %2.22
Albumin serum-low (hypoalbuminemia),1/44 %2.27,1/45 %2.22
Alkaline phosphatase,1/44 %2.27,0/45 %0.0
Bilirubin (hyperbilirubinemia),3/44 %6.82,2/45 %4.44
Creatinine,3/44 %6.82,2/45 %4.44
Magnesium serum-low (hypomagnesemia),0/44 %0.0,1/45 %2.22
Phosphate serum-low (hypophosphatemia),1/44 %2.27,1/45 %2.22
Potassium serum-high (hyperkalemia),0/44 %0.0,1/45 %2.22
Potassium serum-low (hypokalemia),0/44 %0.0,1/45 %2.22
Sodium serum-low (hyponatremia),1/44 %2.27,0/45 %0.0
Uric acid serum-high (hyperuricemia),0/44 %0.0,1/45 %2.22
Arthritis (non-septic),1/44 %2.27,0/45 %0.0
Muscle weakness generalized or specific area (not due to neuropathy)::Right-sided,0/44 %0.0,1/45 %2.22
Musculoskeletal/Soft Tissue - Other,0/44 %0.0,1/45 %2.22
Myositis (inflammation/damage of muscle),0/44 %0.0,2/45 %4.44
Pain::Back,0/44 %0.0,1/45 %2.22
Secondary Malignancy - possibly related to cancer treatment (AML);,0/44 %0.0,4/45 %8.89
Secondary Malignancy - possibly related to cancer treatment (metastat. test cancer in lung),1/44 %2.27,0/45 %0.0
Ataxia (incoordination),0/44 %0.0,1/45 %2.22
CNS cerebrovascular ischemia,0/44 %0.0,1/45 %2.22
Cognitive disturbance,0/44 %0.0,1/45 %2.22
Confusion,1/44 %2.27,1/45 %2.22
Encephalopathy,0/44 %0.0,3/45 %6.67
Hemorrhage CNS,0/44 %0.0,2/45 %4.44
Leukoencephalopathy (radiographic findings),0/44 %0.0,1/45 %2.22
Seizure,0/44 %0.0,1/45 %2.22
Somnolence/depressed level of consciousness,0/44 %0.0,1/45 %2.22
Cystitis,1/44 %2.27,0/45 %0.0
Renal failure,10/44 %22.73,6/45 %13.33
Renal/Genitourinary - Other (AKI required CVVH),0/44 %0.0,1/45 %2.22
Adult Respiratory Distress Syndrome (ARDS),0/44 %0.0,5/45 %11.11
Carbon monoxide diffusion capacity (DL(co)),0/44 %0.0,1/45 %2.22
Dyspnea (shortness of breath),4/44 %9.09,3/45 %6.67
Hemorrhage pulmonary/upper respiratory::Lung,1/44 %2.27,1/45 %2.22
Hemorrhage pulmonary/upper respiratory::Nose,0/44 %0.0,1/45 %2.22
Hypoxia,7/44 %15.91,8/45 %17.78
Pericardial effusion (non-malignant),2/44 %4.55,0/45 %0.0
Pleural effusion (non-malignant),2/44 %4.55,2/45 %4.44
Pneumonitis/pulmonary infiltrates,2/44 %4.55,5/45 %11.11
Pulmonary/Upper Respiratory - Other (Specify respiratory failure),1/44 %2.27,0/45 %0.0
Pulmonary/Upper Respiratory - Other (pleural thickening),0/44 %0.0,1/45 %2.22
Dermatology/Skin - Other (Deep sclerosis per MRI GVHD possible),1/44 %2.27,0/45 %0.0
Rash/desquamation,4/44 %9.09,7/45 %15.56
Rash: hand-foot skin reaction,1/44 %2.27,0/45 %0.0
Thrombosis/embolism (vascular access-related),2/44 %4.55,0/45 %0.0
Thrombosis/thrombus/embolism,4/44 %9.09,1/45 %2.22

Sunitinib and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery(https://clinicaltrials.gov/show/NCT00524316)
 ,Treatment: Sunitinib and Chemoembolization
 ,Treatment: Cycle (C)1-Sunitinib 37.5mg po d1-7 followed by TACE with doxorubicin in lipodiol on d8 continued sunitinib 37.5mg po qd d15-36 followed by 2 weeks off. C2 onwards- sunitinib 4 weeks on and 2 weeks off with dose escalation to 50 mg in pts without any grade 3 toxicities in C1.
Total serious adverse events,16/16 %100.0
Anaemia,2/16 %12.5
Thrombocytopenia,1/16 %6.25
Abdominal pain,2/16 %12.5
Constipation,1/16 %6.25
Dysphagia,1/16 %6.25
Gastrointestinal haemorrhage,2/16 %12.5
Pancreatitis,1/16 %6.25
Fatigue,1/16 %6.25
Pyrexia,1/16 %6.25
Hyperbilirubinaemia,1/16 %6.25
Lipase increased,1/16 %6.25
Dehydration,2/16 %12.5
Hypokalaemia,1/16 %6.25
Muscular weakness,1/16 %6.25
Confusional state,1/16 %6.25
Renal failure,1/16 %6.25
Dyspnoea,1/16 %6.25
Pulmonary embolism,1/16 %6.25

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia(https://clinicaltrials.gov/show/NCT00558519)
 ,Treatment (Pediatric Regimen)
 ,Patients received induction (Course I) consolidation (Course II) interim maintenance (Course III) delayed intensification (Course IV) and long-term maintenance therapy (Course V). Please see the "Detailed Description" section for more information.
Total all-cause mortality,105/295 %35.59
Total serious adverse events,134/295 %45.42
Blood disorder,4/295 %1.36
Disseminated intravascular coagulation,1/295 %0.34
Febrile neutropenia,67/295 %22.71
Hemoglobin decreased,128/295 %43.39
Lymph node pain,1/295 %0.34
Lymphatic disorder,3/295 %1.02
Arrhythmia,1/295 %0.34
Atrial fibrillation,3/295 %1.02
Atrial flutter,3/295 %1.02
Atrial tachycardia,2/295 %0.68
Cardiac disorder,1/295 %0.34
Cardiac pain,1/295 %0.34
Conduction disorder,1/295 %0.34
Left ventricular dysfunction,1/295 %0.34
Left ventricular failure,1/295 %0.34
Myocardial ischemia,1/295 %0.34
Palpitations,4/295 %1.36
Pericardial effusion,1/295 %0.34
Right ventricular dysfunction,1/295 %0.34
Sinus arrhythmia,2/295 %0.68
Sinus bradycardia,4/295 %1.36
Sinus tachycardia,30/295 %10.17
Supraventricular tachycardia,4/295 %1.36
Ventricular fibrillation,1/295 %0.34
Ventricular tachycardia,4/295 %1.36
Ear disorder,1/295 %0.34
Ear pain,6/295 %2.03
Hearing impaired,1/295 %0.34
Tinnitus,2/295 %0.68
Adrenal insufficiency,1/295 %0.34
Cushingoid,5/295 %1.69
Dry eye syndrome,2/295 %0.68
Extraocular muscle paresis,2/295 %0.68
Eye disorder,4/295 %1.36
Eye pain,4/295 %1.36
Flashing vision,2/295 %0.68
Optic nerve edema,1/295 %0.34
Photophobia,2/295 %0.68
Retinopathy,1/295 %0.34
Vision blurred,13/295 %4.41
Watering eyes,1/295 %0.34
Abdominal distension,7/295 %2.37
Abdominal pain,44/295 %14.92
Anal hemorrhage,1/295 %0.34
Anal pain,1/295 %0.34
Colitis,6/295 %2.03
Colonic hemorrhage,4/295 %1.36
Colonic perforation,1/295 %0.34
Constipation,39/295 %13.22
Diarrhea,49/295 %16.61
Duodenal ulcer,1/295 %0.34
Dyspepsia,20/295 %6.78
Dysphagia,6/295 %2.03
Esophageal mucositis (clin exam),1/295 %0.34
Esophageal mucositis (funct/sympt),1/295 %0.34
Esophageal pain,5/295 %1.69
Fecal incontinence,1/295 %0.34
Gastritis,4/295 %1.36
Gastrointestinal disorder,4/295 %1.36
Hemorrhoids,4/295 %1.36
Ileus,1/295 %0.34
Mucositis oral (clin exam),30/295 %10.17
Nausea,95/295 %32.2
Oral hemorrhage,2/295 %0.68
Oral pain,12/295 %4.07
Pancreatic necrosis,1/295 %0.34
Pancreatitis,13/295 %4.41
Rectal hemorrhage,3/295 %1.02
Rectal pain,4/295 %1.36
Stomach pain,1/295 %0.34
Tooth disorder,1/295 %0.34
Toothache,4/295 %1.36
Typhlitis,4/295 %1.36
Upper gastrointestinal hemorrhage,1/295 %0.34
Vomiting,64/295 %21.69
Chest pain,12/295 %4.07
Chills,30/295 %10.17
Disease progression,1/295 %0.34
Edema limbs,26/295 %8.81
Facial pain,1/295 %0.34
Fatigue,87/295 %29.49
Fever,28/295 %9.49
Flu-like symptoms,1/295 %0.34
Gait abnormal,4/295 %1.36
General symptom,6/295 %2.03
Ill-defined disorder,4/295 %1.36
Injection site reaction,2/295 %0.68
Localized edema,14/295 %4.75
Multi-organ failure,1/295 %0.34
Pain,29/295 %9.83
Bile duct stenosis,1/295 %0.34
Cholecystitis,1/295 %0.34
Hepatic failure,7/295 %2.37
Hepatobiliary disease,5/295 %1.69
Cytokine release syndrome,1/295 %0.34
Hypersensitivity,22/295 %7.46
Immune system disorder,2/295 %0.68
Colitis infectious,4/295 %1.36
Opportunistic infection,1/295 %0.34
Urinary tract infection(gr 0/1/2 ANC),63/295 %21.36
Aortic injury,1/295 %0.34
Bruising,9/295 %3.05
Dermatitis radiation,1/295 %0.34
Intraop. inj. - Appendix,1/295 %0.34
Postoperative hemorrhage,1/295 %0.34
Seroma,1/295 %0.34
Wound dehiscence,1/295 %0.34
Activated partial throm time prolonged,35/295 %11.86
Alanine aminotransferase increased,125/295 %42.37
Alkaline phosphatase increased,56/295 %18.98
Amylase increased,14/295 %4.75
Aspartate aminotransferase increased,116/295 %39.32
Blood bilirubin increased,99/295 %33.56
Blood prolactin abnormal,1/295 %0.34
Cardiac troponin I increased,1/295 %0.34
Coagulopathy,4/295 %1.36
Creatine phosphokinase increased,1/295 %0.34
Creatinine increased,33/295 %11.19
Electrocardiogram QTc interval prolonged,2/295 %0.68
Fibrinogen decreased,73/295 %24.75
Gamma-glutamyltransferase increased,9/295 %3.05
INR increased,19/295 %6.44
Laboratory test abnormal,16/295 %5.42
Leukocyte count decreased,66/295 %22.37
Lipase increased,20/295 %6.78
Lymphocyte count decreased,45/295 %15.25
Neutrophil count decreased,126/295 %42.71
Platelet count decreased,126/295 %42.71
Serum cholesterol increased,15/295 %5.08
Weight gain,7/295 %2.37
Weight loss,18/295 %6.1
Acidosis,3/295 %1.02
Anorexia,36/295 %12.2
Blood bicarbonate decreased,8/295 %2.71
Blood glucose increased,111/295 %37.63
Blood uric acid increased,4/295 %1.36
Dehydration,12/295 %4.07
Glucose intolerance,7/295 %2.37
Obesity,1/295 %0.34
Renal tubular disorder,1/295 %0.34
Serum albumin decreased,69/295 %23.39
Serum calcium decreased,61/295 %20.68
Serum calcium increased,7/295 %2.37
Serum glucose decreased,30/295 %10.17
Serum magnesium decreased,35/295 %11.86
Serum magnesium increased,27/295 %9.15
Serum phosphate decreased,20/295 %6.78
Serum potassium decreased,59/295 %20.0
Serum potassium increased,20/295 %6.78
Serum sodium decreased,62/295 %21.02
Serum sodium increased,11/295 %3.73
Serum triglycerides increased,24/295 %8.14
Tumor lysis syndrome,3/295 %1.02
Arthralgia,21/295 %7.12
Back pain,34/295 %11.53
Buttock pain,2/295 %0.68
Chest wall pain,10/295 %3.39
Joint disorder,3/295 %1.02
Muscle weakness,9/295 %3.05
Muscle weakness lower limb,12/295 %4.07
Muscle weakness right-sided,2/295 %0.68
Muscle weakness upper limb,4/295 %1.36
Myalgia,17/295 %5.76
Myositis,3/295 %1.02
Neck pain,9/295 %3.05
Osteonecrosis,17/295 %5.76
Osteoporosis,3/295 %1.02
Pain in extremity,35/295 %11.86
Soft tissue necrosis lower limb,1/295 %0.34
Superficial soft tissue fibrosis,1/295 %0.34
Treatment related secondary malignancy,1/295 %0.34
Accessory nerve disorder,1/295 %0.34
Arachnoiditis,2/295 %0.68
Ataxia,2/295 %0.68
Central nervous system necrosis,1/295 %0.34
Cerebrospinal fluid leakage,3/295 %1.02
Depressed level of consciousness,5/295 %1.69
Dizziness,36/295 %12.2
Dysgeusia,9/295 %3.05
Encephalopathy,2/295 %0.68
Extrapyramidal disorder,1/295 %0.34
Facial muscle weakness,1/295 %0.34
Headache,86/295 %29.15
Hypoglossal nerve disorder,2/295 %0.68
Intracranial hemorrhage,2/295 %0.68
Ischemia cerebrovascular,2/295 %0.68
Leukoencephalopathy,2/295 %0.68
Memory impairment,4/295 %1.36
Mini mental status examination abnormal,1/295 %0.34
Neuralgia,1/295 %0.34
Neurological disorder NOS,8/295 %2.71
Oculomotor nerve disorder,1/295 %0.34
Peripheral motor neuropathy,14/295 %4.75
Peripheral sensory neuropathy,68/295 %23.05
Seizure,10/295 %3.39
Speech disorder,7/295 %2.37
Syncope,4/295 %1.36
Tremor,5/295 %1.69
Trigeminal nerve disorder,1/295 %0.34
Agitation,4/295 %1.36
Anxiety,22/295 %7.46
Confusion,9/295 %3.05
Depression,26/295 %8.81
Euphoria,1/295 %0.34
Insomnia,41/295 %13.9
Libido decreased,1/295 %0.34
Psychosis,5/295 %1.69
Bladder spasm,1/295 %0.34
Cystitis,1/295 %0.34
Glomerular filtration rate decreased,1/295 %0.34
Hemorrhage urinary tract,1/295 %0.34
Kidney pain,1/295 %0.34
Renal failure,8/295 %2.71
Urethral pain,2/295 %0.68
Urinary frequency,4/295 %1.36
Urinary incontinence,3/295 %1.02
Urine discoloration,5/295 %1.69
Urogenital disorder,2/295 %0.68
Erectile dysfunction,1/295 %0.34
Pelvic pain,1/295 %0.34
Reproductive tract disorder,1/295 %0.34
Scrotal pain,1/295 %0.34
Vaginal hemorrhage,9/295 %3.05
Adult respiratory distress syndrome,2/295 %0.68
Allergic rhinitis,10/295 %3.39
Aspiration,1/295 %0.34
Atelectasis,3/295 %1.02
Bronchopulmonary hemorrhage,1/295 %0.34
Bronchospasm,1/295 %0.34
Cough,32/295 %10.85
Dyspnea,30/295 %10.17
Epistaxis,15/295 %5.08
Hiccups,10/295 %3.39
Hypoxia,12/295 %4.07
Laryngeal stenosis,1/295 %0.34
Nasal congestion,2/295 %0.68
Pharyngeal mucositis (clin exam),2/295 %0.68
Pharyngolaryngeal pain,18/295 %6.1
Pleural effusion,5/295 %1.69
Pleuritic pain,3/295 %1.02
Pneumonitis,7/295 %2.37
Pneumothorax,3/295 %1.02
Respiratory disorder,7/295 %2.37
Voice alteration,2/295 %0.68
Alopecia,20/295 %6.78
Decubitus ulcer,1/295 %0.34
Dry skin,3/295 %1.02
Erythema multiforme,3/295 %1.02
Hand-and-foot syndrome/reaction,1/295 %0.34
Nail disorder,1/295 %0.34
Petechiae,8/295 %2.71
Photosensitivity,1/295 %0.34
Pruritus,7/295 %2.37
Rash acneiform,6/295 %2.03
Rash desquamating,26/295 %8.81
Scalp pain,1/295 %0.34
Skin disorder,6/295 %2.03
Skin hyperpigmentation,1/295 %0.34
Skin hypopigmentation,1/295 %0.34
Skin induration,1/295 %0.34
Skin striae,1/295 %0.34
Skin ulceration,6/295 %2.03
Sweating,15/295 %5.08
Urticaria,4/295 %1.36
Flushing,1/295 %0.34
Hematoma,6/295 %2.03
Hemorrhage,3/295 %1.02
Hypertension,10/295 %3.39
Hypotension,21/295 %7.12
Thrombosis,23/295 %7.8
Vascular disorder,2/295 %0.68

Pegylated Liposomal Doxorubicin  Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM)(https://clinicaltrials.gov/show/NCT00617591)
 ,Induction and Maintenance Therapy
 ,Induction Phase Followed by Maintenance Therapy.  Patients received lenalidomide 25 mg orally on days 1-21 dexamethasone 40 mg orally on days on 1-4 and PLD 40 mg/m^2 intravenously on day 1 (reduced to 30 mg/m^2 after the initial 29 patients were treated). Cycles were repeated every 28 days.  At the best response (4-8 cycles of induction) patients could proceed with either high-dose therapy or maintenance with lenalidomide and dexamethasone at the tolerated doses on the same schedule until disease progression.  Dd-R: Lenalidomide (Revlimid) combined with Pegylated Liposomal Doxorubicin (Doxil) and Dexamethasone (Decadron) as outlined in the Detailed Description.
Total serious adverse events,26/57 %45.61
Hemoglobin,1/57 %1.75
Neutrophils/granulocytes (ANC/AGC),3/57 %5.26
Edema: limb,1/57 %1.75
Edema: trunk/genital,1/57 %1.75
Palpitations,1/57 %1.75
Supraventricular and nodal arrhythmia - Atrial,1/57 %1.75
Cardiac General - Other,2/57 %3.51
Dehydration,1/57 %1.75
Diarrhea,1/57 %1.75
Nausea,1/57 %1.75
Vomiting,1/57 %1.75
Constitutional Symptoms - Other,2/57 %3.51
Fever (in the absence of neutropenia where neutropenia is defined as ANC <1.0 x 10^9/L),4/57 %7.02
Pain - NOS,1/57 %1.75
Syndromes - Other,1/57 %1.75
Febrile neutropenia,2/57 %3.51
Infection(documented clinically or microbiologically) w/Grade 3 or 4 neutrophils - Lung(pneumonia),1/57 %1.75
Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Sinus,1/57 %1.75
Infection - Other,1/57 %1.75
Infection with normal ANC or Grade 1 or 2 neutrophils - Bladder (urinary),1/57 %1.75
Infection with normal ANC or Grade 1 or 2 neutrophils - Blood,1/57 %1.75
Infection with normal ANC or Grade 1 or 2 neutrophils - Foreign body,1/57 %1.75
Infection with normal ANC or Grade 1 or 2 neutrophils - Oral cavity-gums (gingivitis),1/57 %1.75
Infection with unknown ANC - Lung (pneumonia),1/57 %1.75
Magnesium serum-low (hypomagnesemia),1/57 %1.75
Potassium serum-low (hypokalemia),2/57 %3.51
Fracture,4/57 %7.02
Muscle weakness generalized or specific area (not due to neuropathy) - Whole body/generalized,1/57 %1.75
Musculoskeletal/Soft Tissue - Other,1/57 %1.75
Confusion,1/57 %1.75
Renal failure,1/57 %1.75
Dyspnea (shortness of breath),3/57 %5.26
Pleural effusion (non-malignant),1/57 %1.75
Pulmonary/Upper Respiratory - Other,4/57 %7.02
Rash/desquamation,2/57 %3.51
Thrombosis/thrombus/embolism,4/57 %7.02

A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720)(https://clinicaltrials.gov/show/NCT00617890)
 ,Group 1: 0.3mg/kg,Group 1: 10mg/kg,Group 2: 10mg/kg,Group 3: 10mg/kg
 ,Participants received robatumumab 0.3 mg/kg intravenously (IV) as a single dose on Day 1 followed by surgery on Day 10 to 14 and four weeks later resumption of robatumumab 0.3 mg/kg on the same calendar day ( 3 days) once every 2 weeks until disease recurrence or up to 1 year of dosing. This group comprised participants with resectable osteosarcoma that relapsed within 6 months of prior definitive treatment (eg surgical metastasectomy) and having at least one prior chemotherapy regimen containing a platinum agent and doxorubicin.,Participants received robatumumab 10 mg/kg IV as a single dose on Day 1 followed by surgery on Day 10 to 14 and four weeks later resumption of robatumumab 10 mg/kg on the same calendar day ( 3 days) once every 2 weeks until disease recurrence or up to 1 year of dosing. This group comprised participants with resectable osteosarcoma that relapsed within 6 months of prior definitive treatment (eg surgical metastasectomy) and having at least one prior chemotherapy regimen containing a platinum agent and doxorubicin.,Participants received robatumumab 10 mg/kg IV biweekly until disease recurrence or up to 1 year of dosing. This group comprised participants with relapsed and unresectable osteosarcoma refractory to prior chemotherapy with a platinum- and doxorubicin-containing regimen.,Participants received robatumumab 10 mg/kg IV biweekly until disease recurrence or up to 1 year of dosing. This group comprised participants with Ewing's sarcoma refractory to prior treatment with at least 3 of the following agents: ifosfamide etoposide cyclophosphamide doxorubicin or vincristine.
Total serious adverse events,17/34 %50.0,8/33 %24.24,12/34 %35.29,57/115 %49.57
ANAEMIA,0/34 %0.0,0/33 %0.0,0/34 %0.0,3/115 %2.61
FEBRILE BONE MARROW APLASIA,0/34 %0.0,0/33 %0.0,0/34 %0.0,1/115 %0.87
FEBRILE NEUTROPENIA,2/34 %5.88,0/33 %0.0,0/34 %0.0,0/115 %0.0
THROMBOCYTOPENIA,0/34 %0.0,0/33 %0.0,1/34 %2.94,4/115 %3.48
ATRIAL FIBRILLATION,0/34 %0.0,0/33 %0.0,1/34 %2.94,0/115 %0.0
CARDIAC FAILURE,0/34 %0.0,0/33 %0.0,0/34 %0.0,1/115 %0.87
CARDIO-RESPIRATORY ARREST,1/34 %2.94,0/33 %0.0,0/34 %0.0,1/115 %0.87
TACHYCARDIA,0/34 %0.0,0/33 %0.0,0/34 %0.0,1/115 %0.87
APLASIA,0/34 %0.0,0/33 %0.0,0/34 %0.0,1/115 %0.87
BLINDNESS UNILATERAL,0/34 %0.0,0/33 %0.0,1/34 %2.94,1/115 %0.87
VISION BLURRED,0/34 %0.0,0/33 %0.0,0/34 %0.0,1/115 %0.87
ABDOMINAL PAIN,0/34 %0.0,0/33 %0.0,0/34 %0.0,3/115 %2.61
CONSTIPATION,0/34 %0.0,1/33 %3.03,0/34 %0.0,2/115 %1.74
DIARRHOEA,0/34 %0.0,0/33 %0.0,0/34 %0.0,1/115 %0.87
GASTROINTESTINAL PAIN,0/34 %0.0,0/33 %0.0,0/34 %0.0,1/115 %0.87
ILEUS,0/34 %0.0,0/33 %0.0,0/34 %0.0,1/115 %0.87
NAUSEA,0/34 %0.0,0/33 %0.0,0/34 %0.0,1/115 %0.87
RETROPERITONEAL HAEMORRHAGE,0/34 %0.0,0/33 %0.0,0/34 %0.0,1/115 %0.87
UPPER GASTROINTESTINAL HAEMORRHAGE,0/34 %0.0,0/33 %0.0,0/34 %0.0,1/115 %0.87
VOMITING,0/34 %0.0,0/33 %0.0,0/34 %0.0,2/115 %1.74
ASTHENIA,0/34 %0.0,0/33 %0.0,0/34 %0.0,1/115 %0.87
CHEST PAIN,0/34 %0.0,0/33 %0.0,1/34 %2.94,4/115 %3.48
CONDITION AGGRAVATED,1/34 %2.94,0/33 %0.0,0/34 %0.0,0/115 %0.0
DEVICE DISLOCATION,1/34 %2.94,0/33 %0.0,0/34 %0.0,0/115 %0.0
DRUG WITHDRAWAL SYNDROME,0/34 %0.0,0/33 %0.0,0/34 %0.0,1/115 %0.87
FATIGUE,0/34 %0.0,0/33 %0.0,0/34 %0.0,1/115 %0.87
GENERAL PHYSICAL HEALTH DETERIORATION,0/34 %0.0,0/33 %0.0,0/34 %0.0,1/115 %0.87
HYPERTHERMIA,0/34 %0.0,0/33 %0.0,0/34 %0.0,1/115 %0.87
INFLUENZA LIKE ILLNESS,0/34 %0.0,0/33 %0.0,0/34 %0.0,1/115 %0.87
MALAISE,0/34 %0.0,0/33 %0.0,0/34 %0.0,1/115 %0.87
MUCOSAL INFLAMMATION,0/34 %0.0,0/33 %0.0,0/34 %0.0,1/115 %0.87
MULTI-ORGAN FAILURE,0/34 %0.0,0/33 %0.0,0/34 %0.0,1/115 %0.87
OEDEMA PERIPHERAL,1/34 %2.94,0/33 %0.0,0/34 %0.0,0/115 %0.0
PAIN,0/34 %0.0,1/33 %3.03,0/34 %0.0,11/115 %9.57
PERFORMANCE STATUS DECREASED,0/34 %0.0,0/33 %0.0,0/34 %0.0,1/115 %0.87
PYREXIA,1/34 %2.94,1/33 %3.03,0/34 %0.0,7/115 %6.09
HEPATIC HAEMORRHAGE,0/34 %0.0,0/33 %0.0,0/34 %0.0,1/115 %0.87
JAUNDICE,0/34 %0.0,0/33 %0.0,0/34 %0.0,1/115 %0.87
APPENDICITIS,0/34 %0.0,0/33 %0.0,0/34 %0.0,1/115 %0.87
BRONCHOPNEUMONIA,1/34 %2.94,0/33 %0.0,0/34 %0.0,0/115 %0.0
CENTRAL NERVOUS SYSTEM INFECTION,0/34 %0.0,0/33 %0.0,0/34 %0.0,1/115 %0.87
GASTROENTERITIS,0/34 %0.0,0/33 %0.0,0/34 %0.0,1/115 %0.87
GASTROENTERITIS VIRAL,0/34 %0.0,0/33 %0.0,0/34 %0.0,1/115 %0.87
HERPES ZOSTER,0/34 %0.0,0/33 %0.0,0/34 %0.0,1/115 %0.87
INFECTION,0/34 %0.0,0/33 %0.0,0/34 %0.0,1/115 %0.87
OTITIS MEDIA,0/34 %0.0,0/33 %0.0,0/34 %0.0,1/115 %0.87
PNEUMONIA,1/34 %2.94,0/33 %0.0,0/34 %0.0,2/115 %1.74
PNEUMONIA VIRAL,0/34 %0.0,0/33 %0.0,0/34 %0.0,1/115 %0.87
POST PROCEDURAL INFECTION,0/34 %0.0,1/33 %3.03,0/34 %0.0,0/115 %0.0
POSTOPERATIVE WOUND INFECTION,0/34 %0.0,1/33 %3.03,0/34 %0.0,0/115 %0.0
SEPSIS,0/34 %0.0,0/33 %0.0,0/34 %0.0,1/115 %0.87
URINARY TRACT INFECTION,0/34 %0.0,0/33 %0.0,0/34 %0.0,1/115 %0.87
BRAIN HERNIATION,0/34 %0.0,0/33 %0.0,0/34 %0.0,1/115 %0.87
HUMERUS FRACTURE,0/34 %0.0,0/33 %0.0,1/34 %2.94,0/115 %0.0
POSTOPERATIVE RESPIRATORY DISTRESS,1/34 %2.94,0/33 %0.0,0/34 %0.0,0/115 %0.0
PROCEDURAL HYPOTENSION,0/34 %0.0,0/33 %0.0,1/34 %2.94,0/115 %0.0
RIB FRACTURE,0/34 %0.0,0/33 %0.0,0/34 %0.0,1/115 %0.87
TOXICITY TO VARIOUS AGENTS,0/34 %0.0,0/33 %0.0,0/34 %0.0,1/115 %0.87
WOUND NECROSIS,1/34 %2.94,0/33 %0.0,0/34 %0.0,0/115 %0.0
BIOPSY BONE ABNORMAL,0/34 %0.0,1/33 %3.03,0/34 %0.0,0/115 %0.0
BLOOD POTASSIUM DECREASED,0/34 %0.0,0/33 %0.0,1/34 %2.94,0/115 %0.0
DECREASED APPETITE,0/34 %0.0,1/33 %3.03,0/34 %0.0,2/115 %1.74
HYPERGLYCAEMIA,0/34 %0.0,0/33 %0.0,1/34 %2.94,0/115 %0.0
ARTHRALGIA,0/34 %0.0,0/33 %0.0,0/34 %0.0,2/115 %1.74
BACK PAIN,0/34 %0.0,0/33 %0.0,0/34 %0.0,3/115 %2.61
BURSITIS,0/34 %0.0,0/33 %0.0,1/34 %2.94,0/115 %0.0
FLANK PAIN,0/34 %0.0,0/33 %0.0,0/34 %0.0,1/115 %0.87
HYPERCREATINAEMIA,0/34 %0.0,0/33 %0.0,1/34 %2.94,0/115 %0.0
MUSCULOSKELETAL PAIN,0/34 %0.0,0/33 %0.0,0/34 %0.0,1/115 %0.87
CANCER PAIN,0/34 %0.0,0/33 %0.0,0/34 %0.0,1/115 %0.87
MALIGNANT PLEURAL EFFUSION,0/34 %0.0,0/33 %0.0,1/34 %2.94,0/115 %0.0
METASTASES TO LUNG,1/34 %2.94,0/33 %0.0,0/34 %0.0,0/115 %0.0
OSTEOSARCOMA RECURRENT,0/34 %0.0,1/33 %3.03,0/34 %0.0,0/115 %0.0
TUMOUR PAIN,0/34 %0.0,0/33 %0.0,0/34 %0.0,3/115 %2.61
ALTERED STATE OF CONSCIOUSNESS,0/34 %0.0,0/33 %0.0,0/34 %0.0,1/115 %0.87
COMA,0/34 %0.0,0/33 %0.0,1/34 %2.94,1/115 %0.87
CONVULSION,1/34 %2.94,0/33 %0.0,0/34 %0.0,1/115 %0.87
ENCEPHALOPATHY,0/34 %0.0,0/33 %0.0,0/34 %0.0,2/115 %1.74
HEADACHE,0/34 %0.0,0/33 %0.0,0/34 %0.0,1/115 %0.87
HEPATIC ENCEPHALOPATHY,0/34 %0.0,0/33 %0.0,0/34 %0.0,1/115 %0.87
MENINGEAL DISORDER,0/34 %0.0,0/33 %0.0,0/34 %0.0,1/115 %0.87
MYOCLONUS,0/34 %0.0,0/33 %0.0,0/34 %0.0,1/115 %0.87
NERVE COMPRESSION,0/34 %0.0,0/33 %0.0,0/34 %0.0,1/115 %0.87
PERIPHERAL SENSORY NEUROPATHY,0/34 %0.0,0/33 %0.0,0/34 %0.0,1/115 %0.87
SPINAL CORD COMPRESSION,0/34 %0.0,0/33 %0.0,0/34 %0.0,2/115 %1.74
SYNCOPE,0/34 %0.0,0/33 %0.0,0/34 %0.0,1/115 %0.87
TOXIC ENCEPHALOPATHY,0/34 %0.0,0/33 %0.0,0/34 %0.0,1/115 %0.87
AGITATION,0/34 %0.0,0/33 %0.0,1/34 %2.94,0/115 %0.0
ANXIETY,0/34 %0.0,0/33 %0.0,1/34 %2.94,0/115 %0.0
CONFUSIONAL STATE,0/34 %0.0,0/33 %0.0,1/34 %2.94,0/115 %0.0
INSOMNIA,0/34 %0.0,0/33 %0.0,1/34 %2.94,0/115 %0.0
MENTAL STATUS CHANGES,0/34 %0.0,0/33 %0.0,0/34 %0.0,1/115 %0.87
NEPHROLITHIASIS,0/34 %0.0,0/33 %0.0,0/34 %0.0,1/115 %0.87
ACUTE RESPIRATORY DISTRESS SYNDROME,0/34 %0.0,0/33 %0.0,0/34 %0.0,1/115 %0.87
ACUTE RESPIRATORY FAILURE,0/34 %0.0,0/33 %0.0,0/34 %0.0,2/115 %1.74
BRONCHIAL DISORDER,1/34 %2.94,0/33 %0.0,0/34 %0.0,0/115 %0.0
DYSPNOEA,0/34 %0.0,0/33 %0.0,2/34 %5.88,3/115 %2.61
DYSPNOEA AT REST,0/34 %0.0,0/33 %0.0,1/34 %2.94,0/115 %0.0
DYSPNOEA EXERTIONAL,0/34 %0.0,0/33 %0.0,0/34 %0.0,1/115 %0.87
EPISTAXIS,0/34 %0.0,0/33 %0.0,0/34 %0.0,2/115 %1.74
HAEMOTHORAX,1/34 %2.94,0/33 %0.0,0/34 %0.0,0/115 %0.0
HYPOXIA,0/34 %0.0,0/33 %0.0,1/34 %2.94,0/115 %0.0
PLEURAL EFFUSION,1/34 %2.94,0/33 %0.0,1/34 %2.94,0/115 %0.0
PNEUMOTHORAX,4/34 %11.76,1/33 %3.03,0/34 %0.0,1/115 %0.87
PULMONARY EMBOLISM,0/34 %0.0,0/33 %0.0,0/34 %0.0,1/115 %0.87
PULMONARY TOXICITY,0/34 %0.0,0/33 %0.0,0/34 %0.0,1/115 %0.87
RESPIRATORY DISTRESS,0/34 %0.0,0/33 %0.0,0/34 %0.0,6/115 %5.22
RESPIRATORY FAILURE,3/34 %8.82,1/33 %3.03,0/34 %0.0,5/115 %4.35
PETECHIAE,0/34 %0.0,0/33 %0.0,0/34 %0.0,1/115 %0.87
LEG AMPUTATION,1/34 %2.94,0/33 %0.0,0/34 %0.0,0/115 %0.0
MEDICAL DEVICE REMOVAL,0/34 %0.0,0/33 %0.0,0/34 %0.0,1/115 %0.87
THORACOTOMY,1/34 %2.94,0/33 %0.0,0/34 %0.0,0/115 %0.0
WOUND TREATMENT,1/34 %2.94,0/33 %0.0,0/34 %0.0,0/115 %0.0
HAEMORRHAGE,0/34 %0.0,0/33 %0.0,0/34 %0.0,1/115 %0.87
HYPOTENSION,1/34 %2.94,0/33 %0.0,0/34 %0.0,0/115 %0.0
SHOCK HAEMORRHAGIC,1/34 %2.94,0/33 %0.0,0/34 %0.0,0/115 %0.0

Two Regimens of Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Localized Ewing Sarcoma Family of Tumors(https://clinicaltrials.gov/show/NCT00618813)
 ,Treatment (Combination Chemotherapy)
 ,See Detailed Description  radiation therapy: Undergo radiation therapy  therapeutic conventional surgery: Undergo surgery  etoposide: Given IV  ifosfamide: Given IV  doxorubicin hydrochloride: Given IV  cyclophosphamide: Given IV  vincristine sulfate: Given IV  topotecan hydrochloride: Given IV  filgrastim: Given SC
Total serious adverse events,2/35 %5.71
Anemia,1/35 %2.86
Upper gastrointestinal hemorrhage,1/35 %2.86
Platelet count decreased,1/35 %2.86
Apnea,1/35 %2.86

Therapy for Locally Advanced Breast Cancer Using Doxil  Paclitaxel  and Cyclophosphamide With Avastin(https://clinicaltrials.gov/show/NCT00635050)
 ,Doxil Paclitaxel Cyclophosphamide + Avastin
 ,Two staged phase II single arm trial to evaluate the pathologic complete response rate to sequential dose dense chemotherapy using Doxil paclitaxel and cyclophosphamide with concurrent Avastin in patients with advanced invasive breast cancer.  Doxil Paclitaxel Cyclophosphamide Avastin: Regimen A: Sequential Doxil 25 mg/m2 every 2 weeks for 3 doses will be followed by paclitaxel 175 mg/m2 i.v. every 2 weeks for 3 doses then by cyclophosphamide 600 mg/M 2 i.v. every 2 weeks for 3 doses. Avastin 10 mg/kg i.v. every 2 weeks will be given concurrently with all 3 agents. Patients who experience <pCR to primary chemotherapy will receive an additional year of Avastin at the same dose equivalent beginning 6-8 weeks after definitive operation.  Regimen B: Sequential Doxil 30 mg/m2 every 2 weeks for 3 doses will be followed by paclitaxel 175 mg/m2 i.v. every 2 weeks for 3 doses then by cyclophosphamide 600 mg/m 2 i.v. every 2 weeks for 3 doses. Avastin 10 mg/kg i.v. every 2 week
Total serious adverse events,1/32 %3.12
hospitalization,1/32 %3.12

Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma(https://clinicaltrials.gov/show/NCT00653328)
 ,Altrasentan + Doxil
 ,Atrasentan 10 mg orally everyday continuously beginning on Day 1. Doxil. 50 mg/m2 intravenously every 28 days
Total serious adverse events,5/15 %33.33
Pericardial effusion,1/15 %6.67
Nausea,2/15 %13.33
Vomiting,2/15 %13.33
abdominal cramping,1/15 %6.67
Fatigue,3/15 %20.0
Death,1/15 %6.67
edema,1/15 %6.67
fever,2/15 %13.33
fatigue,2/15 %13.33
hemoglobin,2/15 %13.33
Dehydration,1/15 %6.67
Hypoalbuminemia,1/15 %6.67
Hyponatremia,1/15 %6.67
urinary frequency,1/15 %6.67
pelvic pain,1/15 %6.67
Dyspnea,2/15 %13.33
Hypoxia,1/15 %6.67
Pleural effusion,2/15 %13.33
Thromboembolism,1/15 %6.67
hot flashes,1/15 %6.67

Exploratory Study of Sunitinib Malate as a Component of Neoadjuvant Therapy for Breast Cancer(https://clinicaltrials.gov/show/NCT00656669)
 ,Single Agent Sunitinib,Paclitaxel/Sunitinib,AC Dosing
 ,Single-agent sunitinib for 2 weeks for the purpose of biomarker and IFP evaluation.,4 cycles (16 weeks) of neoadjuvant treatment with the combination of sunitinib and paclitaxel.,4 cycles (8 weeks) of neoadjuvant treatment with AC.
Total serious adverse events,0/23 %0.0,2/23 %8.7,2/16 %12.5
LEFT VENTRICULAR SYSTOLIC DYSFUNCTION,0/23 %0.0,1/23 %4.35,0/16 %0.0
NAUSEA,0/23 %0.0,1/23 %4.35,0/16 %0.0
VOMITING,0/23 %0.0,1/23 %4.35,0/16 %0.0
BILIRUBIN (HYPERBILIRUBINEMIA),0/23 %0.0,1/23 %4.35,0/16 %0.0
INFECTION (DOCUMENTED CLINICALLY OR MICROBIOLOGICALLY) WITH GRADE 3 OR 4 NEUTROPHILS (ANC <1.0 X 10E,0/23 %0.0,1/23 %4.35,0/16 %0.0
NEUTROPHILS/GRANULOCYTES (ANC/AGC),0/23 %0.0,0/23 %0.0,1/16 %6.25
FEBRILE NEUTROPENIA (FEVER OF UNKNOWN ORIGIN WITHOUT CLINICALLY OR MICROBIOLOGICALLY DOCUMENTED INFE,0/23 %0.0,0/23 %0.0,2/16 %12.5

Biomarkers in Women Receiving Chemotherapy and Celecoxib for Stage II or Stage III Breast Cancer That Can Be Removed by Surgery(https://clinicaltrials.gov/show/NCT00665457)
 ,Celecoxib
 ,Neoadjuvant chemotherapy: Patients receive docetaxel IV over 1 hour on days 1 8 and 15 oral capecitabine twice daily on days 1-14 and oral celecoxib twice daily on days 1-21. Courses repeat every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.  Patients then receive doxorubicin hydrochloride IV and cyclophosphamide IV once daily on day 1 oral celecoxib twice daily on days 1-14 and filgrastim subcutaneously once daily on days 3-10. Courses repeat every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Celecoxib is stopped one week prior to surgery.  Surgery: standard of care
Total serious adverse events,1/3 %33.33
Neutropenic Fever,1/3 %33.33

Combination Chemotherapy and Bevacizumab in Treating Women With HER2/Neu-Negative Stage II or Stage III Breast Cancer(https://clinicaltrials.gov/show/NCT00679029)
 ,Arm I
 ,AC = Doxorubicin 60 mg /M2 followed by cyclophosphamide 600 mg/M2 will be given every 2 weeks for cycles 1-4.  TG = Paclitaxel 175 mg/M2 followed by gemcitabine 1500 mg/M2 will be given every 2 weeks for cycles 5-8.  Beginning cycle 5 B1= Avastin 10 mg/kg will be given as a single IV dose following each TG treatment every 2 weeks for cycles 5-7.  N=Growth factor pegfilgastrim 6 mg will be administered subcutaneously on day 1 after AC and TG treatment every 2 weeks for 8 cycles.
Total all-cause mortality,1/15 %6.67
Total serious adverse events,4/15 %26.67
Febrile Neutropenia,1/15 %6.67
Anemia,1/15 %6.67
colonic perforation,1/15 %6.67
Other enteritis,1/15 %6.67
Other Weakness,1/15 %6.67
Lung Infection,1/15 %6.67
Platelet count decrease,1/15 %6.67
White blood cell decreased,1/15 %6.67
Neutrophil count decreased,1/15 %6.67
Other cellulitis,1/15 %6.67
dyspnea,1/15 %6.67
Other alveolar hemorrhage,1/15 %6.67

Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma(https://clinicaltrials.gov/show/NCT00715208)
 ,VELCADE R-CAP,VELCADE R-CP
 ,VELCADE rituximab cyclophosphamide prednisone and Doxorubicin,VELCADE rituximab cyclophosphamide and prednisone
Total serious adverse events,2/7 %28.57,12/48 %25.0
Febrile neutropenia,1/7 %14.29,1/48 %2.08
Neutropenia,0/7 %0.0,1/48 %2.08
Lymphadenopathy,0/7 %0.0,2/48 %4.17
Leukopenia NOS,1/7 %14.29,0/48 %0.0
Cardiac failure congestive,0/7 %0.0,1/48 %2.08
Myocardial infarction,0/7 %0.0,1/48 %2.08
Atrial fibrillation,0/7 %0.0,1/48 %2.08
Vision blurred,0/7 %0.0,1/48 %2.08
Ascites,0/7 %0.0,1/48 %2.08
Abdominal pain NOS,0/7 %0.0,1/48 %2.08
Pyrexia,1/7 %14.29,3/48 %6.25
Fatigue,0/7 %0.0,1/48 %2.08
Weakness,0/7 %0.0,1/48 %2.08
Bronchitis NOS,0/7 %0.0,1/48 %2.08
Bronchitis acute NOS,0/7 %0.0,1/48 %2.08
Pneumonia NOS,0/7 %0.0,1/48 %2.08
Bacteraemia,0/7 %0.0,1/48 %2.08
Neutropenic sepsis,1/7 %14.29,0/48 %0.0
Oropharyngeal candidiasis,1/7 %14.29,0/48 %0.0
Respiratory tract infection NOS,0/7 %0.0,1/48 %2.08
Cellulitis,0/7 %0.0,1/48 %2.08
Viral infection NOS,0/7 %0.0,1/48 %2.08
Blood culture positive,0/7 %0.0,2/48 %4.17
Electrocardiogram T wave abnormal,0/7 %0.0,1/48 %2.08
Back pain,0/7 %0.0,1/48 %2.08
Pain in limb,0/7 %0.0,1/48 %2.08
Syncope,0/7 %0.0,1/48 %2.08
Headache NOS,0/7 %0.0,1/48 %2.08
Dyspnoea NOS,0/7 %0.0,1/48 %2.08
Chronic obstructive airways disease exacerbated,0/7 %0.0,1/48 %2.08
Lung infiltration NOS,0/7 %0.0,1/48 %2.08
Pleural effusion,0/7 %0.0,1/48 %2.08
Respiratory failure (excl neonatal),0/7 %0.0,1/48 %2.08
Hypertension aggravated,0/7 %0.0,1/48 %2.08

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE)(https://clinicaltrials.gov/show/NCT00719472)
 ,Rituximab 375 mg/m^2
 ,Patients received 6 or 8 21-day cycles of CHOP (cyclophosphamide hydroxydaunorubicin [doxorubicin] Oncovin [vincristine] prednisone) or CVP (cyclophosphamide vincristine prednisone) in combination with rituximab 375 mg/m^2 administered by intravenous (IV) infusion on Day 1 of each cycle.
Total serious adverse events,107/425 %25.18
Febrile neutropenia,33/425 %7.76
Neutropenia,10/425 %2.35
Pancytopenia,7/425 %1.65
Anaemia,5/425 %1.18
Leukopenia,1/425 %0.24
Thrombocytopenia,1/425 %0.24
Cardiac arrest,2/425 %0.47
Ventricular tachycardia,2/425 %0.47
Cardiac failure congestive,3/425 %0.71
Atrial fibrillation,3/425 %0.71
Cardiomyopathy,1/425 %0.24
Acute myocardial infarction,1/425 %0.24
Abdominal pain,6/425 %1.41
Nausea,3/425 %0.71
Vomiting,3/425 %0.71
Constipation,3/425 %0.71
Small intestinal obstruction,2/425 %0.47
Pancreatitis,1/425 %0.24
Colitis,1/425 %0.24
Diarrhoea,1/425 %0.24
Faecaloma,1/425 %0.24
Gastric perforation,1/425 %0.24
Gastritis,1/425 %0.24
Intestinal mass,1/425 %0.24
Dysphagia,1/425 %0.24
Haemorrhoids,1/425 %0.24
Small intestinal perforation,1/425 %0.24
Colonic obstruction,1/425 %0.24
Megacolon,1/425 %0.24
Gastrointestinal haemorrhage,1/425 %0.24
Stomatitis,1/425 %0.24
Pyrexia,3/425 %0.71
Chest pain,3/425 %0.71
Asthenia,2/425 %0.47
Hepatic failure,2/425 %0.47
Ischaemic hepatitis,1/425 %0.24
Pneumonia,7/425 %1.65
Bronchitis,1/425 %0.24
Lung infection,1/425 %0.24
Sepsis,5/425 %1.18
Device related sepsis,1/425 %0.24
Fungal sepsis,1/425 %0.24
Neutropenic sepsis,1/425 %0.24
Septic shock,1/425 %0.24
Staphylococcal infection,2/425 %0.47
Staphylococcal sepsis,1/425 %0.24
Pseudomonal sepsis,2/425 %0.47
Gastroenteritis,1/425 %0.24
Cellulitis,1/425 %0.24
Mastitis,1/425 %0.24
Meningitis aseptic,1/425 %0.24
Hepatitis B,1/425 %0.24
Herpes zoster,1/425 %0.24
Streptococcal bacteraemia,1/425 %0.24
Urinary tract infection,1/425 %0.24
Fall,1/425 %0.24
Wound dehiscence,1/425 %0.24
Accidental overdose,1/425 %0.24
Dehydration,12/425 %2.82
Failure to thrive,1/425 %0.24
Malnutrition,1/425 %0.24
Decreased appetite,1/425 %0.24
Hypercalcaemia,1/425 %0.24
Hypoglycaemia,1/425 %0.24
Hypokalaemia,1/425 %0.24
Muscular weakness,1/425 %0.24
Musculoskeletal pain,1/425 %0.24
Breast cancer,1/425 %0.24
Lymphoma,1/425 %0.24
Cerebrovascular accident,2/425 %0.47
Cerebral ischaemia,1/425 %0.24
Convulsion,1/425 %0.24
Anxiety,1/425 %0.24
Renal failure,1/425 %0.24
Renal failure acute,1/425 %0.24
Dyspnoea,2/425 %0.47
Respiratory distress,1/425 %0.24
Acute respiratory failure,2/425 %0.47
Respiratory failure,2/425 %0.47
Pneumonia aspiration,1/425 %0.24
Pleural effusion,1/425 %0.24
Deep vein thrombosis,3/425 %0.71
Jugular vein thrombosis,1/425 %0.24
Venous thrombosis limb,1/425 %0.24
Hypotension,2/425 %0.47
Orthostatic hypotension,1/425 %0.24
Thrombosis,1/425 %0.24
Superior vena cava syndrome,1/425 %0.24

Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma(https://clinicaltrials.gov/show/NCT00722137)
 ,R-CHOP,VcR-CAP
 ,Rituximab 375 mg/m^2 Cyclophosphamide 750 mg/m^2 Doxorubicin 50 mg/m^2 Vincristine 1.4 mg/m^2 and Prednisone 100 mg/m^2 Rituximab: Rituximab intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles. Cyclophosphamide: Cyclophosphamide intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles Doxorubicin: Intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles Prednisone: Prednisone orally on Day 1 to Day 5 of a 21 day (3 week) cycle for 6 cycles Vincristine: Vincristine intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles.,Rituximab 375 mg/m^2 Cyclophosphamide 750 mg/m^2 Doxorubicin 50 mg/m^2 VELCADE 1.3 mg/m^2 and Prednisone 100 mg/m^2 Rituximab: Rituximab intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles. Cyclophosphamide: Cyclophosphamide intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles Doxorubicin: Intravenous on Day of a 21 day (3 week) cycle for 6 cycles VELCADE: VELCADE intravenous on Days 148 and 11 of a 21 day (3 week) cycle for 6 cycles Prednisone: Prednisone orally on Day 1 to Day 5 of a 21 day (3 week) cycle for 6 cycles.
Total serious adverse events,72/242 %29.75,91/240 %37.92
Febrile neutropenia,20/242 %8.26,26/240 %10.83
Neutropenia,13/242 %5.37,12/240 %5.0
Thrombocytopenia,1/242 %0.41,8/240 %3.33
Leukopenia,3/242 %1.24,6/240 %2.5
Anaemia,5/242 %2.07,4/240 %1.67
Lymphopenia,0/242 %0.0,1/240 %0.42
Bone marrow failure,0/242 %0.0,1/240 %0.42
Left ventricular dysfunction,0/242 %0.0,3/240 %1.25
Cardiac failure,0/242 %0.0,2/240 %0.83
Atrial fibrillation,2/242 %0.83,1/240 %0.42
Cardiac failure congestive,0/242 %0.0,1/240 %0.42
Cardiogenic shock,0/242 %0.0,1/240 %0.42
Myocardial ischaemia,1/242 %0.41,1/240 %0.42
Sinus tachycardia,0/242 %0.0,1/240 %0.42
Supraventricular extrasystoles,0/242 %0.0,1/240 %0.42
Acute left ventricular failure,1/242 %0.41,0/240 %0.0
Acute myocardial infarction,1/242 %0.41,0/240 %0.0
Cardiac arrest,1/242 %0.41,0/240 %0.0
Cardiac failure acute,1/242 %0.41,0/240 %0.0
Cardio-respiratory arrest,2/242 %0.83,0/240 %0.0
Cardiomyopathy,1/242 %0.41,0/240 %0.0
Cardiopulmonary failure,1/242 %0.41,0/240 %0.0
Left ventricular failure,1/242 %0.41,0/240 %0.0
Myocardial infarction,2/242 %0.83,0/240 %0.0
Tachycardia,2/242 %0.83,0/240 %0.0
Diarrhoea,3/242 %1.24,4/240 %1.67
Vomiting,1/242 %0.41,2/240 %0.83
Abdominal adhesions,0/242 %0.0,1/240 %0.42
Colitis,1/242 %0.41,1/240 %0.42
Gastritis,0/242 %0.0,1/240 %0.42
Gastrointestinal haemorrhage,0/242 %0.0,1/240 %0.42
Ileus paralytic,0/242 %0.0,1/240 %0.42
Melaena,1/242 %0.41,1/240 %0.42
Mouth ulceration,0/242 %0.0,1/240 %0.42
Oesophagitis,0/242 %0.0,1/240 %0.42
Stomatitis,2/242 %0.83,1/240 %0.42
Anal fissure,1/242 %0.41,0/240 %0.0
Constipation,1/242 %0.41,0/240 %0.0
Haematemesis,1/242 %0.41,0/240 %0.0
Pancreatitis,1/242 %0.41,0/240 %0.0
Periproctitis,1/242 %0.41,0/240 %0.0
Small intestinal obstruction,1/242 %0.41,0/240 %0.0
Pyrexia,4/242 %1.65,10/240 %4.17
Acute phase reaction,0/242 %0.0,1/240 %0.42
Asthenia,0/242 %0.0,1/240 %0.42
Chills,1/242 %0.41,1/240 %0.42
Death,0/242 %0.0,1/240 %0.42
Cardiac death,1/242 %0.41,0/240 %0.0
Chest pain,1/242 %0.41,0/240 %0.0
Fatigue,3/242 %1.24,0/240 %0.0
Oedema peripheral,1/242 %0.41,0/240 %0.0
Hepatic failure,0/242 %0.0,1/240 %0.42
Bile duct stone,1/242 %0.41,0/240 %0.0
Hepatic function abnormal,1/242 %0.41,0/240 %0.0
Pneumonia,7/242 %2.89,19/240 %7.92
Sepsis,1/242 %0.41,4/240 %1.67
Bronchitis,2/242 %0.83,2/240 %0.83
Lobar pneumonia,1/242 %0.41,2/240 %0.83
Lung infection,1/242 %0.41,2/240 %0.83
Pneumonia streptococcal,0/242 %0.0,2/240 %0.83
Septic shock,1/242 %0.41,2/240 %0.83
Abscess neck,0/242 %0.0,1/240 %0.42
Bronchopneumonia,1/242 %0.41,1/240 %0.42
Candidiasis,0/242 %0.0,1/240 %0.42
Cellulitis,0/242 %0.0,1/240 %0.42
Erysipelas,0/242 %0.0,1/240 %0.42
Hepatitis B,2/242 %0.83,1/240 %0.42
Herpes zoster,1/242 %0.41,1/240 %0.42
Klebsiella sepsis,0/242 %0.0,1/240 %0.42
Nosocomial infection,0/242 %0.0,1/240 %0.42
Parotitis,0/242 %0.0,1/240 %0.42
Pneumonia bacterial,0/242 %0.0,1/240 %0.42
Pneumonia cytomegaloviral,0/242 %0.0,1/240 %0.42
Postoperative abscess,0/242 %0.0,1/240 %0.42
Pulmonary mycosis,0/242 %0.0,1/240 %0.42
Respiratory tract infection,1/242 %0.41,1/240 %0.42
Salmonellosis,0/242 %0.0,1/240 %0.42
Upper respiratory tract infection,1/242 %0.41,1/240 %0.42
Urinary tract infection,0/242 %0.0,1/240 %0.42
Anal abscess,1/242 %0.41,0/240 %0.0
Bacterial sepsis,1/242 %0.41,0/240 %0.0
Clostridium difficile infection,1/242 %0.41,0/240 %0.0
Endocarditis bacterial,1/242 %0.41,0/240 %0.0
Escherichia urinary tract infection,1/242 %0.41,0/240 %0.0
Gastroenteritis,2/242 %0.83,0/240 %0.0
Oral fungal infection,1/242 %0.41,0/240 %0.0
Oral herpes,1/242 %0.41,0/240 %0.0
Oropharyngeal candidiasis,1/242 %0.41,0/240 %0.0
Paronychia,1/242 %0.41,0/240 %0.0
Peritonsillar abscess,1/242 %0.41,0/240 %0.0
Pulmonary tuberculosis,1/242 %0.41,0/240 %0.0
Rectal abscess,1/242 %0.41,0/240 %0.0
Tracheobronchitis,1/242 %0.41,0/240 %0.0
Femur fracture,1/242 %0.41,1/240 %0.42
Compression fracture,1/242 %0.41,0/240 %0.0
Traumatic lung injury,1/242 %0.41,0/240 %0.0
Hypokalaemia,0/242 %0.0,2/240 %0.83
Decreased appetite,0/242 %0.0,1/240 %0.42
Fluid retention,0/242 %0.0,1/240 %0.42
Hyponatraemia,0/242 %0.0,1/240 %0.42
Tumour lysis syndrome,2/242 %0.83,1/240 %0.42
Dehydration,1/242 %0.41,0/240 %0.0
Diabetes mellitus,1/242 %0.41,0/240 %0.0
Soft tissue necrosis,1/242 %0.41,0/240 %0.0
Malignant melanoma,1/242 %0.41,0/240 %0.0
Gastric cancer,0/242 %0.0,1/240 %0.42
Neuralgia,0/242 %0.0,2/240 %0.83
Autonomic neuropathy,0/242 %0.0,1/240 %0.42
Cerebral ischaemia,0/242 %0.0,1/240 %0.42
Depressed level of consciousness,0/242 %0.0,1/240 %0.42
Encephalitis,0/242 %0.0,1/240 %0.42
Peripheral sensorimotor neuropathy,0/242 %0.0,1/240 %0.42
Peripheral sensory neuropathy,0/242 %0.0,1/240 %0.42
Syncope,0/242 %0.0,1/240 %0.42
Cerebrovascular accident,1/242 %0.41,0/240 %0.0
Convulsion,1/242 %0.41,0/240 %0.0
Renal failure,1/242 %0.41,0/240 %0.0
Renal impairment,1/242 %0.41,0/240 %0.0
Pulmonary embolism,1/242 %0.41,4/240 %1.67
Pleural effusion,1/242 %0.41,3/240 %1.25
Dyspnoea,5/242 %2.07,2/240 %0.83
Acute respiratory distress syndrome,0/242 %0.0,1/240 %0.42
Aspiration,0/242 %0.0,1/240 %0.42
Pneumonia aspiration,0/242 %0.0,1/240 %0.42
Pulmonary hypertension,0/242 %0.0,1/240 %0.42
Pulmonary oedema,0/242 %0.0,1/240 %0.42
Respiratory failure,0/242 %0.0,1/240 %0.42
Tonsillar haemorrhage,0/242 %0.0,1/240 %0.42
Acute respiratory failure,1/242 %0.41,0/240 %0.0
Epistaxis,1/242 %0.41,0/240 %0.0
Lung infiltration,1/242 %0.41,0/240 %0.0
Respiratory distress,2/242 %0.83,0/240 %0.0
Hypotension,1/242 %0.41,3/240 %1.25
Orthostatic hypotension,0/242 %0.0,2/240 %0.83
Poor venous access,0/242 %0.0,2/240 %0.83
Deep vein thrombosis,3/242 %1.24,1/240 %0.42
Hypertension,0/242 %0.0,1/240 %0.42
Venous thrombosis,0/242 %0.0,1/240 %0.42

Zoledronic Acid and Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma(https://clinicaltrials.gov/show/NCT00742924)
 ,Arm 1- Chemotherapy and 1.2 mg/m2 Zoledronic Acid,Arm 2 - Chemotherapy and 2.3 mg/m2 Zoledronic Acid,Arm 3 - Chemotherapy and 3.5 mg/m2 Zoledronic Acid,Chemotherapy and 2.3 mg/m2 Zoledronic Acid After MTD
 ,(Weeks 1-11) Patients receive dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; and G-CSF SC. (Week 12) Patients undergo therapeutic conventional surgery .  (Weeks 13-25): Patients receive etoposide IV; ifosfamide IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; G-CSF SC. (Week 26) Patients may undergo surgical procedure.  (Weeks 27-36): Patients receive dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; etoposide IV; ifosfamide IV; and filgrastim (G-CSF) SC.  See Detailed Description.  cisplatin: Given IV  dexrazoxane hydrochloride: Given IV  doxorubicin hydrochloride: Given IV  etoposide: Given IV  ifosfamide: Given IV  leucovorin calcium: Given IV or orally,(Weeks 1-11) Patients receive dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; and G-CSF SC. (Week 12) Patients undergo therapeutic conventional surgery.  (Weeks 13-25): Patients receive etoposide IV; ifosfamide IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; G-CSF SC. (Week 26) Patients may undergo surgical procedure.  (Weeks 27-36): Patients receive dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; etoposide IV; ifosfamide IV; and filgrastim (G-CSF) SC.  See Detailed Description.  cisplatin: Given IV  dexrazoxane hydrochloride: Given IV  doxorubicin hydrochloride: Given IV  etoposide: Given IV  ifosfamide: Given IV  leucovorin calcium: Given IV or orally,(Weeks 1-11) Patients receive dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; and G-CSF SC. (Week 12) Patients undergo therapeutic conventional surgery.  (Weeks 13-25): Patients receive etoposide IV; ifosfamide IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; G-CSF SC. (Week 26) Patients may undergo surgical procedure.  (Weeks 27-36): Patients receive dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; etoposide IV; ifosfamide IV; and filgrastim (G-CSF) SC.  See Detailed Description.  cisplatin: Given IV  dexrazoxane hydrochloride: Given IV  doxorubicin hydrochloride: Given IV  etoposide: Given IV  ifosfamide: Given IV  leucovorin calcium: Given IV or orally,(Weeks 1-11) Patients receive dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; and G-CSF SC. (Week 12) Patients undergo therapeutic conventional surgery.(Weeks 13-25): Patients receive etoposide IV; ifosfamide IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; G-CSF SC. (Week 26) Patients may undergo surgical procedure.(Weeks 27-36): Patients receive dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; etoposide IV; ifosfamide IV; and filgrastim (G-CSF) SC.See Detailed Description.  cisplatin: Given IV  dexrazoxane hydrochloride: Given IV  doxorubicin hydrochloride: Given IV  etoposide: Given IV  ifosfamide: Given IV  leucovorin calcium: Given IV or orally
Total serious adverse events,0/6 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0

S0801 Iodine I 131 Tositumomab  Rituximab  and Combination Chemotherapy in Previously Untreated Stage II  Stage III  or Stage IV Follicular Non-Hodgkin Lymphoma(https://clinicaltrials.gov/show/NCT00770224)
 ,R-CHOP+I-131 Tositumomab,Rituximab Maintenance
 ,Cyclophosphamide 750 mg/m2 IV Day 1 Doxorubicin 50 mg/m2 IV Day 1 Vincristine 1.4 mg/m2 IV Day 1 Prednisone 100 mg PO Days 1-5 Rituximab 375 mg/m2 IV Day 1 Q 21 Days x 6 Cycles  Patients are restaged by CT scan. Unlabeled tositumomab antibody 450 mg IV within 12 after Cycle 6 of CHOP. Dosimetric dose 35 mg IV after infusion of unlabeled tositumomab antibody. Unlabeled tositumomab antibody 450 mg IV 7-14 days after dosimetric dose. Therapeutic dose 35 mg IV after infusion of unlabeled tositumomab antibody.,Rituximab 375 mg/m2 IV q 3 months x 4 years beginning 1 year after registration.
Total all-cause mortality,0/84 %0.0,0/69 %0.0
Total serious adverse events,0/84 %0.0,1/69 %1.45
Secondary Malignancy-poss rel to cancer Tx,0/84 %0.0,1/69 %1.45

S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma(https://clinicaltrials.gov/show/NCT00822120)
 ,HIV-negative: Initial ABVD,HIV-negative and PET-negative: Continued ABVD,HIV-negative and PET-positive: BEACOPP Escalated,HIV-positive: Initial ABVD,HIV-positive and PET-negative: Continued ABVD,HIV-positive and PET-positive: BEACOPP Standard
 ,Doxorubicin 25 mg/m^2 IV Bleomycin 10u/m^2 IV Vinblastine 6mg/m^2 IV Dacarbazine 375 mg/m^2 IV Days 115 Q 28 Days x 2 cycles,Doxorubicin 25 mg/m^2 IV Bleomycin 10u/m^2 IV Vinblastine 6mg/m^2 IV Dacarbazine 375 mg/m^2 IV Days 115 Q 28 Days x 4 cycles,Etoposide 200 mg/m^2 IV Days 1 2 3 Doxorubicin 35 mg/m^2 IV Day 1 Cyclophosphamide 1250 mg/m^2 IV Day 1 Procarbzine 100 mg/m^2 PO Days 1-7 Prednisone 40 mg/m^2 PO Days 1-14 Bleomycin 10u/m^2 IV Day 8 Vincristine 1.4 mg/m^2 IV Day 8 G-CSF 5mcg/kg/day SQ Days 8-14 Q 21 Days x 6 cycles,Doxorubicin 25 mg/m^2 IV Bleomycin 10u/m^2 IV Vinblastine 6mg/m^2 IV Dacarbazine 375 mg/m^2 IV Days 115 Q 28 Days x 2 cycles,Doxorubicin 25 mg/m^2 IV Bleomycin 10u/m^2 IV Vinblastine 6mg/m^2 IV Dacarbazine 375 mg/m^2 IV Days 115 Q 28 Days x 4 cycles,Etoposide 100 mg/m^2 IV Days 1 2 3 Doxorubicin 25 mg/m^2 IV Day 1 Cyclophosphamide 650 mg/m^2 IV Day 1 Procarbzine 100 mg/m^2 PO Days 1-7 Prednisone 40 mg/m^2 PO Days 1-14 Bleomycin 10u/m^2 IV Day 8 Vincristine 1.4 mg/m^2 IV Day 8 Q 21 Days x 6 cycles
Total serious adverse events,1/336 %0.3,6/270 %2.22,2/49 %4.08,1/12 %8.33,0/10 %0.0,0/1 %0.0
Febrile neutropenia,0/336 %0.0,0/270 %0.0,1/49 %2.04,0/12 %0.0,0/10 %0.0,0/1 %0.0
Hemoglobin,0/336 %0.0,1/270 %0.37,0/49 %0.0,0/12 %0.0,0/10 %0.0,0/1 %0.0
Colitis,0/336 %0.0,1/270 %0.37,0/49 %0.0,0/12 %0.0,0/10 %0.0,0/1 %0.0
Inf (clin/microbio) w/Gr 3-4 neuts - Blood,0/336 %0.0,0/270 %0.0,1/49 %2.04,0/12 %0.0,0/10 %0.0,0/1 %0.0
Infection with unknown ANC - Lung (pneumonia),0/336 %0.0,1/270 %0.37,0/49 %0.0,0/12 %0.0,0/10 %0.0,0/1 %0.0
Leukocytes (total WBC),0/336 %0.0,0/270 %0.0,0/49 %0.0,1/12 %8.33,0/10 %0.0,0/1 %0.0
Neutrophils/granulocytes (ANC/AGC),0/336 %0.0,1/270 %0.37,0/49 %0.0,1/12 %8.33,0/10 %0.0,0/1 %0.0
Sodium serum-low (hyponatremia),0/336 %0.0,0/270 %0.0,0/49 %0.0,1/12 %8.33,0/10 %0.0,0/1 %0.0
Mood alteration - agitation,1/336 %0.3,0/270 %0.0,0/49 %0.0,0/12 %0.0,0/10 %0.0,0/1 %0.0
Mood alteration - depression,1/336 %0.3,0/270 %0.0,0/49 %0.0,0/12 %0.0,0/10 %0.0,0/1 %0.0
Dyspnea (shortness of breath),0/336 %0.0,0/270 %0.0,1/49 %2.04,0/12 %0.0,0/10 %0.0,0/1 %0.0
Pneumonitis/pulmonary infiltrates,0/336 %0.0,1/270 %0.37,1/49 %2.04,0/12 %0.0,0/10 %0.0,0/1 %0.0
Thrombosis/thrombus/embolism,0/336 %0.0,2/270 %0.74,0/49 %0.0,0/12 %0.0,0/10 %0.0,0/1 %0.0

Study of Sorafenib and Transarterial Chemoembolization (TACE) to Treat Hepatocellular Carcinoma(https://clinicaltrials.gov/show/NCT00844883)
 ,Sorafenib and Drug Eluting Beads
 ,single arm  sorafenib: sorafenib: given 400 mg twice per day for as long as it is beneficial  LC Bead-TACE: LC Beads loaded with doxorubicin  Doxorubicin loaded LC Beads: given intra-arterially into the liver up to fours times in a 6 month period
Total all-cause mortality,3/50 %6.0
Total serious adverse events,8/50 %16.0
Abdominal pain,1/50 %2.0
Non-cardiac chest pain,2/50 %4.0
Overdose on pain medication,1/50 %2.0
Cholangitis,1/50 %2.0
Elevated creatinine,1/50 %2.0
Tumor rupture,1/50 %2.0
Encephalopathy,1/50 %2.0

Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Favorable-Risk Hodgkin Lymphoma(https://clinicaltrials.gov/show/NCT00846742)
 ,Stanford V Chemotherapy
 ,Ann Arbor stage IA or IIA with:  Non-bulky mediastinal disease (<33% mediastinal to thoracic ratio on chest x-ray)  < 3 nodal regions involved on the same side of the diaphragm  No extranodal extension of disease
Total all-cause mortality,1/85 %1.18
Total serious adverse events,1/85 %1.18
Leukocytes (total WBC),1/85 %1.18
Neutrophils/granulocytes (ANC/AGC),1/85 %1.18

Pegylated Liposomal Doxorubicin Hydrochloride  Bortezomib  Cyclophosphamide  and Dexamethasone in Treating Patients With Multiple Myeloma(https://clinicaltrials.gov/show/NCT00849251)
 ,Treatment (Chemotherapy and Enzyme Inhibitor)
 ,Patients receive cyclophosphamide IV or PO over 1 hour bortezomib IV over 3 minutes and dexamethasone IV or PO on days 1 8 and 15. Patients also receive pegylated liposomal doxorubicin hydrochloride IV over 1 hour on day 8. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.  cyclophosphamide: Given IV or PO  pegylated liposomal doxorubicin hydrochloride: Given IV  bortezomib: Given IV  dexamethasone: Given IV or PO
Total serious adverse events,1/31 %3.23
Thromboembolic event,1/31 %3.23

Treatment With Pazopanib for Neoadjuvant Breast Cancer(https://clinicaltrials.gov/show/NCT00849472)
 ,AC Followed by Weekly Paclitaxel and Concurrent Pazopanib
 ,Participants were treated with intravenous (IV) doxorubicin (60 milligrams per meters squared [mg/m^2]) and cyclophosphamide (AC) (600 mg/m^2) every 21 days for 4 cycles. This was followed by weekly paclitaxel (WP) 80 mg/m^2 IV on Days 1 8 and 15 every 28 days for 4 cycles given concurrently with oral pazopanib 800 mg (2 tablets taken at the same time each day either 1 hour before or 2 hours after a meal) taken daily and continuing until 7 days before surgery. Pazopanib was resumed at the same oral dose 4-6 weeks after surgery and was continued daily for 6 months.
Total serious adverse events,15/101 %14.85
Anaemia,1/101 %0.99
Febrile neutropenia,1/101 %0.99
Myocardial ischaemia,1/101 %0.99
Nausea,1/101 %0.99
Vomiting,1/101 %0.99
Pyrexia,2/101 %1.98
Herpes zoster,1/101 %0.99
Infection,2/101 %1.98
Perineal abscess,1/101 %0.99
Cellulitis,1/101 %0.99
Thermal burn,1/101 %0.99
Alanine aminotransferase increased,1/101 %0.99
Convulsion,1/101 %0.99
Depression,1/101 %0.99
Pulmonary embolism,3/101 %2.97
Hypertension,1/101 %0.99

S0800  Nab-Paclitaxel  Doxorubicin  Cyclophosphamide  and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer(https://clinicaltrials.gov/show/NCT00856492)
 ,Arm I (Nab-Paclitaxel + Bevacizumab - AC+PEG-G)),Arm II (Nab-Paclitaxel - AC+PEG-G),Arm III (AC+PEG-G - Nab-Paclitaxel)
 ,Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on day 1 and bevacizumab IV over 30- to 90-minutes on day 1 of weeks 1-12. Patients then receive doxorubicin hydrochloride IV and cyclophosphamide IV on day 1 and pegfilgrastim SC on day 2 of weeks 14 16 18 20 22 and 24.,Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on day 1 of weeks 1-12. Patients then receive doxorubicin hydrochloride IV and cyclophosphamide IV on day 1 and pegfilgrastim SC on day 2 of weeks 14 16 18 20 22 and 24.,Patients receive doxorubicin hydrochloride IV and cyclophosphamide IV on day 1 and pegfilgrastim SC on day 2 of weeks 1 3 5 7 9 and 11. Patients then receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on day 1 of weeks 14-25.
Total serious adverse events,22/96 %22.92,3/60 %5.0,3/51 %5.88
Anemia,1/96 %1.04,1/60 %1.67,1/51 %1.96
Febrile neutropenia,4/96 %4.17,1/60 %1.67,0/51 %0.0
Heart failure,1/96 %1.04,1/60 %1.67,0/51 %0.0
Abdominal pain,1/96 %1.04,0/60 %0.0,0/51 %0.0
Dysphagia,1/96 %1.04,0/60 %0.0,0/51 %0.0
Mucositis oral,1/96 %1.04,0/60 %0.0,0/51 %0.0
Nausea,1/96 %1.04,0/60 %0.0,1/51 %1.96
Vomiting,2/96 %2.08,0/60 %0.0,1/51 %1.96
Death NOS,0/96 %0.0,1/60 %1.67,0/51 %0.0
Pain,1/96 %1.04,0/60 %0.0,0/51 %0.0
Catheter related infection,1/96 %1.04,0/60 %0.0,0/51 %0.0
Enterocolitis infectious,0/96 %0.0,1/60 %1.67,0/51 %0.0
Lung infection,0/96 %0.0,0/60 %0.0,1/51 %1.96
Sepsis,2/96 %2.08,1/60 %1.67,0/51 %0.0
Skin infection,2/96 %2.08,0/60 %0.0,1/51 %1.96
Urinary tract infection,1/96 %1.04,0/60 %0.0,0/51 %0.0
Ejection fraction decreased,1/96 %1.04,0/60 %0.0,0/51 %0.0
Investigations-Other,1/96 %1.04,0/60 %0.0,0/51 %0.0
Neutrophil count decreased,5/96 %5.21,0/60 %0.0,2/51 %3.92
Platelet count decreased,1/96 %1.04,1/60 %1.67,0/51 %0.0
Weight gain,1/96 %1.04,0/60 %0.0,0/51 %0.0
White blood cell decreased,4/96 %4.17,1/60 %1.67,1/51 %1.96
Dehydration,1/96 %1.04,0/60 %0.0,0/51 %0.0
Hyperglycemia,1/96 %1.04,0/60 %0.0,0/51 %0.0
Hypokalemia,1/96 %1.04,0/60 %0.0,0/51 %0.0
Hyponatremia,1/96 %1.04,0/60 %0.0,0/51 %0.0
Pain in extremity,1/96 %1.04,0/60 %0.0,0/51 %0.0
Neoplasms benign malignant and unspecified - Other,1/96 %1.04,0/60 %0.0,0/51 %0.0
Headache,1/96 %1.04,0/60 %0.0,0/51 %0.0
Peripheral sensory neuropathy,1/96 %1.04,0/60 %0.0,0/51 %0.0
Reversible posterior leukoencephalopathy syndrome,1/96 %1.04,0/60 %0.0,0/51 %0.0
Confusion,2/96 %2.08,0/60 %0.0,0/51 %0.0
Acute kidney injury,1/96 %1.04,0/60 %0.0,0/51 %0.0
Adult respiratory distress syndrome,1/96 %1.04,0/60 %0.0,0/51 %0.0
Dyspnea,0/96 %0.0,0/60 %0.0,1/51 %1.96
Pneumonitis,2/96 %2.08,0/60 %0.0,0/51 %0.0
Respiratory failure,0/96 %0.0,1/60 %1.67,0/51 %0.0
Hypertension,2/96 %2.08,0/60 %0.0,0/51 %0.0
Thromboembolic event,2/96 %2.08,0/60 %0.0,0/51 %0.0

Addition of Vandetanib to Standard Therapy Pegliposomal Doxorubicin (PLD)(https://clinicaltrials.gov/show/NCT00862836)
 ,Vandetanib 100 mg
 ,Once daily oral Vandetanib 100 mg added to standard therapy (pegylated liposomal doxorubicin 50 mg/m2 iv every 4 weeks)
Total serious adverse events,3/14 %21.43
Arrhythmia,1/14 %7.14
Abdominal pain,1/14 %7.14
Ascites,1/14 %7.14
Ileus,1/14 %7.14
Nausea,1/14 %7.14
Vomiting,1/14 %7.14
General physical health deterioration,1/14 %7.14
Dyspnoea,1/14 %7.14

Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma(https://clinicaltrials.gov/show/NCT00873093)
 ,Pre-B ALL Relapse < 36 Mths From Dx (Chemotherapy) Age >21 Yrs,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs,T-cell ALL (Chemotherapy),T-cell Lymphoblastic Lymphoma (LL) (Chemotherapy)
 ,Re-Induction Block 1 patients receive liposomal vincristine sulfate  Prednisone pegaspargase and Doxorubicin hydrochloride. Re-Induction Block 2 patients receive Cyclophosphamide Etoposide phosphate and Methotrexate. Re-Induction Block 3 patients receive Cytarabine and L-Asparaginase. Patients receive Bortezomib on days 1 4 8 & 11 of Block 1 and days 1 4 & 8 of Block 2.,Re-Induction Block 1 patients receive liposomal vincristine sulfate  Prednisone pegaspargase and Doxorubicin hydrochloride. Re-Induction Block 2 patients receive Cyclophosphamide Etoposide phosphate and Methotrexate. Re-Induction Block 3 patients receive Cytarabine and L-Asparaginase. Patients receive Bortezomib on days 1 4 8 & 11 of Block 1 and days 1 4 & 8 of Block 2.,Re-Induction Block 1 patients receive liposomal vincristine sulfate  Prednisone pegaspargase and Doxorubicin hydrochloride. Re-Induction Block 2 patients receive Cyclophosphamide Etoposide phosphate and Methotrexate. Re-Induction Block 3 patients receive Cytarabine and L-Asparaginase. Patients receive Bortezomib on days 1 4 8 & 11 of Block 1 and days 1 4 & 8 of Block 2.,Re-Induction Block 1 patients receive liposomal vincristine sulfate  Prednisone pegaspargase and Doxorubicin hydrochloride. Re-Induction Block 2 patients receive Cyclophosphamide Etoposide phosphate and Methotrexate. Re-Induction Block 3 patients receive Cytarabine and L-Asparaginase. Patients receive Bortezomib on days 1 4 8 & 11 of Block 1 and days 1 4 & 8 of Block 2.,Re-Induction Block 1 patients receive liposomal vincristine sulfate  Prednisone pegaspargase and Doxorubicin hydrochloride. Re-Induction Block 2 patients receive Cyclophosphamide Etoposide phosphate and Methotrexate. Re-Induction Block 3 patients receive Cytarabine and L-Asparaginase. Patients receive Bortezomib on days 1 4 8 & 11 of Block 1 and days 1 4 & 8 of Block 2.
Total serious adverse events,2/4 %50.0,47/61 %77.05,40/49 %81.63,18/22 %81.82,7/10 %70.0
Anemia,0/4 %0.0,0/61 %0.0,1/49 %2.04,0/22 %0.0,0/10 %0.0
Disseminated intravascular coagulation,0/4 %0.0,1/61 %1.64,0/49 %0.0,0/22 %0.0,0/10 %0.0
Febrile neutropenia,0/4 %0.0,3/61 %4.92,3/49 %6.12,2/22 %9.09,0/10 %0.0
Cardiac arrest,0/4 %0.0,2/61 %3.28,1/49 %2.04,0/22 %0.0,0/10 %0.0
Cardiac disorders - Other specify,0/4 %0.0,0/61 %0.0,2/49 %4.08,0/22 %0.0,0/10 %0.0
Heart failure,0/4 %0.0,1/61 %1.64,1/49 %2.04,0/22 %0.0,0/10 %0.0
Left ventricular systolic dysfunction,0/4 %0.0,1/61 %1.64,0/49 %0.0,0/22 %0.0,0/10 %0.0
Pericardial tamponade,0/4 %0.0,0/61 %0.0,0/49 %0.0,0/22 %0.0,1/10 %10.0
Sinus bradycardia,0/4 %0.0,0/61 %0.0,1/49 %2.04,0/22 %0.0,0/10 %0.0
Sinus tachycardia,0/4 %0.0,0/61 %0.0,1/49 %2.04,0/22 %0.0,0/10 %0.0
Ventricular tachycardia,0/4 %0.0,1/61 %1.64,0/49 %0.0,0/22 %0.0,0/10 %0.0
Eye pain,0/4 %0.0,1/61 %1.64,0/49 %0.0,0/22 %0.0,0/10 %0.0
Abdominal pain,0/4 %0.0,2/61 %3.28,1/49 %2.04,1/22 %4.55,1/10 %10.0
Anal pain,0/4 %0.0,1/61 %1.64,0/49 %0.0,0/22 %0.0,0/10 %0.0
Colitis,0/4 %0.0,1/61 %1.64,0/49 %0.0,0/22 %0.0,0/10 %0.0
Dental caries,0/4 %0.0,1/61 %1.64,0/49 %0.0,0/22 %0.0,0/10 %0.0
Diarrhea,0/4 %0.0,1/61 %1.64,1/49 %2.04,0/22 %0.0,0/10 %0.0
Enterocolitis,0/4 %0.0,1/61 %1.64,1/49 %2.04,0/22 %0.0,0/10 %0.0
Esophagitis,0/4 %0.0,1/61 %1.64,0/49 %0.0,0/22 %0.0,0/10 %0.0
Gastric hemorrhage,0/4 %0.0,1/61 %1.64,0/49 %0.0,0/22 %0.0,0/10 %0.0
Ileus,0/4 %0.0,0/61 %0.0,1/49 %2.04,1/22 %4.55,0/10 %0.0
Lower gastrointestinal hemorrhage,0/4 %0.0,1/61 %1.64,0/49 %0.0,0/22 %0.0,0/10 %0.0
Mucositis oral,0/4 %0.0,3/61 %4.92,1/49 %2.04,1/22 %4.55,0/10 %0.0
Nausea,0/4 %0.0,2/61 %3.28,1/49 %2.04,0/22 %0.0,0/10 %0.0
Oral pain,0/4 %0.0,1/61 %1.64,0/49 %0.0,0/22 %0.0,0/10 %0.0
Pancreatic necrosis,0/4 %0.0,0/61 %0.0,0/49 %0.0,0/22 %0.0,1/10 %10.0
Pancreatitis,0/4 %0.0,1/61 %1.64,3/49 %6.12,3/22 %13.64,1/10 %10.0
Peritoneal necrosis,0/4 %0.0,1/61 %1.64,0/49 %0.0,0/22 %0.0,0/10 %0.0
Rectal fistula,0/4 %0.0,1/61 %1.64,0/49 %0.0,0/22 %0.0,0/10 %0.0
Typhlitis,0/4 %0.0,4/61 %6.56,1/49 %2.04,2/22 %9.09,1/10 %10.0
Vomiting,0/4 %0.0,0/61 %0.0,1/49 %2.04,0/22 %0.0,0/10 %0.0
Chills,0/4 %0.0,0/61 %0.0,1/49 %2.04,1/22 %4.55,0/10 %0.0
Death NOS,2/4 %50.0,24/61 %39.34,24/49 %48.98,9/22 %40.91,5/10 %50.0
Fever,0/4 %0.0,1/61 %1.64,2/49 %4.08,0/22 %0.0,0/10 %0.0
Flu like symptoms,0/4 %0.0,0/61 %0.0,1/49 %2.04,0/22 %0.0,0/10 %0.0
Hypothermia,0/4 %0.0,0/61 %0.0,1/49 %2.04,0/22 %0.0,0/10 %0.0
Multi-organ failure,0/4 %0.0,3/61 %4.92,0/49 %0.0,0/22 %0.0,0/10 %0.0
Pain,0/4 %0.0,1/61 %1.64,0/49 %0.0,1/22 %4.55,0/10 %0.0
Hepatobiliary disorders - Other specify,0/4 %0.0,1/61 %1.64,0/49 %0.0,0/22 %0.0,0/10 %0.0
Allergic reaction,0/4 %0.0,2/61 %3.28,0/49 %0.0,0/22 %0.0,0/10 %0.0
Cytokine release syndrome,0/4 %0.0,1/61 %1.64,0/49 %0.0,0/22 %0.0,0/10 %0.0
Appendicitis,0/4 %0.0,0/61 %0.0,1/49 %2.04,0/22 %0.0,0/10 %0.0
Appendicitis perforated,0/4 %0.0,1/61 %1.64,0/49 %0.0,1/22 %4.55,0/10 %0.0
Catheter related infection,0/4 %0.0,3/61 %4.92,1/49 %2.04,0/22 %0.0,0/10 %0.0
Encephalitis infection,0/4 %0.0,0/61 %0.0,1/49 %2.04,0/22 %0.0,0/10 %0.0
Enterocolitis infectious,0/4 %0.0,1/61 %1.64,0/49 %0.0,0/22 %0.0,0/10 %0.0
Infections and infestations - Other specify,0/4 %0.0,5/61 %8.2,3/49 %6.12,2/22 %9.09,1/10 %10.0
Infective myositis,0/4 %0.0,1/61 %1.64,0/49 %0.0,0/22 %0.0,0/10 %0.0
Joint infection,0/4 %0.0,1/61 %1.64,0/49 %0.0,0/22 %0.0,0/10 %0.0
Lung infection,0/4 %0.0,2/61 %3.28,2/49 %4.08,0/22 %0.0,1/10 %10.0
Mucosal infection,0/4 %0.0,2/61 %3.28,1/49 %2.04,0/22 %0.0,0/10 %0.0
Papulopustular rash,0/4 %0.0,1/61 %1.64,0/49 %0.0,0/22 %0.0,0/10 %0.0
Pharyngitis,0/4 %0.0,1/61 %1.64,0/49 %0.0,0/22 %0.0,0/10 %0.0
Sepsis,0/4 %0.0,8/61 %13.11,8/49 %16.33,2/22 %9.09,1/10 %10.0
Sinusitis,0/4 %0.0,1/61 %1.64,0/49 %0.0,0/22 %0.0,0/10 %0.0
Soft tissue infection,0/4 %0.0,0/61 %0.0,1/49 %2.04,0/22 %0.0,0/10 %0.0
Urinary tract infection,0/4 %0.0,0/61 %0.0,0/49 %0.0,0/22 %0.0,1/10 %10.0
Alanine aminotransferase increased,0/4 %0.0,1/61 %1.64,0/49 %0.0,1/22 %4.55,0/10 %0.0
Aspartate aminotransferase increased,0/4 %0.0,1/61 %1.64,0/49 %0.0,0/22 %0.0,0/10 %0.0
Blood bilirubin increased,1/4 %25.0,0/61 %0.0,0/49 %0.0,2/22 %9.09,1/10 %10.0
Cholesterol high,0/4 %0.0,0/61 %0.0,0/49 %0.0,1/22 %4.55,0/10 %0.0
Creatinine increased,0/4 %0.0,0/61 %0.0,1/49 %2.04,0/22 %0.0,0/10 %0.0
Investigations - Other specify,0/4 %0.0,0/61 %0.0,0/49 %0.0,0/22 %0.0,1/10 %10.0
Lipase increased,0/4 %0.0,2/61 %3.28,0/49 %0.0,3/22 %13.64,1/10 %10.0
Neutrophil count decreased,0/4 %0.0,1/61 %1.64,0/49 %0.0,0/22 %0.0,0/10 %0.0
Platelet count decreased,0/4 %0.0,1/61 %1.64,2/49 %4.08,0/22 %0.0,0/10 %0.0
Serum amylase increased,0/4 %0.0,0/61 %0.0,0/49 %0.0,1/22 %4.55,1/10 %10.0
White blood cell decreased,0/4 %0.0,1/61 %1.64,2/49 %4.08,0/22 %0.0,0/10 %0.0
Acidosis,0/4 %0.0,2/61 %3.28,1/49 %2.04,0/22 %0.0,0/10 %0.0
Anorexia,0/4 %0.0,3/61 %4.92,0/49 %0.0,0/22 %0.0,0/10 %0.0
Dehydration,0/4 %0.0,1/61 %1.64,0/49 %0.0,0/22 %0.0,0/10 %0.0
Hyperglycemia,0/4 %0.0,1/61 %1.64,1/49 %2.04,1/22 %4.55,0/10 %0.0
Hyperkalemia,0/4 %0.0,1/61 %1.64,1/49 %2.04,0/22 %0.0,0/10 %0.0
Hypernatremia,0/4 %0.0,1/61 %1.64,0/49 %0.0,0/22 %0.0,0/10 %0.0
Hypertriglyceridemia,0/4 %0.0,1/61 %1.64,1/49 %2.04,1/22 %4.55,1/10 %10.0
Hypoalbuminemia,0/4 %0.0,1/61 %1.64,1/49 %2.04,2/22 %9.09,0/10 %0.0
Hypocalcemia,0/4 %0.0,0/61 %0.0,0/49 %0.0,2/22 %9.09,0/10 %0.0
Hypokalemia,0/4 %0.0,8/61 %13.11,1/49 %2.04,1/22 %4.55,0/10 %0.0
Hyponatremia,0/4 %0.0,4/61 %6.56,4/49 %8.16,1/22 %4.55,1/10 %10.0
Hypophosphatemia,0/4 %0.0,0/61 %0.0,0/49 %0.0,0/22 %0.0,1/10 %10.0
Tumor lysis syndrome,0/4 %0.0,0/61 %0.0,0/49 %0.0,1/22 %4.55,0/10 %0.0
Arthralgia,0/4 %0.0,1/61 %1.64,0/49 %0.0,0/22 %0.0,0/10 %0.0
Back pain,0/4 %0.0,2/61 %3.28,0/49 %0.0,0/22 %0.0,0/10 %0.0
Joint effusion,0/4 %0.0,1/61 %1.64,0/49 %0.0,0/22 %0.0,0/10 %0.0
Pain in extremity,0/4 %0.0,2/61 %3.28,0/49 %0.0,0/22 %0.0,0/10 %0.0
Neoplasms benign malignant and unspecified (incl cysts and polyps) - Other specify,0/4 %0.0,3/61 %4.92,4/49 %8.16,2/22 %9.09,0/10 %0.0
Akathisia,0/4 %0.0,0/61 %0.0,0/49 %0.0,1/22 %4.55,0/10 %0.0
Depressed level of consciousness,0/4 %0.0,1/61 %1.64,1/49 %2.04,0/22 %0.0,0/10 %0.0
Dysarthria,0/4 %0.0,1/61 %1.64,0/49 %0.0,0/22 %0.0,0/10 %0.0
Encephalopathy,0/4 %0.0,1/61 %1.64,0/49 %0.0,0/22 %0.0,0/10 %0.0
Headache,0/4 %0.0,2/61 %3.28,1/49 %2.04,0/22 %0.0,0/10 %0.0
Memory impairment,0/4 %0.0,0/61 %0.0,0/49 %0.0,1/22 %4.55,0/10 %0.0
Nervous system disorders - Other specify,0/4 %0.0,1/61 %1.64,0/49 %0.0,0/22 %0.0,0/10 %0.0
Neuralgia,0/4 %0.0,1/61 %1.64,0/49 %0.0,0/22 %0.0,0/10 %0.0
Paresthesia,0/4 %0.0,0/61 %0.0,0/49 %0.0,1/22 %4.55,0/10 %0.0
Peripheral sensory neuropathy,1/4 %25.0,0/61 %0.0,1/49 %2.04,1/22 %4.55,0/10 %0.0
Reversible posterior leukoencephalopathy syndrome,0/4 %0.0,0/61 %0.0,1/49 %2.04,0/22 %0.0,0/10 %0.0
Seizure,0/4 %0.0,2/61 %3.28,1/49 %2.04,0/22 %0.0,0/10 %0.0
Stroke,0/4 %0.0,0/61 %0.0,2/49 %4.08,0/22 %0.0,0/10 %0.0
Syncope,0/4 %0.0,1/61 %1.64,0/49 %0.0,0/22 %0.0,0/10 %0.0
Anxiety,0/4 %0.0,0/61 %0.0,0/49 %0.0,1/22 %4.55,0/10 %0.0
Confusion,0/4 %0.0,0/61 %0.0,0/49 %0.0,1/22 %4.55,0/10 %0.0
Psychiatric disorders - Other specify,0/4 %0.0,0/61 %0.0,0/49 %0.0,1/22 %4.55,0/10 %0.0
Acute kidney injury,0/4 %0.0,1/61 %1.64,0/49 %0.0,0/22 %0.0,0/10 %0.0
Urinary retention,0/4 %0.0,0/61 %0.0,1/49 %2.04,0/22 %0.0,0/10 %0.0
Adult respiratory distress syndrome,0/4 %0.0,2/61 %3.28,2/49 %4.08,0/22 %0.0,0/10 %0.0
Atelectasis,0/4 %0.0,0/61 %0.0,1/49 %2.04,0/22 %0.0,0/10 %0.0
Bronchopulmonary hemorrhage,0/4 %0.0,1/61 %1.64,0/49 %0.0,0/22 %0.0,0/10 %0.0
Dyspnea,0/4 %0.0,2/61 %3.28,3/49 %6.12,0/22 %0.0,0/10 %0.0
Epistaxis,0/4 %0.0,0/61 %0.0,2/49 %4.08,0/22 %0.0,0/10 %0.0
Hypoxia,0/4 %0.0,8/61 %13.11,3/49 %6.12,0/22 %0.0,0/10 %0.0
Pharyngolaryngeal pain,0/4 %0.0,1/61 %1.64,0/49 %0.0,0/22 %0.0,0/10 %0.0
Pleural effusion,0/4 %0.0,2/61 %3.28,0/49 %0.0,0/22 %0.0,0/10 %0.0
Pneumonitis,0/4 %0.0,2/61 %3.28,2/49 %4.08,0/22 %0.0,0/10 %0.0
Pneumothorax,0/4 %0.0,0/61 %0.0,1/49 %2.04,0/22 %0.0,0/10 %0.0
Pulmonary edema,0/4 %0.0,3/61 %4.92,1/49 %2.04,0/22 %0.0,0/10 %0.0
Respiratory failure,0/4 %0.0,5/61 %8.2,4/49 %8.16,1/22 %4.55,0/10 %0.0
Respiratory thoracic and mediastinal disorders - Other specify,0/4 %0.0,1/61 %1.64,1/49 %2.04,0/22 %0.0,0/10 %0.0
Stridor,0/4 %0.0,0/61 %0.0,1/49 %2.04,0/22 %0.0,0/10 %0.0
Wheezing,0/4 %0.0,0/61 %0.0,1/49 %2.04,0/22 %0.0,0/10 %0.0
Pruritus,0/4 %0.0,1/61 %1.64,0/49 %0.0,1/22 %4.55,0/10 %0.0
Rash maculo-papular,0/4 %0.0,1/61 %1.64,0/49 %0.0,0/22 %0.0,0/10 %0.0
Skin ulceration,0/4 %0.0,1/61 %1.64,1/49 %2.04,0/22 %0.0,0/10 %0.0
Toxic epidermal necrolysis,0/4 %0.0,1/61 %1.64,0/49 %0.0,0/22 %0.0,0/10 %0.0
Capillary leak syndrome,0/4 %0.0,0/61 %0.0,1/49 %2.04,0/22 %0.0,1/10 %10.0
Hypertension,0/4 %0.0,3/61 %4.92,2/49 %4.08,0/22 %0.0,0/10 %0.0
Hypotension,0/4 %0.0,8/61 %13.11,5/49 %10.2,3/22 %13.64,1/10 %10.0

Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study(https://clinicaltrials.gov/show/NCT00877006)
 ,Bendamustine and Rituximab (BR),R-CHOP/CVP
 ,Participants received the investigational bendamustine and rituximab regimen for 6 to 8 28-day cycles: bendamustine 90 mg/m^2 intravenous (IV) on Days 1 and 2; rituximab 375 mg/m^2 IV on Day 1.,Participants received the standard regimen (R-CHOP or R-CVP) for 6 to 8 21-days cycles.  R-CHOP: rituximab 375 mg/m^2 IV on Day 1; vincristine 1.4 mg/m^2 (up to 2 mg/m^2 maximum dose) IV on Day 1; doxorubicin 50 mg/m^2 IV Day 1; cyclophosphamide 750 mg/m^2 IV Day 1; prednisone 100 mg oral on Days 1 to 5  R-CVP: rituximab 375 mg/m^2 IV on Day 1; cyclophosphamide 750 mg/m^2 IV on Day 1 or cyclophosphamide 1000 mg/m^2 IV on Day 1; vincristine 1.4 mg/m^2 (up to 2 mg/m^2 maximum dose) IV on Day 1; prednisone 100 mg oral on Days 1 to 5
Total serious adverse events,60/221 %27.15,49/215 %22.79
Aplasia pure red cell,1/221 %0.45,0/215 %0.0
Febrile neutropenia,7/221 %3.17,9/215 %4.19
Lymphadenopathy,0/221 %0.0,1/215 %0.47
Neutropenia,4/221 %1.81,5/215 %2.33
Splenomegaly,1/221 %0.45,0/215 %0.0
Atrial fibrillation,0/221 %0.0,1/215 %0.47
Atrioventricular block first degree,1/221 %0.45,0/215 %0.0
Bundle branch block left,0/221 %0.0,1/215 %0.47
Cardiac arrest,1/221 %0.45,1/215 %0.47
Cardiac failure congestive,0/221 %0.0,1/215 %0.47
Left ventricular dysfunction,1/221 %0.45,1/215 %0.47
Myocardial infarction,0/221 %0.0,1/215 %0.47
Pericardial effusion,1/221 %0.45,0/215 %0.0
Supraventricular tachycardia,0/221 %0.0,1/215 %0.47
Vitreous floaters,1/221 %0.45,0/215 %0.0
Abdominal pain,2/221 %0.9,1/215 %0.47
Ascites,1/221 %0.45,0/215 %0.0
Constipation,1/221 %0.45,0/215 %0.0
Diarrhoea,1/221 %0.45,0/215 %0.0
Diverticular perforation,0/221 %0.0,1/215 %0.47
Gastrooesophageal reflux disease,1/221 %0.45,0/215 %0.0
Ileus,1/221 %0.45,0/215 %0.0
Nausea,3/221 %1.36,0/215 %0.0
Rectal haemorrhage,1/221 %0.45,0/215 %0.0
Small intestinal obstruction,1/221 %0.45,1/215 %0.47
Vomiting,3/221 %1.36,0/215 %0.0
Chills,1/221 %0.45,0/215 %0.0
Non-cardiac chest pain,0/221 %0.0,3/215 %1.4
Pyrexia,5/221 %2.26,4/215 %1.86
Cholelithiasis,1/221 %0.45,0/215 %0.0
Portal vein thrombosis,1/221 %0.45,0/215 %0.0
Anaphylactic shock,1/221 %0.45,0/215 %0.0
Drug hypersensitivity,4/221 %1.81,0/215 %0.0
Abscess limb,0/221 %0.0,1/215 %0.47
Anal infection,0/221 %0.0,1/215 %0.47
Bacteraemia,1/221 %0.45,0/215 %0.0
Clostridium difficile colitis,1/221 %0.45,0/215 %0.0
Diverticulitis,2/221 %0.9,1/215 %0.47
Gastroenteritis,1/221 %0.45,0/215 %0.0
Gastrointestinal infection,1/221 %0.45,0/215 %0.0
Infection,1/221 %0.45,0/215 %0.0
Infective exacerbation of chronic obstructive airways disease,1/221 %0.45,0/215 %0.0
Lower respiratory tract infection,0/221 %0.0,1/215 %0.47
Pharyngitis,0/221 %0.0,1/215 %0.47
Pneumocystis jiroveci infection,1/221 %0.45,0/215 %0.0
Pneumocystis jiroveci pneumonia,1/221 %0.45,1/215 %0.47
Pneumonia,7/221 %3.17,1/215 %0.47
Postoperative wound infection,0/221 %0.0,1/215 %0.47
Septic shock,1/221 %0.45,1/215 %0.47
Tooth abscess,1/221 %0.45,0/215 %0.0
Tooth infection,0/221 %0.0,1/215 %0.47
Tracheobronchitis,1/221 %0.45,0/215 %0.0
Upper respiratory tract infection,1/221 %0.45,0/215 %0.0
Urinary tract infection,1/221 %0.45,0/215 %0.0
Viral infection,2/221 %0.9,0/215 %0.0
Ankle fracture,0/221 %0.0,1/215 %0.47
Cervical vertebral fracture,0/221 %0.0,1/215 %0.47
Clavicle fracture,0/221 %0.0,1/215 %0.47
Fall,0/221 %0.0,1/215 %0.47
Infusion related reaction,8/221 %3.62,4/215 %1.86
Procedural complication,0/221 %0.0,1/215 %0.47
Rib fracture,1/221 %0.45,1/215 %0.47
Spinal compression fracture,0/221 %0.0,1/215 %0.47
Toxicity to various agents,1/221 %0.45,0/215 %0.0
Electrocardiogram QT prolonged,0/221 %0.0,1/215 %0.47
Dehydration,0/221 %0.0,1/215 %0.47
Hyperglycaemia,0/221 %0.0,1/215 %0.47
Tumour lysis syndrome,1/221 %0.45,0/215 %0.0
Back pain,0/221 %0.0,2/215 %0.93
Lung neoplasm malignant,1/221 %0.45,0/215 %0.0
Renal cell carcinoma,0/221 %0.0,1/215 %0.47
Sarcoma,1/221 %0.45,0/215 %0.0
Dystonia,0/221 %0.0,1/215 %0.47
Headache,1/221 %0.45,0/215 %0.0
Intracranial aneurysm,0/221 %0.0,1/215 %0.47
Neuropathy peripheral,1/221 %0.45,0/215 %0.0
Syncope,1/221 %0.45,1/215 %0.47
Confusional state,1/221 %0.45,0/215 %0.0
Depression,0/221 %0.0,1/215 %0.47
Haematuria,1/221 %0.45,0/215 %0.0
Renal failure acute,1/221 %0.45,0/215 %0.0
Renal tubular necrosis,1/221 %0.45,0/215 %0.0
Urinary retention,1/221 %0.45,0/215 %0.0
Prostatitis,1/221 %0.45,0/215 %0.0
Acute respiratory failure,1/221 %0.45,0/215 %0.0
Chronic obstructive pulmonary disease,2/221 %0.9,0/215 %0.0
Dyspnoea,0/221 %0.0,1/215 %0.47
Hypoxia,1/221 %0.45,1/215 %0.47
Interstitial lung disease,1/221 %0.45,0/215 %0.0
Pleural effusion,1/221 %0.45,0/215 %0.0
Pulmonary embolism,1/221 %0.45,1/215 %0.47
Respiratory failure,2/221 %0.9,0/215 %0.0
Rash,1/221 %0.45,0/215 %0.0
Rash maculo-papular,0/221 %0.0,1/215 %0.47
Hypertension,0/221 %0.0,1/215 %0.47
Hypotension,1/221 %0.45,0/215 %0.0

A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer(https://clinicaltrials.gov/show/NCT00883116)
 ,Ixabepilone 40 mg/m^2 Intravenously (IV),Control With Chemotherapy (Doxorubicin 60 mg/m^2 IV),Control With Chemotherapy (Paclitaxel 175 mg/m^2 IV)
 ,Participants received ixabepilone 40 mg/m^2 given intravenously (IV) over 3 hours every 21 days until unacceptable toxicity or disease progression,Participants received doxorubicin 60 mg/m^2 given intravenously (IV) per institutional guidelines every 21 days depending on the prior therapy received until disease progression unacceptable toxicity or cumulative dose of 500 mg/m^2.,Participants received paclitaxel 175 mg/m^2 given IV over 3 hours or per institutional guidelines but not exceeding 3 hours every 21 days until disease progression or unacceptable toxicity.
Total serious adverse events,89/248 %35.89,59/171 %34.5,11/68 %16.18
Febrile neutropenia,10/248 %4.03,10/171 %5.85,1/68 %1.47
Leukopenia,3/248 %1.21,1/171 %0.58,0/68 %0.0
Neutropenia,6/248 %2.42,4/171 %2.34,0/68 %0.0
Thrombocytopenia,1/248 %0.4,1/171 %0.58,1/68 %1.47
Anaemia,5/248 %2.02,7/171 %4.09,1/68 %1.47
Pancytopenia,1/248 %0.4,1/171 %0.58,0/68 %0.0
Myocardial ischaemia,0/248 %0.0,0/171 %0.0,1/68 %1.47
Pericardial effusion,1/248 %0.4,0/171 %0.0,0/68 %0.0
Right ventricular failure,1/248 %0.4,0/171 %0.0,0/68 %0.0
Cardiac tamponade,1/248 %0.4,0/171 %0.0,0/68 %0.0
Cardio-respiratory arrest,1/248 %0.4,0/171 %0.0,0/68 %0.0
Atrial fibrillation,2/248 %0.81,0/171 %0.0,0/68 %0.0
Cardiac failure congestive,1/248 %0.4,0/171 %0.0,0/68 %0.0
Tachycardia,0/248 %0.0,1/171 %0.58,0/68 %0.0
Intracardiac thrombus,0/248 %0.0,1/171 %0.58,0/68 %0.0
Tachyarrhythmia,1/248 %0.4,0/171 %0.0,0/68 %0.0
Hypothyroidism,1/248 %0.4,0/171 %0.0,0/68 %0.0
Dyspepsia,1/248 %0.4,0/171 %0.0,0/68 %0.0
Rectal obstruction,0/248 %0.0,1/171 %0.58,0/68 %0.0
Small intestinal obstruction,1/248 %0.4,2/171 %1.17,1/68 %1.47
Upper gastrointestinal haemorrhage,1/248 %0.4,1/171 %0.58,0/68 %0.0
Ascites,3/248 %1.21,1/171 %0.58,0/68 %0.0
Intestinal obstruction,1/248 %0.4,3/171 %1.75,0/68 %0.0
Oesophagitis,1/248 %0.4,0/171 %0.0,0/68 %0.0
Gastrointestinal obstruction,1/248 %0.4,0/171 %0.0,0/68 %0.0
Rectal haemorrhage,1/248 %0.4,2/171 %1.17,0/68 %0.0
Dysphagia,1/248 %0.4,0/171 %0.0,0/68 %0.0
Nausea,8/248 %3.23,7/171 %4.09,0/68 %0.0
Abdominal pain,4/248 %1.61,6/171 %3.51,2/68 %2.94
Haematemesis,1/248 %0.4,1/171 %0.58,0/68 %0.0
Ileus,0/248 %0.0,1/171 %0.58,0/68 %0.0
Large intestinal haemorrhage,1/248 %0.4,0/171 %0.0,0/68 %0.0
Constipation,4/248 %1.61,4/171 %2.34,0/68 %0.0
Diarrhoea,9/248 %3.63,2/171 %1.17,1/68 %1.47
Stomatitis,0/248 %0.0,1/171 %0.58,0/68 %0.0
Vomiting,9/248 %3.63,4/171 %2.34,0/68 %0.0
Abdominal distension,1/248 %0.4,1/171 %0.58,0/68 %0.0
Enterovesical fistula,0/248 %0.0,1/171 %0.58,0/68 %0.0
Intestinal perforation,2/248 %0.81,2/171 %1.17,0/68 %0.0
Device malfunction,0/248 %0.0,0/171 %0.0,1/68 %1.47
Oedema,1/248 %0.4,0/171 %0.0,0/68 %0.0
Sudden death,1/248 %0.4,0/171 %0.0,0/68 %0.0
Performance status decreased,0/248 %0.0,1/171 %0.58,0/68 %0.0
Inflammation,1/248 %0.4,0/171 %0.0,0/68 %0.0
Pyrexia,4/248 %1.61,4/171 %2.34,0/68 %0.0
Asthenia,3/248 %1.21,0/171 %0.0,0/68 %0.0
Mucosal inflammation,0/248 %0.0,1/171 %0.58,0/68 %0.0
Pain,1/248 %0.4,0/171 %0.0,1/68 %1.47
General physical health deterioration,1/248 %0.4,0/171 %0.0,1/68 %1.47
Death,1/248 %0.4,0/171 %0.0,0/68 %0.0
Fatigue,4/248 %1.61,1/171 %0.58,0/68 %0.0
Hyperbilirubinaemia,1/248 %0.4,0/171 %0.0,0/68 %0.0
Cholecystitis,1/248 %0.4,0/171 %0.0,0/68 %0.0
Endocarditis,1/248 %0.4,0/171 %0.0,1/68 %1.47
Pyelonephritis,0/248 %0.0,0/171 %0.0,1/68 %1.47
Neutropenic sepsis,0/248 %0.0,2/171 %1.17,0/68 %0.0
Pneumonia,0/248 %0.0,3/171 %1.75,0/68 %0.0
Pyelonephritis chronic,0/248 %0.0,0/171 %0.0,1/68 %1.47
Cellulitis,2/248 %0.81,0/171 %0.0,0/68 %0.0
Clostridium bacteraemia,1/248 %0.4,0/171 %0.0,0/68 %0.0
Device related infection,2/248 %0.81,0/171 %0.0,0/68 %0.0
Localised infection,0/248 %0.0,1/171 %0.58,0/68 %0.0
Salmonellosis,0/248 %0.0,1/171 %0.58,0/68 %0.0
Sepsis,3/248 %1.21,2/171 %1.17,1/68 %1.47
Upper respiratory tract infection,1/248 %0.4,0/171 %0.0,0/68 %0.0
Infection,0/248 %0.0,0/171 %0.0,1/68 %1.47
Respiratory moniliasis,1/248 %0.4,0/171 %0.0,0/68 %0.0
Infectious peritonitis,0/248 %0.0,1/171 %0.58,0/68 %0.0
Septic shock,0/248 %0.0,1/171 %0.58,0/68 %0.0
Candidiasis,1/248 %0.4,0/171 %0.0,0/68 %0.0
Urinary tract infection,4/248 %1.61,3/171 %1.75,0/68 %0.0
Humerus fracture,1/248 %0.4,0/171 %0.0,0/68 %0.0
Overdose,1/248 %0.4,0/171 %0.0,0/68 %0.0
Hip fracture,1/248 %0.4,0/171 %0.0,0/68 %0.0
Incorrect dose administered,1/248 %0.4,0/171 %0.0,0/68 %0.0
Blood creatinine increased,3/248 %1.21,0/171 %0.0,0/68 %0.0
White blood cell count decreased,2/248 %0.81,1/171 %0.58,0/68 %0.0
Glomerular filtration rate decreased,1/248 %0.4,0/171 %0.0,0/68 %0.0
Haemoglobin decreased,2/248 %0.81,0/171 %0.0,0/68 %0.0
International normalised ratio increased,0/248 %0.0,2/171 %1.17,0/68 %0.0
Neutrophil count decreased,1/248 %0.4,1/171 %0.58,0/68 %0.0
Alanine aminotransferase increased,1/248 %0.4,0/171 %0.0,0/68 %0.0
Platelet count decreased,1/248 %0.4,1/171 %0.58,0/68 %0.0
Hyperkalaemia,1/248 %0.4,0/171 %0.0,0/68 %0.0
Decreased appetite,2/248 %0.81,0/171 %0.0,0/68 %0.0
Type 2 diabetes mellitus,0/248 %0.0,0/171 %0.0,1/68 %1.47
Hypomagnesaemia,1/248 %0.4,0/171 %0.0,0/68 %0.0
Hypoglycaemia,1/248 %0.4,0/171 %0.0,0/68 %0.0
Hyponatraemia,2/248 %0.81,0/171 %0.0,0/68 %0.0
Dehydration,5/248 %2.02,5/171 %2.92,0/68 %0.0
Hypoalbuminaemia,1/248 %0.4,0/171 %0.0,0/68 %0.0
Hypocalcaemia,0/248 %0.0,1/171 %0.58,1/68 %1.47
Hypokalaemia,3/248 %1.21,0/171 %0.0,0/68 %0.0
Pain in extremity,1/248 %0.4,0/171 %0.0,0/68 %0.0
Arthralgia,0/248 %0.0,0/171 %0.0,1/68 %1.47
Muscular weakness,2/248 %0.81,0/171 %0.0,0/68 %0.0
Endometrial cancer,0/248 %0.0,0/171 %0.0,1/68 %1.47
Metastases to central nervous system,1/248 %0.4,0/171 %0.0,1/68 %1.47
Neoplasm malignant,4/248 %1.61,5/171 %2.92,0/68 %0.0
Malignant pleural effusion,1/248 %0.4,0/171 %0.0,0/68 %0.0
Dizziness,2/248 %0.81,0/171 %0.0,0/68 %0.0
Peripheral motor neuropathy,0/248 %0.0,0/171 %0.0,1/68 %1.47
Presyncope,2/248 %0.81,0/171 %0.0,0/68 %0.0
Syncope,1/248 %0.4,0/171 %0.0,0/68 %0.0
Cerebrovascular accident,2/248 %0.81,1/171 %0.58,0/68 %0.0
Anxiety,1/248 %0.4,0/171 %0.0,0/68 %0.0
Confusional state,1/248 %0.4,1/171 %0.58,0/68 %0.0
Depression,0/248 %0.0,0/171 %0.0,1/68 %1.47
Haemorrhage urinary tract,0/248 %0.0,1/171 %0.58,0/68 %0.0
Urinary tract obstruction,1/248 %0.4,0/171 %0.0,0/68 %0.0
Hydronephrosis,2/248 %0.81,0/171 %0.0,0/68 %0.0
Renal failure,1/248 %0.4,1/171 %0.58,0/68 %0.0
Haematuria,0/248 %0.0,1/171 %0.58,0/68 %0.0
Chromaturia,0/248 %0.0,1/171 %0.58,0/68 %0.0
Renal failure acute,2/248 %0.81,2/171 %1.17,1/68 %1.47
Ureteric obstruction,1/248 %0.4,0/171 %0.0,0/68 %0.0
Anuria,2/248 %0.81,0/171 %0.0,0/68 %0.0
Urinary bladder haemorrhage,0/248 %0.0,2/171 %1.17,0/68 %0.0
Dyspnoea exertional,0/248 %0.0,1/171 %0.58,0/68 %0.0
Vaginal haemorrhage,2/248 %0.81,1/171 %0.58,0/68 %0.0
Female genital tract fistula,0/248 %0.0,0/171 %0.0,1/68 %1.47
Haemoptysis,1/248 %0.4,0/171 %0.0,0/68 %0.0
Pulmonary embolism,3/248 %1.21,6/171 %3.51,0/68 %0.0
Respiratory failure,1/248 %0.4,0/171 %0.0,0/68 %0.0
Dyspnoea,0/248 %0.0,6/171 %3.51,0/68 %0.0
Pneumonia aspiration,1/248 %0.4,0/171 %0.0,0/68 %0.0
Acute pulmonary oedema,0/248 %0.0,1/171 %0.58,0/68 %0.0
Apnoea,1/248 %0.4,0/171 %0.0,0/68 %0.0
Pulmonary oedema,1/248 %0.4,0/171 %0.0,0/68 %0.0
Pleural effusion,3/248 %1.21,1/171 %0.58,1/68 %1.47
Intertrigo,1/248 %0.4,0/171 %0.0,0/68 %0.0
Embolism,1/248 %0.4,0/171 %0.0,0/68 %0.0
Orthostatic hypotension,1/248 %0.4,0/171 %0.0,0/68 %0.0
Deep vein thrombosis,1/248 %0.4,4/171 %2.34,0/68 %0.0
Hypertension,0/248 %0.0,0/171 %0.0,1/68 %1.47

A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer(https://clinicaltrials.gov/show/NCT00913835)
 ,Olaratumab and Liposomal Doxorubicin,Liposomal Doxorubicin,Liposomal Doxorubicin: Optional Olaratumab Monotherapy
 ,20 mg/kg of Olaratumab was administered as an IV infusion every 2 weeks (14 days) until there was evidence of PD or development of unacceptable toxicity up to 130 weeks.  40 mg/m of liposomal doxorubicin was administered according to the manufacturer's instructions every 4 weeks (28 days) until there was evidence of PD or development of unacceptable toxicity.,40 mg/m of liposomal doxorubicin was administered according to the manufacturer's instructions every 4 weeks (28 days). Treatment continued until there was evidence of PD or development of unacceptable toxicity up to 130 weeks.  Upon disease progression the participant had the option to receive Olaratumab monotherapy.,40 mg/m of liposomal doxorubicin was administered according to the manufacturer's instructions every 4 weeks (28 days). Treatment continued until there was evidence of PD or development of unacceptable toxicity followed by 20 mg/kg of Olaratumab administered as an IV infusion every 2 weeks (14 days) until there was evidence of PD or development of unacceptable toxicity up to 130 weeks.
Total serious adverse events,27/62 %43.55,23/61 %37.7,14/28 %50.0
Anaemia,1/62 %1.61,1/61 %1.64,1/28 %3.57
Cardiac failure congestive,0/62 %0.0,1/61 %1.64,0/28 %0.0
Coronary artery stenosis,1/62 %1.61,0/61 %0.0,0/28 %0.0
Pyloric stenosis,0/62 %0.0,1/61 %1.64,0/28 %0.0
Abdominal discomfort,1/62 %1.61,0/61 %0.0,0/28 %0.0
Abdominal distension,2/62 %3.23,2/61 %3.28,0/28 %0.0
Abdominal pain,0/62 %0.0,3/61 %4.92,1/28 %3.57
Ascites,0/62 %0.0,3/61 %4.92,0/28 %0.0
Constipation,1/62 %1.61,2/61 %3.28,0/28 %0.0
Diarrhoea,1/62 %1.61,0/61 %0.0,0/28 %0.0
Duodenal stenosis,0/62 %0.0,0/61 %0.0,1/28 %3.57
Gastrointestinal obstruction,0/62 %0.0,0/61 %0.0,1/28 %3.57
Ileus,0/62 %0.0,2/61 %3.28,0/28 %0.0
Intestinal obstruction,3/62 %4.84,2/61 %3.28,1/28 %3.57
Nausea,1/62 %1.61,1/61 %1.64,2/28 %7.14
Proctitis,1/62 %1.61,0/61 %0.0,0/28 %0.0
Rectal haemorrhage,0/62 %0.0,0/61 %0.0,1/28 %3.57
Small intestinal obstruction,1/62 %1.61,4/61 %6.56,0/28 %0.0
Vomiting,3/62 %4.84,3/61 %4.92,2/28 %7.14
Chills,1/62 %1.61,0/61 %0.0,0/28 %0.0
Disease progression,0/62 %0.0,1/61 %1.64,0/28 %0.0
Extravasation,0/62 %0.0,1/61 %1.64,0/28 %0.0
Infusion site erythema,0/62 %0.0,1/61 %1.64,0/28 %0.0
Mucosal inflammation,0/62 %0.0,0/61 %0.0,1/28 %3.57
Pyrexia,2/62 %3.23,0/61 %0.0,2/28 %7.14
Bile duct obstruction,0/62 %0.0,0/61 %0.0,1/28 %3.57
Hypersensitivity,0/62 %0.0,0/61 %0.0,1/28 %3.57
Bacillus infection,0/62 %0.0,1/61 %1.64,0/28 %0.0
Cellulitis,0/62 %0.0,1/61 %1.64,0/28 %0.0
Device related infection,2/62 %3.23,1/61 %1.64,0/28 %0.0
Febrile infection,0/62 %0.0,1/61 %1.64,0/28 %0.0
Gastroenteritis,0/62 %0.0,1/61 %1.64,0/28 %0.0
Infection,2/62 %3.23,1/61 %1.64,0/28 %0.0
Pharyngitis,0/62 %0.0,0/61 %0.0,1/28 %3.57
Pneumonia,1/62 %1.61,0/61 %0.0,0/28 %0.0
Urinary tract infection,0/62 %0.0,2/61 %3.28,0/28 %0.0
Urinary tract infection fungal,0/62 %0.0,1/61 %1.64,0/28 %0.0
Urosepsis,1/62 %1.61,0/61 %0.0,0/28 %0.0
Viral infection,1/62 %1.61,0/61 %0.0,0/28 %0.0
Femur fracture,0/62 %0.0,1/61 %1.64,0/28 %0.0
Incorrect drug administration duration,1/62 %1.61,0/61 %0.0,0/28 %0.0
Medication error,1/62 %1.61,0/61 %0.0,1/28 %3.57
Decreased appetite,1/62 %1.61,1/61 %1.64,0/28 %0.0
Dehydration,3/62 %4.84,1/61 %1.64,0/28 %0.0
Flank pain,0/62 %0.0,0/61 %0.0,1/28 %3.57
Dizziness,0/62 %0.0,1/61 %1.64,0/28 %0.0
Haemorrhage intracranial,1/62 %1.61,0/61 %0.0,0/28 %0.0
Syncope,1/62 %1.61,0/61 %0.0,0/28 %0.0
Bradyphrenia,1/62 %1.61,0/61 %0.0,0/28 %0.0
Hydronephrosis,1/62 %1.61,1/61 %1.64,1/28 %3.57
Renal failure,0/62 %0.0,1/61 %1.64,0/28 %0.0
Renal failure acute,1/62 %1.61,0/61 %0.0,0/28 %0.0
Dyspnoea,0/62 %0.0,0/61 %0.0,1/28 %3.57
Interstitial lung disease,0/62 %0.0,1/61 %1.64,0/28 %0.0
Pleural effusion,0/62 %0.0,0/61 %0.0,1/28 %3.57
Pulmonary embolism,2/62 %3.23,4/61 %6.56,0/28 %0.0
Venous thrombosis,0/62 %0.0,1/61 %1.64,0/28 %0.0

Pilot Study of Liposomal Doxorubicin Combined With Bevacizumab Followed by Bevacizumab Monotherapy in Adults With Advanced Kaposi s Sarcoma(https://clinicaltrials.gov/show/NCT00923936)
 ,KS; Classic or HIV+ Not Improved on Antivirals,All Other Advanced HIV-associated Kaposi's Sarcoma (KS)
 ,Kaposi's sarcoma (KS) in patients who are Human immunodeficiency virus (HIV) Negative HIV infected with stable disease for one year despite antiretroviral therapy or progressive disease despite 4 months of antiretroviral therapy.  Liposomal Doxorubicin: Induction phase dose: Intravenous (IV) bevacizumab 15 mg/kg once followed 7 days later by liposomal doxorubicin mg/m^2 and bevacizumab every 3 weeks for six cycles.  Bevacizumab: Induction phase dose: Intravenous (IV) bevacizumab 15 mg/kg once followed 7 days later by liposomal doxorubicin mg/m^2 and bevacizumab every 3 weeks for six cycles. Maintenance phase dose: IV bevacizumab every 3 weeks for 11 cycles.,All other patients with advanced AIDS-associated KS  Liposomal Doxorubicin: Induction phase dose: Intravenous (IV) bevacizumab 15 mg/kg once followed 7 days later by liposomal doxorubicin mg/m^2 and bevacizumab every 3 weeks for six cycles.  Bevacizumab: Induction phase dose: Intravenous (IV) bevacizumab 15 mg/kg once followed 7 days later by liposomal doxorubicin mg/m^2 and bevacizumab every 3 weeks for six cycles. Maintenance phase dose: IV bevacizumab every 3 weeks for 11 cycles.
Total all-cause mortality,0/10 %0.0,0/6 %0.0
Total serious adverse events,0/10 %0.0,1/6 %16.67
Hemorrhage GI::Rectum,0/10 %0.0,1/6 %16.67

Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients(https://clinicaltrials.gov/show/NCT00931918)
 ,RCHOP,Vc-RCHOP
 ,RCHOP [rituximab cyclophosphamide doxorubicin prednisone] administered as follows: rituximab 375 mg/m^2 intravenous (IV) infusion cyclophosphamide 750 mg/m^2 IV infusion doxorubicin 50 mg/m^2 IV injection and vincristine 1.4 mg/m^2 (maximum total dose 2 mg) IV injection on Day 1 with prednisone orally on Days 1 through 5 of a 21-day (3-week) cycle for 6 cycles.,Vc-RCHOP [bortezomib (VELCADE) rituximab cyclophosphamide doxorubicin prednisone] administered as follows: bortezomib (VELCADE ) 1.3 mg/m^2 administered intravenous (IV) push on Days 1 and 4 of each cycle with RCHOP administered as follows: rituximab 375 mg/m^2 intravenous (IV) infusion cyclophosphamide 750 mg/m^2 IV infusion doxorubicin 50 mg/m^2 IV injection and vincristine 1.4 mg/m^2 (maximum total dose 2 mg) IV injection on Day 1 with prednisone orally on Days 1 through 5 of a 21-day (3-week) cycle for 6 cycles.
Total serious adverse events,31/100 %31.0,34/101 %33.66
Febrile neutropenia,8/100 %8.0,7/101 %6.93
Neutropenia,5/100 %5.0,1/101 %0.99
Pancytopenia,2/100 %2.0,1/101 %0.99
Bone marrow failure,1/100 %1.0,0/101 %0.0
Anaemia,2/100 %2.0,1/101 %0.99
Leukopenia,2/100 %2.0,1/101 %0.99
Thrombocytopenia,0/100 %0.0,2/101 %1.98
Myocardial infarction,2/100 %2.0,0/101 %0.0
Angina unstable,1/100 %1.0,0/101 %0.0
Bradycardia,0/100 %0.0,1/101 %0.99
Tachycardia,1/100 %1.0,0/101 %0.0
Pericardial effusion,1/100 %1.0,0/101 %0.0
Atrial fibrillation,1/100 %1.0,0/101 %0.0
Cardio-respiratory arrest,0/100 %0.0,1/101 %0.99
Adrenal insufficiency,1/100 %1.0,0/101 %0.0
Diarrhoea,2/100 %2.0,2/101 %1.98
Vomiting,2/100 %2.0,1/101 %0.99
Nausea,1/100 %1.0,1/101 %0.99
Duodenal obstruction,0/100 %0.0,1/101 %0.99
Small intestinal obstruction,0/100 %0.0,1/101 %0.99
Gastrointestinal haemorrhage,0/100 %0.0,2/101 %1.98
Melaena,0/100 %0.0,1/101 %0.99
Diverticulum,0/100 %0.0,1/101 %0.99
Faecaloma,0/100 %0.0,1/101 %0.99
Gastric ulcer,1/100 %1.0,0/101 %0.0
Abdominal pain,1/100 %1.0,0/101 %0.0
Dysphagia,0/100 %0.0,1/101 %0.99
Intestinal obstruction,0/100 %0.0,1/101 %0.99
Stomatitis,0/100 %0.0,1/101 %0.99
Pyrexia,4/100 %4.0,4/101 %3.96
Asthenia,1/100 %1.0,2/101 %1.98
Fatigue,0/100 %0.0,1/101 %0.99
Chest pain,0/100 %0.0,1/101 %0.99
Non-cardiac chest pain,0/100 %0.0,1/101 %0.99
Cholangitis,0/100 %0.0,1/101 %0.99
Herpes zoster,1/100 %1.0,3/101 %2.97
Pneumonia,3/100 %3.0,1/101 %0.99
Sepsis,1/100 %1.0,1/101 %0.99
Bacteraemia,1/100 %1.0,0/101 %0.0
Septic shock,1/100 %1.0,0/101 %0.0
Gastroenteritis,1/100 %1.0,0/101 %0.0
Cellulitis,0/100 %0.0,1/101 %0.99
Oesophageal candidiasis,0/100 %0.0,1/101 %0.99
Clostridium difficile colitis,0/100 %0.0,1/101 %0.99
Escherichia bacteraemia,1/100 %1.0,0/101 %0.0
Liver abscess,1/100 %1.0,0/101 %0.0
Cellulitis staphylococcal,0/100 %0.0,1/101 %0.99
Upper respiratory tract infection,1/100 %1.0,0/101 %0.0
Compression fracture,0/100 %0.0,1/101 %0.99
Nuclear magnetic resonance imaging abnormal,1/100 %1.0,0/101 %0.0
Transaminases increased,0/100 %0.0,1/101 %0.99
Platelet count decreased,1/100 %1.0,0/101 %0.0
Blood creatinine increased,1/100 %1.0,0/101 %0.0
Troponin increased,0/100 %0.0,1/101 %0.99
Neutrophil count decreased,0/100 %0.0,1/101 %0.99
White blood cell count decreased,0/100 %0.0,1/101 %0.99
Dehydration,2/100 %2.0,6/101 %5.94
Tumour lysis syndrome,0/100 %0.0,1/101 %0.99
Failure to thrive,1/100 %1.0,0/101 %0.0
Hypoglycaemia,0/100 %0.0,1/101 %0.99
Hypokalaemia,0/100 %0.0,1/101 %0.99
Syncope,0/100 %0.0,4/101 %3.96
Metabolic encephalopathy,0/100 %0.0,1/101 %0.99
Presyncope,1/100 %1.0,0/101 %0.0
Post herpetic neuralgia,0/100 %0.0,1/101 %0.99
Transient ischaemic attack,1/100 %1.0,0/101 %0.0
Anxiety,1/100 %1.0,0/101 %0.0
Mental status changes,1/100 %1.0,0/101 %0.0
Acute kidney injury,0/100 %0.0,1/101 %0.99
Dyspnoea,1/100 %1.0,1/101 %0.99
Pulmonary embolism,0/100 %0.0,2/101 %1.98
Pleural effusion,1/100 %1.0,0/101 %0.0
Respiratory failure,1/100 %1.0,0/101 %0.0
Aspiration,0/100 %0.0,1/101 %0.99
Skin haemorrhage,0/100 %0.0,1/101 %0.99
Fluid replacement,0/100 %0.0,1/101 %0.99
Orthostatic hypotension,1/100 %1.0,3/101 %2.97
Hypotension,0/100 %0.0,2/101 %1.98
Deep vein thrombosis,0/100 %0.0,1/101 %0.99

Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma(https://clinicaltrials.gov/show/NCT00949325)
 ,Temsirolimus Plus Liposomal Doxorubicin
 ,Single arm consists of temsirolimus (Torisel) plus liposomal doxorubicin (Doxil). Temsirolimus is administered IV in sequentially escalating cohorts at doses between 15 and 50 mg/M2 (body surface area) once weekly. Liposomal doxorubicin is administered IV at 30 mg per M2 (body surface area) once every 28 days. Treatment may continue with both drugs for 2 years. Temsirolimus may continue beyond 2 years.  temsirolimus plus liposomal doxorubicin: Patients will be treated with temsirolimus (Torisel) temsirolimus weekly by iv and with liposomal doxorubicin (Doxil) (standard dose) by iv once every 28 days. Cohorts of patients receive sequentially increasing dose of temsirolimus until maximally tolerated dose (MTD) is reached. Once MTD (standard dose) is achieved dosing will be with standard doses for each drug but dosing will be modified based on toxicity.
Total serious adverse events,7/24 %29.17
Anorexia,1/24 %4.17
Respiratory failure,2/24 %8.33
Fever and chills,1/24 %4.17
Dyspnea,2/24 %8.33
pneumothorax,1/24 %4.17
Plural effusion,2/24 %8.33

A Study of Robatumumab (SCH 717454  MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883  MK-7454-006)(https://clinicaltrials.gov/show/NCT00960063)
 ,Temozolomide+Irinotecan+Robatumumab,Vincristine+Doxorubicin+Cyclophosphamide+Robatumumab,Ifosfamide+Etoposide+Robatumumab
 ,Participants receive temozolomide 100 mg/m^2/day IV on Days 1-5 PLUS irinotecan 10 mg/m^2/day IV on Days 1-5 and Days 8-12 PLUS robatumumab 10 mg/kg or 20 mg/kg IV on Day 1 of each 3-week cycle.,Participants receive vincristine 2 mg/m^2 (maximum 2 mg) IV on Day 1 PLUS cyclophosphamide 1200 mg/m^2 IV on Day 1 PLUS doxorubicin hydrochloride 75 mg/m^2 IV continuously over 48 hours PLUS robatumumab 10 mg/kg or 20 mg/kg IV on Day 1 of each 3-week cycle.,Participants receive ifosfamide 1800 mg/m^2 per day IV PLUS etoposide 100 mg/m^2 per day IV on Days 1-5 PLUS robatumumab 10 mg/kg or 20 mg/kg IV on Day 1 of each 3-week cycle.
Total serious adverse events,0/1 %0.0,0/0 %0.0,3/3 %100.0
Febrile neutropenia,0/1 %0.0,0/0 %0.0,3/3 %100.0
Chills,0/1 %0.0,0/0 %0.0,1/3 %33.33
Pyrexia,0/1 %0.0,0/0 %0.0,1/3 %33.33
Lobar pneumonia,0/1 %0.0,0/0 %0.0,1/3 %33.33
Transfusion reaction,0/1 %0.0,0/0 %0.0,1/3 %33.33
White blood cell count decreased,0/1 %0.0,0/0 %0.0,1/3 %33.33
Hypotension,0/1 %0.0,0/0 %0.0,1/3 %33.33

RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia(https://clinicaltrials.gov/show/NCT00968253)
 ,Phase I: RAD001 5 mg + Combination Chemo,Phase I: RAD001 10 mg + Combination Chemo,Phase II: MTD RAD001 + Combination Chemo
 ,RAD001 oral dose 5 mg every other day before chemo + two different chemotherapy combinations during alternating cycles Hyper-CVAD on Odd Cycles and Methotrexate & Ara-C during Even Cycles.,RAD001 oral dose 10 mg every other day before chemo + two different chemotherapy combinations during alternating cycles Hyper-CVAD on Odd Cycles and Methotrexate & Ara-C during Even Cycles.,RAD001 MTD oral dose 5 mg every other day before chemo + two different chemotherapy combinations during alternating cycles Hyper-CVAD on Odd Cycles and Methotrexate & Ara-C during Even Cycles.
Total serious adverse events,1/3 %33.33,7/9 %77.78,11/12 %91.67
Febrile Neutropenia,0/3 %0.0,5/9 %55.56,1/12 %8.33
Neutropenic Fever,1/3 %33.33,0/9 %0.0,5/12 %41.67
Pancytopenia,0/3 %0.0,0/9 %0.0,1/12 %8.33
Hyponatremia,0/3 %0.0,0/9 %0.0,1/12 %8.33
Chest Pain,0/3 %0.0,0/9 %0.0,1/12 %8.33
Sinus Tachycardia,0/3 %0.0,1/9 %11.11,0/12 %0.0
Mucositis/Stomatitis,0/3 %0.0,4/9 %44.44,1/12 %8.33
Multi-Organ Failure,0/3 %0.0,0/9 %0.0,1/12 %8.33
Death,0/3 %0.0,2/9 %22.22,3/12 %25.0
Septic Shock,0/3 %0.0,0/9 %0.0,2/12 %16.67
Infection - E Coli Bacterium,0/3 %0.0,1/9 %11.11,1/12 %8.33
Pneumonia,0/3 %0.0,3/9 %33.33,2/12 %16.67
Alanine aminotransferase increased,0/3 %0.0,0/9 %0.0,1/12 %8.33
Aspartate aminotransferase increased,0/3 %0.0,0/9 %0.0,1/12 %8.33
Cystitis,0/3 %0.0,1/9 %11.11,0/12 %0.0
Pleural effusions,0/3 %0.0,0/9 %0.0,1/12 %8.33

Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma(https://clinicaltrials.gov/show/NCT00972478)
 ,Ph I: R-CHOP+Vorinostat (400mg D1-9),Ph II: R-CHOP+Vorinostat
 ,Patients receive vorinostat 400 mg PO once daily on days 1-9 (according to dose level) rituximab IV cyclophosphamide IV over 30-60 minutes doxorubicin hydrochloride IV and vincristine sulfate IV on day 3. Patients also receive prednisone PO once daily on days 3-7. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity.,Patients receive vorinostat 400 mg PO once daily on days 1-5 or 1-9 (according to dose level) rituximab IV cyclophosphamide IV over 30-60 minutes doxorubicin hydrochloride IV and vincristine sulfate IV on day 3. Patients also receive prednisone PO once daily on days 3-7. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity.
Total serious adverse events,5/9 %55.56,44/63 %69.84
Anemia,3/9 %33.33,13/63 %20.63
Disseminated intravascular coagulation,1/9 %11.11,0/63 %0.0
Febrile neutropenia,3/9 %33.33,22/63 %34.92
Atrial fibrillation,0/9 %0.0,1/63 %1.59
Cardiac arrest,0/9 %0.0,1/63 %1.59
Left ventricular systolic dysfunction,0/9 %0.0,1/63 %1.59
Myocardial infarction,0/9 %0.0,3/63 %4.76
Abdominal pain,1/9 %11.11,1/63 %1.59
Colitis,1/9 %11.11,0/63 %0.0
Constipation,0/9 %0.0,1/63 %1.59
Diarrhea,0/9 %0.0,1/63 %1.59
Dysphagia,0/9 %0.0,1/63 %1.59
Gastroesophageal reflux disease,0/9 %0.0,1/63 %1.59
Gastrointestinal disorders-Other,0/9 %0.0,2/63 %3.17
Jejunal perforation,0/9 %0.0,1/63 %1.59
Mucositis oral,1/9 %11.11,0/63 %0.0
Nausea,0/9 %0.0,2/63 %3.17
Small intestinal obstruction,0/9 %0.0,1/63 %1.59
Vomiting,0/9 %0.0,2/63 %3.17
Death NOS,0/9 %0.0,1/63 %1.59
Fatigue,1/9 %11.11,3/63 %4.76
Fever,0/9 %0.0,2/63 %3.17
Malaise,0/9 %0.0,1/63 %1.59
Multi-organ failure,1/9 %11.11,0/63 %0.0
Non-cardiac chest pain,0/9 %0.0,1/63 %1.59
Pain,0/9 %0.0,2/63 %3.17
Bronchial infection,0/9 %0.0,1/63 %1.59
Infections and infestations-Other,0/9 %0.0,2/63 %3.17
Lung infection,1/9 %11.11,4/63 %6.35
Paronychia,0/9 %0.0,1/63 %1.59
Sepsis,3/9 %33.33,8/63 %12.7
Sinusitis,0/9 %0.0,1/63 %1.59
Stoma site infection,0/9 %0.0,1/63 %1.59
Urinary tract infection,0/9 %0.0,2/63 %3.17
Aspartate aminotransferase increased,0/9 %0.0,1/63 %1.59
Creatinine increased,1/9 %11.11,2/63 %3.17
Electrocardiogram QT corrected interval prolonged,1/9 %11.11,1/63 %1.59
Lymphocyte count decreased,1/9 %11.11,4/63 %6.35
Neutrophil count decreased,3/9 %33.33,16/63 %25.4
Platelet count decreased,4/9 %44.44,16/63 %25.4
Weight loss,0/9 %0.0,1/63 %1.59
White blood cell decreased,2/9 %22.22,10/63 %15.87
Anorexia,0/9 %0.0,2/63 %3.17
Dehydration,1/9 %11.11,4/63 %6.35
Hypercalcemia,0/9 %0.0,1/63 %1.59
Hypoalbuminemia,0/9 %0.0,1/63 %1.59
Hypocalcemia,1/9 %11.11,0/63 %0.0
Hypokalemia,2/9 %22.22,3/63 %4.76
Hypophosphatemia,1/9 %11.11,0/63 %0.0
Generalized muscle weakness,0/9 %0.0,1/63 %1.59
Neoplasms benign malignant and unspecified - Other,0/9 %0.0,1/63 %1.59
Cognitive disturbance,0/9 %0.0,1/63 %1.59
Dizziness,0/9 %0.0,1/63 %1.59
Recurrent laryngeal nerve palsy,0/9 %0.0,1/63 %1.59
Reversible posterior leukoencephalopathy syndrome,0/9 %0.0,1/63 %1.59
Syncope,0/9 %0.0,3/63 %4.76
Confusion,0/9 %0.0,2/63 %3.17
Acute kidney injury,0/9 %0.0,1/63 %1.59
Cystitis noninfective,0/9 %0.0,1/63 %1.59
Urinary frequency,0/9 %0.0,1/63 %1.59
Urinary tract pain,0/9 %0.0,1/63 %1.59
Cough,0/9 %0.0,1/63 %1.59
Dyspnea,0/9 %0.0,1/63 %1.59
Hiccups,0/9 %0.0,1/63 %1.59
Pneumonitis,0/9 %0.0,2/63 %3.17
Pulmonary edema,0/9 %0.0,1/63 %1.59
Respiratory failure,0/9 %0.0,1/63 %1.59
Hypotension,0/9 %0.0,3/63 %4.76
Thromboembolic event,0/9 %0.0,2/63 %3.17
Visceral arterial ischemia,1/9 %11.11,0/63 %0.0

Doxil + Melphalan + Velcade (DMV) in Relapsed/Refractory Multiple Myeloma(https://clinicaltrials.gov/show/NCT00985907)
 ,Phase 1 Doxil + Melphalan + Velcade (DMV)
 ,Doxil melphalan bortezomib: Doxil: IV over 30-60 min Day 1 q28d  Melphalan: IV over 30 min Day 1 q28d  Velcade: IV bolus Day 1 4 8 11 q28d  Dose Level 1: Doxil 10 mg/m2 Melphalan 5 mg/m2 Velcade 0.7 mg/m2  Dose Level 2: Doxil 10 mg/m2 Melphalan 10 mg/m2 Velcade 0.7 mg/m2  Dose Level 3: Doxil 20 mg/m2 Melphalan 10 mg/m2 Velcade 0.7 mg/m2  Dose Level 4: Doxil 20 mg/m2 Melphalan 10 mg/m2 Velcade 1.0 mg/m2
Total all-cause mortality,2/13 %15.38
Total serious adverse events,6/13 %46.15
Cholecystitis,1/13 %7.69
Infection,1/13 %7.69
Lung Infection,1/13 %7.69
Hyperbilirubinemia,1/13 %7.69
Bone Fracture,1/13 %7.69
Neurological disorder NOS,1/13 %7.69
Hypotension,1/13 %7.69
Thrombosis,1/13 %7.69

Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma(https://clinicaltrials.gov/show/NCT00992992)
 ,Iodine I-131 Tositumomab + CHOP
 ,Participants (par.) with previously untreated mantle cell lymphoma (MCL) were dosed with iodine I-131 tositumomab in two phases followed by six cycles (21 days per cycle) of cyclophosphamide doxorubicin vincristine and prednisone (CHOP). In the first phase (dosimetric dose) par. received an infusion of unlabeled tositumomab (450 milligrams [mg]) over the course of 60 minutes followed by a 30-minute infusion of tositumomab (35 mg) containing 5 millicurie (mCi) of iodine-131. In the second phase (therapeutic dose) par. received a 60-minute infusion of tositumomab (450 mg) followed by a 30-minute infusion of 35 mg tositumomab containing a participant-specific dose of iodine-131. This dose was calculated based on the dosimetric dose results to deliver a total body radiation dose of 75 centigray (cGy).
Total serious adverse events,19/25 %76.0
Febrile neutropenia,7/25 %28.0
Neutropenia,2/25 %8.0
Lymphadenitis,1/25 %4.0
Thrombocytopenia,1/25 %4.0
Cardiac failure congestive,1/25 %4.0
Cardio-respiratory arrest,1/25 %4.0
Pericarditis,1/25 %4.0
Intussusception,1/25 %4.0
Upper gastrointestinal haemorrhage,1/25 %4.0
Pyrexia,1/25 %4.0
Herpes zoster,1/25 %4.0
Pneumonia,1/25 %4.0
Sepsis,1/25 %4.0
Basal cell carcinoma,2/25 %8.0
Myelodysplastic syndrome,2/25 %8.0
Endometrial adenocarcinoma,1/25 %4.0
Malignant melanoma,1/25 %4.0
Malignant melanoma in situ,1/25 %4.0
Oesophageal adenocarcinoma,1/25 %4.0
Plasma cell myeloma,1/25 %4.0
Squamous cell carcinoma,1/25 %4.0
Squamous cell carcinoma of skin,1/25 %4.0
Cerebrovascular accident,1/25 %4.0
Peroneal nerve palsy,1/25 %4.0
Syncope,1/25 %4.0
Renal failure,1/25 %4.0
Renal failure acute,1/25 %4.0
Pleurisy,1/25 %4.0
Pulmonary embolism,1/25 %4.0
Orthostatic hypotension,1/25 %4.0

EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia Lymphoma(https://clinicaltrials.gov/show/NCT01000285)
 ,EPOCH Chemotherapy & Bortezomib
 ,Bortezomib 1.0 mg/m2 IV Days 1-4  Etoposide 50 mg/m2/d 96 hour CIVI on Days 1-4  Vincristine 0.4 mg/m2/d 96 hour CIVI on Days 1-4  Doxorubicin 10 mg/m2/d 96 hour CIVI on Days 1-4  Prednisone 60 mg/m2/d PO on Days 1-5  Cyclophosphamide 375 mg/m2 IV on Day 5  Raltegravir 400 mg PO BID every day starting with cycle 2 therapy for the entire duration of the cycle.  Cycles will be repeated every 21-28 days for 2 cycles beyond best response or a maximum of 6 cycles.
Total serious adverse events,1/18 %5.56
Sepsis,1/18 %5.56

Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer(https://clinicaltrials.gov/show/NCT01008150)
 ,Arm 1: Paclitaxel + Trastuzumab Then A C,Arm 2: Paclitaxel + Neratinib Then A C,Arm 3: Paclitaxel + Trastuzumab + Neratinib Then A C,Arm 3 NR: Paclitaxel + Trastuzumab + Neratinib Then AC
 ,4 cycles of paclitaxel 80 mg/m2 on Days 1 8 and 15 of a 28-day cycle. Trastuzumab concurrently with paclitaxel weekly for a total of 16 doses (4 mg/kg loading dose then 2 mg/kg weekly). Following paclitaxel/trastuzumab standard AC every 21 days for 4 cycles. Following surgery trastuzumab (8 mg/kg loading dose then 6 mg/kg) every 3 weeks to complete 1 year of targeted therapy (either preoperative trastuzumab therapy or neratinib therapy)  Paclitaxel  Trastuzumab  Doxorubicin  Cyclophosphamide,4 cycles of paclitaxel 80 mg/m2 on Days 1 8 and 15 of a 28-day cycle. Neratinib 240 mg orally once daily beginning on Day 1 of paclitaxel and continuing through Day 28 of the final cycle of paclitaxel. Following paclitaxel/neratinib therapy standard AC every 21 days for 4 cycles. Following surgery trastuzumab (8 mg/kg loading dose then 6 mg/kg) every 3 weeks to complete 1 year of targeted therapy (either preoperative trastuzumab therapy or neratinib therapy)  Paclitaxel  Neratinib  Doxorubicin  Cyclophosphamide,4 cycles of paclitaxel 80 mg/m2 on days 1 8 and 15 of a 28 day cycle. Trastuzumab concurrently with paclitaxel weekly for a total of 16 doses (4 mg/kg loading dose then 2 mg/kg weekly). Neratinib 200 mg orally once daily beginning on Day 1 of paclitaxel and continuing through Day 28 of the final cycle of paclitaxel. Following paclitaxel/trastuzumab/neratinib therapy standard AC every 21 days for 4 cycles. Following surgery trastuzumab (8 mg/kg loading dose then 6 mg/kg) every 3 weeks to complete 1 year of targeted therapy (either preoperative trastuzumab therapy or neratinib therapy)  Paclitaxel  Trastuzumab  Neratinib  Doxorubicin  Cyclophosphamide,4 cycles of paclitaxel 80 mg/m2 on days 1 8 and 15 of a 28 day cycle. Trastuzumab concurrently with paclitaxel weekly for a total of 16 doses (4 mg/kg loading dose then 2 mg/kg weekly). Neratinib 200 mg orally once daily beginning on Day 1 of paclitaxel and continuing through Day 28 of the final cycle of paclitaxel. Following paclitaxel/trastuzumab/neratinib therapy standard AC every 21 days for 4 cycles. Following surgery trastuzumab (8 mg/kg loading dose then 6 mg/kg) every 3 weeks to complete 1 year of targeted therapy (either preoperative trastuzumab therapy or neratinib therapy)  Paclitaxel  Trastuzumab  Neratinib  Doxorubicin  Cyclophosphamide
Total serious adverse events,7/42 %16.67,7/42 %16.67,10/42 %23.81,2/12 %16.67
Febrile neutropenia,1/42 %2.38,0/42 %0.0,1/42 %2.38,0/12 %0.0
Left venrticular dysfunction,1/42 %2.38,1/42 %2.38,0/42 %0.0,0/12 %0.0
Cardiac valve disease,1/42 %2.38,0/42 %0.0,0/42 %0.0,0/12 %0.0
Diarrhoea,0/42 %0.0,0/42 %0.0,2/42 %4.76,0/12 %0.0
Abdominal pain,1/42 %2.38,0/42 %0.0,0/42 %0.0,0/12 %0.0
Colitis,0/42 %0.0,0/42 %0.0,1/42 %2.38,0/12 %0.0
Nausea,0/42 %0.0,0/42 %0.0,1/42 %2.38,0/12 %0.0
Vomiting,0/42 %0.0,0/42 %0.0,1/42 %2.38,0/12 %0.0
Pyrexia,0/42 %0.0,2/42 %4.76,1/42 %2.38,0/12 %0.0
Influenza like illness,1/42 %2.38,0/42 %0.0,0/42 %0.0,0/12 %0.0
Oedema peripheral,1/42 %2.38,0/42 %0.0,0/42 %0.0,0/12 %0.0
Fatigue,0/42 %0.0,0/42 %0.0,1/42 %2.38,0/12 %0.0
Cholecystitis,0/42 %0.0,0/42 %0.0,0/42 %0.0,1/12 %8.33
Infection,1/42 %2.38,0/42 %0.0,1/42 %2.38,0/12 %0.0
Erysipelas,0/42 %0.0,1/42 %2.38,1/42 %2.38,0/12 %0.0
Cellulitis,1/42 %2.38,0/42 %0.0,0/42 %0.0,1/12 %8.33
Neutropenic infection,1/42 %2.38,0/42 %0.0,0/42 %0.0,0/12 %0.0
Osteomyelitis,1/42 %2.38,0/42 %0.0,0/42 %0.0,0/12 %0.0
Bacteraemia,0/42 %0.0,1/42 %2.38,0/42 %0.0,0/12 %0.0
Cystitis,0/42 %0.0,1/42 %2.38,0/42 %0.0,0/12 %0.0
Device related infection,0/42 %0.0,1/42 %2.38,0/42 %0.0,0/12 %0.0
Radiation skin injury,1/42 %2.38,0/42 %0.0,0/42 %0.0,0/12 %0.0
Hypokalaemia,0/42 %0.0,0/42 %0.0,1/42 %2.38,0/12 %0.0
Hyponatraemia,0/42 %0.0,0/42 %0.0,1/42 %2.38,0/12 %0.0
Syncope,0/42 %0.0,1/42 %2.38,0/42 %0.0,0/12 %0.0
Anxiety,0/42 %0.0,1/42 %2.38,0/42 %0.0,0/12 %0.0
Depression,0/42 %0.0,1/42 %2.38,0/42 %0.0,0/12 %0.0
Dyspnoea,1/42 %2.38,1/42 %2.38,0/42 %0.0,0/12 %0.0
Embolism,2/42 %4.76,1/42 %2.38,1/42 %2.38,0/12 %0.0
Haematoma,0/42 %0.0,0/42 %0.0,1/42 %2.38,0/12 %0.0

LC Bead Embolization Agent With Doxorubicin in the Treatment Liver Metastasis From Melanoma(https://clinicaltrials.gov/show/NCT01010984)
 ,Single Arm
 ,Tace using LC beads loaded with 150mg of Doxorubicin. May have up to 6 treatments.
Total all-cause mortality,19/20 %95.0
Total serious adverse events,19/20 %95.0
Bradycardia,1/20 %5.0
Intractable Nausea,3/20 %15.0
Cholecystitis,1/20 %5.0
Gastrointestinal Enteritis,1/20 %5.0
Pancreatitis,1/20 %5.0
Perforated Bowel,1/20 %5.0
Over Sedation,1/20 %5.0
Fever,1/20 %5.0
Hepatic Biliary Dilitation,3/20 %15.0
Ruptured Hepatic Lesion,1/20 %5.0
Staph Infection,1/20 %5.0
Stroke,1/20 %5.0
Urinary Tract Infection,1/20 %5.0
Pleural Effusion,1/20 %5.0
Hypertension,1/20 %5.0

Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer(https://clinicaltrials.gov/show/NCT01015833)
 ,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),Arm II (Sorafenib Tosylate)
 ,Patients receive 60 mg/m2 doxorubicin hydrochloride IV on day 1 and 400 mg sorafenib tosylate PO QD or BID on days 1-21. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After 6 courses patients may continue to receive sorafenib tosylate PO QD or BID in the absence of disease progression or unacceptable toxicity.,Patients receive 400 mg sorafenib tosylate PO QD or BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Total all-cause mortality,12/167 %7.19,16/171 %9.36
Total serious adverse events,71/167 %42.51,57/171 %33.33
Anemia,9/167 %5.39,4/171 %2.34
Febrile neutropenia,7/167 %4.19,0/171 %0.0
Leukocytosis,1/167 %0.6,0/171 %0.0
Spleen disorder,0/167 %0.0,1/171 %0.58
Thrombotic thrombocytopenic purpura,0/167 %0.0,1/171 %0.58
Atrial fibrillation,3/167 %1.8,1/171 %0.58
Cardiac disorder,1/167 %0.6,0/171 %0.0
Chest pain - cardiac,0/167 %0.0,1/171 %0.58
Left ventricular systolic dysfunction,3/167 %1.8,0/171 %0.0
Myocardial infarction,1/167 %0.6,0/171 %0.0
Palpitations,1/167 %0.6,0/171 %0.0
Sinus bradycardia,0/167 %0.0,1/171 %0.58
Sinus tachycardia,1/167 %0.6,1/171 %0.58
Hypothyroidism,1/167 %0.6,1/171 %0.58
Conjunctivitis,1/167 %0.6,0/171 %0.0
Abdominal distension,0/167 %0.0,1/171 %0.58
Abdominal pain,22/167 %13.17,28/171 %16.37
Anal mucositis,1/167 %0.6,0/171 %0.0
Ascites,3/167 %1.8,2/171 %1.17
Colitis,2/167 %1.2,0/171 %0.0
Constipation,1/167 %0.6,0/171 %0.0
Diarrhea,27/167 %16.17,13/171 %7.6
Dyspepsia,1/167 %0.6,0/171 %0.0
Dysphagia,3/167 %1.8,0/171 %0.0
Esophageal ulcer,1/167 %0.6,0/171 %0.0
Esophageal varices hemorrhage,1/167 %0.6,4/171 %2.34
Esophagitis,2/167 %1.2,0/171 %0.0
Gastric hemorrhage,0/167 %0.0,2/171 %1.17
Gastrointestinal disorders - Other specify,0/167 %0.0,1/171 %0.58
Hemorrhoidal hemorrhage,0/167 %0.0,1/171 %0.58
Lower gastrointestinal hemorrhage,1/167 %0.6,0/171 %0.0
Mucositis oral,17/167 %10.18,4/171 %2.34
Nausea,34/167 %20.36,24/171 %14.04
Pancreatitis,2/167 %1.2,0/171 %0.0
Rectal hemorrhage,1/167 %0.6,0/171 %0.0
Rectal mucositis,1/167 %0.6,0/171 %0.0
Upper gastrointestinal hemorrhage,1/167 %0.6,3/171 %1.75
Vomiting,4/167 %2.4,6/171 %3.51
Death NOS,4/167 %2.4,7/171 %4.09
Edema limbs,1/167 %0.6,0/171 %0.0
Edema trunk,0/167 %0.0,1/171 %0.58
Fatigue,49/167 %29.34,32/171 %18.71
Fever,2/167 %1.2,1/171 %0.58
Localized edema,0/167 %0.0,1/171 %0.58
Multi-organ failure,1/167 %0.6,0/171 %0.0
Non-cardiac chest pain,0/167 %0.0,2/171 %1.17
Pain,1/167 %0.6,0/171 %0.0
Sudden death NOS,1/167 %0.6,2/171 %1.17
Cholecystitis,0/167 %0.0,1/171 %0.58
Gallbladder obstruction,1/167 %0.6,1/171 %0.58
Hepatic failure,3/167 %1.8,1/171 %0.58
Hepatic hemorrhage,0/167 %0.0,2/171 %1.17
Hepatobiliary disorders - Other specify,0/167 %0.0,1/171 %0.58
Anaphylaxis,1/167 %0.6,0/171 %0.0
Abdominal infection,0/167 %0.0,1/171 %0.58
Bone infection,1/167 %0.6,1/171 %0.58
Infections and infestations - Other specify,3/167 %1.8,1/171 %0.58
Lung infection,6/167 %3.59,0/171 %0.0
Peritoneal infection,1/167 %0.6,1/171 %0.58
Rash pustular,1/167 %0.6,0/171 %0.0
Sepsis,5/167 %2.99,2/171 %1.17
Skin infection,2/167 %1.2,2/171 %1.17
Urinary tract infection,1/167 %0.6,0/171 %0.0
Wound infection,0/167 %0.0,1/171 %0.58
Fall,0/167 %0.0,2/171 %1.17
Fracture,0/167 %0.0,1/171 %0.58
Wound complication,1/167 %0.6,0/171 %0.0
Activated partial thromboplastin time prolonged,0/167 %0.0,1/171 %0.58
Alanine aminotransferase increased,3/167 %1.8,3/171 %1.75
Alkaline phosphatase increased,3/167 %1.8,4/171 %2.34
Aspartate aminotransferase increased,4/167 %2.4,6/171 %3.51
Blood bilirubin increased,8/167 %4.79,7/171 %4.09
Creatinine increased,3/167 %1.8,0/171 %0.0
Ejection fraction decreased,3/167 %1.8,1/171 %0.58
Haptoglobin decreased,1/167 %0.6,0/171 %0.0
INR increased,2/167 %1.2,1/171 %0.58
Leukocyte count decreased,1/167 %0.6,0/171 %0.0
Lipase increased,1/167 %0.6,0/171 %0.0
Lymphocyte count decreased,6/167 %3.59,2/171 %1.17
Neutrophil count decreased,31/167 %18.56,0/171 %0.0
Platelet count decreased,35/167 %20.96,20/171 %11.7
Weight loss,2/167 %1.2,1/171 %0.58
White blood cell decreased,10/167 %5.99,0/171 %0.0
Anorexia,5/167 %2.99,4/171 %2.34
Dehydration,14/167 %8.38,5/171 %2.92
Hyperglycemia,2/167 %1.2,2/171 %1.17
Hyperkalemia,4/167 %2.4,1/171 %0.58
Hypernatremia,0/167 %0.0,1/171 %0.58
Hypoalbuminemia,4/167 %2.4,1/171 %0.58
Hypokalemia,2/167 %1.2,0/171 %0.0
Hypomagnesemia,0/167 %0.0,1/171 %0.58
Hyponatremia,10/167 %5.99,4/171 %2.34
Hypophosphatemia,4/167 %2.4,1/171 %0.58
Metabolism and nutrition disorders - Other specify,0/167 %0.0,1/171 %0.58
Serum phosphate decreased,1/167 %0.6,0/171 %0.0
Back pain,1/167 %0.6,1/171 %0.58
Bone pain,0/167 %0.0,1/171 %0.58
Generalized muscle weakness,1/167 %0.6,1/171 %0.58
Myalgia,1/167 %0.6,0/171 %0.0
Neoplasms benign malignant and unspecified (incl cysts and polyps) - Other specify,1/167 %0.6,3/171 %1.75
Treatment related secondary malignancy,2/167 %1.2,0/171 %0.0
Amnesia,1/167 %0.6,0/171 %0.0
Headache,0/167 %0.0,1/171 %0.58
Intracranial hemorrhage,0/167 %0.0,1/171 %0.58
Nervous system disorders - Other specify,1/167 %0.6,0/171 %0.0
Seizure,0/167 %0.0,1/171 %0.58
Syncope vasovagal,1/167 %0.6,0/171 %0.0
Anxiety,1/167 %0.6,1/171 %0.58
Confusion,1/167 %0.6,2/171 %1.17
Acute kidney injury,1/167 %0.6,0/171 %0.0
Hematuria,2/167 %1.2,1/171 %0.58
Urogenital disorder,1/167 %0.6,0/171 %0.0
Dyspnea,4/167 %2.4,4/171 %2.34
Epistaxis,1/167 %0.6,3/171 %1.75
Hypoxia,1/167 %0.6,1/171 %0.58
Pulmonary edema,0/167 %0.0,1/171 %0.58
Sore throat,1/167 %0.6,0/171 %0.0
Alopecia,2/167 %1.2,0/171 %0.0
Erythema multiforme,1/167 %0.6,0/171 %0.0
Palmar-plantar erythrodysesthesia syndrome,13/167 %7.78,10/171 %5.85
Pruritus,1/167 %0.6,0/171 %0.0
Rash maculo-papular,1/167 %0.6,2/171 %1.17
Scalp pain,0/167 %0.0,1/171 %0.58
Skin ulceration,3/167 %1.8,3/171 %1.75
Stevens-Johnson syndrome,1/167 %0.6,0/171 %0.0
Hypertension,21/167 %12.57,16/171 %9.36
Hypotension,2/167 %1.2,1/171 %0.58
Thromboembolic event,0/167 %0.0,3/171 %1.75

Study of Pazopanib and Doxil in Patients With Advanced Relapsed Platinum-Sensitive or Platinum-Resistant Ovarian  Fallopian Tube or Primary Peritoneal Adenocarcinoma(https://clinicaltrials.gov/show/NCT01035658)
 ,Dose Level 1,Dose Level -1,Dose Level 1 Sequential,Dose Level 2 Sequential
 ,Systemic therapy with pazopanib and liposomal doxorubicin (Doxil). Single-agent pazopanib will be given for a 7 day run-in period followed by a combination of pazopanib (400mg) and liposomal doxorubicin (40mg) administered in 28-day treatment cycles. Cycles will continue until disease progression unacceptable toxicity or withdrawal.  Pazopanib: All patients will begin treatment with a 7-day run in period of single-agent pazopanib. Patients will receive pazopanib orally days 1-28 of a 28 day cycle.  Doxil: Liposomal doxorubicin (Doxil) will be administered IV on day 1 of a 28-day treatment cycle,Systemic therapy with pazopanib and liposomal doxorubicin (Doxil). Single-agent pazopanib will be given for a 7 day run-in period followed by a combination of pazopanib (400mg) and liposomal doxorubicin (30mg) administered in 28-day treatment cycles. Cycles will continue until disease progression unacceptable toxicity or withdrawal.  Pazopanib: All patients will begin treatment with a 7-day run in period of single-agent pazopanib. Patients will receive pazopanib orally days 1-28 of a 28 day cycle.  Doxil: Liposomal doxorubicin (Doxil) will be administered IV on day 1 of a 28-day treatment cycle,Systemic therapy with pazopanib and liposomal doxorubicin (Doxil). In this schedule liposomal doxorubicin (30mg) was given on day 1 and pazopanib (400mg) was given days 3 - 26 of each 28 day cycle. Cycles will continue until disease progression unacceptable toxicity or withdrawal.  Pazopanib: All patients will begin treatment with a 7-day run in period of single-agent pazopanib. Patients will receive pazopanib orally days 1-28 of a 28 day cycle.  Doxil: Liposomal doxorubicin (Doxil) will be administered IV on day 1 of a 28-day treatment cycle,Systemic therapy with pazopanib and liposomal doxorubicin (Doxil). In this schedule liposomal doxorubicin (40mg) was given on day 1 and pazopanib (400mg) was given days 3 - 26 of each 28 day cycle. Cycles will continue until disease progression unacceptable toxicity or withdrawal.  Pazopanib: All patients will begin treatment with a 7-day run in period of single-agent pazopanib. Patients will receive pazopanib orally days 1-28 of a 28 day cycle.  Doxil: Liposomal doxorubicin (Doxil) will be administered IV on day 1 of a 28-day treatment cycle
Total serious adverse events,3/5 %60.0,1/8 %12.5,2/3 %66.67,1/6 %16.67
Atrial Fibrillation,0/5 %0.0,0/8 %0.0,1/3 %33.33,0/6 %0.0
Abdominal pain,1/5 %20.0,0/8 %0.0,0/3 %0.0,0/6 %0.0
Pancreatitis,1/5 %20.0,0/8 %0.0,0/3 %0.0,0/6 %0.0
General disorders and administration site conditions - Other disease progression,0/5 %0.0,1/8 %12.5,0/3 %0.0,0/6 %0.0
Urinary tract infection,0/5 %0.0,1/8 %12.5,0/3 %0.0,0/6 %0.0
Infections and infestations - Other pneumonia,0/5 %0.0,0/8 %0.0,2/3 %66.67,0/6 %0.0
Fracture,0/5 %0.0,0/8 %0.0,0/3 %0.0,1/6 %16.67
Alanine aminotransferase increased,1/5 %20.0,0/8 %0.0,0/3 %0.0,0/6 %0.0
Aspartate aminotransferase increased,1/5 %20.0,0/8 %0.0,0/3 %0.0,0/6 %0.0
Dehydration,1/5 %20.0,1/8 %12.5,0/3 %0.0,0/6 %0.0
Generalized muscle weakness,1/5 %20.0,0/8 %0.0,0/3 %0.0,0/6 %0.0
Respiratory thoracic and mediastinal disorders - Other COPD exacerbation,0/5 %0.0,0/8 %0.0,1/3 %33.33,0/6 %0.0

Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma(https://clinicaltrials.gov/show/NCT01055314)
 ,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),Group 2 (Chemotherapy Radiation Therapy Temozolomide)
 ,Patients receive vincristine sulfate IV over 1 minute on day 1 of weeks 1-5 7 8 11 12 15 16 20-24 28 29 32 33 35 38 41-44 47 48 50 & 51; irinotecan hydrochloride IV over 90 minutes on days 1-5 of weeks 1 4 20 23 47 & 50; ifosfamide IV over 1 hour and etoposide IV over 1-2 hours on days 1-5 of weeks 9 13 17 26 & 30; doxorubicin hydrochloride IV over 1-15 minutes on days 1 and 2 of weeks 7 11 15 28 & 32; cyclophosphamide IV over 30-60 minutes on day 1 of weeks 7 11 15 28 32 35 38 41 & 44; dactinomycin IV over 1-5 minutes on day 1 of weeks 35 38 41 & 44; and cixutumumab IV over 1 hour on day 1 of weeks 1-51. Patients also undergo radiation therapy on days 1-5 of weeks 20-24.  Cixutumumab: Given IV  Cyclophosphamide: Given IV  Dactinomycin: Given IV  Doxorubicin Hydrochloride: Given IV  Etoposide: Given IV  Ifosfamide: Given IV  Irinotecan Hydrochloride: Given IV  Laboratory Biomarker Analysis: Correlative studies  Vincristine Sulfate,Patients receive vincristine sulfate irinotecan hydrochloride ifosfamide etoposide doxorubicin hydrochloride cyclophosphamide and dactinomycin and undergo radiation therapy as in group 1. Patients also receive temozolomide PO on days 1-5 of weeks 1 4 20 23 47 and 50.  Cyclophosphamide: Given IV  Dactinomycin: Given IV  Doxorubicin Hydrochloride: Given IV  Etoposide: Given IV  Ifosfamide: Given IV  Irinotecan Hydrochloride: Given IV  Laboratory Biomarker Analysis: Correlative studies  Temozolomide: Given PO  Vincristine Sulfate Liposome: Given IV
Total serious adverse events,79/96 %82.29,40/70 %57.14
Anemia,4/96 %4.17,1/70 %1.43
Bone marrow hypocellular,1/96 %1.04,0/70 %0.0
Disseminated intravascular coagulation,1/96 %1.04,0/70 %0.0
Febrile neutropenia,7/96 %7.29,0/70 %0.0
Cardiac arrest,0/96 %0.0,1/70 %1.43
Heart failure,1/96 %1.04,0/70 %0.0
Left ventricular systolic dysfunction,2/96 %2.08,1/70 %1.43
Sinus tachycardia,2/96 %2.08,0/70 %0.0
Ear and labyrinth disorders - Other specify,1/96 %1.04,0/70 %0.0
Endocrine disorders - Other specify,1/96 %1.04,0/70 %0.0
Abdominal distension,1/96 %1.04,0/70 %0.0
Abdominal pain,5/96 %5.21,0/70 %0.0
Anal ulcer,1/96 %1.04,0/70 %0.0
Ascites,1/96 %1.04,0/70 %0.0
Colitis,5/96 %5.21,0/70 %0.0
Diarrhea,8/96 %8.33,1/70 %1.43
Esophageal pain,1/96 %1.04,0/70 %0.0
Esophageal stenosis,1/96 %1.04,0/70 %0.0
Esophagitis,1/96 %1.04,0/70 %0.0
Gastric hemorrhage,1/96 %1.04,0/70 %0.0
Ileus,1/96 %1.04,0/70 %0.0
Mucositis oral,7/96 %7.29,0/70 %0.0
Nausea,4/96 %4.17,0/70 %0.0
Oral hemorrhage,1/96 %1.04,0/70 %0.0
Oral pain,1/96 %1.04,0/70 %0.0
Pancreatitis,2/96 %2.08,0/70 %0.0
Rectal fistula,1/96 %1.04,0/70 %0.0
Rectal hemorrhage,2/96 %2.08,0/70 %0.0
Rectal pain,1/96 %1.04,0/70 %0.0
Typhlitis,5/96 %5.21,0/70 %0.0
Upper gastrointestinal hemorrhage,2/96 %2.08,0/70 %0.0
Vomiting,5/96 %5.21,0/70 %0.0
Death NOS,30/96 %31.25,30/70 %42.86
Fever,1/96 %1.04,0/70 %0.0
Multi-organ failure,1/96 %1.04,0/70 %0.0
Pain,2/96 %2.08,0/70 %0.0
Hepatobiliary disorders - Other specify,1/96 %1.04,0/70 %0.0
Portal hypertension,2/96 %2.08,0/70 %0.0
Allergic reaction,2/96 %2.08,0/70 %0.0
Appendicitis,1/96 %1.04,0/70 %0.0
Catheter related infection,2/96 %2.08,0/70 %0.0
Enterocolitis infectious,1/96 %1.04,0/70 %0.0
Esophageal infection,1/96 %1.04,0/70 %0.0
Gum infection,1/96 %1.04,0/70 %0.0
Infections and infestations - Other specify,4/96 %4.17,1/70 %1.43
Lung infection,2/96 %2.08,0/70 %0.0
Mucosal infection,0/96 %0.0,1/70 %1.43
Sepsis,8/96 %8.33,0/70 %0.0
Sinusitis,1/96 %1.04,0/70 %0.0
Skin infection,4/96 %4.17,0/70 %0.0
Stoma site infection,1/96 %1.04,0/70 %0.0
Tracheitis,1/96 %1.04,0/70 %0.0
Dermatitis radiation,1/96 %1.04,0/70 %0.0
Fracture,1/96 %1.04,0/70 %0.0
Alanine aminotransferase increased,9/96 %9.38,0/70 %0.0
Alkaline phosphatase increased,1/96 %1.04,0/70 %0.0
Aspartate aminotransferase increased,5/96 %5.21,0/70 %0.0
Blood bilirubin increased,3/96 %3.12,0/70 %0.0
Ejection fraction decreased,1/96 %1.04,0/70 %0.0
GGT increased,3/96 %3.12,0/70 %0.0
INR increased,1/96 %1.04,0/70 %0.0
Lipase increased,3/96 %3.12,0/70 %0.0
Lymphocyte count decreased,2/96 %2.08,0/70 %0.0
Neutrophil count decreased,5/96 %5.21,1/70 %1.43
Platelet count decreased,8/96 %8.33,0/70 %0.0
Serum amylase increased,1/96 %1.04,0/70 %0.0
Weight loss,6/96 %6.25,1/70 %1.43
White blood cell decreased,5/96 %5.21,0/70 %0.0
Anorexia,4/96 %4.17,1/70 %1.43
Dehydration,7/96 %7.29,0/70 %0.0
Hypercalcemia,1/96 %1.04,0/70 %0.0
Hyperglycemia,10/96 %10.42,0/70 %0.0
Hypertriglyceridemia,1/96 %1.04,0/70 %0.0
Hypoalbuminemia,1/96 %1.04,0/70 %0.0
Hypocalcemia,1/96 %1.04,0/70 %0.0
Hypokalemia,5/96 %5.21,0/70 %0.0
Hyponatremia,3/96 %3.12,0/70 %0.0
Hypophosphatemia,3/96 %3.12,0/70 %0.0
Musculoskeletal and connective tissue disorder - Other specify,1/96 %1.04,0/70 %0.0
Pain in extremity,1/96 %1.04,0/70 %0.0
Myelodysplastic syndrome,1/96 %1.04,0/70 %0.0
Neoplasms benign malignant and unspecified (incl cysts and polyps) - Other specify,7/96 %7.29,5/70 %7.14
Depressed level of consciousness,2/96 %2.08,0/70 %0.0
Hydrocephalus,1/96 %1.04,0/70 %0.0
Peripheral sensory neuropathy,2/96 %2.08,0/70 %0.0
Seizure,0/96 %0.0,1/70 %1.43
Syncope,3/96 %3.12,0/70 %0.0
Vasovagal reaction,1/96 %1.04,0/70 %0.0
Delirium,1/96 %1.04,0/70 %0.0
Acute kidney injury,2/96 %2.08,0/70 %0.0
Hematuria,2/96 %2.08,0/70 %0.0
Penile pain,1/96 %1.04,0/70 %0.0
Adult respiratory distress syndrome,0/96 %0.0,1/70 %1.43
Apnea,2/96 %2.08,0/70 %0.0
Epistaxis,1/96 %1.04,0/70 %0.0
Hypoxia,1/96 %1.04,0/70 %0.0
Laryngeal edema,1/96 %1.04,0/70 %0.0
Pulmonary edema,1/96 %1.04,0/70 %0.0
Respiratory failure,1/96 %1.04,1/70 %1.43
Sore throat,1/96 %1.04,0/70 %0.0
Stridor,2/96 %2.08,0/70 %0.0
Rash maculo-papular,1/96 %1.04,0/70 %0.0
Hypotension,6/96 %6.25,0/70 %0.0
Thromboembolic event,2/96 %2.08,0/70 %0.0
Vascular disorders - Other specify,1/96 %1.04,0/70 %0.0

NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed(https://clinicaltrials.gov/show/NCT01098266)
 ,A: NGR-hTNF + BIC,B: Placebo+BIC
 ,NGR-hTNF plus Best Investigator's Choice  NGR-hTNF plus Best Investigator's Choice (BIC): - NGR-hTNF: 0.8 mcg/m as 60-minute intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs.  Best Supportive Care: antibiotics analgesics antiemetics thoracentesis pleurodesis blood transfusions nutritional support and focal external-beam radiation for control of pain cough dyspnea or hemoptysis  Investigator's Choice: one of the following single-agent chemotherapy might be administered in combination:  Doxorubicin: 60-75 mg/m2 every 3 weeks for a maximum of 6 cycles  Gemcitabine: 1000-1250 mg/m2 on days 1 and 8 every 3 weeks for a maximum of 6 cycles  Vinorelbine: 25 mg/m2 iv (or 60 mg/m2 per os) on days 1 and 8 every 3 weeks for a maximum of 6 cycles (or weekly for 12 weeks),Placebo plus Best Investigator's Choice  Placebo plus Best Investigator's Choice (BIC): - Placebo: 0.8 mcg/m as 60-minute intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs.  Best Supportive Care: antibiotics analgesics antiemetics thoracentesis pleurodesis blood transfusions nutritional support and focal external-beam radiation for control of pain cough dyspnea or hemoptysis  Investigator's Choice: one of the following single-agent chemotherapy might be administered in combination:  Doxorubicin: 60-75 mg/m2 every 3 weeks for a maximum of 6 cycles  Gemcitabine: 1000-1250 mg/m2 on days 1 and 8 every 3 weeks for a maximum of 6 cycles  Vinorelbine: 25 mg/m2 iv (or 60 mg/m2 per os) on days 1 and 8 every 3 weeks for a maximum of 6 cycles (or weekly for 12 weeks)
Total all-cause mortality,12/193 %6.22,13/193 %6.74
Total serious adverse events,56/193 %29.02,54/193 %27.98
Neutropenia,2/193 %1.04,4/193 %2.07
Thrombocytopenia,1/193 %0.52,0/193 %0.0
Leukopenia,0/193 %0.0,1/193 %0.52
Neutropenic fever,0/193 %0.0,2/193 %1.04
Anaemia,0/193 %0.0,1/193 %0.52
Pericardial effusion,1/193 %0.52,2/193 %1.04
Atrial fibrillation,1/193 %0.52,1/193 %0.52
Cardiac disorder,1/193 %0.52,0/193 %0.0
Cardiac failure,1/193 %0.52,0/193 %0.0
Myocardial infarction,0/193 %0.0,1/193 %0.52
Pericarditis,0/193 %0.0,1/193 %0.52
Cardiac arresr,0/193 %0.0,1/193 %0.52
Intestinal obstruction,0/193 %0.0,1/193 %0.52
Diarrhoea,2/193 %1.04,0/193 %0.0
Pancreatitis,0/193 %0.0,1/193 %0.52
Constipation,2/193 %1.04,1/193 %0.52
Abdominal pain,0/193 %0.0,2/193 %1.04
Abdominal ascites,1/193 %0.52,1/193 %0.52
Dysphagia,1/193 %0.52,0/193 %0.0
Vomiting,2/193 %1.04,0/193 %0.0
Chills,2/193 %1.04,0/193 %0.0
Mucositis,0/193 %0.0,1/193 %0.52
Pyrexia,2/193 %1.04,2/193 %1.04
Death,3/193 %1.55,2/193 %1.04
Hyperpyrexia,1/193 %0.52,0/193 %0.0
Ischaemic ulcer to left heel,0/193 %0.0,1/193 %0.52
Chest pain,3/193 %1.55,3/193 %1.55
Deterioration of clinical status,1/193 %0.52,1/193 %0.52
Admitted for pain control,1/193 %0.52,0/193 %0.0
Fatigue,0/193 %0.0,1/193 %0.52
Condition aggraveted,4/193 %2.07,5/193 %2.59
Acute hepatitis,0/193 %0.0,1/193 %0.52
Brain mets,1/193 %0.52,0/193 %0.0
Cellulitis,0/193 %0.0,1/193 %0.52
Pneumonia,0/193 %0.0,3/193 %1.55
Neutropenic sepsis,1/193 %0.52,1/193 %0.52
Appendiceal abscess,0/193 %0.0,1/193 %0.52
Sepsis,2/193 %1.04,1/193 %0.52
Infection - source unknown,1/193 %0.52,0/193 %0.0
Viral gastroenteritis,1/193 %0.52,0/193 %0.0
Lower Respiratory Tract Infection,2/193 %1.04,1/193 %0.52
Lung Infection,0/193 %0.0,1/193 %0.52
. Respiratory Tract Infection,0/193 %0.0,1/193 %0.52
Uncertain study medication dose delivered,4/193 %2.07,9/193 %4.66
Drug infusion reaction,2/193 %1.04,0/193 %0.0
Overdose,1/193 %0.52,0/193 %0.0
Humerus fracture,1/193 %0.52,0/193 %0.0
Hip fracture,1/193 %0.52,0/193 %0.0
Occipital trauma,1/193 %0.52,0/193 %0.0
Hyperglycaemia,1/193 %0.52,0/193 %0.0
Cachexia,1/193 %0.52,1/193 %0.52
Pleural Mesothelioma,1/193 %0.52,0/193 %0.0
Pain right chest wall + right shoulder,0/193 %0.0,1/193 %0.52
Paraneoplastic fever,1/193 %0.52,0/193 %0.0
Brain mets,0/193 %0.0,1/193 %0.52
Transient ischaemic attack,0/193 %0.0,1/193 %0.52
Superior sagittal sinus thrombosis,0/193 %0.0,1/193 %0.52
Right hemispheric cerebrovascular accident,1/193 %0.52,0/193 %0.0
Encephalopathy,1/193 %0.52,0/193 %0.0
Jacksonian seizure,1/193 %0.52,0/193 %0.0
Abnormal renal function,1/193 %0.52,0/193 %0.0
Pulmonary embolism,2/193 %1.04,2/193 %1.04
Dyspnoea,4/193 %2.07,1/193 %0.52
Respiratory failure,2/193 %1.04,2/193 %1.04
Bronchospasm,1/193 %0.52,0/193 %0.0
Pneumonitis,0/193 %0.0,1/193 %0.52
Infection (chest) with normal ANC,0/193 %0.0,1/193 %0.52
Pleural effusion,2/193 %1.04,0/193 %0.0
Pleural pain,0/193 %0.0,1/193 %0.52
Pneumothorax,1/193 %0.52,0/193 %0.0
Haemoptysis,0/193 %0.0,1/193 %0.52

A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin  Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic  Malignancies(https://clinicaltrials.gov/show/NCT01100944)
 ,All Participants
 ,All participants who had at least one dose of belinostat.
Total all-cause mortality,13/26 %50.0
Total serious adverse events,20/26 %76.92
Anemia,1/26 %3.85
Febrile neutropenia,1/26 %3.85
Atrial fibrillation,1/26 %3.85
Diarrhea,1/26 %3.85
Death NOS,11/26 %42.31
Infusion related reaction,1/26 %3.85
Localized edema,1/26 %3.85
Catheter related infection,2/26 %7.69
Infections and infestations - Other Meningoencephylitis,1/26 %3.85
Infections and infestations - Other West Nile virus,1/26 %3.85
Lung infection,1/26 %3.85
Electrocardiogram QT corrected interval prolonged,1/26 %3.85
Neutrophil count decreased,1/26 %3.85
Neoplasms benign malignant and unspecified (incl cysts and polyps) - OtherBasal cell carcinoma,1/26 %3.85
Neoplasms benign malignant and unspecified (incl cysts and polyps) - Other Death,2/26 %7.69
Respiratory failure,1/26 %3.85
Thromboembolic event,5/26 %19.23

BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer(https://clinicaltrials.gov/show/NCT01121406)
 ,Volasertib (BI 6727),Cytotoxic,Cytotoxic to Volasertib Switch
 ,Volasertib (BI 6727 300 mg) was administered as intravenous infusion over 2 hours at Day 1 of each 21-day treatment course.  Treatment was to be administered until disease progression or occurrence of toxicity leading to treatment discontinuation. Patients withdrawn from volasertib treatment could receive a treatment according to investigator's choice. The patients were to be followed for survival status.,Patients received a non-platinum cytotoxic single agent. The investigator chose the most appropriate drug according to patient status (previous chemotherapy effects cumulative toxic effects performance status and nutritional status) the product Summary of Product Characteristics (SPC) and the local standard of care. The following non-platinum regimens were recommended because they are regarded efficacious and safe in patients with resistant ovarian cancer:  Pegylated liposomal doxorubicin (PLD): 40 mg/m at Day 1 (1 course = 28 days)  Topotecan: 1.25 mg/m from Days 1 to 5 (1 course = 21 days) or 4 mg/m at Days 1 8 and 15 (1 course = 28 days)  Paclitaxel: 80 mg/m at Days 1 8 15 and 21 (1 course = 28 days)  Gemcitabine: 1000 mg/m at Days 1 and 8 (1 course = 21 days),Patients of the cytotoxic arm who switched to treatment with Volasertib (BI 6727).
Total serious adverse events,24/54 %44.44,19/55 %34.55,12/24 %50.0
Anaemia,1/54 %1.85,0/55 %0.0,0/24 %0.0
Febrile neutropenia,1/54 %1.85,0/55 %0.0,0/24 %0.0
Neutropenia,0/54 %0.0,0/55 %0.0,2/24 %8.33
Thrombocytopenia,2/54 %3.7,0/55 %0.0,0/24 %0.0
Atrial fibrillation,0/54 %0.0,0/55 %0.0,1/24 %4.17
Abdominal distension,1/54 %1.85,0/55 %0.0,0/24 %0.0
Abdominal pain,4/54 %7.41,1/55 %1.82,2/24 %8.33
Abdominal pain upper,2/54 %3.7,0/55 %0.0,0/24 %0.0
Ascites,0/54 %0.0,1/55 %1.82,0/24 %0.0
Constipation,0/54 %0.0,1/55 %1.82,0/24 %0.0
Diarrhoea,1/54 %1.85,1/55 %1.82,0/24 %0.0
Gastrointestinal haemorrhage,0/54 %0.0,0/55 %0.0,1/24 %4.17
Gastrointestinal obstruction,0/54 %0.0,1/55 %1.82,0/24 %0.0
Ileal perforation,1/54 %1.85,0/55 %0.0,0/24 %0.0
Ileus,2/54 %3.7,0/55 %0.0,0/24 %0.0
Intestinal obstruction,1/54 %1.85,3/55 %5.45,1/24 %4.17
Large intestine perforation,1/54 %1.85,0/55 %0.0,0/24 %0.0
Nausea,1/54 %1.85,2/55 %3.64,0/24 %0.0
Rectal haemorrhage,1/54 %1.85,0/55 %0.0,0/24 %0.0
Small intestinal obstruction,0/54 %0.0,1/55 %1.82,0/24 %0.0
Subileus,0/54 %0.0,1/55 %1.82,0/24 %0.0
Vomiting,3/54 %5.56,2/55 %3.64,0/24 %0.0
Chest pain,1/54 %1.85,0/55 %0.0,0/24 %0.0
Condition aggravated,1/54 %1.85,0/55 %0.0,0/24 %0.0
Death,0/54 %0.0,1/55 %1.82,0/24 %0.0
Euthanasia,0/54 %0.0,0/55 %0.0,1/24 %4.17
General physical health deterioration,0/54 %0.0,1/55 %1.82,0/24 %0.0
Multi-organ failure,1/54 %1.85,0/55 %0.0,0/24 %0.0
Obstruction,2/54 %3.7,1/55 %1.82,0/24 %0.0
Pyrexia,2/54 %3.7,2/55 %3.64,0/24 %0.0
Cholecystitis,0/54 %0.0,1/55 %1.82,0/24 %0.0
Drug hypersensitivity,0/54 %0.0,1/55 %1.82,0/24 %0.0
Device related sepsis,0/54 %0.0,0/55 %0.0,1/24 %4.17
Pneumonia,0/54 %0.0,1/55 %1.82,0/24 %0.0
Pyelonephritis,0/54 %0.0,1/55 %1.82,0/24 %0.0
Sepsis,1/54 %1.85,1/55 %1.82,1/24 %4.17
Urinary tract infection,0/54 %0.0,0/55 %0.0,1/24 %4.17
Blood alkaline phosphatase increased,1/54 %1.85,0/55 %0.0,0/24 %0.0
Blood creatinine increased,1/54 %1.85,0/55 %0.0,0/24 %0.0
Gamma-glutamyltransferase increased,1/54 %1.85,0/55 %0.0,0/24 %0.0
Neutrophil count decreased,0/54 %0.0,0/55 %0.0,1/24 %4.17
Decreased appetite,0/54 %0.0,1/55 %1.82,0/24 %0.0
Dehydration,1/54 %1.85,0/55 %0.0,1/24 %4.17
Invasive ductal breast carcinoma,0/54 %0.0,0/55 %0.0,1/24 %4.17
Metastases to heart,1/54 %1.85,0/55 %0.0,0/24 %0.0
Neoplasm progression,0/54 %0.0,1/55 %1.82,1/24 %4.17
Tumour invasion,0/54 %0.0,0/55 %0.0,1/24 %4.17
Cerebrovascular accident,0/54 %0.0,1/55 %1.82,0/24 %0.0
Anxiety,0/54 %0.0,1/55 %1.82,0/24 %0.0
Panic reaction,1/54 %1.85,0/55 %0.0,0/24 %0.0
Pyelocaliectasis,0/54 %0.0,0/55 %0.0,1/24 %4.17
Atelectasis,1/54 %1.85,0/55 %0.0,0/24 %0.0
Dyspnoea,4/54 %7.41,0/55 %0.0,0/24 %0.0
Pleural effusion,0/54 %0.0,1/55 %1.82,1/24 %4.17
Pulmonary embolism,2/54 %3.7,0/55 %0.0,0/24 %0.0
Respiratory distress,1/54 %1.85,0/55 %0.0,0/24 %0.0
Hypertension,1/54 %1.85,0/55 %0.0,0/24 %0.0
Poor venous access,1/54 %1.85,0/55 %0.0,0/24 %0.0

Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer(https://clinicaltrials.gov/show/NCT01167192)
 ,Neoadjuvant Cisplatin or Carboplatin AUC 6 & Radiation
 ,Cisplatin 75 mg/m^2 IV every 21 days for 4 cycles or Carboplatin AUC 6 IV every 21 days for 4 cycles.  Radiation beginning cycle 2 day 1 daily for 5-6 weeks 45-50 Gy.  Recommended mastectomy  Recommended adjuvant chemotherapy  -Doxorubicin 60 mg/m^2 and cyclophosphamide 600 mg/m^2 for 14 days for 4 cycles followed by paclitaxel 175 mg/m^2 for 14 days for 4 cycles)
Total serious adverse events,3/8 %37.5
Anemia,2/8 %25.0
Leukocytosis,1/8 %12.5
Bradycardia,1/8 %12.5
Cardiac arrest,1/8 %12.5
Pulseless electrical activity,1/8 %12.5
Nausea,1/8 %12.5
Vomiting,2/8 %25.0
Chills,2/8 %25.0
Fever,2/8 %25.0
Bacteremia,1/8 %12.5
Urinary tract infection,1/8 %12.5
Decreased lymphocytes,2/8 %25.0
Decreased platelets,1/8 %12.5
Increased creatinine,2/8 %25.0
Increased international normalized ratio (INR),1/8 %12.5
Alkaline phosphatase increased,2/8 %25.0
Anorexia,1/8 %12.5
Hypercalcemia,1/8 %12.5
Hyperglycemia,1/8 %12.5
Hyperkalemia,1/8 %12.5
Hypertriglyceridemia,1/8 %12.5
Hypoalbuminemia,2/8 %25.0
Hypocalcemia,1/8 %12.5
Hypoglycemia,1/8 %12.5
Hypomagnesemia,1/8 %12.5
Hyponatremia,1/8 %12.5
Back pain,1/8 %12.5
Ataxia,1/8 %12.5
Cerebral-vascular accident,1/8 %12.5
Dysarthia,1/8 %12.5
Acute renal injury,1/8 %12.5
Cellulitis,1/8 %12.5
Hypertension,1/8 %12.5

A Study of Olaratumab in Soft Tissue Sarcoma(https://clinicaltrials.gov/show/NCT01185964)
 ,Phase 1b: Olaratumab + Doxorubicin,Phase 2: Olaratumab + Doxorubicin,Phase 2: Doxorubicin,Phase 2: Doxorubicin: Optional Olaratumab After Progression
 ,All cycles are 21 days.  Cycles 1-8: Olaratumab 15 milligram/kilogram (mg/kg) on days 1+8 and doxorubicin 75 milligram/square meter (mg/m2) on day 1  All subsequent cycles until progression:  Olaratumab 15 mg/kg by intravenous IV on days 1+8 of a 21-day cycle,All cycles are 21 days.  Cycles 1-8: Olaratumab 15 mg/kg on days 1+8 and doxorubicin 75 mg/m2 on day 1  All subsequent cycles until progression:  Olaratumab 15 mg/kg by IV on days 1+8 of a 21-day cycle,All cycles are 21 days.  Cycles 1-8: doxorubicin 75 mg/m2 on day 1  At disease progression: optional Olaratumab 15 mg/kg on days 1+8 until further progression.,All subsequent cycles: Participants from doxorubicin monotherapy arm received optional Olaratumab 15 mg/kg on days 1+8 of a 21-day cycle.
Total serious adverse events,7/15 %46.67,27/64 %42.19,26/65 %40.0,9/30 %30.0
Anaemia,0/15 %0.0,0/64 %0.0,1/65 %1.54,0/30 %0.0
Febrile neutropenia,2/15 %13.33,8/64 %12.5,8/65 %12.31,0/30 %0.0
Neutropenia,0/15 %0.0,3/64 %4.69,3/65 %4.62,0/30 %0.0
Thrombocytopenia,0/15 %0.0,0/64 %0.0,2/65 %3.08,0/30 %0.0
Cardiac arrest,0/15 %0.0,0/64 %0.0,0/65 %0.0,1/30 %3.33
Sinus bradycardia,0/15 %0.0,1/64 %1.56,0/65 %0.0,0/30 %0.0
Inappropriate antidiuretic hormone secretion,0/15 %0.0,0/64 %0.0,1/65 %1.54,0/30 %0.0
Abdominal pain,1/15 %6.67,1/64 %1.56,1/65 %1.54,0/30 %0.0
Abdominal pain upper,1/15 %6.67,1/64 %1.56,0/65 %0.0,0/30 %0.0
Ascites,0/15 %0.0,0/64 %0.0,1/65 %1.54,0/30 %0.0
Constipation,0/15 %0.0,1/64 %1.56,1/65 %1.54,0/30 %0.0
Diarrhoea,1/15 %6.67,0/64 %0.0,1/65 %1.54,0/30 %0.0
Dry mouth,0/15 %0.0,1/64 %1.56,0/65 %0.0,0/30 %0.0
Gastric perforation,0/15 %0.0,1/64 %1.56,0/65 %0.0,0/30 %0.0
Gastric ulcer,1/15 %6.67,0/64 %0.0,0/65 %0.0,0/30 %0.0
Gastrointestinal haemorrhage,0/15 %0.0,0/64 %0.0,1/65 %1.54,1/30 %3.33
Ileus,0/15 %0.0,1/64 %1.56,0/65 %0.0,0/30 %0.0
Nausea,2/15 %13.33,1/64 %1.56,2/65 %3.08,0/30 %0.0
Small intestinal obstruction,1/15 %6.67,1/64 %1.56,2/65 %3.08,0/30 %0.0
Upper gastrointestinal haemorrhage,0/15 %0.0,0/64 %0.0,0/65 %0.0,1/30 %3.33
Vomiting,3/15 %20.0,1/64 %1.56,0/65 %0.0,0/30 %0.0
Asthenia,0/15 %0.0,1/64 %1.56,0/65 %0.0,0/30 %0.0
Death,1/15 %6.67,0/64 %0.0,0/65 %0.0,0/30 %0.0
Device breakage,0/15 %0.0,1/64 %1.56,0/65 %0.0,0/30 %0.0
Disease progression,0/15 %0.0,0/64 %0.0,0/65 %0.0,1/30 %3.33
Non-cardiac chest pain,1/15 %6.67,1/64 %1.56,1/65 %1.54,0/30 %0.0
Pyrexia,0/15 %0.0,0/64 %0.0,1/65 %1.54,0/30 %0.0
Hepatic haemorrhage,0/15 %0.0,1/64 %1.56,0/65 %0.0,0/30 %0.0
Hypersensitivity,0/15 %0.0,2/64 %3.12,0/65 %0.0,0/30 %0.0
Actinomycotic skin infection,0/15 %0.0,1/64 %1.56,0/65 %0.0,0/30 %0.0
Cellulitis,0/15 %0.0,1/64 %1.56,2/65 %3.08,0/30 %0.0
Clostridium difficile colitis,0/15 %0.0,1/64 %1.56,0/65 %0.0,0/30 %0.0
Influenza,0/15 %0.0,0/64 %0.0,0/65 %0.0,1/30 %3.33
Neutropenic sepsis,0/15 %0.0,0/64 %0.0,2/65 %3.08,0/30 %0.0
Sepsis,0/15 %0.0,0/64 %0.0,1/65 %1.54,0/30 %0.0
Septic shock,0/15 %0.0,0/64 %0.0,1/65 %1.54,0/30 %0.0
Sinusitis,0/15 %0.0,1/64 %1.56,0/65 %0.0,0/30 %0.0
Skin infection,0/15 %0.0,0/64 %0.0,1/65 %1.54,0/30 %0.0
Staphylococcal bacteraemia,0/15 %0.0,1/64 %1.56,0/65 %0.0,0/30 %0.0
Urinary tract infection,0/15 %0.0,1/64 %1.56,3/65 %4.62,0/30 %0.0
Anastomotic ulcer,0/15 %0.0,0/64 %0.0,1/65 %1.54,0/30 %0.0
Fracture,1/15 %6.67,0/64 %0.0,0/65 %0.0,0/30 %0.0
Infusion related reaction,0/15 %0.0,0/64 %0.0,0/65 %0.0,1/30 %3.33
Procedural pain,0/15 %0.0,0/64 %0.0,1/65 %1.54,0/30 %0.0
Wound necrosis,0/15 %0.0,1/64 %1.56,0/65 %0.0,0/30 %0.0
Blood creatinine increased,0/15 %0.0,0/64 %0.0,1/65 %1.54,0/30 %0.0
Troponin increased,0/15 %0.0,1/64 %1.56,0/65 %0.0,0/30 %0.0
White blood cell count decreased,0/15 %0.0,1/64 %1.56,0/65 %0.0,0/30 %0.0
Decreased appetite,0/15 %0.0,1/64 %1.56,0/65 %0.0,0/30 %0.0
Dehydration,0/15 %0.0,1/64 %1.56,0/65 %0.0,0/30 %0.0
Hypocalcaemia,0/15 %0.0,1/64 %1.56,0/65 %0.0,0/30 %0.0
Hypokalaemia,0/15 %0.0,1/64 %1.56,1/65 %1.54,0/30 %0.0
Hypomagnesaemia,0/15 %0.0,1/64 %1.56,0/65 %0.0,0/30 %0.0
Arthralgia,0/15 %0.0,1/64 %1.56,0/65 %0.0,0/30 %0.0
Back pain,2/15 %13.33,2/64 %3.12,0/65 %0.0,2/30 %6.67
Musculoskeletal chest pain,0/15 %0.0,0/64 %0.0,1/65 %1.54,0/30 %0.0
Pain in extremity,0/15 %0.0,1/64 %1.56,0/65 %0.0,1/30 %3.33
Tumour pain,0/15 %0.0,0/64 %0.0,0/65 %0.0,1/30 %3.33
Cerebrovascular accident,0/15 %0.0,0/64 %0.0,1/65 %1.54,0/30 %0.0
Convulsion,0/15 %0.0,0/64 %0.0,1/65 %1.54,0/30 %0.0
Syncope,0/15 %0.0,0/64 %0.0,1/65 %1.54,0/30 %0.0
Renal failure acute,0/15 %0.0,0/64 %0.0,1/65 %1.54,0/30 %0.0
Dyspnoea,0/15 %0.0,0/64 %0.0,1/65 %1.54,1/30 %3.33
Obstructive airways disorder,0/15 %0.0,0/64 %0.0,1/65 %1.54,0/30 %0.0
Pleural effusion,1/15 %6.67,1/64 %1.56,1/65 %1.54,0/30 %0.0
Pleuritic pain,0/15 %0.0,1/64 %1.56,0/65 %0.0,0/30 %0.0
Pneumonia aspiration,0/15 %0.0,0/64 %0.0,1/65 %1.54,0/30 %0.0
Pneumothorax,0/15 %0.0,2/64 %3.12,2/65 %3.08,0/30 %0.0
Pulmonary embolism,1/15 %6.67,0/64 %0.0,1/65 %1.54,0/30 %0.0
Respiratory failure,0/15 %0.0,1/64 %1.56,1/65 %1.54,0/30 %0.0
Hypotension,0/15 %0.0,0/64 %0.0,1/65 %1.54,0/30 %0.0

Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors(https://clinicaltrials.gov/show/NCT01188499)
 ,Arm 1: Carboplatin/Paclitaxel + Birinapant,Arm 2: Irinotecan + Birinapant,Arm 3: Docetaxel + Birinapant,Arm 4: Gemcitabine + Birinapant,Arm 5: Liposomal Doxorubicin + Birinapant
 ,Carboplatin (AUC 6/Paclitaxel (175 mg/m2/IV) once every 3 (q3) weeks + TL32711 once weekly (7 days +/- 2 days) for 2 consecutive weeks followed by 1 week off for each cycle (3 weeks per cycle).  TL32711: 30 minute intravenous (IV) infusion of TL32711 administered once weekly for two consecutive weeks followed by one week off repeated every 3 weeks as tolerated in combination with chemotherapy,Irinotecan (350 mg/m2/IV) once every 3 (q3) weeks + TL32711 once weekly (7 days +/- 2 days) for 2 consecutive weeks followed by 1 week off for each cycle (3 weeks per cycle).  TL32711: 30 minute intravenous (IV) infusion of TL32711 administered once weekly for two consecutive weeks followed by one week off repeated every 3 weeks as tolerated in combination with chemotherapy,Docetaxel (75 mg/m2/IV) once every 3 (q3) weeks + TL32711 once weekly (7 days +/- 2 days) for 2 consecutive weeks followed by 1 week off for each cycle (3 weeks per cycle).  TL32711: 30 minute intravenous (IV) infusion of TL32711 administered once weekly for two consecutive weeks followed by one week off repeated every 3 weeks as tolerated in combination with chemotherapy,Gemcitabine (1000 mg/m2/IV) once weekly (7 days +/- 2 days) for 3 consecutive weeks followed by 1 week off + TL32711 once weekly (7 days +/- 2 days) for 2 consecutive weeks followed by 2 week off for each cycle (4 weeks per cycle).  TL32711: 30 minute intravenous (IV) infusion of TL32711 administered once weekly for two consecutive weeks followed by two weeks off repeated every 4 weeks as tolerated in combination with chemotherapy.,Liposomal doxorubicin (40 mg/m2/IV) every 4 weeks + TL32711 once weekly (7 days +/- 2 days) for 2 consecutive weeks followed by 2 weeks off for each cycle (4 weeks per cycle).  TL32711: 30 minute intravenous (IV) infusion of TL32711 administered once weekly for two consecutive weeks followed by two weeks off repeated every 4 weeks as tolerated in combination with chemotherapy.
Total serious adverse events,9/24 %37.5,41/83 %49.4,16/33 %48.48,13/18 %72.22,9/18 %50.0
Anaemia,2/24 %8.33,3/83 %3.61,2/33 %6.06,1/18 %5.56,1/18 %5.56
Coagulopathy,0/24 %0.0,1/83 %1.2,0/33 %0.0,1/18 %5.56,0/18 %0.0
Disseminated intravascular coagulation,0/24 %0.0,0/83 %0.0,0/33 %0.0,0/18 %0.0,1/18 %5.56
Febrile neutropenia,0/24 %0.0,7/83 %8.43,1/33 %3.03,0/18 %0.0,0/18 %0.0
Neutropenia,0/24 %0.0,5/83 %6.02,1/33 %3.03,0/18 %0.0,0/18 %0.0
Leukocytosis,1/24 %4.17,0/83 %0.0,0/33 %0.0,0/18 %0.0,0/18 %0.0
Thrombocytopenia,0/24 %0.0,3/83 %3.61,1/33 %3.03,0/18 %0.0,0/18 %0.0
Pancytopenia,0/24 %0.0,3/83 %3.61,0/33 %0.0,0/18 %0.0,0/18 %0.0
Cardiac tamponade,0/24 %0.0,0/83 %0.0,0/33 %0.0,0/18 %0.0,1/18 %5.56
Stress cardiomyopathy,0/24 %0.0,0/83 %0.0,0/33 %0.0,1/18 %5.56,0/18 %0.0
Pyloric stenosis,0/24 %0.0,0/83 %0.0,1/33 %3.03,0/18 %0.0,0/18 %0.0
Abdominal pain,0/24 %0.0,4/83 %4.82,1/33 %3.03,0/18 %0.0,2/18 %11.11
Abdominal pain upper,1/24 %4.17,1/83 %1.2,0/33 %0.0,0/18 %0.0,0/18 %0.0
Anal fissure,0/24 %0.0,1/83 %1.2,0/33 %0.0,0/18 %0.0,0/18 %0.0
Ascites,0/24 %0.0,0/83 %0.0,1/33 %3.03,0/18 %0.0,0/18 %0.0
Colitis,0/24 %0.0,3/83 %3.61,0/33 %0.0,0/18 %0.0,0/18 %0.0
Constipation,2/24 %8.33,0/83 %0.0,0/33 %0.0,0/18 %0.0,0/18 %0.0
Diarrhoea,0/24 %0.0,6/83 %7.23,0/33 %0.0,0/18 %0.0,0/18 %0.0
Gastrointestinal haemorrhage,0/24 %0.0,2/83 %2.41,1/33 %3.03,0/18 %0.0,0/18 %0.0
Intestinal obstruction,0/24 %0.0,0/83 %0.0,1/33 %3.03,0/18 %0.0,0/18 %0.0
Intestinal perforation,0/24 %0.0,0/83 %0.0,1/33 %3.03,0/18 %0.0,0/18 %0.0
Lower gastrointestinal haemorrhage,0/24 %0.0,0/83 %0.0,1/33 %3.03,0/18 %0.0,0/18 %0.0
Nausea,1/24 %4.17,2/83 %2.41,0/33 %0.0,1/18 %5.56,1/18 %5.56
Oesophagitis,0/24 %0.0,0/83 %0.0,0/33 %0.0,0/18 %0.0,1/18 %5.56
Reflux gastritis,0/24 %0.0,0/83 %0.0,0/33 %0.0,0/18 %0.0,1/18 %5.56
Small intestinal obstruction,1/24 %4.17,3/83 %3.61,1/33 %3.03,0/18 %0.0,0/18 %0.0
Upper gastrointestinal haemorrhage,0/24 %0.0,1/83 %1.2,0/33 %0.0,0/18 %0.0,0/18 %0.0
Vomiting,1/24 %4.17,5/83 %6.02,0/33 %0.0,2/18 %11.11,2/18 %11.11
Caecitis,0/24 %0.0,2/83 %2.41,0/33 %0.0,0/18 %0.0,0/18 %0.0
Gastric ulcer,0/24 %0.0,1/83 %1.2,0/33 %0.0,0/18 %0.0,0/18 %0.0
Gastritis,0/24 %0.0,1/83 %1.2,0/33 %0.0,0/18 %0.0,0/18 %0.0
Haematemesis,0/24 %0.0,1/83 %1.2,0/33 %0.0,0/18 %0.0,0/18 %0.0
Oesophageal varices haemorrhage,0/24 %0.0,1/83 %1.2,0/33 %0.0,0/18 %0.0,0/18 %0.0
Chest pain,0/24 %0.0,0/83 %0.0,0/33 %0.0,0/18 %0.0,1/18 %5.56
Death,1/24 %4.17,0/83 %0.0,0/33 %0.0,0/18 %0.0,0/18 %0.0
Disease progression,0/24 %0.0,4/83 %4.82,5/33 %15.15,1/18 %5.56,1/18 %5.56
Generalized oedema,0/24 %0.0,0/83 %0.0,1/33 %3.03,0/18 %0.0,0/18 %0.0
Oedema peripheral,1/24 %4.17,0/83 %0.0,0/33 %0.0,0/18 %0.0,0/18 %0.0
Pain,0/24 %0.0,0/83 %0.0,0/33 %0.0,1/18 %5.56,0/18 %0.0
Pyrexia,0/24 %0.0,1/83 %1.2,2/33 %6.06,3/18 %16.67,1/18 %5.56
Asthenia,0/24 %0.0,1/83 %1.2,0/33 %0.0,0/18 %0.0,0/18 %0.0
Fatigue,0/24 %0.0,1/83 %1.2,0/33 %0.0,0/18 %0.0,0/18 %0.0
Bile duct stenosis,0/24 %0.0,0/83 %0.0,1/33 %3.03,0/18 %0.0,0/18 %0.0
Cholelithiasis,0/24 %0.0,0/83 %0.0,0/33 %0.0,0/18 %0.0,1/18 %5.56
Jaundice cholestatic,0/24 %0.0,0/83 %0.0,0/33 %0.0,1/18 %5.56,0/18 %0.0
Bronchitis,0/24 %0.0,0/83 %0.0,1/33 %3.03,0/18 %0.0,0/18 %0.0
Cholangitis suppurative,0/24 %0.0,0/83 %0.0,1/33 %3.03,0/18 %0.0,0/18 %0.0
Cystitis,0/24 %0.0,0/83 %0.0,0/33 %0.0,1/18 %5.56,0/18 %0.0
Device related infection,0/24 %0.0,0/83 %0.0,0/33 %0.0,1/18 %5.56,0/18 %0.0
Empyema,0/24 %0.0,0/83 %0.0,0/33 %0.0,1/18 %5.56,0/18 %0.0
Escherichia bacteraemia,0/24 %0.0,0/83 %0.0,1/33 %3.03,0/18 %0.0,0/18 %0.0
Kidney infection,0/24 %0.0,0/83 %0.0,0/33 %0.0,2/18 %11.11,0/18 %0.0
Pneumonia,3/24 %12.5,2/83 %2.41,5/33 %15.15,2/18 %11.11,1/18 %5.56
Sepsis,1/24 %4.17,4/83 %4.82,1/33 %3.03,0/18 %0.0,0/18 %0.0
Septic shock,0/24 %0.0,0/83 %0.0,0/33 %0.0,0/18 %0.0,1/18 %5.56
Upper respiratory tract infection,0/24 %0.0,0/83 %0.0,0/33 %0.0,0/18 %0.0,1/18 %5.56
Urinary tract infection,0/24 %0.0,5/83 %6.02,0/33 %0.0,0/18 %0.0,0/18 %0.0
Bacterial sepsis,0/24 %0.0,1/83 %1.2,0/33 %0.0,0/18 %0.0,0/18 %0.0
Fall,1/24 %4.17,0/83 %0.0,0/33 %0.0,0/18 %0.0,0/18 %0.0
Femoral neck fracture,0/24 %0.0,1/83 %1.2,0/33 %0.0,0/18 %0.0,0/18 %0.0
Electrocardiogram QT prolonged,0/24 %0.0,0/83 %0.0,0/33 %0.0,1/18 %5.56,0/18 %0.0
International normalised ratio increased,0/24 %0.0,1/83 %1.2,0/33 %0.0,0/18 %0.0,0/18 %0.0
Dehydration,1/24 %4.17,8/83 %9.64,1/33 %3.03,1/18 %5.56,1/18 %5.56
Failure to thrive,0/24 %0.0,0/83 %0.0,2/33 %6.06,0/18 %0.0,0/18 %0.0
Fluid overload,0/24 %0.0,0/83 %0.0,1/33 %3.03,0/18 %0.0,0/18 %0.0
Hyperglycaemia,0/24 %0.0,0/83 %0.0,1/33 %3.03,0/18 %0.0,0/18 %0.0
Hyponatraemia,0/24 %0.0,0/83 %0.0,1/33 %3.03,0/18 %0.0,0/18 %0.0
Metabolic acidosis,0/24 %0.0,1/83 %1.2,0/33 %0.0,0/18 %0.0,0/18 %0.0
Hypokalaemia,0/24 %0.0,1/83 %1.2,0/33 %0.0,0/18 %0.0,0/18 %0.0
Hypovolaemia,0/24 %0.0,1/83 %1.2,0/33 %0.0,0/18 %0.0,0/18 %0.0
Back pain,0/24 %0.0,0/83 %0.0,0/33 %0.0,2/18 %11.11,0/18 %0.0
Intracranial tumour haemorrhage,1/24 %4.17,0/83 %0.0,0/33 %0.0,0/18 %0.0,0/18 %0.0
Colon cancer stage IV,0/24 %0.0,1/83 %1.2,0/33 %0.0,0/18 %0.0,0/18 %0.0
Spinal cord compression,1/24 %4.17,0/83 %0.0,0/33 %0.0,0/18 %0.0,0/18 %0.0
Confusional state,1/24 %4.17,1/83 %1.2,0/33 %0.0,0/18 %0.0,0/18 %0.0
Mental status changes,0/24 %0.0,0/83 %0.0,0/33 %0.0,0/18 %0.0,1/18 %5.56
Hydronephrosis,0/24 %0.0,1/83 %1.2,0/33 %0.0,0/18 %0.0,1/18 %5.56
Renal failure acute,0/24 %0.0,4/83 %4.82,0/33 %0.0,0/18 %0.0,1/18 %5.56
Urinary incontinence,0/24 %0.0,1/83 %1.2,0/33 %0.0,0/18 %0.0,0/18 %0.0
Acute respiratory failure,0/24 %0.0,2/83 %2.41,1/33 %3.03,0/18 %0.0,0/18 %0.0
Bronchial fistula,0/24 %0.0,0/83 %0.0,0/33 %0.0,1/18 %5.56,0/18 %0.0
Dyspnoea,0/24 %0.0,0/83 %0.0,1/33 %3.03,0/18 %0.0,0/18 %0.0
Haemoptysis,0/24 %0.0,0/83 %0.0,0/33 %0.0,0/18 %0.0,1/18 %5.56
Pleural effusion,0/24 %0.0,0/83 %0.0,0/33 %0.0,3/18 %16.67,1/18 %5.56
Pleurisy,1/24 %4.17,0/83 %0.0,0/33 %0.0,0/18 %0.0,0/18 %0.0
Pneumonitis,0/24 %0.0,0/83 %0.0,0/33 %0.0,1/18 %5.56,0/18 %0.0
Pulmonary embolism,0/24 %0.0,4/83 %4.82,1/33 %3.03,1/18 %5.56,0/18 %0.0
Pulmonary haemorrhage,0/24 %0.0,0/83 %0.0,0/33 %0.0,1/18 %5.56,0/18 %0.0
Pulmonary oedema,0/24 %0.0,1/83 %1.2,0/33 %0.0,0/18 %0.0,0/18 %0.0
Respiratory failure,0/24 %0.0,0/83 %0.0,0/33 %0.0,0/18 %0.0,1/18 %5.56
Aspiration,0/24 %0.0,1/83 %1.2,0/33 %0.0,0/18 %0.0,0/18 %0.0
Respiratory distress,0/24 %0.0,1/83 %1.2,0/33 %0.0,0/18 %0.0,0/18 %0.0
Deep vein thrombosis,0/24 %0.0,1/83 %1.2,1/33 %3.03,1/18 %5.56,2/18 %11.11
Venous thrombosis limb,0/24 %0.0,1/83 %1.2,0/33 %0.0,0/18 %0.0,0/18 %0.0
Hypotension,0/24 %0.0,5/83 %6.02,0/33 %0.0,0/18 %0.0,0/18 %0.0

Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas(https://clinicaltrials.gov/show/NCT01193842)
 ,Phase I: VR-DA-EPOCH Dose Level 1,Phase I: VR-DA-EPOCH Dose Level 2,Phase I: VR-CHOP Dose Level 1,Phase II: VR-DA-EPOCH,Phase II: DA-R-EPOCH
 ,Arm A (VR-DA-EPOCH) with Vorinostat at 300 mg once a day on days 1-5 of a cycle (Phase I Dose Level 1),Arm A (VR-DA-EPOCH) with Vorinostat at 400 mg once a day on days 1-5 of a cycle (Phase I Dose Level 2),Arm C (VR-CHOP) with Vorinostat at 300 mg once a day on days 1-5 of a cycle (Phase I Dose Level 1 for low risk participants). This arm was discontinued due to low accrual.,Arm A (VR-DA-EPOCH) at the recommended phase II dose of Vorinostat (300 mg once a day for days 1-5 of a cycle),Arm B (DA-R-EPOCH) which is the same treatment as Arm A but without Vorinostat
Total all-cause mortality,2/7 %28.57,1/7 %14.29,0/2 %0.0,13/45 %28.89,9/46 %19.57
Total serious adverse events,5/7 %71.43,3/7 %42.86,0/2 %0.0,25/45 %55.56,21/46 %45.65
Febrile Neutropenia,1/7 %14.29,0/7 %0.0,0/2 %0.0,10/45 %22.22,8/46 %17.39
Anemia,1/7 %14.29,0/7 %0.0,0/2 %0.0,1/45 %2.22,2/46 %4.35
Atrial Fibrillation,0/7 %0.0,0/7 %0.0,0/2 %0.0,1/45 %2.22,0/46 %0.0
Cardiac Arrest,0/7 %0.0,1/7 %14.29,0/2 %0.0,3/45 %6.67,2/46 %4.35
Cardiac Disorders - Other Specify,0/7 %0.0,0/7 %0.0,0/2 %0.0,1/45 %2.22,0/46 %0.0
Pericardial Effusion,1/7 %14.29,0/7 %0.0,0/2 %0.0,0/45 %0.0,0/46 %0.0
Abdominal Pain,2/7 %28.57,0/7 %0.0,0/2 %0.0,2/45 %4.44,1/46 %2.17
Colitis,2/7 %28.57,0/7 %0.0,0/2 %0.0,0/45 %0.0,1/46 %2.17
Diarrhea,2/7 %28.57,0/7 %0.0,0/2 %0.0,0/45 %0.0,0/46 %0.0
Esophageal Ulcer,0/7 %0.0,0/7 %0.0,0/2 %0.0,0/45 %0.0,1/46 %2.17
Esophagitis,1/7 %14.29,0/7 %0.0,0/2 %0.0,0/45 %0.0,1/46 %2.17
Gastric Hemorrhage,0/7 %0.0,0/7 %0.0,0/2 %0.0,0/45 %0.0,1/46 %2.17
Intra-Abdominal Hemorrhage,1/7 %14.29,0/7 %0.0,0/2 %0.0,0/45 %0.0,0/46 %0.0
Mucositis Oral,0/7 %0.0,0/7 %0.0,0/2 %0.0,1/45 %2.22,0/46 %0.0
Nausea,0/7 %0.0,0/7 %0.0,0/2 %0.0,1/45 %2.22,1/46 %2.17
Rectal Pain,0/7 %0.0,0/7 %0.0,0/2 %0.0,0/45 %0.0,1/46 %2.17
Small Intestinal Obstruction,0/7 %0.0,0/7 %0.0,0/2 %0.0,1/45 %2.22,0/46 %0.0
Vomiting,1/7 %14.29,0/7 %0.0,0/2 %0.0,1/45 %2.22,3/46 %6.52
Death Nos,1/7 %14.29,0/7 %0.0,0/2 %0.0,1/45 %2.22,0/46 %0.0
Fatigue,0/7 %0.0,1/7 %14.29,0/2 %0.0,0/45 %0.0,0/46 %0.0
Multi-Organ Failure,0/7 %0.0,0/7 %0.0,0/2 %0.0,1/45 %2.22,0/46 %0.0
Non-Cardiac Chest Pain,0/7 %0.0,0/7 %0.0,0/2 %0.0,0/45 %0.0,1/46 %2.17
Enterocolitis Infectious,0/7 %0.0,0/7 %0.0,0/2 %0.0,0/45 %0.0,1/46 %2.17
Infections And Infestations - Other Specify,0/7 %0.0,0/7 %0.0,0/2 %0.0,1/45 %2.22,0/46 %0.0
Kidney Infection,0/7 %0.0,0/7 %0.0,0/2 %0.0,0/45 %0.0,1/46 %2.17
Lung Infection,1/7 %14.29,0/7 %0.0,0/2 %0.0,1/45 %2.22,2/46 %4.35
Sepsis,1/7 %14.29,0/7 %0.0,0/2 %0.0,3/45 %6.67,3/46 %6.52
Soft Tissue Infection,0/7 %0.0,0/7 %0.0,0/2 %0.0,1/45 %2.22,0/46 %0.0
Tooth Infection,1/7 %14.29,0/7 %0.0,0/2 %0.0,0/45 %0.0,0/46 %0.0
Urinary Tract Infection,0/7 %0.0,0/7 %0.0,0/2 %0.0,0/45 %0.0,1/46 %2.17
Spinal Fracture,0/7 %0.0,0/7 %0.0,0/2 %0.0,0/45 %0.0,1/46 %2.17
Alanine Aminotransferase Increased,0/7 %0.0,0/7 %0.0,0/2 %0.0,1/45 %2.22,0/46 %0.0
Lymphocyte Count Decreased,0/7 %0.0,0/7 %0.0,0/2 %0.0,2/45 %4.44,0/46 %0.0
Neutrophil Count Decreased,5/7 %71.43,2/7 %28.57,0/2 %0.0,12/45 %26.67,2/46 %4.35
Platelet Count Decreased,0/7 %0.0,3/7 %42.86,0/2 %0.0,11/45 %24.44,0/46 %0.0
White Blood Cell Decreased,5/7 %71.43,0/7 %0.0,0/2 %0.0,5/45 %11.11,1/46 %2.17
Dehydration,1/7 %14.29,1/7 %14.29,0/2 %0.0,0/45 %0.0,1/46 %2.17
Hyperglycemia,0/7 %0.0,0/7 %0.0,0/2 %0.0,1/45 %2.22,0/46 %0.0
Neoplasms Benign Malignant And Unspecified (Incl Cysts And Polyps) - Other Specify,0/7 %0.0,0/7 %0.0,0/2 %0.0,7/45 %15.56,4/46 %8.7
Encephalopathy,0/7 %0.0,0/7 %0.0,0/2 %0.0,2/45 %4.44,0/46 %0.0
Headache,0/7 %0.0,0/7 %0.0,0/2 %0.0,1/45 %2.22,0/46 %0.0
Nervous System Disorders - Other Specify,0/7 %0.0,0/7 %0.0,0/2 %0.0,1/45 %2.22,0/46 %0.0
Delirium,0/7 %0.0,0/7 %0.0,0/2 %0.0,1/45 %2.22,0/46 %0.0
Acute Kidney Injury,0/7 %0.0,0/7 %0.0,0/2 %0.0,0/45 %0.0,1/46 %2.17
Renal And Urinary Disorders - Other Specify,0/7 %0.0,0/7 %0.0,0/2 %0.0,0/45 %0.0,1/46 %2.17
Renal Colic,0/7 %0.0,0/7 %0.0,0/2 %0.0,0/45 %0.0,1/46 %2.17
Dyspnea,0/7 %0.0,0/7 %0.0,0/2 %0.0,2/45 %4.44,0/46 %0.0
Pneumonitis,0/7 %0.0,0/7 %0.0,0/2 %0.0,1/45 %2.22,0/46 %0.0
Respiratory Failure,0/7 %0.0,0/7 %0.0,0/2 %0.0,1/45 %2.22,0/46 %0.0
Surgical And Medical Procedures - Other Specify,0/7 %0.0,0/7 %0.0,0/2 %0.0,0/45 %0.0,1/46 %2.17
Thromboembolic Event,1/7 %14.29,0/7 %0.0,0/2 %0.0,1/45 %2.22,0/46 %0.0

Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors(https://clinicaltrials.gov/show/NCT01214668)
 ,LY 300 g/mL + Dox,LY 320 g/mL + Dox,LY 340 g/mL + Dox,LY 360 g/mL + Dox,LY 380 g/mL + Dox,LY Albumin and Day 15 PK Tailored + Dox
 ,LY573636 targeting a maximum concentration (Cmax) of 300 micrograms per milliliter (g/mL) (LY 300 g/mL) as a 2-hour infusion on Day 1 of a 28-day cycle in combination with liposomal doxorubicin (Dox) at a dose of 40 milligrams per square meter (mg/m) during the Dose-Escalation Phase.,LY573636 targeting a Cmax of 320 g/mL (LY 320 g/mL) as a 2-hour infusion on Day 1 of a 28-day cycle in combination with liposomal doxorubicin (Dox) at a dose of 40 mg/m during the Dose-Escalation Phase.,LY573636 targeting a Cmax of 340 g/mL (LY 340 g/mL) as a 2-hour infusion on Day 1 of a 28-day cycle in combination with liposomal doxorubicin (Dox) at a dose of 40 mg/m during the Dose-Escalation Phase.,LY573636 targeting a Cmax of 360 g/mL (LY 360 g/mL) as a 2-hour infusion on Day 1 of a 28-day cycle in combination with liposomal doxorubicin (Dox) at a dose of 40 mg/m during the Dose-Escalation Phase.,LY573636 targeting a Cmax of 380 g/mL (LY 380 g/mL) as a 2-hour infusion on Day 1 of a 28-day cycle in combination with liposomal doxorubicin (Dox) at a dose of 40 mg/m during the Dose-Escalation Phase.,LY573636 dosing was given as a 2-hour infusion on Day 1 of a 28-day cycle in combination with liposomal doxorubicin (Dox) at a dose of 40 mg/m during the Dose-Confirmation Phase. LY573636 dose was based on an albumin-corrected exposure (AUCalb) target range of 75th percentile of 3500 hour*micrograms per milliliter (h*g/mL) and the Cycle 1 Day 15 LY573636 total drug level (Day 15 pharmacokinetic [PK]) (LY Albumin and Day 15 PK Tailored).
Total serious adverse events,2/4 %50.0,0/3 %0.0,5/6 %83.33,3/6 %50.0,3/6 %50.0,3/6 %50.0
Anaemia,1/4 %25.0,0/3 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
Neutropenia,1/4 %25.0,0/3 %0.0,1/6 %16.67,0/6 %0.0,0/6 %0.0,0/6 %0.0
Thrombocytopenia,1/4 %25.0,0/3 %0.0,2/6 %33.33,0/6 %0.0,0/6 %0.0,1/6 %16.67
Cardiac arrest,0/4 %0.0,0/3 %0.0,1/6 %16.67,0/6 %0.0,0/6 %0.0,0/6 %0.0
Vertigo,0/4 %0.0,0/3 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0,1/6 %16.67
Abdominal pain,0/4 %0.0,0/3 %0.0,0/6 %0.0,1/6 %16.67,0/6 %0.0,1/6 %16.67
Constipation,0/4 %0.0,0/3 %0.0,0/6 %0.0,1/6 %16.67,0/6 %0.0,1/6 %16.67
Dysphagia,0/4 %0.0,0/3 %0.0,2/6 %33.33,0/6 %0.0,0/6 %0.0,0/6 %0.0
Gastrointestinal haemorrhage,0/4 %0.0,0/3 %0.0,1/6 %16.67,0/6 %0.0,0/6 %0.0,0/6 %0.0
Impaired gastric emptying,0/4 %0.0,0/3 %0.0,0/6 %0.0,1/6 %16.67,0/6 %0.0,0/6 %0.0
Intestinal obstruction,0/4 %0.0,0/3 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0,1/6 %16.67
Large intestinal obstruction,1/4 %25.0,0/3 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
Nausea,0/4 %0.0,0/3 %0.0,0/6 %0.0,1/6 %16.67,0/6 %0.0,0/6 %0.0
Oesophagitis,0/4 %0.0,0/3 %0.0,2/6 %33.33,0/6 %0.0,0/6 %0.0,0/6 %0.0
Small intestinal obstruction,0/4 %0.0,0/3 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0,2/6 %33.33
Stomatitis,0/4 %0.0,0/3 %0.0,1/6 %16.67,0/6 %0.0,0/6 %0.0,0/6 %0.0
Vomiting,0/4 %0.0,0/3 %0.0,0/6 %0.0,1/6 %16.67,0/6 %0.0,0/6 %0.0
Mucosal inflammation,0/4 %0.0,0/3 %0.0,1/6 %16.67,0/6 %0.0,0/6 %0.0,0/6 %0.0
Dilatation intrahepatic duct acquired,0/4 %0.0,0/3 %0.0,0/6 %0.0,0/6 %0.0,1/6 %16.67,0/6 %0.0
Drug hypersensitivity,0/4 %0.0,0/3 %0.0,1/6 %16.67,0/6 %0.0,0/6 %0.0,0/6 %0.0
H1n1 influenza,0/4 %0.0,0/3 %0.0,1/6 %16.67,0/6 %0.0,0/6 %0.0,0/6 %0.0
Postoperative wound infection,0/4 %0.0,0/3 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0,1/6 %16.67
Sepsis syndrome,0/4 %0.0,0/3 %0.0,0/6 %0.0,0/6 %0.0,1/6 %16.67,0/6 %0.0
Wound infection,0/4 %0.0,0/3 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0,1/6 %16.67
Blood creatinine increased,1/4 %25.0,0/3 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
White blood cell count decreased,0/4 %0.0,0/3 %0.0,1/6 %16.67,0/6 %0.0,0/6 %0.0,0/6 %0.0
Dehydration,0/4 %0.0,0/3 %0.0,1/6 %16.67,1/6 %16.67,0/6 %0.0,0/6 %0.0
Hypokalaemia,1/4 %25.0,0/3 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
Muscular weakness,0/4 %0.0,0/3 %0.0,0/6 %0.0,1/6 %16.67,0/6 %0.0,1/6 %16.67
Subarachnoid haemorrhage,0/4 %0.0,0/3 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0,1/6 %16.67
Vocal cord paralysis,0/4 %0.0,0/3 %0.0,0/6 %0.0,1/6 %16.67,0/6 %0.0,0/6 %0.0
Confusional state,1/4 %25.0,0/3 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
Asthma,0/4 %0.0,0/3 %0.0,0/6 %0.0,1/6 %16.67,0/6 %0.0,0/6 %0.0
Pneumonia aspiration,0/4 %0.0,0/3 %0.0,0/6 %0.0,1/6 %16.67,0/6 %0.0,0/6 %0.0
Pneumonitis,0/4 %0.0,0/3 %0.0,0/6 %0.0,0/6 %0.0,1/6 %16.67,0/6 %0.0
Exfoliative rash,0/4 %0.0,0/3 %0.0,1/6 %16.67,0/6 %0.0,0/6 %0.0,0/6 %0.0
Hypotension,1/4 %25.0,0/3 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0

Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer(https://clinicaltrials.gov/show/NCT01220128)
 ,Cohort A-GSK2302024A Group,Cohort A-Placebo Group,Cohort B-GSK2302024A Group,Cohort B-Placebo Group,Cohort C-GSK2302024A Group,Cohort C-Placebo Group,Cohort D-GSK2302024A-D14 Group
 ,This group included postmenopausal patients with hormone receptor-positive breast cancer who received aromatase inhibitor (AI) as neoadjuvant therapy concurrently with administration of GSK2302024A according to the treatment schedule.,This group included postmenopausal patients with hormone receptor-positive breast cancer who received aromatase inhibitor (AI) as neoadjuvant therapy concurrently with administration of placebo 5-Fluorouracil Cyclophosphamide Docetaxel Doxorubicin Epirubicin and Paclitaxel according to the treatment schedule.,This group included breast cancer patients who received GSK2302024A and intravenous chemotherapy.,This group included breast cancer patients who received placebo 5-Fluorouracil Cyclophosphamide Docetaxel Doxorubicin Epirubicin and Paclitaxel according to the treatment schedule.,This group included patients with Human Epidermal Growth Factor Receptor 2 (HER2)-overexpressing breast cancer who received neoadjuvant trastuzumab (Herceptin) therapy concurrently with administration of GSK2302024A 5-Fluorouracil Carboplatin AUC Cyclophosphamide Docetaxel Doxorubicin Epirubicin and Paclitaxel according to the treatment schedule.,This group included patients with Human Epidermal Growth Factor Receptor 2 (HER2)-overexpressing breast cancer who received neoadjuvant trastuzumab (Herceptin) therapy concurrently with administration of placebo 5-Fluorouracil Carboplatin AUC Cyclophosphamide Docetaxel Doxorubicin Epirubicin and Paclitaxel according to the treatment schedule,This group included patients with hormone receptor-positive and HER2 non-overexpressing breast cancer who received GSK2302024A 5-Fluorouracil Cyclophosphamide Docetaxel Doxorubicin Epirubicin and Paclitaxel according to the treatment schedule.
Total serious adverse events,3/15 %20.0,0/7 %0.0,4/9 %44.44,2/6 %33.33,5/11 %45.45,1/4 %25.0,5/8 %62.5
Neutropenia,0/15 %0.0,0/7 %0.0,1/9 %11.11,1/6 %16.67,4/11 %36.36,0/4 %0.0,3/8 %37.5
Febrile neutropenia,0/15 %0.0,0/7 %0.0,1/9 %11.11,1/6 %16.67,1/11 %9.09,1/4 %25.0,2/8 %25.0
Leukopenia,0/15 %0.0,0/7 %0.0,1/9 %11.11,0/6 %0.0,1/11 %9.09,0/4 %0.0,1/8 %12.5
Vestibular disorder,1/15 %6.67,0/7 %0.0,0/9 %0.0,0/6 %0.0,0/11 %0.0,0/4 %0.0,0/8 %0.0
Diarrhoea,0/15 %0.0,0/7 %0.0,0/9 %0.0,0/6 %0.0,2/11 %18.18,0/4 %0.0,0/8 %0.0
Haemorrhoidal haemorrhage,1/15 %6.67,0/7 %0.0,0/9 %0.0,0/6 %0.0,0/11 %0.0,0/4 %0.0,0/8 %0.0
Nausea,0/15 %0.0,0/7 %0.0,0/9 %0.0,0/6 %0.0,1/11 %9.09,0/4 %0.0,0/8 %0.0
Stomatitis,0/15 %0.0,0/7 %0.0,0/9 %0.0,0/6 %0.0,0/11 %0.0,0/4 %0.0,1/8 %12.5
Vomiting,0/15 %0.0,0/7 %0.0,0/9 %0.0,0/6 %0.0,1/11 %9.09,0/4 %0.0,0/8 %0.0
Death,0/15 %0.0,0/7 %0.0,1/9 %11.11,0/6 %0.0,0/11 %0.0,0/4 %0.0,0/8 %0.0
Cholecystitis,0/15 %0.0,0/7 %0.0,1/9 %11.11,0/6 %0.0,0/11 %0.0,0/4 %0.0,0/8 %0.0
Dehydration,0/15 %0.0,0/7 %0.0,0/9 %0.0,0/6 %0.0,1/11 %9.09,0/4 %0.0,0/8 %0.0
Hyponatraemia,0/15 %0.0,0/7 %0.0,1/9 %11.11,0/6 %0.0,0/11 %0.0,0/4 %0.0,0/8 %0.0
Myalgia,0/15 %0.0,0/7 %0.0,0/9 %0.0,0/6 %0.0,0/11 %0.0,0/4 %0.0,1/8 %12.5
Polymyalgia rheumatica,1/15 %6.67,0/7 %0.0,0/9 %0.0,0/6 %0.0,0/11 %0.0,0/4 %0.0,0/8 %0.0
Renal cancer,1/15 %6.67,0/7 %0.0,0/9 %0.0,0/6 %0.0,0/11 %0.0,0/4 %0.0,0/8 %0.0

Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer(https://clinicaltrials.gov/show/NCT01275677)
 ,Arm I (Chemotherapy),Arm II (Chemotherapy Trastuzumab)
 ,Arm I (chemotherapy),Arm II (chemotherapy trastuzumab)
Total all-cause mortality,48/1622 %2.96,61/1628 %3.75
Total serious adverse events,31/1615 %1.92,96/1625 %5.91
Blood and lymphatic system disorders - Other specify,0/1615 %0.0,1/1625 %0.06
Disseminated intravascular coagulation,0/1615 %0.0,1/1625 %0.06
Asystole,0/1615 %0.0,1/1625 %0.06
Heart failure,1/1615 %0.06,18/1625 %1.11
Myocardial infarction,2/1615 %0.12,2/1625 %0.12
Pericardial effusion,1/1615 %0.06,0/1625 %0.0
Supraventricular tachycardia,0/1615 %0.0,3/1625 %0.18
Ventricular tachycardia,0/1615 %0.0,1/1625 %0.06
Acute coronary syndrome,1/1615 %0.06,0/1625 %0.0
Tricuspid valve disease,0/1615 %0.0,1/1625 %0.06
Mitral valve disease,0/1615 %0.0,1/1625 %0.06
Aortic valve disease,0/1615 %0.0,1/1625 %0.06
Left ventricular systolic dysfunction,5/1615 %0.31,29/1625 %1.78
Colonic perforation,1/1615 %0.06,0/1625 %0.0
Diarrhea,0/1615 %0.0,1/1625 %0.06
Typhlitis,0/1615 %0.0,1/1625 %0.06
Upper gastrointestinal hemorrhage,0/1615 %0.0,1/1625 %0.06
Multi-organ failure,1/1615 %0.06,1/1625 %0.06
Hepatic failure,0/1615 %0.0,1/1625 %0.06
Catheter related infection,0/1615 %0.0,1/1625 %0.06
Hepatitis viral,0/1615 %0.0,1/1625 %0.06
Sepsis,2/1615 %0.12,7/1625 %0.43
Enterocolitis infectious,0/1615 %0.0,2/1625 %0.12
Lung infection,1/1615 %0.06,1/1625 %0.06
Small intestine infection,1/1615 %0.06,0/1625 %0.0
Injury poisoning and procedural complications - Other specify,0/1615 %0.0,1/1625 %0.06
Vascular access complication,1/1615 %0.06,0/1625 %0.0
Alanine aminotransferase increased (ALT/SGPT),0/1615 %0.0,1/1625 %0.06
Aspartate aminotransferase increased (AST/SGOT),0/1615 %0.0,1/1625 %0.06
Lipase increased,1/1615 %0.06,0/1625 %0.0
Ejection fraction decreased,1/1615 %0.06,10/1625 %0.62
Hypercalcemia,1/1615 %0.06,0/1625 %0.0
Hyperglycemia,2/1615 %0.12,4/1625 %0.25
Hypertriglyceridemia,0/1615 %0.0,1/1625 %0.06
Hyperuricemia,1/1615 %0.06,0/1625 %0.0
Hypocalcemia,0/1615 %0.0,1/1625 %0.06
Hypokalemia,2/1615 %0.12,6/1625 %0.37
Hypomagnesemia,0/1615 %0.0,1/1625 %0.06
Hyponatremia,0/1615 %0.0,1/1625 %0.06
Myelodysplastic syndrome,2/1615 %0.12,0/1625 %0.0
Leukemia secondary to oncology chemotherapy,1/1615 %0.06,1/1625 %0.06
Intracranial hemorrhage,0/1615 %0.0,1/1625 %0.06
Stroke,0/1615 %0.0,1/1625 %0.06
Syncope,0/1615 %0.0,2/1625 %0.12
Pregnancy puerperium and perinatal conditions - Other specify,0/1615 %0.0,2/1625 %0.12
Delirium,1/1615 %0.06,1/1625 %0.06
Depression,3/1615 %0.19,4/1625 %0.25
Psychosis,0/1615 %0.0,1/1625 %0.06
Suicide attempt,0/1615 %0.0,1/1625 %0.06
Acute kidney injury,0/1615 %0.0,1/1625 %0.06
Vaginal dryness,0/1615 %0.0,1/1625 %0.06
Adult respiratory distress syndrome,0/1615 %0.0,1/1625 %0.06
Dyspnea,0/1615 %0.0,1/1625 %0.06
Hypoxia,1/1615 %0.06,0/1625 %0.0
Pneumonitis,7/1615 %0.43,5/1625 %0.31
Pneumothorax,0/1615 %0.0,1/1625 %0.06
Respiratory failure,1/1615 %0.06,0/1625 %0.0
Erythema multiforme,0/1615 %0.0,1/1625 %0.06
Hypertension,0/1615 %0.0,2/1625 %0.12
Hypotension,0/1615 %0.0,1/1625 %0.06
Thromboembolic event,1/1615 %0.06,0/1625 %0.0

A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)(https://clinicaltrials.gov/show/NCT01287741)
 ,Rituximab+Chemotherapy,Obinutuzumab+Chemotherapy
 ,Participants received eight 21-day cycles of rituximab combined with six or eight cycles of standard cyclophosphamide doxorubicin vincristine and prednisone/prednisolone (CHOP) chemotherapy (21-day cycles). Prior to study start study centers chose whether they planned to administer 6 or 8 cycles of CHOP chemotherapy.,Participants received eight 21-day cycles of obinutuzumab combined with six or eight cycles of standard cyclophosphamide doxorubicin vincristine and prednisone/prednisolone (CHOP) chemotherapy (21-day cycles). Participants received an additional two doses of obinutuzumab on Days 8 and 15 of Cycle 1. Prior to study start study centers chose whether they planned to administer 6 or 8 cycles of CHOP chemotherapy.
Total serious adverse events,269/701 %38.37,312/702 %44.44
Anaemia,6/701 %0.86,9/702 %1.28
Febrile neutropenia,71/701 %10.13,85/702 %12.11
Haemolytic anaemia,1/701 %0.14,0/702 %0.0
Histiocytosis haematophagic,0/701 %0.0,1/702 %0.14
Immune thrombocytopenic purpura,0/701 %0.0,1/702 %0.14
Leukopenia,6/701 %0.86,14/702 %1.99
Neutropenia,38/701 %5.42,54/702 %7.69
Splenic haematoma,0/701 %0.0,1/702 %0.14
Thrombocytopenia,2/701 %0.29,12/702 %1.71
Bone Marrow Failure,1/701 %0.14,0/702 %0.0
Acute coronary syndrome,0/701 %0.0,1/702 %0.14
Acute myocardial infarction,5/701 %0.71,2/702 %0.28
Angina pectoris,2/701 %0.29,0/702 %0.0
Atrial fibrillation,4/701 %0.57,9/702 %1.28
Atrial flutter,1/701 %0.14,1/702 %0.14
Bradycardia,0/701 %0.0,1/702 %0.14
Cardiac arrest,1/701 %0.14,1/702 %0.14
Cardiac failure,3/701 %0.43,7/702 %1.0
Cardiac failure congestive,1/701 %0.14,3/702 %0.43
Cardiac perforation,0/701 %0.0,1/702 %0.14
Cardiomyopathy,0/701 %0.0,1/702 %0.14
Cardiopulmonary failure,1/701 %0.14,0/702 %0.0
Congestive cardiomyopathy,1/701 %0.14,0/702 %0.0
Coronary artery disease,1/701 %0.14,0/702 %0.0
Coronary artery thrombosis,0/701 %0.0,1/702 %0.14
Hypertensive heart disease,0/701 %0.0,1/702 %0.14
Left ventricular dysfunction,0/701 %0.0,1/702 %0.14
Mitral valve disease,0/701 %0.0,1/702 %0.14
Myocardial infarction,2/701 %0.29,3/702 %0.43
Myocardial ischaemia,1/701 %0.14,0/702 %0.0
Pericardial effusion,0/701 %0.0,1/702 %0.14
Supraventricular tachycardia,1/701 %0.14,0/702 %0.0
Ventricular flutter,0/701 %0.0,1/702 %0.14
Vertigo positional,0/701 %0.0,1/702 %0.14
Addison's disease,0/701 %0.0,1/702 %0.14
Goitre,1/701 %0.14,0/702 %0.0
Cataract,2/701 %0.29,0/702 %0.0
Lacrimation increased,0/701 %0.0,1/702 %0.14
Abdominal pain,6/701 %0.86,4/702 %0.57
Abdominal pain upper,1/701 %0.14,2/702 %0.28
Anal fistula,1/701 %0.14,0/702 %0.0
Colitis,2/701 %0.29,2/702 %0.28
Constipation,1/701 %0.14,0/702 %0.0
Diarrhoea,6/701 %0.86,5/702 %0.71
Dysphagia,0/701 %0.0,1/702 %0.14
Gastric haemorrhage,2/701 %0.29,1/702 %0.14
Gastric perforation,3/701 %0.43,1/702 %0.14
Gastric ulcer,0/701 %0.0,1/702 %0.14
Gastritis,0/701 %0.0,1/702 %0.14
Gastritis haemorrhagic,0/701 %0.0,1/702 %0.14
Gastrointestinal haemorrhage,3/701 %0.43,2/702 %0.28
Haematemesis,0/701 %0.0,1/702 %0.14
Haematochezia,1/701 %0.14,0/702 %0.0
Haemorrhoids,0/701 %0.0,2/702 %0.28
Ileal perforation,0/701 %0.0,1/702 %0.14
Ileus,2/701 %0.29,1/702 %0.14
Ileus paralytic,1/701 %0.14,0/702 %0.0
Impaired gastric emptying,1/701 %0.14,0/702 %0.0
Inguinal hernia,1/701 %0.14,1/702 %0.14
Intestinal ischaemia,0/701 %0.0,1/702 %0.14
Intestinal obstruction,5/701 %0.71,2/702 %0.28
Intestinal perforation,3/701 %0.43,3/702 %0.43
Large intestine polyp,0/701 %0.0,2/702 %0.28
Lower gastrointestinal haemorrhage,1/701 %0.14,0/702 %0.0
Melaena,1/701 %0.14,0/702 %0.0
Nausea,2/701 %0.29,1/702 %0.14
Pancreatitis acute,0/701 %0.0,1/702 %0.14
Pneumoperitoneum,0/701 %0.0,1/702 %0.14
Small intestinal obstruction,1/701 %0.14,2/702 %0.28
Small intestinal perforation,1/701 %0.14,1/702 %0.14
Stomatitis,1/701 %0.14,0/702 %0.0
Subileus,1/701 %0.14,1/702 %0.14
Upper gastrointestinal haemorrhage,1/701 %0.14,3/702 %0.43
Vomiting,2/701 %0.29,2/702 %0.28
Asthenia,4/701 %0.57,2/702 %0.28
Axillary pain,0/701 %0.0,1/702 %0.14
Chest pain,2/701 %0.29,0/702 %0.0
Chills,1/701 %0.14,2/702 %0.28
Death,2/701 %0.29,3/702 %0.43
Extravasation,1/701 %0.14,0/702 %0.0
Fatigue,5/701 %0.71,4/702 %0.57
General physical health deterioration,1/701 %0.14,2/702 %0.28
Hernia,0/701 %0.0,1/702 %0.14
Hyperpyrexia,0/701 %0.0,1/702 %0.14
Incarcerated hernia,0/701 %0.0,1/702 %0.14
Malaise,0/701 %0.0,2/702 %0.28
Mucosal inflammation,1/701 %0.14,1/702 %0.14
Non-cardiac chest pain,2/701 %0.29,0/702 %0.0
Oedema peripheral,0/701 %0.0,2/702 %0.28
Pain,1/701 %0.14,0/702 %0.0
Peripheral swelling,1/701 %0.14,0/702 %0.0
Pyrexia,11/701 %1.57,17/702 %2.42
Sudden death,1/701 %0.14,1/702 %0.14
Bile duct obstruction,0/701 %0.0,1/702 %0.14
Cholecystitis,2/701 %0.29,1/702 %0.14
Cholecystitis acute,1/701 %0.14,1/702 %0.14
Cholelithiasis,1/701 %0.14,0/702 %0.0
Hepatic function abnormal,1/701 %0.14,0/702 %0.0
Anal abscess,0/701 %0.0,2/702 %0.28
Appendiceal abscess,0/701 %0.0,1/702 %0.14
Appendicitis,3/701 %0.43,1/702 %0.14
Atypical pneumonia,2/701 %0.29,0/702 %0.0
Bacterial infection,1/701 %0.14,0/702 %0.0
Bacterial sepsis,0/701 %0.0,1/702 %0.14
Bronchitis,4/701 %0.57,1/702 %0.14
Bronchopulmonary aspergillosis,1/701 %0.14,1/702 %0.14
Candida sepsis,1/701 %0.14,0/702 %0.0
Cellulitis,2/701 %0.29,2/702 %0.28
Cholecystitis infective,0/701 %0.0,1/702 %0.14
Clostridium difficile colitis,1/701 %0.14,1/702 %0.14
Clostridium difficile infection,0/701 %0.0,1/702 %0.14
Cytomegalovirus chorioretinitis,1/701 %0.14,3/702 %0.43
Cytomegalovirus colitis,0/701 %0.0,1/702 %0.14
Cytomegalovirus infection,2/701 %0.29,0/702 %0.0
Device related infection,2/701 %0.29,1/702 %0.14
Device related sepsis,0/701 %0.0,1/702 %0.14
Diabetic foot infection,1/701 %0.14,0/702 %0.0
Diarrhoea infectious,0/701 %0.0,2/702 %0.28
Diverticulitis,0/701 %0.0,1/702 %0.14
Enterobacter infection,0/701 %0.0,1/702 %0.14
Enterocolitis infectious,0/701 %0.0,1/702 %0.14
Escherichia sepsis,1/701 %0.14,0/702 %0.0
Fungal infection,1/701 %0.14,0/702 %0.0
Gastroenteritis,3/701 %0.43,2/702 %0.28
H1N1 influenza,0/701 %0.0,1/702 %0.14
Hepatitis B Reactivation,0/701 %0.0,1/702 %0.14
Herpes simplex,0/701 %0.0,1/702 %0.14
Herpes virus infection,0/701 %0.0,2/702 %0.28
Herpes zoster,3/701 %0.43,4/702 %0.57
Herpes zoster disseminated,0/701 %0.0,1/702 %0.14
Infected lymphocele,0/701 %0.0,1/702 %0.14
Infection,0/701 %0.0,2/702 %0.28
Infectious pleural effusion,0/701 %0.0,2/702 %0.28
Infective glossitis,0/701 %0.0,1/702 %0.14
Influenza,2/701 %0.29,1/702 %0.14
Klebsiella sepsis,1/701 %0.14,1/702 %0.14
Laryngitis,0/701 %0.0,1/702 %0.14
Localised infection,1/701 %0.14,0/702 %0.0
Lower respiratory tract infection,1/701 %0.14,3/702 %0.43
Lung infection,3/701 %0.43,6/702 %0.85
Measles,0/701 %0.0,1/702 %0.14
Meningitis,0/701 %0.0,1/702 %0.14
Meningitis cryptococcal,1/701 %0.14,0/702 %0.0
Meningitis viral,0/701 %0.0,1/702 %0.14
Nasopharyngitis,2/701 %0.29,0/702 %0.0
Necrotising fasciitis,1/701 %0.14,0/702 %0.0
Neutropenic infection,1/701 %0.14,1/702 %0.14
Neutropenic sepsis,3/701 %0.43,3/702 %0.43
Oral infection,2/701 %0.29,0/702 %0.0
Orchitis,1/701 %0.14,0/702 %0.0
Osteomyelitis,1/701 %0.14,1/702 %0.14
Peritonitis,2/701 %0.29,2/702 %0.28
Pharyngitis streptococcal,0/701 %0.0,1/702 %0.14
Pneumocystis jirovecii pneumonia,3/701 %0.43,1/702 %0.14
Pneumonia,33/701 %4.71,43/702 %6.13
Pneumonia bacterial,0/701 %0.0,1/702 %0.14
Progressive multifocal leukoencephalopathy,0/701 %0.0,1/702 %0.14
Prostatic abscess,1/701 %0.14,0/702 %0.0
Pseudomonal sepsis,1/701 %0.14,0/702 %0.0
Pulmonary sepsis,1/701 %0.14,0/702 %0.0
Rectal abscess,1/701 %0.14,1/702 %0.14
Respiratory tract infection,0/701 %0.0,2/702 %0.28
Scrotal abscess,1/701 %0.14,0/702 %0.0
Sepsis,10/701 %1.43,16/702 %2.28
Sepsis syndrome,0/701 %0.0,1/702 %0.14
Septic shock,3/701 %0.43,12/702 %1.71
Sinusitis fungal,0/701 %0.0,1/702 %0.14
Soft tissue infection,1/701 %0.14,0/702 %0.0
Subcutaneous abscess,0/701 %0.0,1/702 %0.14
Tuberculosis,1/701 %0.14,0/702 %0.0
Tuberculosis of central nervous system,1/701 %0.14,0/702 %0.0
Upper respiratory tract infection,1/701 %0.14,1/702 %0.14
Urinary tract infection,3/701 %0.43,3/702 %0.43
Urosepsis,1/701 %0.14,1/702 %0.14
Varicella,1/701 %0.14,1/702 %0.14
Viral infection,0/701 %0.0,1/702 %0.14
Viral pharyngitis,1/701 %0.14,0/702 %0.0
Wound infection,0/701 %0.0,1/702 %0.14
Anorectal cellulitis,1/701 %0.14,0/702 %0.0
Gastrointestinal Infection,1/701 %0.14,0/702 %0.0
Abdominal wound dehiscence,1/701 %0.14,0/702 %0.0
Facial bones fracture,1/701 %0.14,0/702 %0.0
Fall,0/701 %0.0,1/702 %0.14
Femoral neck fracture,1/701 %0.14,0/702 %0.0
Femur fracture,2/701 %0.29,1/702 %0.14
Fracture,0/701 %0.0,1/702 %0.14
Hip fracture,1/701 %0.14,1/702 %0.14
Infusion related reaction,1/701 %0.14,8/702 %1.14
Kidney rupture,1/701 %0.14,0/702 %0.0
Lumbar vertebral fracture,1/701 %0.14,0/702 %0.0
Nerve injury,0/701 %0.0,1/702 %0.14
Pelvic fracture,0/701 %0.0,1/702 %0.14
Postoperative respiratory failure,0/701 %0.0,1/702 %0.14
Procedural complication,0/701 %0.0,1/702 %0.14
Spinal compression fracture,1/701 %0.14,0/702 %0.0
Subdural haematoma,0/701 %0.0,3/702 %0.43
Toxicity to various agents,0/701 %0.0,1/702 %0.14
Vascular pseudoaneurysm,1/701 %0.14,0/702 %0.0
Wound haemorrhage,0/701 %0.0,1/702 %0.14
Compression fracture,0/701 %0.0,1/702 %0.14
Ejection fraction decreased,0/701 %0.0,1/702 %0.14
HIV antibody positive,0/701 %0.0,1/702 %0.14
Oxygen saturation decreased,1/701 %0.14,0/702 %0.0
Cachexia,0/701 %0.0,1/702 %0.14
Decreased appetite,1/701 %0.14,2/702 %0.28
Dehydration,4/701 %0.57,5/702 %0.71
Diabetes mellitus,0/701 %0.0,1/702 %0.14
Failure to thrive,3/701 %0.43,0/702 %0.0
Hyperglycaemia,1/701 %0.14,0/702 %0.0
Hyperkalaemia,0/701 %0.0,1/702 %0.14
Hypokalaemia,2/701 %0.29,2/702 %0.28
Hyponatraemia,2/701 %0.29,0/702 %0.0
Hypophosphataemia,1/701 %0.14,0/702 %0.0
Malnutrition,2/701 %0.29,1/702 %0.14
Tumour lysis syndrome,2/701 %0.29,1/702 %0.14
Arthralgia,2/701 %0.29,1/702 %0.14
Back pain,1/701 %0.14,2/702 %0.28
Costochondritis,1/701 %0.14,0/702 %0.0
Intervertebral disc protrusion,0/701 %0.0,1/702 %0.14
Joint swelling,1/701 %0.14,0/702 %0.0
Myalgia,0/701 %0.0,1/702 %0.14
Osteoarthritis,0/701 %0.0,1/702 %0.14
Pain in extremity,1/701 %0.14,0/702 %0.0
Acute myeloid leukaemia,2/701 %0.29,1/702 %0.14
Adenocarcinoma of colon,2/701 %0.29,0/702 %0.0
B-cell lymphoma,1/701 %0.14,0/702 %0.0
Breast cancer,3/701 %0.43,1/702 %0.14
Colon adenoma,0/701 %0.0,1/702 %0.14
Colon cancer,2/701 %0.29,0/702 %0.0
Colorectal cancer,1/701 %0.14,1/702 %0.14
Hepatocellular carcinoma,1/701 %0.14,2/702 %0.28
Liposarcoma,0/701 %0.0,1/702 %0.14
Lung adenocarcinoma,2/701 %0.29,3/702 %0.43
Marginal zone lymphoma,1/701 %0.14,0/702 %0.0
Oesophageal carcinoma,1/701 %0.14,0/702 %0.0
Papillary cystadenoma lymphomatosum,0/701 %0.0,1/702 %0.14
Prostate cancer,2/701 %0.29,2/702 %0.28
Small cell lung cancer metastatic,0/701 %0.0,1/702 %0.14
Tumour perforation,0/701 %0.0,1/702 %0.14
Angioimmuoblastic T-cell lymphoma,0/701 %0.0,1/702 %0.14
Myelodysplastic syndrome,0/701 %0.0,1/702 %0.14
Squamous cell carincoma of pharynx,1/701 %0.14,0/702 %0.0
Lung neoplasm malignant,0/701 %0.0,1/702 %0.14
Plasma cell myeloma,1/701 %0.14,0/702 %0.0
Amyotrophic lateral sclerosis,0/701 %0.0,1/702 %0.14
Cerebral haemorrhage,0/701 %0.0,1/702 %0.14
Cerebral infarction,1/701 %0.14,0/702 %0.0
Cerebral ischaemia,1/701 %0.14,1/702 %0.14
Cerebrovascular accident,2/701 %0.29,3/702 %0.43
Depressed level of consciousness,0/701 %0.0,1/702 %0.14
Dizziness,0/701 %0.0,2/702 %0.28
Embolic stroke,1/701 %0.14,0/702 %0.0
Epilepsy,1/701 %0.14,0/702 %0.0
Headache,2/701 %0.29,3/702 %0.43
Hemiparesis,0/701 %0.0,1/702 %0.14
Iiird nerve paralysis,0/701 %0.0,1/702 %0.14
Ischaemic stroke,0/701 %0.0,1/702 %0.14
Loss of consciousness,1/701 %0.14,0/702 %0.0
Neuropathy peripheral,1/701 %0.14,1/702 %0.14
Peripheral motor neuropathy,1/701 %0.14,0/702 %0.0
Peripheral sensory neuropathy,1/701 %0.14,0/702 %0.0
Polyneuropathy,1/701 %0.14,0/702 %0.0
Presyncope,1/701 %0.14,2/702 %0.28
Stroke in evolution,0/701 %0.0,1/702 %0.14
Syncope,3/701 %0.43,0/702 %0.0
Toxic encephalopathy,1/701 %0.14,0/702 %0.0
Transient ischaemic attack,1/701 %0.14,0/702 %0.0
Vocal cord paralysis,1/701 %0.14,0/702 %0.0
Seizure,0/701 %0.0,1/702 %0.14
Anxiety,0/701 %0.0,1/702 %0.14
Completed suicide,0/701 %0.0,1/702 %0.14
Delirium,0/701 %0.0,1/702 %0.14
Depression,1/701 %0.14,0/702 %0.0
Emotional distress,0/701 %0.0,1/702 %0.14
Mental status changes,0/701 %0.0,1/702 %0.14
Acute kidney injury,2/701 %0.29,2/702 %0.28
Cystitis glandularis,0/701 %0.0,1/702 %0.14
Haematuria,0/701 %0.0,2/702 %0.28
Renal colic,1/701 %0.14,0/702 %0.0
Renal failure,1/701 %0.14,1/702 %0.14
Renal impairment,0/701 %0.0,1/702 %0.14
Urinary retention,0/701 %0.0,1/702 %0.14
Uterine haemorrhage,0/701 %0.0,1/702 %0.14
Acquired tracheo-oesophageal fistula,0/701 %0.0,1/702 %0.14
Acute pulmonary oedema,0/701 %0.0,1/702 %0.14
Acute respiratory distress syndrome,1/701 %0.14,1/702 %0.14
Acute respiratory failure,3/701 %0.43,1/702 %0.14
Alveolitis,0/701 %0.0,1/702 %0.14
Asthma,0/701 %0.0,1/702 %0.14
Bronchial obstruction,1/701 %0.14,0/702 %0.0
Bronchospasm,1/701 %0.14,1/702 %0.14
Chronic obstructive pulmonary disease,1/701 %0.14,2/702 %0.28
Dyspnoea,1/701 %0.14,2/702 %0.28
Dyspnoea exertional,0/701 %0.0,1/702 %0.14
Emphysema,0/701 %0.0,2/702 %0.28
Haemoptysis,0/701 %0.0,1/702 %0.14
Haemothorax,0/701 %0.0,1/702 %0.14
Hypoxia,1/701 %0.14,1/702 %0.14
Interstitial lung disease,6/701 %0.86,3/702 %0.43
Lung infiltration,0/701 %0.0,1/702 %0.14
Organising pneumonia,1/701 %0.14,0/702 %0.0
Pleural effusion,2/701 %0.29,4/702 %0.57
Pneumonia aspiration,0/701 %0.0,1/702 %0.14
Pneumonitis,1/701 %0.14,5/702 %0.71
Pneumothorax,1/701 %0.14,1/702 %0.14
Pulmonary embolism,4/701 %0.57,4/702 %0.57
Pulmonary fibrosis,0/701 %0.0,1/702 %0.14
Pulmonary oedema,0/701 %0.0,1/702 %0.14
Respiratory failure,2/701 %0.29,0/702 %0.0
Cough,0/701 %0.0,1/702 %0.14
Diabetic foot,1/701 %0.14,0/702 %0.0
Skin ulcer,1/701 %0.14,2/702 %0.28
Deep vein thrombosis,0/701 %0.0,2/702 %0.28
Haemorrhage,0/701 %0.0,1/702 %0.14
Hypertension,0/701 %0.0,1/702 %0.14
Hypotension,2/701 %0.29,3/702 %0.43
Orthostatic hypotension,1/701 %0.14,0/702 %0.0
Phlebitis,0/701 %0.0,1/702 %0.14
Thrombophlebitis,2/701 %0.29,0/702 %0.0
Thrombophlebitis superficial,0/701 %0.0,1/702 %0.14
Venous occlusion,0/701 %0.0,1/702 %0.14
Venous thrombosis limb,0/701 %0.0,1/702 %0.14
Axillary vein thrombosis,1/701 %0.14,0/702 %0.0
Jugular vein thrombosis,1/701 %0.14,0/702 %0.0
Subclavian vein thrombosis,1/701 %0.14,0/702 %0.0

BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer  Fallopian Tube Carcinoma or Primary Peritoneal Cancer(https://clinicaltrials.gov/show/NCT01314105)
 ,Nintedanib 150mg,Nintedanib 200mg
 ,Nintedanib (150 mg twice daily (BID) except the day of chemotherapy infusion) administered orally plus standard therapy of carboplatin (Area Under the Curve (AUC) 5 mg/mL*min) and PLD (30 mg/m2) which were administered by intravenous infusion once every 28 days.,Nintedanib (200 mg twice daily (BID) except the day of chemotherapy infusion) administered orally plus standard therapy of carboplatin (Area Under the Curve (AUC) 5 mg/mL*min) and PLD (30 mg/m2) which were administered by intravenous infusion once every 28 days.
Total serious adverse events,3/7 %42.86,4/12 %33.33
Ileus,0/7 %0.0,1/12 %8.33
Intestinal obstruction,0/7 %0.0,1/12 %8.33
Small intestinal obstruction,0/7 %0.0,1/12 %8.33
Hypersensitivity,1/7 %14.29,0/12 %0.0
Alanine aminotransferase increased,1/7 %14.29,0/12 %0.0
Platelet count decreased,1/7 %14.29,0/12 %0.0
Pulmonary embolism,0/7 %0.0,1/12 %8.33

Dose Dense Doxorubucin and Cyclophosphamide Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer(https://clinicaltrials.gov/show/NCT01328249)
 ,Cohort 1: Eribulin Mesylate With Filgrastim as Needed,Cohort 2: Eribulin Mesylate With Prophylactic Filgrastim
 ,Participants initially received doxorubicin (60 mg/m^2) plus cyclophosphamide (600 mg/m^2) intravenously (IV) on Day 1 of every 14-day cycle for 4 cycles. Eribulin mesylate was administered following the doxorubicin plus cyclophosphamide regimen at a dose of 1.4 mg/m^2 IV over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle for 4 cycles (Cycles 5 to 8). In this Cohort growth factors subcutaneous pegfilgrastim (6 mg) or filgrastim could be used with eribulin therapy at the physician's discretion if neutropenia occurred that recovered to Grade 2.,Participants initially received doxorubicin (60 mg/m^2) plus cyclophosphamide (600 mg/m^2) IV on Day 1 of every 14-day cycle for 4 cycles. Eribulin mesylate was administered following the doxorubicin plus cyclophosphamide regimen at a dose of 1.4 mg/m^2 IV over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle for 4 cycles (Cycles 5 to 8). In this Cohort filgrastim was used with eribulin therapy at a dose of 300 micrograms for participants 60 kg or 480 micrograms for participants >60 kg administered subcutaneously on Days 3 and 4 and Days 10 and 11 of each eribulin cycle.
Total all-cause mortality,3/55 %5.45,0/26 %0.0
Total serious adverse events,6/55 %10.91,4/26 %15.38
Febrile neutropenia,2/55 %3.64,1/26 %3.85
Nausea,2/55 %3.64,0/26 %0.0
Oesophagitis,2/55 %3.64,0/26 %0.0
Vomiting,2/55 %3.64,0/26 %0.0
Mucosal inflammation,0/55 %0.0,1/26 %3.85
Pyrexia,2/55 %3.64,1/26 %3.85
Breast abscess,0/55 %0.0,1/26 %3.85
Catheter site cellulitis,0/55 %0.0,1/26 %3.85
Genital herpes,1/55 %1.82,0/26 %0.0
Lung infection,0/55 %0.0,1/26 %3.85
Upper respiratory tract infection,1/55 %1.82,0/26 %0.0
Weight decreased,1/55 %1.82,0/26 %0.0
Dehydration,2/55 %3.64,0/26 %0.0
Syncope,1/55 %1.82,0/26 %0.0

A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)(https://clinicaltrials.gov/show/NCT01332968)
 ,Rituximab+Chemotherapy,Obinutuzumab+Chemotherapy
 ,Participants will receive either 8 cycles of rituximab along with 6 cycles of cyclophosphamide doxorubicin vincristine and prednisone (CHOP) (21-day cycle) or 8 cycles of rituximab along with 8 cycles of cyclophosphamide vincristine and prednisone (CVP) (21-day cycles) or 6 cycles of rituximab along with 6 cycles of bendamustine (28-day cycle) during the induction period. The induction period will be followed by either a maintenance or observation period for responders or non-responders respectively. Responders will receive rituximab monotherapy every 2 months for 2 years during the maintenance period. Non-responders will receive no protocol specified treatment during the 2-year observation period. Finally participants will be followed during a 5-year follow-up period. The chemotherapy regimen (CHOP or CVP or bendamustine) for individual participant will be chosen by the site prior to initiation of the study.,Participants will receive either 8 cycles of obinutuzumab along with 6 cycles of CHOP (21-day cycle) or 8 cycles of obinutuzumab along with 8 cycles of CVP (21-day cycles) or 6 cycles of obinutuzumab along with 6 cycles of bendamustine (28-day cycle) during induction period. The induction period will be followed by either a maintenance or observation period for responders or non-responders respectively. Responders will receive obinutuzumab monotherapy every 2 months for 2 years during the maintenance period. Non-responders will receive no protocol specified treatment during the 2-year observation period. Finally participants will be followed during a 5-year follow-up period. The chemotherapy regimen (CHOP or CVP or bendamustine) for individual participant will be chosen by the site prior to initiation of the study.
Total serious adverse events,286/692 %41.33,340/698 %48.71
Anaemia,0/692 %0.0,5/698 %0.72
Autoimmune haemolytic anaemia,1/692 %0.14,0/698 %0.0
Bone marrow failure,0/692 %0.0,1/698 %0.14
Disseminated intravascular coagulation,0/692 %0.0,1/698 %0.14
Febrile Neutropenia,24/692 %3.47,34/698 %4.87
Haemolysis,1/692 %0.14,0/698 %0.0
Haemolytic anaemia,1/692 %0.14,0/698 %0.0
Histiocytosis haematophagic,1/692 %0.14,0/698 %0.0
Immune thrombocytopenic purpura,0/692 %0.0,1/698 %0.14
Leukopenia,5/692 %0.72,3/698 %0.43
Neutropenia,30/692 %4.34,25/698 %3.58
Splenomegaly,1/692 %0.14,2/698 %0.29
Thrombocytopenia,2/692 %0.29,5/698 %0.72
Acute myocardial infarction,0/692 %0.0,4/698 %0.57
Angina pectoris,1/692 %0.14,1/698 %0.14
Aortic valve stenosis,1/692 %0.14,0/698 %0.0
Arrhythmia,0/692 %0.0,2/698 %0.29
Atrial fibrillation,2/692 %0.29,9/698 %1.29
Atrial flutter,0/692 %0.0,1/698 %0.14
Bradycardia,0/692 %0.0,1/698 %0.14
Cardiac arrest,1/692 %0.14,1/698 %0.14
Cardiac failure,3/692 %0.43,2/698 %0.29
Cardiac failure congestive,0/692 %0.0,2/698 %0.29
Cardio-respiratory arrest,0/692 %0.0,1/698 %0.14
Cardiogenic shock,1/692 %0.14,2/698 %0.29
Coronary artery disease,2/692 %0.29,0/698 %0.0
Coronary artery stenosis,1/692 %0.14,0/698 %0.0
Myocardial infarction,1/692 %0.14,1/698 %0.14
Myocardial ischaemia,0/692 %0.0,1/698 %0.14
Palpitations,1/692 %0.14,0/698 %0.0
Right ventricular failure,0/692 %0.0,1/698 %0.14
Sinus bradycardia,0/692 %0.0,5/698 %0.72
Sinus tachycardia,0/692 %0.0,3/698 %0.43
Supraventricular bradycardia,1/692 %0.14,1/698 %0.14
Tachycardia,0/692 %0.0,3/698 %0.43
Ventricular tachycardia,0/692 %0.0,1/698 %0.14
Peroneal muscular atrophy,1/692 %0.14,0/698 %0.0
Deafness,0/692 %0.0,1/698 %0.14
Ear pain,1/692 %0.14,0/698 %0.0
Corneal opacity,0/692 %0.0,1/698 %0.14
Abdominal pain,5/692 %0.72,10/698 %1.43
Abdominal pain upper,2/692 %0.29,0/698 %0.0
Ascites,2/692 %0.29,1/698 %0.14
Colitis,2/692 %0.29,3/698 %0.43
Constipation,1/692 %0.14,3/698 %0.43
Diarrhoea,7/692 %1.01,11/698 %1.58
Dyspepsia,0/692 %0.0,1/698 %0.14
Dysphagia,0/692 %0.0,1/698 %0.14
Enterovesical fistula,0/692 %0.0,1/698 %0.14
Faecaloma,0/692 %0.0,1/698 %0.14
Gastric haemorrhage,0/692 %0.0,1/698 %0.14
Gastric ulcer,0/692 %0.0,1/698 %0.14
Gastritis,0/692 %0.0,1/698 %0.14
Gastritis erosive,1/692 %0.14,0/698 %0.0
Gastroenteritis eosinophilic,1/692 %0.14,0/698 %0.0
Gastrooesophageal reflux disease,1/692 %0.14,0/698 %0.0
Haematemesis,0/692 %0.0,1/698 %0.14
Haemorrhoids,0/692 %0.0,1/698 %0.14
Hiatus hernia,1/692 %0.14,0/698 %0.0
Ileus,0/692 %0.0,1/698 %0.14
Inguinal hernia,0/692 %0.0,1/698 %0.14
Intestinal ischaemia,0/692 %0.0,1/698 %0.14
Intestinal obstruction,0/692 %0.0,3/698 %0.43
Intestinal villi atrophy,1/692 %0.14,0/698 %0.0
Large intestinal obstruction,1/692 %0.14,0/698 %0.0
Large intestine polyp,0/692 %0.0,1/698 %0.14
Melaena,0/692 %0.0,1/698 %0.14
Mikulicz's syndrome,1/692 %0.14,0/698 %0.0
Mouth ulceration,1/692 %0.14,1/698 %0.14
Nausea,3/692 %0.43,6/698 %0.86
Pancreatitis,1/692 %0.14,5/698 %0.72
Pancreatitis acute,1/692 %0.14,1/698 %0.14
Rectal haemorrhage,0/692 %0.0,1/698 %0.14
Small intestinal obstruction,0/692 %0.0,2/698 %0.29
Stomatitis,0/692 %0.0,1/698 %0.14
Upper gastrointestinal heamorrhage,0/692 %0.0,1/698 %0.14
Vomiting,9/692 %1.3,6/698 %0.86
Adverse drug reaction,1/692 %0.14,0/698 %0.0
Chest discomfort,0/692 %0.0,1/698 %0.14
Chest pain,4/692 %0.58,2/698 %0.29
Chills,3/692 %0.43,4/698 %0.57
Cyst rupture,0/692 %0.0,1/698 %0.14
Death,2/692 %0.29,1/698 %0.14
General physical health deterioration,2/692 %0.29,3/698 %0.43
Hyperthermia,1/692 %0.14,0/698 %0.0
Ill-defined disorder,0/692 %0.0,1/698 %0.14
Influenza like illness,1/692 %0.14,1/698 %0.14
Injection site extravasation,0/692 %0.0,1/698 %0.14
Mucosal inflammation,1/692 %0.14,1/698 %0.14
Multi-organ failure,3/692 %0.43,0/698 %0.0
Non-cardiac chest pain,0/692 %0.0,2/698 %0.29
Oedema peripheral,1/692 %0.14,0/698 %0.0
Pain,3/692 %0.43,0/698 %0.0
Pyrexia,24/692 %3.47,37/698 %5.3
Stent-graft endoleak,1/692 %0.14,0/698 %0.0
Device breakage,0/692 %0.0,1/698 %0.14
Bile duct stenosis,1/692 %0.14,0/698 %0.0
Bile duct stone,0/692 %0.0,1/698 %0.14
Biliary colic,1/692 %0.14,2/698 %0.29
Cholangitis,1/692 %0.14,0/698 %0.0
Cholecystitis,6/692 %0.87,4/698 %0.57
Cholecystitis acute,1/692 %0.14,0/698 %0.0
Cholelithiasis,1/692 %0.14,1/698 %0.14
Drug-induced liver injury,0/692 %0.0,2/698 %0.29
Gallbladder pain,0/692 %0.0,1/698 %0.14
Hepatic function abnormal,1/692 %0.14,0/698 %0.0
Hepatitis acute,0/692 %0.0,1/698 %0.14
Allergy to arthropod bite,0/692 %0.0,1/698 %0.14
Anaphylactic reaction,0/692 %0.0,1/698 %0.14
Anaphylactic shock,0/692 %0.0,1/698 %0.14
Cytokine release syndrome,0/692 %0.0,2/698 %0.29
Drug hypersensitivity,1/692 %0.14,0/698 %0.0
Hypersensitivity,3/692 %0.43,0/698 %0.0
Hypogammaglobulinaemia,1/692 %0.14,0/698 %0.0
Abdominal abscess,0/692 %0.0,1/698 %0.14
Abscess,1/692 %0.14,0/698 %0.0
Abscess intestinal,0/692 %0.0,1/698 %0.14
Appendicitis,4/692 %0.58,1/698 %0.14
Arthritis bacterial,1/692 %0.14,0/698 %0.0
Arthritis infective,1/692 %0.14,0/698 %0.0
Atypical pneumonia,3/692 %0.43,1/698 %0.14
Bacteraemia,1/692 %0.14,1/698 %0.14
Bacterial tracheitis,0/692 %0.0,1/698 %0.14
Bk virus infection,0/692 %0.0,1/698 %0.14
Breast abscess,0/692 %0.0,1/698 %0.14
Bronchitis,3/692 %0.43,7/698 %1.0
Campylobacter infection,0/692 %0.0,1/698 %0.14
Catheter site cellulitis,0/692 %0.0,1/698 %0.14
Cellulitis,3/692 %0.43,3/698 %0.43
Chronic sinusitis,0/692 %0.0,1/698 %0.14
Clostridium difficile colitis,0/692 %0.0,1/698 %0.14
Cystitis,0/692 %0.0,1/698 %0.14
Cytomegalovirus infection,0/692 %0.0,1/698 %0.14
Device related infection,3/692 %0.43,2/698 %0.29
Device related sepsis,0/692 %0.0,1/698 %0.14
Diverticulitis,1/692 %0.14,0/698 %0.0
Encephalitis enteroviral,0/692 %0.0,1/698 %0.14
Enterococcal infection,0/692 %0.0,1/698 %0.14
Epiglottitis,0/692 %0.0,1/698 %0.14
Escherichia infection,0/692 %0.0,1/698 %0.14
Escherichia urinary tract infection,0/692 %0.0,1/698 %0.14
Febrile infection,1/692 %0.14,0/698 %0.0
Gastroenteritis,1/692 %0.14,7/698 %1.0
Gastroenteritis Escherichia coli,0/692 %0.0,1/698 %0.14
Gastroenteritis viral,1/692 %0.14,0/698 %0.0
Herpes zoster,8/692 %1.16,7/698 %1.0
Herpes zoster disseminated,0/692 %0.0,2/698 %0.29
Herpes zoster infection neurological,1/692 %0.14,0/698 %0.0
Herpes zoster oticus,0/692 %0.0,1/698 %0.14
Infected cyst,0/692 %0.0,1/698 %0.14
Infection,8/692 %1.16,6/698 %0.86
Infective exacerbation of chronic obstructive airways disease,0/692 %0.0,4/698 %0.57
Influenza,0/692 %0.0,3/698 %0.43
Intervertebral discitis,1/692 %0.14,0/698 %0.0
Lower respiratory tract infection,7/692 %1.01,12/698 %1.72
Lung infection,6/692 %0.87,8/698 %1.15
Mastoiditis,1/692 %0.14,0/698 %0.0
Meningitis enteroviral,0/692 %0.0,1/698 %0.14
Mucosal infection,0/692 %0.0,1/698 %0.14
Neuroborreliosis,1/692 %0.14,0/698 %0.0
Neutropenic infection,1/692 %0.14,1/698 %0.14
Neutropenic sepsis,5/692 %0.72,5/698 %0.72
Oesophageal candidiasis,0/692 %0.0,1/698 %0.14
Oesophageal infection,0/692 %0.0,1/698 %0.14
Oral herpes,0/692 %0.0,1/698 %0.14
Ovarian bacterial infection,1/692 %0.14,0/698 %0.0
Pelvic abscess,0/692 %0.0,1/698 %0.14
Periodontitis,0/692 %0.0,1/698 %0.14
Peritonsillar abscess,0/692 %0.0,1/698 %0.14
Pharyngeal abscess,0/692 %0.0,1/698 %0.14
Pheumocystitis jirovecii infection,1/692 %0.14,0/698 %0.0
Pneumocystitis jirovecii pneumonia,0/692 %0.0,1/698 %0.14
Pneumonia,30/692 %4.34,42/698 %6.02
Pneumonia bacterial,1/692 %0.14,1/698 %0.14
Pneumonia fungal,0/692 %0.0,1/698 %0.14
Pneumonia pneumococcal,1/692 %0.14,0/698 %0.0
Post procedural infection,1/692 %0.14,0/698 %0.0
Pulmonary sepsis,0/692 %0.0,1/698 %0.14
Pyelonephritis,0/692 %0.0,1/698 %0.14
Respiratory tract infection,4/692 %0.58,5/698 %0.72
Rhinitis,0/692 %0.0,1/698 %0.14
Rhinovirus infection,0/692 %0.0,1/698 %0.14
Sepsis,6/692 %0.87,13/698 %1.86
Septic shock,2/692 %0.29,0/698 %0.0
Sinusitis,2/692 %0.29,1/698 %0.14
Sinusitis bacterial,0/692 %0.0,1/698 %0.14
Sinusitis fungal,0/692 %0.0,1/698 %0.14
Staphylococcal bacteraemia,0/692 %0.0,1/698 %0.14
Staphylococcal infection,0/692 %0.0,1/698 %0.14
Subcutaneous abscess,2/692 %0.29,0/698 %0.0
Tuberculosis,0/692 %0.0,1/698 %0.14
Tubo-ovarian abscess,0/692 %0.0,1/698 %0.14
Upper respiratory tract infection,3/692 %0.43,6/698 %0.86
Urinary tract infection,6/692 %0.87,9/698 %1.29
Urosepsis,3/692 %0.43,3/698 %0.43
Viral infection,3/692 %0.43,1/698 %0.14
Viral myositis,0/692 %0.0,1/698 %0.14
Accident,0/692 %0.0,1/698 %0.14
Alcohol poisoning,0/692 %0.0,1/698 %0.14
Anastomotic stenosis,0/692 %0.0,1/698 %0.14
Ankle fracture,2/692 %0.29,1/698 %0.14
Brain contusion,0/692 %0.0,1/698 %0.14
Cartilage injury,0/692 %0.0,1/698 %0.14
Compression fracture,1/692 %0.14,0/698 %0.0
Facial bones fracture,1/692 %0.14,0/698 %0.0
Fall,1/692 %0.14,3/698 %0.43
Femur fracture,1/692 %0.14,2/698 %0.29
Foot fracture,0/692 %0.0,1/698 %0.14
Humerus fracture,0/692 %0.0,1/698 %0.14
Infusion related reaction,18/692 %2.6,36/698 %5.16
Ligament sprain,0/692 %0.0,1/698 %0.14
Lumbar vertebral fracture,1/692 %0.14,0/698 %0.0
Medication error,0/692 %0.0,1/698 %0.14
Meniscus injury,0/692 %0.0,1/698 %0.14
Multiple fractures,1/692 %0.14,0/698 %0.0
Pneumothorax traumatic,0/692 %0.0,1/698 %0.14
Seroma,0/692 %0.0,1/698 %0.14
Spinal compression fracture,1/692 %0.14,1/698 %0.14
Spinal fracture,1/692 %0.14,0/698 %0.0
Upper limb fracture,3/692 %0.43,1/698 %0.14
Blood creatinine increased,1/692 %0.14,1/698 %0.14
Eastern cooperative oncology group performance status worsened,0/692 %0.0,1/698 %0.14
Hepatic enzyme increased,1/692 %0.14,0/698 %0.0
International normalised ratio increased,0/692 %0.0,1/698 %0.14
Liver function test abnormal,0/692 %0.0,1/698 %0.14
Dehydration,2/692 %0.29,3/698 %0.43
Diabetes mellitus,0/692 %0.0,2/698 %0.29
Fluid overload,0/692 %0.0,1/698 %0.14
Hypercalcaemia,2/692 %0.29,2/698 %0.29
Hyperglycaemia,0/692 %0.0,1/698 %0.14
Hypokalaemia,1/692 %0.14,1/698 %0.14
Hyponatraemia,1/692 %0.14,4/698 %0.57
Tumour lysis syndrome,1/692 %0.14,3/698 %0.43
Arthropathy,0/692 %0.0,1/698 %0.14
Back pain,3/692 %0.43,2/698 %0.29
Flank pain,1/692 %0.14,1/698 %0.14
Haemarthrosis,1/692 %0.14,0/698 %0.0
Intervertebral disc protrusion,1/692 %0.14,1/698 %0.14
Muscular weakness,1/692 %0.14,0/698 %0.0
Myopathy,1/692 %0.14,1/698 %0.14
Myositis,1/692 %0.14,1/698 %0.14
Neck pain,0/692 %0.0,1/698 %0.14
Osteitis deformans,1/692 %0.14,0/698 %0.0
Osteoarthritis,3/692 %0.43,2/698 %0.29
Pain in extremity,1/692 %0.14,0/698 %0.0
Pathological fracture,0/692 %0.0,1/698 %0.14
Rotator cuff syndrome,0/692 %0.0,1/698 %0.14
Spinal column stenosis,2/692 %0.29,0/698 %0.0
Spinal pain,0/692 %0.0,1/698 %0.14
Synovitis,1/692 %0.14,0/698 %0.0
Temporomandibular joint syndrome,0/692 %0.0,1/698 %0.14
Acoustic neuroma,0/692 %0.0,1/698 %0.14
Acute lymphocytic leukaemia,0/692 %0.0,1/698 %0.14
Acute myeloid leukaemia,0/692 %0.0,2/698 %0.29
Adenocarcinoma,1/692 %0.14,0/698 %0.0
Adenocarcinoma of colon,0/692 %0.0,1/698 %0.14
Adenoma benign,1/692 %0.14,0/698 %0.0
Basal cell carcinoma,2/692 %0.29,5/698 %0.72
Benign neoplasm,0/692 %0.0,1/698 %0.14
Breast cancer,0/692 %0.0,4/698 %0.57
Cancer pain,0/692 %0.0,1/698 %0.14
Colon cancer,2/692 %0.29,1/698 %0.14
Colorectal cancer,1/692 %0.14,0/698 %0.0
Ductal adenocarcinoma of pancreas,1/692 %0.14,0/698 %0.0
Gastric cancer,1/692 %0.14,0/698 %0.0
Hepatic neoplasm,0/692 %0.0,1/698 %0.14
Hodgkin's disease,0/692 %0.0,2/698 %0.29
Hodgkin's disease nodular sclerosis,0/692 %0.0,1/698 %0.14
Intraductal proliferative breast lesion,1/692 %0.14,0/698 %0.0
Intraocular melanoma,1/692 %0.14,0/698 %0.0
Invasive ductal breast carcinoma,1/692 %0.14,1/698 %0.14
Keratoacanthoma,1/692 %0.14,0/698 %0.0
Lung adenocarcinoma,1/692 %0.14,0/698 %0.0
Lung neoplasm malignant,1/692 %0.14,0/698 %0.0
Malignant melanoma,2/692 %0.29,1/698 %0.14
Meningioma,0/692 %0.0,1/698 %0.14
Myelodysplastic syndrome,0/692 %0.0,2/698 %0.29
Neuroendocrine carcinoma of the skin,1/692 %0.14,0/698 %0.0
Non-small cell lung cancer,0/692 %0.0,2/698 %0.29
Non-small cell lung cancer stage IV,0/692 %0.0,1/698 %0.14
Oesophageal carcinoma,0/692 %0.0,1/698 %0.14
Oestrogen receptor positive breast cancer,0/692 %0.0,1/698 %0.14
Papillary thyroid cancer,0/692 %0.0,1/698 %0.14
Prostate cancer,3/692 %0.43,3/698 %0.43
Rectal adenocarcinoma,1/692 %0.14,1/698 %0.14
Renal cancer,0/692 %0.0,1/698 %0.14
Renal cell carcinoma,1/692 %0.14,0/698 %0.0
Schwannoma,0/692 %0.0,1/698 %0.14
Squamous cell carcinoma,2/692 %0.29,4/698 %0.57
Squamous cell carcinoma of skin,1/692 %0.14,2/698 %0.29
Thyroid cancer,0/692 %0.0,1/698 %0.14
Transitional cell carcinoma,0/692 %0.0,1/698 %0.14
Tumour flare,1/692 %0.14,0/698 %0.0
Vulvovaginal warts,1/692 %0.14,0/698 %0.0
Ataxia,1/692 %0.14,0/698 %0.0
Brachial plexopathy,1/692 %0.14,0/698 %0.0
Carotid artery stenosis,1/692 %0.14,0/698 %0.0
Cerebellar syndrome,1/692 %0.14,0/698 %0.0
Cerebral disorder,0/692 %0.0,1/698 %0.14
Cerebral haematoma,1/692 %0.14,0/698 %0.0
Cerebral ischaemia,1/692 %0.14,1/698 %0.14
Cerebrovascular accident,1/692 %0.14,0/698 %0.0
Dementia,0/692 %0.0,1/698 %0.14
Dizziness,2/692 %0.29,1/698 %0.14
Dizziness postural,0/692 %0.0,1/698 %0.14
Encephalopathy,1/692 %0.14,0/698 %0.0
Epilepsy,0/692 %0.0,1/698 %0.14
Haemorrhage intracranial,1/692 %0.14,0/698 %0.0
Haemorrhagic stroke,1/692 %0.14,0/698 %0.0
Hypotonia,0/692 %0.0,1/698 %0.14
Ischaemic stroke,1/692 %0.14,1/698 %0.14
Lethargy,0/692 %0.0,2/698 %0.29
Loss of consiousness,0/692 %0.0,1/698 %0.14
Monoparesis,0/692 %0.0,1/698 %0.14
Nervous system disorder,1/692 %0.14,0/698 %0.0
Neuralgia,1/692 %0.14,1/698 %0.14
Neuropathy peripheral,1/692 %0.14,0/698 %0.0
Orthostatic intolerance,0/692 %0.0,1/698 %0.14
Orthostatic tremor,1/692 %0.14,0/698 %0.0
Parkinson's disease,1/692 %0.14,0/698 %0.0
Polyneuropathy,1/692 %0.14,0/698 %0.0
Presyncope,3/692 %0.43,0/698 %0.0
Seizure,1/692 %0.14,1/698 %0.14
Spinal cord compression,0/692 %0.0,1/698 %0.14
Syncope,3/692 %0.43,3/698 %0.43
Transient ischaemic attack,1/692 %0.14,4/698 %0.57
Tremor,1/692 %0.14,0/698 %0.0
Subarachnoid haemorrhage,1/692 %0.14,0/698 %0.0
VIIth nerve paralysis,0/692 %0.0,1/698 %0.14
Abortion,0/692 %0.0,1/698 %0.14
Alcohol problem,0/692 %0.0,1/698 %0.14
Anxiety,0/692 %0.0,1/698 %0.14
Confusional state,1/692 %0.14,1/698 %0.14
Depression,2/692 %0.29,2/698 %0.29
Emotional disorder,1/692 %0.14,0/698 %0.0
Mental status changes,0/692 %0.0,2/698 %0.29
Psychotic disorder,0/692 %0.0,1/698 %0.14
Substance-induced psychotic disorder,1/692 %0.14,0/698 %0.0
Suicide attempt,0/692 %0.0,1/698 %0.14
Acute kidney injury,1/692 %0.14,3/698 %0.43
Acute prerenal failure,1/692 %0.14,0/698 %0.0
Dysuria,1/692 %0.14,0/698 %0.0
Nephrolithiasis,0/692 %0.0,1/698 %0.14
Renal colic,1/692 %0.14,0/698 %0.0
Renal failure,2/692 %0.29,1/698 %0.14
Renal infarct,1/692 %0.14,0/698 %0.0
Ureteric obstruction,1/692 %0.14,1/698 %0.14
Hydronephrosis,0/692 %0.0,1/698 %0.14
Ovarian cyst,0/692 %0.0,1/698 %0.14
Ovarian mass,0/692 %0.0,1/698 %0.14
Prostatitis,2/692 %0.29,1/698 %0.14
Vaginal ulceration,1/692 %0.14,0/698 %0.0
Vulvovaginal pain,0/692 %0.0,1/698 %0.14
Acute lung injury,0/692 %0.0,1/698 %0.14
Acute respiratory distress syndrome,0/692 %0.0,2/698 %0.29
Acute respiratory failure,0/692 %0.0,1/698 %0.14
Asthma,2/692 %0.29,2/698 %0.29
Bronchospasm,1/692 %0.14,1/698 %0.14
Chronic obstructive pulmonary disease,3/692 %0.43,1/698 %0.14
Cough,2/692 %0.29,0/698 %0.0
Dyspnoea,8/692 %1.16,10/698 %1.43
Dyspnoea exertional,1/692 %0.14,0/698 %0.0
Emphysema,0/692 %0.0,1/698 %0.14
Epistaxis,1/692 %0.14,1/698 %0.14
Haemoptysis,1/692 %0.14,0/698 %0.0
Hypoxia,0/692 %0.0,2/698 %0.29
Interstitial lung disease,4/692 %0.58,2/698 %0.29
Lung consolidation,1/692 %0.14,0/698 %0.0
Lung disorder,0/692 %0.0,1/698 %0.14
Oropharyngeal pain,1/692 %0.14,0/698 %0.0
Paranasal cyst,0/692 %0.0,1/698 %0.14
Pharyngeal inflammation,0/692 %0.0,1/698 %0.14
Pharyngeal paraesthesia,0/692 %0.0,1/698 %0.14
Pleural effusion,5/692 %0.72,5/698 %0.72
Pleurisy,0/692 %0.0,1/698 %0.14
Pleuritic pain,2/692 %0.29,1/698 %0.14
Pneumonia aspiration,0/692 %0.0,1/698 %0.14
Pneumonitis,1/692 %0.14,1/698 %0.14
Pneumothorax,0/692 %0.0,1/698 %0.14
Productive cough,1/692 %0.14,0/698 %0.0
Pulmonary arterial hypertension,0/692 %0.0,1/698 %0.14
Pulmonary congestion,1/692 %0.14,0/698 %0.0
Pulmonary embolism,2/692 %0.29,8/698 %1.15
Respiratory arrest,0/692 %0.0,1/698 %0.14
Respiratory disorder,1/692 %0.14,0/698 %0.0
Respiratory failure,2/692 %0.29,3/698 %0.43
Vocal cord thickening,1/692 %0.14,0/698 %0.0
Pulmonary oedema,0/692 %0.0,2/698 %0.29
Dermatitis contact,0/692 %0.0,1/698 %0.14
Dermatitis exfoliative,0/692 %0.0,1/698 %0.14
Rash,2/692 %0.29,5/698 %0.72
Rash maculo-papular,1/692 %0.14,1/698 %0.14
Swelling face,1/692 %0.14,0/698 %0.0
Urticaria,1/692 %0.14,1/698 %0.14
Cancer surgery,1/692 %0.14,0/698 %0.0
Ileectomy,1/692 %0.14,0/698 %0.0
Thyroidectomy,0/692 %0.0,1/698 %0.14
Axillary vein thrombosis,0/692 %0.0,1/698 %0.14
Circulatory collapse,0/692 %0.0,1/698 %0.14
Deep vein thrombosis,2/692 %0.29,1/698 %0.14
Embolism,3/692 %0.43,0/698 %0.0
Hypertensive crisis,1/692 %0.14,2/698 %0.29
Hypotension,2/692 %0.29,7/698 %1.0
Peripheral artery aneurysm,1/692 %0.14,0/698 %0.0
Peripheral ischaemia,0/692 %0.0,1/698 %0.14

S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma(https://clinicaltrials.gov/show/NCT01412879)
 ,R-HCVAD/MTX/Ara-C (Induction Therapy),R-Bendamustine (Induction Therapy),Stem Cell Transplant (Consolidation Therapy)
 ,The R-HCVAD/MTX/ARA-C combination are rituximab cyclophosphamide vincristine doxorubicin dexamethasone methotrexate and cytarabine. Cycle 1 and 3: Patients receive induction therapy comprising rituximab IV on day 1; cyclophosphamide IV over 3 hours every 12 hours on days 2-4; doxorubicin hydrochloride IV over 72 hours on days 5-7; vincristine sulfate IV on days 5 and 12; and dexamethasone IV or orally (PO) once daily (QD) on days 2-5 and 12-15. Patients with responsive disease after course 1 proceed to course 2. Cycle 2 and 4: Patients receive rituximab IV on day 1; methotrexate IV over 2-22 hours on day 2; cytarabine IV over 2 hours every 12 hours on days 3-4; and leucovorin calcium PO or IV on days 3-6. Patients undergo stem cell collection after completion of Cycle 2 (1 cycle = 21 days).,R-bendamustine combinations are rituximab and bendamustine. Patients receive rituximab IV on day 1 and bendamustine hydrochloride IV over 30 minutes on days 1-2. Treatment repeats every 28 days for 4 cycles (1 cycle = 28 days). Patients with responsive disease receive 2 additional cycles of treatment. Patients undergo stem cell collection after completion of 6 Cycles of treatment.,Patients receive stem cell transplant with non-TBI containing regimen (BCV or BEAM Chemotherapy) for patients 61 years or older or TBI-containing regimen (TBI/VP-16/Cyclophosphamide). BCV chemotherapy: Carmustine IV over 2 hours on days -6 to -4; etoposide IV over 4 hours on day -4; and cyclophosphamide IV over 1 hour on day -2. BEAM chemotherapy: Carmustine IV over 4 hours on days -7 and -6; etoposide IV over 1 hour twice daily and cytarabine IV over 2 hours twice daily on days -5 to -2 and melphalan IV on day -1.  TBI etoposide cyclophosphamide: Patients undergo total-body irradiation (TBI)** twice daily on days -8 to -5. Patients also receive etoposide IV on day -4 and cyclophosphamide IV over 1 hour on day -2. * *TBI may not be used for patients 61 years of age and older. Stem cell transplantation: Patients then undergo autologous peripheral blood stem cell transplantation on day 0.
Total serious adverse events,0/17 %0.0,0/35 %0.0,1/26 %3.85
Diarrhea,0/17 %0.0,0/35 %0.0,1/26 %3.85
Enterocolitis infectious,0/17 %0.0,0/35 %0.0,1/26 %3.85
Adult respiratory distress syndrome,0/17 %0.0,0/35 %0.0,1/26 %3.85

A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER)(https://clinicaltrials.gov/show/NCT01414855)
 ,Obinutuzumab + CHOP
 ,Participants received 1000 mg obinutuzumab intravenously on Day 1 of each 21-day cycle for 8 cycles; during Cycle 1 administration also on Days 8 and 15. Participants also received standard CHOP therapy for 6 cycles.
Total serious adverse events,38/100 %38.0
Febrile neutropenia,14/100 %14.0
Anaemia,1/100 %1.0
Neutropenia,1/100 %1.0
Pancytopenia,1/100 %1.0
Cardiac failure congestive,1/100 %1.0
Acute left ventricular failure,1/100 %1.0
Cardiovascular disorder,1/100 %1.0
Left ventricular dysfunction,1/100 %1.0
Diarrhoea,2/100 %2.0
Abdominal pain,1/100 %1.0
Abdominal pain lower,1/100 %1.0
Intestinal perforation,1/100 %1.0
Intra-abdominal haemorrhage,1/100 %1.0
Rectal haemorrhage,1/100 %1.0
Small intestinal obstruction,1/100 %1.0
Upper gastrointestinal haemorrhage,1/100 %1.0
Asthenia,1/100 %1.0
Chest pain,1/100 %1.0
Death,1/100 %1.0
Pneumonia,6/100 %6.0
Sepsis,2/100 %2.0
Catheter site cellulitis,1/100 %1.0
Cellulitis,1/100 %1.0
Clostridium difficile infection,1/100 %1.0
Pneumonia cytomegaloviral,1/100 %1.0
Device related infection,1/100 %1.0
Encephalitis,1/100 %1.0
Enterococcal infection,1/100 %1.0
Herpes zoster,1/100 %1.0
Herpes zoster disseminated,1/100 %1.0
Colonic abscess,1/100 %1.0
Localised infection,1/100 %1.0
Pneumonia legionella,1/100 %1.0
Septic shock,1/100 %1.0
Urinary tract infection,1/100 %1.0
Femur fracture,1/100 %1.0
Hip fracture,1/100 %1.0
Dehydration,2/100 %2.0
Hyponatraemia,1/100 %1.0
Arthralgia,1/100 %1.0
Pathological fracture,1/100 %1.0
Cerebrovascular accident,1/100 %1.0
Hemiparesis,1/100 %1.0
Presyncope,1/100 %1.0
Spondylitic myelopathy,1/100 %1.0
Syncope,1/100 %1.0
Mental status changes,2/100 %2.0
Delirium,1/100 %1.0
Suicide attempt,1/100 %1.0
Hypoxia,2/100 %2.0
Pulmonary embolism,2/100 %2.0
Dyspnoea,1/100 %1.0
Ecchymosis,1/100 %1.0

Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas(https://clinicaltrials.gov/show/NCT01445535)
 ,Cohort 1 - 3.4 mg/kg,Cohort 2 - 4.8 mg/kg,Cohort 3 - 8.5 mg/kg,Cohort 4 - 15 mg/kg
 ,3.4 mg/kg siplizumab was given on day 1 of each cycle followed by etoposide prednisone vincristine cyclophosphamide doxorubicin and rituximab (EPOCH) (combo chemo) on days 1-5 for 21 days.,4.8 mg/kg siplizumab was given on day 1 of each cycle followed by etoposide prednisone vincristine cyclophosphamide doxorubicin and rituximab (EPOCH) (combo chemo) on days 1-5 for 21 days.,8.5 mg/kg siplizumab was given on day 1 of each cycle followed by etoposide prednisone vincristine cyclophosphamide doxorubicin and rituximab (EPOCH) (combo chemo) on days 1-5 for 21 days.,15 mg/kg siplizumab was given on day 1 of each cycle followed by etoposide prednisone vincristine cyclophosphamide doxorubicin and rituximab (EPOCH) (combo chemo) on days 1-5 for 21 days.
Total all-cause mortality,2/3 %66.67,3/3 %100.0,3/3 %100.0,4/6 %66.67
Total serious adverse events,0/3 %0.0,2/3 %66.67,2/3 %66.67,1/6 %16.67
Fever (in the absence of neutropenia where neutropenia is defined as ANC <1.0 x 10e9/L),0/3 %0.0,1/3 %33.33,0/3 %0.0,0/6 %0.0
Infection,0/3 %0.0,1/3 %33.33,0/3 %0.0,0/6 %0.0
Febrile neutropenia,0/3 %0.0,0/3 %0.0,2/3 %66.67,0/6 %0.0
Fracture,0/3 %0.0,0/3 %0.0,0/3 %0.0,1/6 %16.67

Fosaprepitant in Patients Receiving Ifosfamide-based Regimen(https://clinicaltrials.gov/show/NCT01490060)
 ,Control Cycle (Arm A/Arm B),Arm A: Single Dose Day 1,Arm B: Two Doses Day 1 + Day 4
 ,Control cycle without fosaprepitant.,Fosaprepitant 150 mg intravenous (IV) Day 1 of Cycle 1 (Group 1) or Day 1 of Cycle 2 (Group 2). Participants Randomized to Group 1 (Fosaprepitant Cycle 1 + No Fosaprepitant Cycle 2) or Group 2 (No Fosaprepitant Cycle 1 + Fosaprepitant Cycle 2).,Fosaprepitant 150 mg IV Day 1 + Day 4 of Cycle 1 (Group 1) or Day 1 + Day 4 of Cycle 2 (Group 2). Participants Randomized to Group 1 (Fosaprepitant Cycle 1 + No Fosaprepitant Cycle 2) or Group 2 (No Fosaprepitant Cycle 1 + Fosaprepitant Cycle 2).
Total serious adverse events,4/37 %10.81,1/22 %4.55,1/17 %5.88
Neutropenic Fever,4/37 %10.81,1/22 %4.55,1/17 %5.88

Trial of Eribulin Followed by Doxorubicin & Cyclophosphamide for Her2-negative  Locally Advanced Breast Cancer(https://clinicaltrials.gov/show/NCT01498588)
 ,Eribulin+Doxorubicin+Cyclophosphamide
 ,Neoadjuvant eribulin followed by dose-dense doxorubicin and cyclophosphamide  Eribulin Day 1 and Day 8 of a 21 day cycle x 4 cycles:  Day 1: Eribulin 1.4mg/m IV  Day 8: Eribulin 1.4mg/m IV  Dose-dense doxorubicin and cyclophosphamide every 14 days x 4 cycles:  Day 1: Doxorubicin 60mg/m IV  Day 1: Cyclophosphamide 600mg/m IV  Day 2: Pegfilgrastim support 6mg sc at least 24 hours after chemotherapy
Total serious adverse events,0/7 %0.0

Ofatumumab in Combination With Cyclophosphamide  Doxorubicin Hydrochloride  Vincristine Sulfate  and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma(https://clinicaltrials.gov/show/NCT01527149)
 ,Treatment (Monoclonal Antibody and Combination Chemotherapy)
 ,COURSES 1 3 and 5 (O-HyperCVAD): Patients receive ofatumumab IV on day 1 cyclophosphamide IV over 2 hours every 12 hours for 6 doses on days 3-5 doxorubicin hydrochloride IV continuously over 72 hours on days 6-8 vincristine sulfate IV on days 6 and 13 and dexamethasone IV or PO on days 3-6 and 13-16.  COURSES 2 4 and 6 (O-HD-MA): Patients receive ofatumumab IV on day 1 methotrexate IV continuously over 24 hours on day 3 and cytarabine IV over 2 hours every 12 hours on days 4-5.  All courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.  Eligible patients then undergo standard HDC-ASCT.  Autologous Hematopoietic Stem Cell Transplantation: Undergo autologous HDC-ASCT  Cyclophosphamide: Given IV  Cytarabine: Given IV  Dexamethasone: Given IV or PO  Doxorubicin Hydrochloride: Given IV  Laboratory Biomarker Analysis: Correlative studies  Methotrexate: Given IV  Ofatumumab: Given IV  Vincristine Sulfate: Given IV
Total all-cause mortality,16/37 %43.24
Total serious adverse events,19/37 %51.35
Acute coronary syndrome,1/37 %2.7
Periorbital oedema,1/37 %2.7
Diarrhoea,1/37 %2.7
Pyrexia,1/37 %2.7
Diverticulitis,1/37 %2.7
Enterocolitis infectious,1/37 %2.7
Infusion site infection,3/37 %8.11
Lung infection,2/37 %5.41
Neutropenic sepsis,1/37 %2.7
Parainfluenzae virus infection,1/37 %2.7
Pneumonia,1/37 %2.7
Sepsis,8/37 %21.62
Neutrophil count decreased,1/37 %2.7
Cytarabine syndrome,1/37 %2.7
Pain in extremity,1/37 %2.7
Leukaemia,1/37 %2.7
Malignant melanoma,1/37 %2.7
Arachnoiditis,1/37 %2.7
Headache,1/37 %2.7
Dyspnoea,1/37 %2.7
Pulmonary embolism,1/37 %2.7
Blister,1/37 %2.7
Hypotension,1/37 %2.7

Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery(https://clinicaltrials.gov/show/NCT01533207)
 ,Regimen 1,Regimen II
 ,Gemcitabine 900 mg/m2 IV days 1 and 8 Docetaxel 75 mg/m2 IV day 8 GCSF 5 micrograms/kg days 9-15 or pegfilgrastim 6 mg day 9 or 10 Every 21 days for 4 cycles CT/MRI imaging to confirm disease-free Doxorubicin 60 mg/m2 IV every 21 days for 4 cycles,Observation
Total all-cause mortality,5/20 %25.0,1/18 %5.56
Total serious adverse events,5/20 %25.0,0/18 %0.0
Mucositis Oral,1/20 %5.0,0/18 %0.0
Wound Infection,1/20 %5.0,0/18 %0.0
Skin Infection,1/20 %5.0,0/18 %0.0
Catheter Related Infection,1/20 %5.0,0/18 %0.0
Vascular Access Complication,1/20 %5.0,0/18 %0.0
Neutrophil Count Decreased,1/20 %5.0,0/18 %0.0
Skin And Subcutaneous Tissue Disorders - Other,1/20 %5.0,0/18 %0.0

Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma(https://clinicaltrials.gov/show/NCT01534078)
 ,Treatment Arm
 ,Brentuximab Vedotin in combination with Adriamycin Vinblastine and Dacarbazine  Brentuximab Vedotin: 2 doses administered 14 days apart; followed by combination therapy with AVD for 4-6 cycles; 1.2 mg/kg  Adriamycin vinblastine and dacarbazine: Combination therapy with brentuximab for 4-6 cycles; 25 mg/m2 Adriamycin; 6 mg/m2 Vinblastine; 375 mg/m2 Dacarbazine
Total all-cause mortality,1/34 %2.94
Total serious adverse events,15/34 %44.12
Febrile Neutropenia,8/34 %23.53
Chest Pain - Cardiac,1/34 %2.94
Viral Gastritis,1/34 %2.94
Abdominal Pain,2/34 %5.88
Gastric Hemorrhage,1/34 %2.94
Ileus,1/34 %2.94
Nausea Vomiting Dehydration,1/34 %2.94
Anorexia Nausea Vomiting,1/34 %2.94
Diarrhea Hypotension,1/34 %2.94
Ileus Esophagitis Transaminase elevation low white blood cell count dehydration,1/34 %2.94
Fever,1/34 %2.94
Fever Sinus Congestion,1/34 %2.94
Sepsis,1/34 %2.94
Bronchial Infection,1/34 %2.94
Line Infection,1/34 %2.94
Soft Tissue Infection,1/34 %2.94
Neutrophil Count Decreased,2/34 %5.88
White Blood Cell Decreased,1/34 %2.94
Dehydration,1/34 %2.94
Anorexia Fatigue,1/34 %2.94
Hip pain back pain,1/34 %2.94
Confusion,1/34 %2.94
Aspiration,1/34 %2.94
Hidradenitis Suppurativa,1/34 %2.94

Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment(https://clinicaltrials.gov/show/NCT01548573)
 ,Tandem Transplant in MM <12 Mos of Prior Treatment
 ,This was a single arm study for myeloma patients with <12 months of prior treatment to determine whether the incorporation of bortezomib into a tandem transplant regimen followed by 2 years of maintenance therapy would increase event-free survival.
Total all-cause mortality,3/19 %15.79
Total serious adverse events,13/19 %68.42
Nausea failure-to-thrive and line-associated deep vein thrombosis,1/19 %5.26
Chest pain air embolism,1/19 %5.26
Myocardial infarction,1/19 %5.26
Atrial Fibrillation with RVR,2/19 %10.53
Pneumonia Atrial fib w/ cardioversion,1/19 %5.26
Cholecystitis,1/19 %5.26
Nausea and abdominal pain,1/19 %5.26
Fever,2/19 %10.53
Neutropenic fever,2/19 %10.53
Fever,3/19 %15.79
Malaise and abrupt chest pain,1/19 %5.26
Neutropenic fever abdominal pain and loose stools,1/19 %5.26
Hypoxia fever pulmonary infiltrates with nodules and C Diff + diarrhea,1/19 %5.26
Chills cough throat pain dyspnea. Mucositis. + hMPV. Engraftment syndrome,1/19 %5.26
Sepsis,1/19 %5.26
Viral pneumonia,1/19 %5.26
Bone pain,1/19 %5.26
Severe back pain,1/19 %5.26
Stoke secondary to cardio-embolism,1/19 %5.26
Acute kidney injury uncontrolled hypertension thrombotic microangiopathy,1/19 %5.26
Pneumonia,1/19 %5.26
Respiratory distress fevers and pneumonia,1/19 %5.26

Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed  Non-Bulky Stage I/II Hodgkin Lymphoma(https://clinicaltrials.gov/show/NCT01578967)
 ,ABVD Followed by Brentuximab Vedotin
 ,Single arm trial  Brentuximab vedotin: IV 1.8mg/kg every 3 weeks for 6 cycles.  ABVD: Doxorubicin - 25mg/m2 IV over 3-5 minutes Day 1 and 15 every 28 days 2-6 cycles.  Bleomycin - 10u/m2 IV Day 1 and 15 every 28 days 2-6 cycles Vinblastine - 6mg/m2 IV over 3-5 minutes Day 1 and 15 every 28 days 2-6 cycles.  Dacarbazine - 375mg/m2 IV over 30 minutes Day 1 and 15 every 28 days 2-6 cycles.
Total all-cause mortality,1/41 %2.44
Total serious adverse events,6/41 %14.63
Cholecystitis,1/41 %2.44
Catheter related infection,1/41 %2.44
Lung infection,2/41 %4.88
Meningitis,1/41 %2.44
Alanine aminotransferase increased,1/41 %2.44
Aspartate aminotransferase increased,1/41 %2.44
Intracranial hemorrhage,1/41 %2.44
Transient ischemic attacks,1/41 %2.44
Pulmonary edema,1/41 %2.44
Hypotension,1/41 %2.44

A Phase II Combined Modality Protocol of Debulking Surgery With HIPEC Followed by Intraperitoneal Chemotherapy for the Treatment of Recurrent Ovarian  Primary Peritoneal & Fallopian Tube Cancers(https://clinicaltrials.gov/show/NCT01659554)
 ,Intraoperative Cisplatin Followed by IP Chemotherapy
 ,Intraoperative (hyperthermic) cisplatin followed by 4 courses of intraperitoneal cisplatin and doxorubicin given on days 1 & 8 during a 3 week cycle  Intraoperative (hyperthermic) cisplatin followed by IP Cisplatin; Doxorubicin: Cisplatin 75 mg/m2 at 40.5-42.5 Celsius intraoperatively administered; IP Cisplatin 75 mg/m2 (Day 1) week 1 followed by IP Doxorubicin 25 mg week 2 (day 8) for four sequential 3 week cycles;
Total serious adverse events,1/4 %25.0
Ileus Grade 3,1/4 %25.0
Nausea & vomiting,1/4 %25.0
Grade 2 Abdominal Pain,1/4 %25.0
IP drain infection grade 3,1/4 %25.0
Right Shoulder cellulitis,1/4 %25.0
Fever with catheter related infection,1/4 %25.0
No Oliguric Acute Renal Injury,1/4 %25.0
Urinary Trasct Infection Grade 3,1/4 %25.0

VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer(https://clinicaltrials.gov/show/NCT01666444)
 ,Pegylated Liposomal Doxorubicin (PLD) + Placebo,Pegylated Liposomal Doxorubicin (PLD)+VTX-2337 (VTX)
 ,Pegylated Liposomal Doxorubicin (PLD) 40 mg/m2 plus placebo,Pegylated Liposomal Doxorubicin (PLD) 40 mg/m2 plus VTX-2337 3.0 mg/m2
Total serious adverse events,30/147 %20.41,36/147 %24.49
Anemia,3/147 %2.04,2/147 %1.36
Atrial Fibrillation,1/147 %0.68,1/147 %0.68
Constipation,0/147 %0.0,2/147 %1.36
Diarrhea,1/147 %0.68,4/147 %2.72
Vomiting,5/147 %3.4,7/147 %4.76
Upper Gastrointestinal Hemorrhage,0/147 %0.0,1/147 %0.68
Bloating,0/147 %0.0,1/147 %0.68
Small Intestinal Obstruction,3/147 %2.04,0/147 %0.0
Abdominal Pain,3/147 %2.04,6/147 %4.08
Mucositis Oral,1/147 %0.68,0/147 %0.0
Gastrointestinal Disorders - Other,1/147 %0.68,1/147 %0.68
Ileus,0/147 %0.0,1/147 %0.68
Abdominal Distension,1/147 %0.68,2/147 %1.36
Nausea,8/147 %5.44,9/147 %6.12
Esophageal Ulcer,0/147 %0.0,1/147 %0.68
Esophagitis,1/147 %0.68,0/147 %0.0
Ascites,2/147 %1.36,1/147 %0.68
Pain,0/147 %0.0,2/147 %1.36
Malaise,1/147 %0.68,1/147 %0.68
Injection Site Reaction,0/147 %0.0,1/147 %0.68
Non-Cardiac Chest Pain,1/147 %0.68,0/147 %0.0
Edema Limbs,0/147 %0.0,1/147 %0.68
Fatigue,2/147 %1.36,4/147 %2.72
Death Nos,0/147 %0.0,1/147 %0.68
Fever,1/147 %0.68,3/147 %2.04
Chills,0/147 %0.0,1/147 %0.68
Sinusitis,1/147 %0.68,0/147 %0.0
Sepsis,5/147 %3.4,1/147 %0.68
Lung Infection,0/147 %0.0,1/147 %0.68
Cecal Infection,0/147 %0.0,1/147 %0.68
Urinary Tract Infection,2/147 %1.36,2/147 %1.36
Enterocolitis Infectious,1/147 %0.68,0/147 %0.0
Biliary Tract Infection,1/147 %0.68,0/147 %0.0
Spinal Fracture,1/147 %0.68,0/147 %0.0
Lymphocyte Count Decreased,1/147 %0.68,0/147 %0.0
Inr Increased,0/147 %0.0,1/147 %0.68
Creatinine Increased,4/147 %2.72,0/147 %0.0
Neutrophil Count Decreased,1/147 %0.68,2/147 %1.36
Blood Bilirubin Increased,0/147 %0.0,1/147 %0.68
White Blood Cell Decreased,0/147 %0.0,1/147 %0.68
Aspartate Aminotransferase Increased,0/147 %0.0,1/147 %0.68
Alkaline Phosphatase Increased,0/147 %0.0,1/147 %0.68
Alanine Aminotransferase Increased,0/147 %0.0,1/147 %0.68
Hyponatremia,1/147 %0.68,1/147 %0.68
Hypomagnesemia,1/147 %0.68,0/147 %0.0
Hypokalemia,1/147 %0.68,0/147 %0.0
Hypocalcemia,0/147 %0.0,1/147 %0.68
Hypoalbuminemia,0/147 %0.0,1/147 %0.68
Hyperglycemia,1/147 %0.68,0/147 %0.0
Dehydration,1/147 %0.68,2/147 %1.36
Anorexia,0/147 %0.0,3/147 %2.04
Pain In Extremity,1/147 %0.68,1/147 %0.68
Generalized Muscle Weakness,0/147 %0.0,2/147 %1.36
Neoplasms Benign Malignant And Unspecified (Incl,0/147 %0.0,1/147 %0.68
Stroke,0/147 %0.0,1/147 %0.68
Dysarthria,0/147 %0.0,1/147 %0.68
Cognitive Disturbance,0/147 %0.0,1/147 %0.68
Confusion,0/147 %0.0,1/147 %0.68
Urinary Tract Obstruction,1/147 %0.68,1/147 %0.68
Acute Kidney Injury,0/147 %0.0,2/147 %1.36
Respiratory Thoracic And Mediastinal Disorders -,1/147 %0.68,0/147 %0.0
Respiratory Failure,1/147 %0.68,1/147 %0.68
Pleural Effusion,3/147 %2.04,3/147 %2.04
Hypoxia,1/147 %0.68,0/147 %0.0
Dyspnea,0/147 %0.0,3/147 %2.04
Aspiration,0/147 %0.0,1/147 %0.68
Thromboembolic Event,1/147 %0.68,0/147 %0.0
Hypotension,0/147 %0.0,1/147 %0.68
Hypertension,1/147 %0.68,0/147 %0.0

Cisplatin vs. Doxorubicin/Cyclophosphamide in BrCa(https://clinicaltrials.gov/show/NCT01670500)
 ,Doxorubicin-Cyclophosphamide,Cisplatin
 ,Doxorubicin q 2-3 wk x 4 Cyclophosphamide q 2-3 wk x 4  Cyclophosphamide: administered with doxorubicin intravenously every 2 or 3 weeks for 4 doses  Doxorubicin: administered with Cyclophosphamide intravenously every 2 or 3 weeks for 4 doses,Cisplatin q 3 wk x 4  Cisplatin: administered intravenously every 3 weeks for 4 doses
Total all-cause mortality,0/57 %0.0,0/60 %0.0
Total serious adverse events,6/57 %10.53,5/60 %8.33
Febrile Neutropenia,1/57 %1.75,0/60 %0.0
Non-Cardiac Chest Pain,0/57 %0.0,1/60 %1.67
Allergic Reaction,1/57 %1.75,0/60 %0.0
Breast Infection,0/57 %0.0,1/60 %1.67
Neutrophil Count Decreased,4/57 %7.02,0/60 %0.0
Increased Creatinine,0/57 %0.0,2/60 %3.33
Dehydration,0/57 %0.0,1/60 %1.67
Thromboembolic event,0/57 %0.0,2/60 %3.33

Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer(https://clinicaltrials.gov/show/NCT01705691)
 ,Arm 1: Paclitaxel Then AC,Arm 2: Eribulin Then AC
 ,Paclitaxel 80 mg/m2 IV weekly for 12 doses followed by doxorubicin and cyclophosphamide IV every 21 days for 4 cycles  Paclitaxel: 80 mg/m2 IV over 60 minutes weekly for 12 weeks  Doxorubicin: 60 mg/m2 IV over 15 minutes on day 1 every 21 days for 4 cycles  Cyclophosphamide: 600 mg/m2 IV over 30 minutes on day 1 every 21 days for 4 cycles,Eribulin 1.4 mg/m2 IV on days 1 and 8 of a 21-day cycle for 4 cycles followed by doxorubicin and cyclophosphamide IV every 21 days for 4 cycles  Eribulin: 1.4 mg/m2 IV over 2 to 5 minutes on Days 1 and 8 every 21 days for 4 cycles  Doxorubicin: 60 mg/m2 IV over 15 minutes on day 1 every 21 days for 4 cycles  Cyclophosphamide: 600 mg/m2 IV over 30 minutes on day 1 every 21 days for 4 cycles
Total serious adverse events,3/19 %15.79,4/30 %13.33
Febrile neutropenia,1/19 %5.26,1/30 %3.33
Colitis,1/19 %5.26,0/30 %0.0
Pain in extremity,0/19 %0.0,1/30 %3.33
Nephrolithiasis,0/19 %0.0,1/30 %3.33
Pulmonary embolism,1/19 %5.26,0/30 %0.0
Dyspnoea,0/19 %0.0,1/30 %3.33
Haematoma,0/19 %0.0,1/30 %3.33

A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma(https://clinicaltrials.gov/show/NCT01712490)
 ,A+AVD,ABVD
 ,Brentuximab vedotin 1.2 milligram per kilogram (mg/kg) infusion intravenously over 30-minutes plus doxorubicin 25 milligram per square meter (mg/m^2) vinblastine 6 mg/m^2 and dacarbazine 375 mg/m^2 infusion intravenously once on Days 1 and 15 of each 28-day treatment cycle for up to a maximum of 6 cycles. Brentuximab vedotin was administered within approximately 1 hour after completion of AVD.,Doxorubicin 25 mg/m^2 bleomycin 10 units per square meter (units/m^2) vinblastine 6 mg/m^2 and dacarbazine 375 mg/m^2 infusion intravenously once on Days 1 and 15 of each 28-day treatment cycle for up to a maximum of 6 cycles.
Total all-cause mortality,9/662 %1.36,13/659 %1.97
Total serious adverse events,284/662 %42.9,178/659 %27.01
Febrile neutropenia,114/662 %17.22,43/659 %6.53
Neutropenia,19/662 %2.87,4/659 %0.61
Anaemia,7/662 %1.06,3/659 %0.46
Lymphadenitis,0/662 %0.0,1/659 %0.15
Lymphadenopathy mediastinal,1/662 %0.15,0/659 %0.0
Pancytopenia,2/662 %0.3,0/659 %0.0
Thrombocytopenia,1/662 %0.15,1/659 %0.15
Histiocytosis haematophagic,1/662 %0.15,0/659 %0.0
Myocardial infarction,3/662 %0.45,1/659 %0.15
Acute myocardial infarction,0/662 %0.0,1/659 %0.15
Angina pectoris,1/662 %0.15,0/659 %0.0
Microvascular coronary artery disease,0/662 %0.0,1/659 %0.15
Supraventricular tachycardia,2/662 %0.3,1/659 %0.15
Atrial fibrillation,2/662 %0.3,0/659 %0.0
Sinus tachycardia,1/662 %0.15,1/659 %0.15
Tachycardia,2/662 %0.3,1/659 %0.15
Cardiac arrest,0/662 %0.0,2/659 %0.3
Cardio-respiratory arrest,1/662 %0.15,0/659 %0.0
Cardiac failure,1/662 %0.15,0/659 %0.0
Cardiopulmonary failure,0/662 %0.0,1/659 %0.15
Pericarditis,1/662 %0.15,1/659 %0.15
Atrial thrombosis,1/662 %0.15,0/659 %0.0
Branchial cyst,1/662 %0.15,0/659 %0.0
Cushing's syndrome,0/662 %0.0,1/659 %0.15
Vision blurred,0/662 %0.0,1/659 %0.15
Abdominal pain,14/662 %2.11,4/659 %0.61
Abdominal pain lower,1/662 %0.15,0/659 %0.0
Vomiting,11/662 %1.66,3/659 %0.46
Nausea,7/662 %1.06,3/659 %0.46
Constipation,11/662 %1.66,6/659 %0.91
Diarrhoea,11/662 %1.66,1/659 %0.15
Colitis,4/662 %0.6,0/659 %0.0
Neutropenic colitis,1/662 %0.15,0/659 %0.0
Gastritis,2/662 %0.3,3/659 %0.46
Ileus,3/662 %0.45,1/659 %0.15
Ileus paralytic,4/662 %0.6,0/659 %0.0
Pancreatitis,1/662 %0.15,0/659 %0.0
Pancreatitis acute,1/662 %0.15,0/659 %0.0
Enterocolitis,1/662 %0.15,1/659 %0.15
Mouth ulceration,0/662 %0.0,1/659 %0.15
Stomatitis,0/662 %0.0,1/659 %0.15
Anal ulcer,0/662 %0.0,1/659 %0.15
Gastrointestinal disorder,1/662 %0.15,0/659 %0.0
Haemorrhoids,1/662 %0.15,0/659 %0.0
Pyrexia,44/662 %6.65,28/659 %4.25
Non-cardiac chest pain,1/662 %0.15,2/659 %0.3
Pain,1/662 %0.15,1/659 %0.15
Chest pain,0/662 %0.0,1/659 %0.15
Fatigue,2/662 %0.3,0/659 %0.0
Asthenia,1/662 %0.15,0/659 %0.0
Malaise,1/662 %0.15,0/659 %0.0
Multiple organ dysfunction syndrome,1/662 %0.15,1/659 %0.15
Influenza like illness,1/662 %0.15,0/659 %0.0
Peripheral swelling,0/662 %0.0,1/659 %0.15
Chills,1/662 %0.15,2/659 %0.3
Death,1/662 %0.15,1/659 %0.15
Catheter site haemorrhage,0/662 %0.0,1/659 %0.15
Catheter site pain,0/662 %0.0,1/659 %0.15
Infusion site extravasation,1/662 %0.15,1/659 %0.15
Complication associated with device,0/662 %0.0,1/659 %0.15
Oedema peripheral,1/662 %0.15,0/659 %0.0
Adverse drug reaction,0/662 %0.0,1/659 %0.15
Device related thrombosis,0/662 %0.0,1/659 %0.15
Cholecystitis acute,1/662 %0.15,1/659 %0.15
Cholelithiasis,1/662 %0.15,0/659 %0.0
Hepatotoxicity,2/662 %0.3,0/659 %0.0
Gallbladder obstruction,1/662 %0.15,0/659 %0.0
Liver disorder,0/662 %0.0,1/659 %0.15
Hepatic function abnormal,1/662 %0.15,0/659 %0.0
Hepatic failure,1/662 %0.15,0/659 %0.0
Drug hypersensitivity,1/662 %0.15,1/659 %0.15
Pneumonia,18/662 %2.72,15/659 %2.28
Lung infection,4/662 %0.6,2/659 %0.3
Lower respiratory tract infection,2/662 %0.3,3/659 %0.46
Bronchitis,1/662 %0.15,2/659 %0.3
Atypical pneumonia,0/662 %0.0,1/659 %0.15
Sepsis,14/662 %2.11,4/659 %0.61
Neutropenic sepsis,8/662 %1.21,2/659 %0.3
Bacteraemia,1/662 %0.15,4/659 %0.61
Septic shock,4/662 %0.6,0/659 %0.0
Septic embolus,0/662 %0.0,1/659 %0.15
Device related infection,7/662 %1.06,2/659 %0.3
Respiratory tract infection,1/662 %0.15,2/659 %0.3
Infection,1/662 %0.15,1/659 %0.15
Catheter site infection,1/662 %0.15,0/659 %0.0
Lymph gland infection,0/662 %0.0,1/659 %0.15
Pelvic infection,0/662 %0.0,1/659 %0.15
Wound infection,0/662 %0.0,1/659 %0.15
Upper respiratory tract infection,3/662 %0.45,2/659 %0.3
Tonsillitis,1/662 %0.15,1/659 %0.15
Laryngitis,0/662 %0.0,1/659 %0.15
Pharyngeal abscess,1/662 %0.15,0/659 %0.0
Pharyngitis,1/662 %0.15,0/659 %0.0
Sinusitis,1/662 %0.15,0/659 %0.0
Cellulitis,5/662 %0.76,2/659 %0.3
Bacterial infection,0/662 %0.0,1/659 %0.15
Cellulitis orbital,1/662 %0.15,0/659 %0.0
Gangrene,0/662 %0.0,1/659 %0.15
Pneumocystis jirovecii pneumonia,5/662 %0.76,2/659 %0.3
Pneumocystis jirovecii infection,1/662 %0.15,0/659 %0.0
Anal abscess,2/662 %0.3,0/659 %0.0
Abdominal abscess,0/662 %0.0,1/659 %0.15
Appendicitis,1/662 %0.15,0/659 %0.0
Diverticulitis,1/662 %0.15,0/659 %0.0
Enteritis infectious,0/662 %0.0,1/659 %0.15
Skin infection,2/662 %0.3,1/659 %0.15
Subcutaneous abscess,1/662 %0.15,1/659 %0.15
Folliculitis,1/662 %0.15,0/659 %0.0
Gastroenteritis viral,1/662 %0.15,2/659 %0.3
Pneumonia viral,2/662 %0.3,0/659 %0.0
Viral infection,1/662 %0.15,0/659 %0.0
Clostridium difficile colitis,2/662 %0.3,1/659 %0.15
Clostridium difficile infection,1/662 %0.15,0/659 %0.0
Tooth abscess,2/662 %0.3,0/659 %0.0
Pericoronitis,1/662 %0.15,0/659 %0.0
Periodontitis,0/662 %0.0,1/659 %0.15
Staphylococcal infection,1/662 %0.15,1/659 %0.15
Staphylococcal bacteraemia,0/662 %0.0,1/659 %0.15
Staphylococcal sepsis,1/662 %0.15,0/659 %0.0
Urinary tract infection,2/662 %0.3,1/659 %0.15
Pyelonephritis,0/662 %0.0,1/659 %0.15
Soft tissue infection,1/662 %0.15,2/659 %0.3
Aspergillus infection,0/662 %0.0,1/659 %0.15
Bronchopulmonary aspergillosis,1/662 %0.15,0/659 %0.0
Genital infection female,0/662 %0.0,1/659 %0.15
Vulvitis,1/662 %0.15,0/659 %0.0
Fungal sepsis,0/662 %0.0,1/659 %0.15
Pneumonia fungal,0/662 %0.0,1/659 %0.15
Herpes virus infection,1/662 %0.15,0/659 %0.0
Herpes zoster,0/662 %0.0,1/659 %0.15
Ophthalmic herpes zoster,0/662 %0.0,1/659 %0.15
Infected lymphocele,1/662 %0.15,0/659 %0.0
Phlebitis infective,0/662 %0.0,1/659 %0.15
Endocarditis,0/662 %0.0,1/659 %0.15
Encephalitis,1/662 %0.15,0/659 %0.0
Flavivirus infection,1/662 %0.15,0/659 %0.0
Hepatitis B,0/662 %0.0,1/659 %0.15
Influenza,1/662 %0.15,0/659 %0.0
Moraxella infection,0/662 %0.0,1/659 %0.15
Parainfluenzae virus infection,0/662 %0.0,1/659 %0.15
Pneumonia streptococcal,1/662 %0.15,0/659 %0.0
Hip fracture,2/662 %0.3,0/659 %0.0
Ankle fracture,1/662 %0.15,0/659 %0.0
Femur fracture,1/662 %0.15,0/659 %0.0
Infusion related reaction,1/662 %0.15,1/659 %0.15
Fall,0/662 %0.0,1/659 %0.15
Neutrophil count decreased,3/662 %0.45,1/659 %0.15
Pseudomonas test positive,0/662 %0.0,1/659 %0.15
Staphylococcus test positive,0/662 %0.0,1/659 %0.15
Blood glucose increased,1/662 %0.15,0/659 %0.0
Amylase increased,1/662 %0.15,0/659 %0.0
Lipase increased,1/662 %0.15,0/659 %0.0
Electrocardiogram QT prolonged,1/662 %0.15,0/659 %0.0
Blood bilirubin increased,1/662 %0.15,0/659 %0.0
Body temperature increased,0/662 %0.0,1/659 %0.15
Dehydration,10/662 %1.51,3/659 %0.46
Hyponatraemia,4/662 %0.6,3/659 %0.46
Hyperglycaemia,3/662 %0.45,1/659 %0.15
Hypokalaemia,2/662 %0.3,1/659 %0.15
Hyperkalaemia,0/662 %0.0,1/659 %0.15
Failure to thrive,1/662 %0.15,0/659 %0.0
Malnutrition,1/662 %0.15,0/659 %0.0
Hypomagnesaemia,2/662 %0.3,0/659 %0.0
Type 2 diabetes mellitus,1/662 %0.15,0/659 %0.0
Hypophosphataemia,1/662 %0.15,0/659 %0.0
Pain in extremity,2/662 %0.3,1/659 %0.15
Back pain,2/662 %0.3,0/659 %0.0
Flank pain,2/662 %0.3,0/659 %0.0
Musculoskeletal pain,1/662 %0.15,0/659 %0.0
Myalgia,1/662 %0.15,1/659 %0.15
Bone pain,1/662 %0.15,0/659 %0.0
Arthralgia,0/662 %0.0,1/659 %0.15
Muscular weakness,0/662 %0.0,1/659 %0.15
Neuroendocrine tumour,0/662 %0.0,1/659 %0.15
Pituitary tumour,1/662 %0.15,0/659 %0.0
T-cell lymphoma,0/662 %0.0,1/659 %0.15
Bile duct cancer,0/662 %0.0,1/659 %0.15
Gastrointestinal stromal tumour,1/662 %0.15,0/659 %0.0
Benign ovarian tumour,0/662 %0.0,1/659 %0.15
Plasma cell myeloma,1/662 %0.15,0/659 %0.0
Syncope,2/662 %0.3,2/659 %0.3
Lethargy,2/662 %0.3,1/659 %0.15
Somnolence,0/662 %0.0,1/659 %0.15
Headache,3/662 %0.45,3/659 %0.46
Peripheral motor neuropathy,3/662 %0.45,0/659 %0.0
Peripheral sensory neuropathy,2/662 %0.3,0/659 %0.0
Polyneuropathy,1/662 %0.15,1/659 %0.15
Cerebrovascular accident,1/662 %0.15,1/659 %0.15
Lacunar infarction,0/662 %0.0,1/659 %0.15
Autonomic neuropathy,0/662 %0.0,1/659 %0.15
Facial paralysis,1/662 %0.15,0/659 %0.0
Hypoaesthesia,1/662 %0.15,0/659 %0.0
Hemiparesis,1/662 %0.15,0/659 %0.0
Neuralgia,1/662 %0.15,0/659 %0.0
Spinal cord ischaemia,1/662 %0.15,0/659 %0.0
Anxiety,2/662 %0.3,1/659 %0.15
Agitation,0/662 %0.0,1/659 %0.15
Delirium,2/662 %0.3,0/659 %0.0
Schizoaffective disorder bipolar type,0/662 %0.0,1/659 %0.15
Suicidal ideation,1/662 %0.15,0/659 %0.0
Acute kidney injury,3/662 %0.45,0/659 %0.0
Anuria,1/662 %0.15,0/659 %0.0
Ureteric obstruction,1/662 %0.15,1/659 %0.15
Haematuria,0/662 %0.0,1/659 %0.15
Metrorrhagia,0/662 %0.0,1/659 %0.15
Vaginal haemorrhage,0/662 %0.0,1/659 %0.15
Pulmonary embolism,11/662 %1.66,9/659 %1.37
Pulmonary thrombosis,1/662 %0.15,0/659 %0.0
Pneumonitis,2/662 %0.3,12/659 %1.82
Pulmonary toxicity,0/662 %0.0,5/659 %0.76
Interstitial lung disease,1/662 %0.15,2/659 %0.3
Lung infiltration,2/662 %0.3,0/659 %0.0
Organising pneumonia,0/662 %0.0,1/659 %0.15
Dyspnoea,3/662 %0.45,5/659 %0.76
Respiratory failure,2/662 %0.3,4/659 %0.61
Hypoxia,1/662 %0.15,2/659 %0.3
Cough,1/662 %0.15,1/659 %0.15
Acute pulmonary oedema,1/662 %0.15,0/659 %0.0
Acute respiratory distress syndrome,0/662 %0.0,1/659 %0.15
Lung disorder,1/662 %0.15,0/659 %0.0
Respiratory disorder,0/662 %0.0,1/659 %0.15
Chronic obstructive pulmonary disease,1/662 %0.15,0/659 %0.0
Stridor,1/662 %0.15,0/659 %0.0
Pleuritic pain,0/662 %0.0,1/659 %0.15
Pleurisy,1/662 %0.15,0/659 %0.0
Pneumothorax,1/662 %0.15,0/659 %0.0
Rash macular,1/662 %0.15,0/659 %0.0
Rash maculo-papular,1/662 %0.15,0/659 %0.0
Hidradenitis,0/662 %0.0,1/659 %0.15
Drug eruption,0/662 %0.0,1/659 %0.15
Skin ulcer,0/662 %0.0,1/659 %0.15
Deep vein thrombosis,5/662 %0.76,2/659 %0.3
Thrombophlebitis superficial,1/662 %0.15,1/659 %0.15
Jugular vein thrombosis,0/662 %0.0,1/659 %0.15
Pelvic venous thrombosis,1/662 %0.15,0/659 %0.0
Peripheral artery thrombosis,1/662 %0.15,0/659 %0.0
Venous thrombosis limb,0/662 %0.0,1/659 %0.15
Hypotension,4/662 %0.6,1/659 %0.15
Orthostatic hypotension,0/662 %0.0,1/659 %0.15
Embolism,0/662 %0.0,4/659 %0.61
Venous thrombosis,1/662 %0.15,0/659 %0.0
Brachiocephalic vein occlusion,0/662 %0.0,1/659 %0.15
Superior vena cava syndrome,1/662 %0.15,0/659 %0.0
Phlebitis,1/662 %0.15,0/659 %0.0
Vena cava thrombosis,0/662 %0.0,1/659 %0.15

A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a(https://clinicaltrials.gov/show/NCT01724021)
 ,Arm A,Arm B
 ,Participants in Arm A received one cycle of rituximab 375 mg/m^2 intravenously (IV) then three cycles of rituximab 1400mg subcutaneously (SC) followed by four cycles of rituximab 375 mg/m^2 IV in combination with a standard chemotherapy of cyclophosphamide hydroxydaunorubicin Oncovin prednisone/prednisolone (CHOP) cyclophosphamide vincristine prednisone/prednisolone (CVP) or bendamustine. Rituximab was administered on Day 1 of each treatment cycle followed by administration of the preselected chemotherapy. Cycles were repeated every 14 21 or 28 days depending on the combination chemotherapy regimen selected by the investigator.,Participants in Arm B received four cycles of rituximab 375 mg/m^2 IV followed by four cycles of rituximab 1400mg SC in combination with a standard chemotherapy of CHOP CVP or bendamustine. Rituximab was administered on Day 1 of each treatment cycle followed by administration of the preselected chemotherapy. Cycles were repeated every 14 21 or 28 days depending on the combination chemotherapy regimen selected by the investigator.
Total serious adverse events,126/371 %33.96,116/369 %31.44
Febrile Neutropenia,31/371 %8.36,30/369 %8.13
Neutropenia,16/371 %4.31,13/369 %3.52
Anaemia,3/371 %0.81,5/369 %1.36
Leukopenia,5/371 %1.35,1/369 %0.27
Pancytopenia,1/371 %0.27,2/369 %0.54
Lymphopenia,0/371 %0.0,1/369 %0.27
Atrial fibrillation,2/371 %0.54,1/369 %0.27
Cardiac failure,1/371 %0.27,2/369 %0.54
Acute coronary syndrome,1/371 %0.27,0/369 %0.0
Angina pectoris,0/371 %0.0,1/369 %0.27
Bradycardia,0/371 %0.0,1/369 %0.27
Myocardial infarction,0/371 %0.0,1/369 %0.27
Diabetes insipidus,1/371 %0.27,0/369 %0.0
Hyperthyroidism,0/371 %0.0,1/369 %0.27
Diarrhoea,1/371 %0.27,3/369 %0.81
Vomiting,2/371 %0.54,2/369 %0.54
Abdominal pain,2/371 %0.54,1/369 %0.27
Constipation,2/371 %0.54,1/369 %0.27
Intestinal perforation,1/371 %0.27,2/369 %0.54
Abdominal pain lower,0/371 %0.0,1/369 %0.27
Abdominal wall haematoma,0/371 %0.0,1/369 %0.27
Anal fistula,0/371 %0.0,1/369 %0.27
Enterocolitis,0/371 %0.0,1/369 %0.27
Gastrointestinal obstruction,0/371 %0.0,1/369 %0.27
Ileal perforation,1/371 %0.27,0/369 %0.0
Ileus,0/371 %0.0,1/369 %0.27
Ileus paralytic,0/371 %0.0,1/369 %0.27
Intra-abdominal haemorrhage,1/371 %0.27,0/369 %0.0
Oesophagitis,1/371 %0.27,0/369 %0.0
Small intestinal perforation,1/371 %0.27,0/369 %0.0
Subileus,0/371 %0.0,1/369 %0.27
Upper gastrointestinal haemorrhage,0/371 %0.0,1/369 %0.27
Pyrexia,10/371 %2.7,3/369 %0.81
Asthenia,4/371 %1.08,1/369 %0.27
General physical health deterioration,3/371 %0.81,0/369 %0.0
Chest pain,1/371 %0.27,0/369 %0.0
Injection site warmth,1/371 %0.27,0/369 %0.0
Adverse drug reaction,1/371 %0.27,0/369 %0.0
Cholecystitis Acute,0/371 %0.0,1/369 %0.27
Cholestasis,1/371 %0.27,0/369 %0.0
Hypersensitivity,0/371 %0.0,2/369 %0.54
Anaphylactic reaction,1/371 %0.27,0/369 %0.0
Cytokine release syndrome,0/371 %0.0,1/369 %0.27
Pneumonia,12/371 %3.23,9/369 %2.44
Sepsis,3/371 %0.81,5/369 %1.36
Lung Infection,3/371 %0.81,3/369 %0.81
Herpes Zoster,1/371 %0.27,3/369 %0.81
Urinary Tract Infection,3/371 %0.81,3/369 %0.81
Septic Shock,2/371 %0.54,2/369 %0.54
Atypical pneumonia,1/371 %0.27,2/369 %0.54
Bronchitis,1/371 %0.27,3/369 %0.81
Infection,3/371 %0.81,0/369 %0.0
Upper Respiratory Tract Infection,1/371 %0.27,2/369 %0.54
Cellulitis,1/371 %0.27,1/369 %0.27
Erysipelas,1/371 %0.27,1/369 %0.27
Gastroenteritis,1/371 %0.27,1/369 %0.27
Influenza,2/371 %0.54,0/369 %0.0
Neutropenic sepsis,0/371 %0.0,1/369 %0.27
Pneumocystis Jirovecii Pneumonia,2/371 %0.54,0/369 %0.0
Pneumonia viral,1/371 %0.27,1/369 %0.27
Respiratory Tract Infection,0/371 %0.0,2/369 %0.54
Soft tissue infection,0/371 %0.0,2/369 %0.54
Anal abscess,1/371 %0.27,0/369 %0.0
Appendicitis,1/371 %0.27,0/369 %0.0
Bronchopulmonary Aspergillosis,0/371 %0.0,2/369 %0.54
Cystitis,1/371 %0.27,0/369 %0.0
Diverticulitis,1/371 %0.27,0/369 %0.0
Fungal infection,1/371 %0.27,0/369 %0.0
Gastroenteritis Bacterial,0/371 %0.0,1/369 %0.27
Injection site abscess,0/371 %0.0,1/369 %0.27
Kidney infection,1/371 %0.27,0/369 %0.0
Localised infection,0/371 %0.0,1/369 %0.27
Lower respiratory tract infection,1/371 %0.27,0/369 %0.0
Lymph node abscess,0/371 %0.0,1/369 %0.27
Mucosal infection,0/371 %0.0,1/369 %0.27
Oral fungal infection,1/371 %0.27,0/369 %0.0
Oropharyngeal candidiasis,0/371 %0.0,1/369 %0.27
Peritonsillitis,0/371 %0.0,1/369 %0.27
Post procedural infection,0/371 %0.0,1/369 %0.27
Progressive multifocal leukoencephalopathy,1/371 %0.27,0/369 %0.0
Pyoderma,1/371 %0.27,0/369 %0.0
Skin infection,1/371 %0.27,0/369 %0.0
Staphylococcal sepsis,1/371 %0.27,0/369 %0.0
Subcutaneous abscess,0/371 %0.0,1/369 %0.27
Tooth infection,1/371 %0.27,0/369 %0.0
Viral infection,0/371 %0.0,1/369 %0.27
Bacteraemia,0/371 %0.0,1/369 %0.27
Genital infection bacterial,0/371 %0.0,1/369 %0.27
Oral candidiasis,1/371 %0.27,0/369 %0.0
Systemic infection,1/371 %0.27,0/369 %0.0
Varicella zoster virus infection,1/371 %0.27,0/369 %0.0
Fall,2/371 %0.54,1/369 %0.27
Overdose,0/371 %0.0,1/369 %0.27
Radius fracture,1/371 %0.27,0/369 %0.0
Spinal fracture,0/371 %0.0,1/369 %0.27
Spinal compression fracture,1/371 %0.27,0/369 %0.0
Neutrophil count decreased,11/371 %2.96,10/369 %2.71
White blood cell count decreased,3/371 %0.81,3/369 %0.81
Alanine aminotransferase increased,1/371 %0.27,0/369 %0.0
Platelet count decreased,1/371 %0.27,0/369 %0.0
Body temperature increased,1/371 %0.27,0/369 %0.0
Dehydration,1/371 %0.27,1/369 %0.27
Hyperglycaemia,0/371 %0.0,2/369 %0.54
Decreased appetite,0/371 %0.0,1/369 %0.27
Gout,1/371 %0.27,0/369 %0.0
Hypernataemia,0/371 %0.0,1/369 %0.27
Hyponatraemia,0/371 %0.0,1/369 %0.27
Tumor lysis syndrome,1/371 %0.27,0/369 %0.0
Back pain,1/371 %0.27,0/369 %0.0
Bone pain,1/371 %0.27,0/369 %0.0
Gouty arthritis,0/371 %0.0,1/369 %0.27
Myofascial pain syndrome,1/371 %0.27,0/369 %0.0
Myopathy,0/371 %0.0,1/369 %0.27
Papillary thyroid cancer,0/371 %0.0,1/369 %0.27
Renal cell cancer,0/371 %0.0,1/369 %0.27
Lung adenocarcinoma,0/371 %0.0,1/369 %0.27
Neoplasm,1/371 %0.27,0/369 %0.0
Dizziness,2/371 %0.54,0/369 %0.0
Syncope,2/371 %0.54,1/369 %0.27
Depressed level of consciousness,0/371 %0.0,1/369 %0.27
Haemorrhage intracranial,1/371 %0.27,0/369 %0.0
Headache,1/371 %0.27,0/369 %0.0
Hemiparesis,0/371 %0.0,1/369 %0.27
Hypertensive encephalopathy,0/371 %0.0,1/369 %0.27
Neuropathy peripheral,0/371 %0.0,1/369 %0.27
Paraparesis,0/371 %0.0,1/369 %0.27
Peripheral sensory neuropathy,0/371 %0.0,1/369 %0.27
Transient ischaemic attack,0/371 %0.0,1/369 %0.27
Vith nerve paralysis,1/371 %0.27,0/369 %0.0
Encephalopathy,0/371 %0.0,1/369 %0.27
Anxiety,0/371 %0.0,1/369 %0.27
Depression,1/371 %0.27,1/369 %0.27
Suicide attempt,0/371 %0.0,1/369 %0.27
Nephropathy toxic,1/371 %0.27,0/369 %0.0
Urinary tract pain,0/371 %0.0,1/369 %0.27
Acute kidney injury,1/371 %0.27,2/369 %0.54
Pulmonary embolism,3/371 %0.81,1/369 %0.27
Dyspnoea,2/371 %0.54,0/369 %0.0
Interstitial lung disease,2/371 %0.54,0/369 %0.0
Acute respiratory distress syndrome,1/371 %0.27,0/369 %0.0
Bronchospasm,1/371 %0.27,0/369 %0.0
Pleural effusion,0/371 %0.0,1/369 %0.27
Respiratory failure,0/371 %0.0,1/369 %0.27
Rash,2/371 %0.54,1/369 %0.27
Angioedema,1/371 %0.27,0/369 %0.0
Purpura,1/371 %0.27,0/369 %0.0
Stevens-Johnson syndrome,0/371 %0.0,1/369 %0.27
Deep vein thrombosis,0/371 %0.0,3/369 %0.81
Circulatory collapse,0/371 %0.0,1/369 %0.27
Orthostatic hypotension,1/371 %0.27,0/369 %0.0
Vasculitis,0/371 %0.0,1/369 %0.27
Venous thrombosis,0/371 %0.0,1/369 %0.27
Venous thrombosis limb,0/371 %0.0,1/369 %0.27

Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia(https://clinicaltrials.gov/show/NCT01769209)
 ,Bortezomib + Chemotherapy
 ,Patients receive bortezomib on Days 1 4 8 and 11; doxorubicin hydrochloride on Day 1; PEG-asparaginase on Days 5 and 22; vincristine sulfate on Days 1 8 15 and 22; dexamethasone daily on Days 1 to 14; cytarabine on Day 1 and methotrexate on Day 15.  Bortezomib: Administered subcutaneously (SC) at 1.3 mg/m on Days 1 4 8 and 11.  Doxorubicin hydrochloride (HCl): Administered intravenously (IV) over 15 min at 60mg/m on Day 1.  PEG-Asparaginase: Administered intravenously (IV) or intramuscularly (IM) 2500 U/m (maximum 3750 U) on Days 5 and 22.  Vincristine sulfate: Administered by intravenous (IV) push at 1.5 mg/m (maximum 2 mg) on Days 1 8 15 and 22.  Dexamethasone: Administered orally (PO) at 10 mg/m daily on Days 1 to 14.  Cytarabine: Administered intrathecally (IT) at 100 mg on Day 1  Methotrexate: Administered intrathecally (IT) at 15 mg on Day 15.
Total all-cause mortality,13/18 %72.22
Total serious adverse events,10/18 %55.56
Neutropenic fever (febrile neutropenia),1/18 %5.56
Disseminated intravascular coagulation (DIC),1/18 %5.56
Colon and caecum inflammation (typhilitis colitis),1/18 %5.56
Hepatobilliary Disorders-Other veno-occlusive disease,1/18 %5.56
Septic shock (sepsis),5/18 %27.78
Intracranial hemorrhage,1/18 %5.56

ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas(https://clinicaltrials.gov/show/NCT01777152)
 ,A+CHP,CHOP
 ,brentuximab vedotin cyclophosphamide doxorubicin and prednisone  brentuximab vedotin: 1.8 mg/kg every 3 weeks by IV infusion for 6-8 cycles  doxorubicin: 50 mg/m2 every 3 weeks by IV infusion for 6-8 cycles  prednisone: 100 mg on Days 1 to 5 of each 3-week cycle orally for 6-8 cycles  cyclophosphamide: 750 mg/m2 every 3 weeks by IV infusion for 6-8 cycles,cyclophosphamide doxorubicin vincristine and prednisone  doxorubicin: 50 mg/m2 every 3 weeks by IV infusion for 6-8 cycles  prednisone: 100 mg on Days 1 to 5 of each 3-week cycle orally for 6-8 cycles  vincristine: 1.4 mg/m2 (maximum 2 mg) every 3 weeks by IV infusion for 6-8 cycles  cyclophosphamide: 750 mg/m2 every 3 weeks by IV infusion for 6-8 cycles
Total all-cause mortality,50/223 %22.42,73/226 %32.3
Total serious adverse events,87/223 %39.01,87/226 %38.5
Febrile neutropenia,31/223 %13.9,26/226 %11.5
Neutropenia,8/223 %3.59,6/226 %2.65
Anaemia,1/223 %0.45,1/226 %0.44
Leukopenia,1/223 %0.45,3/226 %1.33
Lymphadenopathy,1/223 %0.45,0/226 %0.0
Lymphopenia,1/223 %0.45,0/226 %0.0
Thrombocytopenia,1/223 %0.45,1/226 %0.44
Pancytopenia,0/223 %0.0,1/226 %0.44
Atrial fibrillation,1/223 %0.45,1/226 %0.44
Cardiac arrest,1/223 %0.45,1/226 %0.44
Sinus tachycardia,1/223 %0.45,0/226 %0.0
Supraventricular tachycardia,1/223 %0.45,0/226 %0.0
Tachycardia,1/223 %0.45,2/226 %0.88
Ventricular fibrillation,1/223 %0.45,0/226 %0.0
Arrhythmia,0/223 %0.0,1/226 %0.44
Cardiac failure acute,0/223 %0.0,1/226 %0.44
Diarrhoea,4/223 %1.79,3/226 %1.33
Abdominal pain,1/223 %0.45,1/226 %0.44
Constipation,1/223 %0.45,1/226 %0.44
Duodenal ulcer haemorrhage,1/223 %0.45,0/226 %0.0
Duodenitis haemorrhagic,1/223 %0.45,0/226 %0.0
Enterocolitis,1/223 %0.45,1/226 %0.44
Inguinal hernia strangulated,1/223 %0.45,0/226 %0.0
Intestinal perforation,1/223 %0.45,0/226 %0.0
Nausea,1/223 %0.45,4/226 %1.77
Upper gastrointestinal haemorrhage,1/223 %0.45,0/226 %0.0
Vomiting,1/223 %0.45,3/226 %1.33
Colitis,0/223 %0.0,1/226 %0.44
Gastric ulcer,0/223 %0.0,2/226 %0.88
Haematemesis,0/223 %0.0,1/226 %0.44
Intestinal obstruction,0/223 %0.0,1/226 %0.44
Lower gastrointestinal haemorrhage,0/223 %0.0,1/226 %0.44
Odynophagia,0/223 %0.0,1/226 %0.44
Oesophagitis,0/223 %0.0,1/226 %0.44
Small intestinal obstruction,0/223 %0.0,1/226 %0.44
Stomatitis,0/223 %0.0,2/226 %0.88
Subileus,0/223 %0.0,1/226 %0.44
Pyrexia,9/223 %4.04,7/226 %3.1
Asthenia,1/223 %0.45,0/226 %0.0
Extravasation,1/223 %0.45,0/226 %0.0
Hyperthermia,1/223 %0.45,0/226 %0.0
Mucosal inflammation,1/223 %0.45,1/226 %0.44
Non-cardiac chest pain,1/223 %0.45,0/226 %0.0
Death,0/223 %0.0,1/226 %0.44
Multiple organ dysfunction syndrome,0/223 %0.0,3/226 %1.33
Hepatic function abnormal,1/223 %0.45,0/226 %0.0
Cholangitis,0/223 %0.0,1/226 %0.44
Pneumonia,11/223 %4.93,3/226 %1.33
Sepsis,5/223 %2.24,4/226 %1.77
Cellulitis,2/223 %0.9,0/226 %0.0
Clostridium difficile colitis,2/223 %0.9,0/226 %0.0
Device related infection,2/223 %0.9,0/226 %0.0
Influenza,2/223 %0.9,0/226 %0.0
Neutropenic infection,2/223 %0.9,1/226 %0.44
Pneumocystis jirovecii pneumonia,2/223 %0.9,0/226 %0.0
Urinary tract infection,2/223 %0.9,0/226 %0.0
Abscess soft tissue,1/223 %0.45,0/226 %0.0
Anal fistula infection,1/223 %0.45,0/226 %0.0
Bacterial pyelonephritis,1/223 %0.45,0/226 %0.0
Bacterial sepsis,1/223 %0.45,0/226 %0.0
Bronchopulmonary aspergillosis,1/223 %0.45,0/226 %0.0
Catheter site cellulitis,1/223 %0.45,0/226 %0.0
Clostridium difficile infection,1/223 %0.45,0/226 %0.0
Cytomegalovirus infection,1/223 %0.45,0/226 %0.0
Enterocolitis infectious,1/223 %0.45,0/226 %0.0
Epstein-Barr virus infection,1/223 %0.45,0/226 %0.0
H1N1 influenza,1/223 %0.45,0/226 %0.0
Infected skin ulcer,1/223 %0.45,0/226 %0.0
Infection,1/223 %0.45,1/226 %0.44
Injection site infection,1/223 %0.45,0/226 %0.0
Lymph gland infection,1/223 %0.45,0/226 %0.0
Otitis externa,1/223 %0.45,0/226 %0.0
Perirectal abscess,1/223 %0.45,0/226 %0.0
Respiratory syncytial virus infection,1/223 %0.45,0/226 %0.0
Septic shock,1/223 %0.45,2/226 %0.88
Soft tissue infection,1/223 %0.45,1/226 %0.44
Staphylococcal infection,1/223 %0.45,2/226 %0.88
Erysipelas,0/223 %0.0,1/226 %0.44
Escherichia sepsis,0/223 %0.0,2/226 %0.88
Groin abscess,0/223 %0.0,1/226 %0.44
Laryngitis,0/223 %0.0,1/226 %0.44
Neutropenic sepsis,0/223 %0.0,3/226 %1.33
Rhinovirus infection,0/223 %0.0,1/226 %0.44
Skin infection,0/223 %0.0,2/226 %0.88
Staphylococcal sepsis,0/223 %0.0,1/226 %0.44
Streptococcal sepsis,0/223 %0.0,1/226 %0.44
Viral upper respiratory tract infection,0/223 %0.0,1/226 %0.44
Splenic rupture,1/223 %0.45,0/226 %0.0
Hip fracture,0/223 %0.0,1/226 %0.44
Spinal compression fracture,0/223 %0.0,1/226 %0.44
Weight decreased,1/223 %0.45,0/226 %0.0
CSF volume decreased,0/223 %0.0,1/226 %0.44
Tumour lysis syndrome,3/223 %1.35,0/226 %0.0
Dehydration,2/223 %0.9,3/226 %1.33
Decreased appetite,1/223 %0.45,0/226 %0.0
Fluid overload,1/223 %0.45,0/226 %0.0
Hypokalaemia,1/223 %0.45,0/226 %0.0
Hyperuricaemia,0/223 %0.0,1/226 %0.44
Hyponatraemia,0/223 %0.0,1/226 %0.44
Bone pain,1/223 %0.45,0/226 %0.0
Pain in extremity,1/223 %0.45,0/226 %0.0
Muscular weakness,0/223 %0.0,1/226 %0.44
Vertebral column mass,0/223 %0.0,1/226 %0.44
Mycosis fungoides,1/223 %0.45,0/226 %0.0
Papillary thyroid cancer,1/223 %0.45,0/226 %0.0
Peripheral T-cell lymphoma unspecified,1/223 %0.45,0/226 %0.0
Tumour haemorrhage,1/223 %0.45,0/226 %0.0
Anaplastic large cell lymphoma T- and null-cell types,0/223 %0.0,11/226 %4.87
Cancer pain,0/223 %0.0,1/226 %0.44
Metastases to central nervous system,0/223 %0.0,2/226 %0.88
Transitional cell carcinoma,0/223 %0.0,1/226 %0.44
Tumour associated fever,0/223 %0.0,1/226 %0.44
Peripheral sensory neuropathy,2/223 %0.9,0/226 %0.0
Dizziness,1/223 %0.45,0/226 %0.0
Headache,1/223 %0.45,0/226 %0.0
Peripheral motor neuropathy,1/223 %0.45,0/226 %0.0
Seizure,1/223 %0.45,1/226 %0.44
Syncope,1/223 %0.45,0/226 %0.0
Autonomic neuropathy,0/223 %0.0,1/226 %0.44
Cerebral infarction,0/223 %0.0,1/226 %0.44
Hydrocephalus,0/223 %0.0,1/226 %0.44
Intracranial hypotension,0/223 %0.0,1/226 %0.44
Paraesthesia,0/223 %0.0,1/226 %0.44
Device issue,0/223 %0.0,1/226 %0.44
Mental status changes,1/223 %0.45,0/226 %0.0
Confusional state,0/223 %0.0,1/226 %0.44
Acute kidney injury,3/223 %1.35,0/226 %0.0
Haematuria,1/223 %0.45,1/226 %0.44
Renal failure,1/223 %0.45,1/226 %0.44
Urinary retention,1/223 %0.45,0/226 %0.0
Oliguria,0/223 %0.0,1/226 %0.44
Pneumonitis,5/223 %2.24,0/226 %0.0
Respiratory failure,3/223 %1.35,2/226 %0.88
Pulmonary embolism,2/223 %0.9,5/226 %2.21
Acute respiratory failure,1/223 %0.45,0/226 %0.0
Cough,1/223 %0.45,0/226 %0.0
Dyspnoea,1/223 %0.45,0/226 %0.0
Haemoptysis,1/223 %0.45,0/226 %0.0
Pleural effusion,1/223 %0.45,0/226 %0.0
Pneumonia aspiration,1/223 %0.45,0/226 %0.0
Pulmonary cavitation,1/223 %0.45,0/226 %0.0
Acute respiratory distress syndrome,0/223 %0.0,1/226 %0.44
Rash,1/223 %0.45,0/226 %0.0
Rash maculo-papular,1/223 %0.45,0/226 %0.0
Blister,0/223 %0.0,1/226 %0.44
Deep vein thrombosis,3/223 %1.35,2/226 %0.88
Embolism,1/223 %0.45,0/226 %0.0
Hypotension,1/223 %0.45,1/226 %0.44
Thrombophlebitis superficial,0/223 %0.0,1/226 %0.44

Microparticle Enhanced Cytotoxic Transarterial Embolization Therapy in Hepatocellular Carcinoma(https://clinicaltrials.gov/show/NCT01798134)
 ,DEB-TACE
 ,Transarterial Chemoembolization with TANDEM - DOX Microspheres (DEB-TACE)  Treatment: Lobes; Dosing: TANDEM/Doxorubicin; Second Treatment:TANDEM/Doxorubicin  TANDEM
Total serious adverse events,10/25 %40.0
Anaemia,1/25 %4.0
Angina pectoris,1/25 %4.0
Cardiac failure,1/25 %4.0
Gastritis,1/25 %4.0
Haemorrhoidal haemorrhage,1/25 %4.0
Melaena,1/25 %4.0
Ascites,1/25 %4.0
Hepatic Failure,1/25 %4.0
Hepatic necrosis,1/25 %4.0
Liver abscess,1/25 %4.0
Sepsis,1/25 %4.0
Peritonitis bacterial,1/25 %4.0
Urinary tract infection,1/25 %4.0
Spinal column injury,1/25 %4.0
Haemoglobin decreased,1/25 %4.0
Hepatic encephalopathy,1/25 %4.0
Ataxia,1/25 %4.0
Confusional state,1/25 %4.0
Dyspnoea,1/25 %4.0
Skin ulcer,1/25 %4.0
Hypotension,1/25 %4.0

A Study to Compare CAELYX With Topotecan HCL in Patients With Recurrent Epithelial Ovarian Carcinoma Following Failure of First-Line  Platinum-Based Chemotherapy(https://clinicaltrials.gov/show/NCT01840943)
 ,CAELYX,Topotecan Hydrocloride (HCl)
 ,Participants received 50 milligram per square meters (mg/m^2) of Caelyx as a 90-minute or 60 to 90-minute intravenous infusion every 4 weeks.,Participants received topotecan HCl 1.25 mg per square meter per day intravenously for 30-minutes duration on Day 1 to Day 5 of each cycle.
Total serious adverse events,1/14 %7.14,1/12 %8.33
Pulmonary tuberculosis,1/14 %7.14,0/12 %0.0
Platelet count decreased,0/14 %0.0,1/12 %8.33

Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy(https://clinicaltrials.gov/show/NCT01847001)
 ,Propranolol + Neoadjuvant Chemotherapy
 ,Subjects will receive 2 types of chemotherapy regimens plus propranolol treatment.  Regimen I involves paclitaxel (may be substituted with nab-paclitaxel; maybe given with premedication) and  Regimen II involves doxorubicin (maybe given with anti-nausea therapy) and cyclophosphamide (maybe given with Pegfilgrastim).  If your tumor is HER2 positive you will also receive trastuzumab and pertuzumab.  After you complete all chemotherapy plus propranolol treatment you will then have surgery to remove the breast tumor.  DOT imaging will be done at 4 additional time points including beo.  Propranolol: Propranolol starting dose is 20mg b.i.d.; propranolol dose is up-titrated to 40mg b.i.d. to 80 mg daily with chemotherapy depending on tolerability. Tolerability is assessed every 2 weeks.
Total all-cause mortality,0/10 %0.0
Total serious adverse events,0/10 %0.0

Vincristine  Doxorubicin  And Dexamethasone + Ixazomib in Acute Lymphoblastic Leukemia (ALL)  Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia(https://clinicaltrials.gov/show/NCT01887587)
 ,(Modified VXLD) Plus MLN9708
 ,Vincristine-1.5 mg/m2 to a max dose of 2 mg IV on days 1 8 15 and 22  Dexamethasone- 10 mg/m2 orally or IV on days 1-14  Doxorubicin- 60 mg/m2 on day 1 by IV bolus.  For patients without CNS involvement:  Cytarabine 100 mg will be administered intrathecally on day 1 (+/-1 day) (cytarabine dose should be reduced to 50 mg if given through a central ommaya reservoir)  Methotrexate 12 mg will be administered intrathecally on day 8 (+/-1 day)  For patients with CNS involvement:  -Cytarabine 100 mg will be administered intrathecally on day 1 (+/-1 day) (cytarabine dose should be reduced to 50 mg if given through a central ommaya reservoir) Triple intrathecal chemotherapy with cytarabine 30 mg methotrexate 15 mg and hydrocortisone 15 mg on (Day 1 8 15 and 22 (+/-1 day)).  MLN9708  Vincristine  Doxorubicin  Dexamethasone
Total all-cause mortality,1/5 %20.0
Total serious adverse events,4/5 %80.0
Febrile neutropenia,1/5 %20.0
Sinus tachycardia,1/5 %20.0
Lactic acidosis,1/5 %20.0
Increased blood bilirubin,1/5 %20.0
Sepsis,3/5 %60.0
Methemoglobinemia,1/5 %20.0
Hypotension,1/5 %20.0

A Study to Evaluate Safety  Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL)(https://clinicaltrials.gov/show/NCT01889069)
 ,Diffuse Large B-Cell Lymphoma (DLBCL),Follicular Lymphoma (FL)
 ,Participants with DLBCL who had received at least 4 doses of rituximab 1400 mg SC once a month during the treatment phase up to a maxium of 7 cycles in addition to standard chemotherapy. Standard chemotherapy regimen included cyclophosphamide vincristine doxorubicin and prednisone (CHOP); or cyclophosphamide vincristine and prednisone (CVP); as per standard local practice.,Participants with CD20+ non-Hodgkin's (FL) who had received at least 4 doses of rituximab 1400 mg SC once a month during the Induction period and at least 6 doses of rituximab 1400 mg SC once every two months during the Maintenance period in addition to standard chemotherapy. Standard chemotherapy regimen included cyclophosphamide vincristine doxorubicin and prednisone (CHOP); or cyclophosphamide vincristine and prednisone (CVP); or bendamustine as per standard local practice.
Total all-cause mortality,14/72 %19.44,4/86 %4.65
Total serious adverse events,26/72 %36.11,23/86 %26.74
Neutropenia,15/72 %20.83,13/86 %15.12
Febrile Neutropenia,4/72 %5.56,2/86 %2.33
Leukopenia,1/72 %1.39,1/86 %1.16
Lymphopenia,0/72 %0.0,2/86 %2.33
Thrombocytopenia,0/72 %0.0,2/86 %2.33
Acute Coronary Syndrome,1/72 %1.39,1/86 %1.16
Cardiac Failure,1/72 %1.39,0/86 %0.0
Myocarditis,0/72 %0.0,1/86 %1.16
Sinus Tachycardia,1/72 %1.39,0/86 %0.0
Subileus,1/72 %1.39,0/86 %0.0
Chest Pain,0/72 %0.0,1/86 %1.16
Cholecystitis Acute,0/72 %0.0,2/86 %2.33
Cholelithiasis,0/72 %0.0,2/86 %2.33
Pneumonia,2/72 %2.78,0/86 %0.0
Klebsiella Infection,1/72 %1.39,0/86 %0.0
Micrococcus Infection,1/72 %1.39,0/86 %0.0
Pneumocystis Jirovecii Pneumonia,0/72 %0.0,1/86 %1.16
Septic Shock,1/72 %1.39,0/86 %0.0
Staphylococcal Infection,1/72 %1.39,0/86 %0.0
Meniscus Injury,0/72 %0.0,1/86 %1.16
Neutrophil Count Decreased,5/72 %6.94,1/86 %1.16
White Blood Cell Count Decreased,2/72 %2.78,0/86 %0.0
Diabetes Mellitus,0/72 %0.0,1/86 %1.16
Hypokalaemia,1/72 %1.39,0/86 %0.0
Arthralgia,1/72 %1.39,0/86 %0.0
Prostatic Adenoma,0/72 %0.0,1/86 %1.16
Monoparesis,0/72 %0.0,1/86 %1.16
Syncope,1/72 %1.39,0/86 %0.0
Bladder Diverticulum,0/72 %0.0,1/86 %1.16
Chylothorax,1/72 %1.39,0/86 %0.0
Pneumonitis,1/72 %1.39,0/86 %0.0
Respiratory Failure,1/72 %1.39,0/86 %0.0
Hypertension,1/72 %1.39,0/86 %0.0

Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL)(https://clinicaltrials.gov/show/NCT01925612)
 ,Part 1: BV(1.2 mg/kg) + RCHOP,Part 1: BV(1.8 mg/kg) + RCHOP,Part 2: BV(1.8 mg/kg) + RCHP,Part 3: BV(1.8 mg/kg) + RCHP,Part 3: RCHOP
 ,Brentuximab vedotin 1.2 mg/kg plus rituximab cyclophosphamide doxorubicin vincristine prednisone  brentuximab vedotin: 1.2 mg/kg by IV infusion every 3 weeks for up to 6 cycles  rituximab: 375 mg/m2 every 3 weeks by IV infusion for up to 6 cycles  vincristine: 1.4 mg/m2 every 3 weeks by IV infusion for up to 6 cycles (dose capped at 2 mg total)  cyclophosphamide: 750 mg/m2 every 3 weeks by IV infusion for up to 6 cycles  prednisone: 100 mg on Days 1 to 5 of each 3-week cycle orally for up to 6 cycles  doxorubicin: 50 mg/m2 every 3 weeks by IV infusion for up to 6 cycles,Brentuximab vedotin 1.8 mg/kg plus rituximab cyclophosphamide doxorubicin vincristine prednisone  brentuximab vedotin: 1.8 mg/kg by IV infusion every 3 weeks for up to 6 cycles  rituximab: 375 mg/m2 every 3 weeks by IV infusion for up to 6 cycles  vincristine: 1.4 mg/m2 every 3 weeks by IV infusion for up to 6 cycles (dose capped at 2 mg total)  cyclophosphamide: 750 mg/m2 every 3 weeks by IV infusion for up to 6 cycles  prednisone: 100 mg on Days 1 to 5 of each 3-week cycle orally for up to 6 cycles  doxorubicin: 50 mg/m2 every 3 weeks by IV infusion for up to 6 cycles,Brentuximab vedotin 1.8 mg/kg plus rituximab cyclophosphamide doxorubicin prednisone  brentuximab vedotin: 1.8 mg/kg by IV infusion every 3 weeks for up to 6 cycles  rituximab: 375 mg/m2 every 3 weeks by IV infusion for up to 6 cycles  cyclophosphamide: 750 mg/m2 every 3 weeks by IV infusion for up to 6 cycles  prednisone: 100 mg on Days 1 to 5 of each 3-week cycle orally for up to 6 cycles  doxorubicin: 50 mg/m2 every 3 weeks by IV infusion for up to 6 cycles,Brentuximab vedotin 1.8 mg/kg plus rituximab cyclophosphamide doxorubicin prednisone  brentuximab vedotin: 1.8 mg/kg by IV infusion every 3 weeks for up to 6 cycles  rituximab: 375 mg/m2 every 3 weeks by IV infusion for up to 6 cycles  cyclophosphamide: 750 mg/m2 every 3 weeks by IV infusion for up to 6 cycles  prednisone: 100 mg on Days 1 to 5 of each 3-week cycle orally for up to 6 cycles  doxorubicin: 50 mg/m2 every 3 weeks by IV infusion for up to 6 cycles,Rituximab cyclophosphamide doxorubicin vincristine prednisone  rituximab: 375 mg/m2 every 3 weeks by IV infusion for up to 6 cycles  vincristine: 1.4 mg/m2 every 3 weeks by IV infusion for up to 6 cycles (dose capped at 2 mg total)  cyclophosphamide: 750 mg/m2 every 3 weeks by IV infusion for up to 6 cycles  prednisone: 100 mg on Days 1 to 5 of each 3-week cycle orally for up to 6 cycles  doxorubicin: 50 mg/m2 every 3 weeks by IV infusion for up to 6 cycles
Total all-cause mortality,1/29 %3.45,2/22 %9.09,0/11 %0.0,1/11 %9.09,2/12 %16.67
Total serious adverse events,16/29 %55.17,14/22 %63.64,5/11 %45.45,4/11 %36.36,4/12 %33.33
Febrile Neutropenia,8/29 %27.59,8/22 %36.36,2/11 %18.18,0/11 %0.0,1/12 %8.33
Neutropenia,2/29 %6.9,1/22 %4.55,0/11 %0.0,0/11 %0.0,0/12 %0.0
Anaemia,0/29 %0.0,0/22 %0.0,0/11 %0.0,0/11 %0.0,1/12 %8.33
Pancytopenia,1/29 %3.45,0/22 %0.0,0/11 %0.0,1/11 %9.09,0/12 %0.0
Atrial fibrillation,0/29 %0.0,0/22 %0.0,0/11 %0.0,1/11 %9.09,0/12 %0.0
Cardiac arrest,0/29 %0.0,0/22 %0.0,0/11 %0.0,1/11 %9.09,0/12 %0.0
Cardiac failure congestive,2/29 %6.9,0/22 %0.0,0/11 %0.0,0/11 %0.0,0/12 %0.0
Cardiomyopathy,1/29 %3.45,0/22 %0.0,0/11 %0.0,0/11 %0.0,0/12 %0.0
Left ventricular dysfunction,1/29 %3.45,0/22 %0.0,0/11 %0.0,0/11 %0.0,0/12 %0.0
Visual impairment,1/29 %3.45,0/22 %0.0,0/11 %0.0,0/11 %0.0,0/12 %0.0
Diarrhoea,0/29 %0.0,0/22 %0.0,0/11 %0.0,2/11 %18.18,0/12 %0.0
Nausea,0/29 %0.0,0/22 %0.0,1/11 %9.09,1/11 %9.09,0/12 %0.0
Vomiting,0/29 %0.0,0/22 %0.0,1/11 %9.09,1/11 %9.09,0/12 %0.0
Gastric ulcer haemorrhage,0/29 %0.0,0/22 %0.0,0/11 %0.0,1/11 %9.09,0/12 %0.0
Gastrointestinal haemorrhage,1/29 %3.45,1/22 %4.55,0/11 %0.0,0/11 %0.0,0/12 %0.0
Ileus,1/29 %3.45,0/22 %0.0,0/11 %0.0,0/11 %0.0,0/12 %0.0
Intestinal perforation,1/29 %3.45,0/22 %0.0,0/11 %0.0,0/11 %0.0,0/12 %0.0
Large intestinal obstruction,0/29 %0.0,1/22 %4.55,0/11 %0.0,0/11 %0.0,0/12 %0.0
Neutropenic colitis,1/29 %3.45,0/22 %0.0,0/11 %0.0,0/11 %0.0,0/12 %0.0
Stomatitis,1/29 %3.45,0/22 %0.0,0/11 %0.0,0/11 %0.0,0/12 %0.0
Asthenia,0/29 %0.0,0/22 %0.0,0/11 %0.0,0/11 %0.0,1/12 %8.33
Chest pain,0/29 %0.0,0/22 %0.0,0/11 %0.0,0/11 %0.0,1/12 %8.33
Bacteraemia,2/29 %6.9,0/22 %0.0,1/11 %9.09,0/11 %0.0,0/12 %0.0
Pneumocystis jirovecii pneumonia,0/29 %0.0,0/22 %0.0,1/11 %9.09,0/11 %0.0,0/12 %0.0
Pneumonia,1/29 %3.45,2/22 %9.09,0/11 %0.0,0/11 %0.0,0/12 %0.0
Escherichia sepsis,0/29 %0.0,0/22 %0.0,0/11 %0.0,1/11 %9.09,0/12 %0.0
Sepsis,0/29 %0.0,1/22 %4.55,0/11 %0.0,0/11 %0.0,1/12 %8.33
Bronchiolitis,0/29 %0.0,1/22 %4.55,0/11 %0.0,0/11 %0.0,0/12 %0.0
Clostridium difficile colitis,0/29 %0.0,1/22 %4.55,0/11 %0.0,0/11 %0.0,0/12 %0.0
Escherichia infection,1/29 %3.45,0/22 %0.0,0/11 %0.0,0/11 %0.0,0/12 %0.0
Pantoea agglomerans infection,1/29 %3.45,0/22 %0.0,0/11 %0.0,0/11 %0.0,0/12 %0.0
Urinary tract infection,0/29 %0.0,1/22 %4.55,0/11 %0.0,0/11 %0.0,0/12 %0.0
Neutrophil count decreased,0/29 %0.0,0/22 %0.0,0/11 %0.0,1/11 %9.09,0/12 %0.0
Cytomegalovirus test positive,1/29 %3.45,0/22 %0.0,0/11 %0.0,0/11 %0.0,0/12 %0.0
Platelet count decreased,1/29 %3.45,0/22 %0.0,0/11 %0.0,0/11 %0.0,0/12 %0.0
White blood cell count decreased,1/29 %3.45,0/22 %0.0,0/11 %0.0,0/11 %0.0,0/12 %0.0
Dehydration,0/29 %0.0,1/22 %4.55,0/11 %0.0,0/11 %0.0,1/12 %8.33
Musculoskeletal pain,1/29 %3.45,0/22 %0.0,0/11 %0.0,0/11 %0.0,0/12 %0.0
Colorectal cancer metastatic,0/29 %0.0,0/22 %0.0,0/11 %0.0,0/11 %0.0,1/12 %8.33
Metastases to central nervous system,0/29 %0.0,1/22 %4.55,0/11 %0.0,0/11 %0.0,0/12 %0.0
Myelodysplastic syndrome,0/29 %0.0,1/22 %4.55,0/11 %0.0,0/11 %0.0,0/12 %0.0
Cerebrovascular accident,0/29 %0.0,0/22 %0.0,0/11 %0.0,0/11 %0.0,1/12 %8.33
Guillain-barre syndrome,1/29 %3.45,0/22 %0.0,0/11 %0.0,0/11 %0.0,0/12 %0.0
Seizure,1/29 %3.45,0/22 %0.0,0/11 %0.0,0/11 %0.0,0/12 %0.0
Acute kidney injury,0/29 %0.0,0/22 %0.0,0/11 %0.0,0/11 %0.0,1/12 %8.33
Renal failure,0/29 %0.0,1/22 %4.55,0/11 %0.0,0/11 %0.0,0/12 %0.0
Pulmonary embolism,0/29 %0.0,0/22 %0.0,1/11 %9.09,0/11 %0.0,0/12 %0.0
Acute respiratory failure,1/29 %3.45,0/22 %0.0,0/11 %0.0,1/11 %9.09,0/12 %0.0
Dyspnoea exertional,0/29 %0.0,0/22 %0.0,0/11 %0.0,0/11 %0.0,1/12 %8.33
Respiratory failure,0/29 %0.0,1/22 %4.55,0/11 %0.0,0/11 %0.0,1/12 %8.33
Acute respiratory distress syndrome,0/29 %0.0,1/22 %4.55,0/11 %0.0,0/11 %0.0,0/12 %0.0
Dyspnoea,0/29 %0.0,1/22 %4.55,0/11 %0.0,0/11 %0.0,0/12 %0.0
Pulmonary oedema,0/29 %0.0,1/22 %4.55,0/11 %0.0,0/11 %0.0,0/12 %0.0
Stevens-johnson syndrome,0/29 %0.0,1/22 %4.55,0/11 %0.0,0/11 %0.0,0/12 %0.0
Hypovolaemic shock,1/29 %3.45,0/22 %0.0,0/11 %0.0,0/11 %0.0,0/12 %0.0

A Study of the Safety of Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Early and Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer(https://clinicaltrials.gov/show/NCT01940497)
 ,Trastuzumab (Vial): Adjuvant,Trastuzumab (Vial): Neoadjuvant,Trastuzumab (SID) Adjuvant,Trastuzumab (SID) Neoadjuvant
 ,Participants received trastuzumab 600 mg subcutaneously using a vial every 3 weeks (1 cycle) for 1 year (4 cycles in combination with adjuvant chemotherapy [consisting of doxorubicin paclitaxel or docetaxel] and 14 cycles administered alone).,Participants received trastuzumab 600 mg subcutaneously using a vial every 3 weeks (1 cycle) for 1 year (4 cycles in combination with neoadjuvant chemotherapy [consisting of doxorubicin paclitaxel or docetaxel] and 14 cycles administered alone).,Participants received trastuzumab 600 mg subcutaneously using SID every 3 weeks (1 cycle) for 1 year (4 cycles in combination with adjuvant chemotherapy [consisting of doxorubicin paclitaxel or docetaxel] and 14 cycles administered alone).,Participants received trastuzumab 600 mg subcutaneously using SID every 3 weeks (1 cycle) for 1 year (4 cycles in combination with neoadjuvant chemotherapy [consisting of doxorubicin paclitaxel or docetaxel] and 14 cycles administered alone).
Total all-cause mortality,5/95 %5.26,1/20 %5.0,0/92 %0.0,1/21 %4.76
Total serious adverse events,5/95 %5.26,3/20 %15.0,7/92 %7.61,2/21 %9.52
Febrile neutropenia,0/95 %0.0,0/20 %0.0,1/92 %1.09,0/21 %0.0
Neutropenia,0/95 %0.0,0/20 %0.0,0/92 %0.0,1/21 %4.76
Atrial fibrillation,0/95 %0.0,1/20 %5.0,0/92 %0.0,0/21 %0.0
Pleuropericarditis,0/95 %0.0,1/20 %5.0,0/92 %0.0,0/21 %0.0
Vomiting,0/95 %0.0,0/20 %0.0,0/92 %0.0,1/21 %4.76
Pryexia,0/95 %0.0,0/20 %0.0,1/92 %1.09,0/21 %0.0
Anaphylactic shock,1/95 %1.05,0/20 %0.0,1/92 %1.09,0/21 %0.0
Gastroenteritis,0/95 %0.0,1/20 %5.0,0/92 %0.0,0/21 %0.0
Fibula fracture,1/95 %1.05,0/20 %0.0,0/92 %0.0,0/21 %0.0
Tibia fracture,1/95 %1.05,0/20 %0.0,0/92 %0.0,0/21 %0.0
Intervertebral disc protrusion,0/95 %0.0,1/20 %5.0,0/92 %0.0,0/21 %0.0
Bladder transitional cell carcinoma,0/95 %0.0,0/20 %0.0,1/92 %1.09,0/21 %0.0
Intracranial tumour haemorrhage,1/95 %1.05,0/20 %0.0,0/92 %0.0,0/21 %0.0
Ovarian epithelial cancer metastatic,1/95 %1.05,0/20 %0.0,0/92 %0.0,0/21 %0.0
Adenocarcinoma pancreas,0/95 %0.0,0/20 %0.0,1/92 %1.09,0/21 %0.0
Syncope,1/95 %1.05,0/20 %0.0,0/92 %0.0,0/21 %0.0
Generalised anxiety disorder,0/95 %0.0,0/20 %0.0,1/92 %1.09,0/21 %0.0
Acute kidney injury,0/95 %0.0,0/20 %0.0,1/92 %1.09,0/21 %0.0

Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma(https://clinicaltrials.gov/show/NCT01964755)
 ,Chemotherapy + Antiviral-Based Therapy
 ,Combination Chemotherapy for up to six (6) 21-day cycles and Antiviral-Based Therapy per study protocol:  Chemotherapy: Up to 6 cycles 21 days each:  Doxorubicin: 20 mg/m2 intravenously (IV) on Day 1;  Rituximab: 375mg/m2 (optional) IV on Day 1;  Methotrexate: 3.5 gm/m2 IV on Day 2;  Leucovorin: 10 mg/m2 IV starting approximately 24 hours after start of Methotrexate infusion and then 25 mg orally every 6 hours for at least 10 doses;  Antiviral-Based Therapy  Zidovudine: Starting 750 mg/m2 IV on Day 2 then 1200 mg orally twice daily for 10 doses;  Hydroxyurea: 1000 mg orally twice daily starting Day 2 for a total of 10 doses.  Doxorubicin: Doxorubicin 20 mg/m2 intravenously will be administered on Day 1 in patients with systemic (non-primary CNS) lymphoma as per institutional guidelines  Methotrexate: Methotrexate administered starting on Day 2.
Total all-cause mortality,2/6 %33.33
Total serious adverse events,2/6 %33.33
Febrile Neutropenia,1/6 %16.67
Platelet count decreased,1/6 %16.67
Dehydration,1/6 %16.67
Hypophosphatemia,1/6 %16.67
Hypoxia,1/6 %16.67
Pneumonitis,1/6 %16.67
Adult respiratory distress syndrome,1/6 %16.67

A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab  Cyclophosphamide  Doxorubicin  and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma(https://clinicaltrials.gov/show/NCT01992653)
 ,Polatuzumab Vedotin (1.0mg) + R-CHP,Polatuzumab Vedotin (1.4mg) + R-CHP,Polatuzumab Vedotin (1.8mg) + R-CHP,Polatuzumab Vedotin (2.4mg) + R-CHP,Polatuzumab Vedotin (1.4mg) + G-CHP,Polatuzumab Vedotin (1.8mg) + G-CHP,Expansion: Polatuzumab Vedotin (1.8mg) + R-CHP,Expansion: Polatuzumab Vedotin (1.8mg) + G-CHP
 ,Dose Escalation: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with R-CHP.,Dose Escalation: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with R-CHP.,Dose Escalation: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with R-CHP.,Dose Escalation: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with R-CHP. The participant in this group was incorrectly dosed on 2.4mg Pola R-CHP group and should have been assigned to the 1.8mg Pola R-CHP group.,Dose Escalation: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with G-CHP.,Dose Escalation: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with G-CHP.,Dose Expansion: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with R-CHP. Participants treated with MTD determined from dose escalation cohorts.,Dose Expansion: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with G-CHP. Participants treated with MTD determined from dose escalation cohorts.
Total all-cause mortality,0/3 %0.0,0/3 %0.0,1/6 %16.67,0/1 %0.0,1/6 %16.67,0/6 %0.0,4/40 %10.0,2/17 %11.76
Total serious adverse events,1/3 %33.33,1/3 %33.33,4/6 %66.67,0/1 %0.0,1/6 %16.67,3/6 %50.0,15/40 %37.5,6/17 %35.29
FEBRILE NEUTROPENIA,0/3 %0.0,1/3 %33.33,0/6 %0.0,0/1 %0.0,1/6 %16.67,2/6 %33.33,3/40 %7.5,4/17 %23.53
NEUTROPENIA,0/3 %0.0,0/3 %0.0,2/6 %33.33,0/1 %0.0,0/6 %0.0,1/6 %16.67,0/40 %0.0,1/17 %5.88
THROMBOCYTOPENIA,0/3 %0.0,0/3 %0.0,0/6 %0.0,0/1 %0.0,1/6 %16.67,0/6 %0.0,0/40 %0.0,0/17 %0.0
ATRIAL FIBRILLATION,0/3 %0.0,0/3 %0.0,0/6 %0.0,0/1 %0.0,1/6 %16.67,0/6 %0.0,2/40 %5.0,0/17 %0.0
CORONARY ARTERY DISEASE,0/3 %0.0,0/3 %0.0,0/6 %0.0,0/1 %0.0,0/6 %0.0,1/6 %16.67,0/40 %0.0,0/17 %0.0
SUPRAVENTRICULAR TACHYCARDIA,0/3 %0.0,0/3 %0.0,0/6 %0.0,0/1 %0.0,0/6 %0.0,1/6 %16.67,0/40 %0.0,0/17 %0.0
DIARRHOEA,0/3 %0.0,0/3 %0.0,0/6 %0.0,0/1 %0.0,0/6 %0.0,0/6 %0.0,1/40 %2.5,0/17 %0.0
DYSPHAGIA,0/3 %0.0,0/3 %0.0,1/6 %16.67,0/1 %0.0,0/6 %0.0,0/6 %0.0,0/40 %0.0,0/17 %0.0
VOMITING,0/3 %0.0,0/3 %0.0,0/6 %0.0,0/1 %0.0,0/6 %0.0,0/6 %0.0,0/40 %0.0,1/17 %5.88
ASTHENIA,0/3 %0.0,0/3 %0.0,0/6 %0.0,0/1 %0.0,0/6 %0.0,0/6 %0.0,0/40 %0.0,1/17 %5.88
SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,0/3 %0.0,0/3 %0.0,0/6 %0.0,0/1 %0.0,0/6 %0.0,0/6 %0.0,1/40 %2.5,0/17 %0.0
CLOSTRIDIUM DIFFICILE INFECTION,0/3 %0.0,0/3 %0.0,0/6 %0.0,0/1 %0.0,0/6 %0.0,1/6 %16.67,0/40 %0.0,0/17 %0.0
ESCHERICHIA URINARY TRACT INFECTION,0/3 %0.0,0/3 %0.0,0/6 %0.0,0/1 %0.0,0/6 %0.0,0/6 %0.0,1/40 %2.5,0/17 %0.0
LUNG INFECTION,0/3 %0.0,0/3 %0.0,0/6 %0.0,0/1 %0.0,0/6 %0.0,0/6 %0.0,1/40 %2.5,0/17 %0.0
ORAL FUNGAL INFECTION,0/3 %0.0,0/3 %0.0,0/6 %0.0,0/1 %0.0,0/6 %0.0,0/6 %0.0,1/40 %2.5,0/17 %0.0
PNEUMONIA,0/3 %0.0,0/3 %0.0,2/6 %33.33,0/1 %0.0,0/6 %0.0,1/6 %16.67,0/40 %0.0,1/17 %5.88
SEPSIS,0/3 %0.0,0/3 %0.0,0/6 %0.0,0/1 %0.0,0/6 %0.0,1/6 %16.67,0/40 %0.0,0/17 %0.0
SEPTIC SHOCK,0/3 %0.0,0/3 %0.0,0/6 %0.0,0/1 %0.0,0/6 %0.0,0/6 %0.0,0/40 %0.0,1/17 %5.88
FEMUR FRACTURE,0/3 %0.0,0/3 %0.0,0/6 %0.0,0/1 %0.0,0/6 %0.0,0/6 %0.0,1/40 %2.5,0/17 %0.0
INFUSION RELATED REACTION,1/3 %33.33,0/3 %0.0,0/6 %0.0,0/1 %0.0,0/6 %0.0,0/6 %0.0,0/40 %0.0,0/17 %0.0
PELVIC FRACTURE,0/3 %0.0,0/3 %0.0,0/6 %0.0,0/1 %0.0,0/6 %0.0,0/6 %0.0,1/40 %2.5,0/17 %0.0
INFLUENZA A VIRUS TEST POSITIVE,0/3 %0.0,0/3 %0.0,0/6 %0.0,0/1 %0.0,0/6 %0.0,0/6 %0.0,2/40 %5.0,0/17 %0.0
HYPERGLYCAEMIA,0/3 %0.0,0/3 %0.0,0/6 %0.0,0/1 %0.0,0/6 %0.0,0/6 %0.0,0/40 %0.0,1/17 %5.88
HYPONATRAEMIA,0/3 %0.0,0/3 %0.0,0/6 %0.0,0/1 %0.0,0/6 %0.0,0/6 %0.0,1/40 %2.5,0/17 %0.0
MALNUTRITION,0/3 %0.0,0/3 %0.0,0/6 %0.0,0/1 %0.0,0/6 %0.0,0/6 %0.0,1/40 %2.5,0/17 %0.0
ARTHRITIS,0/3 %0.0,0/3 %0.0,0/6 %0.0,0/1 %0.0,0/6 %0.0,0/6 %0.0,1/40 %2.5,0/17 %0.0
RHEUMATOID ARTHRITIS,0/3 %0.0,0/3 %0.0,0/6 %0.0,0/1 %0.0,0/6 %0.0,0/6 %0.0,1/40 %2.5,0/17 %0.0
SYNCOPE,0/3 %0.0,0/3 %0.0,0/6 %0.0,0/1 %0.0,0/6 %0.0,1/6 %16.67,1/40 %2.5,0/17 %0.0
ANXIETY,0/3 %0.0,0/3 %0.0,0/6 %0.0,0/1 %0.0,0/6 %0.0,0/6 %0.0,1/40 %2.5,0/17 %0.0
MENTAL STATUS CHANGES,0/3 %0.0,0/3 %0.0,0/6 %0.0,0/1 %0.0,0/6 %0.0,0/6 %0.0,0/40 %0.0,1/17 %5.88
ACUTE KIDNEY INJURY,0/3 %0.0,0/3 %0.0,0/6 %0.0,0/1 %0.0,0/6 %0.0,1/6 %16.67,0/40 %0.0,0/17 %0.0
CHYLOTHORAX,0/3 %0.0,0/3 %0.0,0/6 %0.0,0/1 %0.0,0/6 %0.0,0/6 %0.0,1/40 %2.5,0/17 %0.0
PULMONARY EMBOLISM,0/3 %0.0,0/3 %0.0,1/6 %16.67,0/1 %0.0,0/6 %0.0,0/6 %0.0,1/40 %2.5,0/17 %0.0

Doxorubicin-eluting LC Bead M1 for Patients With Hepatocellular Carcinoma(https://clinicaltrials.gov/show/NCT02007954)
 ,DEBDOX
 ,DEBDOX: DEBDOX loaded with doxorubicin is a device that utilizes beads in place of lipiodol to deliver the chemotherapy into the liver tumor. The device allows for continuous elution of doxorubicin into the liver tumor tissue. The advantages of this method of delivery in comparison to conventional TACE are that the beads are able to deliver a greater volume and concentration of the drugs to the tumor because of their unique ability to elute the drug over a period of several days. As a result of this unique delivery systemic toxicity is significantly reduced. The potential advantages of the smaller beads are deeper penetration into the tumor bed while avoiding premature proximal occlusion of vessels feeding the tumor and more consistent dosing. These properties translate into greater potency of therapy and potentially improved patient survival.
Total all-cause mortality,1/24 %4.17
Total serious adverse events,4/24 %16.67
Cardiac arrest,1/24 %4.17
Upper gastrointestinal hemorrhage,1/24 %4.17
Renal failure,1/24 %4.17
Hypoxia,1/24 %4.17
Respiratory failure,1/24 %4.17
Thromboembolic event,1/24 %4.17

Safety Study Of Chemotherapy Combined With Dendritic Cell Vaccine to Treat Breast Cancer(https://clinicaltrials.gov/show/NCT02018458)
 ,LA TNBC: DC Vaccine+Preop Chemo
 ,Patients will undergo a 2-week run-in treatment of daily anakinra alone. This will be followed by daily anakinra (100 mg SC) plus the physician's chemotherapy ( TPC) choice of standard of care (SOC) for a maximum of 6 months.
Total all-cause mortality,4/10 %40.0
Total serious adverse events,3/10 %30.0
Right atrial thrombosis,1/10 %10.0
Death,1/10 %10.0
Pulmonary Embolism,1/10 %10.0
dyspnea,1/10 %10.0
cellulitis of right breast,1/10 %10.0

A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL(https://clinicaltrials.gov/show/NCT02055820)
 ,Venetoclax 200 mg +R-CHOP,Venetoclax 400 mg +R-CHOP,Venetoclax 600 mg +R-CHOP,Venetoclax 800 mg +R-CHOP,Venetoclax 800 mg +R-CHOP Phase II,Venetoclax 200 mg +G-CHOP,Venetoclax 400 mg +G-CHOP,Venetoclax 600 mg +G-CHOP,Venetoclax 800 mg + G-CHOP A,Venetoclax 800 mg +G-CHOP B
 ,Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.,Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.,Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.,Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.,Phase II: Participants received 6 cycles of CHOP and 8 cycles of venetoclax (at dose determined in Phase I) + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.,Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.,Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.,Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.,Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. In this arm venetoclax was administered as follows: Cycle 1 Days 4-10; Cycles 2-8 Days 1-10 Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.,Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. In this arm venetoclax was administered as follows: Cycle 1 Days 4-8; Cycles 2-8 Days 1-5. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
Total all-cause mortality,1/7 %14.29,0/3 %0.0,1/8 %12.5,4/6 %66.67,33/208 %15.87,1/7 %14.29,1/7 %14.29,0/6 %0.0,0/6 %0.0,0/6 %0.0
Total serious adverse events,5/7 %71.43,2/3 %66.67,4/8 %50.0,3/6 %50.0,116/208 %55.77,5/7 %71.43,4/7 %57.14,3/6 %50.0,5/6 %83.33,5/6 %83.33
AGRANULOCYTOSIS,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,1/208 %0.48,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
ANAEMIA,0/7 %0.0,1/3 %33.33,0/8 %0.0,0/6 %0.0,4/208 %1.92,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
FEBRILE NEUTROPENIA,3/7 %42.86,0/3 %0.0,1/8 %12.5,2/6 %33.33,57/208 %27.4,1/7 %14.29,2/7 %28.57,0/6 %0.0,0/6 %0.0,1/6 %16.67
HAEMOLYTIC ANAEMIA,1/7 %14.29,0/3 %0.0,0/8 %0.0,0/6 %0.0,0/208 %0.0,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
LEUKOPENIA,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,1/208 %0.48,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
NEUTROPENIA,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,19/208 %9.13,1/7 %14.29,0/7 %0.0,0/6 %0.0,0/6 %0.0,1/6 %16.67
THROMBOCYTOPENIA,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,2/208 %0.96,0/7 %0.0,0/7 %0.0,0/6 %0.0,2/6 %33.33,0/6 %0.0
ACUTE CORONARY SYNDROME,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,0/208 %0.0,1/7 %14.29,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
ATRIAL FIBRILLATION,1/7 %14.29,1/3 %33.33,0/8 %0.0,0/6 %0.0,6/208 %2.88,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
ATRIOVENTRICULAR BLOCK,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,2/208 %0.96,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
CARDIAC ARREST,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,0/208 %0.0,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,1/6 %16.67
CARDIAC FAILURE,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,1/208 %0.48,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
CARDIAC FAILURE CONGESTIVE,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,1/208 %0.48,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
CARDIOGENIC SHOCK,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,1/208 %0.48,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
CARDIOMYOPATHY,0/7 %0.0,1/3 %33.33,0/8 %0.0,0/6 %0.0,0/208 %0.0,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
LEFT VENTRICULAR FAILURE,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,1/208 %0.48,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
MYOCARDIAL ISCHAEMIA,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,1/208 %0.48,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
SINUS TACHYCARDIA,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,1/208 %0.48,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
SUPRAVENTRICULAR TACHYCARDIA,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,1/208 %0.48,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
TACHYCARDIA,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,1/208 %0.48,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,1/6 %16.67
OPTIC NEUROPATHY,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,1/208 %0.48,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
DIARRHOEA,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,4/208 %1.92,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
DIVERTICULAR PERFORATION,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,1/208 %0.48,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
DUODENAL STENOSIS,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,1/208 %0.48,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
DYSPHAGIA,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,0/208 %0.0,0/7 %0.0,0/7 %0.0,1/6 %16.67,0/6 %0.0,0/6 %0.0
ENTEROCOLITIS,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,1/208 %0.48,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
GASTRIC DILATATION,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,1/208 %0.48,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
GASTRIC PERFORATION,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,1/208 %0.48,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
GASTRIC STENOSIS,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,1/208 %0.48,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
GASTRIC ULCER,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,1/208 %0.48,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
GASTRIC ULCER PERFORATION,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,0/208 %0.0,0/7 %0.0,0/7 %0.0,0/6 %0.0,1/6 %16.67,0/6 %0.0
GASTROINTESTINAL PAIN,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,1/208 %0.48,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
HAEMATEMESIS,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,1/208 %0.48,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
ILEAL PERFORATION,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,1/208 %0.48,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
ILEUS,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,0/208 %0.0,0/7 %0.0,0/7 %0.0,1/6 %16.67,0/6 %0.0,0/6 %0.0
NAUSEA,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,1/208 %0.48,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
OBSTRUCTION GASTRIC,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,1/208 %0.48,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
OESOPHAGEAL STENOSIS,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,0/208 %0.0,1/7 %14.29,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
PANCREATITIS,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,2/208 %0.96,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
RECTAL HAEMORRHAGE,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,1/208 %0.48,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
SMALL INTESTINAL OBSTRUCTION,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,1/208 %0.48,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
STOMATITIS,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,1/208 %0.48,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
UPPER GASTROINTESTINAL HAEMORRHAGE,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,1/208 %0.48,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
VOMITING,0/7 %0.0,1/3 %33.33,0/8 %0.0,0/6 %0.0,5/208 %2.4,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
ASTHENIA,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,0/208 %0.0,0/7 %0.0,0/7 %0.0,0/6 %0.0,1/6 %16.67,0/6 %0.0
FATIGUE,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,2/208 %0.96,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
INFLAMMATION,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,1/208 %0.48,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
PYREXIA,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,7/208 %3.37,1/7 %14.29,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
SUDDEN CARDIAC DEATH,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,1/208 %0.48,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
BILE DUCT STONE,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,1/208 %0.48,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
CHOLECYSTITIS,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,0/208 %0.0,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,1/6 %16.67
CHOLECYSTITIS ACUTE,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,1/208 %0.48,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
DRUG-INDUCED LIVER INJURY,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,0/208 %0.0,1/7 %14.29,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
HYPOGAMMAGLOBULINAEMIA,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,1/208 %0.48,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
ACUTE SINUSITIS,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,1/208 %0.48,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
ATYPICAL PNEUMONIA,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,2/208 %0.96,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
BACTERIAL SEPSIS,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,1/208 %0.48,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
BRONCHITIS,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,1/208 %0.48,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
CELLULITIS,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,1/208 %0.48,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
CLOSTRIDIUM COLITIS,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,1/208 %0.48,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
CLOSTRIDIUM DIFFICILE INFECTION,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,1/208 %0.48,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
DEVICE RELATED INFECTION,1/7 %14.29,0/3 %0.0,0/8 %0.0,0/6 %0.0,0/208 %0.0,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
DIVERTICULITIS,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,0/208 %0.0,0/7 %0.0,0/7 %0.0,0/6 %0.0,1/6 %16.67,0/6 %0.0
EMPYEMA,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,0/208 %0.0,0/7 %0.0,1/7 %14.29,0/6 %0.0,0/6 %0.0,0/6 %0.0
ESCHERICHIA PYELONEPHRITIS,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,1/208 %0.48,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
ESCHERICHIA URINARY TRACT INFECTION,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,1/208 %0.48,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
GASTROENTERITIS,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,1/208 %0.48,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
GASTROENTERITIS NOROVIRUS,0/7 %0.0,0/3 %0.0,0/8 %0.0,1/6 %16.67,0/208 %0.0,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
HERPES SIMPLEX,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,1/208 %0.48,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
INFECTION,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,4/208 %1.92,1/7 %14.29,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
INFLUENZA,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,2/208 %0.96,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
LOWER RESPIRATORY TRACT INFECTION,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,2/208 %0.96,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
LUNG INFECTION,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,3/208 %1.44,0/7 %0.0,1/7 %14.29,0/6 %0.0,1/6 %16.67,0/6 %0.0
MENINGITIS VIRAL,0/7 %0.0,0/3 %0.0,0/8 %0.0,1/6 %16.67,0/208 %0.0,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
NASOPHARYNGITIS,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,1/208 %0.48,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
OOPHORITIS,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,0/208 %0.0,0/7 %0.0,1/7 %14.29,0/6 %0.0,0/6 %0.0,0/6 %0.0
ORAL CANDIDIASIS,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,1/208 %0.48,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
ORAL HERPES,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,1/208 %0.48,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
PNEUMOCYSTIS JIROVECII INFECTION,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,1/208 %0.48,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
PNEUMOCYSTIS JIROVECII PNEUMONIA,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,2/208 %0.96,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,1/6 %16.67
PNEUMONIA,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,9/208 %4.33,1/7 %14.29,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
PNEUMONIA RESPIRATORY SYNCYTIAL VIRAL,1/7 %14.29,0/3 %0.0,0/8 %0.0,0/6 %0.0,0/208 %0.0,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
PSEUDOMONAL SEPSIS,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,2/208 %0.96,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
RECTAL ABSCESS,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,1/208 %0.48,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
RESPIRATORY TRACT INFECTION,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,1/208 %0.48,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
RHINOVIRUS INFECTION,1/7 %14.29,0/3 %0.0,1/8 %12.5,0/6 %0.0,0/208 %0.0,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
SEPSIS,0/7 %0.0,0/3 %0.0,0/8 %0.0,1/6 %16.67,6/208 %2.88,0/7 %0.0,0/7 %0.0,1/6 %16.67,0/6 %0.0,0/6 %0.0
SIALOADENITIS,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,1/208 %0.48,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
SINUSITIS,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,1/208 %0.48,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
SKIN INFECTION,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,1/208 %0.48,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
STAPHYLOCOCCAL SEPSIS,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,1/208 %0.48,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
UPPER RESPIRATORY TRACT INFECTION,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,1/208 %0.48,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
URINARY TRACT INFECTION,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,2/208 %0.96,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
URINARY TRACT INFECTION PSEUDOMONAL,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,1/208 %0.48,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
VASCULAR DEVICE INFECTION,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,2/208 %0.96,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
CONTUSION,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,1/208 %0.48,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
INFUSION RELATED REACTION,0/7 %0.0,0/3 %0.0,1/8 %12.5,0/6 %0.0,1/208 %0.48,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
LIGAMENT RUPTURE,0/7 %0.0,0/3 %0.0,1/8 %12.5,0/6 %0.0,0/208 %0.0,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
POST LUMBAR PUNCTURE SYNDROME,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,1/208 %0.48,1/7 %14.29,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
SPINAL FRACTURE,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,1/208 %0.48,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
TOXICITY TO VARIOUS AGENTS,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,1/208 %0.48,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
BLOOD POTASSIUM INCREASED,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,0/208 %0.0,1/7 %14.29,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
C-REACTIVE PROTEIN INCREASED,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,1/208 %0.48,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
DECREASED APPETITE,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,1/208 %0.48,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
DEHYDRATION,1/7 %14.29,0/3 %0.0,0/8 %0.0,0/6 %0.0,1/208 %0.48,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
DIABETES MELLITUS INADEQUATE CONTROL,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,2/208 %0.96,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
HYPERKALAEMIA,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,0/208 %0.0,0/7 %0.0,0/7 %0.0,0/6 %0.0,1/6 %16.67,1/6 %16.67
HYPOKALAEMIA,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,1/208 %0.48,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
HYPONATRAEMIA,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,1/208 %0.48,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
TUMOUR LYSIS SYNDROME,0/7 %0.0,0/3 %0.0,1/8 %12.5,0/6 %0.0,0/208 %0.0,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
BACK PAIN,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,1/208 %0.48,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
JOINT SWELLING,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,1/208 %0.48,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
PAIN IN EXTREMITY,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,2/208 %0.96,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
SPONDYLOLISTHESIS,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,1/208 %0.48,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
ACUTE MYELOID LEUKAEMIA,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,3/208 %1.44,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
ADENOLYMPHOMA,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,1/208 %0.48,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
GLIOBLASTOMA,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,1/208 %0.48,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
HISTIOCYTOSIS,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,0/208 %0.0,0/7 %0.0,0/7 %0.0,1/6 %16.67,0/6 %0.0,0/6 %0.0
LUNG NEOPLASM MALIGNANT,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,0/208 %0.0,1/7 %14.29,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
MYELODYSPLASTIC SYNDROME,0/7 %0.0,0/3 %0.0,1/8 %12.5,0/6 %0.0,2/208 %0.96,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
CAROTID SINUS SYNDROME,1/7 %14.29,0/3 %0.0,0/8 %0.0,0/6 %0.0,0/208 %0.0,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
EPILEPSY,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,1/208 %0.48,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
HYPOGLOSSAL NERVE PARESIS,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,1/208 %0.48,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
POLYNEUROPATHY,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,1/208 %0.48,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
PRESYNCOPE,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,1/208 %0.48,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
SYNCOPE,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,2/208 %0.96,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
TRANSIENT ISCHAEMIC ATTACK,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,1/208 %0.48,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
CONFUSIONAL STATE,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,0/208 %0.0,0/7 %0.0,0/7 %0.0,0/6 %0.0,1/6 %16.67,0/6 %0.0
PSYCHOTIC DISORDER,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,0/208 %0.0,1/7 %14.29,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
ACUTE KIDNEY INJURY,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,2/208 %0.96,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
CHRONIC OBSTRUCTIVE PULMONARY DISEASE,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,1/208 %0.48,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
COUGH,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,1/208 %0.48,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
DYSPNOEA,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,2/208 %0.96,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
HAEMOPTYSIS,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,1/208 %0.48,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
INTERSTITIAL LUNG DISEASE,0/7 %0.0,0/3 %0.0,1/8 %12.5,0/6 %0.0,0/208 %0.0,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
ORGANISING PNEUMONIA,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,1/208 %0.48,0/7 %0.0,1/7 %14.29,0/6 %0.0,0/6 %0.0,0/6 %0.0
PLEURAL EFFUSION,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,1/208 %0.48,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
PNEUMOTHORAX,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,1/208 %0.48,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
PRODUCTIVE COUGH,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,1/208 %0.48,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
PULMONARY EMBOLISM,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,1/208 %0.48,0/7 %0.0,1/7 %14.29,0/6 %0.0,0/6 %0.0,0/6 %0.0
RASH MACULO-PAPULAR,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,1/208 %0.48,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0
EMBOLISM,0/7 %0.0,0/3 %0.0,0/8 %0.0,0/6 %0.0,0/208 %0.0,0/7 %0.0,1/7 %14.29,0/6 %0.0,0/6 %0.0,0/6 %0.0
HYPOTENSION,1/7 %14.29,0/3 %0.0,0/8 %0.0,0/6 %0.0,2/208 %0.96,0/7 %0.0,0/7 %0.0,0/6 %0.0,0/6 %0.0,0/6 %0.0

Detection and Prevention of Anthracycline-Related Cardiac Toxicity With Concurrent Simvastatin(https://clinicaltrials.gov/show/NCT02096588)
 ,Simvastatin,No Drug
 ,Simvastatin will be administered on an outpatient basis orally at a dose of 40 mg once daily. Treatment will start 7 days prior to the planned doxorubicin/cyclophosphamide chemotherapy initiation and will continue for a total of 25 weeks.  Simvastatin: Simvastatin will be administered on an outpatient basis orally at a dose of 40 mg once daily.  Doxorubicin/cyclophosphamide: The standard chemotherapy regimen that must be planned for all participants in order to take part in this study. The regimen is given every 2 or 3 weeks per standard of care at the direction of the treating physician.,Participant not randomized to simvastatin will participate in all aspects of the study including planned doxorubicin/cyclophosphamide chemotherapy with the exception of simvastatin administration.  Doxorubicin/cyclophosphamide: The standard chemotherapy regimen that must be planned for all participants in order to take part in this study. The regimen is given every 2 or 3 weeks per standard of care at the direction of the treating physician.
Total all-cause mortality,1/15 %6.67,0/0 %0.0
Total serious adverse events,1/15 %6.67,0/0 %0.0
CPK increased,1/15 %6.67,0/0 %0.0

Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer(https://clinicaltrials.gov/show/NCT02101788)
 ,Arm A - Control Arm,Arm B - Experimental Arm,Crossover From Control to Experimental Arm
 ,Investigators choice of Letrozole 2.5 mg po qd continuously tamoxifen 20mg po bid continuously paclitaxel 80mg/m2 IV over 1 hr on day 1q 7d 3 wks on 1 wk off Pegylated Liposomal Doxorubicin 40 or 50mg/m2 IV over 1 hr on day 1 q. 28d Topotecan 4.0mg/m2 over 30 min on day 18 and 15 of a 28 day cycle. For each arm 1 cycle - 28 days,Trametinib 2 mg po daily continuous treatment For each arm 1 cycle = 28 days,Patients randomized to the control arm who crossed over to the experimental arm after disease progression.
Total all-cause mortality,60/127 %47.24,51/127 %40.16,3/88 %3.41
Total serious adverse events,43/127 %33.86,45/127 %35.43,25/88 %28.41
Anemia,1/127 %0.79,4/127 %3.15,1/88 %1.14
Cardiac Arrest,0/127 %0.0,0/127 %0.0,1/88 %1.14
Eye Disorders - Other,2/127 %1.57,2/127 %1.57,0/88 %0.0
Retinal Vascular Disorder,0/127 %0.0,1/127 %0.79,0/88 %0.0
Colonic Obstruction,4/127 %3.15,0/127 %0.0,5/88 %5.68
Colonic Stenosis,0/127 %0.0,1/127 %0.79,1/88 %1.14
Colonic Perforation,1/127 %0.79,0/127 %0.0,0/88 %0.0
Diarrhea,2/127 %1.57,1/127 %0.79,0/88 %0.0
Vomiting,1/127 %0.79,3/127 %2.36,1/88 %1.14
Small Intestinal Obstruction,2/127 %1.57,11/127 %8.66,3/88 %3.41
Abdominal Pain,10/127 %7.87,2/127 %1.57,2/88 %2.27
Mucositis Oral,1/127 %0.79,1/127 %0.79,0/88 %0.0
Lower Gastrointestinal Hemorrhage,0/127 %0.0,1/127 %0.79,0/88 %0.0
Gastrointestinal Disorders - Other,1/127 %0.79,0/127 %0.0,0/88 %0.0
Nausea,5/127 %3.94,1/127 %0.79,0/88 %0.0
Ascites,1/127 %0.79,0/127 %0.0,0/88 %0.0
Jejunal Obstruction,0/127 %0.0,1/127 %0.79,0/88 %0.0
Obstruction Gastric,0/127 %0.0,0/127 %0.0,2/88 %2.27
Ileus,0/127 %0.0,0/127 %0.0,1/88 %1.14
Pain,1/127 %0.79,0/127 %0.0,1/88 %1.14
Flu Like Symptoms,0/127 %0.0,1/127 %0.79,0/88 %0.0
Non-Cardiac Chest Pain,1/127 %0.79,0/127 %0.0,0/88 %0.0
Edema Limbs,1/127 %0.79,0/127 %0.0,0/88 %0.0
Death Nos,1/127 %0.79,2/127 %1.57,0/88 %0.0
Cholecystitis,1/127 %0.79,0/127 %0.0,0/88 %0.0
Infections And Infestations - Other,1/127 %0.79,1/127 %0.79,0/88 %0.0
Upper Respiratory Infection,0/127 %0.0,1/127 %0.79,0/88 %0.0
Soft Tissue Infection,0/127 %0.0,1/127 %0.79,0/88 %0.0
Sepsis,1/127 %0.79,2/127 %1.57,1/88 %1.14
Lung Infection,1/127 %0.79,2/127 %1.57,0/88 %0.0
Kidney Infection,2/127 %1.57,1/127 %0.79,0/88 %0.0
Device Related Infection,0/127 %0.0,1/127 %0.79,0/88 %0.0
Urinary Tract Infection,4/127 %3.15,6/127 %4.72,2/88 %2.27
Skin Infection,0/127 %0.0,0/127 %0.0,1/88 %1.14
Lung Infection,0/127 %0.0,0/127 %0.0,1/88 %1.14
Intestinal Stoma Obstruction,1/127 %0.79,0/127 %0.0,0/88 %0.0
Ejection Fraction Decreased,1/127 %0.79,2/127 %1.57,0/88 %0.0
Neutrophil Count Decreased,1/127 %0.79,0/127 %0.0,0/88 %0.0
Alkaline Phosphatase Increased,0/127 %0.0,1/127 %0.79,0/88 %0.0
Alanine Aminotransferase Increased,0/127 %0.0,1/127 %0.79,0/88 %0.0
Hyponatremia,2/127 %1.57,0/127 %0.0,1/88 %1.14
Hypokalemia,0/127 %0.0,1/127 %0.79,0/88 %0.0
Dehydration,2/127 %1.57,0/127 %0.0,0/88 %0.0
Anorexia,0/127 %0.0,1/127 %0.79,0/88 %0.0
Hypoalbuminemia,0/127 %0.0,0/127 %0.0,1/88 %1.14
Delirium,0/127 %0.0,0/127 %0.0,1/88 %1.14
Renal And Urinary Disorders - Other,0/127 %0.0,1/127 %0.79,1/88 %1.14
Urinary Tract Obstruction,0/127 %0.0,1/127 %0.79,1/88 %1.14
Hematuria,0/127 %0.0,1/127 %0.79,0/88 %0.0
Acute Kidney Injury,1/127 %0.79,0/127 %0.0,1/88 %1.14
Urinary Retention,0/127 %0.0,0/127 %0.0,1/88 %1.14
Vaginal Hemorrhage,3/127 %2.36,0/127 %0.0,1/88 %1.14
Respiratory Failure,0/127 %0.0,1/127 %0.79,0/88 %0.0
Pneumonitis,0/127 %0.0,1/127 %0.79,1/88 %1.14
Pleural Effusion,1/127 %0.79,2/127 %1.57,2/88 %2.27
Dyspnea,2/127 %1.57,2/127 %1.57,0/88 %0.0
Chylothorax,0/127 %0.0,1/127 %0.79,0/88 %0.0
Bronchopulmonary Hemorrhage,0/127 %0.0,1/127 %0.79,0/88 %0.0
Skin And Subcutaneous Tissue Disorders - Other,0/127 %0.0,1/127 %0.79,0/88 %0.0
Rash Maculo-Papular,0/127 %0.0,1/127 %0.79,0/88 %0.0
Thromboembolic Event,1/127 %0.79,4/127 %3.15,0/88 %0.0
Hypotension,1/127 %0.79,0/127 %0.0,0/88 %0.0
Hypertension,0/127 %0.0,1/127 %0.79,0/88 %0.0

Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma(https://clinicaltrials.gov/show/NCT02142049)
 ,Part 1: Dose Level 1,Part 1: Dose Level 2,Part 1: Dose Level 3,Part 1: Dose Level 4,All Subjects Treated at RP2D
 ,Ibrutinib 560 mg PO + DA-EPOCH-R + lenalidomide 0 (PO)  DA-EPOCH-R: Etoposide Prednisone Doxorubicin Cyclophosphamide Vincristine Rituximab Pegfilgrastim,Ibrutinib 560 mg PO + DA-EPOCH-R + lenalidomide 15 (PO)  DA-EPOCH-R: Etoposide Prednisone Doxorubicin Cyclophosphamide Vincristine Rituximab Pegfilgrastim,Ibrutinib 560 mg PO + DA-EPOCH-R + lenalidomide 20 (PO)  DA-EPOCH-R: Etoposide Prednisone Doxorubicin Cyclophosphamide Vincristine Rituximab Pegfilgrastim,Ibrutinib 560 mg PO + DA-EPOCH-R + lenalidomide 25 mg (PO)  DA-EPOCH-R: Etoposide Prednisone Doxorubicin Cyclophosphamide Vincristine Rituximab Pegfilgrastim,Ibrutinib 560 mg (PO) +lenalidomide 25 mg (PO) + DA-EPOCH-R  DA-EPOCH-R: Etoposide Prednisone Doxorubicin Cyclophosphamide Vincristine Rituximab Pegfilgrastim
Total all-cause mortality,3/3 %100.0,3/3 %100.0,3/3 %100.0,5/6 %83.33,3/26 %11.54
Total serious adverse events,3/3 %100.0,3/3 %100.0,3/3 %100.0,5/6 %83.33,19/26 %73.08
Febrile neutropenia,1/3 %33.33,1/3 %33.33,1/3 %33.33,0/6 %0.0,6/26 %23.08
Anaemia,0/3 %0.0,0/3 %0.0,1/3 %33.33,2/6 %33.33,2/26 %7.69
Thrombocytopenia,1/3 %33.33,0/3 %0.0,1/3 %33.33,0/6 %0.0,1/26 %3.85
Atrial fibrillation,0/3 %0.0,1/3 %33.33,1/3 %33.33,0/6 %0.0,1/26 %3.85
Abdominal pain,0/3 %0.0,0/3 %0.0,0/3 %0.0,1/6 %16.67,1/26 %3.85
Colitis,0/3 %0.0,0/3 %0.0,0/3 %0.0,1/6 %16.67,2/26 %7.69
Gastrointestinal haemorrhage,0/3 %0.0,0/3 %0.0,1/3 %33.33,0/6 %0.0,0/26 %0.0
Neutropenic colitis,0/3 %0.0,0/3 %0.0,0/3 %0.0,1/6 %16.67,1/26 %3.85
Vomiting,1/3 %33.33,0/3 %0.0,0/3 %0.0,0/6 %0.0,1/26 %3.85
Death,1/3 %33.33,0/3 %0.0,0/3 %0.0,0/6 %0.0,0/26 %0.0
Pyrexia,0/3 %0.0,0/3 %0.0,0/3 %0.0,1/6 %16.67,3/26 %11.54
Abdominal wall abscess,0/3 %0.0,0/3 %0.0,0/3 %0.0,1/6 %16.67,1/26 %3.85
Clostridium difficile infection,0/3 %0.0,0/3 %0.0,0/3 %0.0,1/6 %16.67,1/26 %3.85
Enterococcal sepsis,0/3 %0.0,0/3 %0.0,0/3 %0.0,1/6 %16.67,1/26 %3.85
Pneumonia,0/3 %0.0,1/3 %33.33,0/3 %0.0,0/6 %0.0,2/26 %7.69
Pneumococcal sepsis,0/3 %0.0,1/3 %33.33,0/3 %0.0,0/6 %0.0,0/26 %0.0
Septic shock,1/3 %33.33,0/3 %0.0,0/3 %0.0,0/6 %0.0,0/26 %0.0
Fall,0/3 %0.0,0/3 %0.0,0/3 %0.0,1/6 %16.67,1/26 %3.85
Dehydration,1/3 %33.33,0/3 %0.0,0/3 %0.0,1/6 %16.67,1/26 %3.85
Hypokalaemia,0/3 %0.0,0/3 %0.0,0/3 %0.0,1/6 %16.67,1/26 %3.85
Syncope,0/3 %0.0,0/3 %0.0,0/3 %0.0,2/6 %33.33,2/26 %7.69
Acute kidney injury,0/3 %0.0,0/3 %0.0,0/3 %0.0,1/6 %16.67,1/26 %3.85
Hydronephrosis,0/3 %0.0,0/3 %0.0,0/3 %0.0,1/6 %16.67,1/26 %3.85
Urinary tract obstruction,0/3 %0.0,0/3 %0.0,0/3 %0.0,1/6 %16.67,1/26 %3.85
Diffuse alveolar damage,0/3 %0.0,0/3 %0.0,0/3 %0.0,1/6 %16.67,1/26 %3.85
Hypotension,1/3 %33.33,1/3 %33.33,0/3 %0.0,1/6 %16.67,2/26 %7.69
Orthostatic hypotension,0/3 %0.0,1/3 %33.33,0/3 %0.0,0/6 %0.0,0/26 %0.0

TACE Using Doxorubicin-eluting Beads for Patients With HCC and Marginal Hepatic Reserve(https://clinicaltrials.gov/show/NCT02147301)
 ,DEB-TACE
 ,Doxorubicin Eluting Bead Transarterial Chemoembolization (DEB-TACE):  Doxorubicin-loaded LC Beads are administered via a co-axially placed commercially available hepatic artery catheter into hepatic arteries targeted for treatment. Procedure is performed under direct fluoroscopic visualization until stasis of arterial flow is achieved or until a total of 4 ml of microspheres have been administered whichever occurs first  LC Bead: Doxorubicin Eluting Bead Transarterial Chemoembolization (DEB-TACE):  Doxorubicin-loaded LC Beads are administered via a co-axially placed commercially available hepatic artery catheter into hepatic arteries targeted for treatment. Procedure is performed under direct fluoroscopic visualization until stasis of arterial flow is achieved or until a total of 4 ml of microspheres have been administered whichever occurs first.
Total all-cause mortality,12/17 %70.59
Total serious adverse events,13/17 %76.47
Anemia,2/17 %11.76
Thrombocytopenia,3/17 %17.65
Hepatic failure,4/17 %23.53
Ascites,1/17 %5.88
Hyperbilirubinemia,3/17 %17.65
AST elevation,3/17 %17.65
Edema of legs,2/17 %11.76
Hyponatremia,4/17 %23.53

Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery(https://clinicaltrials.gov/show/NCT02180867)
 ,Dose-Finding Level 1 CR,Dose-Finding Level 1 RT,Dose-Finding Level 2 RT,Regimen A,Regimen B,Regimen C,Regimen D
 ,Dose-Finding Level 1 CR:  Adult: Pazopanib 600 mg; Pediatric: Pazopanib 350 mg/m2,Dose-Finding Level 1 RT:  Adult: Pazopanib 600 mg; Pediatric: Pazopanib 350 mg/m2,Dose-Finding Level 2 RT:  Adult: Pazopanib 800 mg; Pediatric: Pazopanib 450 mg/m2,Regimen A: Chemoradiation plus pazopanib,Regimen B: Chemoradiation alone,Regimen C: Radiation therapy plus pazopanib,Regimen D: Radiation therapy alone
Total all-cause mortality,1/9 %11.11,4/9 %44.44,3/10 %30.0,5/46 %10.87,9/43 %20.93,0/6 %0.0,2/6 %33.33
Total serious adverse events,6/9 %66.67,6/9 %66.67,2/10 %20.0,33/46 %71.74,8/43 %18.6,1/6 %16.67,0/6 %0.0
Febrile neutropenia,1/5 %20.0,0/3 %0.0,0/3 %0.0,7/16 %43.75,0/18 %0.0,0/1 %0.0,0/0 %0.0
Anemia,0/4 %0.0,1/6 %16.67,0/7 %0.0,2/30 %6.67,1/25 %4.0,0/5 %0.0,0/6 %0.0
Blood and lymphatic system disorders - Other specify,0/4 %0.0,0/6 %0.0,0/7 %0.0,1/30 %3.33,0/25 %0.0,0/5 %0.0,0/6 %0.0
Febrile neutropenia,1/4 %25.0,0/6 %0.0,0/7 %0.0,11/30 %36.67,1/25 %4.0,0/5 %0.0,0/6 %0.0
Atrial fibrillation,0/4 %0.0,0/6 %0.0,0/7 %0.0,1/30 %3.33,0/25 %0.0,0/5 %0.0,0/6 %0.0
Atrial flutter,0/4 %0.0,0/6 %0.0,0/7 %0.0,1/30 %3.33,0/25 %0.0,0/5 %0.0,0/6 %0.0
Sinus tachycardia,0/4 %0.0,0/6 %0.0,0/7 %0.0,1/30 %3.33,0/25 %0.0,0/5 %0.0,0/6 %0.0
Blurred vision,0/4 %0.0,0/6 %0.0,0/7 %0.0,1/30 %3.33,0/25 %0.0,0/5 %0.0,0/6 %0.0
Photophobia,0/4 %0.0,0/6 %0.0,1/7 %14.29,0/30 %0.0,0/25 %0.0,0/5 %0.0,0/6 %0.0
Diarrhea,0/5 %0.0,0/3 %0.0,1/3 %33.33,0/16 %0.0,0/18 %0.0,0/1 %0.0,0/0 %0.0
Ileus,0/5 %0.0,0/3 %0.0,0/3 %0.0,1/16 %6.25,0/18 %0.0,0/1 %0.0,0/0 %0.0
Mucositis oral,0/5 %0.0,0/3 %0.0,0/3 %0.0,3/16 %18.75,0/18 %0.0,0/1 %0.0,0/0 %0.0
Vomiting,0/5 %0.0,0/3 %0.0,0/3 %0.0,2/16 %12.5,0/18 %0.0,0/1 %0.0,0/0 %0.0
Diarrhea,0/4 %0.0,0/6 %0.0,1/7 %14.29,1/30 %3.33,0/25 %0.0,0/5 %0.0,0/6 %0.0
Esophagitis,0/4 %0.0,0/6 %0.0,0/7 %0.0,1/30 %3.33,0/25 %0.0,0/5 %0.0,0/6 %0.0
Mucositis oral,0/4 %0.0,0/6 %0.0,0/7 %0.0,1/30 %3.33,0/25 %0.0,0/5 %0.0,0/6 %0.0
Nausea,1/4 %25.0,0/6 %0.0,0/7 %0.0,1/30 %3.33,0/25 %0.0,1/5 %20.0,0/6 %0.0
Vomiting,1/4 %25.0,0/6 %0.0,1/7 %14.29,2/30 %6.67,0/25 %0.0,0/5 %0.0,0/6 %0.0
Fever,0/5 %0.0,0/3 %0.0,0/3 %0.0,1/16 %6.25,0/18 %0.0,0/1 %0.0,0/0 %0.0
Pain,0/5 %0.0,0/3 %0.0,0/3 %0.0,1/16 %6.25,0/18 %0.0,0/1 %0.0,0/0 %0.0
Chills,0/4 %0.0,0/6 %0.0,0/7 %0.0,1/30 %3.33,0/25 %0.0,1/5 %20.0,0/6 %0.0
Death NOS,0/4 %0.0,0/6 %0.0,0/7 %0.0,0/30 %0.0,1/25 %4.0,0/5 %0.0,0/6 %0.0
Fatigue,0/4 %0.0,0/6 %0.0,0/7 %0.0,2/30 %6.67,0/25 %0.0,1/5 %20.0,0/6 %0.0
Fever,0/4 %0.0,0/6 %0.0,0/7 %0.0,2/30 %6.67,2/25 %8.0,1/5 %20.0,0/6 %0.0
Gait disturbance,0/4 %0.0,1/6 %16.67,0/7 %0.0,0/30 %0.0,0/25 %0.0,0/5 %0.0,0/6 %0.0
General disorders and administration site conditions - Other specify,0/4 %0.0,0/6 %0.0,0/7 %0.0,1/30 %3.33,0/25 %0.0,0/5 %0.0,0/6 %0.0
Multi-organ failure,0/4 %0.0,0/6 %0.0,0/7 %0.0,0/30 %0.0,1/25 %4.0,0/5 %0.0,0/6 %0.0
Non-cardiac chest pain,0/4 %0.0,0/6 %0.0,0/7 %0.0,1/30 %3.33,0/25 %0.0,0/5 %0.0,0/6 %0.0
Perforation bile duct,0/5 %0.0,0/3 %0.0,0/3 %0.0,1/16 %6.25,0/18 %0.0,0/1 %0.0,0/0 %0.0
Sepsis,0/5 %0.0,0/3 %0.0,0/3 %0.0,0/16 %0.0,1/18 %5.56,0/1 %0.0,0/0 %0.0
Skin infection,0/5 %0.0,0/3 %0.0,0/3 %0.0,1/16 %6.25,0/18 %0.0,0/1 %0.0,0/0 %0.0
Wound infection,0/5 %0.0,1/3 %33.33,0/3 %0.0,1/16 %6.25,0/18 %0.0,0/1 %0.0,0/0 %0.0
Sepsis,0/4 %0.0,0/6 %0.0,0/7 %0.0,4/30 %13.33,1/25 %4.0,0/5 %0.0,0/6 %0.0
Skin infection,0/4 %0.0,0/6 %0.0,0/7 %0.0,2/30 %6.67,1/25 %4.0,0/5 %0.0,0/6 %0.0
Upper respiratory infection,0/4 %0.0,0/6 %0.0,0/7 %0.0,0/30 %0.0,1/25 %4.0,0/5 %0.0,0/6 %0.0
Urinary tract infection,0/4 %0.0,0/6 %0.0,0/7 %0.0,1/30 %3.33,0/25 %0.0,0/5 %0.0,0/6 %0.0
Wound infection,1/4 %25.0,3/6 %50.0,1/7 %14.29,1/30 %3.33,1/25 %4.0,0/5 %0.0,0/6 %0.0
Lung infection,0/4 %0.0,0/6 %0.0,0/7 %0.0,0/30 %0.0,1/25 %4.0,0/5 %0.0,0/6 %0.0
Soft tissue infection,0/4 %0.0,1/6 %16.67,0/7 %0.0,0/30 %0.0,0/25 %0.0,0/5 %0.0,0/6 %0.0
Device related infection,0/4 %0.0,0/6 %0.0,0/7 %0.0,1/30 %3.33,1/25 %4.0,0/5 %0.0,0/6 %0.0
Wound dehiscence,0/5 %0.0,1/3 %33.33,0/3 %0.0,1/16 %6.25,1/18 %5.56,0/1 %0.0,0/0 %0.0
Wound complication,0/5 %0.0,0/3 %0.0,0/3 %0.0,1/16 %6.25,0/18 %0.0,0/1 %0.0,0/0 %0.0
Wound dehiscence,2/4 %50.0,0/6 %0.0,0/7 %0.0,4/30 %13.33,0/25 %0.0,0/5 %0.0,0/6 %0.0
Wound complication,0/4 %0.0,0/6 %0.0,0/7 %0.0,2/30 %6.67,1/25 %4.0,0/5 %0.0,0/6 %0.0
Postoperative hemorrhage,0/4 %0.0,0/6 %0.0,0/7 %0.0,1/30 %3.33,0/25 %0.0,0/5 %0.0,0/6 %0.0
Dermatitis radiation,0/4 %0.0,0/6 %0.0,1/7 %14.29,1/30 %3.33,0/25 %0.0,0/5 %0.0,0/6 %0.0
Creatinine increased,0/5 %0.0,1/3 %33.33,0/3 %0.0,0/16 %0.0,0/18 %0.0,0/1 %0.0,0/0 %0.0
Alanine aminotransferase increased,0/4 %0.0,0/6 %0.0,0/7 %0.0,1/30 %3.33,0/25 %0.0,0/5 %0.0,0/6 %0.0
Blood bilirubin increased,0/4 %0.0,0/6 %0.0,0/7 %0.0,1/30 %3.33,0/25 %0.0,0/5 %0.0,0/6 %0.0
Electrocardiogram QT corrected interval prolonged,0/4 %0.0,0/6 %0.0,0/7 %0.0,1/30 %3.33,0/25 %0.0,0/5 %0.0,0/6 %0.0
Lymphocyte count decreased,0/4 %0.0,0/6 %0.0,0/7 %0.0,2/30 %6.67,1/25 %4.0,0/5 %0.0,0/6 %0.0
Neutrophil count decreased,0/4 %0.0,0/6 %0.0,0/7 %0.0,5/30 %16.67,0/25 %0.0,0/5 %0.0,0/6 %0.0
Platelet count decreased,0/4 %0.0,0/6 %0.0,0/7 %0.0,5/30 %16.67,0/25 %0.0,0/5 %0.0,0/6 %0.0
White blood cell decreased,0/4 %0.0,0/6 %0.0,0/7 %0.0,8/30 %26.67,0/25 %0.0,0/5 %0.0,0/6 %0.0
Ejection fraction decreased,0/4 %0.0,0/6 %0.0,0/7 %0.0,1/30 %3.33,0/25 %0.0,0/5 %0.0,0/6 %0.0
Anorexia,0/5 %0.0,0/3 %0.0,0/3 %0.0,2/16 %12.5,0/18 %0.0,0/1 %0.0,0/0 %0.0
Dehydration,0/5 %0.0,0/3 %0.0,0/3 %0.0,2/16 %12.5,0/18 %0.0,0/1 %0.0,0/0 %0.0
Hyperkalemia,0/5 %0.0,0/3 %0.0,1/3 %33.33,0/16 %0.0,0/18 %0.0,0/1 %0.0,0/0 %0.0
Dehydration,1/4 %25.0,0/6 %0.0,1/7 %14.29,0/30 %0.0,0/25 %0.0,0/5 %0.0,0/6 %0.0
Hyperglycemia,0/4 %0.0,1/6 %16.67,0/7 %0.0,0/30 %0.0,1/25 %4.0,0/5 %0.0,0/6 %0.0
Hypokalemia,0/4 %0.0,1/6 %16.67,0/7 %0.0,2/30 %6.67,0/25 %0.0,0/5 %0.0,0/6 %0.0
Hyponatremia,0/4 %0.0,0/6 %0.0,0/7 %0.0,3/30 %10.0,1/25 %4.0,1/5 %20.0,0/6 %0.0
Hypophosphatemia,0/4 %0.0,0/6 %0.0,0/7 %0.0,3/30 %10.0,0/25 %0.0,1/5 %20.0,0/6 %0.0
Pain in extremity,0/5 %0.0,0/3 %0.0,0/3 %0.0,1/16 %6.25,0/18 %0.0,0/1 %0.0,0/0 %0.0
Pain in extremity,0/4 %0.0,1/6 %16.67,0/7 %0.0,1/30 %3.33,0/25 %0.0,0/5 %0.0,0/6 %0.0
Cognitive disturbance,0/4 %0.0,0/6 %0.0,0/7 %0.0,1/30 %3.33,0/25 %0.0,0/5 %0.0,0/6 %0.0
Dizziness,0/4 %0.0,0/6 %0.0,0/7 %0.0,1/30 %3.33,0/25 %0.0,0/5 %0.0,0/6 %0.0
Encephalopathy,0/4 %0.0,0/6 %0.0,0/7 %0.0,1/30 %3.33,0/25 %0.0,0/5 %0.0,0/6 %0.0
Headache,0/4 %0.0,0/6 %0.0,1/7 %14.29,0/30 %0.0,0/25 %0.0,0/5 %0.0,0/6 %0.0
Stroke,0/4 %0.0,0/6 %0.0,0/7 %0.0,1/30 %3.33,0/25 %0.0,0/5 %0.0,0/6 %0.0
Syncope,1/4 %25.0,0/6 %0.0,0/7 %0.0,0/30 %0.0,0/25 %0.0,0/5 %0.0,0/6 %0.0
Hallucinations,0/5 %0.0,0/3 %0.0,0/3 %0.0,1/16 %6.25,0/18 %0.0,0/1 %0.0,0/0 %0.0
Delirium,0/4 %0.0,0/6 %0.0,0/7 %0.0,3/30 %10.0,0/25 %0.0,0/5 %0.0,0/6 %0.0
Depression,0/4 %0.0,0/6 %0.0,1/7 %14.29,1/30 %3.33,0/25 %0.0,0/5 %0.0,0/6 %0.0
Acute kidney injury,0/5 %0.0,1/3 %33.33,0/3 %0.0,0/16 %0.0,0/18 %0.0,0/1 %0.0,0/0 %0.0
Renal and urinary disorders - Other specify,0/4 %0.0,0/6 %0.0,0/7 %0.0,0/30 %0.0,1/25 %4.0,0/5 %0.0,0/6 %0.0
Uterine hemorrhage,0/4 %0.0,0/6 %0.0,0/7 %0.0,1/30 %3.33,0/25 %0.0,0/5 %0.0,0/6 %0.0
Hypoxia,0/5 %0.0,0/3 %0.0,0/3 %0.0,1/16 %6.25,0/18 %0.0,0/1 %0.0,0/0 %0.0
Dyspnea,0/4 %0.0,0/6 %0.0,0/7 %0.0,1/30 %3.33,1/25 %4.0,0/5 %0.0,0/6 %0.0
Hypoxia,0/4 %0.0,0/6 %0.0,0/7 %0.0,1/30 %3.33,0/25 %0.0,0/5 %0.0,0/6 %0.0
Laryngospasm,0/4 %0.0,0/6 %0.0,0/7 %0.0,1/30 %3.33,0/25 %0.0,0/5 %0.0,0/6 %0.0
Pleural effusion,0/4 %0.0,0/6 %0.0,0/7 %0.0,0/30 %0.0,1/25 %4.0,0/5 %0.0,0/6 %0.0
Pneumothorax,0/4 %0.0,0/6 %0.0,0/7 %0.0,1/30 %3.33,0/25 %0.0,0/5 %0.0,0/6 %0.0
Pulmonary edema,0/4 %0.0,0/6 %0.0,0/7 %0.0,2/30 %6.67,0/25 %0.0,0/5 %0.0,0/6 %0.0
Skin hypopigmentation,0/4 %0.0,0/6 %0.0,1/7 %14.29,0/30 %0.0,0/25 %0.0,0/5 %0.0,0/6 %0.0
Thromboembolic event,1/5 %20.0,0/3 %0.0,0/3 %0.0,1/16 %6.25,0/18 %0.0,0/1 %0.0,0/0 %0.0
Thromboembolic event,1/4 %25.0,1/6 %16.67,0/7 %0.0,4/30 %13.33,0/25 %0.0,0/5 %0.0,0/6 %0.0

Targeted Chemotherapy Using Focused Ultrasound for Liver Tumours(https://clinicaltrials.gov/show/NCT02181075)
 ,Part I (Patients Enrolled Between March 2015-April 2017),Part II (Patients Enrolled Between June 2016-Feb 2017)
 ,Arm 1 - see above,Arm 2 - see above
Total all-cause mortality,0/6 %0.0,0/4 %0.0
Total serious adverse events,3/6 %50.0,3/4 %75.0
Neutropenia,3/6 %50.0,2/4 %50.0
Confusion,0/6 %0.0,1/4 %25.0

Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational)(https://clinicaltrials.gov/show/NCT02181738)
 ,COHORT A,COHORT B,COHORT C,Cohort D
 ,Nivolumab 3mg/kg Q2wk Brentuximab vedotin Naive,Nivolumab 3mg/kg Q2wk Post Transplant Brentuximab vedotin,Nivolumab 3mg/kg Q2wk Post Transplant with Brentuximab vedotin prior and or after ASCT,Nivolumab 240 mg IV Q2wk 8 doses monotherapy followed by twelve doses in combination with AVD
Total all-cause mortality,6/63 %9.52,10/80 %12.5,13/100 %13.0,1/51 %1.96
Total serious adverse events,9/63 %14.29,25/80 %31.25,32/100 %32.0,12/51 %23.53
Febrile neutropenia,0/63 %0.0,1/80 %1.25,0/100 %0.0,2/51 %3.92
Acute myocardial infarction,0/63 %0.0,1/80 %1.25,0/100 %0.0,0/51 %0.0
Arrhythmia,0/63 %0.0,2/80 %2.5,0/100 %0.0,0/51 %0.0
Cardiac arrest,0/63 %0.0,0/80 %0.0,1/100 %1.0,0/51 %0.0
Cardiac failure,0/63 %0.0,1/80 %1.25,0/100 %0.0,0/51 %0.0
Cardiac failure congestive,0/63 %0.0,0/80 %0.0,0/100 %0.0,1/51 %1.96
Pericardial effusion,0/63 %0.0,1/80 %1.25,1/100 %1.0,0/51 %0.0
Tracheo-oesophageal fistula,0/63 %0.0,0/80 %0.0,1/100 %1.0,0/51 %0.0
Hyperthyroidism,0/63 %0.0,0/80 %0.0,0/100 %0.0,1/51 %1.96
Abdominal pain,0/63 %0.0,0/80 %0.0,1/100 %1.0,0/51 %0.0
Colitis,0/63 %0.0,0/80 %0.0,2/100 %2.0,1/51 %1.96
Diarrhoea,1/63 %1.59,0/80 %0.0,1/100 %1.0,0/51 %0.0
Gastritis,1/63 %1.59,0/80 %0.0,0/100 %0.0,0/51 %0.0
Nausea,0/63 %0.0,0/80 %0.0,1/100 %1.0,0/51 %0.0
Pancreatitis,0/63 %0.0,0/80 %0.0,1/100 %1.0,0/51 %0.0
Vomiting,0/63 %0.0,0/80 %0.0,1/100 %1.0,0/51 %0.0
Generalised oedema,0/63 %0.0,1/80 %1.25,0/100 %0.0,0/51 %0.0
Multiple organ dysfunction syndrome,0/63 %0.0,1/80 %1.25,0/100 %0.0,0/51 %0.0
Pyrexia,0/63 %0.0,3/80 %3.75,1/100 %1.0,3/51 %5.88
Systemic inflammatory response syndrome,1/63 %1.59,0/80 %0.0,0/100 %0.0,0/51 %0.0
Autoimmune hepatitis,0/63 %0.0,0/80 %0.0,1/100 %1.0,0/51 %0.0
Cholelithiasis,1/63 %1.59,0/80 %0.0,0/100 %0.0,0/51 %0.0
Hyperbilirubinaemia,0/63 %0.0,0/80 %0.0,1/100 %1.0,0/51 %0.0
Arthritis infective,1/63 %1.59,0/80 %0.0,0/100 %0.0,0/51 %0.0
Atypical pneumonia,1/63 %1.59,0/80 %0.0,0/100 %0.0,0/51 %0.0
Bacteraemia,0/63 %0.0,0/80 %0.0,1/100 %1.0,0/51 %0.0
Cystitis,0/63 %0.0,1/80 %1.25,0/100 %0.0,0/51 %0.0
Device related sepsis,1/63 %1.59,0/80 %0.0,0/100 %0.0,0/51 %0.0
Erysipelas,0/63 %0.0,0/80 %0.0,2/100 %2.0,0/51 %0.0
Gastroenteritis,1/63 %1.59,0/80 %0.0,0/100 %0.0,1/51 %1.96
Infection,0/63 %0.0,1/80 %1.25,0/100 %0.0,0/51 %0.0
Influenza,0/63 %0.0,1/80 %1.25,1/100 %1.0,2/51 %3.92
Lung infection,0/63 %0.0,1/80 %1.25,0/100 %0.0,1/51 %1.96
Lyme disease,0/63 %0.0,0/80 %0.0,1/100 %1.0,0/51 %0.0
Meningitis,0/63 %0.0,2/80 %2.5,0/100 %0.0,0/51 %0.0
Parainfluenzae virus infection,0/63 %0.0,0/80 %0.0,1/100 %1.0,0/51 %0.0
Pharyngitis,0/63 %0.0,0/80 %0.0,0/100 %0.0,1/51 %1.96
Pneumocystis jirovecii pneumonia,1/63 %1.59,0/80 %0.0,0/100 %0.0,0/51 %0.0
Pneumonia,0/63 %0.0,3/80 %3.75,3/100 %3.0,0/51 %0.0
Pyelonephritis,0/63 %0.0,0/80 %0.0,1/100 %1.0,0/51 %0.0
Respiratory tract infection,0/63 %0.0,0/80 %0.0,1/100 %1.0,1/51 %1.96
Sepsis,0/63 %0.0,0/80 %0.0,1/100 %1.0,0/51 %0.0
Upper respiratory tract infection,0/63 %0.0,1/80 %1.25,0/100 %0.0,0/51 %0.0
Viral upper respiratory tract infection,1/63 %1.59,0/80 %0.0,0/100 %0.0,0/51 %0.0
Infusion related reaction,1/63 %1.59,2/80 %2.5,2/100 %2.0,0/51 %0.0
Spinal compression fracture,0/63 %0.0,1/80 %1.25,0/100 %0.0,0/51 %0.0
Alanine aminotransferase increased,0/63 %0.0,0/80 %0.0,1/100 %1.0,1/51 %1.96
Aspartate aminotransferase increased,0/63 %0.0,1/80 %1.25,0/100 %0.0,1/51 %1.96
Bronchoscopy,0/63 %0.0,1/80 %1.25,0/100 %0.0,0/51 %0.0
Platelet count decreased,0/63 %0.0,1/80 %1.25,0/100 %0.0,0/51 %0.0
Viral test,0/63 %0.0,1/80 %1.25,0/100 %0.0,0/51 %0.0
Dehydration,0/63 %0.0,0/80 %0.0,1/100 %1.0,1/51 %1.96
Diabetic ketoacidosis,0/63 %0.0,0/80 %0.0,1/100 %1.0,0/51 %0.0
Glucose tolerance impaired,0/63 %0.0,0/80 %0.0,1/100 %1.0,0/51 %0.0
Hypercalcaemia,0/63 %0.0,1/80 %1.25,1/100 %1.0,0/51 %0.0
Hypokalaemia,0/63 %0.0,1/80 %1.25,0/100 %0.0,0/51 %0.0
Hyponatraemia,0/63 %0.0,0/80 %0.0,1/100 %1.0,0/51 %0.0
Osteonecrosis,0/63 %0.0,1/80 %1.25,0/100 %0.0,0/51 %0.0
Pain in extremity,0/63 %0.0,1/80 %1.25,1/100 %1.0,0/51 %0.0
Polyarthritis,0/63 %0.0,1/80 %1.25,0/100 %0.0,0/51 %0.0
Soft tissue disorder,1/63 %1.59,0/80 %0.0,0/100 %0.0,0/51 %0.0
Gastrointestinal stromal tumour,0/63 %0.0,1/80 %1.25,0/100 %0.0,0/51 %0.0
Malignant neoplasm progression,0/63 %0.0,2/80 %2.5,3/100 %3.0,0/51 %0.0
Peripheral t-cell lymphoma unspecified,0/63 %0.0,1/80 %1.25,0/100 %0.0,0/51 %0.0
Carotid artery stenosis,0/63 %0.0,1/80 %1.25,0/100 %0.0,0/51 %0.0
Polyneuropathy,0/63 %0.0,0/80 %0.0,0/100 %0.0,1/51 %1.96
Seizure,0/63 %0.0,0/80 %0.0,2/100 %2.0,0/51 %0.0
Syncope,0/63 %0.0,1/80 %1.25,0/100 %0.0,0/51 %0.0
Suicide attempt,0/63 %0.0,0/80 %0.0,1/100 %1.0,0/51 %0.0
Acute kidney injury,0/63 %0.0,1/80 %1.25,0/100 %0.0,0/51 %0.0
Dyspnoea,0/63 %0.0,1/80 %1.25,1/100 %1.0,0/51 %0.0
Pleural effusion,1/63 %1.59,0/80 %0.0,3/100 %3.0,0/51 %0.0
Pneumonitis,1/63 %1.59,0/80 %0.0,2/100 %2.0,0/51 %0.0
Pneumothorax,0/63 %0.0,0/80 %0.0,1/100 %1.0,0/51 %0.0
Pulmonary embolism,0/63 %0.0,0/80 %0.0,1/100 %1.0,0/51 %0.0
Rash,0/63 %0.0,1/80 %1.25,1/100 %1.0,0/51 %0.0
Rash maculo-papular,0/63 %0.0,1/80 %1.25,1/100 %1.0,0/51 %0.0
Abortion induced,0/63 %0.0,0/80 %0.0,1/100 %1.0,0/51 %0.0
Embolism,0/63 %0.0,1/80 %1.25,0/100 %0.0,0/51 %0.0
Peripheral ischaemia,0/63 %0.0,1/80 %1.25,0/100 %0.0,0/51 %0.0

A Japanese Trial of TH-302 in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma(https://clinicaltrials.gov/show/NCT02255110)
 ,TH-302 and Doxorubicin
 ,Subjects received TH-302 at a dose of 300 milligram per square meter (mg/m^2) by intravenous infusion over 30 minutes on Day 1 and 8 of every 21-day cycle and Doxorubicin at a dose of 75 mg/m^2 by intravenous injection (over at least 5 minutes) or by intravenous infusion over 6-96 hours on Day 1 of every 21-day cycle starting 2 to 4 hours after completion of TH-302 administration until the evidence of significant treatment-related toxicity or progressive disease.
Total serious adverse events,4/6 %66.67
Febrile neutropenia,1/6 %16.67
Abdominal pain,1/6 %16.67
Nausea,1/6 %16.67
Pneumonia,1/6 %16.67
Tumour haemorrhage,1/6 %16.67

Efficacy and Safety Study of GPX-150 to Treat Soft Tissue Sarcoma(https://clinicaltrials.gov/show/NCT02267083)
 ,GPX-150
 ,GPX-150 for Injection 265 mg/m2 every 21 days for 16 cycles or until death disease progression or unacceptable toxicity or subject withdrawal.  GPX-150 for Injection: GPX-150 at a starting dose of 265 mg/m2 every 21 days for 16 cycles or until death disease progression or unacceptable toxicity. The dose of GPX-150 may be reduced by 25% if any dose reduction criteria are met. Two reductions are allowed per subject during the course of the study.
Total all-cause mortality,2/22 %9.09
Total serious adverse events,22/22 %100.0
Febrile neutropenia,1/22 %4.55
Anaemia,1/22 %4.55
Myocardial infarction,1/22 %4.55
Abdominal pain,1/22 %4.55
Diarrhoea,1/22 %4.55
Ileus,1/22 %4.55
Nausea,1/22 %4.55
Small intestine obstruction,1/22 %4.55
Vomiting,2/22 %9.09
Cholecystitis chronic,1/22 %4.55
Influenza,1/22 %4.55
Soft tissue infection,1/22 %4.55
Fracture,1/22 %4.55
Lymphocyte count decreased,1/22 %4.55
White blood cell count decreased,1/22 %4.55
Dehydration,1/22 %4.55
Liposarcoma metastatic,1/22 %4.55
Sarcoma metastatic,1/22 %4.55
Central nervous system lesion,1/22 %4.55
Dizziness,1/22 %4.55
Spinal cord compression,1/22 %4.55
Respiratory failure,1/22 %4.55

Study of RTXM83 Plus CHOP Chemotherapy Versus a Rituximab Plus CHOP Therapy in Patients With Non Hodgkin's Lymphoma(https://clinicaltrials.gov/show/NCT02268045)
 ,RTXM83-CHOP,MabThera-CHOP
 ,Patients treated with Rituximab biosimilar in combination with CHOP chemotherapy,Patients treated with Rituximab in combination with CHOP chemotherapy
Total all-cause mortality,8/136 %5.88,12/136 %8.82
Total serious adverse events,47/136 %34.56,45/136 %33.09
Neutropenia,10/136 %7.35,8/136 %5.88
Leukopenia,6/136 %4.41,5/136 %3.68
Febrile neutropenia,19/136 %13.97,7/136 %5.15
Diarrhoea,4/136 %2.94,3/136 %2.21
Pyrexia,5/136 %3.68,5/136 %3.68
Pneumonia,6/136 %4.41,5/136 %3.68
Septic shock,3/136 %2.21,3/136 %2.21
Lung infection,2/136 %1.47,1/136 %0.74
Dehydration,3/136 %2.21,3/136 %2.21
Hyponatremia,3/136 %2.21,3/136 %2.21
Pharyngeal inflammation,2/136 %1.47,2/136 %1.47

Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian  Fallopian Tube  or Primary Peritoneal Cancer(https://clinicaltrials.gov/show/NCT02272790)
 ,Arm A,Arm B,Arm C,Arm C2,Arm D-175 mg,Arm D-225 mg
 ,Adavosertib 175 mg orally QD on Days 1 2 8 9 15 and 16 of 28 day cycles. Gemcitabine 800 mg/m IV on Days 1 8 and 15 of 28 day cycles.,Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3 8-10 and 15-17 of 28 day cycles. Paclitaxel 80 mg/m IV on Days 1 8 and 15 of 28 day cycles.,Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3 of 21 day cycles.  Carboplatin AUC 5 IV on Day 1 of 21 day cycles.,Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3 8-10 and 15-17 of 21 day cycles. Carboplatin AUC 5 IV on Day 1 of 21 day cycles.,Adavosertib 175 mg orally BID (5 doses over 3 days) on Days 1-3 of 28 day cycles.  Pegylated liposomal doxorubicin 40 mg/m IV on Day 1 of 28 day cycles.,Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3 of 28 day cycles.  Pegylated liposomal doxorubicin 40 mg/m IV on Day 1 of 28 day cycles.
Total all-cause mortality,5/9 %55.56,12/38 %31.58,9/23 %39.13,2/12 %16.67,3/6 %50.0,0/6 %0.0
Total serious adverse events,4/9 %44.44,17/38 %44.74,12/23 %52.17,8/12 %66.67,2/6 %33.33,1/6 %16.67
Anaemia,0/9 %0.0,0/38 %0.0,4/23 %17.39,0/12 %0.0,0/6 %0.0,0/6 %0.0
Febrile Neutropenia,0/9 %0.0,3/38 %7.89,2/23 %8.7,1/12 %8.33,0/6 %0.0,0/6 %0.0
Leukopenia,0/9 %0.0,0/38 %0.0,1/23 %4.35,0/12 %0.0,0/6 %0.0,0/6 %0.0
Neutropenia,0/9 %0.0,1/38 %2.63,0/23 %0.0,2/12 %16.67,0/6 %0.0,1/6 %16.67
Pancytopenia,0/9 %0.0,1/38 %2.63,0/23 %0.0,0/12 %0.0,0/6 %0.0,0/6 %0.0
Thrombocytopenia,0/9 %0.0,0/38 %0.0,3/23 %13.04,5/12 %41.67,0/6 %0.0,0/6 %0.0
Atrial Fibrillation,0/9 %0.0,1/38 %2.63,0/23 %0.0,0/12 %0.0,0/6 %0.0,0/6 %0.0
Abdominal Pain,0/9 %0.0,0/38 %0.0,1/23 %4.35,0/12 %0.0,0/6 %0.0,0/6 %0.0
Colitis,0/9 %0.0,1/38 %2.63,0/23 %0.0,0/12 %0.0,0/6 %0.0,0/6 %0.0
Diarrhoea,0/9 %0.0,0/38 %0.0,2/23 %8.7,0/12 %0.0,0/6 %0.0,0/6 %0.0
Ileus,0/9 %0.0,1/38 %2.63,0/23 %0.0,0/12 %0.0,0/6 %0.0,0/6 %0.0
Intestinal Obstruction,0/9 %0.0,1/38 %2.63,0/23 %0.0,1/12 %8.33,0/6 %0.0,0/6 %0.0
Nausea,1/9 %11.11,1/38 %2.63,2/23 %8.7,0/12 %0.0,1/6 %16.67,0/6 %0.0
Small Intestinal Obstruction,2/9 %22.22,3/38 %7.89,1/23 %4.35,0/12 %0.0,0/6 %0.0,0/6 %0.0
Vomiting,1/9 %11.11,1/38 %2.63,2/23 %8.7,1/12 %8.33,1/6 %16.67,0/6 %0.0
Fatigue,1/9 %11.11,0/38 %0.0,0/23 %0.0,0/12 %0.0,0/6 %0.0,0/6 %0.0
Pyrexia,1/9 %11.11,1/38 %2.63,0/23 %0.0,0/12 %0.0,1/6 %16.67,0/6 %0.0
Anaphylactic Reaction,0/9 %0.0,0/38 %0.0,0/23 %0.0,1/12 %8.33,0/6 %0.0,0/6 %0.0
Chest Pain,0/9 %0.0,0/38 %0.0,1/23 %4.35,1/12 %8.33,0/6 %0.0,0/6 %0.0
Bacteraemia,0/9 %0.0,3/38 %7.89,0/23 %0.0,1/12 %8.33,0/6 %0.0,0/6 %0.0
Cellulitis,1/9 %11.11,1/38 %2.63,0/23 %0.0,0/12 %0.0,0/6 %0.0,0/6 %0.0
Kidney Infection,0/9 %0.0,0/38 %0.0,0/23 %0.0,0/12 %0.0,1/6 %16.67,0/6 %0.0
Liver Abscess,0/9 %0.0,1/38 %2.63,0/23 %0.0,0/12 %0.0,0/6 %0.0,0/6 %0.0
Neutropenic Sepsis,0/9 %0.0,1/38 %2.63,0/23 %0.0,0/12 %0.0,0/6 %0.0,0/6 %0.0
Paraspinal Abscess,0/9 %0.0,1/38 %2.63,0/23 %0.0,0/12 %0.0,0/6 %0.0,0/6 %0.0
Sepsis,1/9 %11.11,0/38 %0.0,0/23 %0.0,1/12 %8.33,0/6 %0.0,0/6 %0.0
Septic Shock,0/9 %0.0,1/38 %2.63,0/23 %0.0,0/12 %0.0,0/6 %0.0,0/6 %0.0
Urinary Tract Infection,0/9 %0.0,1/38 %2.63,0/23 %0.0,0/12 %0.0,0/6 %0.0,0/6 %0.0
Vascular Device Infection,0/9 %0.0,1/38 %2.63,0/23 %0.0,0/12 %0.0,0/6 %0.0,0/6 %0.0
Gastrointestinal Stoma Complication,0/9 %0.0,0/38 %0.0,1/23 %4.35,0/12 %0.0,0/6 %0.0,0/6 %0.0
Infusion Related Reaction,0/9 %0.0,0/38 %0.0,2/23 %8.7,0/12 %0.0,0/6 %0.0,0/6 %0.0
Neutrophil Count Decreased,0/9 %0.0,0/38 %0.0,1/23 %4.35,0/12 %0.0,0/6 %0.0,0/6 %0.0
Platelet Count Decreased,0/9 %0.0,0/38 %0.0,2/23 %8.7,0/12 %0.0,0/6 %0.0,0/6 %0.0
Type 2 Diabetes Mellitus,0/9 %0.0,0/38 %0.0,0/23 %0.0,1/12 %8.33,0/6 %0.0,0/6 %0.0
Flank Pain,1/9 %11.11,0/38 %0.0,0/23 %0.0,0/12 %0.0,0/6 %0.0,0/6 %0.0
Transient Ischaemic Attack,0/9 %0.0,1/38 %2.63,0/23 %0.0,0/12 %0.0,0/6 %0.0,0/6 %0.0
Dyspnoea,0/9 %0.0,0/38 %0.0,0/23 %0.0,1/12 %8.33,0/6 %0.0,0/6 %0.0
Pulmonary Embolism,0/9 %0.0,1/38 %2.63,1/23 %4.35,2/12 %16.67,0/6 %0.0,0/6 %0.0
Wheezing,0/9 %0.0,0/38 %0.0,0/23 %0.0,0/12 %0.0,1/6 %16.67,0/6 %0.0
Skin Ulcer,0/9 %0.0,0/38 %0.0,0/23 %0.0,1/12 %8.33,0/6 %0.0,0/6 %0.0

Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments(https://clinicaltrials.gov/show/NCT02282020)
 ,Olaparib 300mg BID,Selected Chemotherapy
 ,Participants received olaparib twice daily as a 300 mg tablet.,Participants received physician's choice of chemotherapy out of weekly paclitaxel topotecan pegylated liposomal doxorubicin or gemcitabine.
Total all-cause mortality,56/178 %31.46,21/88 %23.86
Total serious adverse events,42/178 %23.6,14/76 %18.42
Anaemia,5/178 %2.81,0/76 %0.0
Pancytopenia,2/178 %1.12,0/76 %0.0
Cardiopulmonary failure,1/178 %0.56,0/76 %0.0
Tinnitus,1/178 %0.56,0/76 %0.0
Vertigo,1/178 %0.56,0/76 %0.0
Abdominal pain,1/178 %0.56,0/76 %0.0
Abdominal pain upper,0/178 %0.0,1/76 %1.32
Anal inflammation,0/178 %0.0,1/76 %1.32
Ascites,1/178 %0.56,0/76 %0.0
Ileus,2/178 %1.12,0/76 %0.0
Intestinal obstruction,2/178 %1.12,1/76 %1.32
Mesenteric vein thrombosis,0/178 %0.0,1/76 %1.32
Nausea,2/178 %1.12,2/76 %2.63
Oesophagitis,1/178 %0.56,0/76 %0.0
Small intestinal obstruction,2/178 %1.12,0/76 %0.0
Vomiting,3/178 %1.69,3/76 %3.95
Asthenia,2/178 %1.12,1/76 %1.32
Chest pain,1/178 %0.56,0/76 %0.0
Malaise,0/178 %0.0,1/76 %1.32
Oedema peripheral,0/178 %0.0,1/76 %1.32
Pyrexia,2/178 %1.12,2/76 %2.63
Cholecystitis,1/178 %0.56,0/76 %0.0
Anaphylactic reaction,1/178 %0.56,0/76 %0.0
Corneal abscess,1/178 %0.56,0/76 %0.0
Device related infection,0/178 %0.0,1/76 %1.32
Gastroenteritis,2/178 %1.12,0/76 %0.0
Herpes zoster,1/178 %0.56,0/76 %0.0
Pneumonia,2/178 %1.12,1/76 %1.32
Sepsis,2/178 %1.12,0/76 %0.0
Procedural pain,1/178 %0.56,0/76 %0.0
Radius fracture,1/178 %0.56,1/76 %1.32
Spinal compression fracture,1/178 %0.56,0/76 %0.0
Subarachnoid haemorrhage,1/178 %0.56,0/76 %0.0
Blood creatinine increased,1/178 %0.56,0/76 %0.0
Electrolyte imbalance,1/178 %0.56,0/76 %0.0
Pain in extremity,0/178 %0.0,1/76 %1.32
Rotator cuff syndrome,1/178 %0.56,0/76 %0.0
Acute myeloid leukaemia,1/178 %0.56,1/76 %1.32
Breast cancer,1/178 %0.56,0/76 %0.0
Gastric cancer,1/178 %0.56,0/76 %0.0
Lung neoplasm malignant,1/178 %0.56,0/76 %0.0
Metastases to lymph nodes,1/178 %0.56,0/76 %0.0
Myelodysplastic syndrome,2/178 %1.12,0/76 %0.0
Ischaemic stroke,1/178 %0.56,0/76 %0.0
Syncope,2/178 %1.12,0/76 %0.0
Renal failure,1/178 %0.56,0/76 %0.0
Pleural effusion,3/178 %1.69,2/76 %2.63
Pulmonary embolism,2/178 %1.12,0/76 %0.0
Deep vein thrombosis,3/178 %1.69,0/76 %0.0
Embolism,1/178 %0.56,0/76 %0.0

Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma(https://clinicaltrials.gov/show/NCT02285062)
 ,Lenalidomide Plus R-CHOP (R2-CHOP),Placebo Plus R-CHOP
 ,Participants received lenalidomide 15 mg capsules on days 1 to 14 of each 21 day treatment cycle followed by R-CHOP: rituximab 375 mg/m^2 by intravenous (IV) administration on Day 1 doxorubicin 50 mg/m^2 IV on Day 1 vincristine 1.4 mg/m^2 IV on Day 1 (maximum dose of 2.0 mg total) cyclophosphamide 750 mg/m^2 IV on Day 1 and oral or IV prednisone/prednisolone 100 mg on Day 1 to Day 5 of each 21 day treatment cycle for 6 cycles. Treatment continued until completed unless unacceptable toxicity treatment change disease progression or withdrawal of consent whichever occurred first. An additional two doses (1 dose per 21-day cycle) of single agent rituximab after the 6 cycles of treatment were completed if considered standard of care per local practice.,Participants received identically matching placebo capsules on days 1 to 14 of each 21 day treatment cycle followed by R-CHOP: rituximab 375 mg/m^2 by intravenous (IV) administration on Day 1 doxorubicin 50 mg/m^2 IV on Day 1 vincristine 1.4 mg/m^2 IV on Day 1 (maximum dose of 2.0 mg total) cyclophosphamide 750 mg/m^2 IV on Day 1 and oral or IV prednisone/prednisolone 100 mg on Day 1 to Day 5 of each 21 day treatment cycle for 6 to 8 cycles. Treatment continued until 6-8 cycles were completed unless unacceptable toxicity treatment change disease progression or withdrawal of consent occurred first. An additional two doses (1 dose per 21-day cycle) of single agent rituximab after the 6 cycles of treatment were completed if considered standard of care per local practice.
Total all-cause mortality,58/285 %20.35,62/285 %21.75
Total serious adverse events,104/283 %36.75,88/284 %30.99
Agranulocytosis,1/283 %0.35,1/284 %0.35
Anaemia,6/283 %2.12,6/284 %2.11
Cytopenia,1/283 %0.35,0/284 %0.0
Febrile neutropenia,31/283 %10.95,14/284 %4.93
Leukopenia,2/283 %0.71,0/284 %0.0
Lymphadenopathy,0/283 %0.0,1/284 %0.35
Neutropenia,19/283 %6.71,13/284 %4.58
Splenic necrosis,0/283 %0.0,1/284 %0.35
Thrombocytopenia,16/283 %5.65,1/284 %0.35
Acute coronary syndrome,1/283 %0.35,0/284 %0.0
Acute myocardial infarction,2/283 %0.71,0/284 %0.0
Arrhythmia supraventricular,1/283 %0.35,0/284 %0.0
Atrial fibrillation,2/283 %0.71,4/284 %1.41
Atrial flutter,0/283 %0.0,1/284 %0.35
Cardiac arrest,0/283 %0.0,1/284 %0.35
Cardiac disorder,0/283 %0.0,1/284 %0.35
Cardiac failure,0/283 %0.0,3/284 %1.06
Cardiac failure congestive,0/283 %0.0,1/284 %0.35
Coronary artery disease,0/283 %0.0,1/284 %0.35
Sinus tachycardia,0/283 %0.0,1/284 %0.35
Abdominal distension,1/283 %0.35,0/284 %0.0
Abdominal pain,4/283 %1.41,0/284 %0.0
Dental caries,0/283 %0.0,1/284 %0.35
Diarrhoea,6/283 %2.12,4/284 %1.41
Diverticular perforation,0/283 %0.0,1/284 %0.35
Enterocutaneous fistula,0/283 %0.0,1/284 %0.35
Flatulence,1/283 %0.35,0/284 %0.0
Gastric haemorrhage,2/283 %0.71,1/284 %0.35
Gastroduodenal haemorrhage,0/283 %0.0,1/284 %0.35
Gastrointestinal haemorrhage,1/283 %0.35,0/284 %0.0
Haematochezia,1/283 %0.35,0/284 %0.0
Intestinal obstruction,1/283 %0.35,0/284 %0.0
Large intestine perforation,0/283 %0.0,1/284 %0.35
Nausea,2/283 %0.71,2/284 %0.7
Neutropenic colitis,0/283 %0.0,1/284 %0.35
Stomatitis,2/283 %0.71,0/284 %0.0
Vomiting,3/283 %1.06,1/284 %0.35
Asthenia,2/283 %0.71,1/284 %0.35
Death,1/283 %0.35,0/284 %0.0
Extravasation,1/283 %0.35,0/284 %0.0
Face oedema,1/283 %0.35,0/284 %0.0
General physical health deterioration,1/283 %0.35,0/284 %0.0
Hypothermia,1/283 %0.35,0/284 %0.0
Malaise,1/283 %0.35,0/284 %0.0
Non-cardiac chest pain,0/283 %0.0,1/284 %0.35
Oedema peripheral,1/283 %0.35,0/284 %0.0
Pyrexia,7/283 %2.47,9/284 %3.17
Sudden cardiac death,1/283 %0.35,0/284 %0.0
Bile duct stone,1/283 %0.35,0/284 %0.0
Drug-induced liver injury,1/283 %0.35,0/284 %0.0
Hepatic function abnormal,0/283 %0.0,1/284 %0.35
Hepatitis,0/283 %0.0,1/284 %0.35
Jaundice cholestatic,1/283 %0.35,0/284 %0.0
Liver injury,0/283 %0.0,1/284 %0.35
Contrast media allergy,0/283 %0.0,1/284 %0.35
Abdominal infection,0/283 %0.0,1/284 %0.35
Anal abscess,1/283 %0.35,0/284 %0.0
Appendicitis,1/283 %0.35,1/284 %0.35
Arthritis bacterial,1/283 %0.35,0/284 %0.0
Bacterial infection,1/283 %0.35,0/284 %0.0
Bronchitis,0/283 %0.0,1/284 %0.35
Campylobacter gastroenteritis,1/283 %0.35,0/284 %0.0
Cellulitis,3/283 %1.06,0/284 %0.0
Clostridium difficile colitis,1/283 %0.35,1/284 %0.35
Cytomegalovirus infection,1/283 %0.35,1/284 %0.35
Device related infection,1/283 %0.35,2/284 %0.7
Device related sepsis,2/283 %0.71,0/284 %0.0
Escherichia sepsis,1/283 %0.35,0/284 %0.0
Escherichia urinary tract infection,1/283 %0.35,0/284 %0.0
Groin abscess,1/283 %0.35,0/284 %0.0
Hepatitis B,0/283 %0.0,1/284 %0.35
Herpes zoster,0/283 %0.0,1/284 %0.35
Influenza,1/283 %0.35,0/284 %0.0
Klebsiella infection,1/283 %0.35,0/284 %0.0
Lower respiratory tract infection,0/283 %0.0,1/284 %0.35
Lower respiratory tract infection bacterial,1/283 %0.35,0/284 %0.0
Lung infection,4/283 %1.41,2/284 %0.7
Neutropenic sepsis,1/283 %0.35,0/284 %0.0
Osteomyelitis,0/283 %0.0,1/284 %0.35
Parainfluenzae virus infection,1/283 %0.35,0/284 %0.0
Pharyngitis,0/283 %0.0,1/284 %0.35
Pneumocystis jirovecii pneumonia,0/283 %0.0,1/284 %0.35
Pneumonia,11/283 %3.89,7/284 %2.46
Pulmonary sepsis,1/283 %0.35,0/284 %0.0
Salmonellosis,1/283 %0.35,0/284 %0.0
Sepsis,2/283 %0.71,2/284 %0.7
Septic shock,2/283 %0.71,1/284 %0.35
Soft tissue infection,0/283 %0.0,1/284 %0.35
Tracheobronchitis,0/283 %0.0,1/284 %0.35
Upper respiratory tract infection,2/283 %0.71,1/284 %0.35
Urinary tract infection,0/283 %0.0,4/284 %1.41
Varicella,1/283 %0.35,0/284 %0.0
Craniofacial fracture,0/283 %0.0,1/284 %0.35
Femur fracture,0/283 %0.0,1/284 %0.35
Infusion related reaction,1/283 %0.35,3/284 %1.06
Lower limb fracture,1/283 %0.35,0/284 %0.0
Lumbar vertebral fracture,1/283 %0.35,0/284 %0.0
Procedural headache,1/283 %0.35,0/284 %0.0
Procedural nausea,1/283 %0.35,0/284 %0.0
Procedural vomiting,1/283 %0.35,0/284 %0.0
Spinal compression fracture,1/283 %0.35,1/284 %0.35
Spinal fracture,0/283 %0.0,1/284 %0.35
Traumatic intracranial haemorrhage,0/283 %0.0,1/284 %0.35
Neutrophil count decreased,0/283 %0.0,2/284 %0.7
Platelet count decreased,0/283 %0.0,1/284 %0.35
White blood cell count decreased,1/283 %0.35,0/284 %0.0
Dehydration,0/283 %0.0,2/284 %0.7
Electrolyte imbalance,1/283 %0.35,0/284 %0.0
Hypercalcaemia,2/283 %0.71,0/284 %0.0
Hyperglycaemia,1/283 %0.35,1/284 %0.35
Hypokalaemia,0/283 %0.0,1/284 %0.35
Hyponatraemia,1/283 %0.35,0/284 %0.0
Tumour lysis syndrome,1/283 %0.35,1/284 %0.35
Back pain,1/283 %0.35,1/284 %0.35
Bladder transitional cell carcinoma,0/283 %0.0,1/284 %0.35
Central nervous system lymphoma,1/283 %0.35,0/284 %0.0
Diffuse large B-cell lymphoma,3/283 %1.06,0/284 %0.0
Lung adenocarcinoma,0/283 %0.0,1/284 %0.35
Malignant melanoma in situ,1/283 %0.35,0/284 %0.0
Tumour haemorrhage,0/283 %0.0,1/284 %0.35
Altered state of consciousness,1/283 %0.35,0/284 %0.0
Amnesia,1/283 %0.35,0/284 %0.0
Aphasia,1/283 %0.35,0/284 %0.0
Cerebrovascular accident,0/283 %0.0,2/284 %0.7
Cognitive disorder,1/283 %0.35,0/284 %0.0
Dizziness,1/283 %0.35,0/284 %0.0
Dysarthria,1/283 %0.35,0/284 %0.0
Epilepsy,1/283 %0.35,0/284 %0.0
Guillain-Barre syndrome,0/283 %0.0,1/284 %0.35
Haemorrhage intracranial,0/283 %0.0,1/284 %0.35
Hemiparesis,1/283 %0.35,2/284 %0.7
Lethargy,0/283 %0.0,1/284 %0.35
Memory impairment,1/283 %0.35,0/284 %0.0
Nervous system disorder,1/283 %0.35,0/284 %0.0
Neuralgia,0/283 %0.0,1/284 %0.35
Presyncope,1/283 %0.35,0/284 %0.0
Syncope,2/283 %0.71,2/284 %0.7
Vocal cord paralysis,1/283 %0.35,0/284 %0.0
Confusional state,1/283 %0.35,0/284 %0.0
Psychotic disorder,1/283 %0.35,0/284 %0.0
Tic,0/283 %0.0,1/284 %0.35
Acute kidney injury,2/283 %0.71,1/284 %0.35
Urinary retention,1/283 %0.35,0/284 %0.0
Acute respiratory failure,0/283 %0.0,1/284 %0.35
Cough,1/283 %0.35,0/284 %0.0
Dyspnoea,0/283 %0.0,2/284 %0.7
Interstitial lung disease,1/283 %0.35,4/284 %1.41
Pleural effusion,1/283 %0.35,0/284 %0.0
Pleuritic pain,1/283 %0.35,0/284 %0.0
Pneumonitis,0/283 %0.0,1/284 %0.35
Pulmonary embolism,5/283 %1.77,3/284 %1.06
Pulmonary oedema,0/283 %0.0,2/284 %0.7
Respiratory failure,1/283 %0.35,3/284 %1.06
Decubitus ulcer,1/283 %0.35,0/284 %0.0
Drug eruption,1/283 %0.35,0/284 %0.0
Rash generalised,1/283 %0.35,0/284 %0.0
Deep vein thrombosis,2/283 %0.71,1/284 %0.35
Hypertension,1/283 %0.35,1/284 %0.35
Hypotension,0/283 %0.0,1/284 %0.35
Jugular vein thrombosis,1/283 %0.35,0/284 %0.0
Thrombophlebitis superficial,0/283 %0.0,1/284 %0.35

Phase 1/2 Study of Motolimod  Doxorubicin  and Durvalumab in Recurrent  Platinum-Resistant Ovarian Cancer(https://clinicaltrials.gov/show/NCT02431559)
 ,Phase 1 Dose Level 0a,Phase 1 Dose Level 0b,Phase 1 Dose Level +1,Phase 2
 ,Subjects received PLD (40 mg/m^2 IV on Day 1 of every cycle) + durvalumab (3 mg/kg Q2W [equivalent to 450 mg Q4W] IV on Days 3 and 17 of every cycle) for up to 12 continuous 28-day cycles (Core Study) with extended durvalumab monotherapy permitted for subjects tolerating and benefiting from treatment. Prior to removal of motolimod from the study subjects received motolimod (2.5 mg/m^2 SC) on Days 3 10 and 17 of Cycles 1-3 and Days 3 and 17 of Cycles 4-12.,Subjects received PLD (40 mg/m^2 IV on Day 1 of every cycle) + durvalumab (1500 mg Q4W IV on Day 3 of every cycle) for up to 12 continuous 28-day cycles (Core Study) with extended durvalumab monotherapy permitted for subjects tolerating and benefiting from treatment. Prior to removal of motolimod from the study subjects received motolimod (2.0 mg/m^2 SC) on Days 3 10 and 17 of Cycles 1-3 and Day 3 of Cycles 4-12.,Subjects received PLD (40 mg/m^2 IV on Day 1 of every cycle) + durvalumab (1500 mg Q4W IV on Day 3 of every cycle) for up to 12 continuous 28-day cycles (Core Study) with extended durvalumab monotherapy permitted for subjects tolerating and benefiting from treatment. Prior to removal of motolimod from the study subjects received motolimod (2.5 mg/m^2 SC) on Days 3 10 and 17 of Cycles 1-3 and Day 3 of Cycles 4-12.,Subjects received the MTD determined in Phase 1 comprising PLD (40 mg/m^2 IV on Day 1 of every cycle) + durvalumab (1500 mg Q4W IV on Day 3 of every cycle) for up to 12 continuous 28-day cycles (Core Study) with extended durvalumab monotherapy permitted for subjects tolerating and benefiting from treatment.
Total all-cause mortality,0/3 %0.0,0/4 %0.0,0/6 %0.0,2/40 %5.0
Total serious adverse events,0/3 %0.0,2/4 %50.0,1/6 %16.67,23/40 %57.5
Vision blurred,0/3 %0.0,0/4 %0.0,0/6 %0.0,1/40 %2.5
Abdominal pain,0/3 %0.0,0/4 %0.0,0/6 %0.0,3/40 %7.5
Ascites,0/3 %0.0,0/4 %0.0,0/6 %0.0,1/40 %2.5
Diarrhoea,0/3 %0.0,0/4 %0.0,0/6 %0.0,1/40 %2.5
Ileus,0/3 %0.0,0/4 %0.0,1/6 %16.67,2/40 %5.0
Pancreatitis,0/3 %0.0,0/4 %0.0,0/6 %0.0,1/40 %2.5
Rectal obstruction,0/3 %0.0,0/4 %0.0,0/6 %0.0,1/40 %2.5
Small intestinal obstruction,0/3 %0.0,0/4 %0.0,0/6 %0.0,1/40 %2.5
Stomatitis,0/3 %0.0,1/4 %25.0,0/6 %0.0,1/40 %2.5
Subileus,0/3 %0.0,0/4 %0.0,0/6 %0.0,1/40 %2.5
General physical health deterioration,0/3 %0.0,0/4 %0.0,0/6 %0.0,1/40 %2.5
Pyrexia,0/3 %0.0,0/4 %0.0,0/6 %0.0,3/40 %7.5
Mucosal inflammation,0/3 %0.0,0/4 %0.0,0/6 %0.0,1/40 %2.5
Bacteraemia,0/3 %0.0,0/4 %0.0,0/6 %0.0,1/40 %2.5
Bacterial translocation,0/3 %0.0,0/4 %0.0,0/6 %0.0,1/40 %2.5
Lung infection,0/3 %0.0,0/4 %0.0,0/6 %0.0,2/40 %5.0
Sepsis,0/3 %0.0,0/4 %0.0,0/6 %0.0,1/40 %2.5
Fall,0/3 %0.0,0/4 %0.0,0/6 %0.0,1/40 %2.5
Fracture,0/3 %0.0,0/4 %0.0,0/6 %0.0,2/40 %5.0
Hip fracture,0/3 %0.0,0/4 %0.0,0/6 %0.0,1/40 %2.5
Infusion related reaction,0/3 %0.0,0/4 %0.0,0/6 %0.0,1/40 %2.5
Wound dehiscence,0/3 %0.0,0/4 %0.0,0/6 %0.0,1/40 %2.5
Nutritional condition abnormal,0/3 %0.0,0/4 %0.0,0/6 %0.0,1/40 %2.5
Hypercalcaemia,0/3 %0.0,1/4 %25.0,0/6 %0.0,0/40 %0.0
Back pain,0/3 %0.0,0/4 %0.0,0/6 %0.0,1/40 %2.5
Muscular weakness,0/3 %0.0,0/4 %0.0,0/6 %0.0,1/40 %2.5
Malignant neoplasm progression,0/3 %0.0,0/4 %0.0,0/6 %0.0,3/40 %7.5
Aphasia,0/3 %0.0,0/4 %0.0,0/6 %0.0,1/40 %2.5
Transient ischaemic attack,0/3 %0.0,0/4 %0.0,0/6 %0.0,1/40 %2.5
Urinary tract obstruction,0/3 %0.0,1/4 %25.0,0/6 %0.0,0/40 %0.0
Bronchial obstruction,0/3 %0.0,1/4 %25.0,0/6 %0.0,0/40 %0.0
Pleural effusion,0/3 %0.0,0/4 %0.0,0/6 %0.0,2/40 %5.0
Pleural fibrosis,0/3 %0.0,0/4 %0.0,0/6 %0.0,1/40 %2.5
Dermatitis bullous,0/3 %0.0,1/4 %25.0,0/6 %0.0,0/40 %0.0
Palmar-plantar erythrodysaesthesia syndrome,0/3 %0.0,1/4 %25.0,0/6 %0.0,0/40 %0.0
Lymphadenectomy,0/3 %0.0,0/4 %0.0,0/6 %0.0,1/40 %2.5

A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas(https://clinicaltrials.gov/show/NCT02448537)
 ,Stratum A,Stratum B,Stratum C
 ,Anthracycline-nave patients will receive combination of PM01183 and Doxorubicin per cycle.  PM01183 predetermined dose daily via IV per cycle  Doxorubicin predetermined dose daily via IV per cycle  PM01183  Doxorubicin,Prior anthracycline exposure and without prior gemcitabine exposure  PM01183 predetermined dose given twice via IV per cycle  Gemcitabine predetermined dose given twice via IV per cycle  PM01183  Gemcitabine,Patients who have received at least both prior anthracycline and prior gemcitabine  -PM01183 predetermined dose once via IV per cycle  PM01183
Total all-cause mortality,0/20 %0.0,0/10 %0.0,0/12 %0.0
Total serious adverse events,6/20 %30.0,6/10 %60.0,4/12 %33.33
Anemia,0/20 %0.0,1/10 %10.0,0/12 %0.0
Febrile neutropenia,1/20 %5.0,1/10 %10.0,0/12 %0.0
Ventricular arrhythmia,1/20 %5.0,0/10 %0.0,0/12 %0.0
Constipation,0/20 %0.0,0/10 %0.0,1/12 %8.33
Diarrhea,1/20 %5.0,0/10 %0.0,1/12 %8.33
Ileus,1/20 %5.0,0/10 %0.0,0/12 %0.0
Nausea,1/20 %5.0,0/10 %0.0,1/12 %8.33
Small intestinal obstruction,1/20 %5.0,0/10 %0.0,1/12 %8.33
Vomiting,1/20 %5.0,0/10 %0.0,1/12 %8.33
Infections and infestations - Other Port Infection,0/20 %0.0,1/10 %10.0,0/12 %0.0
Infections and infestations - Other Spontaneous Bacterial Peritonitis,1/20 %5.0,0/10 %0.0,0/12 %0.0
Lymphocyte count decreased,2/20 %10.0,1/10 %10.0,0/12 %0.0
Neutrophil count decreased,4/20 %20.0,4/10 %40.0,1/12 %8.33
Platelet count decreased,1/20 %5.0,1/10 %10.0,0/12 %0.0
White blood cell decreased,3/20 %15.0,1/10 %10.0,0/12 %0.0
Intracranial hemorrhage,0/20 %0.0,1/10 %10.0,0/12 %0.0
Urinary incontinence,1/20 %5.0,0/10 %0.0,0/12 %0.0
Pleural effusion,0/20 %0.0,0/10 %0.0,1/12 %8.33
Surgical and medical procedures - Other Grade 3 Decompression and Spinal Stabilization,1/20 %5.0,0/10 %0.0,0/12 %0.0

A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma(https://clinicaltrials.gov/show/NCT02460991)
 ,DEB-TACE,Sorafenib
 ,ONCO-DOX (Doxorubicin loaded Microspheres) up to 150 mg per treatment; treatments could be repeated every 4-8 weeks until complete tumor response was achieved,200 mg of Sorafenib twice daily; continue until unacceptable toxicity or unequivocal tumor progression
Total all-cause mortality,0/0 %0.0,0/2 %0.0
Total serious adverse events,0/0 %0.0,1/2 %50.0
Hypertensive Emergency,0/0 %0.0,1/2 %50.0

Hormonal Therapy and Chemotherapy Followed by Prostatectomy in Patients With Prostate Cancer(https://clinicaltrials.gov/show/NCT02494713)
 ,ADT + Chemotherapy
 ,Patients will be treated with 4 monthly injections of degarelix along with two 8-week cycles of chemotherapy (doxorubicin and ketoconazole weeks 1 3 5 and docetaxel and estramustine weeks 2 4 6). Each cycle of chemotherapy will consist of 6 weeks of chemotherapy and 2 weeks of rest. In the absence of toxicity or disease progression patients will receive 2 cycles of treatment prior to radical prostatectomy.  Degarelix: Subcutaneous injection once/month for 4 months  Doxorubicin: 20 mg/m2 as a 24-hour intravenous infusion on day 1 each week weeks 1 3 and 5  Ketoconazole: 400 mg orally 3 times daily for 7 days in weeks 1 3 and 5  Docetaxel: 35 mg/m2 intravenously on day 1 of each week weeks 2 4 and 6  Estramustine: 280 mg orally 3 times daily for 7 days in weeks 2 4 and 6
Total all-cause mortality,0/4 %0.0
Total serious adverse events,0/4 %0.0

GA101-miniCHOP Regimen for the Treatment of Elderly Unfit Patients With Diffuse Large B-cell Non-Hodgkin's Lymphoma(https://clinicaltrials.gov/show/NCT02495454)
 ,Single Arm
 ,6 courses of GA101-miniCHOP regimen and 2 additional infusions of GA101 every 21 days (for a total of 6 courses of miniCHOP and 10 infusions of GA101).  NOTE: One SAE (atrial fibrillation) was recorded in patient excluded from analysis (not eligible for transformed lymphoma) exit before starting the 1st cycle of treatment.
Total all-cause mortality,11/33 %33.33
Total serious adverse events,6/33 %18.18
Congestive heart failure,2/33 %6.06
BCPO-Heart failure,1/33 %3.03
Atrial fibrillation,1/33 %3.03
Nausea,1/33 %3.03
Femur fracture,2/33 %6.06
-sepsis,4/33 %12.12
Lumbar pain vertebral collapse,1/33 %3.03
Breast cancer,3/33 %9.09
Non small cell lung cancer,3/33 %9.09

Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma(https://clinicaltrials.gov/show/NCT02505269)
 ,Brentuximab Vedotin
 ,The following procedures will take place during study visits beginning after the screening procedures:  - Participants will receive combination therapy:  Brentuximab Vedotin intravenously on predetermined days per cycle  Adriamycin intravenously on predetermined days per cycle  Dacarbazine intravenously on predetermined days per cycle  Brentuximab Vedotin  Adriamycin  Dacarbazine
Total all-cause mortality,0/34 %0.0
Total serious adverse events,5/34 %14.71
Colitis,1/34 %2.94
Nausea,1/34 %2.94
Vomiting,1/34 %2.94
Diarrhea,1/34 %2.94
Upper respiratory infection,1/34 %2.94
Arthralgia,1/34 %2.94
Thromboembolic event,1/34 %2.94

Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma or Grade 3b Follicular Lymphoma(https://clinicaltrials.gov/show/NCT02541565)
 ,Treatment (Pembrolizumab Combination Chemotherapy)
 ,Patients will receive pembrolizumab IV over 30 minutes on day 1 and prednisone PO on days 1-5. Patients also receive rituximab IV cyclophosphamide IV doxorubicin hydrochloride IV and vincristine sulfate IV on day 2 of course 1 and on day 1 of subsequent courses. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.  Cyclophosphamide: Given IV  Doxorubicin Hydrochloride: Given IV  Laboratory Biomarker Analysis: Correlative studies  Pembrolizumab: Given IV  Prednisone: Given PO  Rituximab: Given IV  Vincristine Sulfate: Given IV
Total all-cause mortality,1/30 %3.33
Total serious adverse events,13/30 %43.33
Febrile Neutropenia,4/30 %13.33
Worsening Systolic Function,1/30 %3.33
Upper GI Bleed,1/30 %3.33
Abdominal Pain,1/30 %3.33
Constipation,1/30 %3.33
Diarrhea,1/30 %3.33
Fever,1/30 %3.33
Rigors,1/30 %3.33
Infection-RSV,1/30 %3.33
Hypoxia,1/30 %3.33
Pneumonitis,1/30 %3.33

Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer(https://clinicaltrials.gov/show/NCT02560051)
 ,Definitive Local Therapy,Nodal Only/Low-volume Bone,High Volume/no Prior tx
 ,3 cycles of chemotherapy (doxorubicin ketoconazole docetaxel and estramustine) + 12 months ADT (degarelix)  Doxorubicin: In weeks 1 3 and 5 of each 8-week cycle participants will receive doxorubicin (20 mg/m2 as a 24-hour intravenous infusion on day 1 of each applicable week)  Ketoconazole: In weeks 1 3 and 5 of each 8-week cycle participants will receive ketoconazole (400 mg orally 3 times daily for 7 days)  Docetaxel: In weeks 2 4 and 6 of each 8-week cycle participants will receive docetaxel (35 mg/m2 intravenously on day 1 of each applicable week)  Estramustine: In weeks 2 4 and 6 of each 8-week cycle participants will receive estramustine (280 mg orally 3 times daily for 7 days)  Degarelix: The starting dose (240 mg given as two injections of 120 mg each) is followed by maintenance doses of 80 mg administered as a single injection every 28 days,4 cycles of chemotherapy (doxorubicin ketoconazole docetaxel and estramustine) + 18 months ADT (degarelix)  Doxorubicin: In weeks 1 3 and 5 of each 8-week cycle participants will receive doxorubicin (20 mg/m2 as a 24-hour intravenous infusion on day 1 of each applicable week)  Ketoconazole: In weeks 1 3 and 5 of each 8-week cycle participants will receive ketoconazole (400 mg orally 3 times daily for 7 days)  Docetaxel: In weeks 2 4 and 6 of each 8-week cycle participants will receive docetaxel (35 mg/m2 intravenously on day 1 of each applicable week)  Estramustine: In weeks 2 4 and 6 of each 8-week cycle participants will receive estramustine (280 mg orally 3 times daily for 7 days)  Degarelix: The starting dose (240 mg given as two injections of 120 mg each) is followed by maintenance doses of 80 mg administered as a single injection every 28 days,5 cycles of chemotherapy (doxorubicin ketoconazole docetaxel and estramustine) + 24 months ADT (degarelix)  Doxorubicin: In weeks 1 3 and 5 of each 8-week cycle participants will receive doxorubicin (20 mg/m2 as a 24-hour intravenous infusion on day 1 of each applicable week)  Ketoconazole: In weeks 1 3 and 5 of each 8-week cycle participants will receive ketoconazole (400 mg orally 3 times daily for 7 days)  Docetaxel: In weeks 2 4 and 6 of each 8-week cycle participants will receive docetaxel (35 mg/m2 intravenously on day 1 of each applicable week)  Estramustine: In weeks 2 4 and 6 of each 8-week cycle participants will receive estramustine (280 mg orally 3 times daily for 7 days)  Degarelix: The starting dose (240 mg given as two injections of 120 mg each) is followed by maintenance doses of 80 mg administered as a single injection every 28 days
Total all-cause mortality,0/6 %0.0,0/8 %0.0,0/5 %0.0
Total serious adverse events,3/6 %50.0,2/8 %25.0,0/5 %0.0
Anemia,0/6 %0.0,1/8 %12.5,0/5 %0.0
Sinus Tachycardia,0/6 %0.0,1/8 %12.5,0/5 %0.0
Abdominal Pain,0/6 %0.0,1/8 %12.5,0/5 %0.0
Diarrhea,0/6 %0.0,1/8 %12.5,0/5 %0.0
Nausea,0/6 %0.0,1/8 %12.5,0/5 %0.0
Vomiting,0/6 %0.0,1/8 %12.5,0/5 %0.0
Fever,3/6 %50.0,2/8 %25.0,0/5 %0.0
Chills,0/6 %0.0,1/8 %12.5,0/5 %0.0
Fatigue,1/6 %16.67,0/8 %0.0,0/5 %0.0
Urinary Tract Infection,0/6 %0.0,1/8 %12.5,0/5 %0.0
Sepsis,0/6 %0.0,1/8 %12.5,0/5 %0.0
Creatinine Increased,0/6 %0.0,1/8 %12.5,0/5 %0.0
White blood cell decreased,0/6 %0.0,2/8 %25.0,0/5 %0.0
Hypokalemia,0/6 %0.0,1/8 %12.5,0/5 %0.0
Hypoalbuminemia,0/6 %0.0,2/8 %25.0,0/5 %0.0
Anorexia,0/6 %0.0,2/8 %25.0,0/5 %0.0
Hypophosphatemia,0/6 %0.0,1/8 %12.5,0/5 %0.0
Cough,1/6 %16.67,1/8 %12.5,0/5 %0.0
Post nasal drip,0/6 %0.0,1/8 %12.5,0/5 %0.0
Dyspnea,0/6 %0.0,2/8 %25.0,0/5 %0.0
Hypoxia,0/6 %0.0,1/8 %12.5,0/5 %0.0
Respiratory thoracic and mediastinal disorders Pulmonary inflammation,1/6 %16.67,0/8 %0.0,0/5 %0.0
Thromboembolic event,1/6 %16.67,0/8 %0.0,0/5 %0.0

A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200)(https://clinicaltrials.gov/show/NCT02580058)
 ,Avelumab,Avelumab + PLD,Pegylated Liposomal Doxorubicin (PLD)
 ,Avelumab 10 milligram (mg)/kilogram (kg) given as a 1-hour intravenous (IV) infusion every 2 weeks (Q2W) in 4-week cycles.,Avelumab 10 mg/kg given as a 1-hour IV Q2W in 4-week cycles + pegylated liposomal doxorubicin (PLD) 40 mg/square meter given as a 1-hour IV infusion every 4 weeks (Q4W) in 4-week cycles.,PLD 40 mg/square meter given as a 1-hour IV infusion Q4W in 4-week cycles.
Total all-cause mortality,109/188 %57.98,102/188 %54.26,104/190 %54.74
Total serious adverse events,71/187 %37.97,75/182 %41.21,51/177 %28.81
Anaemia,0/187 %0.0,0/182 %0.0,1/177 %0.56
Febrile neutropenia,0/187 %0.0,1/182 %0.55,3/177 %1.69
Neutropenia,0/187 %0.0,0/182 %0.0,1/177 %0.56
Thrombocytopenia,0/187 %0.0,1/182 %0.55,1/177 %0.56
Atrial fibrillation,1/187 %0.53,0/182 %0.0,0/177 %0.0
Myocardial infarction,0/187 %0.0,1/182 %0.55,0/177 %0.0
Tachycardia,0/187 %0.0,1/182 %0.55,0/177 %0.0
Adrenal insufficiency,0/187 %0.0,1/182 %0.55,0/177 %0.0
Basedow's disease,0/187 %0.0,1/182 %0.55,0/177 %0.0
Hypopituitarism,0/187 %0.0,2/182 %1.1,0/177 %0.0
Retinal detachment,1/187 %0.53,0/182 %0.0,0/177 %0.0
Abdominal distension,3/187 %1.6,1/182 %0.55,1/177 %0.56
Abdominal pain,9/187 %4.81,6/182 %3.3,6/177 %3.39
Abdominal pain upper,1/187 %0.53,0/182 %0.0,1/177 %0.56
Ascites,2/187 %1.07,1/182 %0.55,1/177 %0.56
Colitis,0/187 %0.0,1/182 %0.55,0/177 %0.0
Constipation,2/187 %1.07,5/182 %2.75,1/177 %0.56
Diarrhoea,4/187 %2.14,1/182 %0.55,1/177 %0.56
Faecaloma,0/187 %0.0,1/182 %0.55,0/177 %0.0
Haematemesis,0/187 %0.0,0/182 %0.0,1/177 %0.56
Ileus,1/187 %0.53,4/182 %2.2,2/177 %1.13
Intestinal obstruction,11/187 %5.88,9/182 %4.95,6/177 %3.39
Intestinal pseudo-obstruction,0/187 %0.0,0/182 %0.0,1/177 %0.56
Intussusception,0/187 %0.0,1/182 %0.55,0/177 %0.0
Large intestinal obstruction,0/187 %0.0,1/182 %0.55,0/177 %0.0
Malignant bowel obstruction,1/187 %0.53,1/182 %0.55,1/177 %0.56
Mechanical ileus,1/187 %0.53,0/182 %0.0,0/177 %0.0
Nausea,7/187 %3.74,4/182 %2.2,1/177 %0.56
Obstruction gastric,1/187 %0.53,0/182 %0.0,0/177 %0.0
Oesophagitis,1/187 %0.53,0/182 %0.0,0/177 %0.0
Pancreatitis acute,1/187 %0.53,0/182 %0.0,0/177 %0.0
Small intestinal obstruction,5/187 %2.67,4/182 %2.2,2/177 %1.13
Stomatitis,0/187 %0.0,2/182 %1.1,1/177 %0.56
Subileus,1/187 %0.53,1/182 %0.55,2/177 %1.13
Umbilical hernia,0/187 %0.0,0/182 %0.0,1/177 %0.56
Vomiting,7/187 %3.74,4/182 %2.2,3/177 %1.69
Administration site extravasation,0/187 %0.0,0/182 %0.0,1/177 %0.56
Asthenia,0/187 %0.0,2/182 %1.1,0/177 %0.0
Chest discomfort,1/187 %0.53,0/182 %0.0,0/177 %0.0
Chills,1/187 %0.53,1/182 %0.55,0/177 %0.0
Complication associated with device,0/187 %0.0,0/182 %0.0,1/177 %0.56
Disease progression,9/187 %4.81,5/182 %2.75,2/177 %1.13
Fatigue,0/187 %0.0,2/182 %1.1,0/177 %0.0
General physical health deterioration,2/187 %1.07,2/182 %1.1,0/177 %0.0
Influenza like illness,1/187 %0.53,0/182 %0.0,0/177 %0.0
Localised oedema,0/187 %0.0,1/182 %0.55,0/177 %0.0
Malaise,0/187 %0.0,2/182 %1.1,0/177 %0.0
Mucosal inflammation,0/187 %0.0,1/182 %0.55,0/177 %0.0
Oedema peripheral,0/187 %0.0,1/182 %0.55,0/177 %0.0
Pain,0/187 %0.0,1/182 %0.55,0/177 %0.0
Pyrexia,7/187 %3.74,9/182 %4.95,1/177 %0.56
Autoimmune hepatitis,1/187 %0.53,0/182 %0.0,0/177 %0.0
Drug-induced liver injury,1/187 %0.53,0/182 %0.0,0/177 %0.0
Hepatic failure,0/187 %0.0,0/182 %0.0,1/177 %0.56
Anaphylactic reaction,0/187 %0.0,0/182 %0.0,1/177 %0.56
Cytokine release syndrome,0/187 %0.0,1/182 %0.55,0/177 %0.0
Hypersensitivity,0/187 %0.0,1/182 %0.55,0/177 %0.0
Immune-mediated adverse reaction,1/187 %0.53,0/182 %0.0,0/177 %0.0
Bacteraemia,1/187 %0.53,1/182 %0.55,0/177 %0.0
Cellulitis,1/187 %0.53,0/182 %0.0,0/177 %0.0
Cholangitis infective,1/187 %0.53,0/182 %0.0,0/177 %0.0
Cystitis,1/187 %0.53,0/182 %0.0,0/177 %0.0
Device related infection,1/187 %0.53,1/182 %0.55,1/177 %0.56
Erysipelas,0/187 %0.0,0/182 %0.0,1/177 %0.56
Gastroenteritis,1/187 %0.53,0/182 %0.0,1/177 %0.56
Infectious pleural effusion,0/187 %0.0,0/182 %0.0,1/177 %0.56
Influenza,0/187 %0.0,1/182 %0.55,2/177 %1.13
Lymph gland infection,0/187 %0.0,1/182 %0.55,0/177 %0.0
Medical device site infection,0/187 %0.0,1/182 %0.55,0/177 %0.0
Meningitis,0/187 %0.0,1/182 %0.55,0/177 %0.0
Nail infection,0/187 %0.0,0/182 %0.0,1/177 %0.56
Oral fungal infection,0/187 %0.0,1/182 %0.55,0/177 %0.0
Peritonitis,1/187 %0.53,0/182 %0.0,0/177 %0.0
Peritonitis bacterial,0/187 %0.0,1/182 %0.55,0/177 %0.0
Pneumonia,3/187 %1.6,3/182 %1.65,0/177 %0.0
Pyelonephritis,1/187 %0.53,0/182 %0.0,1/177 %0.56
Respiratory tract infection,0/187 %0.0,0/182 %0.0,1/177 %0.56
Sepsis,0/187 %0.0,0/182 %0.0,2/177 %1.13
Septic embolus,0/187 %0.0,0/182 %0.0,1/177 %0.56
Septic shock,0/187 %0.0,0/182 %0.0,1/177 %0.56
Sinusitis,0/187 %0.0,1/182 %0.55,0/177 %0.0
Staphylococcal infection,0/187 %0.0,1/182 %0.55,1/177 %0.56
Urinary tract infection,1/187 %0.53,1/182 %0.55,2/177 %1.13
Urosepsis,0/187 %0.0,1/182 %0.55,0/177 %0.0
Viral upper respiratory tract infection,0/187 %0.0,1/182 %0.55,0/177 %0.0
Infusion related reaction,1/187 %0.53,3/182 %1.65,1/177 %0.56
Patella fracture,1/187 %0.53,0/182 %0.0,0/177 %0.0
Stoma complication,1/187 %0.53,0/182 %0.0,0/177 %0.0
Upper limb fracture,0/187 %0.0,1/182 %0.55,0/177 %0.0
Vascular access complication,0/187 %0.0,1/182 %0.55,0/177 %0.0
Aspartate aminotransferase increased,0/187 %0.0,1/182 %0.55,0/177 %0.0
Blood creatine phosphokinase increased,0/187 %0.0,1/182 %0.55,0/177 %0.0
Haemoglobin decreased,1/187 %0.53,0/182 %0.0,0/177 %0.0
Neutrophil count decreased,0/187 %0.0,0/182 %0.0,1/177 %0.56
Urine output decreased,0/187 %0.0,0/182 %0.0,1/177 %0.56
White blood cell count decreased,0/187 %0.0,0/182 %0.0,1/177 %0.56
Decreased appetite,3/187 %1.6,1/182 %0.55,1/177 %0.56
Dehydration,2/187 %1.07,1/182 %0.55,1/177 %0.56
Hypercalcaemia,0/187 %0.0,5/182 %2.75,1/177 %0.56
Hypokalaemia,0/187 %0.0,1/182 %0.55,0/177 %0.0
Hypomagnesaemia,0/187 %0.0,1/182 %0.55,0/177 %0.0
Hyponatraemia,0/187 %0.0,0/182 %0.0,2/177 %1.13
Back pain,0/187 %0.0,0/182 %0.0,2/177 %1.13
Malignant neoplasm progression,0/187 %0.0,1/182 %0.55,0/177 %0.0
Aphasia,1/187 %0.53,0/182 %0.0,0/177 %0.0
Clonic convulsion,0/187 %0.0,0/182 %0.0,1/177 %0.56
Tremor,1/187 %0.53,0/182 %0.0,0/177 %0.0
Device dislocation,1/187 %0.53,0/182 %0.0,0/177 %0.0
Confusional state,0/187 %0.0,1/182 %0.55,1/177 %0.56
Mental status changes,1/187 %0.53,0/182 %0.0,0/177 %0.0
Acute kidney injury,1/187 %0.53,0/182 %0.0,0/177 %0.0
Chronic kidney disease,0/187 %0.0,1/182 %0.55,0/177 %0.0
Haematuria,1/187 %0.53,0/182 %0.0,0/177 %0.0
Obstructive nephropathy,0/187 %0.0,1/182 %0.55,0/177 %0.0
Renal failure,1/187 %0.53,0/182 %0.0,0/177 %0.0
Urinary tract obstruction,0/187 %0.0,1/182 %0.55,0/177 %0.0
Vaginal haemorrhage,1/187 %0.53,0/182 %0.0,0/177 %0.0
Cough,0/187 %0.0,1/182 %0.55,0/177 %0.0
Dyspnoea,4/187 %2.14,5/182 %2.75,0/177 %0.0
Lung disorder,0/187 %0.0,0/182 %0.0,1/177 %0.56
Oropharyngeal pain,0/187 %0.0,1/182 %0.55,0/177 %0.0
Pleural effusion,2/187 %1.07,0/182 %0.0,0/177 %0.0
Pneumonia aspiration,1/187 %0.53,0/182 %0.0,0/177 %0.0
Pneumonitis,1/187 %0.53,1/182 %0.55,1/177 %0.56
Productive cough,1/187 %0.53,0/182 %0.0,0/177 %0.0
Pulmonary embolism,2/187 %1.07,4/182 %2.2,2/177 %1.13
Respiratory failure,1/187 %0.53,0/182 %0.0,0/177 %0.0
Dermatitis exfoliative generalised,0/187 %0.0,0/182 %0.0,1/177 %0.56
Palmar-plantar erythrodysaesthesia syndrome,0/187 %0.0,2/182 %1.1,1/177 %0.56
Vasculitic ulcer,0/187 %0.0,1/182 %0.55,0/177 %0.0
Deep vein thrombosis,0/187 %0.0,1/182 %0.55,0/177 %0.0
Embolism,0/187 %0.0,0/182 %0.0,3/177 %1.69
Embolism venous,0/187 %0.0,1/182 %0.55,0/177 %0.0
Hypotension,1/187 %0.53,0/182 %0.0,0/177 %0.0

A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)(https://clinicaltrials.gov/show/NCT02596971)
 ,Atezo-G-Benda Cohort (Safety Run-In and Expansion Phases),Atezo-G-CHOP Cohort (Safety Run-In Phase),Atezo-R-CHOP Cohort (Expansion Phase)
 ,Safety run-in phase: Participants with previously untreated or relapsed or refractory FL received obinutuzumab (G) and bendamustine during Cycle 1 (28-day cycle) and atezolizumab obinutuzumab and bendamustine during Cycles 2-6 during induction treatment followed by atezolizumab (once monthly) and obinutuzumab (every other month [q2m]) for 24 months during maintenance treatment. Expansion phase: Participants with previously untreated FL received same treatment regimen as described for safety run-in phase.,Safety run-in phase: Participants with previously untreated or relapsed or refractory FL received obinutuzumab and CHOP during Cycle 1 (21-day cycle) and atezolizumab obinutuzumab and CHOP during Cycles 2-6 during induction treatment followed by atezolizumab (once monthly) and obinutuzumab (q2m) for 24 months during maintenance treatment.,Participants with previously untreated DLBCL received rituximab and CHOP during Cycle 1 (21-day cycle) and atezolizumab rituximab and CHOP during Cycles 2-8 (atezolizumab and rituximab for 8 cycles and CHOP for either 6 or 8 cycles as determined by the investigator) during induction treatment followed by atezolizumab from Cycles 9-25 during consolidation treatment.
Total all-cause mortality,2/42 %4.76,0/7 %0.0,0/42 %0.0
Total serious adverse events,12/42 %28.57,2/7 %28.57,16/42 %38.1
Neutropenia,0/42 %0.0,1/7 %14.29,0/42 %0.0
Febrile Neutropenia,0/42 %0.0,0/7 %0.0,5/42 %11.9
Pancytopenia,0/42 %0.0,0/7 %0.0,1/42 %2.38
Thrombocytopenia,0/42 %0.0,0/7 %0.0,1/42 %2.38
Cardiac Arrest,1/42 %2.38,0/7 %0.0,0/42 %0.0
Myocarditis,1/42 %2.38,0/7 %0.0,0/42 %0.0
Atrial Fibrillation,0/42 %0.0,0/7 %0.0,1/42 %2.38
Diplopia,0/42 %0.0,0/7 %0.0,1/42 %2.38
Nausea,1/42 %2.38,0/7 %0.0,0/42 %0.0
Small Intestinal Obstruction,1/42 %2.38,0/7 %0.0,0/42 %0.0
Abdominal Pain,0/42 %0.0,0/7 %0.0,1/42 %2.38
Intestinal Obstruction,0/42 %0.0,0/7 %0.0,1/42 %2.38
Pyrexia,3/42 %7.14,0/7 %0.0,1/42 %2.38
Sudden Death,1/42 %2.38,0/7 %0.0,0/42 %0.0
Pneumonia,1/42 %2.38,0/7 %0.0,1/42 %2.38
Skin Infection,1/42 %2.38,0/7 %0.0,0/42 %0.0
Upper Respiratory Tract Infection,1/42 %2.38,0/7 %0.0,0/42 %0.0
Urinary Tract Infection Staphylococcal,1/42 %2.38,0/7 %0.0,0/42 %0.0
Kidney Infection,0/42 %0.0,1/7 %14.29,0/42 %0.0
Diverticulitis,0/42 %0.0,0/7 %0.0,1/42 %2.38
Epstein-Barr Virus Infection,0/42 %0.0,0/7 %0.0,1/42 %2.38
Lung Infection,0/42 %0.0,0/7 %0.0,1/42 %2.38
Sepsis,0/42 %0.0,0/7 %0.0,1/42 %2.38
Sinusitis,0/42 %0.0,0/7 %0.0,1/42 %2.38
Infusion Related Reaction,2/42 %4.76,0/7 %0.0,0/42 %0.0
Colon Cancer,1/42 %2.38,0/7 %0.0,0/42 %0.0
Migraine,1/42 %2.38,0/7 %0.0,0/42 %0.0
Syncope,1/42 %2.38,0/7 %0.0,1/42 %2.38
Dyspnoea,1/42 %2.38,0/7 %0.0,0/42 %0.0
Obliterative Bronchiolitis,1/42 %2.38,0/7 %0.0,0/42 %0.0
Pulmonary Embolism,1/42 %2.38,0/7 %0.0,0/42 %0.0
Laryngeal Inflammation,0/42 %0.0,0/7 %0.0,1/42 %2.38

Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173)(https://clinicaltrials.gov/show/NCT02622074)
 ,Cohort A: KNp / KAC,Cohort B: KNpCb (Regimen 1) / KAC,Cohort C: KNpCb (Regimen 2) / KAC,Cohort D: KNpCb (Regimen 3) / KAC,Cohort E: KTCb (Regimen 1) / KAC,Cohort F: KTCb (Regimen 2) / KAC
 ,Participants received pembrolizumab (K) 200 mg on Cycle 1 Day 1 followed by pembrolizumab 200 mg in Cycles 2-5 on Day 1 (once every 3 weeks; Q3W) PLUS nab-paclitaxel (KNp) starting at 125 mg/m^2 in Cycles 2-5 on Days 1 8 and 15 (once each week; QW). This was followed by pembrolizumab (K) 200 mg in Cycles 6-9 on Day 1 (Q3W) PLUS doxorubicin (A) 60 mg/m^2 in Cycles 6-9 on Day 1 (Q3W) PLUS cyclophosphamide (C) 600 mg/m^2 in Cycles 6-9 on Day 1 (Q3W). All treatments were administered via intravenous (IV) infusion except for doxorubicin (A) which was administered via IV injection. Each cycle was 21 days.,Participants first received KNpCb Regimen 1 which consisted of: pembrolizumab (K) 200 mg on Cycle 1 Day 1 PLUS nab-paclitaxel (KNp) starting at 100 mg/m^2 in Cycles 2-5 on Days 1 8 and 15 (QW) PLUS carboplatin (Cb) starting at AUC 6 in Cycles 2-5 on Day 1 (Q3W). This was followed by pembrolizumab (K) 200 mg in Cycles 6-9 on Day 1 (Q3W) PLUS doxorubicin (A) 60 mg/m^2 in Cycles 6-9 on Day 1 (Q3W) PLUS cyclophosphamide (C) 600 mg/m^2 in Cycles 6-9 on Day 1 (Q3W). All treatments were administered via IV infusion except for doxorubicin (A) which was administered via IV injection. Each cycle was 21 days.,Participants first received KNpCb Regimen 2 which consisted of: pembrolizumab (K) 200 mg on Cycle 1 Day 1 PLUS nab-paclitaxel (KNp) starting at 125 mg/m^2 in Cycles 2-5 on Days 1 8 and 15 (QW) PLUS carboplatin (Cb) starting at AUC 5 in Cycles 2-5 on Day 1 (Q3W). This was followed by pembrolizumab (K) 200 mg in Cycles 6-9 on Day 1 (Q3W) PLUS doxorubicin (A) 60 mg/m^2 in Cycles 6-9 on Day 1 (Q3W) PLUS cyclophosphamide (C) 600 mg/m^2 in Cycles 6-9 on Day 1 (Q3W). All treatments were administered via IV infusion except for doxorubicin (A) which was administered via IV injection. Each cycle was 21 days.,Participants first received KNpCb Regimen 3 which consisted of: pembrolizumab (K) 200 mg on Cycle 1 Day 1 PLUS nab-paclitaxel (KNp) starting at 125 mg/m^2 in Cycles 2-5 on Days 1 8 and 15 (QW) PLUS carboplatin (Cb) starting at AUC 2 in Cycles 2-5 on Days 1 8 and 15 (QW). This was followed by pembrolizumab (K) 200 mg in Cycles 6-9 on Day 1 PLUS doxorubicin (A) 60 mg/m^2 in Cycles 6-9 on Day 1 (Q3W) PLUS cyclophosphamide (C) 600 mg/m^2 in Cycles 6-9 on Day 1 (Q3W) in Cycles 6-9 on Day 1 (Q3W). All treatments were administered via IV infusion except for doxorubicin (A) which was administered via IV injection. Each cycle was 21 days.,Participants first received KTCb Regimen 1 which consisted of: pembrolizumab (K) 200 mg on Cycle 1 Day 1 PLUS paclitaxel (T) starting at 80mg/m^2 in Cycles 2-5 on Days 1 8 and 15 (QW) PLUS carboplatin (Cb) starting at AUC 5 in Cycles 2-5 on Day 1 (Q3W). This was followed by pembrolizumab (K) 200 mg in Cycles 6-9 on Day 1 (Q3W) PLUS doxorubicin (A) 60 mg/m^2 in Cycles 6-9 on Day 1 (Q3W) PLUS cyclophosphamide (C) 600 mg/m^2 in Cycles 6-9 on Day 1 (Q3W). All treatments were administered via IV infusion except for doxorubicin (A) which was administered via IV injection. Each cycle was 21 days.,Participants first received KTCb Regimen 2 which consisted of: pembrolizumab (K) 200 mg on Cycle 1 Day 1 PLUS paclitaxel (T) starting at 80mg/m^2 in Cycles 2-5 on Days 1 8 and 15 PLUS carboplatin (Cb) starting at AUC 2 in Cycles 2-5 on Days 1 8 and 15 (QW). This was followed by pembrolizumab (K) 200 mg in Cycles 6-9 on Day 1 (Q3W) PLUS doxorubicin (A) 60 mg/m^2 in Cycles 6-9 on Day 1 (Q3W) PLUS cyclophosphamide (C) 600 mg/m^2 in Cycles 6-9 on Day 1 (Q3W). All treatments were administered via IV infusion except for doxorubicin (A) which was administered via IV injection. Each cycle was 21 days.
Total all-cause mortality,4/10 %40.0,0/10 %0.0,0/10 %0.0,1/10 %10.0,1/10 %10.0,0/10 %0.0
Total serious adverse events,5/10 %50.0,4/10 %40.0,8/10 %80.0,7/10 %70.0,3/10 %30.0,4/10 %40.0
Anaemia,0/10 %0.0,0/10 %0.0,0/10 %0.0,0/10 %0.0,0/10 %0.0,1/10 %10.0
Febrile neutropenia,1/10 %10.0,2/10 %20.0,4/10 %40.0,4/10 %40.0,0/10 %0.0,0/10 %0.0
Lymphadenitis,0/10 %0.0,0/10 %0.0,1/10 %10.0,0/10 %0.0,0/10 %0.0,0/10 %0.0
Neutropenia,0/10 %0.0,1/10 %10.0,0/10 %0.0,0/10 %0.0,0/10 %0.0,1/10 %10.0
Abdominal pain upper,0/10 %0.0,0/10 %0.0,0/10 %0.0,0/10 %0.0,1/10 %10.0,0/10 %0.0
Colitis,0/10 %0.0,0/10 %0.0,1/10 %10.0,0/10 %0.0,0/10 %0.0,1/10 %10.0
Diarrhoea,0/10 %0.0,0/10 %0.0,0/10 %0.0,1/10 %10.0,0/10 %0.0,0/10 %0.0
Nausea,1/10 %10.0,0/10 %0.0,0/10 %0.0,0/10 %0.0,0/10 %0.0,0/10 %0.0
Oesophagitis,0/10 %0.0,0/10 %0.0,1/10 %10.0,0/10 %0.0,0/10 %0.0,0/10 %0.0
Pyrexia,0/10 %0.0,1/10 %10.0,1/10 %10.0,0/10 %0.0,1/10 %10.0,1/10 %10.0
Autoimmune hepatitis,0/10 %0.0,0/10 %0.0,0/10 %0.0,1/10 %10.0,0/10 %0.0,0/10 %0.0
Influenza,0/10 %0.0,0/10 %0.0,1/10 %10.0,0/10 %0.0,0/10 %0.0,0/10 %0.0
Neutropenic sepsis,0/10 %0.0,0/10 %0.0,0/10 %0.0,0/10 %0.0,0/10 %0.0,1/10 %10.0
Pneumocystis jirovecii pneumonia,0/10 %0.0,0/10 %0.0,0/10 %0.0,1/10 %10.0,0/10 %0.0,0/10 %0.0
Pneumonia,1/10 %10.0,0/10 %0.0,0/10 %0.0,1/10 %10.0,0/10 %0.0,1/10 %10.0
Respiratory tract infection,0/10 %0.0,0/10 %0.0,0/10 %0.0,0/10 %0.0,0/10 %0.0,1/10 %10.0
Septic shock,0/10 %0.0,0/10 %0.0,0/10 %0.0,1/10 %10.0,0/10 %0.0,0/10 %0.0
Tooth infection,0/10 %0.0,1/10 %10.0,0/10 %0.0,0/10 %0.0,0/10 %0.0,0/10 %0.0
Urinary tract infection,0/10 %0.0,0/10 %0.0,1/10 %10.0,0/10 %0.0,0/10 %0.0,0/10 %0.0
Tendon rupture,0/10 %0.0,0/10 %0.0,1/10 %10.0,0/10 %0.0,0/10 %0.0,0/10 %0.0
Alanine aminotransferase increased,1/10 %10.0,0/10 %0.0,0/10 %0.0,0/10 %0.0,0/10 %0.0,0/10 %0.0
Aspartate aminotransferase increased,1/10 %10.0,0/10 %0.0,0/10 %0.0,0/10 %0.0,0/10 %0.0,0/10 %0.0
Blood creatinine increased,0/10 %0.0,0/10 %0.0,0/10 %0.0,1/10 %10.0,0/10 %0.0,0/10 %0.0
White blood cell count decreased,0/10 %0.0,0/10 %0.0,0/10 %0.0,1/10 %10.0,0/10 %0.0,0/10 %0.0
Decreased appetite,1/10 %10.0,0/10 %0.0,0/10 %0.0,0/10 %0.0,0/10 %0.0,0/10 %0.0
Back pain,0/10 %0.0,0/10 %0.0,0/10 %0.0,0/10 %0.0,1/10 %10.0,0/10 %0.0
Autonomic neuropathy,0/10 %0.0,0/10 %0.0,1/10 %10.0,0/10 %0.0,0/10 %0.0,0/10 %0.0
Brachial plexopathy,0/10 %0.0,0/10 %0.0,0/10 %0.0,0/10 %0.0,1/10 %10.0,0/10 %0.0
Ischaemic stroke,0/10 %0.0,0/10 %0.0,0/10 %0.0,1/10 %10.0,0/10 %0.0,0/10 %0.0
Subacute cutaneous lupus erythematosus,0/10 %0.0,0/10 %0.0,0/10 %0.0,1/10 %10.0,0/10 %0.0,0/10 %0.0
Deep vein thrombosis,0/10 %0.0,1/10 %10.0,0/10 %0.0,0/10 %0.0,0/10 %0.0,0/10 %0.0
Orthostatic hypotension,0/10 %0.0,0/10 %0.0,1/10 %10.0,0/10 %0.0,0/10 %0.0,0/10 %0.0

A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer(https://clinicaltrials.gov/show/NCT02631876)
 ,Mirvetuximab Soravtansine,Investigator's Choice (IC) Chemotherapy
 ,Participants received mirvetuximab soravtansine at 6 mg/kg AIBW administered IV on Day 1 of a 3 week cycle. Participants continued to receive study drug until they experienced PD per RECIST version 1.1 (as assessed by BIRC) experienced unacceptable toxicity or withdrew consent whichever came first or until the sponsor terminated the study. (Maximum exposure: 86.9 weeks),Participants received a dose of IC chemotherapeutic agent calculated using BSA. Paclitaxel administered at 80 mg/m^2 as a 1-hour IV infusion on Days 1 8 15 and 22 of a 4-week cycle; or topotecan administered at 4 mg/m^2 over 30 minutes on Days 1 8 and 15 of a 4-week cycle. Alternatively topotecan could have been administered at 1.25 mg/m^2 over 30 minutes on Days 1 to 5 of a 3-week cycle; or pegylated liposomal doxorubicin administered at 40 mg/m^2 as a 1 mg/minute IV infusion on Day 1 of a 4-week cycle. After Cycle 1 if tolerated pegylated liposomal doxorubicin could have been administered as a 1-hour infusion. Participants continued to receive study drug until they experienced PD per RECIST version 1.1 (as assessed by BIRC) experienced unacceptable toxicity or withdrew consent whichever came first or until the sponsor terminated the study. (Maximum exposure: 62.9 weeks)
Total all-cause mortality,96/243 %39.51,50/109 %45.87
Total serious adverse events,67/243 %27.57,31/109 %28.44
Anaemia,0/243 %0.0,1/109 %0.92
Febrile neutropenia,0/243 %0.0,1/109 %0.92
Cardiac arrest,2/243 %0.82,0/109 %0.0
Eye pain,1/243 %0.41,0/109 %0.0
Punctate keratitis,1/243 %0.41,0/109 %0.0
Intestinal obstruction,10/243 %4.12,3/109 %2.75
Small intestinal obstruction,5/243 %2.06,4/109 %3.67
Constipation,4/243 %1.65,1/109 %0.92
Large intestinal obstruction,4/243 %1.65,2/109 %1.83
Abdominal pain,2/243 %0.82,2/109 %1.83
Nausea,2/243 %0.82,1/109 %0.92
Vomiting,2/243 %0.82,2/109 %1.83
Abdominal incarcerated hernia,1/243 %0.41,0/109 %0.0
Abdominal pain upper,1/243 %0.41,0/109 %0.0
Ascites,1/243 %0.41,2/109 %1.83
Gastritis,1/243 %0.41,0/109 %0.0
Intestinal perforation,1/243 %0.41,0/109 %0.0
Asthenia,1/243 %0.41,0/109 %0.0
Complication associated with device,1/243 %0.41,0/109 %0.0
Systemic inflammatory response syndrome,1/243 %0.41,1/109 %0.92
Fatigue,0/243 %0.0,1/109 %0.92
General physical health deterioration,0/243 %0.0,1/109 %0.92
Pyrexia,0/243 %0.0,3/109 %2.75
Cholecystitis acute,0/243 %0.0,1/109 %0.92
Sepsis,3/243 %1.23,3/109 %2.75
Urinary tract infection,2/243 %0.82,1/109 %0.92
Campylobacter gastroenteritis,1/243 %0.41,0/109 %0.0
Gastroenteritis viral,1/243 %0.41,0/109 %0.0
Influenza,1/243 %0.41,0/109 %0.0
Oesophageal infection,1/243 %0.41,0/109 %0.0
Pyelonephritis,1/243 %0.41,0/109 %0.0
Systemic infection,1/243 %0.41,0/109 %0.0
Upper respiratory tract infection,1/243 %0.41,0/109 %0.0
Urosepsis,1/243 %0.41,1/109 %0.92
Vestibular neuronitis,1/243 %0.41,0/109 %0.0
Salmonellosis,0/243 %0.0,1/109 %0.92
Acetabulum fracture,1/243 %0.41,0/109 %0.0
Facial bones fracture,1/243 %0.41,0/109 %0.0
Infusion related reaction,1/243 %0.41,0/109 %0.0
Lumbar vertebral fracture,1/243 %0.41,0/109 %0.0
Rib fracture,1/243 %0.41,0/109 %0.0
Subdural haematoma,1/243 %0.41,0/109 %0.0
Hip fracture,0/243 %0.0,1/109 %0.92
Dehydration,4/243 %1.65,0/109 %0.0
Failure to thrive,1/243 %0.41,0/109 %0.0
Hypocalcaemia,1/243 %0.41,0/109 %0.0
Hypokalaemia,1/243 %0.41,0/109 %0.0
Hyponatraemia,1/243 %0.41,0/109 %0.0
Decreased appetite,0/243 %0.0,1/109 %0.92
Malignant pleural effusion,1/243 %0.41,0/109 %0.0
Tumour obstruction,1/243 %0.41,0/109 %0.0
Syncope,2/243 %0.82,0/109 %0.0
Headache,1/243 %0.41,0/109 %0.0
Presyncope,1/243 %0.41,0/109 %0.0
Cerebrovascular accident,0/243 %0.0,1/109 %0.92
Mania,0/243 %0.0,1/109 %0.92
Hydronephrosis,1/243 %0.41,0/109 %0.0
Urinary tract obstruction,0/243 %0.0,1/109 %0.92
Pneumonitis,7/243 %2.88,2/109 %1.83
Pleural effusion,5/243 %2.06,3/109 %2.75
Pulmonary embolism,3/243 %1.23,0/109 %0.0
Dyspnoea,2/243 %0.82,2/109 %1.83
Pneumonia aspiration,1/243 %0.41,0/109 %0.0
Pneumothorax,1/243 %0.41,0/109 %0.0
Embolism,1/243 %0.41,0/109 %0.0

First-in-Human Study of the Safety  Tolerability  and Pharmacokinetic/Pharmacodynamic Profile of VX-984 in Combination With Chemotherapy(https://clinicaltrials.gov/show/NCT02644278)
 ,VX-984 120 mg + PLD 40 mg/m^2,VX-984 240 mg + PLD 40 mg/m^2,VX-984 480 mg + PLD 40 mg/m^2,VX-984 720 mg + PLD 40 mg/m^2
 ,Participants received VX-984 orally 120 milligram (mg) once daily alone on Days -14 to -12 of a 14-day Lead-in Period followed by VX-984 120 mg in combination with pegylated liposomal doxorubicin (PLD) 40 milligram per square meter (mg/m^2) administered intravenous infusion with PLD administered on Day 1 and VX-984 administered on Day 2 to Day 4 for up to six 28-day cycle or until disease progression unacceptable toxicities withdrawal of consent or until exposure to PLD exceeded 550 mg/m^2.,Participants received VX-984 orally 240 mg orally once daily alone on Days -14 to -12 of a 14-day Lead-in Period followed by VX-984 240 mg in combination with PLD 40 mg/m^2 administered intravenous infusion with PLD administered on Day 1 and VX-984 administered on Day 2 to Day 4 for up to six 28-day cycle or until disease progression unacceptable toxicities withdrawal of consent or until exposure to PLD exceeded 550 mg/m^2.,Participants received VX-984 orally 480 mg orally once daily alone on Days -14 to -12 of a 14-day Lead-in Period followed by VX-984 480 mg in combination with PLD 40 mg/m^2 administered intravenous infusion with PLD administered on Day 1 and VX-984 administered on Day 2 to Day 4 for up to six 28-day cycle or until disease progression unacceptable toxicities withdrawal of consent or until exposure to PLD exceeded 550 mg/m^2.,Participants received VX-984 orally 720 mg orally once daily alone on Days -14 to -12 of a 14-day Lead-in Period followed by VX-984 720 mg in combination with PLD 40 mg/m^2 administered intravenous infusion with PLD administered on Day 1 and VX-984 administered on Day 2 to Day 4 for up to six 28-day cycle or until disease progression unacceptable toxicities withdrawal of consent or until exposure to PLD exceeded 550 mg/m^2.
Total all-cause mortality,0/3 %0.0,0/3 %0.0,2/6 %33.33,0/3 %0.0
Total serious adverse events,2/3 %66.67,0/3 %0.0,3/6 %50.0,1/3 %33.33
Abdominal pain,2/3 %66.67,0/3 %0.0,0/6 %0.0,0/3 %0.0
Nausea,1/3 %33.33,0/3 %0.0,1/6 %16.67,0/3 %0.0
Small intestinal obstruction,1/3 %33.33,0/3 %0.0,0/6 %0.0,1/3 %33.33
Lung infection,0/3 %0.0,0/3 %0.0,1/6 %16.67,0/3 %0.0
Sepsis,0/3 %0.0,0/3 %0.0,1/6 %16.67,0/3 %0.0
Cancer pain,1/3 %33.33,0/3 %0.0,0/6 %0.0,0/3 %0.0
Pleural effusion,0/3 %0.0,0/3 %0.0,1/6 %16.67,0/3 %0.0
Pulmonary embolism,0/3 %0.0,0/3 %0.0,1/6 %16.67,0/3 %0.0
Deep vein thrombosis,0/3 %0.0,0/3 %0.0,1/6 %16.67,0/3 %0.0

A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer(https://clinicaltrials.gov/show/NCT02677116)
 ,Olaratumab + Vincristine + Irinotecan (Part A),Olaratumab + Ifosfamide (Part A),Olaratumab + Doxorubicin (Part A),Olaratumab + Vincristine + Irinotecan (Part B),Olaratumab + Ifosfamide (Part B),Olaratumab + Doxorubicin (Part B),Olaratumab + Vincristine + Irinotecan (Part C),Olaratumab + Ifosfamide (Part C),Olaratumab + Doxorubicin (Part C)
 ,Cycle 1: Olaratumab 15 mg/kg was administered alone IV on Days 1 and 8.  Cycle 2 and beyond: Olaratumab 15 mg/kg and vincristine administered IV on Days 1 and 8. Irinotecan administered IV on Days 1 through 5. Treatment will cease when discontinuation criterion is met.  All cycles are 21 days.,Cycle 1: Olaratumab 15 mg/kg was administered alone IV on Days 1 and 8. Cycle 2 and beyond: Olaratumab 15 mg/kg administered IV on Days 1 and 8 of each cycle. Ifosfamide administered IV on Days 1 through 5. Treatment will cease when discontinuation criterion is met.  All cycles are 21 days.,Cycle 1: Olaratumab 15 mg/kg was administered alone IV on Days 1 and 8. Cycle 2 and beyond: Olaratumab 15 mg/kg administered IV on Days 1 and 8 and doxorubicin administered IV on Days 1 and 2. Treatment will cease when discontinuation criterion is met.  All cycles are 21 days.,Cycle 1: Olaratumab 20 mg/kg administered alone IV on Days 1 and 8. Cycle 2 and beyond: Olaratumab 20 mg/kg and vincristine administered IV on Days 1 and 8. Irinotecan administered IV on Days 1 through 5. Treatment will cease when discontinuation criterion is met.  All cycles are 21 days.,Cycle 1: Olaratumab 20 mg/kg was administered alone IV on Days 1 and 8.  Cycle 2 and beyond: Olaratumab 20 mg/kg administered IV on Days 1 and 8 of each cycle. Ifosfamide administered IV on Days 1 through 5. Treatment will cease when discontinuation criterion is met.  All cycles are 21 days.,Cycle 1: Olaratumab 20 mg/kg alone was administered alone IV on Days 1 and 8. Cycle 2 and beyond: Olaratumab 20 mg/kg administered IV on Days 1 and 8 and doxorubicin administered IV on Days 1 and 2. Treatment will cease when discontinuation criterion is met.  All cycles are 21 days.,Cycle 1 and beyond: Olaratumab 20 mg/kg and vincristine administered IV on Days 1 and 8. Irinotecan administered IV on Days 1 through 5. Treatment will cease when discontinuation criterion is met.  All cycles are 21 days.,Cycle 1 and beyond: Olaratumab 20 mg/kg administered IV on Days 1 and 8 of each cycle. Ifosfamide administered IV on Days 1 through 5. Treatment will cease when discontinuation criterion is met.  All cycles are 21 days.,Cycle 1 and beyond: Olaratumab 20 mg/kg administered IV on Days 1 and 8 and doxorubicin administered IV on Days 1 and 2. Treatment will cease when discontinuation criterion is met.  All cycles are 21 days.
Total all-cause mortality,2/10 %20.0,1/9 %11.11,2/11 %18.18,2/10 %20.0,2/13 %15.38,0/1 %0.0,0/6 %0.0,0/4 %0.0,0/4 %0.0
Total serious adverse events,3/10 %30.0,4/9 %44.44,2/11 %18.18,5/10 %50.0,7/13 %53.85,0/1 %0.0,2/6 %33.33,1/4 %25.0,4/4 %100.0
Anaemia,0/10 %0.0,2/9 %22.22,0/11 %0.0,0/10 %0.0,0/13 %0.0,0/1 %0.0,0/6 %0.0,0/4 %0.0,0/4 %0.0
Febrile neutropenia,0/10 %0.0,0/9 %0.0,0/11 %0.0,1/10 %10.0,6/13 %46.15,0/1 %0.0,1/6 %16.67,1/4 %25.0,2/4 %50.0
Methaemoglobinaemia,1/10 %10.0,0/9 %0.0,0/11 %0.0,0/10 %0.0,0/13 %0.0,0/1 %0.0,0/6 %0.0,0/4 %0.0,0/4 %0.0
Abdominal pain lower,0/10 %0.0,0/9 %0.0,1/11 %9.09,0/10 %0.0,0/13 %0.0,0/1 %0.0,0/6 %0.0,0/4 %0.0,0/4 %0.0
Diarrhoea,0/10 %0.0,0/9 %0.0,0/11 %0.0,3/10 %30.0,0/13 %0.0,0/1 %0.0,1/6 %16.67,0/4 %0.0,0/4 %0.0
Nausea,0/10 %0.0,0/9 %0.0,0/11 %0.0,0/10 %0.0,1/13 %7.69,0/1 %0.0,0/6 %0.0,0/4 %0.0,0/4 %0.0
Vomiting,0/10 %0.0,0/9 %0.0,0/11 %0.0,1/10 %10.0,0/13 %0.0,0/1 %0.0,0/6 %0.0,0/4 %0.0,0/4 %0.0
Pain,0/10 %0.0,0/9 %0.0,0/11 %0.0,1/10 %10.0,0/13 %0.0,0/1 %0.0,0/6 %0.0,0/4 %0.0,0/4 %0.0
Abdominal infection,0/10 %0.0,0/9 %0.0,0/11 %0.0,0/10 %0.0,0/13 %0.0,0/1 %0.0,0/6 %0.0,0/4 %0.0,1/4 %25.0
Influenza,0/10 %0.0,0/9 %0.0,1/11 %9.09,0/10 %0.0,0/13 %0.0,0/1 %0.0,0/6 %0.0,0/4 %0.0,0/4 %0.0
Lung infection,1/10 %10.0,0/9 %0.0,0/11 %0.0,1/10 %10.0,0/13 %0.0,0/1 %0.0,0/6 %0.0,0/4 %0.0,0/4 %0.0
Penile infection,0/6 %0.0,1/7 %14.29,0/8 %0.0,0/4 %0.0,0/7 %0.0,0/1 %0.0,0/2 %0.0,0/3 %0.0,0/2 %0.0
Urinary tract infection,0/10 %0.0,1/9 %11.11,0/11 %0.0,0/10 %0.0,0/13 %0.0,0/1 %0.0,0/6 %0.0,0/4 %0.0,0/4 %0.0
Shunt occlusion,1/10 %10.0,0/9 %0.0,0/11 %0.0,0/10 %0.0,0/13 %0.0,0/1 %0.0,0/6 %0.0,0/4 %0.0,0/4 %0.0
Tibia fracture,0/10 %0.0,0/9 %0.0,0/11 %0.0,1/10 %10.0,0/13 %0.0,0/1 %0.0,0/6 %0.0,0/4 %0.0,0/4 %0.0
Alanine aminotransferase increased,0/10 %0.0,1/9 %11.11,0/11 %0.0,0/10 %0.0,0/13 %0.0,0/1 %0.0,0/6 %0.0,0/4 %0.0,0/4 %0.0
Aspartate aminotransferase increased,0/10 %0.0,1/9 %11.11,0/11 %0.0,0/10 %0.0,0/13 %0.0,0/1 %0.0,0/6 %0.0,0/4 %0.0,0/4 %0.0
Neutrophil count decreased,0/10 %0.0,1/9 %11.11,1/11 %9.09,0/10 %0.0,0/13 %0.0,0/1 %0.0,0/6 %0.0,0/4 %0.0,0/4 %0.0
Staphylococcus test positive,0/10 %0.0,0/9 %0.0,0/11 %0.0,0/10 %0.0,0/13 %0.0,0/1 %0.0,1/6 %16.67,0/4 %0.0,0/4 %0.0
Dehydration,0/10 %0.0,0/9 %0.0,0/11 %0.0,2/10 %20.0,0/13 %0.0,0/1 %0.0,0/6 %0.0,0/4 %0.0,0/4 %0.0
Arthralgia,0/10 %0.0,0/9 %0.0,1/11 %9.09,1/10 %10.0,0/13 %0.0,0/1 %0.0,0/6 %0.0,0/4 %0.0,0/4 %0.0
Pain in extremity,0/10 %0.0,0/9 %0.0,0/11 %0.0,1/10 %10.0,0/13 %0.0,0/1 %0.0,0/6 %0.0,0/4 %0.0,0/4 %0.0
Tumour pain,0/10 %0.0,0/9 %0.0,0/11 %0.0,0/10 %0.0,1/13 %7.69,0/1 %0.0,0/6 %0.0,0/4 %0.0,0/4 %0.0
Hydrocephalus,0/10 %0.0,1/9 %11.11,0/11 %0.0,0/10 %0.0,0/13 %0.0,0/1 %0.0,0/6 %0.0,0/4 %0.0,0/4 %0.0
Seizure,0/10 %0.0,1/9 %11.11,0/11 %0.0,0/10 %0.0,0/13 %0.0,0/1 %0.0,0/6 %0.0,0/4 %0.0,0/4 %0.0
Acute kidney injury,0/10 %0.0,0/9 %0.0,0/11 %0.0,1/10 %10.0,0/13 %0.0,0/1 %0.0,0/6 %0.0,0/4 %0.0,0/4 %0.0
Urinary retention,0/10 %0.0,0/9 %0.0,0/11 %0.0,0/10 %0.0,0/13 %0.0,0/1 %0.0,0/6 %0.0,0/4 %0.0,1/4 %25.0
Aspiration,0/10 %0.0,1/9 %11.11,0/11 %0.0,0/10 %0.0,0/13 %0.0,0/1 %0.0,0/6 %0.0,0/4 %0.0,0/4 %0.0
Hypoxia,0/10 %0.0,1/9 %11.11,0/11 %0.0,0/10 %0.0,1/13 %7.69,0/1 %0.0,0/6 %0.0,0/4 %0.0,0/4 %0.0
Pneumothorax,0/10 %0.0,0/9 %0.0,0/11 %0.0,0/10 %0.0,1/13 %7.69,0/1 %0.0,0/6 %0.0,0/4 %0.0,0/4 %0.0
Vena cava thrombosis,0/10 %0.0,0/9 %0.0,0/11 %0.0,0/10 %0.0,0/13 %0.0,0/1 %0.0,1/6 %16.67,0/4 %0.0,0/4 %0.0

Pharmacokinetics of Doxorubicin in cTACE of Liver Cancer(https://clinicaltrials.gov/show/NCT02753881)
 ,Superselective cTACE Doxorubicin (One Segment),Superselective cTACE (2+ Segments),Whole Liver Lobe cTACE Doxorubicin
 ,Participants in this arm are administered 10 cc of chemotherapy with 50mg doxorubicin and 10 mg of mitomycin-C via Lipiodol cTACE delivered in a super-selective (close to the tumor) manner.  superselective cTACE doxorubicin: Doxorubicin CTACE administered in a super-selective (close to the tumor) manner. Lipiodol delivered to single segment.,Participants in this arm are administered 10 cc of chemotherapy with 50mg doxorubicin and 10 mg of mitomycin-C via Lipiodol cTACE delivered in a super-selective (close to the tumor) manner.  superselective cTACE doxorubicin: Doxorubicin CTACE administered in a super-selective (close to the tumor) manner. Lipiodol distributed to multiple segments.,Participants in this arm are administered 10 cc of chemotherapy with 50mg doxorubicin and 10 mg of mitomycin-C via Lipiodol cTACE delivered in a lobar (whole liver) manner.  whole liver lobe cTACE doxorubicin: Doxorubicin CTACE administered in a whole liver lobe manner. Lipiodol distributed to entire liver lobe.
Total all-cause mortality,1/10 %10.0,0/10 %0.0,0/10 %0.0
Total serious adverse events,1/10 %10.0,1/10 %10.0,0/10 %0.0
Cardiac arrest,1/10 %10.0,0/10 %0.0,0/10 %0.0
Hyponatremia,0/10 %0.0,1/10 %10.0,0/10 %0.0

Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma(https://clinicaltrials.gov/show/NCT02788201)
 ,Doxorubicin 75mg/m^2,Paclitaxel 100 mg/m^2 and Erlotinib 150 mg,Paclitaxel 135mg/m^2 and Doxorubicin 40mg/m^2,Sunitinib 50mg,Vorinostat 500mg and Etoposide 100mg/m^2 and 60mg/m^2,Participants Who Were Enrolled But Not Treated
 ,All participants that received Doxorubicin 75mg/m^2.,All participants that received Paclitaxel 100 mg/m^2 and Erlotinib 150 mg.,All participants that received Paclitaxel 135mg/m^2 and Doxorubicin 40mg/m^2.,All participants that received Sunitinib 50mg.,All participants that received Vorinostat 500mg and Etoposide 100mg/m^2 and 60mg/m^2.,3 participants were enrolled and signed consent to this study but never started treatment. Treatment was assigned on course initiation.
Total all-cause mortality,1/1 %100.0,1/1 %100.0,1/1 %100.0,1/1 %100.0,0/1 %0.0,1/1 %100.0
Total serious adverse events,1/1 %100.0,1/1 %100.0,1/1 %100.0,1/1 %100.0,1/1 %100.0,0/0 %0.0
Febrile neutropenia,0/1 %0.0,0/1 %0.0,0/1 %0.0,0/1 %0.0,1/1 %100.0,0/0 %0.0
Death NOS,1/1 %100.0,1/1 %100.0,1/1 %100.0,1/1 %100.0,0/1 %0.0,0/0 %0.0

Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma(https://clinicaltrials.gov/show/NCT02855359)
 ,Denintuzumab Mafodotin + RCHP,Denintuzumab Mafodotin + RCHOP
 ,Part A: denintuzumab mafodotin (SGN-CD19A) + RCHP (rituximab cyclophosphamide doxorubicin and prednisone)  denintuzumab mafodotin: SGN-CD19A at 3 mg/kg will be administered every 6 weeks via intravenous (IV) infusion up to a maximum of three (3) doses on Day 1 of Cycles 1 3 and 5 of 21-day cycles  rituximab: 375 mg/m2 every 3 weeks by IV infusion for up to 6 cycles  cyclophosphamide: 750 mg/m2 every 3 weeks by IV infusion for up to 6 cycles  doxorubicin: 50 mg/m2 every 3 weeks by IV infusion for up to 6 cycles  prednisone: 100 mg on Days 1 to 5 of each 3-week cycle orally for up to 6 cycles,Part A: denintuzumab mafodotin (SGN-CD19A) + RCHOP (rituximab cyclophosphamide doxorubicin vincristine and prednisone)  denintuzumab mafodotin: SGN-CD19A at 3 mg/kg will be administered every 6 weeks via intravenous (IV) infusion up to a maximum of three (3) doses on Day 1 of Cycles 1 3 and 5 of 21-day cycles  rituximab: 375 mg/m2 every 3 weeks by IV infusion for up to 6 cycles  cyclophosphamide: 750 mg/m2 every 3 weeks by IV infusion for up to 6 cycles  doxorubicin: 50 mg/m2 every 3 weeks by IV infusion for up to 6 cycles  vincristine: 1.4 mg/m2 every 3 weeks by IV infusion for up to 6 cycles (dose capped at 2 mg total)  prednisone: 100 mg on Days 1 to 5 of each 3-week cycle orally for up to 6 cycles
Total all-cause mortality,2/11 %18.18,2/13 %15.38
Total serious adverse events,5/11 %45.45,4/13 %30.77
Febrile neutropenia,2/11 %18.18,3/13 %23.08
Neutropenia,0/11 %0.0,1/13 %7.69
Thrombocytopenia,0/11 %0.0,1/13 %7.69
Coronary artery disease,0/11 %0.0,1/13 %7.69
Palpitations,1/11 %9.09,0/13 %0.0
Asthenia,1/11 %9.09,0/13 %0.0
Fatigue,0/11 %0.0,1/13 %7.69
Pyrexia,0/11 %0.0,1/13 %7.69
Pneumocystis jirovecii pneumonia,0/11 %0.0,1/13 %7.69
Pneumonia bacterial,1/11 %9.09,0/13 %0.0
Septic shock,0/11 %0.0,1/13 %7.69
Staphylococcal bacteraemia,0/11 %0.0,1/13 %7.69
Tumour lysis syndrome,1/11 %9.09,0/13 %0.0
Arthralgia,0/11 %0.0,1/13 %7.69
Cerebrovascular accident,1/11 %9.09,0/13 %0.0
Acute kidney injury,1/11 %9.09,0/13 %0.0
Pneumonia aspiration,1/11 %9.09,0/13 %0.0
Pulmonary embolism,0/11 %0.0,1/13 %7.69
Respiratory failure,0/11 %0.0,1/13 %7.69
Hypotension,1/11 %9.09,1/13 %7.69

A Trial of Systemic Chemotherapy in Combination With Conventional Transarterial Chemoembolization in Patients With Advanced Intra-Hepatic Cholangiocarcinoma(https://clinicaltrials.gov/show/NCT02994251)
 ,All Subjects
 ,Patients must have advanced unresectable intrahepatic cholangiocarcinoma (ICC) defined as biopsy-confirmed adenocarcinoma in the liver with an immunohistochemical profile consistent with a pancreatico-biliary primary not involving the common bile duct or bifurcation and not amenable to surgical resection.  gemcitabine: 1000 mg/m^2 of gemcitabine on Day 1 and 8 Dosages may be modified or delayed due to toxicities  Cisplatin: 25 mg/m^2 on Day 1 and 8 Dosages may be modified or delayed due to toxicities  Conventional TACE (transarterial chemoembolization) with Doxorubicin/Mitomycin-C: If conventional transarterial chemoembolization (TACE) is warranted based on MRI assessment and the patient meets all the eligibility criteria for TACE therapy then cTACE will be scheduled to take place during Week 3 of that cycle. Patients will always receive the first cTACE for study; follow-up cTACE will occur on demand.
Total all-cause mortality,0/0 %0.0
Total serious adverse events,0/0 %0.0

A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma(https://clinicaltrials.gov/show/NCT03003520)
 ,DUR + R-CHOP,DUR + R2-CHOP
 ,On Day 1 of each 21-day cycle participants received durvalumab 1125 mg intravenously (IV) followed by R-CHOP (IV rituximab 375 mg/m^2 doxorubicin 50 mg/m^2 vincristine 1.4 mg/m^2 (maximum dose of 2.0 mg total) cyclophosphamide 750 mg/m^2; and daily oral or IV prednisone/prednisolone 100 mg on Days 1 to 5. Induction treatment continued for a total of 6-8 cycles. Participants who achieve a complete response or partial response continue with consolidation therapy treatment and receive durvalumab monotherapy 1500 mg by IV on Day 1 of each 28-day cycle for up to a total of 12 months.,Participants start the study on durvalumab in combination with R-CHOP (as described in Arm DUR + R-CHOP). Based on their DLBCL Cell-of-Origin subtype (test typically done between cycles 1 and 2) participants with ABC subtype continue the study taking durvalumab in combination with R2-CHOP. On Day 1 of each 21-day cycle participants received durvalumab 1125 mg IV followed by R-CHOP. In addition participants receive oral lenalidomide 15 mg by mouth on Days 1 to 14 of each 21-day cycle. Induction treatment continued for a total of 6-8 cycles. Participants who achieve a complete response or partial response continue with consolidation therapy treatment and receive durvalumab monotherapy 1500 mg by IV on Day 1 of each 28-day cycle for up to a total of 12 months.  Enrollment into Arm B was discontinued.
Total all-cause mortality,2/43 %4.65,1/3 %33.33
Total serious adverse events,22/43 %51.16,1/3 %33.33
Anaemia,1/43 %2.33,0/3 %0.0
Febrile neutropenia,6/43 %13.95,1/3 %33.33
Histiocytosis haematophagic,1/43 %2.33,0/3 %0.0
Leukopenia,1/43 %2.33,0/3 %0.0
Neutropenia,1/43 %2.33,0/3 %0.0
Pancytopenia,1/43 %2.33,0/3 %0.0
Atrial fibrillation,2/43 %4.65,0/3 %0.0
Cardiac arrest,1/43 %2.33,0/3 %0.0
Myocardial ischaemia,1/43 %2.33,0/3 %0.0
Nausea,2/43 %4.65,0/3 %0.0
Vomiting,1/43 %2.33,0/3 %0.0
Fatigue,1/43 %2.33,0/3 %0.0
General physical health deterioration,2/43 %4.65,0/3 %0.0
Pyrexia,3/43 %6.98,0/3 %0.0
Autoimmune hepatitis,1/43 %2.33,0/3 %0.0
Device related infection,1/43 %2.33,0/3 %0.0
Infection,2/43 %4.65,0/3 %0.0
Influenza,2/43 %4.65,0/3 %0.0
Perirectal abscess,1/43 %2.33,0/3 %0.0
Pneumonia,2/43 %4.65,0/3 %0.0
Viral diarrhoea,1/43 %2.33,0/3 %0.0
Infusion related reaction,1/43 %2.33,0/3 %0.0
Hyponatraemia,1/43 %2.33,0/3 %0.0
Spinal pain,1/43 %2.33,0/3 %0.0
Clear cell renal cell carcinoma,1/43 %2.33,0/3 %0.0
Lymphoma,1/43 %2.33,0/3 %0.0
Tumour pain,1/43 %2.33,0/3 %0.0
Cerebrovascular accident,1/43 %2.33,0/3 %0.0
Acute kidney injury,1/43 %2.33,0/3 %0.0
Seborrhoeic dermatitis,1/43 %2.33,0/3 %0.0
Deep vein thrombosis,1/43 %2.33,0/3 %0.0
Venous thrombosis,1/43 %2.33,0/3 %0.0

Safety and Efficacy of Blinatumomab in Adults With Newly Diagnosed High-risk Diffuse Large B-Cell Lymphoma(https://clinicaltrials.gov/show/NCT03023878)
 ,Blinatumomab
 ,Blinatumomab was administered as a continuous intravenous (IV) infusion. Cycle 1 was 12 weeks (84 days) in duration with step dosing of 9 g/day for 7 days 28 g/day for 7 days 112 g/day for 6 weeks followed by a 4-week treatment free time.  An optional 4-week Cycle 2 of blinatumomab was available for participants whose disease did not progress with step dosing of 9 g/day for 7 days 28 g/day for 7 days and 112 g/day for 14 days.  There was a safety follow-up for 30 days. And a long-term follow-up of up to 8 months for a maximum of 1 year from first dose of blinatumomab or until participant death.
Total all-cause mortality,3/47 %6.38
Total serious adverse events,7/28 %25.0
Neutropenia,1/28 %3.57
Pyrexia,2/28 %7.14
Bacteraemia,1/28 %3.57
Pneumonia,1/28 %3.57
Sepsis,1/28 %3.57
Aphasia,1/28 %3.57
Neurotoxicity,1/28 %3.57

Pembrolizumab  Chemotherapy  and Radiation Therapy With or Without Surgery in Treating Patients With Anaplastic Thyroid Cancer(https://clinicaltrials.gov/show/NCT03211117)
 ,Cohort B (Pembrolizumab Chemoradiation),Cohort A
 ,Pembrolizumab: Given IV,Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment with pembrolizumab repeats every 21 days for up to 17 courses after chemoradiation if no residual disease is found or for up to 35 courses after chemoradiation if residual disease is found. After 3 days patients undergo surgery. Within 42 days of surgery patients also receive docetaxel IV over 1 hour Q1W and doxorubicin hydrochloride IV Q1W and undergo IMRT once daily 5 days per week for 6.5 weeks in the absence of disease progression or unacceptable toxicity.  Docetaxel: Given IV Doxorubicin Hydrochloride: Given IV Intensity-Modulated Radiation Therapy: Undergo IMRT Laboratory Biomarker Analysis: Correlative studies Pembrolizumab: Given IV Therapeutic Conventional Surgery: Undergo surgery
Total all-cause mortality,3/3 %100.0,0/0 %0.0
Total serious adverse events,3/3 %100.0,0/0 %0.0
Anemia,1/3 %33.33,0/0 %0.0
Enterocolitis,1/3 %33.33,0/0 %0.0
Nausea,1/3 %33.33,0/0 %0.0
Vomiting,1/3 %33.33,0/0 %0.0
Fever,1/3 %33.33,0/0 %0.0
Infections and infestations - Other specify,1/3 %33.33,0/0 %0.0
Lung infection,1/3 %33.33,0/0 %0.0
Sepsis,1/3 %33.33,0/0 %0.0
Urinary tract infection,1/3 %33.33,0/0 %0.0
Dehydration,1/3 %33.33,0/0 %0.0
Hyperglycemia,1/3 %33.33,0/0 %0.0
Hypophosphatemia,1/3 %33.33,0/0 %0.0
Generalized muscle weakness,1/3 %33.33,0/0 %0.0
Dyspnea,1/3 %33.33,0/0 %0.0
Laryngeal edema,1/3 %33.33,0/0 %0.0
Pneumonitis,2/3 %66.67,0/0 %0.0
Respiratory failure,2/3 %66.67,0/0 %0.0
Hypotension,1/3 %33.33,0/0 %0.0

PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma(https://clinicaltrials.gov/show/NCT03226249)
 ,Treatment: Pembrolizumab and AVD Chemotherapy Guided by PET-CT
 ,All patients get 3 cycles (21-days each) of pembrolizumab (PEM) induction then a PET-CT (PET#2). PET#2 required for primary endpoint analysis. Patients evaluable for response assessment if they had at least one dose of PEM.  After all patients get 2 cycles (28-days each) of AVD (doxorubicin vinblastine dacarbazine) followed by an interim PET-CT (PET#3) for response analysis.  Depending on age stage and PET#3 results per Deauville (DV) Score patients get additional 2-4 cycles of AVD or AVD and escBEACOPP (escalated bleomycin etoposide doxorubicin cyclophosphamide vincristine procarbazine prednisone) + radiotherapy (RT). Then patients will have a PET-CT (PET#4) or a CT (CT if Stage I/II disease and negative for PET#3).  Patients under 60 go to survival follow-up. Patients over 60 go to survival follow-up or 1-2 years of PEM consolidation based on bulky vs non bulky disease results of the PET#3 and the number of AVD cycles received.  See schema for details.
Total all-cause mortality,0/30 %0.0
Total serious adverse events,6/30 %20.0
Febrile Neutropenia,1/30 %3.33
Febrile Neutropenia,2/30 %6.67
Pericarditis,1/30 %3.33
Fever,1/30 %3.33
Facial nerve disorder,1/30 %3.33

A Study of Olaratumab (LY3012207)  Doxorubicin  and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma(https://clinicaltrials.gov/show/NCT03283696)
 ,Olaratumab 15 mg/kg + Doxorubicin + Ifosfamide,Olaratumab 20 mg/kg + Doxorubicin + Ifosfamide
 ,Participants received olaratumab 15 mg/kg on days 1 8 plus doxorubicin 25 mg/m^2 on days 1 2 3 plus ifosfamide 2.5 g/m^2 per day on days 1 2 3 4 plus mesna dose  60% of ifosfamide dose on days 1 2 3 of a 21-day cycle for a maximum of 6 cycles or until a discontinuation criterion was met. All treatments were administered intravenously.,Participants received olaratumab 20 mg/kg loading dose on days 1 8 of cycle 1. From cycle 2 they received olaratumab 15 mg/kg on days 1 8 plus doxorubicin 25 mg/m^2 on days 1 2 3 plus ifosfamide 2.5 g/m^2 per day on days 1 2 3 4 plus mesna dose 60% of ifosfamide dose on days 1 2 3 of a 21-day cycle for a maximum of 6 cycles or until a discontinuation criterion was met. All treatments were administered intravenously.
Total all-cause mortality,7/16 %43.75,2/8 %25.0
Total serious adverse events,9/16 %56.25,7/8 %87.5
Anaemia,2/16 %12.5,1/8 %12.5
Febrile neutropenia,6/16 %37.5,4/8 %50.0
Neutropenia,1/16 %6.25,0/8 %0.0
Atrial fibrillation,0/16 %0.0,1/8 %12.5
Haemorrhoids,1/16 %6.25,0/8 %0.0
Nausea,1/16 %6.25,0/8 %0.0
Oesophagitis,1/16 %6.25,0/8 %0.0
Vomiting,1/16 %6.25,0/8 %0.0
Fatigue,2/16 %12.5,0/8 %0.0
Mucosal inflammation,1/16 %6.25,0/8 %0.0
Device related infection,1/16 %6.25,0/8 %0.0
Pneumonia,0/16 %0.0,2/8 %25.0
Fracture,0/16 %0.0,1/8 %12.5
Blood creatinine increased,0/16 %0.0,1/8 %12.5
Platelet count decreased,2/16 %12.5,2/8 %25.0
White blood cell count decreased,0/16 %0.0,1/8 %12.5
Dehydration,1/16 %6.25,0/8 %0.0
Hyponatraemia,1/16 %6.25,0/8 %0.0
Muscular weakness,1/16 %6.25,0/8 %0.0
Metastatic neoplasm,1/16 %6.25,0/8 %0.0
Tumour haemorrhage,1/16 %6.25,0/8 %0.0
Tumour pain,1/16 %6.25,0/8 %0.0
Device dislocation,0/16 %0.0,1/8 %12.5
Pulmonary embolism,1/16 %6.25,0/8 %0.0
Haemodynamic instability,1/16 %6.25,0/8 %0.0
Hypotension,1/16 %6.25,0/8 %0.0

A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer(https://clinicaltrials.gov/show/NCT03493854)
 ,Arm A: Pertuzumab IV + Trastuzumab IV + Chemotherapy,Arm B: Pertuzumab and Trastuzumab FDC SC + Chemotherapy
 ,Participants received 8 cycles of investigator's choice of neoadjuvant chemotherapy. This included either: 1) 4 cycles of dose-dense doxorubicin plus cyclophosphamide (ddAC) once every 2 weeks (Q2W) (given with granulocyte colony-stimulating factor [G-CSF] support as needed according to local guidelines) followed by paclitaxel QW for 12 weeks; or 2) 4 cycles of doxorubicin plus cyclophosphamide (AC) once every 3 weeks (Q3W) followed by docetaxel Q3W for 4 cycles. Pertuzumab and trastuzumab were given intravenously (IV) for 4 cycles Q3W concurrently with the taxane component of chemotherapy. After completing their neoadjuvant therapy participants underwent surgery. Thereafter participants received an additional 14 cycles of pertuzumab IV and trastuzumab IV for a total of 18 cycles.,Participants received 8 cycles of investigator's choice of neoadjuvant chemotherapy. This included either: 1) 4 cycles of ddAC Q2W (given with G-CSF support as needed according to local guidelines) followed by paclitaxel once every week (QW) for 12 weeks; or 2) 4 cycles of AC Q3W followed by docetaxel Q3W for 4 cycles. The fixed-dose combination (FDC) of pertuzumab and trastuzumab was given subcutaneously (SC) for 4 cycles (Q3W) concurrently with the taxane component of chemotherapy. After completing their neoadjuvant therapy participants underwent surgery. Thereafter participants received an additional 14 cycles of the FDC of pertuzumab and trastuzumab SC for a total of 18 cycles.
Total all-cause mortality,1/252 %0.4,1/248 %0.4
Total serious adverse events,45/252 %17.86,40/248 %16.13
ANAEMIA,1/252 %0.4,1/248 %0.4
FEBRILE NEUTROPENIA,10/252 %3.97,9/248 %3.63
NEUTROPENIA,3/252 %1.19,1/248 %0.4
ACUTE MYOCARDIAL INFARCTION,0/252 %0.0,1/248 %0.4
ARRHYTHMIA,0/252 %0.0,1/248 %0.4
CARDIAC FAILURE,2/252 %0.79,2/248 %0.81
GOITRE,1/252 %0.4,0/248 %0.0
ABDOMINAL PAIN,0/252 %0.0,1/248 %0.4
ANAL INCONTINENCE,0/252 %0.0,1/248 %0.4
COLITIS,1/252 %0.4,1/248 %0.4
DIARRHOEA,2/252 %0.79,1/248 %0.4
GASTRITIS HAEMORRHAGIC,0/252 %0.0,1/248 %0.4
GASTROINTESTINAL TOXICITY,0/252 %0.0,1/248 %0.4
PANCREATITIS,0/252 %0.0,1/248 %0.4
VOMITING,1/252 %0.4,0/248 %0.0
CHEST PAIN,1/252 %0.4,0/248 %0.0
FATIGUE,1/252 %0.4,0/248 %0.0
LITHIASIS,0/252 %0.0,1/248 %0.4
MUCOSAL INFLAMMATION,1/252 %0.4,0/248 %0.0
PYREXIA,4/252 %1.59,2/248 %0.81
ANAL ABSCESS,1/252 %0.4,0/248 %0.0
APPENDICITIS,1/252 %0.4,1/248 %0.4
CELLULITIS,1/252 %0.4,0/248 %0.0
CLOSTRIDIUM DIFFICILE COLITIS,1/252 %0.4,0/248 %0.0
ESCHERICHIA BACTERAEMIA,0/252 %0.0,1/248 %0.4
GASTROENTERITIS,1/252 %0.4,1/248 %0.4
INFLUENZA,0/252 %0.0,1/248 %0.4
LOWER RESPIRATORY TRACT INFECTION,0/252 %0.0,1/248 %0.4
MASTITIS,2/252 %0.79,1/248 %0.4
NEUTROPENIC SEPSIS,1/252 %0.4,3/248 %1.21
PHARYNGITIS,1/252 %0.4,0/248 %0.0
PNEUMONIA,1/252 %0.4,0/248 %0.0
POSTOPERATIVE WOUND INFECTION,2/252 %0.79,0/248 %0.0
PSEUDOMONAS INFECTION,0/252 %0.0,1/248 %0.4
PYELONEPHRITIS ACUTE,1/252 %0.4,0/248 %0.0
RESPIRATORY TRACT INFECTION,1/252 %0.4,0/248 %0.0
SEPSIS,2/252 %0.79,1/248 %0.4
UROSEPSIS,1/252 %0.4,0/248 %0.0
FEMUR FRACTURE,0/252 %0.0,1/248 %0.4
FLAP NECROSIS,0/252 %0.0,1/248 %0.4
INFUSION RELATED REACTION,3/252 %1.19,0/248 %0.0
POST PROCEDURAL HAEMATOMA,0/252 %0.0,1/248 %0.4
POST PROCEDURAL HAEMORRHAGE,0/252 %0.0,1/248 %0.4
CLOSTRIDIUM TEST POSITIVE,1/252 %0.4,0/248 %0.0
NEUTROPHIL COUNT DECREASED,1/252 %0.4,3/248 %1.21
WHITE BLOOD CELL COUNT DECREASED,0/252 %0.0,1/248 %0.4
PERIOSTITIS,1/252 %0.4,0/248 %0.0
RENAL CELL CARCINOMA,1/252 %0.4,0/248 %0.0
SEIZURE,1/252 %0.4,1/248 %0.4
DEPRESSION,1/252 %0.4,0/248 %0.0
RENAL FAILURE,0/252 %0.0,1/248 %0.4
BREAST HAEMATOMA,1/252 %0.4,0/248 %0.0
BREAST INFLAMMATION,0/252 %0.0,1/248 %0.4
METRORRHAGIA,1/252 %0.4,0/248 %0.0
DYSPNOEA,0/252 %0.0,1/248 %0.4
HYPOXIA,1/252 %0.4,0/248 %0.0
PNEUMONITIS,1/252 %0.4,2/248 %0.81
PNEUMOTHORAX,1/252 %0.4,0/248 %0.0
PULMONARY EMBOLISM,1/252 %0.4,2/248 %0.81
PULMONARY OEDEMA,0/252 %0.0,1/248 %0.4
ERYTHEMA,0/252 %0.0,1/248 %0.4
EMBOLISM,0/252 %0.0,1/248 %0.4
HAEMATOMA,1/252 %0.4,0/248 %0.0
HYPERTENSION,0/252 %0.0,1/248 %0.4
ILIAC ARTERY OCCLUSION,1/252 %0.4,0/248 %0.0

Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer(https://clinicaltrials.gov/show/NCT00054327)
 ,Regimen A,Regimen B-1,Regimen B-2,Regimen B-3,Regimen C,Regimen D
 ,Patients receive cytarabine 3.0gm/M IV over 1 hour twice daily on days -9 to -7 and cyclophosphamide 45mg/kg IV over 2 hours on days -6 and -5. Patients also undergo total body irradiation (TBI) 165 cGY twice daily on days -4 to -1 for a total of 1320 cGY.,Patients receive cyclophosphamide 60 mg/kg IV on days -6 and -5. Patients also undergo total body irradiation (TBI) twice daily on days -4 to -1 for a total of 1320 cGY..,Patients receive cyclophosphamide 60 mg/kg IV over 2 hours on days -5 and -4. Patients also undergo TBI twice daily on days -3 to -1 for a total of 1200 cGY.,Patients undergo total body irradiation (TBI) twice daily on days -7 to -5 for a total of 1200 cGY. Patients then receive cyclophosphamide 60 mg/kg IV on days -4 and -3.,Patients receive oral busulfan 1mg/kg/dose (or 40mg/m2/dose for young children)4 times daily on days -8 to -5 and cyclophosphamide 60 mg/kg IV over 2 hours on days -4 to -2.,Patients receive total body irradiation (TBI) on days T -6 -5 and -4 for a total of 1320 cGy  then etoposide (60mg/kg/dose) on day -3.
Total serious adverse events,0/11 %0.0,0/4 %0.0,1/3 %33.33,2/4 %50.0,2/10 %20.0,0/2 %0.0
Melena/GI bleeding,0/11 %0.0,0/4 %0.0,1/3 %33.33,0/4 %0.0,0/10 %0.0,0/2 %0.0
Stomatitis/pharyngitis (oral/pharyngeal mucositis),0/11 %0.0,0/4 %0.0,0/3 %0.0,1/4 %25.0,0/10 %0.0,0/2 %0.0
Petechiae/purpura (hemorrhage/bleeding into skin or mucosa),0/11 %0.0,0/4 %0.0,0/3 %0.0,1/4 %25.0,0/10 %0.0,0/2 %0.0
Edema,0/11 %0.0,0/4 %0.0,1/3 %33.33,0/4 %0.0,0/10 %0.0,0/2 %0.0
Death not associated with CTCAE term - Multi-organ failure,0/11 %0.0,0/4 %0.0,0/3 %0.0,0/4 %0.0,1/10 %10.0,0/2 %0.0
Elevated Bilirubin associated with graft versus host disease (GVHD),0/11 %0.0,0/4 %0.0,1/3 %33.33,0/4 %0.0,0/10 %0.0,0/2 %0.0
Memory loss,0/11 %0.0,0/4 %0.0,1/3 %33.33,0/4 %0.0,0/10 %0.0,0/2 %0.0
Mood alteration-anxiety agitation,0/11 %0.0,0/4 %0.0,0/3 %0.0,1/4 %25.0,0/10 %0.0,0/2 %0.0
Confusion,0/11 %0.0,0/4 %0.0,0/3 %0.0,1/4 %25.0,0/10 %0.0,0/2 %0.0
Hematuria,0/11 %0.0,0/4 %0.0,0/3 %0.0,1/4 %25.0,0/10 %0.0,0/2 %0.0
Pleural effusion (non-malignant),0/11 %0.0,0/4 %0.0,0/3 %0.0,1/4 %25.0,0/10 %0.0,0/2 %0.0
Dyspnea (shortness of breath),0/11 %0.0,0/4 %0.0,0/3 %0.0,1/4 %25.0,1/10 %10.0,0/2 %0.0
Hypoxia,0/11 %0.0,0/4 %0.0,0/3 %0.0,0/4 %0.0,1/10 %10.0,0/2 %0.0
Rash/dermatitis associated with high-dose chemotherapy or BMT studies.,0/11 %0.0,0/4 %0.0,0/3 %0.0,1/4 %25.0,0/10 %0.0,0/2 %0.0
Hypertension,0/11 %0.0,0/4 %0.0,0/3 %0.0,1/4 %25.0,0/10 %0.0,0/2 %0.0

A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care(https://clinicaltrials.gov/show/NCT00071799)
 ,Azacitidine,Best Supportive Care Only,Low-dose Cytarabine,Standard Chemotherapy
 ,Azacitidine 75 mg/m2/day given by subcutaneous injection for 7 days of every 28 day cycle plus best supportive care.,Care can include transfusions antibiotics myeloid growth factors [G-CSF and GM CSF] for neutropenic infections until the end of the study.,Cytarabine 20 mg/m2/day subcutaneously on Days 1-14 with 28-42 days between cycles. Plus best supportive care.,Induction cycle: Cytarabine infusion 100-200 mg/m2/day on days 1-7 + anthracycline on days 1 2 3 Consolidation cycle: Cytarabine infusion 100-200 mg/m2/day for 3-7 days + anthracycline on days 1 and 2 There are 28-70 days between cycles - 1 induction cycle and maximum of 2 consolidation cycles; best supportive care follows the final consolidation cycle.
Total serious adverse events,114/175 %65.14,71/102 %69.61,27/44 %61.36,14/19 %73.68
Anaemia,12/175 %6.86,3/102 %2.94,2/44 %4.55,0/19 %0.0
Bone marrow failure,2/175 %1.14,0/102 %0.0,0/44 %0.0,1/19 %5.26
Febrile bone marrow aplasia,0/175 %0.0,0/102 %0.0,2/44 %4.55,0/19 %0.0
Febrile neutropenia,19/175 %10.86,3/102 %2.94,1/44 %2.27,5/19 %26.32
Haemolysis,0/175 %0.0,1/102 %0.98,0/44 %0.0,0/19 %0.0
Haemorrhagic diathesis,0/175 %0.0,0/102 %0.0,0/44 %0.0,1/19 %5.26
Leukocytosis,0/175 %0.0,0/102 %0.0,1/44 %2.27,0/19 %0.0
Leukopenia,1/175 %0.57,0/102 %0.0,0/44 %0.0,0/19 %0.0
Neutropenia,5/175 %2.86,0/102 %0.0,0/44 %0.0,1/19 %5.26
Pancytopenia,2/175 %1.14,0/102 %0.0,0/44 %0.0,0/19 %0.0
Thrombocytopenia,8/175 %4.57,2/102 %1.96,2/44 %4.55,1/19 %5.26
Acute myocardial infarction,0/175 %0.0,1/102 %0.98,0/44 %0.0,0/19 %0.0
Angina pectoris,2/175 %1.14,1/102 %0.98,0/44 %0.0,0/19 %0.0
Atrial fibrillation,1/175 %0.57,1/102 %0.98,0/44 %0.0,1/19 %5.26
Cardiac failure,3/175 %1.71,2/102 %1.96,1/44 %2.27,0/19 %0.0
Cardiac failure acute,2/175 %1.14,1/102 %0.98,0/44 %0.0,0/19 %0.0
Cardiac failure congestive,0/175 %0.0,2/102 %1.96,0/44 %0.0,0/19 %0.0
Cardiomyopathy,0/175 %0.0,1/102 %0.98,0/44 %0.0,0/19 %0.0
Coronary artery disease,0/175 %0.0,0/102 %0.0,0/44 %0.0,1/19 %5.26
Coronary artery occlusion,0/175 %0.0,1/102 %0.98,0/44 %0.0,0/19 %0.0
Left ventricular failure,0/175 %0.0,1/102 %0.98,0/44 %0.0,0/19 %0.0
Myocardial infarction,2/175 %1.14,0/102 %0.0,0/44 %0.0,1/19 %5.26
Pericardial effusion,1/175 %0.57,0/102 %0.0,0/44 %0.0,0/19 %0.0
Ventricular tachycardia,1/175 %0.57,0/102 %0.0,0/44 %0.0,0/19 %0.0
Vertigo,1/175 %0.57,2/102 %1.96,0/44 %0.0,0/19 %0.0
Vestibular disorder,0/175 %0.0,1/102 %0.98,0/44 %0.0,0/19 %0.0
Hypothyroidism,1/175 %0.57,0/102 %0.0,0/44 %0.0,0/19 %0.0
Angle closure glaucoma,1/175 %0.57,0/102 %0.0,0/44 %0.0,0/19 %0.0
Endophthalmitis,1/175 %0.57,0/102 %0.0,0/44 %0.0,0/19 %0.0
Eye Haemorrhage,2/175 %1.14,0/102 %0.0,0/44 %0.0,0/19 %0.0
Myopia,1/175 %0.57,0/102 %0.0,0/44 %0.0,0/19 %0.0
Retinal artery occlusion,1/175 %0.57,0/102 %0.0,0/44 %0.0,0/19 %0.0
Retinal Haemorrhage,1/175 %0.57,0/102 %0.0,0/44 %0.0,0/19 %0.0
Retinal tear,1/175 %0.57,0/102 %0.0,0/44 %0.0,0/19 %0.0
Strabismus,1/175 %0.57,0/102 %0.0,0/44 %0.0,0/19 %0.0
Abdominal pain,2/175 %1.14,0/102 %0.0,0/44 %0.0,0/19 %0.0
Anal fissure,0/175 %0.0,1/102 %0.98,0/44 %0.0,0/19 %0.0
Anal fistula,0/175 %0.0,0/102 %0.0,1/44 %2.27,0/19 %0.0
Caecitis,0/175 %0.0,0/102 %0.0,1/44 %2.27,0/19 %0.0
Colitis ulcerative,1/175 %0.57,0/102 %0.0,0/44 %0.0,0/19 %0.0
Constipation,1/175 %0.57,0/102 %0.0,0/44 %0.0,0/19 %0.0
Diarrhoea,0/175 %0.0,1/102 %0.98,0/44 %0.0,0/19 %0.0
Dysphagia,0/175 %0.0,0/102 %0.0,0/44 %0.0,1/19 %5.26
Food poisoning,1/175 %0.57,0/102 %0.0,0/44 %0.0,0/19 %0.0
Gastritis,0/175 %0.0,1/102 %0.98,0/44 %0.0,0/19 %0.0
Gastritis haemorrhagic,0/175 %0.0,1/102 %0.98,0/44 %0.0,0/19 %0.0
Gastrointestinal haemorrhage,1/175 %0.57,1/102 %0.98,0/44 %0.0,0/19 %0.0
Gingival bleeding,2/175 %1.14,0/102 %0.0,0/44 %0.0,0/19 %0.0
Haematemesis,1/175 %0.57,0/102 %0.0,0/44 %0.0,0/19 %0.0
Haemorrhoidal haemorrhage,1/175 %0.57,0/102 %0.0,0/44 %0.0,0/19 %0.0
Ileitis,0/175 %0.0,0/102 %0.0,1/44 %2.27,0/19 %0.0
Intestinal haemorrhage,1/175 %0.57,0/102 %0.0,0/44 %0.0,0/19 %0.0
Large intestinal haemorrhage,0/175 %0.0,1/102 %0.98,0/44 %0.0,0/19 %0.0
Melaena,0/175 %0.0,2/102 %1.96,0/44 %0.0,0/19 %0.0
Mouth haemorrhage,1/175 %0.57,0/102 %0.0,0/44 %0.0,0/19 %0.0
Neutropenic colitis,0/175 %0.0,0/102 %0.0,0/44 %0.0,2/19 %10.53
Rectal haemorrhage,2/175 %1.14,0/102 %0.0,0/44 %0.0,0/19 %0.0
Stomatitis,1/175 %0.57,0/102 %0.0,0/44 %0.0,0/19 %0.0
Subileus,1/175 %0.57,0/102 %0.0,0/44 %0.0,0/19 %0.0
Tooth disorder,1/175 %0.57,0/102 %0.0,0/44 %0.0,0/19 %0.0
Asthenia,1/175 %0.57,0/102 %0.0,1/44 %2.27,0/19 %0.0
Catheter site inflammation,0/175 %0.0,0/102 %0.0,1/44 %2.27,0/19 %0.0
Chest pain,1/175 %0.57,0/102 %0.0,0/44 %0.0,0/19 %0.0
Death,0/175 %0.0,2/102 %1.96,0/44 %0.0,0/19 %0.0
Facial pain,0/175 %0.0,1/102 %0.98,0/44 %0.0,0/19 %0.0
Fatigue,0/175 %0.0,1/102 %0.98,0/44 %0.0,0/19 %0.0
General physical health deterioration,2/175 %1.14,0/102 %0.0,0/44 %0.0,0/19 %0.0
Injection site nodule,1/175 %0.57,0/102 %0.0,0/44 %0.0,0/19 %0.0
Injection site pain,1/175 %0.57,0/102 %0.0,0/44 %0.0,0/19 %0.0
Mucosal inflammation,0/175 %0.0,0/102 %0.0,1/44 %2.27,1/19 %5.26
Pain,0/175 %0.0,0/102 %0.0,1/44 %2.27,0/19 %0.0
Pyrexia,10/175 %5.71,3/102 %2.94,5/44 %11.36,0/19 %0.0
Bile duct stone,1/175 %0.57,0/102 %0.0,0/44 %0.0,0/19 %0.0
Hepatic function abnormal,1/175 %0.57,0/102 %0.0,0/44 %0.0,0/19 %0.0
Drug hypersensitivity,0/175 %0.0,1/102 %0.98,0/44 %0.0,0/19 %0.0
Abdominal wall abscess,1/175 %0.57,0/102 %0.0,0/44 %0.0,0/19 %0.0
Abscess neck,1/175 %0.57,0/102 %0.0,0/44 %0.0,0/19 %0.0
Arthritis infection,0/175 %0.0,0/102 %0.0,1/44 %2.27,0/19 %0.0
Aspergillosis,0/175 %0.0,0/102 %0.0,0/44 %0.0,1/19 %5.26
Bacteraemia,2/175 %1.14,0/102 %0.0,0/44 %0.0,2/19 %10.53
Bronchitis,1/175 %0.57,0/102 %0.0,1/44 %2.27,0/19 %0.0
Bronchopneumonia,3/175 %1.71,3/102 %2.94,0/44 %0.0,0/19 %0.0
Candidiasis,0/175 %0.0,0/102 %0.0,1/44 %2.27,0/19 %0.0
Cellulitis,2/175 %1.14,2/102 %1.96,2/44 %4.55,0/19 %0.0
Clostridium difficile colitis,1/175 %0.57,0/102 %0.0,0/44 %0.0,0/19 %0.0
Corynebacterium infection,1/175 %0.57,0/102 %0.0,0/44 %0.0,0/19 %0.0
Disseminated tuberculosis,0/175 %0.0,0/102 %0.0,1/44 %2.27,0/19 %0.0
Diverticulitis,0/175 %0.0,0/102 %0.0,0/44 %0.0,1/19 %5.26
Ear infection,1/175 %0.57,0/102 %0.0,0/44 %0.0,0/19 %0.0
Enterobacter bacteraemia,1/175 %0.57,0/102 %0.0,0/44 %0.0,0/19 %0.0
Escherichia sepsis,0/175 %0.0,2/102 %1.96,0/44 %0.0,0/19 %0.0
Escherichia urinary tract infection,0/175 %0.0,1/102 %0.98,0/44 %0.0,0/19 %0.0
Fungal sepsis,1/175 %0.57,0/102 %0.0,1/44 %2.27,0/19 %0.0
Gasteroenteritis,1/175 %0.57,1/102 %0.98,0/44 %0.0,0/19 %0.0
Gasteroenteritis salmonella,1/175 %0.57,0/102 %0.0,0/44 %0.0,0/19 %0.0
Gingival infection,0/175 %0.0,1/102 %0.98,0/44 %0.0,0/19 %0.0
Herpes zoster,1/175 %0.57,0/102 %0.0,0/44 %0.0,0/19 %0.0
Infection,0/175 %0.0,1/102 %0.98,0/44 %0.0,1/19 %5.26
Klebsiella bacteraemia,0/175 %0.0,0/102 %0.0,0/44 %0.0,1/19 %5.26
Laryngopharyngitis,1/175 %0.57,0/102 %0.0,0/44 %0.0,0/19 %0.0
Lobar pneumonia,1/175 %0.57,0/102 %0.0,0/44 %0.0,0/19 %0.0
Lower respiratory tract infection,2/175 %1.14,0/102 %0.0,0/44 %0.0,0/19 %0.0
Lung infection,2/175 %1.14,0/102 %0.0,0/44 %0.0,0/19 %0.0
Meningitis,1/175 %0.57,0/102 %0.0,0/44 %0.0,0/19 %0.0
Mucormycosis,1/175 %0.57,0/102 %0.0,0/44 %0.0,0/19 %0.0
Neutropenic infection,1/175 %0.57,0/102 %0.0,0/44 %0.0,0/19 %0.0
Neutropenic sepsis,4/175 %2.29,1/102 %0.98,1/44 %2.27,2/19 %10.53
Oral herpes,1/175 %0.57,0/102 %0.0,1/44 %2.27,0/19 %0.0
Parotitis,1/175 %0.57,0/102 %0.0,0/44 %0.0,0/19 %0.0
Perianal abscess,2/175 %1.14,0/102 %0.0,0/44 %0.0,0/19 %0.0
Pneumonia,20/175 %11.43,12/102 %11.76,2/44 %4.55,3/19 %15.79
Pneumonia bacterial,0/175 %0.0,1/102 %0.98,0/44 %0.0,0/19 %0.0
Pneumonia fungal,1/175 %0.57,0/102 %0.0,0/44 %0.0,2/19 %10.53
Pseudomembranous colitis,0/175 %0.0,1/102 %0.98,0/44 %0.0,0/19 %0.0
Pseudomonal sepsis,0/175 %0.0,1/102 %0.98,0/44 %0.0,0/19 %0.0
Pulmonary tuberculosis,1/175 %0.57,0/102 %0.0,0/44 %0.0,0/19 %0.0
Renal abscess,0/175 %0.0,1/102 %0.98,0/44 %0.0,0/19 %0.0
Respiratory tract infection,1/175 %0.57,1/102 %0.98,0/44 %0.0,0/19 %0.0
Salmonella sepsis,1/175 %0.57,0/102 %0.0,0/44 %0.0,0/19 %0.0
Sepsis,6/175 %3.43,3/102 %2.94,2/44 %4.55,0/19 %0.0
Septic shock,3/175 %1.71,1/102 %0.98,2/44 %4.55,0/19 %0.0
Sialoadenitis,1/175 %0.57,0/102 %0.0,0/44 %0.0,0/19 %0.0
Splenic abscess,1/175 %0.57,0/102 %0.0,0/44 %0.0,0/19 %0.0
Staphylococcal bacteraemia,1/175 %0.57,0/102 %0.0,0/44 %0.0,0/19 %0.0
Subcutaneous abscess,1/175 %0.57,0/102 %0.0,0/44 %0.0,0/19 %0.0
Subdiaphragmatic abscess,1/175 %0.57,0/102 %0.0,0/44 %0.0,0/19 %0.0
Tooth abscess,1/175 %0.57,0/102 %0.0,0/44 %0.0,0/19 %0.0
Tuberculosis,0/175 %0.0,1/102 %0.98,0/44 %0.0,0/19 %0.0
Upper respiratory tract infection,2/175 %1.14,0/102 %0.0,0/44 %0.0,0/19 %0.0
Urinary tract infection,5/175 %2.86,0/102 %0.0,2/44 %4.55,1/19 %5.26
Bronchopulmonary aspergillosis,2/175 %1.14,0/102 %0.0,0/44 %0.0,0/19 %0.0
Clavicle fracture,1/175 %0.57,0/102 %0.0,0/44 %0.0,0/19 %0.0
Hip fracture,1/175 %0.57,0/102 %0.0,0/44 %0.0,0/19 %0.0
Subdural haematoma,0/175 %0.0,0/102 %0.0,1/44 %2.27,0/19 %0.0
Synovial rupture,1/175 %0.57,0/102 %0.0,0/44 %0.0,0/19 %0.0
Transfusion reaction,3/175 %1.71,0/102 %0.0,1/44 %2.27,0/19 %0.0
Traumatic intracranial haemorrhage,1/175 %0.57,0/102 %0.0,0/44 %0.0,0/19 %0.0
Upper limb fracture,0/175 %0.0,1/102 %0.98,0/44 %0.0,0/19 %0.0
Diabetes mellitus,1/175 %0.57,0/102 %0.0,0/44 %0.0,0/19 %0.0
Haemosiderosis,0/175 %0.0,1/102 %0.98,0/44 %0.0,0/19 %0.0
Hyperkalaemia,0/175 %0.0,1/102 %0.98,0/44 %0.0,0/19 %0.0
Hypokalaemia,0/175 %0.0,1/102 %0.98,0/44 %0.0,0/19 %0.0
Arthralgia,0/175 %0.0,1/102 %0.98,0/44 %0.0,0/19 %0.0
Arthritis,0/175 %0.0,1/102 %0.98,0/44 %0.0,0/19 %0.0
Back pain,0/175 %0.0,1/102 %0.98,0/44 %0.0,0/19 %0.0
Bursitis,0/175 %0.0,1/102 %0.98,0/44 %0.0,0/19 %0.0
Chondrocalcinosis pyrophosphate,0/175 %0.0,0/102 %0.0,0/44 %0.0,1/19 %5.26
Osteoporosis,1/175 %0.57,0/102 %0.0,0/44 %0.0,0/19 %0.0
Pain in extremity,0/175 %0.0,1/102 %0.98,0/44 %0.0,0/19 %0.0
Pathological fracture,0/175 %0.0,1/102 %0.98,0/44 %0.0,0/19 %0.0
Acute myeloid leukaemia,30/175 %17.14,35/102 %34.31,6/44 %13.64,1/19 %5.26
Colon cancer,1/175 %0.57,0/102 %0.0,0/44 %0.0,0/19 %0.0
Lung adenocarcinoma,1/175 %0.57,0/102 %0.0,0/44 %0.0,0/19 %0.0
Myelodysplastic syndrome,4/175 %2.29,2/102 %1.96,1/44 %2.27,0/19 %0.0
Myelofibrosis,1/175 %0.57,0/102 %0.0,0/44 %0.0,0/19 %0.0
Neoplasm prostate,1/175 %0.57,0/102 %0.0,0/44 %0.0,0/19 %0.0
Oesophageal carcinoma,1/175 %0.57,0/102 %0.0,0/44 %0.0,0/19 %0.0
Squamous cell carcinoma of skin,1/175 %0.57,0/102 %0.0,0/44 %0.0,0/19 %0.0
Urinary tract neoplasm,1/175 %0.57,0/102 %0.0,0/44 %0.0,0/19 %0.0
Cerebral haemorrhage,4/175 %2.29,3/102 %2.94,0/44 %0.0,0/19 %0.0
Cerebral ischaemia,0/175 %0.0,0/102 %0.0,1/44 %2.27,0/19 %0.0
Coma,1/175 %0.57,0/102 %0.0,0/44 %0.0,0/19 %0.0
Convulsion,0/175 %0.0,1/102 %0.98,0/44 %0.0,0/19 %0.0
Dizziness,0/175 %0.0,0/102 %0.0,0/44 %0.0,1/19 %5.26
Grand mal convulsion,0/175 %0.0,1/102 %0.98,0/44 %0.0,0/19 %0.0
Haemorrhage intracranial,1/175 %0.57,1/102 %0.98,0/44 %0.0,0/19 %0.0
Headache,0/175 %0.0,1/102 %0.98,0/44 %0.0,0/19 %0.0
Intracranial haematoma,0/175 %0.0,1/102 %0.98,0/44 %0.0,0/19 %0.0
Loss of consciousness,1/175 %0.57,0/102 %0.0,0/44 %0.0,0/19 %0.0
Somnolence,0/175 %0.0,0/102 %0.0,1/44 %2.27,0/19 %0.0
Syncope,2/175 %1.14,0/102 %0.0,0/44 %0.0,0/19 %0.0
Transient ischaemic attack,1/175 %0.57,0/102 %0.0,0/44 %0.0,0/19 %0.0
Confusional state,1/175 %0.57,0/102 %0.0,0/44 %0.0,0/19 %0.0
Delirium,1/175 %0.57,0/102 %0.0,0/44 %0.0,0/19 %0.0
Depression,1/175 %0.57,0/102 %0.0,0/44 %0.0,0/19 %0.0
Psychotic disorder,1/175 %0.57,0/102 %0.0,0/44 %0.0,0/19 %0.0
Haematuria,2/175 %1.14,1/102 %0.98,0/44 %0.0,0/19 %0.0
Nephrolithiasis,0/175 %0.0,1/102 %0.98,0/44 %0.0,0/19 %0.0
Renal colic,1/175 %0.57,0/102 %0.0,0/44 %0.0,0/19 %0.0
Renal failure,1/175 %0.57,1/102 %0.98,0/44 %0.0,0/19 %0.0
Renal failure acute,0/175 %0.0,2/102 %1.96,0/44 %0.0,0/19 %0.0
Renal impairment,0/175 %0.0,1/102 %0.98,0/44 %0.0,0/19 %0.0
Urethral stenosis,1/175 %0.57,0/102 %0.0,0/44 %0.0,0/19 %0.0
Urinary retention,1/175 %0.57,0/102 %0.0,0/44 %0.0,0/19 %0.0
Benign prostatic hyperplasia,1/175 %0.57,0/102 %0.0,0/44 %0.0,0/19 %0.0
Metrorrhagia,0/175 %0.0,1/102 %0.98,0/44 %0.0,0/19 %0.0
Prostatitis,0/175 %0.0,1/102 %0.98,0/44 %0.0,0/19 %0.0
Vaginal haemorrhage,0/175 %0.0,1/102 %0.98,0/44 %0.0,0/19 %0.0
Acute pulmonary oedema,1/175 %0.57,0/102 %0.0,0/44 %0.0,0/19 %0.0
Acute respiratory failure,1/175 %0.57,0/102 %0.0,0/44 %0.0,0/19 %0.0
Bronchitis chronic,0/175 %0.0,1/102 %0.98,0/44 %0.0,0/19 %0.0
Chronic obstructive pulmonary disease,0/175 %0.0,1/102 %0.98,0/44 %0.0,0/19 %0.0
Epistaxis,4/175 %2.29,3/102 %2.94,2/44 %4.55,0/19 %0.0
Haemoptysis,1/175 %0.57,0/102 %0.0,1/44 %2.27,0/19 %0.0
Lung infiltration,1/175 %0.57,0/102 %0.0,0/44 %0.0,0/19 %0.0
Pleural effusion,2/175 %1.14,1/102 %0.98,0/44 %0.0,0/19 %0.0
Pleuritic pain,0/175 %0.0,1/102 %0.98,0/44 %0.0,0/19 %0.0
Pneumonitis,1/175 %0.57,0/102 %0.0,0/44 %0.0,0/19 %0.0
Pulmonary embolism,1/175 %0.57,0/102 %0.0,0/44 %0.0,1/19 %5.26
Pulmonary fibrosis,1/175 %0.57,0/102 %0.0,0/44 %0.0,0/19 %0.0
Pulmonary hypertension,0/175 %0.0,1/102 %0.98,0/44 %0.0,0/19 %0.0
Respiratory failure,1/175 %0.57,1/102 %0.98,0/44 %0.0,0/19 %0.0
Actinic keratosis,1/175 %0.57,0/102 %0.0,0/44 %0.0,0/19 %0.0
Pruritus,1/175 %0.57,0/102 %0.0,0/44 %0.0,0/19 %0.0
Purpura,0/175 %0.0,0/102 %0.0,1/44 %2.27,0/19 %0.0
Aortic aneurysm,1/175 %0.57,0/102 %0.0,0/44 %0.0,0/19 %0.0
Circulatory collapse,1/175 %0.57,0/102 %0.0,0/44 %0.0,0/19 %0.0
Hypotension,0/175 %0.0,1/102 %0.98,0/44 %0.0,0/19 %0.0
Shock,0/175 %0.0,1/102 %0.98,0/44 %0.0,0/19 %0.0

Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma(https://clinicaltrials.gov/show/NCT00078949)
 ,Salvage GDP,Salvage DHAP,Maintenance,Observation
 ,Patients receive cisplatin IV over 60 minutes on day 1 dexamethasone IV or orally on days 1-4 and gemcitabine IV over 30 minutes on days 1 and 8.  cisplatin: Given IV  dexamethasone: Given IV  gemcitabine hydrochloride: Given IV,Patients receive cisplatin IV over 24 hours on day 1 dexamethasone as in arm I and cytarabine IV over 3 hours every 12 hours for a total of 2 doses on day 2.  cisplatin: Given IV  cytarabine: Given IV  dexamethasone: Given IV,Beginning on day 28 posttransplantation patients receive rituximab IV once every 2 months for 6 doses (a total of 12 months) in the absence of disease progression or unacceptable toxicity.  rituximab: Given IV,Patients undergo observation only.
Total all-cause mortality,177/310 %57.1,181/309 %58.58,39/115 %33.91,42/115 %36.52
Total serious adverse events,36/306 %11.76,26/304 %8.55,16/112 %14.29,8/112 %7.14
Hemoglobin,1/306 %0.33,0/304 %0.0,0/112 %0.0,0/112 %0.0
DIC,1/306 %0.33,0/304 %0.0,0/112 %0.0,0/112 %0.0
Febrile neutropenia,3/306 %0.98,11/304 %3.62,3/112 %2.68,1/112 %0.89
Edema,1/306 %0.33,0/304 %0.0,0/112 %0.0,0/112 %0.0
Ischemia/infarction,1/306 %0.33,1/304 %0.33,0/112 %0.0,0/112 %0.0
Pericardial effusion,0/306 %0.0,1/304 %0.33,0/112 %0.0,0/112 %0.0
Sinus tachycardia,0/306 %0.0,1/304 %0.33,0/112 %0.0,0/112 %0.0
Colitis,0/306 %0.0,2/304 %0.66,1/112 %0.89,1/112 %0.89
Constipation,0/306 %0.0,0/304 %0.0,1/112 %0.89,0/112 %0.0
Diarrhea,2/306 %0.65,2/304 %0.66,3/112 %2.68,0/112 %0.0
Dysphagia,1/306 %0.33,0/304 %0.0,0/112 %0.0,0/112 %0.0
Nausea,4/306 %1.31,0/304 %0.0,2/112 %1.79,1/112 %0.89
Duodenal ulcer,1/306 %0.33,0/304 %0.0,0/112 %0.0,0/112 %0.0
Gastric ulcer,1/306 %0.33,0/304 %0.0,1/112 %0.89,0/112 %0.0
Vomiting,2/306 %0.65,2/304 %0.66,2/112 %1.79,0/112 %0.0
Melena/GI bleeding,1/306 %0.33,0/304 %0.0,0/112 %0.0,0/112 %0.0
Rectal bleeding,1/306 %0.33,1/304 %0.33,0/112 %0.0,0/112 %0.0
Hematemesis,1/306 %0.33,0/304 %0.0,0/112 %0.0,0/112 %0.0
Abdominal pain,4/306 %1.31,2/304 %0.66,1/112 %0.89,1/112 %0.89
Fatigue,0/306 %0.0,1/304 %0.33,0/112 %0.0,0/112 %0.0
Pain-Other,2/306 %0.65,0/304 %0.0,1/112 %0.89,1/112 %0.89
Other,1/306 %0.33,1/304 %0.33,0/112 %0.0,0/112 %0.0
Other,3/306 %0.98,0/304 %0.0,0/112 %0.0,1/112 %0.89
Fever,3/306 %0.98,3/304 %0.99,2/112 %1.79,0/112 %0.0
Other,1/306 %0.33,0/304 %0.0,1/112 %0.89,0/112 %0.0
Other,1/306 %0.33,0/304 %0.0,0/112 %0.0,0/112 %0.0
Wound-infectious,1/306 %0.33,0/304 %0.0,0/112 %0.0,0/112 %0.0
Granulocytes,2/306 %0.65,0/304 %0.0,1/112 %0.89,0/112 %0.0
Lymphopenia,1/306 %0.33,0/304 %0.0,0/112 %0.0,0/112 %0.0
Platelets,0/306 %0.0,1/304 %0.33,0/112 %0.0,0/112 %0.0
Leukocytes (total WBC),1/306 %0.33,1/304 %0.33,0/112 %0.0,0/112 %0.0
Cardiac troponin T,0/306 %0.0,1/304 %0.33,0/112 %0.0,0/112 %0.0
Creatinine,1/306 %0.33,2/304 %0.66,1/112 %0.89,0/112 %0.0
SGPT (ALT),1/306 %0.33,0/304 %0.0,0/112 %0.0,0/112 %0.0
SGOT (AST),1/306 %0.33,0/304 %0.0,0/112 %0.0,0/112 %0.0
Bilirubin,1/306 %0.33,0/304 %0.0,0/112 %0.0,0/112 %0.0
Weight loss,1/306 %0.33,0/304 %0.0,1/112 %0.89,0/112 %0.0
Dehydration,1/306 %0.33,1/304 %0.33,1/112 %0.89,0/112 %0.0
Secondary Malignancy,2/306 %0.65,4/304 %1.32,3/112 %2.68,3/112 %2.68
Hemorrhage/bleeding,1/306 %0.33,0/304 %0.0,0/112 %0.0,0/112 %0.0
Speech impairment,2/306 %0.65,0/304 %0.0,0/112 %0.0,0/112 %0.0
Neuropathy-sensory,1/306 %0.33,0/304 %0.0,0/112 %0.0,0/112 %0.0
Syncope,1/306 %0.33,0/304 %0.0,1/112 %0.89,0/112 %0.0
Headache,1/306 %0.33,0/304 %0.0,1/112 %0.89,0/112 %0.0
Confusion,0/306 %0.0,1/304 %0.33,0/112 %0.0,0/112 %0.0
Renal failure,0/306 %0.0,1/304 %0.33,0/112 %0.0,0/112 %0.0
Dysuria,1/306 %0.33,0/304 %0.0,0/112 %0.0,0/112 %0.0
Hematuria,2/306 %0.65,0/304 %0.0,0/112 %0.0,0/112 %0.0
ARDS,0/306 %0.0,1/304 %0.33,0/112 %0.0,0/112 %0.0
Cough,0/306 %0.0,1/304 %0.33,0/112 %0.0,0/112 %0.0
Pleural effusion,1/306 %0.33,0/304 %0.0,0/112 %0.0,0/112 %0.0
Dyspnea,2/306 %0.65,3/304 %0.99,2/112 %1.79,0/112 %0.0
Hypertension,0/306 %0.0,1/304 %0.33,0/112 %0.0,0/112 %0.0
Hypotension,1/306 %0.33,1/304 %0.33,1/112 %0.89,0/112 %0.0
Thrombosis/embolism,5/306 %1.63,2/304 %0.66,3/112 %2.68,1/112 %0.89

S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML(https://clinicaltrials.gov/show/NCT00085709)
 ,Induction 7 + 3 + G.O.,Induction 7 + 3,Ara-C Consolidation,Post-consolidation G.O.
 ,A 21 day treatment cycle of Induction 7+3+G.O. with a 2nd 21 day cycle of the same for patients who did not achieve a complete remission (CR) during the first cycle of treatment,A 21 day treatment cycle of Induction 7+3 with a 2nd 21 day cycle of the same for patients who did not achieve a complete remission during the first cycle of treatment,For patients who achieved a CR during induction patients may receive up to 3 28 day cycles of treatment with Ara-C consolidation. Patients who relapse from CR are taken off protocol consolidation treatment.,For patients who remain in CR without relapse patients may receive up to 3 doses of G.O. 28 days apart.
Total serious adverse events,47/293 %16.04,9/293 %3.07,13/375 %3.47,19/78 %24.36
DIC (disseminated intravascular coagulation),1/293 %0.34,0/293 %0.0,0/375 %0.0,0/78 %0.0
Febrile neutropenia,7/293 %2.39,1/293 %0.34,4/375 %1.07,9/78 %11.54
Hemoglobin,1/293 %0.34,0/293 %0.0,0/375 %0.0,0/78 %0.0
Cardiac-ischemia/infarction,1/293 %0.34,0/293 %0.0,0/375 %0.0,0/78 %0.0
Pericardial effusion (non-malignant),1/293 %0.34,0/293 %0.0,0/375 %0.0,0/78 %0.0
Pericarditis,1/293 %0.34,0/293 %0.0,0/375 %0.0,0/78 %0.0
Colitis,0/293 %0.0,1/293 %0.34,0/375 %0.0,0/78 %0.0
Mucositis/stomatitis (clinical exam) - Oral cavity,0/293 %0.0,0/293 %0.0,0/375 %0.0,1/78 %1.28
Nausea,0/293 %0.0,0/293 %0.0,0/375 %0.0,1/78 %1.28
Pain - Rectum,0/293 %0.0,0/293 %0.0,0/375 %0.0,1/78 %1.28
Perforation GI - Colon,0/293 %0.0,1/293 %0.34,0/375 %0.0,0/78 %0.0
Typhlitis (cecal inflammation),1/293 %0.34,1/293 %0.34,0/375 %0.0,0/78 %0.0
Vomiting,0/293 %0.0,0/293 %0.0,0/375 %0.0,1/78 %1.28
Death not associated with CTCAE term - Multi-organ failure,1/293 %0.34,0/293 %0.0,0/375 %0.0,0/78 %0.0
Fatigue (asthenia lethargy malaise),1/293 %0.34,0/293 %0.0,0/375 %0.0,0/78 %0.0
Syndromes-Other (Specify),0/293 %0.0,0/293 %0.0,1/375 %0.27,0/78 %0.0
Hepatobiliary/Pancreas-Other (Specify),1/293 %0.34,0/293 %0.0,0/375 %0.0,0/78 %0.0
Liver dysfunction/failure (clinical),4/293 %1.37,0/293 %0.0,0/375 %0.0,0/78 %0.0
Portal vein flow,1/293 %0.34,0/293 %0.0,0/375 %0.0,0/78 %0.0
Allergic reaction/hypersensitivity (including drug fever),2/293 %0.68,0/293 %0.0,0/375 %0.0,0/78 %0.0
Colitis infectious (e.g. Clostridium difficile),1/293 %0.34,0/293 %0.0,0/375 %0.0,0/78 %0.0
Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Blood,8/293 %2.73,2/293 %0.68,1/375 %0.27,3/78 %3.85
Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Colon,1/293 %0.34,0/293 %0.0,0/375 %0.0,0/78 %0.0
Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Heart (endoca,1/293 %0.34,0/293 %0.0,0/375 %0.0,0/78 %0.0
Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Lung (pneumon,3/293 %1.02,1/293 %0.34,1/375 %0.27,0/78 %0.0
Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Pelvis NOS,1/293 %0.34,0/293 %0.0,0/375 %0.0,0/78 %0.0
Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Skin (celluli,1/293 %0.34,0/293 %0.0,0/375 %0.0,1/78 %1.28
Infection-Other (Specify),0/293 %0.0,0/293 %0.0,0/375 %0.0,1/78 %1.28
ALT SGPT (serum glutamic pyruvic transaminase),5/293 %1.71,0/293 %0.0,1/375 %0.27,1/78 %1.28
AST SGOT (serum glutamic oxaloacetic transaminase),4/293 %1.37,0/293 %0.0,1/375 %0.27,1/78 %1.28
Alkaline phosphatase,0/293 %0.0,0/293 %0.0,1/375 %0.27,0/78 %0.0
Bilirubin (hyperbilirubinemia),3/293 %1.02,0/293 %0.0,0/375 %0.0,0/78 %0.0
Creatinine,1/293 %0.34,0/293 %0.0,0/375 %0.0,0/78 %0.0
Leukocytes (total WBC),5/293 %1.71,0/293 %0.0,1/375 %0.27,2/78 %2.56
Metabolic/Laboratory-Other (Specify),0/293 %0.0,0/293 %0.0,1/375 %0.27,0/78 %0.0
Neutrophils/granulocytes (ANC/AGC),3/293 %1.02,0/293 %0.0,1/375 %0.27,5/78 %6.41
Platelets,9/293 %3.07,1/293 %0.34,1/375 %0.27,2/78 %2.56
Calcium serum-low (hypocalcemia),3/293 %1.02,0/293 %0.0,0/375 %0.0,0/78 %0.0
Dehydration,0/293 %0.0,0/293 %0.0,0/375 %0.0,1/78 %1.28
Glucose serum-high (hyperglycemia),0/293 %0.0,0/293 %0.0,0/375 %0.0,1/78 %1.28
Glucose serum-low (hypoglycemia),1/293 %0.34,0/293 %0.0,0/375 %0.0,0/78 %0.0
Pancreatic endocrine: glucose intolerance,1/293 %0.34,0/293 %0.0,0/375 %0.0,0/78 %0.0
Potassium serum-low (hypokalemia),1/293 %0.34,1/293 %0.34,0/375 %0.0,0/78 %0.0
Uric acid serum-high (hyperuricemia),1/293 %0.34,0/293 %0.0,0/375 %0.0,0/78 %0.0
Pain - Joint,1/293 %0.34,0/293 %0.0,0/375 %0.0,0/78 %0.0
Hemorrhage CNS,5/293 %1.71,1/293 %0.34,0/375 %0.0,0/78 %0.0
Leukoencephalopathy (radiolographic findings),0/293 %0.0,0/293 %0.0,1/375 %0.27,0/78 %0.0
Neurology-Other (Specify),1/293 %0.34,1/293 %0.34,0/375 %0.0,0/78 %0.0
Hemorrhage GU - Bladder,1/293 %0.34,0/293 %0.0,0/375 %0.0,0/78 %0.0
Hemorrhage GU - Kidney,2/293 %0.68,0/293 %0.0,0/375 %0.0,0/78 %0.0
Adult respiratory distress syndrome (ARDS),5/293 %1.71,0/293 %0.0,1/375 %0.27,0/78 %0.0
Dyspnea (shortness of breath),1/293 %0.34,0/293 %0.0,0/375 %0.0,0/78 %0.0
Hemorrhage pulmonary/upper respiratory - Lung,5/293 %1.71,0/293 %0.0,0/375 %0.0,0/78 %0.0
Hypoxia,4/293 %1.37,0/293 %0.0,1/375 %0.27,0/78 %0.0
Pleural effusion (non-malignant),2/293 %0.68,0/293 %0.0,0/375 %0.0,0/78 %0.0
Pneumonitis/pulmonary infiltrates,2/293 %0.68,0/293 %0.0,1/375 %0.27,0/78 %0.0
Pulmonary/Upper Respiratory-Other (Specify),0/293 %0.0,0/293 %0.0,1/375 %0.27,0/78 %0.0
Rash/desquamation,1/293 %0.34,0/293 %0.0,0/375 %0.0,0/78 %0.0
Hemorrhage/Bleeding-Other (Specify),0/293 %0.0,0/293 %0.0,1/375 %0.27,0/78 %0.0
Hypotension,1/293 %0.34,0/293 %0.0,1/375 %0.27,0/78 %0.0
Phlebitis (including superficial thrombosis),1/293 %0.34,0/293 %0.0,0/375 %0.0,0/78 %0.0
Thrombosis/thrombus/embolism,0/293 %0.0,0/293 %0.0,1/375 %0.27,0/78 %0.0

Universal Granulocyte Macrophage-colony Stimulating Factor (GM-CSF)-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell Lymphoma(https://clinicaltrials.gov/show/NCT00101101)
 ,Vaccine and Conventional Therapy
 ,Patients were treated with 3-6 cycles of chemotherapy +/- rituximab with type and duration at the discretion of the individual clinician.  Chemotherapy: 6 courses of cyclophosphamide doxorubicin vincristine and prednisone (CHOP) OR 3 courses of hyperfractionated cyclophosphamide vincristine doxorubicin and dexamethasone alternating with high-dose methotrexate and cytarabine (hyper-CVAD) for patients who have relapsed after CHOP.  Patients who achieve a partial or complete response after completion of chemotherapy proceed to autologous tumor cell-based vaccine therapy.  Patients who have stable or responding disease at 12 months receive 4 additional courses of booster vaccine and low-dose IL-2.  Treatment continues in the absence of disease progression or unacceptable toxicity.
Total serious adverse events,2/43 %4.65
Leukocyte,1/43 %2.33
Granulocyte,1/43 %2.33
Cough,1/43 %2.33

S0333 Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia(https://clinicaltrials.gov/show/NCT00109837)
 ,First Induction,Second Induction,Consolidation,Maintenance
 ,One induction cycle with allopurinol daunorubicin vincristine prednisone amd PEG- L-asparaginase.,A second induction cycle with allopurinol  dexamergasone G-CSF high-dose ara-C and mitoxantrone,Patients who had a CR after induction could receive one course of consolidation therapy consisting of cyclophosphamide ara-C 6-mercaptopurine G-CSF and methotrexate,Patient with a CR after consolidation could receive up to four courses of maintenance. Course 1 included 6-mercaptopurine and methotrexate. course 2 included vincristine adriamycin and dexamethasone. course 3 included cyclophosphamide 6-thioguanine and ara-C. course 4 included 6-mercaptopurine and methotrexate
Total serious adverse events,2/75 %2.67,2/56 %3.57,1/33 %3.03,0/12 %0.0
Pancreatitis,1/75 %1.33,0/56 %0.0,0/33 %0.0,0/12 %0.0
Death not associated with CTCAE term - Multi-organ failure,1/75 %1.33,0/56 %0.0,0/33 %0.0,0/12 %0.0
Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Blood,0/75 %0.0,1/56 %1.79,0/33 %0.0,0/12 %0.0
Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Lung (pneumon,0/75 %0.0,1/56 %1.79,0/33 %0.0,0/12 %0.0
Hemorrhage/bleeding associated with surgery intra-operative or post-operative,0/75 %0.0,1/56 %1.79,0/33 %0.0,0/12 %0.0
Leukocytes (total WBC),0/75 %0.0,0/56 %0.0,1/33 %3.03,0/12 %0.0
Platelets,0/75 %0.0,0/56 %0.0,1/33 %3.03,0/12 %0.0
Triglyceride serum-high (hypertriglyceridemia),1/75 %1.33,0/56 %0.0,0/33 %0.0,0/12 %0.0

Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Leukemia(https://clinicaltrials.gov/show/NCT00133991)
 ,R-CVP + HiCy
 ,Protocol intervention consists of two fifteen-day cycles of cyclophosphamide (Cy) vincristine (V) prednisone (P) rituximab (R) with filgrastim support. CNS intervention consists of three days of cytarabine and hydrocortisone and one day of methotrexate (with leucovorin support) for each cycle. After those two cycles rituximab and high-dose cyclophosphamide (HiCy) will be given.
Total all-cause mortality,9/21 %42.86
Total serious adverse events,12/21 %57.14
Atrial fibrillation,1/21 %4.76
Hypotension,1/21 %4.76
Pericarditis,1/21 %4.76
Colitis,1/21 %4.76
Somnolence,1/21 %4.76
Ascites,1/21 %4.76
Blood infection,1/21 %4.76
Encephalitis,1/21 %4.76
Febrile neutropenia,2/21 %9.52
Pneumonia,1/21 %4.76
Sepsis,1/21 %4.76
Tumor lysis syndrome,1/21 %4.76
Pain - chest,1/21 %4.76
Wound complication,1/21 %4.76
Stroke,1/21 %4.76
Subdural hematoma,1/21 %4.76
Acute respiratory distress syndrome,1/21 %4.76
Dyspnea,1/21 %4.76
Hypoxia,1/21 %4.76

Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia(https://clinicaltrials.gov/show/NCT00186875)
 ,Standard Risk,High Risk
 ,Participants with isolated extramedullary relapse (with blasts in bone marrow (BM) <5%) regardless of the timing of relapse and participants with B-lineage ALL who develop a late hematological relapse (isolated BM or combined).,Participants with T-cell ALL who develop a hematological [isolated bone marrow (BM) or combined] relapse irrespective of length of initial remission participants with B-lineage ALL who develop early hematological relapse (isolated BM or combined) and participants relapsing after hematopoietic stem cell transplantation.
Total serious adverse events,6/26 %23.08,2/14 %14.29
Iron overload,0/26 %0.0,1/14 %7.14
Hemorrhage GI Stomach,1/26 %3.85,0/14 %0.0
Prolonged QTc interval,1/26 %3.85,0/14 %0.0
Supraventricular and nodal arrhythmia supraventricular tachycardia,0/26 %0.0,1/14 %7.14
Ventricular arrhythmia ventricular arrhythmia NOS,0/26 %0.0,1/14 %7.14
Hypotension,1/26 %3.85,1/14 %7.14
Typhlitis (cecal inflammation),1/26 %3.85,0/14 %0.0
Ulcer GI Stomach,1/26 %3.85,0/14 %0.0
Allergic reaction/hypersensitivity (including drug fever),1/26 %3.85,0/14 %0.0
Infection blood,1/26 %3.85,1/14 %7.14
Infection brain (encephalitis infectious),1/26 %3.85,1/14 %7.14
Infection Catheter-related,1/26 %3.85,0/14 %0.0
Renal failure,0/26 %0.0,1/14 %7.14
Hypoxia,0/26 %0.0,1/14 %7.14

High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study(https://clinicaltrials.gov/show/NCT00288626)
 ,HDIT and HCT
 ,Participants recv'd Granulocyte Colony Stimulating Factor (G-CSF) by injection for 4-5 days to increase the number of blood stem cells in the blood stream by mobilizing them from the bone marrow. Leukapheresis was performed until > 2.0 x 10^6 CD34+ hematopoietic progenitor cells (HPCs) per kg were collected and frozen for future use. After 7 days following the last G-CSF dose patients were hospitalized and received high-dose immunosuppression (HDIT) and immunosuppressive agent thymoglobulin 2.5 mg/kg over the course of 6 days. HDIT consisted of carmustine 300mg/m^2 etoposide 200 mg/m^2 cytarabine 200 mg/m^2 and melphalan 140 mg/m^2. CD34+ HPCs were thawed and infused according to institutional best practice for blood component transfusion over approximately 30 minutes. Patients were hospitalized until recovery of ANC to > 500/uL for at least 2 days. Prednisone was administered (0.5 mg/kg/day) from Days 7 to 21 after HCT and tapered over 2 weeks to prevent engraftment syndrome.
Total serious adverse events,16/25 %64.0
Leukopenia,2/25 %8.0
Lymphopenia,3/25 %12.0
Atrioventricular block,1/25 %4.0
Cardio-respiratory arrest,1/25 %4.0
Arteriovenous malformation,1/25 %4.0
Vision blurred,1/25 %4.0
Constipation,1/25 %4.0
Chest pain,1/25 %4.0
Fatigue,1/25 %4.0
Pyrexia,2/25 %8.0
Gallbladder obstruction,1/25 %4.0
Engraftment syndrome,1/25 %4.0
Acinetobacter infection,1/25 %4.0
Bacteraemia,1/25 %4.0
Cellulitis,1/25 %4.0
Chronic sinusitis,1/25 %4.0
Epstein-Barr virus infection,1/25 %4.0
Meningitis aseptic,1/25 %4.0
Pneumonia,1/25 %4.0
Sepsis,1/25 %4.0
Urinary tract infection,1/25 %4.0
Alanine aminotransferase increased,1/25 %4.0
Dehydration,1/25 %4.0
Hyperuricaemia,1/25 %4.0
Hypokalaemia,2/25 %8.0
Back pain,1/25 %4.0
Pain in extremity,2/25 %8.0
Breast cancer in situ,1/25 %4.0
Anoxic encephalopathy,1/25 %4.0
Headache,1/25 %4.0
Hemiparesis,2/25 %8.0
Motor dysfunction,1/25 %4.0
Multiple sclerosis,3/25 %12.0
Neurological symptom,1/25 %4.0
Pregnancy,1/25 %4.0
Depression,1/25 %4.0
Mania,1/25 %4.0
Suicide attempt,2/25 %8.0
Asthma,1/25 %4.0
Dyspnoea,1/25 %4.0
Pneumonitis,1/25 %4.0
Pulmonary embolism,2/25 %8.0
Respiratory arrest,1/25 %4.0
Respiratory failure,1/25 %4.0
Deep vein thrombosis,1/25 %4.0
Jugular vein thrombosis,1/25 %4.0

Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell Lymphoma(https://clinicaltrials.gov/show/NCT00290433)
 ,HCVIDDOXIL Regimen
 ,Cycle 1: Cyclophosphamide 300 mg/m^2 intravenous (IV) twice a day on Days 1-3. Mesna 600 mg/m^2 continuous IV Days 1-3. Doxil 25 mg/m^2 IV over 1 hour on Day 2. Vincristine 1.4 mg/m^2 IV on Days 4 and 11. Dexamethasone 40 mg Iv or oral on Days 1 - 4 and 11 - 14.  Cycle 2: Methotrexate 200 mg/m^2 over 2 hours on Day 1 and 800 mg/m^2 over 22 hours on day 1. Cytarabine 3 Gm/m^2 IV twice a day on Days 2 and 3.
Total serious adverse events,1/53 %1.89
massive cytomegalovirus infection,1/53 %1.89

Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger(https://clinicaltrials.gov/show/NCT00290498)
 ,RHCVAD,RCHOP
 ,Rituximab 375mg/m2 intravenously on day 1cyclophosphamide 300mg/m2 intravenously every 12 h for six doses on days 13doxorubicin 50mg/m2 intravenously on day 5vincristine 1.4mg/m2 or maximum 2mg intravenously on days 5 and 12and dexamethasone 40mg intravenously or orally on days 25alternating with RMA(cycles 246)rituximab 375mg/2 intravenously on day 1methotrexate 200mg/m2 over 2 h followed by 800mg/m2 over 22 h on day 1 and cytarabine 3g/m2 every 12 h for four doses on days 3 and 4 with a 21 day cycle.,RCHOP consisted of rituximab 375mg/m2 intravenously on day 1cyclophosphamide 750mg/m2 intravenously on day 1doxorubicin 50mg/m2 intravenously on day 1 either over 15min or 48 h  vincristine 1.4mg/m2 or maximum 2mg intravenouslyand prednisone 100mg orally on days 15with a 21d cycle.
Total all-cause mortality,4/49 %8.16,0/10 %0.0
Total serious adverse events,49/49 %100.0,7/10 %70.0
BLOOD BONE MARROW (OTHER),1/49 %2.04,0/10 %0.0
FEBRILE NEUTROPENIA,27/49 %55.1,2/10 %20.0
HEMORRHAGE,8/49 %16.33,1/10 %10.0
PETECHIAE,6/49 %12.24,0/10 %0.0
PHLEBITIS,1/49 %2.04,0/10 %0.0
ATRIAL FIBRILLATION,1/49 %2.04,0/10 %0.0
ATRIAL FLUTTER,2/49 %4.08,0/10 %0.0
HYPERTENSION,9/49 %18.37,0/10 %0.0
HYPOTENSION,13/49 %26.53,0/10 %0.0
PALPITATIONS,1/49 %2.04,1/10 %10.0
PERICARDIAL EFFUSION,1/49 %2.04,1/10 %10.0
SINUS BRADYCARDIA,3/49 %6.12,0/10 %0.0
SINUS TACHYCARDIA,9/49 %18.37,0/10 %0.0
TACHYCARDIA,2/49 %4.08,1/10 %10.0
AUDITORY/EAR (OTHER),1/49 %2.04,0/10 %0.0
TINNITUS,4/49 %8.16,0/10 %0.0
ENDOCRINE (OTHER),1/49 %2.04,0/10 %0.0
HYPERTHYROIDISM,1/49 %2.04,0/10 %0.0
HYPOTHYROIDISM,1/49 %2.04,0/10 %0.0
BLURRED VISION,0/49 %0.0,2/10 %20.0
DRY EYE,2/49 %4.08,0/10 %0.0
OCULAR/VISUAL(OTHER),1/49 %2.04,0/10 %0.0
PAIN (EYE),1/49 %2.04,0/10 %0.0
WATERY EYE,4/49 %8.16,2/10 %20.0
ABDOMINAL CRAMPING,1/49 %2.04,1/10 %10.0
CONSTIPATION,16/49 %32.65,0/10 %0.0
DIARRHEA,11/49 %22.45,2/10 %20.0
DISTENSION/BLOATING,1/49 %2.04,0/10 %0.0
DRY MOUTH,2/49 %4.08,1/10 %10.0
DYSPHAGIA,2/49 %4.08,0/10 %0.0
GASTRITIS,7/49 %14.29,0/10 %0.0
GERD,2/49 %4.08,0/10 %0.0
GASTROINTESTINAL (OTHER),2/49 %4.08,1/10 %10.0
HEARTBURN,5/49 %10.2,0/10 %0.0
HEMORRHOIDS,6/49 %12.24,0/10 %0.0
NAUSEA,30/49 %61.22,6/10 %60.0
OBSTRUCTIONGI,2/49 %4.08,0/10 %0.0
PAIN (ABDOMEN NOS),6/49 %12.24,2/10 %20.0
PAIN (ANUS),0/49 %0.0,1/10 %10.0
PAIN( ORALCAVITY),1/49 %2.04,0/10 %0.0
PAIN( STOMACH),1/49 %2.04,0/10 %0.0
STOMATITIS,3/49 %6.12,2/10 %20.0
TASTE ALTERATION,2/49 %4.08,0/10 %0.0
TEETH,2/49 %4.08,0/10 %0.0
VOMITING,24/49 %48.98,5/10 %50.0
DEATH NOS,2/49 %4.08,0/10 %0.0
DRUG FEVER,1/49 %2.04,0/10 %0.0
EDEMA,8/49 %16.33,3/10 %30.0
EDEMA:HEAD AND NECK,2/49 %4.08,0/10 %0.0
EDEMA:LIMB,13/49 %26.53,3/10 %30.0
EDEMA:TRUNK/GENITAL,2/49 %4.08,0/10 %0.0
EDEMA (LARYNX),1/49 %2.04,0/10 %0.0
FATIGUE,31/49 %63.27,2/10 %20.0
FEVER UNKNOWN ORIGIN,2/49 %4.08,1/10 %10.0
FEVER WITHOUT NEUTROPENI,14/49 %28.57,3/10 %30.0
FLU-LIKE SYNDROME,1/49 %2.04,1/10 %10.0
GAIT/WALKING,1/49 %2.04,0/10 %0.0
PAIN (DENTAL/TEETH/PERID,2/49 %4.08,1/10 %10.0
PAIN (NOS),4/49 %8.16,2/10 %20.0
RIGORS/CHILLS,18/49 %36.73,1/10 %10.0
ALLERGIC REACTION DRUG,10/49 %20.41,1/10 %10.0
ALLERGY (OTHER),1/49 %2.04,1/10 %10.0
AUTOIMMUNE REACTION,1/49 %2.04,0/10 %0.0
CANDIDIASIS,3/49 %6.12,0/10 %0.0
INFECTION(S),47/49 %95.92,6/10 %60.0
BRUISING (NON-THROMBOPENIA),1/49 %2.04,0/10 %0.0
ALKALINE PHOSPHATASE INCR,4/49 %8.16,1/10 %10.0
ALTSGPT INCR,17/49 %34.69,3/10 %30.0
ASTSGOT INCR,17/49 %34.69,1/10 %10.0
BILIRUBIN INCREASE,9/49 %18.37,0/10 %0.0
CHOLESTEROLSERUM-HIGH,1/49 %2.04,0/10 %0.0
CREATININE INCREASE,7/49 %14.29,2/10 %20.0
ELEV LDH (OTHER),6/49 %12.24,3/10 %30.0
GRANULOCYTOPENIA,0/49 %0.0,1/10 %10.0
HEMOGLOBIN DECREASE,48/49 %97.96,7/10 %70.0
HYPERGLYCEMIA,25/49 %51.02,6/10 %60.0
HYPERKALEMIA,2/49 %4.08,0/10 %0.0
HYPERURICEMIA,4/49 %8.16,5/10 %50.0
HYPOALBUMINEMIA,27/49 %55.1,4/10 %40.0
HYPOCALCEMIA,15/49 %30.61,4/10 %40.0
HYPOGLYCEMIA,1/49 %2.04,1/10 %10.0
HYPOKALEMIA,15/49 %30.61,4/10 %40.0
HYPOMAGNESEMIA,14/49 %28.57,6/10 %60.0
HYPONATREMIA,7/49 %14.29,2/10 %20.0
HYPOPHOSPHATEMIA,2/49 %4.08,0/10 %0.0
LEUKOPENIA,48/49 %97.96,7/10 %70.0
NEUTROPENIA,46/49 %93.88,4/10 %40.0
OLIGURIA,1/49 %2.04,0/10 %0.0
PLATELETS DECREASED,39/49 %79.59,3/10 %30.0
THROMBOCYTOPENIA,7/49 %14.29,1/10 %10.0
ANOREXIA,1/49 %2.04,1/10 %10.0
DEHYDRATION,2/49 %4.08,0/10 %0.0
DIABETES,3/49 %6.12,0/10 %0.0
METABOLIC/LABORATORY (OTHER),1/49 %2.04,1/10 %10.0
OBESITY,2/49 %4.08,0/10 %0.0
WEIGHT GAIN,1/49 %2.04,1/10 %10.0
WEIGHT LOSS,1/49 %2.04,1/10 %10.0
MUSCLE WEAKNESS,8/49 %16.33,1/10 %10.0
MYALGIA,3/49 %6.12,0/10 %0.0
MYOSITIS,1/49 %2.04,0/10 %0.0
PAIN (BACK),10/49 %20.41,1/10 %10.0
PAIN (BONE),5/49 %10.2,1/10 %10.0
PAIN (EXTREMITY-LIMB),6/49 %12.24,0/10 %0.0
PAIN (JOINT),3/49 %6.12,0/10 %0.0
PAIN (MUSCLE),7/49 %14.29,2/10 %20.0
PAIN (NECK),5/49 %10.2,0/10 %0.0
PAIN (PELVIS),1/49 %2.04,0/10 %0.0
COGNITIVE DISTURBANCE,1/49 %2.04,0/10 %0.0
DIZZINESS,14/49 %28.57,3/10 %30.0
HEADACHE,1/49 %2.04,0/10 %0.0
MEMORY IMPAIRMENT,1/49 %2.04,0/10 %0.0
NEUROPATHY:MOTOR,1/49 %2.04,3/10 %30.0
NEUROPATHY:SENSORY,20/49 %40.82,4/10 %40.0
PAIN( HEAD/HEADACHE),22/49 %44.9,3/10 %30.0
PAIN (NEURALGIA/PERIPHERALNER,1/49 %2.04,0/10 %0.0
SENSORY,2/49 %4.08,1/10 %10.0
SYNCOPE (FAINTING),7/49 %14.29,0/10 %0.0
CONFUSION,1/49 %2.04,0/10 %0.0
INSOMNIA,12/49 %24.49,2/10 %20.0
MOOD ALTERATION,16/49 %32.65,2/10 %20.0
DYSURIA,1/49 %2.04,1/10 %10.0
HEMATURIA,1/49 %2.04,0/10 %0.0
POLYURIA,1/49 %2.04,0/10 %0.0
RENAL FAILURE,4/49 %8.16,0/10 %0.0
URINARY FREQUENCY,1/49 %2.04,1/10 %10.0
HOT FLASHES,1/49 %2.04,0/10 %0.0
MENORRHAGIA,1/49 %2.04,0/10 %0.0
PAIN (BREAST),1/49 %2.04,0/10 %0.0
PAIN (TESTICLE),2/49 %4.08,0/10 %0.0
PAIN (VAGINA),1/49 %2.04,0/10 %0.0
VAGINAL DRYNESS,1/49 %2.04,0/10 %0.0
ALLERGIC RHINITIS,9/49 %18.37,3/10 %30.0
COUGH,17/49 %34.69,4/10 %40.0
DYSPNEA,22/49 %44.9,3/10 %30.0
HEMOPTYSIS,1/49 %2.04,1/10 %10.0
HORSENESS,0/49 %0.0,1/10 %10.0
HYPOXIA,1/49 %2.04,1/10 %10.0
MUCOSITIS,20/49 %40.82,3/10 %30.0
PAIN (CHEST/THORAX),7/49 %14.29,0/10 %0.0
PAIN (PLEURITIC),0/49 %0.0,1/10 %10.0
PAIN (THROAT/PHARYNX/LARYNX),3/49 %6.12,0/10 %0.0
PLEURAL EFFUSION,8/49 %16.33,0/10 %0.0
PNEUMONITIS,1/49 %2.04,0/10 %0.0
PNEUMOTHORAX,1/49 %2.04,0/10 %0.0
PULMONARY(OTHER),1/49 %2.04,1/10 %10.0
RESPIRATORY FAILURE,1/49 %2.04,0/10 %0.0
RHINORRHEA,6/49 %12.24,0/10 %0.0
SORE THROAT,1/49 %2.04,0/10 %0.0
UPPER RESPIRATORY INFECT,1/49 %2.04,0/10 %0.0
VOICE CHANGES,3/49 %6.12,1/10 %10.0
ALOPECIA,20/49 %40.82,5/10 %50.0
DERMATOLOGY/SKIN (OTHER),1/49 %2.04,0/10 %0.0
DRY SKIN,3/49 %6.12,0/10 %0.0
ERYTHEMA MULTIFORME,5/49 %10.2,0/10 %0.0
HAND-FOOT SYNDROME,4/49 %8.16,0/10 %0.0
HYPERPIGMENTATION,1/49 %2.04,0/10 %0.0
PRURITUS,4/49 %8.16,0/10 %0.0
PRURITUS/ITCHING,1/49 %2.04,0/10 %0.0
PULMONARY EMBOLISM,1/49 %2.04,0/10 %0.0
RASH/DESQUAMATION,14/49 %28.57,2/10 %20.0
SWEATING,7/49 %14.29,1/10 %10.0
ULCERATION,1/49 %2.04,0/10 %0.0
FLUSHING,4/49 %8.16,0/10 %0.0
HEMATOMA,0/49 %0.0,1/10 %10.0
SYNDROMES (OTHER),1/49 %2.04,0/10 %0.0
THROMBOSIS/THROMBUS/EMBOLISM,12/49 %24.49,1/10 %10.0
VASCULAR (OTHER),1/49 %2.04,1/10 %10.0

A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I)(https://clinicaltrials.gov/show/NCT00317642)
 ,Clofarabine (IV Formulation) and Cytarabine,Placebo and Cytarabine,Overall
 ,Participants received clofarabine 40 mg/m^2 administered as a 1-hour intravenous (IV) infusion followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour IV infusion for 5 days (induction and re-induction) or 4 days (consolidation). Participants could receive up to 3 cycles of treatment: induction re-induction (if the participant had not achieved remission following induction but hematological improvement was noted) and consolidation.,Participants received placebo (sodium chloride) administered as a 1-hour IV infusion followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour IV infusion for 5 days (induction and re-induction) or 4 days (consolidation). Participants could receive up to 3 cycles of treatment: induction re-induction and consolidation.,Combined total for the two Arms/Groups
Total serious adverse events,97/161 %60.25,76/155 %49.03,173/316 %54.75
Bone marrow failure,1/161 %0.62,0/155 %0.0,1/316 %0.32
Febrile neutropenia,25/161 %15.53,19/155 %12.26,44/316 %13.92
Leukopenia,1/161 %0.62,2/155 %1.29,3/316 %0.95
Lymphadenitis,0/161 %0.0,1/155 %0.65,1/316 %0.32
Neutropenia,2/161 %1.24,4/155 %2.58,6/316 %1.9
Pancytopenia,0/161 %0.0,2/155 %1.29,2/316 %0.63
Thrombocytopenia,2/161 %1.24,3/155 %1.94,5/316 %1.58
Acute myocardial infarction,3/161 %1.86,0/155 %0.0,3/316 %0.95
Angina pectoris,1/161 %0.62,0/155 %0.0,1/316 %0.32
Atrial fibrillation,2/161 %1.24,1/155 %0.65,3/316 %0.95
Atrial flutter,0/161 %0.0,1/155 %0.65,1/316 %0.32
Bradycardia,1/161 %0.62,0/155 %0.0,1/316 %0.32
Cardiac arrest,1/161 %0.62,1/155 %0.65,2/316 %0.63
Cardiac failure,1/161 %0.62,0/155 %0.0,1/316 %0.32
Cardiac failure congestive,1/161 %0.62,2/155 %1.29,3/316 %0.95
Cardio-respiratory arrest,1/161 %0.62,1/155 %0.65,2/316 %0.63
Cardiogenic shock,1/161 %0.62,0/155 %0.0,1/316 %0.32
Myocardial infarction,2/161 %1.24,0/155 %0.0,2/316 %0.63
Myocardial ischaemia,1/161 %0.62,0/155 %0.0,1/316 %0.32
Pericarditis,1/161 %0.62,0/155 %0.0,1/316 %0.32
Stress cardiomyopathy,1/161 %0.62,0/155 %0.0,1/316 %0.32
Supraventricular tachycardia,1/161 %0.62,0/155 %0.0,1/316 %0.32
Tachycardia,0/161 %0.0,1/155 %0.65,1/316 %0.32
Blindness unilateral,1/161 %0.62,0/155 %0.0,1/316 %0.32
Abdominal pain,1/161 %0.62,1/155 %0.65,2/316 %0.63
Caecitis,0/161 %0.0,2/155 %1.29,2/316 %0.63
Colitis,0/161 %0.0,1/155 %0.65,1/316 %0.32
Diarrhoea,2/161 %1.24,1/155 %0.65,3/316 %0.95
Gastrointestinal haemorrhage,2/161 %1.24,1/155 %0.65,3/316 %0.95
Lower gastrointestinal haemorrhage,0/161 %0.0,1/155 %0.65,1/316 %0.32
Melaena,1/161 %0.62,0/155 %0.0,1/316 %0.32
Asthenia,3/161 %1.86,1/155 %0.65,4/316 %1.27
Death,1/161 %0.62,0/155 %0.0,1/316 %0.32
Fatigue,1/161 %0.62,0/155 %0.0,1/316 %0.32
Generalised oedema,1/161 %0.62,0/155 %0.0,1/316 %0.32
Hypothermia,0/161 %0.0,1/155 %0.65,1/316 %0.32
Inflammation,0/161 %0.0,1/155 %0.65,1/316 %0.32
Multi-organ failure,3/161 %1.86,1/155 %0.65,4/316 %1.27
Oedema peripheral,1/161 %0.62,0/155 %0.0,1/316 %0.32
Pain,1/161 %0.62,0/155 %0.0,1/316 %0.32
Pyrexia,7/161 %4.35,9/155 %5.81,16/316 %5.06
Venoocclusive liver disease,1/161 %0.62,0/155 %0.0,1/316 %0.32
Anaphylactic reaction,0/161 %0.0,1/155 %0.65,1/316 %0.32
Graft versus host disease,0/161 %0.0,1/155 %0.65,1/316 %0.32
Alpha haemolytic streptococcal infection,0/161 %0.0,1/155 %0.65,1/316 %0.32
Appendicitis,0/161 %0.0,1/155 %0.65,1/316 %0.32
Bacteraemia,7/161 %4.35,3/155 %1.94,10/316 %3.16
Bacterial infection,0/161 %0.0,1/155 %0.65,1/316 %0.32
Bacterial sepsis,1/161 %0.62,0/155 %0.0,1/316 %0.32
Bronchopulmonary aspergillosis,2/161 %1.24,1/155 %0.65,3/316 %0.95
Cellulitis,0/161 %0.0,3/155 %1.94,3/316 %0.95
Clostridial infection,1/161 %0.62,0/155 %0.0,1/316 %0.32
Clostridium difficile colitis,3/161 %1.86,2/155 %1.29,5/316 %1.58
Corynebacterium sepsis,1/161 %0.62,0/155 %0.0,1/316 %0.32
Device related infection,1/161 %0.62,0/155 %0.0,1/316 %0.32
Diverticulitis,0/161 %0.0,1/155 %0.65,1/316 %0.32
Enterobacter bacteraemia,0/161 %0.0,2/155 %1.29,2/316 %0.63
Enterobacter sepsis,1/161 %0.62,0/155 %0.0,1/316 %0.32
Enterococcal bacteraemia,6/161 %3.73,1/155 %0.65,7/316 %2.22
Enterococcal sepsis,3/161 %1.86,0/155 %0.0,3/316 %0.95
Escherichia bacteraemia,4/161 %2.48,0/155 %0.0,4/316 %1.27
Escherichia infection,0/161 %0.0,1/155 %0.65,1/316 %0.32
Escherichia sepsis,2/161 %1.24,0/155 %0.0,2/316 %0.63
Fungal infection,1/161 %0.62,0/155 %0.0,1/316 %0.32
Haematoma infection,1/161 %0.62,0/155 %0.0,1/316 %0.32
Herpes zoster,0/161 %0.0,1/155 %0.65,1/316 %0.32
Keratitis herpetic,1/161 %0.62,0/155 %0.0,1/316 %0.32
Klebsiella bacteraemia,1/161 %0.62,0/155 %0.0,1/316 %0.32
Klebsiella sepsis,0/161 %0.0,2/155 %1.29,2/316 %0.63
Lobar pneumonia,0/161 %0.0,1/155 %0.65,1/316 %0.32
Neutropenic sepsis,4/161 %2.48,0/155 %0.0,4/316 %1.27
Oral herpes,1/161 %0.62,0/155 %0.0,1/316 %0.32
Parainfluenzae virus infection,1/161 %0.62,0/155 %0.0,1/316 %0.32
Pneumonia,13/161 %8.07,12/155 %7.74,25/316 %7.91
Pneumonia bacterial,3/161 %1.86,0/155 %0.0,3/316 %0.95
Pneumonia fungal,5/161 %3.11,0/155 %0.0,5/316 %1.58
Pneumonia viral,0/161 %0.0,1/155 %0.65,1/316 %0.32
Pseudomonal bacteraemia,1/161 %0.62,1/155 %0.65,2/316 %0.63
Sepsis,8/161 %4.97,3/155 %1.94,11/316 %3.48
Sepsis syndrome,1/161 %0.62,0/155 %0.0,1/316 %0.32
Septic shock,6/161 %3.73,0/155 %0.0,6/316 %1.9
Serratia sepsis,1/161 %0.62,0/155 %0.0,1/316 %0.32
Sinusitis,1/161 %0.62,0/155 %0.0,1/316 %0.32
Staphylococcal bacteraemia,2/161 %1.24,2/155 %1.29,4/316 %1.27
Staphylococcal infection,1/161 %0.62,1/155 %0.65,2/316 %0.63
Staphylococcal scalded skin syndrome,1/161 %0.62,0/155 %0.0,1/316 %0.32
Staphylococcal sepsis,2/161 %1.24,0/155 %0.0,2/316 %0.63
Streptococcal bacteraemia,4/161 %2.48,0/155 %0.0,4/316 %1.27
Streptococcal sepsis,2/161 %1.24,0/155 %0.0,2/316 %0.63
Systemic candida,1/161 %0.62,0/155 %0.0,1/316 %0.32
Upper respiratory fungal infection,1/161 %0.62,0/155 %0.0,1/316 %0.32
Urinary tract infection,0/161 %0.0,1/155 %0.65,1/316 %0.32
Urinary tract infection bacterial,1/161 %0.62,2/155 %1.29,3/316 %0.95
Urinary tract infection enterococcal,1/161 %0.62,0/155 %0.0,1/316 %0.32
Zygomycosis,0/161 %0.0,1/155 %0.65,1/316 %0.32
Femoral neck fracture,1/161 %0.62,0/155 %0.0,1/316 %0.32
Refractoriness to platelet transfusion,1/161 %0.62,0/155 %0.0,1/316 %0.32
Subdural haematoma,3/161 %1.86,1/155 %0.65,4/316 %1.27
Aspartate aminotransferase increased,1/161 %0.62,0/155 %0.0,1/316 %0.32
Blood bilirubin increased,1/161 %0.62,0/155 %0.0,1/316 %0.32
Blood phosphorus decreased,1/161 %0.62,0/155 %0.0,1/316 %0.32
Ejection fraction decreased,1/161 %0.62,0/155 %0.0,1/316 %0.32
Electrocardiogram QT prolonged,1/161 %0.62,0/155 %0.0,1/316 %0.32
Lipase increased,1/161 %0.62,0/155 %0.0,1/316 %0.32
Troponin I increased,1/161 %0.62,0/155 %0.0,1/316 %0.32
White blood cell count decreased,1/161 %0.62,0/155 %0.0,1/316 %0.32
Acidosis,0/161 %0.0,1/155 %0.65,1/316 %0.32
Dehydration,1/161 %0.62,0/155 %0.0,1/316 %0.32
Fluid overload,1/161 %0.62,0/155 %0.0,1/316 %0.32
Hyperuricaemia,1/161 %0.62,0/155 %0.0,1/316 %0.32
Hypokalaemia,1/161 %0.62,1/155 %0.65,2/316 %0.63
Metabolic acidosis,1/161 %0.62,0/155 %0.0,1/316 %0.32
Tumour lysis syndrome,1/161 %0.62,0/155 %0.0,1/316 %0.32
Back pain,1/161 %0.62,0/155 %0.0,1/316 %0.32
Muscle disorder,1/161 %0.62,0/155 %0.0,1/316 %0.32
Osteoarthritis,0/161 %0.0,1/155 %0.65,1/316 %0.32
Acute myeloid leukaemia,4/161 %2.48,5/155 %3.23,9/316 %2.85
Leukaemia,1/161 %0.62,0/155 %0.0,1/316 %0.32
Neoplasm malignant,2/161 %1.24,4/155 %2.58,6/316 %1.9
Cerebral haemorrhage,2/161 %1.24,2/155 %1.29,4/316 %1.27
Cerebral infarction,0/161 %0.0,1/155 %0.65,1/316 %0.32
Cerebrovascular accident,1/161 %0.62,1/155 %0.65,2/316 %0.63
Convulsion,1/161 %0.62,1/155 %0.65,2/316 %0.63
Encephalopathy,1/161 %0.62,1/155 %0.65,2/316 %0.63
Hypoxic-ischaemic encephalopathy,1/161 %0.62,0/155 %0.0,1/316 %0.32
Neuropathy peripheral,1/161 %0.62,0/155 %0.0,1/316 %0.32
Neurotoxicity,0/161 %0.0,1/155 %0.65,1/316 %0.32
Peripheral sensorimotor neuropathy,1/161 %0.62,0/155 %0.0,1/316 %0.32
Somnolence,0/161 %0.0,1/155 %0.65,1/316 %0.32
Status epilepticus,1/161 %0.62,0/155 %0.0,1/316 %0.32
Syncope,2/161 %1.24,0/155 %0.0,2/316 %0.63
Agitation,1/161 %0.62,1/155 %0.65,2/316 %0.63
Confusional state,0/161 %0.0,2/155 %1.29,2/316 %0.63
Mental status changes,1/161 %0.62,1/155 %0.65,2/316 %0.63
Anuria,0/161 %0.0,1/155 %0.65,1/316 %0.32
Haematuria,0/161 %0.0,1/155 %0.65,1/316 %0.32
Renal failure,1/161 %0.62,0/155 %0.0,1/316 %0.32
Renal failure acute,5/161 %3.11,1/155 %0.65,6/316 %1.9
Renal failure chronic,1/161 %0.62,0/155 %0.0,1/316 %0.32
Renal infarct,0/161 %0.0,1/155 %0.65,1/316 %0.32
Acute respiratory distress syndrome,4/161 %2.48,0/155 %0.0,4/316 %1.27
Acute respiratory failure,2/161 %1.24,0/155 %0.0,2/316 %0.63
Dyspnoea,1/161 %0.62,3/155 %1.94,4/316 %1.27
Epistaxis,1/161 %0.62,0/155 %0.0,1/316 %0.32
Haemoptysis,0/161 %0.0,2/155 %1.29,2/316 %0.63
Hypoxia,0/161 %0.0,1/155 %0.65,1/316 %0.32
Interstitial lung disease,1/161 %0.62,0/155 %0.0,1/316 %0.32
Lung infiltration,0/161 %0.0,2/155 %1.29,2/316 %0.63
Pneumonia aspiration,0/161 %0.0,1/155 %0.65,1/316 %0.32
Pulmonary alveolar haemorrhage,1/161 %0.62,0/155 %0.0,1/316 %0.32
Pulmonary haemorrhage,2/161 %1.24,0/155 %0.0,2/316 %0.63
Pulmonary oedema,1/161 %0.62,0/155 %0.0,1/316 %0.32
Respiratory distress,1/161 %0.62,2/155 %1.29,3/316 %0.95
Respiratory failure,1/161 %0.62,4/155 %2.58,5/316 %1.58
Drug eruption,1/161 %0.62,0/155 %0.0,1/316 %0.32
Exfoliative rash,1/161 %0.62,0/155 %0.0,1/316 %0.32
Generalised erythema,1/161 %0.62,0/155 %0.0,1/316 %0.32
Palmar-plantar erythrodysaesthesia syndrome,1/161 %0.62,0/155 %0.0,1/316 %0.32
Rash,1/161 %0.62,0/155 %0.0,1/316 %0.32
Toxic epidermal necrolysis,1/161 %0.62,0/155 %0.0,1/316 %0.32
Deep vein thrombosis,2/161 %1.24,1/155 %0.65,3/316 %0.95
Hypertension,0/161 %0.0,2/155 %1.29,2/316 %0.63
Hypotension,4/161 %2.48,4/155 %2.58,8/316 %2.53

Safety and Efficacy of Imatinib Versus Interferon- Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia(https://clinicaltrials.gov/show/NCT00333840)
 ,Imatinib (STI571),IFN-a + Ara-C,Imatinib to IFN-a + Ara-C,IFN-a + Ara-C to Imatinib
 ,In the first-line treatment period participants received imatinib 400 mg orally once daily in the morning. Hydroxyurea was permitted in the first 6 months to keep the white blood cell count (WBC) below 20.0 X 10^9/liter. If protocol specific criteria applied participants were eligible to crossover to receive interferon-alpha (IFN-a) and cytarabine (ARA-C) in the second-line treatment period. Maximum study duration was 11.5 years.,In the first-line treatment period participants received interferon-alpha (IFN-a) subcutaneous (SC) injections escalated over 4 weeks to achieve a target dose of 5 MU/m^2/day. After the maximum tolerated dose of IFN-a was achieved participants also received cytarabine (ARA-C) 20 mg/m^2/day (max 40 mg) SC injections for 10 days every month. Hydroxyurea was permitted in the first 6 months to keep the white blood cell count (WBC) below 20.0 X 10^9/liter. If protocol specific criteria applied participants were eligible to crossover to the second-line treatment period to receive imatinib (STI571). IFN treatment was discontinued with protocol amendment 6. Maximum study duration was 8 years.,In the first-line treatment period participants received imatinib 400 mg orally once daily in the morning. Hydroxyurea was permitted in the first 6 months to keep the white blood cell count (WBC) below 20.0 X 10^9/liter. If protocol specific criteria applied participants were eligible to crossover to receive interferon-alpha (IFN-a) subcutaneous (SC) injections escalated over 4 weeks to achieve a target dose of 5 MU/m^2/day. After the maximum tolerated dose of IFN-a was achieved participants also received cytarabine (ARA-C) 20 mg/m^2/day (max 40 mg) SC injections for 10 days every month.,In the first-line treatment period participants received interferon-alpha (IFN-a) subcutaneous (SC) injections escalated over 4 weeks to achieve a target dose of 5 MU/m^2/day. After the maximum tolerated dose of IFN-a was achieved participants also received cytarabine (ARA-C) 20 mg/m^2/day (max 40 mg) SC injections for 10 days every month. Hydroxyurea was permitted in the first 6 months to keep the white blood cell count (WBC) below 20.0 X 10^9/liter. If protocol specific criteria applied participants were eligible to crossover to the second-line treatment period to receive imatinib (STI571) 400 mg orally once daily in the morning.
Total serious adverse events,226/551 %41.02,163/533 %30.58,2/14 %14.29,160/363 %44.08
Acquired Von Willebrand's disease,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Anaemia,6/551 %1.09,10/533 %1.88,0/14 %0.0,5/363 %1.38
Autoimmune thrombocytopenia,0/551 %0.0,1/533 %0.19,0/14 %0.0,0/363 %0.0
Disseminated intravascular coagulation,0/551 %0.0,1/533 %0.19,0/14 %0.0,0/363 %0.0
Febrile neutropenia,2/551 %0.36,0/533 %0.0,0/14 %0.0,2/363 %0.55
Haematotoxicity,1/551 %0.18,0/533 %0.0,0/14 %0.0,1/363 %0.28
Haemolysis,0/551 %0.0,1/533 %0.19,0/14 %0.0,0/363 %0.0
Haemorrhagic anaemia,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Iron deficiency anaemia,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Leukocytosis,0/551 %0.0,3/533 %0.56,0/14 %0.0,0/363 %0.0
Leukopenia,0/551 %0.0,1/533 %0.19,0/14 %0.0,0/363 %0.0
Lymph node pain,0/551 %0.0,1/533 %0.19,0/14 %0.0,0/363 %0.0
Lymphadenopathy,0/551 %0.0,1/533 %0.19,0/14 %0.0,0/363 %0.0
Neutropenia,1/551 %0.18,3/533 %0.56,0/14 %0.0,4/363 %1.1
Pancytopenia,1/551 %0.18,0/533 %0.0,0/14 %0.0,3/363 %0.83
Splenic infarction,0/551 %0.0,1/533 %0.19,0/14 %0.0,0/363 %0.0
Splenomegaly,0/551 %0.0,2/533 %0.38,0/14 %0.0,0/363 %0.0
Thrombocytopenia,1/551 %0.18,10/533 %1.88,0/14 %0.0,1/363 %0.28
Thrombocytosis,1/551 %0.18,0/533 %0.0,0/14 %0.0,1/363 %0.28
Acute myocardial infarction,1/551 %0.18,1/533 %0.19,0/14 %0.0,2/363 %0.55
Angina pectoris,2/551 %0.36,1/533 %0.19,0/14 %0.0,2/363 %0.55
Angina unstable,1/551 %0.18,1/533 %0.19,0/14 %0.0,0/363 %0.0
Aortic valve disease,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Aortic valve stenosis,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Arrhythmia,4/551 %0.73,1/533 %0.19,0/14 %0.0,1/363 %0.28
Arteriosclerosis coronary artery,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Atrial fibrillation,5/551 %0.91,3/533 %0.56,0/14 %0.0,3/363 %0.83
Bradycardia,2/551 %0.36,0/533 %0.0,0/14 %0.0,0/363 %0.0
Bundle branch block left,0/551 %0.0,1/533 %0.19,0/14 %0.0,0/363 %0.0
Cardiac arrest,5/551 %0.91,0/533 %0.0,0/14 %0.0,1/363 %0.28
Cardiac failure,2/551 %0.36,0/533 %0.0,0/14 %0.0,2/363 %0.55
Cardiac failure congestive,4/551 %0.73,4/533 %0.75,0/14 %0.0,2/363 %0.55
Cardiac tamponade,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Cardio-respiratory arrest,1/551 %0.18,1/533 %0.19,0/14 %0.0,1/363 %0.28
Cardiomegaly,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Cardiomyopathy,1/551 %0.18,0/533 %0.0,0/14 %0.0,1/363 %0.28
Cardiovascular disorder,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Conduction disorder,0/551 %0.0,1/533 %0.19,0/14 %0.0,0/363 %0.0
Coronary artery disease,7/551 %1.27,1/533 %0.19,0/14 %0.0,2/363 %0.55
Heart valve incompetence,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Hypertensive heart disease,0/551 %0.0,1/533 %0.19,0/14 %0.0,0/363 %0.0
Ischaemic cardiomyopathy,0/551 %0.0,1/533 %0.19,0/14 %0.0,0/363 %0.0
Left ventricular dysfunction,2/551 %0.36,1/533 %0.19,0/14 %0.0,3/363 %0.83
Left ventricular failure,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Mitral valve stenosis,0/551 %0.0,1/533 %0.19,0/14 %0.0,0/363 %0.0
Myocardial infarction,7/551 %1.27,5/533 %0.94,0/14 %0.0,2/363 %0.55
Nodal arrhythmia,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Palpitations,1/551 %0.18,0/533 %0.0,0/14 %0.0,1/363 %0.28
Pericardial effusion,2/551 %0.36,0/533 %0.0,0/14 %0.0,0/363 %0.0
Pericarditis,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Sick sinus syndrome,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Sinus arrhythmia,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Supraventricular tachycardia,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Tachycardia,0/551 %0.0,1/533 %0.19,0/14 %0.0,0/363 %0.0
Torsade de pointes,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Ventricular extrasystoles,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Ventricular fibrillation,1/551 %0.18,1/533 %0.19,0/14 %0.0,0/363 %0.0
Ventricular tachycardia,1/551 %0.18,1/533 %0.19,0/14 %0.0,0/363 %0.0
Gene mutation,1/551 %0.18,0/533 %0.0,0/14 %0.0,1/363 %0.28
Sensory neuropathy hereditary,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Deafness,0/551 %0.0,1/533 %0.19,0/14 %0.0,0/363 %0.0
Vertigo,0/551 %0.0,1/533 %0.19,0/14 %0.0,0/363 %0.0
Goitre,1/551 %0.18,0/533 %0.0,0/14 %0.0,2/363 %0.55
Hyperparathyroidism,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Hypopituitarism,0/551 %0.0,1/533 %0.19,0/14 %0.0,0/363 %0.0
Hypothyroidism,0/551 %0.0,1/533 %0.19,0/14 %0.0,0/363 %0.0
Blindness,0/551 %0.0,1/533 %0.19,0/14 %0.0,0/363 %0.0
Blindness unilateral,1/551 %0.18,1/533 %0.19,0/14 %0.0,0/363 %0.0
Conjunctival haemorrhage,2/551 %0.36,0/533 %0.0,0/14 %0.0,0/363 %0.0
Diabetic retinopathy,0/551 %0.0,1/533 %0.19,0/14 %0.0,0/363 %0.0
Diplopia,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Eyelid oedema,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Glaucoma,2/551 %0.36,0/533 %0.0,0/14 %0.0,0/363 %0.0
Open angle glaucoma,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Papilloedema,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Retinal detachment,1/551 %0.18,1/533 %0.19,0/14 %0.0,0/363 %0.0
Retinal haemorrhage,1/551 %0.18,1/533 %0.19,0/14 %0.0,0/363 %0.0
Retinal vein thrombosis,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Vision blurred,0/551 %0.0,1/533 %0.19,0/14 %0.0,0/363 %0.0
Vitreous haemorrhage,1/551 %0.18,1/533 %0.19,0/14 %0.0,0/363 %0.0
Abdominal discomfort,0/551 %0.0,1/533 %0.19,0/14 %0.0,0/363 %0.0
Abdominal distension,2/551 %0.36,0/533 %0.0,0/14 %0.0,0/363 %0.0
Abdominal mass,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Abdominal pain,12/551 %2.18,1/533 %0.19,0/14 %0.0,5/363 %1.38
Abdominal pain lower,4/551 %0.73,1/533 %0.19,0/14 %0.0,1/363 %0.28
Abdominal pain upper,7/551 %1.27,3/533 %0.56,0/14 %0.0,2/363 %0.55
Abdominal tenderness,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Acute abdomen,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Anal fissure,0/551 %0.0,1/533 %0.19,0/14 %0.0,0/363 %0.0
Anal fistula,2/551 %0.36,0/533 %0.0,0/14 %0.0,0/363 %0.0
Barrett's oesophagus,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Colitis,2/551 %0.36,1/533 %0.19,0/14 %0.0,0/363 %0.0
Constipation,3/551 %0.54,0/533 %0.0,0/14 %0.0,2/363 %0.55
Crohn's disease,3/551 %0.54,0/533 %0.0,0/14 %0.0,0/363 %0.0
Diarrhoea,9/551 %1.63,2/533 %0.38,0/14 %0.0,5/363 %1.38
Diarrhoea haemorrhagic,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Diverticular perforation,2/551 %0.36,0/533 %0.0,0/14 %0.0,0/363 %0.0
Duodenal ulcer,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Duodenitis,2/551 %0.36,1/533 %0.19,0/14 %0.0,0/363 %0.0
Dyspepsia,0/551 %0.0,1/533 %0.19,0/14 %0.0,0/363 %0.0
Dysphagia,2/551 %0.36,0/533 %0.0,0/14 %0.0,0/363 %0.0
Faecal vomiting,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Faecaloma,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Flatulence,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Gastric ulcer,2/551 %0.36,1/533 %0.19,0/14 %0.0,1/363 %0.28
Gastritis,1/551 %0.18,0/533 %0.0,0/14 %0.0,3/363 %0.83
Gastritis erosive,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Gastritis haemorrhagic,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Gastrointestinal disorder,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Gastrointestinal haemorrhage,3/551 %0.54,0/533 %0.0,0/14 %0.0,2/363 %0.55
Gastrointestinal ulcer,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Gingival bleeding,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Gingival pain,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Haematemesis,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Hiatus hernia,2/551 %0.36,0/533 %0.0,0/14 %0.0,0/363 %0.0
Ileus,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Impaired gastric emptying,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Inflammatory bowel disease,2/551 %0.36,0/533 %0.0,0/14 %0.0,0/363 %0.0
Inguinal hernia,1/551 %0.18,0/533 %0.0,0/14 %0.0,1/363 %0.28
Intestinal haemorrhage,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Intestinal obstruction,0/551 %0.0,0/533 %0.0,0/14 %0.0,2/363 %0.55
Intestinal perforation,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Large intestine perforation,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Mallory-Weiss syndrome,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Melaena,2/551 %0.36,2/533 %0.38,0/14 %0.0,2/363 %0.55
Mouth haemorrhage,0/551 %0.0,1/533 %0.19,0/14 %0.0,0/363 %0.0
Nausea,7/551 %1.27,8/533 %1.5,0/14 %0.0,4/363 %1.1
Odynophagia,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Oedematous pancreatitis,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Painful defaecation,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Pancreatic pseudocyst,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Pancreatitis,3/551 %0.54,2/533 %0.38,0/14 %0.0,2/363 %0.55
Pancreatitis acute,1/551 %0.18,0/533 %0.0,0/14 %0.0,1/363 %0.28
Proctalgia,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Proctitis,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Rectal haemorrhage,2/551 %0.36,0/533 %0.0,0/14 %0.0,1/363 %0.28
Sigmoiditis,2/551 %0.36,0/533 %0.0,0/14 %0.0,1/363 %0.28
Small intestinal obstruction,1/551 %0.18,0/533 %0.0,0/14 %0.0,1/363 %0.28
Subileus,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Tongue cyst,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Upper gastrointestinal haemorrhage,1/551 %0.18,0/533 %0.0,0/14 %0.0,2/363 %0.55
Vomiting,11/551 %2.0,7/533 %1.31,0/14 %0.0,2/363 %0.55
Abasia,1/551 %0.18,0/533 %0.0,0/14 %0.0,1/363 %0.28
Adverse drug reaction,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Asthenia,2/551 %0.36,4/533 %0.75,0/14 %0.0,3/363 %0.83
Cardiac death,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Chest discomfort,1/551 %0.18,1/533 %0.19,0/14 %0.0,1/363 %0.28
Chest pain,14/551 %2.54,4/533 %0.75,0/14 %0.0,7/363 %1.93
Chills,7/551 %1.27,4/533 %0.75,0/14 %0.0,1/363 %0.28
Condition aggravated,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Crepitations,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Device malfunction,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Drug ineffective,1/551 %0.18,1/533 %0.19,0/14 %0.0,2/363 %0.55
Drug interaction,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Drug intolerance,0/551 %0.0,1/533 %0.19,0/14 %0.0,0/363 %0.0
Fatigue,3/551 %0.54,7/533 %1.31,1/14 %7.14,3/363 %0.83
Gait disturbance,0/551 %0.0,1/533 %0.19,0/14 %0.0,0/363 %0.0
General physical health deterioration,0/551 %0.0,2/533 %0.38,0/14 %0.0,3/363 %0.83
Generalised oedema,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Granuloma,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Hernia,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Hyperplasia,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Hyperthermia,0/551 %0.0,1/533 %0.19,0/14 %0.0,0/363 %0.0
Impaired healing,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Influenza like illness,2/551 %0.36,0/533 %0.0,0/14 %0.0,1/363 %0.28
Malaise,4/551 %0.73,2/533 %0.38,0/14 %0.0,0/363 %0.0
Mucosal atrophy,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Multi-organ failure,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Necrosis,0/551 %0.0,1/533 %0.19,0/14 %0.0,0/363 %0.0
Non-cardiac chest pain,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Oedema peripheral,3/551 %0.54,1/533 %0.19,0/14 %0.0,0/363 %0.0
Pain,4/551 %0.73,1/533 %0.19,0/14 %0.0,1/363 %0.28
Performance status decreased,1/551 %0.18,2/533 %0.38,0/14 %0.0,1/363 %0.28
Pyrexia,19/551 %3.45,20/533 %3.75,1/14 %7.14,12/363 %3.31
Soft tissue inflammation,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Spinal pain,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Sudden cardiac death,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Systemic inflammatory response syndrome,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Bile duct stone,2/551 %0.36,0/533 %0.0,0/14 %0.0,0/363 %0.0
Biliary tract disorder,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Cholangitis,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Cholecystitis,6/551 %1.09,0/533 %0.0,0/14 %0.0,1/363 %0.28
Cholecystitis acute,1/551 %0.18,0/533 %0.0,0/14 %0.0,2/363 %0.55
Cholelithiasis,4/551 %0.73,2/533 %0.38,0/14 %0.0,2/363 %0.55
Cytolytic hepatitis,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Drug-induced liver injury,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Gallbladder perforation,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Granulomatous liver disease,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Hepatic failure,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Hepatic function abnormal,0/551 %0.0,1/533 %0.19,0/14 %0.0,0/363 %0.0
Hepatic necrosis,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Hepatitis,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Hepatitis acute,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Hepatomegaly,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Hepatotoxicity,0/551 %0.0,1/533 %0.19,0/14 %0.0,2/363 %0.55
Hyperbilirubinaemia,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Jaundice,1/551 %0.18,1/533 %0.19,0/14 %0.0,1/363 %0.28
Anaphylactic shock,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Drug hypersensitivity,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Transplant rejection,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Abscess,2/551 %0.36,0/533 %0.0,0/14 %0.0,1/363 %0.28
Amoebiasis,0/551 %0.0,1/533 %0.19,0/14 %0.0,0/363 %0.0
Anal abscess,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Anorectal infection,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Appendicitis,4/551 %0.73,0/533 %0.0,0/14 %0.0,1/363 %0.28
Arthritis bacterial,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Bacteraemia,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Bacterial infection,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Bone tuberculosis,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Bronchitis,2/551 %0.36,2/533 %0.38,0/14 %0.0,1/363 %0.28
Bronchitis viral,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Bronchopneumonia,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Bronchopulmonary aspergillosis,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Cellulitis,6/551 %1.09,3/533 %0.56,0/14 %0.0,2/363 %0.55
Clostridium difficile colitis,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Diverticulitis,3/551 %0.54,0/533 %0.0,0/14 %0.0,0/363 %0.0
Ear infection,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Epstein-Barr virus infection,0/551 %0.0,1/533 %0.19,0/14 %0.0,0/363 %0.0
Escherichia bacteraemia,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Escherichia sepsis,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Escherichia urinary tract infection,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Folliculitis,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Gangrene,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Gastritis viral,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Gastroenteritis,3/551 %0.54,0/533 %0.0,0/14 %0.0,3/363 %0.83
Gastroenteritis norovirus,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Gastroenteritis rotavirus,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Gastroenteritis viral,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Gastrointestinal infection,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Haemophilus infection,0/551 %0.0,1/533 %0.19,0/14 %0.0,0/363 %0.0
Hepatitis B,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Herpes zoster,0/551 %0.0,1/533 %0.19,0/14 %0.0,1/363 %0.28
Incision site infection,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Infection,0/551 %0.0,1/533 %0.19,0/14 %0.0,2/363 %0.55
Influenza,1/551 %0.18,0/533 %0.0,0/14 %0.0,1/363 %0.28
Lobar pneumonia,1/551 %0.18,0/533 %0.0,0/14 %0.0,1/363 %0.28
Localised infection,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Lower respiratory tract infection,1/551 %0.18,0/533 %0.0,0/14 %0.0,2/363 %0.55
Lung infection,1/551 %0.18,0/533 %0.0,0/14 %0.0,1/363 %0.28
Malaria,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Meningitis,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Meningitis pneumococcal,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Meningoencephalitis herpetic,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Muscle abscess,1/551 %0.18,1/533 %0.19,0/14 %0.0,0/363 %0.0
Mycoplasma infection,0/551 %0.0,1/533 %0.19,0/14 %0.0,0/363 %0.0
Necrotising fasciitis,0/551 %0.0,1/533 %0.19,0/14 %0.0,0/363 %0.0
Neutropenic sepsis,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Orchitis,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Osteomyelitis,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Parotitis,0/551 %0.0,1/533 %0.19,0/14 %0.0,0/363 %0.0
Pelvic abscess,2/551 %0.36,0/533 %0.0,0/14 %0.0,0/363 %0.0
Peridiverticular abscess,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Perirectal abscess,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Pharyngitis,2/551 %0.36,0/533 %0.0,0/14 %0.0,1/363 %0.28
Pneumococcal sepsis,0/551 %0.0,1/533 %0.19,0/14 %0.0,0/363 %0.0
Pneumocystis jiroveci pneumonia,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Pneumonia,12/551 %2.18,7/533 %1.31,0/14 %0.0,14/363 %3.86
Pneumonia streptococcal,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Post procedural infection,1/551 %0.18,1/533 %0.19,0/14 %0.0,0/363 %0.0
Prostate infection,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Pseudomembranous colitis,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Pyelonephritis,0/551 %0.0,2/533 %0.38,0/14 %0.0,0/363 %0.0
Rectal abscess,1/551 %0.18,0/533 %0.0,0/14 %0.0,1/363 %0.28
Respiratory tract infection,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Respiratory tract infection viral,1/551 %0.18,0/533 %0.0,0/14 %0.0,1/363 %0.28
Rhinitis,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Salmonellosis,0/551 %0.0,0/533 %0.0,0/14 %0.0,2/363 %0.55
Salpingitis,0/551 %0.0,1/533 %0.19,0/14 %0.0,0/363 %0.0
Scrotal abscess,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Scrotal gangrene,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Sepsis,3/551 %0.54,1/533 %0.19,0/14 %0.0,2/363 %0.55
Septic shock,1/551 %0.18,1/533 %0.19,0/14 %0.0,0/363 %0.0
Sinusitis,2/551 %0.36,0/533 %0.0,0/14 %0.0,1/363 %0.28
Staphylococcal infection,2/551 %0.36,1/533 %0.19,0/14 %0.0,0/363 %0.0
Streptococcal infection,0/551 %0.0,1/533 %0.19,0/14 %0.0,0/363 %0.0
Subcutaneous abscess,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Systemic candida,0/551 %0.0,1/533 %0.19,0/14 %0.0,0/363 %0.0
Tonsillitis,2/551 %0.36,0/533 %0.0,0/14 %0.0,0/363 %0.0
Tooth abscess,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Tracheobronchitis,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Tuberculoma of central nervous system,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Upper respiratory tract infection,4/551 %0.73,0/533 %0.0,0/14 %0.0,0/363 %0.0
Urinary tract infection,4/551 %0.73,4/533 %0.75,0/14 %0.0,1/363 %0.28
Urosepsis,1/551 %0.18,0/533 %0.0,0/14 %0.0,1/363 %0.28
Viral infection,3/551 %0.54,0/533 %0.0,0/14 %0.0,1/363 %0.28
Viral upper respiratory tract infection,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Vulvitis,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Wound infection,1/551 %0.18,0/533 %0.0,0/14 %0.0,1/363 %0.28
Wound infection staphylococcal,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Accidental overdose,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Animal bite,0/551 %0.0,1/533 %0.19,0/14 %0.0,0/363 %0.0
Ankle fracture,2/551 %0.36,0/533 %0.0,0/14 %0.0,0/363 %0.0
Arthropod bite,0/551 %0.0,1/533 %0.19,0/14 %0.0,0/363 %0.0
Cervical vertebral fracture,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Compression fracture,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Concussion,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Contusion,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Exposure via father,0/551 %0.0,1/533 %0.19,0/14 %0.0,0/363 %0.0
Facial bones fracture,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Fall,3/551 %0.54,1/533 %0.19,0/14 %0.0,2/363 %0.55
Femoral neck fracture,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Femur fracture,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Fibula fracture,2/551 %0.36,0/533 %0.0,0/14 %0.0,1/363 %0.28
Fracture,0/551 %0.0,1/533 %0.19,0/14 %0.0,0/363 %0.0
Graft dysfunction,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Head injury,2/551 %0.36,0/533 %0.0,0/14 %0.0,0/363 %0.0
Hip fracture,1/551 %0.18,0/533 %0.0,0/14 %0.0,1/363 %0.28
Humerus fracture,2/551 %0.36,0/533 %0.0,0/14 %0.0,0/363 %0.0
Joint dislocation,1/551 %0.18,0/533 %0.0,0/14 %0.0,1/363 %0.28
Limb injury,0/551 %0.0,0/533 %0.0,0/14 %0.0,2/363 %0.55
Lumbar vertebral fracture,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Meniscus lesion,2/551 %0.36,0/533 %0.0,0/14 %0.0,1/363 %0.28
Overdose,1/551 %0.18,0/533 %0.0,0/14 %0.0,1/363 %0.28
Post procedural complication,2/551 %0.36,0/533 %0.0,0/14 %0.0,0/363 %0.0
Post procedural haematoma,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Rib fracture,2/551 %0.36,0/533 %0.0,0/14 %0.0,1/363 %0.28
Road traffic accident,2/551 %0.36,1/533 %0.19,0/14 %0.0,0/363 %0.0
Skull fractured base,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Subdural haematoma,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Tendon rupture,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Thermal burn,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Thoracic vertebral fracture,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Tooth fracture,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Toxicity to various agents,0/551 %0.0,3/533 %0.56,0/14 %0.0,0/363 %0.0
Upper limb fracture,2/551 %0.36,0/533 %0.0,0/14 %0.0,0/363 %0.0
Urethral stricture postoperative,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Vascular graft occlusion,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Vascular injury,0/551 %0.0,1/533 %0.19,0/14 %0.0,0/363 %0.0
Vascular pseudoaneurysm,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Wound secretion,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Alanine aminotransferase increased,2/551 %0.36,1/533 %0.19,0/14 %0.0,1/363 %0.28
Amylase increased,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Aspartate aminotransferase abnormal,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Aspartate aminotransferase increased,2/551 %0.36,1/533 %0.19,0/14 %0.0,1/363 %0.28
Blast cell count increased,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Blast cells present,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Blood alkaline phosphatase increased,1/551 %0.18,0/533 %0.0,0/14 %0.0,1/363 %0.28
Blood bilirubin increased,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Blood creatine increased,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Blood creatine phosphokinase increased,3/551 %0.54,0/533 %0.0,0/14 %0.0,1/363 %0.28
Blood creatinine increased,1/551 %0.18,0/533 %0.0,0/14 %0.0,1/363 %0.28
Blood culture positive,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Blood parathyroid hormone increased,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Blood pressure increased,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Body temperature increased,1/551 %0.18,1/533 %0.19,0/14 %0.0,0/363 %0.0
Creatinine renal clearance decreased,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Echocardiogram abnormal,0/551 %0.0,1/533 %0.19,0/14 %0.0,1/363 %0.28
Gamma-glutamyltransferase increased,0/551 %0.0,1/533 %0.19,0/14 %0.0,1/363 %0.28
Haemoglobin decreased,1/551 %0.18,0/533 %0.0,0/14 %0.0,2/363 %0.55
Heart rate increased,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Hepatic enzyme increased,2/551 %0.36,0/533 %0.0,0/14 %0.0,0/363 %0.0
Lipase increased,2/551 %0.36,0/533 %0.0,0/14 %0.0,0/363 %0.0
Liver function test abnormal,0/551 %0.0,0/533 %0.0,0/14 %0.0,2/363 %0.55
Multiple gated acquisition scan abnormal,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Myelocyte present,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Platelet count increased,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Prostatic specific antigen increased,1/551 %0.18,0/533 %0.0,0/14 %0.0,1/363 %0.28
Troponin increased,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Weight decreased,2/551 %0.36,1/533 %0.19,0/14 %0.0,2/363 %0.55
White blood cell count increased,0/551 %0.0,4/533 %0.75,0/14 %0.0,1/363 %0.28
Cachexia,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Decreased appetite,0/551 %0.0,3/533 %0.56,0/14 %0.0,1/363 %0.28
Dehydration,5/551 %0.91,5/533 %0.94,0/14 %0.0,1/363 %0.28
Diabetes mellitus,0/551 %0.0,1/533 %0.19,0/14 %0.0,0/363 %0.0
Electrolyte imbalance,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Food intolerance,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Gout,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Hypercalcaemia,2/551 %0.36,0/533 %0.0,0/14 %0.0,1/363 %0.28
Hyperglycaemia,0/551 %0.0,2/533 %0.38,0/14 %0.0,0/363 %0.0
Hyperkalaemia,2/551 %0.36,2/533 %0.38,0/14 %0.0,1/363 %0.28
Hypoglycaemia,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Hypokalaemia,2/551 %0.36,1/533 %0.19,0/14 %0.0,0/363 %0.0
Hyponatraemia,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Hypovolaemia,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Arthralgia,4/551 %0.73,11/533 %2.06,1/14 %7.14,2/363 %0.55
Arthritis,2/551 %0.36,1/533 %0.19,0/14 %0.0,0/363 %0.0
Back pain,4/551 %0.73,6/533 %1.13,0/14 %0.0,1/363 %0.28
Bone disorder,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Bone pain,2/551 %0.36,6/533 %1.13,1/14 %7.14,2/363 %0.55
Compartment syndrome,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Flank pain,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Groin pain,0/551 %0.0,1/533 %0.19,0/14 %0.0,0/363 %0.0
Inclusion body myositis,1/551 %0.18,0/533 %0.0,0/14 %0.0,1/363 %0.28
Intervertebral disc protrusion,4/551 %0.73,1/533 %0.19,0/14 %0.0,3/363 %0.83
Joint swelling,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Mixed connective tissue disease,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Muscle atrophy,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Muscle spasms,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Muscular weakness,2/551 %0.36,0/533 %0.0,0/14 %0.0,0/363 %0.0
Musculoskeletal chest pain,1/551 %0.18,0/533 %0.0,0/14 %0.0,4/363 %1.1
Musculoskeletal pain,1/551 %0.18,3/533 %0.56,0/14 %0.0,2/363 %0.55
Myalgia,1/551 %0.18,10/533 %1.88,0/14 %0.0,2/363 %0.55
Myositis,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Neck mass,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Neck pain,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Osteitis,0/551 %0.0,1/533 %0.19,0/14 %0.0,0/363 %0.0
Osteoarthritis,5/551 %0.91,0/533 %0.0,0/14 %0.0,1/363 %0.28
Osteolysis,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Osteonecrosis,1/551 %0.18,3/533 %0.56,0/14 %0.0,1/363 %0.28
Osteoporotic fracture,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Pain in extremity,4/551 %0.73,5/533 %0.94,0/14 %0.0,1/363 %0.28
Pain in jaw,2/551 %0.36,0/533 %0.0,0/14 %0.0,0/363 %0.0
Polyarthritis,1/551 %0.18,0/533 %0.0,0/14 %0.0,1/363 %0.28
Rheumatoid arthritis,1/551 %0.18,1/533 %0.19,0/14 %0.0,0/363 %0.0
Rotator cuff syndrome,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Spinal column stenosis,2/551 %0.36,0/533 %0.0,0/14 %0.0,1/363 %0.28
Spondylolisthesis,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Systemic lupus erythematosus,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Tendonitis,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Acral lentiginous melanoma stage unspecified,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Acute leukaemia,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Acute myeloid leukaemia,1/551 %0.18,0/533 %0.0,0/14 %0.0,3/363 %0.83
Adenocarcinoma,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Basal cell carcinoma,6/551 %1.09,0/533 %0.0,0/14 %0.0,1/363 %0.28
Benign anorectal neoplasm,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Bladder cancer,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Blast cell crisis,1/551 %0.18,0/533 %0.0,0/14 %0.0,1/363 %0.28
Blast crisis in myelogenous leukaemia,4/551 %0.73,5/533 %0.94,0/14 %0.0,12/363 %3.31
Bone neoplasm,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Brain neoplasm,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Breast cancer,3/551 %0.54,1/533 %0.19,0/14 %0.0,3/363 %0.83
Breast neoplasm,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Bronchioloalveolar carcinoma,1/551 %0.18,0/533 %0.0,0/14 %0.0,1/363 %0.28
Carcinoma in situ,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Cervix carcinoma,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Chloroma,0/551 %0.0,1/533 %0.19,0/14 %0.0,1/363 %0.28
Cholesteatoma,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Chronic lymphocytic leukaemia transformation,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Chronic myeloid leukaemia,2/551 %0.36,0/533 %0.0,0/14 %0.0,3/363 %0.83
Colon cancer,2/551 %0.36,0/533 %0.0,0/14 %0.0,1/363 %0.28
Endometrial cancer,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Erythroleukaemia,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Hypergammaglobulinaemia benign monoclonal,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Laryngeal cancer,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Lip and/or oral cavity cancer recurrent,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Lung adenocarcinoma,2/551 %0.36,0/533 %0.0,0/14 %0.0,0/363 %0.0
Lung neoplasm malignant,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Lymphoma,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Malignant melanoma,3/551 %0.54,0/533 %0.0,0/14 %0.0,1/363 %0.28
Malignant melanoma in situ,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Metastases to adrenals,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Metastases to bone,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Metastases to large intestine,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Metastases to liver,0/551 %0.0,0/533 %0.0,0/14 %0.0,2/363 %0.55
Metastatic neoplasm,2/551 %0.36,0/533 %0.0,0/14 %0.0,0/363 %0.0
Metastatic renal cell carcinoma,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Multiple myeloma,4/551 %0.73,0/533 %0.0,0/14 %0.0,1/363 %0.28
Myelodysplastic syndrome,1/551 %0.18,0/533 %0.0,0/14 %0.0,1/363 %0.28
Myelofibrosis,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Neoplasm malignant,4/551 %0.73,2/533 %0.38,1/14 %7.14,3/363 %0.83
Neoplasm of appendix,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Nephroblastoma,0/551 %0.0,1/533 %0.19,0/14 %0.0,0/363 %0.0
Neuroendocrine tumour,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Non-Hodgkin's lymphoma,1/551 %0.18,0/533 %0.0,0/14 %0.0,1/363 %0.28
Oesophageal carcinoma,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Pancreatic neoplasm,1/551 %0.18,0/533 %0.0,0/14 %0.0,1/363 %0.28
Paraneoplastic syndrome,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Parathyroid tumour benign,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Prostate cancer,11/551 %2.0,1/533 %0.19,0/14 %0.0,9/363 %2.48
Prostate cancer metastatic,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Prostatic adenoma,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Rectal cancer,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Rectal cancer metastatic,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Renal cancer,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Renal cell carcinoma,3/551 %0.54,0/533 %0.0,0/14 %0.0,0/363 %0.0
Signet-ring cell carcinoma,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Small cell lung cancer stage unspecified,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Squamous cell carcinoma,6/551 %1.09,0/533 %0.0,0/14 %0.0,1/363 %0.28
Squamous cell carcinoma of the cervix,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Thyroid adenoma,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Thyroid cancer,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Tongue neoplasm malignant stage unspecified,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Transitional cell carcinoma,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Amyotrophic lateral sclerosis,1/551 %0.18,0/533 %0.0,0/14 %0.0,1/363 %0.28
Aphasia,0/551 %0.0,1/533 %0.19,0/14 %0.0,0/363 %0.0
Areflexia,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Ataxia,1/551 %0.18,3/533 %0.56,0/14 %0.0,0/363 %0.0
Balance disorder,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Brain mass,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Brain oedema,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Carotid artery aneurysm,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Carotid artery occlusion,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Carotid artery stenosis,2/551 %0.36,0/533 %0.0,0/14 %0.0,1/363 %0.28
Carpal tunnel syndrome,0/551 %0.0,1/533 %0.19,0/14 %0.0,0/363 %0.0
Cerebellar syndrome,0/551 %0.0,1/533 %0.19,0/14 %0.0,0/363 %0.0
Cerebral artery occlusion,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Cerebral infarction,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Cerebrovascular accident,1/551 %0.18,2/533 %0.38,0/14 %0.0,2/363 %0.55
Cervicobrachial syndrome,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Cognitive disorder,0/551 %0.0,1/533 %0.19,0/14 %0.0,0/363 %0.0
Coma,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Complex regional pain syndrome,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Complicated migraine,0/551 %0.0,1/533 %0.19,0/14 %0.0,0/363 %0.0
Convulsion,1/551 %0.18,1/533 %0.19,0/14 %0.0,1/363 %0.28
Dementia,0/551 %0.0,2/533 %0.38,0/14 %0.0,0/363 %0.0
Dementia Alzheimer's type,0/551 %0.0,1/533 %0.19,0/14 %0.0,0/363 %0.0
Demyelination,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Diabetic neuropathy,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Disturbance in attention,0/551 %0.0,1/533 %0.19,0/14 %0.0,0/363 %0.0
Dizziness,7/551 %1.27,5/533 %0.94,1/14 %7.14,0/363 %0.0
Dizziness postural,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Epilepsy,0/551 %0.0,2/533 %0.38,0/14 %0.0,0/363 %0.0
Extrapyramidal disorder,0/551 %0.0,2/533 %0.38,0/14 %0.0,0/363 %0.0
Grand mal convulsion,0/551 %0.0,1/533 %0.19,0/14 %0.0,0/363 %0.0
Headache,3/551 %0.54,3/533 %0.56,0/14 %0.0,2/363 %0.55
Hemiparesis,1/551 %0.18,1/533 %0.19,0/14 %0.0,0/363 %0.0
Hypoxic-ischaemic encephalopathy,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Intercostal neuralgia,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Intracranial pressure increased,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Ischaemic stroke,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Loss of consciousness,1/551 %0.18,1/533 %0.19,0/14 %0.0,0/363 %0.0
Migraine,0/551 %0.0,2/533 %0.38,0/14 %0.0,0/363 %0.0
Monoparesis,0/551 %0.0,1/533 %0.19,0/14 %0.0,0/363 %0.0
Multiple sclerosis,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Neurological symptom,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Neurotoxicity,0/551 %0.0,2/533 %0.38,0/14 %0.0,0/363 %0.0
Paraesthesia,0/551 %0.0,1/533 %0.19,0/14 %0.0,0/363 %0.0
Paraplegia,0/551 %0.0,1/533 %0.19,0/14 %0.0,0/363 %0.0
Parkinson's disease,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Peripheral sensory neuropathy,0/551 %0.0,1/533 %0.19,0/14 %0.0,0/363 %0.0
Peroneal nerve palsy,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Piriformis syndrome,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Polyneuropathy,0/551 %0.0,1/533 %0.19,0/14 %0.0,0/363 %0.0
Presyncope,1/551 %0.18,1/533 %0.19,0/14 %0.0,0/363 %0.0
Radiculopathy,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Sciatica,2/551 %0.36,2/533 %0.38,0/14 %0.0,0/363 %0.0
Simple partial seizures,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Somnolence,0/551 %0.0,1/533 %0.19,0/14 %0.0,0/363 %0.0
Speech disorder,0/551 %0.0,2/533 %0.38,0/14 %0.0,0/363 %0.0
Subarachnoid haemorrhage,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Syncope,8/551 %1.45,4/533 %0.75,0/14 %0.0,2/363 %0.55
Temporal lobe epilepsy,0/551 %0.0,1/533 %0.19,0/14 %0.0,0/363 %0.0
Transient global amnesia,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Transient ischaemic attack,1/551 %0.18,3/533 %0.56,0/14 %0.0,3/363 %0.83
Tremor,0/551 %0.0,1/533 %0.19,0/14 %0.0,0/363 %0.0
VIIth nerve paralysis,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Abortion spontaneous,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Pregnancy,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Aggression,0/551 %0.0,1/533 %0.19,0/14 %0.0,0/363 %0.0
Agitation,0/551 %0.0,2/533 %0.38,0/14 %0.0,0/363 %0.0
Anxiety,1/551 %0.18,3/533 %0.56,0/14 %0.0,0/363 %0.0
Completed suicide,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Confusional state,0/551 %0.0,3/533 %0.56,0/14 %0.0,0/363 %0.0
Delirium,0/551 %0.0,1/533 %0.19,0/14 %0.0,0/363 %0.0
Depression,2/551 %0.36,15/533 %2.81,0/14 %0.0,2/363 %0.55
Depression suicidal,0/551 %0.0,2/533 %0.38,0/14 %0.0,0/363 %0.0
Disorientation,0/551 %0.0,1/533 %0.19,0/14 %0.0,0/363 %0.0
Homicidal ideation,0/551 %0.0,1/533 %0.19,0/14 %0.0,0/363 %0.0
Mania,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Mental status changes,0/551 %0.0,1/533 %0.19,0/14 %0.0,0/363 %0.0
Mood altered,0/551 %0.0,1/533 %0.19,0/14 %0.0,0/363 %0.0
Paranoia,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Psychotic disorder,0/551 %0.0,1/533 %0.19,0/14 %0.0,1/363 %0.28
Suicidal ideation,0/551 %0.0,5/533 %0.94,0/14 %0.0,0/363 %0.0
Acute prerenal failure,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Calculus ureteric,0/551 %0.0,1/533 %0.19,0/14 %0.0,0/363 %0.0
Calculus urethral,1/551 %0.18,0/533 %0.0,0/14 %0.0,1/363 %0.28
Dysuria,0/551 %0.0,2/533 %0.38,0/14 %0.0,0/363 %0.0
Haematuria,2/551 %0.36,1/533 %0.19,0/14 %0.0,1/363 %0.28
Nephrolithiasis,6/551 %1.09,0/533 %0.0,0/14 %0.0,1/363 %0.28
Nephrotic syndrome,0/551 %0.0,1/533 %0.19,0/14 %0.0,0/363 %0.0
Oliguria,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Pollakiuria,0/551 %0.0,1/533 %0.19,0/14 %0.0,0/363 %0.0
Proteinuria,0/551 %0.0,1/533 %0.19,0/14 %0.0,0/363 %0.0
Renal colic,1/551 %0.18,1/533 %0.19,0/14 %0.0,0/363 %0.0
Renal failure,5/551 %0.91,2/533 %0.38,0/14 %0.0,3/363 %0.83
Renal failure acute,5/551 %0.91,0/533 %0.0,0/14 %0.0,2/363 %0.55
Renal failure chronic,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Urethral stenosis,2/551 %0.36,0/533 %0.0,0/14 %0.0,0/363 %0.0
Urinary tract obstruction,1/551 %0.18,1/533 %0.19,0/14 %0.0,0/363 %0.0
Benign prostatic hyperplasia,1/551 %0.18,1/533 %0.19,0/14 %0.0,0/363 %0.0
Breast mass,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Epididymitis,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Menorrhagia,0/551 %0.0,2/533 %0.38,0/14 %0.0,1/363 %0.28
Metrorrhagia,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Ovarian cyst,1/551 %0.18,1/533 %0.19,0/14 %0.0,2/363 %0.55
Penis disorder,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Prostatic dysplasia,2/551 %0.36,0/533 %0.0,0/14 %0.0,0/363 %0.0
Prostatitis,0/551 %0.0,1/533 %0.19,0/14 %0.0,0/363 %0.0
Testicular swelling,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Vaginal cyst,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Varicose veins pelvic,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Acute respiratory distress syndrome,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Aspiration,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Asthma,2/551 %0.36,0/533 %0.0,0/14 %0.0,0/363 %0.0
Atelectasis,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Bronchial hyperreactivity,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Bronchitis chronic,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Chronic obstructive pulmonary disease,1/551 %0.18,0/533 %0.0,0/14 %0.0,2/363 %0.55
Chronic respiratory failure,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Cough,3/551 %0.54,1/533 %0.19,0/14 %0.0,3/363 %0.83
Dyspnoea,11/551 %2.0,4/533 %0.75,0/14 %0.0,6/363 %1.65
Dyspnoea exertional,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Epistaxis,2/551 %0.36,1/533 %0.19,0/14 %0.0,1/363 %0.28
Haemoptysis,1/551 %0.18,1/533 %0.19,0/14 %0.0,0/363 %0.0
Hiccups,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Hypercapnia,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Hyperventilation,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Hypoxia,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Interstitial lung disease,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Lung disorder,1/551 %0.18,2/533 %0.38,0/14 %0.0,0/363 %0.0
Lung infiltration,1/551 %0.18,1/533 %0.19,0/14 %0.0,1/363 %0.28
Nasal obstruction,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Oropharyngeal pain,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Pharyngeal erythema,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Pharyngeal stenosis,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Pickwickian syndrome,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Pleural effusion,5/551 %0.91,2/533 %0.38,0/14 %0.0,2/363 %0.55
Pleurisy,3/551 %0.54,0/533 %0.0,0/14 %0.0,0/363 %0.0
Pneumonia aspiration,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Pneumonitis,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Pneumothorax,2/551 %0.36,0/533 %0.0,0/14 %0.0,0/363 %0.0
Productive cough,1/551 %0.18,0/533 %0.0,0/14 %0.0,1/363 %0.28
Pulmonary embolism,3/551 %0.54,1/533 %0.19,0/14 %0.0,1/363 %0.28
Pulmonary oedema,3/551 %0.54,1/533 %0.19,0/14 %0.0,3/363 %0.83
Respiratory distress,2/551 %0.36,0/533 %0.0,0/14 %0.0,0/363 %0.0
Respiratory failure,4/551 %0.73,2/533 %0.38,0/14 %0.0,0/363 %0.0
Sleep apnoea syndrome,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Upper respiratory tract inflammation,0/551 %0.0,1/533 %0.19,0/14 %0.0,0/363 %0.0
Wheezing,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Acute febrile neutrophilic dermatosis,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Alopecia,0/551 %0.0,1/533 %0.19,0/14 %0.0,0/363 %0.0
Angioedema,0/551 %0.0,0/533 %0.0,0/14 %0.0,2/363 %0.55
Cutaneous vasculitis,0/551 %0.0,1/533 %0.19,0/14 %0.0,0/363 %0.0
Dermal cyst,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Drug eruption,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Erythema multiforme,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Erythema nodosum,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Hyperhidrosis,0/551 %0.0,1/533 %0.19,0/14 %0.0,1/363 %0.28
Increased tendency to bruise,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Petechiae,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Polymorphic light eruption,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Pruritus,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Rash,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Rash erythematous,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Rash maculo-papular,1/551 %0.18,1/533 %0.19,0/14 %0.0,0/363 %0.0
Skin exfoliation,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Skin lesion,0/551 %0.0,0/533 %0.0,0/14 %0.0,2/363 %0.55
Skin necrosis,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Stevens-Johnson syndrome,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Swelling face,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Urticaria,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Cardiac assistance device user,0/551 %0.0,1/533 %0.19,0/14 %0.0,0/363 %0.0
Disability,0/551 %0.0,1/533 %0.19,0/14 %0.0,0/363 %0.0
Miscarriage of partner,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Abortion induced,1/551 %0.18,0/533 %0.0,0/14 %0.0,1/363 %0.28
Abscess drainage,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Bone marrow transplant,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Coronary arterial stent insertion,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Stem cell transplant,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Aneurysm,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Aortic aneurysm,0/551 %0.0,1/533 %0.19,0/14 %0.0,0/363 %0.0
Aortic stenosis,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Arterial occlusive disease,2/551 %0.36,0/533 %0.0,0/14 %0.0,0/363 %0.0
Arteriosclerosis,2/551 %0.36,0/533 %0.0,0/14 %0.0,0/363 %0.0
Circulatory collapse,2/551 %0.36,0/533 %0.0,0/14 %0.0,0/363 %0.0
Deep vein thrombosis,1/551 %0.18,1/533 %0.19,0/14 %0.0,1/363 %0.28
Femoral artery occlusion,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Haematoma,1/551 %0.18,1/533 %0.19,0/14 %0.0,0/363 %0.0
Haemorrhage,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Hypertension,5/551 %0.91,1/533 %0.19,0/14 %0.0,1/363 %0.28
Hypertensive crisis,0/551 %0.0,1/533 %0.19,0/14 %0.0,0/363 %0.0
Hypotension,1/551 %0.18,4/533 %0.75,0/14 %0.0,0/363 %0.0
Iliac artery occlusion,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Iliac artery stenosis,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Infarction,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Ischaemia,0/551 %0.0,0/533 %0.0,0/14 %0.0,3/363 %0.83
Lymphoedema,0/551 %0.0,0/533 %0.0,0/14 %0.0,1/363 %0.28
Orthostatic hypotension,0/551 %0.0,2/533 %0.38,0/14 %0.0,1/363 %0.28
Peripheral arterial occlusive disease,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Peripheral vascular disorder,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Phlebitis,0/551 %0.0,1/533 %0.19,0/14 %0.0,0/363 %0.0
Varicophlebitis,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0
Vascular occlusion,1/551 %0.18,0/533 %0.0,0/14 %0.0,0/363 %0.0

Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS(https://clinicaltrials.gov/show/NCT00334074)
 ,Clofarabine and Cytarabine
 ,Clofarabine 40 mg/m2 intravenous infusion over 1 hour for 5 days; Cytarabine 1000 mg/m2 intravenous infusion 4 hours post clofarabine IVI.
Total serious adverse events,30/30 %100.0
Edema/Weight Gain,3/30 %10.0
Pancytopenia,24/30 %80.0
Platelet Allosensitization,1/30 %3.33
Thrombocytopenia,1/30 %3.33
Volume Overload,1/30 %3.33
Atrial Fibrillation,3/30 %10.0
Myocardial Infarction,1/30 %3.33
Nausea,1/30 %3.33
Small Bowell Obstruction,1/30 %3.33
Perianal Abcess,1/30 %3.33
Febrile Neutropenia,2/30 %6.67
Fever,3/30 %10.0
Fungal Pneumonia,2/30 %6.67
Sepsis,5/30 %16.67
Staph Bacteremia,1/30 %3.33
Staph epidermitis,1/30 %3.33
Bilateral External Otitis,1/30 %3.33
Multiple System Organ Failure,6/30 %20.0
Elevated LFT,1/30 %3.33
Hyperglycemia,1/30 %3.33
Delirium,1/30 %3.33
Renal Insufficiency / Failure,3/30 %10.0
Pulmonary Infiltrate,1/30 %3.33
Respiratory Failure,3/30 %10.0
Respiratory Distress,2/30 %6.67
Pneumonia,2/30 %6.67
Hand and Foot Syndrome,3/30 %10.0

Etoposide  Methylprednisolone  High-dose Cytarabine and Oxaliplatin as 2nd Line Therapy for Non-Hodgkin's Lymphoma (NHL)(https://clinicaltrials.gov/show/NCT00336583)
 ,ESHAOx
 ,The ESHAOx consisted of Etoposide (40 mg per square meter on days 1-4) Methylprednisolone (500 mg on days 1-5) Cytarabine (2 g per square meter on day 5) and Oxaliplatin (130 mg per square meter on day 1) every 3 weeks to a maximum of six cycles.
Total serious adverse events,1/26 %3.85
febrile neutropenia,1/26 %3.85

S0530 Cytarabine and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia(https://clinicaltrials.gov/show/NCT00337168)
 ,Induction
 ,Up to two induction cycles with clofarabine and cytarabine
Total serious adverse events,5/36 %13.89
Febrile neutropenia,1/36 %2.78
Colitis,1/36 %2.78
Death not associated with CTCAE term - Multi-organ failure,1/36 %2.78
Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Blood,1/36 %2.78
Renal failure,1/36 %2.78
Hypotension,1/36 %2.78

T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts(https://clinicaltrials.gov/show/NCT00368355)
 ,CLINIMACS Device,ISOLEX Device
 ,Subjects will receive transplant conditioning with Ara-C Cyclophosphamide Campath-1H Total Body Irradiation and will then receive T cell depleted stem cell infusion processed by the CLINIMACS Device  Ara-C: day-8 through day-5  3 g/m2 q 12 hours  Cyclophosphamide: day-7 and day-6  45 mg/kg  Campath-1H: day-3 through day-1  Dosing for children:  5 - 15kg : 3mg IV in 30ml NS  15.1 - 30kg : 5mg IV in 50ml NS  >30 kg : 10mg IV in 100ml NS  Adults will receive 10mg IV in 100ml NS  Total Body Irradiation: day-4 through day-1  175 cGy x 2 at 24 cGy/min  Stem Cell Infusion: Stem cells are infused on day 0,Subjects will receive transplant conditioning with Ara-C Cyclophosphamide Campath-1H Total Body Irradiation and will then receive T cell depleted stem cell infusion processed by the ISOLEX Device  Ara-C: day-8 through day-5  3 g/m2 q 12 hours  Cyclophosphamide: day-7 and day-6  45 mg/kg  Campath-1H: day-3 through day-1  Dosing for children:  5 - 15kg : 3mg IV in 30ml NS  15.1 - 30kg : 5mg IV in 50ml NS  >30 kg : 10mg IV in 100ml NS  Adults will receive 10mg IV in 100ml NS  Total Body Irradiation: day-4 through day-1  175 cGy x 2 at 24 cGy/min  Stem Cell Infusion: Stem cells are infused on day 0
Total all-cause mortality,2/18 %11.11,4/28 %14.29
Total serious adverse events,14/18 %77.78,15/28 %53.57
Hemorrhage/bleeding with grade 3 or 4 thrombocytopenia,2/18 %11.11,0/28 %0.0
Hypotension,0/18 %0.0,1/28 %3.57
Sinus tachycardia,0/18 %0.0,1/28 %3.57
Ventricular Arrhythmia,0/18 %0.0,1/28 %3.57
Colitis,1/18 %5.56,0/28 %0.0
Gastrointestinal-Other: Appendicitis,0/18 %0.0,1/28 %3.57
Stomatitis/pharyngitis (oral/pharyngeal mucositis),0/18 %0.0,1/28 %3.57
pharyngeal ulcers,0/18 %0.0,1/28 %3.57
Liver Dysfunction/Failure (clinical),0/18 %0.0,1/28 %3.57
SGOT (AST) (serum glutamic oxaloacetic transaminase),0/18 %0.0,2/28 %7.14
SGPT (ALT) (serum glutamic pyruvic transaminase),0/18 %0.0,1/28 %3.57
Catheter-Related Infection,2/18 %11.11,2/28 %7.14
Infection/Febrile Neutropenia-Other: HHV6 viremia,1/18 %5.56,0/28 %0.0
Infection(documented clinically or microbiologically)with grade 3 or 4 neutropenia(ANC <1.0 x 10e9/L,0/18 %0.0,1/28 %3.57
Infection without neutropenia,10/18 %55.56,6/28 %21.43
Hyperglycemia,0/18 %0.0,1/28 %3.57
Hypokalemia,0/18 %0.0,2/28 %7.14
Ataxia (incoordination),0/18 %0.0,1/28 %3.57
Neuropathy - sensory,1/18 %5.56,0/28 %0.0
Hematuria (in the absence of vaginal bleeding),1/18 %5.56,0/28 %0.0
Renal/Genitourinary-Other: Hemorrhagic Cystitis,0/18 %0.0,2/28 %7.14
Renal/Genitourinary-Other: Hydronephrosis,1/18 %5.56,0/28 %0.0
Renal/Genitourinary-Other: Nephrolithiasis,0/18 %0.0,1/28 %3.57
Renal Failure,0/18 %0.0,1/28 %3.57
Adult Respiratory Distress Syndrome(ARDS),0/18 %0.0,1/28 %3.57
Hypoxia,0/18 %0.0,1/28 %3.57
Pneumothorax,0/18 %0.0,1/28 %3.57
Pulmonary-Other: Acute respiratory failure,1/18 %5.56,0/28 %0.0
Pulmonary-Other: Mediastinal hematoma after replacing central line.,1/18 %5.56,0/28 %0.0
Pulmonary-Other: Respiratory failure,0/18 %0.0,1/28 %3.57

Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes(https://clinicaltrials.gov/show/NCT00369317)
 ,Treatment (Combination Chemotherapy)
 ,INDUCTION THERAPY COURSE I: Patients receive cytarabine IT on day 1 and cytarabine IV continuously over 96 hours daunorubicin hydrochloride IV continuously and oral thioguanine BID on days 1-4. COURSE II: Patients receive high-dose cytarabine IV over 3 hours BID on days 1 2 8 and 9 and asparaginase (IM) on days 2 and 9.  COURSE III: Patients receive treatment as in course I. COURSE IV: Patients receive cytarabine IV daunorubicin hydrochloride IV and oral thioguanine as in course I  INTENSIFICATION THERAPY: Patients receive cytarabine IV continuously over 168 hours on days 1-7 and etoposide IV over 1 hour on days 1-3. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity.  asparaginase: Given IM  daunorubicin hydrochloride: Given IV  cytarabine: Given IV or IT  thioguanine: Given orally  etoposide: Given IV  laboratory biomarker analysis: Correlative studies
Total serious adverse events,3/204 %1.47
Ascites,1/204 %0.49
Typhlitis,1/204 %0.49
Hepatic failure,1/204 %0.49
Immune system disorders - Other,1/204 %0.49
Hypoxia,1/204 %0.49
Respiratory thoracic and mediastinal disorders - Other,1/204 %0.49

Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia(https://clinicaltrials.gov/show/NCT00372593)
 ,Arm A: Standard Arm - No GMTZ AML Pts w/Out Down Syndrome,Arm B: Experimental - With GMTZ AML Pts w/Out Down Syndrome,Arm A: Standard Arm - No GMTZ AML Patients With Down Syndrome
 ,Patients receive intrathecal (IT) cytarabine (ARA-C) at diagnosis or on day 1 of treatment or twice a week for up to 6 doses. They also receive an infusion of ARA-C on days 1-10; a 6-hour infusion of daunorubicin hydrochloride on days 1 3 and 5; and a 4-hr infusion of etoposide on days 1-5. After 3 weeks of rest patients receive IT ARA-C on day 1. They also receive an infusion of ARA-C on days 1-8; a 6-hr infusion of daunorubicin on days 1 3 and 5; and a 4-hr infusion of etoposide on days 1-5. After 3 weeks of rest some patients receive IT ARA-C on day 1 and 1-hr infusions of ARA-C and etoposide on days 1-5. After 3 weeks of rest some patients receive IT ARA-C on day 1; a 2-hr infusion of ARA-C on days 1-4; and a 1-hour infusion of mitoxantrone on days 3-6. After 3 weeks of rest they receive a 3-hr infusion of ARA-C on days 1 2 8 and 9 and an injection of asparaginase on days 2 and 9.,Pts receive IT ARA-C at diagnosis or on day 1 of treatment or twice a week for up to six doses. They also receive an infusion of ARA-C on days 1-10; a 6-hr infusion of daunorubicin on days 1 3 & 5; a 4-hr infusion of etoposide on days 1-5; and a 2-hr infusion of GMTZ - gemtuzumab ozogamicin (Mylotarg) on day 6. After 3 wks of rest patients receive IT ARA-C on day 1. They also receive an infusion of ARA-C on days 1-8; a 6-hr infusion of daunorubicin on days 1 3 and 5; and a 4-hr infusion of etoposide on days 1-5. After 3 weeks of rest some patients receive IT ARA-C on day 1 and 1-hr infusions of ARA-C and etoposide on days 1-5. After 3 wks of rest some patients receive IT ARA-C on day 1; a 2-hr infusion of ARA-C on days 1-4; and a 1-hr infusion of mitoxantrone hydrochloride on days 3-6. They also receive a 2-hr infusion of gemtuzumab on day 7. After 3 weeks of rest they receive a 3-hr infusion of ARA-C on days 1 2 8 and 9 and an injection of asparaginase on days 2 and 9.,Patients receive intrathecal (IT) cytarabine (ARA-C) at diagnosis or on day 1 of treatment or twice a week for up to 6 doses. They also receive an infusion of ARA-C on days 1-10; a 6-hour infusion of daunorubicin hydrochloride on days 1 3 and 5; and a 4-hr infusion of etoposide on days 1-5. After 3 weeks of rest patients receive IT ARA-C on day 1. They also receive an infusion of ARA-C on days 1-8; a 6-hr infusion of daunorubicin on days 1 3 and 5; and a 4-hr infusion of etoposide on days 1-5. After 3 weeks of rest some patients receive IT ARA-C on day 1 and 1-hr infusions of ARA-C and etoposide on days 1-5. After 3 weeks of rest some patients receive IT ARA-C on day 1; a 2-hr infusion of ARA-C on days 1-4; and a 1-hour infusion of mitoxantrone on days 3-6. After 3 weeks of rest they receive a 3-hr infusion of ARA-C on days 1 2 8 and 9 and an injection of asparaginase on days 2 and 9.
Total serious adverse events,26/511 %5.09,32/511 %6.26,2/6 %33.33
Disseminated intravascular coagulation,2/511 %0.39,2/511 %0.39,0/6 %0.0
Febrile neutropenia,0/511 %0.0,2/511 %0.39,0/6 %0.0
Atrial flutter,1/511 %0.2,0/511 %0.0,0/6 %0.0
Cardiac disorders - Other,3/511 %0.59,4/511 %0.78,0/6 %0.0
Heart failure,1/511 %0.2,0/511 %0.0,0/6 %0.0
Left ventricular systolic dysfunction,2/511 %0.39,5/511 %0.98,0/6 %0.0
Pericardial effusion,1/511 %0.2,1/511 %0.2,0/6 %0.0
Pericarditis,1/511 %0.2,0/511 %0.0,0/6 %0.0
Restrictive cardiomyopathy,1/511 %0.2,0/511 %0.0,0/6 %0.0
Right ventricular dysfunction,1/511 %0.2,0/511 %0.0,0/6 %0.0
Ascites,1/511 %0.2,0/511 %0.0,0/6 %0.0
Gastritis,1/511 %0.2,0/511 %0.0,0/6 %0.0
Mucositis oral,1/511 %0.2,0/511 %0.0,0/6 %0.0
Death NOS,3/511 %0.59,3/511 %0.59,1/6 %16.67
Multi-organ failure,6/511 %1.17,2/511 %0.39,0/6 %0.0
Sudden death NOS,1/511 %0.2,1/511 %0.2,0/6 %0.0
Hepatic failure,0/511 %0.0,1/511 %0.2,0/6 %0.0
Portal hypertension,1/511 %0.2,0/511 %0.0,0/6 %0.0
Enterocolitis infectious,0/511 %0.0,0/511 %0.0,1/6 %16.67
Infections and infestations - Other,14/511 %2.74,15/511 %2.94,1/6 %16.67
Lung infection,0/511 %0.0,0/511 %0.0,1/6 %16.67
Sepsis,1/511 %0.2,2/511 %0.39,0/6 %0.0
Alanine aminotransferase increased,0/511 %0.0,2/511 %0.39,0/6 %0.0
Aspartate aminotransferase increased,1/511 %0.2,2/511 %0.39,0/6 %0.0
Blood bilirubin increased,2/511 %0.39,1/511 %0.2,0/6 %0.0
Creatinine increased,0/511 %0.0,1/511 %0.2,0/6 %0.0
Electrocardiogram QT corrected interval prolonged,0/511 %0.0,1/511 %0.2,0/6 %0.0
Fibrinogen decreased,1/511 %0.2,0/511 %0.0,0/6 %0.0
Investigations - Other,1/511 %0.2,1/511 %0.2,0/6 %0.0
Lipase increased,0/511 %0.0,1/511 %0.2,0/6 %0.0
Serum amylase increased,0/511 %0.0,1/511 %0.2,0/6 %0.0
Acidosis,3/511 %0.59,3/511 %0.59,0/6 %0.0
Hyperglycemia,1/511 %0.2,2/511 %0.39,0/6 %0.0
Hyperkalemia,1/511 %0.2,1/511 %0.2,0/6 %0.0
Hypocalcemia,1/511 %0.2,0/511 %0.0,0/6 %0.0
Hypoglycemia,1/511 %0.2,1/511 %0.2,0/6 %0.0
Hypokalemia,2/511 %0.39,0/511 %0.0,0/6 %0.0
Hyponatremia,1/511 %0.2,0/511 %0.0,0/6 %0.0
Pain in extremity,0/511 %0.0,1/511 %0.2,0/6 %0.0
Treatment related secondary malignancy,0/511 %0.0,1/511 %0.2,0/6 %0.0
Encephalopathy,0/511 %0.0,1/511 %0.2,0/6 %0.0
Intracranial hemorrhage,0/511 %0.0,6/511 %1.17,0/6 %0.0
Nervous system disorders - Other,1/511 %0.2,0/511 %0.0,0/6 %0.0
Seizure,1/511 %0.2,1/511 %0.2,1/6 %16.67
Confusion,0/511 %0.0,1/511 %0.2,0/6 %0.0
Acute kidney injury,8/511 %1.57,2/511 %0.39,0/6 %0.0
Adult respiratory distress syndrome,4/511 %0.78,8/511 %1.57,0/6 %0.0
Atelectasis,0/511 %0.0,1/511 %0.2,0/6 %0.0
Bronchopulmonary hemorrhage,2/511 %0.39,1/511 %0.2,0/6 %0.0
Bronchospasm,0/511 %0.0,1/511 %0.2,0/6 %0.0
Dyspnea,0/511 %0.0,2/511 %0.39,0/6 %0.0
Hypoxia,7/511 %1.37,7/511 %1.37,2/6 %33.33
Pleural effusion,0/511 %0.0,2/511 %0.39,0/6 %0.0
Pleural hemorrhage,0/511 %0.0,1/511 %0.2,0/6 %0.0
Pneumonitis,2/511 %0.39,2/511 %0.39,0/6 %0.0
Respiratory thoracic and mediastinal disorders - Other,2/511 %0.39,1/511 %0.2,0/6 %0.0
Hypotension,6/511 %1.17,4/511 %0.78,1/6 %16.67
Vascular disorders - Other,0/511 %0.0,1/511 %0.2,0/6 %0.0

Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia(https://clinicaltrials.gov/show/NCT00372619)
 ,Clofarabine 40 mg/m to Assess Feasibility in ALL Patients.,Clofarabine 40 mg/m to Assess Feasibility in AML Patients.,Clofarabine 52 mg/m to Assess Feasibility in ALL Patients.,Clofarabine 52 mg/m to Assess Efficacy in ALL Patients.,Clofarabine 52 mg/m to Assess Feasibility in AML Patients.,Clofarabine 52 mg/m to Assess Efficacy in AML Patients,Clofarabine 52 mg/m to Assess Efficacy - Ambiguous Lineage pt
 ,Clofarabine 40 mg/m to assess feasibility in ALL patients. Patients receive Cycle 1 (14-42 days) Cytarabine IT (aged based dosage 1-1.99 30 mg 2-2.99 50 mg  3 years 70 mg on Day 0 Clofarabine IV (dosage 40 mg/m2/dose) on days 1-5 and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Cycle 2 (14-42 days) Methotrexate IT (age based dosage 1-1.99 8 mg 2-2.99 10 mg  3 12 mg) on day 1 Clofarabine IV 40 mg/m2/dose on days 1-5 and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Maintenance cycles 1-10 (14-42 days each) Methotrexate IT (age based dosage 1-1.99 8 mg 2-2.99 10 mg  3 12 mg) on day 1 Clofarabine IV 40 mg/m2/dose on days 1-5 and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5.  clofarabine: Given IV for 5 days  cytarabine: Given IV  methotrexate: Given intrathecally or IT age based dosage  laboratory biomarker analysis,Clofarabine 40 mg/m to assess feasibility in AML patients. Patients receive Cycle 1 (14-42 days) Cytarabine IT (aged based dosage 1-1.99 30 mg 2-2.99 50 mg  3 years 70 mg on Day 0 Clofarabine IV (dosage 40 mg/m2/dose) on days 1-5 and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Cycle 2 (14-42 days) Methotrexate IT (age based dosage 1-1.99 8 mg 2-2.99 10 mg  3 12 mg) on day 1 Clofarabine IV 40 mg/m2/dose on days 1-5 and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Maintenance cycles 1-10 (14-42 days each) Methotrexate IT (age based dosage 1-1.99 8 mg 2-2.99 10 mg  3 12 mg) on day 1 Clofarabine IV 40 mg/m2/dose on days 1-5 and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5.  clofarabine: Given IV for 5 days  cytarabine: Given IV  methotrexate: Given intrathecally or IT age based dosage  laboratory biomarker analysis,Clofarabine 52 mg/m to assess feasibility in ALL patients. Patients receive Cycle 1 (14-42 days) Cytarabine IT (aged based dosage 1-1.99 30 mg 2-2.99 50 mg  3 years 70 mg on Day 0 Clofarabine IV (dosage 52 mg/m2/dose) on days 1-5 and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Cycle 2 (14-42 days) Methotrexate IT (age based dosage 1-1.99 8 mg 2-2.99 10 mg  3 12 mg) on day 1 Clofarabine IV 52 mg/m2/dose on days 1-5 and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Maintenance cycles 1-10 (14-42 days each) Methotrexate IT (age based dosage 1-1.99 8 mg 2-2.99 10 mg  3 12 mg) on day 1 Clofarabine IV 52 mg/m2/dose on days 1-5 and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5.  clofarabine: Given IV for 5 days  cytarabine: Given IV  methotrexate: Given intrathecally or IT age based dosage  laboratory biomarker analysis,Clofarabine 52 mg/m to assess efficacy in ALL patients. Patients receive Cycle 1 (14-42 days) Cytarabine IT (aged based dosage 1-1.99 30 mg 2-2.99 50 mg  3 years 70 mg on Day 0 Clofarabine IV (dosage 52 mg/m2/dose) on days 1-5 and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Cycle 2 (14-42 days) Methotrexate IT (age based dosage 1-1.99 8 mg 2-2.99 10 mg  3 12 mg) on day 1 Clofarabine IV 52 mg/m2/dose on days 1-5 and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Maintenance cycles 1-10 (14-42 days each) Methotrexate IT (age based dosage 1-1.99 8 mg 2-2.99 10 mg  3 12 mg) on day 1 Clofarabine IV 52 mg/m2/dose on days 1-5 and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5.  clofarabine: Given IV for 5 days  cytarabine: Given IV  methotrexate: Given intrathecally or IT age based dosage  laboratory biomarker analysis,Clofarabine 52 mg/m to assess feasibility in AML patients. Patients receive Cycle 1 (14-42 days) Cytarabine IT (aged based dosage 1-1.99 30 mg 2-2.99 50 mg  3 years 70 mg on Day 0 Clofarabine IV (dosage 52 mg/m2/dose) on days 1-5 and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Cycle 2 (14-42 days) Methotrexate IT (age based dosage 1-1.99 8 mg 2-2.99 10 mg  3 12 mg) on day 1 Clofarabine IV 52 mg/m2/dose on days 1-5 and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Maintenance cycles 1-10 (14-42 days each) Methotrexate IT (age based dosage 1-1.99 8 mg 2-2.99 10 mg  3 12 mg) on day 1 Clofarabine IV 52 mg/m2/dose on days 1-5 and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5.  clofarabine: Given IV for 5 days  cytarabine: Given IV  methotrexate: Given intrathecally or IT age based dosage  laboratory biomarker analysis,Clofarabine 52 mg/m to assess efficacy in AML patients. Patients receive Cycle 1 (14-42 days) Cytarabine IT (aged based dosage 1-1.99 30 mg 2-2.99 50 mg  3 years 70 mg on Day 0 Clofarabine IV (dosage 52 mg/m2/dose) on days 1-5 and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Cycle 2 (14-42 days) Methotrexate IT (age based dosage 1-1.99 8 mg 2-2.99 10 mg  3 12 mg) on day 1 Clofarabine IV 52 mg/m2/dose on days 1-5 and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Maintenance cycles 1-10 (14-42 days each) Methotrexate IT (age based dosage 1-1.99 8 mg 2-2.99 10 mg  3 12 mg) on day 1 Clofarabine IV 52 mg/m2/dose on days 1-5 and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5.  clofarabine: Given IV for 5 days  cytarabine: Given IV  methotrexate: Given intrathecally or IT age based dosage  laboratory biomarker analysis,Clofarabine 52 mg/m to assess efficacy in acute leukemia of ambiguous lineage patients. Patients receive Cycle 1 (14-42 days) Cytarabine IT (aged based dosage 1-1.99 30 mg 2-2.99 50 mg  3 years 70 mg on Day 0 Clofarabine IV (dosage 52 mg/m2/dose) on days 1-5 and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Cycle 2 (14-42 days) Methotrexate IT (age based dosage 1-1.99 8 mg 2-2.99 10 mg  3 12 mg) on day 1 Clofarabine IV 52 mg/m2/dose on days 1-5 and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Maintenance cycles 1-10 (14-42 days each) Methotrexate IT (age based dosage 1-1.99 8 mg 2-2.99 10 mg  3 12 mg) on day 1 Clofarabine IV 52 mg/m2/dose on days 1-5 and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5.  clofarabine: Given IV for 5 days  cytarabine: Given IV  methotrexate: Given intrathecally or IT age based dosage  laboratory biomarker analysis
Total serious adverse events,5/8 %62.5,2/2 %100.0,2/3 %66.67,7/10 %70.0,3/7 %42.86,14/40 %35.0,2/2 %100.0
Febrile neutropenia,2/8 %25.0,1/2 %50.0,0/3 %0.0,1/10 %10.0,1/7 %14.29,6/40 %15.0,0/2 %0.0
Left ventricular systolic dysfunction,0/8 %0.0,0/2 %0.0,0/3 %0.0,0/10 %0.0,0/7 %0.0,1/40 %2.5,0/2 %0.0
Right ventricular dysfunction,0/8 %0.0,0/2 %0.0,0/3 %0.0,0/10 %0.0,0/7 %0.0,1/40 %2.5,0/2 %0.0
Sinus tachycardia,0/8 %0.0,0/2 %0.0,0/3 %0.0,0/10 %0.0,1/7 %14.29,0/40 %0.0,0/2 %0.0
Abdominal pain,2/8 %25.0,0/2 %0.0,0/3 %0.0,0/10 %0.0,0/7 %0.0,0/40 %0.0,0/2 %0.0
Colitis,0/8 %0.0,0/2 %0.0,0/3 %0.0,0/10 %0.0,0/7 %0.0,1/40 %2.5,0/2 %0.0
Diarrhea,2/8 %25.0,0/2 %0.0,0/3 %0.0,0/10 %0.0,0/7 %0.0,0/40 %0.0,0/2 %0.0
Ileus,0/8 %0.0,0/2 %0.0,0/3 %0.0,1/10 %10.0,0/7 %0.0,0/40 %0.0,0/2 %0.0
Nausea,1/8 %12.5,0/2 %0.0,0/3 %0.0,0/10 %0.0,0/7 %0.0,0/40 %0.0,0/2 %0.0
Pancreatitis,1/8 %12.5,0/2 %0.0,0/3 %0.0,0/10 %0.0,0/7 %0.0,1/40 %2.5,0/2 %0.0
Small intestinal mucositis,0/8 %0.0,0/2 %0.0,0/3 %0.0,1/10 %10.0,0/7 %0.0,0/40 %0.0,0/2 %0.0
Vomiting,1/8 %12.5,0/2 %0.0,0/3 %0.0,0/10 %0.0,0/7 %0.0,0/40 %0.0,0/2 %0.0
Chills,0/8 %0.0,0/2 %0.0,0/3 %0.0,0/10 %0.0,1/7 %14.29,0/40 %0.0,0/2 %0.0
Fatigue,0/8 %0.0,0/2 %0.0,0/3 %0.0,0/10 %0.0,1/7 %14.29,0/40 %0.0,0/2 %0.0
Non-cardiac chest pain,1/8 %12.5,0/2 %0.0,0/3 %0.0,0/10 %0.0,0/7 %0.0,0/40 %0.0,0/2 %0.0
Bladder infection,1/8 %12.5,0/2 %0.0,0/3 %0.0,0/10 %0.0,0/7 %0.0,0/40 %0.0,0/2 %0.0
Infections and infestations - Other,4/8 %50.0,0/2 %0.0,1/3 %33.33,3/10 %30.0,2/7 %28.57,8/40 %20.0,0/2 %0.0
Sepsis,0/8 %0.0,0/2 %0.0,0/3 %0.0,0/10 %0.0,0/7 %0.0,1/40 %2.5,0/2 %0.0
Alanine aminotransferase increased,1/8 %12.5,0/2 %0.0,0/3 %0.0,1/10 %10.0,0/7 %0.0,1/40 %2.5,0/2 %0.0
Aspartate aminotransferase increased,1/8 %12.5,0/2 %0.0,0/3 %0.0,2/10 %20.0,0/7 %0.0,1/40 %2.5,0/2 %0.0
Blood bilirubin increased,1/8 %12.5,0/2 %0.0,0/3 %0.0,0/10 %0.0,0/7 %0.0,0/40 %0.0,0/2 %0.0
Fibrinogen decreased,0/8 %0.0,0/2 %0.0,0/3 %0.0,0/10 %0.0,0/7 %0.0,1/40 %2.5,0/2 %0.0
GGT increased,0/8 %0.0,0/2 %0.0,0/3 %0.0,1/10 %10.0,0/7 %0.0,0/40 %0.0,0/2 %0.0
Lipase increased,1/8 %12.5,0/2 %0.0,1/3 %33.33,0/10 %0.0,0/7 %0.0,3/40 %7.5,1/2 %50.0
Serum amylase increased,0/8 %0.0,0/2 %0.0,0/3 %0.0,0/10 %0.0,0/7 %0.0,2/40 %5.0,0/2 %0.0
Anorexia,1/8 %12.5,0/2 %0.0,0/3 %0.0,0/10 %0.0,0/7 %0.0,0/40 %0.0,0/2 %0.0
Hypercalcemia,0/8 %0.0,0/2 %0.0,0/3 %0.0,0/10 %0.0,0/7 %0.0,2/40 %5.0,1/2 %50.0
Hyperglycemia,0/8 %0.0,0/2 %0.0,0/3 %0.0,0/10 %0.0,0/7 %0.0,0/40 %0.0,1/2 %50.0
Hypermagnesemia,0/8 %0.0,1/2 %50.0,0/3 %0.0,0/10 %0.0,0/7 %0.0,0/40 %0.0,0/2 %0.0
Hypoalbuminemia,0/8 %0.0,0/2 %0.0,0/3 %0.0,0/10 %0.0,0/7 %0.0,0/40 %0.0,1/2 %50.0
Hypokalemia,2/8 %25.0,1/2 %50.0,0/3 %0.0,2/10 %20.0,0/7 %0.0,2/40 %5.0,0/2 %0.0
Hyponatremia,0/8 %0.0,0/2 %0.0,0/3 %0.0,0/10 %0.0,0/7 %0.0,0/40 %0.0,1/2 %50.0
Hypophosphatemia,0/8 %0.0,0/2 %0.0,1/3 %33.33,0/10 %0.0,0/7 %0.0,1/40 %2.5,0/2 %0.0
Tumor lysis syndrome,0/8 %0.0,0/2 %0.0,0/3 %0.0,0/10 %0.0,0/7 %0.0,1/40 %2.5,0/2 %0.0
Back pain,1/8 %12.5,0/2 %0.0,0/3 %0.0,0/10 %0.0,0/7 %0.0,0/40 %0.0,0/2 %0.0
Bone pain,1/8 %12.5,0/2 %0.0,0/3 %0.0,0/10 %0.0,0/7 %0.0,0/40 %0.0,0/2 %0.0
Chest wall pain,1/8 %12.5,0/2 %0.0,0/3 %0.0,0/10 %0.0,0/7 %0.0,0/40 %0.0,0/2 %0.0
Headache,1/8 %12.5,0/2 %0.0,0/3 %0.0,0/10 %0.0,0/7 %0.0,0/40 %0.0,0/2 %0.0
Neuralgia,1/8 %12.5,0/2 %0.0,0/3 %0.0,0/10 %0.0,0/7 %0.0,0/40 %0.0,0/2 %0.0
Peripheral motor neuropathy,1/8 %12.5,0/2 %0.0,0/3 %0.0,0/10 %0.0,0/7 %0.0,1/40 %2.5,0/2 %0.0
Peripheral sensory neuropathy,0/8 %0.0,0/2 %0.0,0/3 %0.0,0/10 %0.0,0/7 %0.0,1/40 %2.5,0/2 %0.0
Proteinuria,0/8 %0.0,0/2 %0.0,1/3 %33.33,0/10 %0.0,0/7 %0.0,0/40 %0.0,0/2 %0.0
Cough,1/8 %12.5,0/2 %0.0,0/3 %0.0,0/10 %0.0,0/7 %0.0,0/40 %0.0,0/2 %0.0
Dyspnea,1/8 %12.5,0/2 %0.0,0/3 %0.0,0/10 %0.0,0/7 %0.0,0/40 %0.0,0/2 %0.0
Hypoxia,2/8 %25.0,0/2 %0.0,0/3 %0.0,0/10 %0.0,0/7 %0.0,2/40 %5.0,0/2 %0.0
Pneumonitis,2/8 %25.0,0/2 %0.0,0/3 %0.0,0/10 %0.0,0/7 %0.0,0/40 %0.0,0/2 %0.0
Alopecia,0/8 %0.0,0/2 %0.0,1/3 %33.33,0/10 %0.0,0/7 %0.0,0/40 %0.0,0/2 %0.0
Palmar-plantar erythrodysesthesia syndrome,0/8 %0.0,0/2 %0.0,0/3 %0.0,1/10 %10.0,0/7 %0.0,0/40 %0.0,0/2 %0.0
Rash maculo-papular,0/8 %0.0,0/2 %0.0,0/3 %0.0,0/10 %0.0,1/7 %14.29,1/40 %2.5,0/2 %0.0
Capillary leak syndrome,0/8 %0.0,0/2 %0.0,0/3 %0.0,1/10 %10.0,0/7 %0.0,3/40 %7.5,0/2 %0.0
Hypertension,1/8 %12.5,0/2 %0.0,0/3 %0.0,0/10 %0.0,0/7 %0.0,0/40 %0.0,0/2 %0.0
Hypotension,1/8 %12.5,0/2 %0.0,0/3 %0.0,0/10 %0.0,1/7 %14.29,2/40 %5.0,0/2 %0.0

Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia(https://clinicaltrials.gov/show/NCT00381680)
 ,Regimen A: Standard Vincristine Dosing,Arm B: Randomized High Dose Vincristine Regimen
 ,See detailed description.  vincristine sulfate: Given IV  prednisone: Given PO  doxorubicin hydrochloride: Given IV  pegaspargase: Given IM  cytarabine: Given IT or IV  methotrexate: Given IT or IV  dexamethasone: Given PO  etoposide: Given IV  cyclophosphamide: Given IV  leucovorin calcium: Given IV or PO  filgrastim: Given IV or SC  asparaginase: Given IM  mercaptopurine: Given PO,See detailed description. Closed to accrual as of 09/2010).  vincristine sulfate: Given IV  prednisone: Given PO  doxorubicin hydrochloride: Given IV  pegaspargase: Given IM  cytarabine: Given IT or IV  methotrexate: Given IT or IV  dexamethasone: Given PO  etoposide: Given IV  cyclophosphamide: Given IV  leucovorin calcium: Given IV or PO  filgrastim: Given IV or SC  asparaginase: Given IM  mercaptopurine: Given PO
Total serious adverse events,40/203 %19.7,11/68 %16.18
Disseminated intravascular coagulation,1/203 %0.49,1/68 %1.47
Febrile neutropenia,4/203 %1.97,0/68 %0.0
Sinus tachycardia,2/203 %0.99,0/68 %0.0
Ventricular arrhythmia,1/203 %0.49,0/68 %0.0
Abdominal pain,1/203 %0.49,0/68 %0.0
Anal necrosis,1/203 %0.49,0/68 %0.0
Anal ulcer,1/203 %0.49,0/68 %0.0
Death NOS,15/203 %7.39,1/68 %1.47
Edema face,1/203 %0.49,0/68 %0.0
Fever,1/203 %0.49,0/68 %0.0
Multi-organ failure,2/203 %0.99,1/68 %1.47
Hepatic failure,0/203 %0.0,1/68 %1.47
Appendicitis,1/203 %0.49,0/68 %0.0
Catheter related infection,2/203 %0.99,0/68 %0.0
Infections and infestations - Other specify,7/203 %3.45,6/68 %8.82
Lung infection,2/203 %0.99,1/68 %1.47
Meningitis,1/203 %0.49,0/68 %0.0
Mucosal infection,1/203 %0.49,0/68 %0.0
Sepsis,8/203 %3.94,1/68 %1.47
Upper respiratory infection,1/203 %0.49,0/68 %0.0
Alanine aminotransferase increased,1/203 %0.49,0/68 %0.0
Aspartate aminotransferase increased,1/203 %0.49,0/68 %0.0
Blood bilirubin increased,2/203 %0.99,0/68 %0.0
Neutrophil count decreased,3/203 %1.48,1/68 %1.47
Platelet count decreased,3/203 %1.48,2/68 %2.94
White blood cell decreased,1/203 %0.49,0/68 %0.0
Acidosis,1/203 %0.49,0/68 %0.0
Dehydration,1/203 %0.49,0/68 %0.0
Hypernatremia,1/203 %0.49,0/68 %0.0
Hyponatremia,1/203 %0.49,0/68 %0.0
Leukemia secondary to oncology chemotherapy,2/203 %0.99,0/68 %0.0
Myelodysplastic syndrome,1/203 %0.49,1/68 %1.47
Treatment related secondary malignancy,1/203 %0.49,0/68 %0.0
Intracranial hemorrhage,0/203 %0.0,2/68 %2.94
Myelitis,1/203 %0.49,0/68 %0.0
Seizure,0/203 %0.0,1/68 %1.47
Stroke,1/203 %0.49,0/68 %0.0
Adult respiratory distress syndrome,1/203 %0.49,0/68 %0.0
Bronchopulmonary hemorrhage,2/203 %0.99,0/68 %0.0
Hypoxia,1/203 %0.49,0/68 %0.0
Pleural effusion,1/203 %0.49,0/68 %0.0
Pneumonitis,1/203 %0.49,0/68 %0.0
Pneumothorax,1/203 %0.49,0/68 %0.0
Respiratory failure,1/203 %0.49,0/68 %0.0
Skin and subcutaneous tissue disorders - Other specify,1/203 %0.49,0/68 %0.0
Hypotension,4/203 %1.97,1/68 %1.47
Thromboembolic event,2/203 %0.99,0/68 %0.0

Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma(https://clinicaltrials.gov/show/NCT00392990)
 ,High Risk - Treated With Alternating R-CODOX-M/R-IVAC Cycles,Low Risk - Treatment With 3 Cycles of R-CODOX-M
 ,Patients are stratified between high risk and low risk disease status.  High risk patients receive 1 cycle of R-CODOX-M chemotherapy IV followed by R-IVAC chemotherapy over 30 minutes(Regimen B); regimens A and B are then repeated.  Regimen A: Cyclophosphamide (800 mg/m2 IV over 1 hour)+ vincristine (1.5 mg/m2 IV PUSH)+ doxorubicin (40 mg/m2 IV)+ high-dose methotrexate (2700 mg/m2 IV over 23 hours)+ rituximab (500 mg/m2 IV)(R-CODOX-M) regimen  Regimen B: Rituximab (500 mg/m2 IV once)+ Ifosfamide (1500 mg/m2 IV daily over 3 hours)+ Etoposide (60 mg/m2 IV daily over 1 hour) and Cytarabine (2 grams/m2 IV over 3 hours for 4 doses),Patients are stratified between high risk and low risk disease status. Low risk patients receive 3 cycles of rituximab (500 mg/m2) R-CODOX-M chemotherapy IV over 2-4 hours with intrathecal chemotherapy (Regimen A).  Regimen A: Cyclophosphamide (800 mg/m2 IV over 1 hour)+ vincristine (1.5 mg/m2 IV PUSH)+ doxorubicin (40 mg/m2 IV)+ high-dose methotrexate (2700 mg/m2 IV over 23 hours)+ rituximab (500 mg/m2 IV)(R-CODOX-M) regimen  Regimen B: Rituximab (500 mg/m2 IV once)+ Ifosfamide (1500 mg/m2 IV daily over 3 hours)+ Etoposide (60 mg/m2 IV daily over 1 hour) and Cytarabine (2 grams/m2 IV over 3 hours for 4 doses)
Total all-cause mortality,4/20 %20.0,0/5 %0.0
Total serious adverse events,20/20 %100.0,2/5 %40.0
myelodysplastic syndrome,1/20 %5.0,0/5 %0.0
Cardiac dysfunction,1/20 %5.0,0/5 %0.0
Pleuritic chest pain,1/20 %5.0,0/5 %0.0
Mucositis,1/20 %5.0,0/5 %0.0
GI bleed,1/20 %5.0,0/5 %0.0
Fever,1/20 %5.0,0/5 %0.0
Cerebritis,1/20 %5.0,0/5 %0.0
Febrile neutropnia,5/20 %25.0,1/5 %20.0
Infection,2/20 %10.0,0/5 %0.0
Bloodinfection,1/20 %5.0,0/5 %0.0
Pancytopenia,3/20 %15.0,1/5 %20.0
Neuro symptoms - Seizure,1/20 %5.0,0/5 %0.0
Renal failuretumor lysis syndrome,1/20 %5.0,0/5 %0.0
Hematoma,0/20 %0.0,1/5 %20.0

Research Study to Determine if an Experimental Agent  LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation(https://clinicaltrials.gov/show/NCT00429416)
 ,LLME to Decrease GVHD Following HSC T
 ,To determine if an experimental agent LLME can decrease the incidence and severity of Graft-Versus-Host-Disease (GVHD) following hematopoietic stem cell transplantation (HSCT).
Total serious adverse events,10/14 %71.43
Diarrhea,2/14 %14.29
Bone marrow cellularity,1/14 %7.14
Infection,3/14 %21.43
Pancyptopenia,1/14 %7.14
Hematoma,1/14 %7.14
Death,7/14 %50.0
Hypersensitivity,1/14 %7.14
Chest pain,2/14 %14.29
Progressive disease,1/14 %7.14
Nausea,3/14 %21.43
Vomiting,2/14 %14.29
Fevers,1/14 %7.14
Rash,1/14 %7.14
Prostatic obstruction,1/14 %7.14
Pericardial effusion,1/14 %7.14
Opportunistic infection,3/14 %21.43
Bladder obstruction,1/14 %7.14
Hepatic failure,1/14 %7.14
Renal insufficiency,1/14 %7.14
Renal failure,1/14 %7.14

Bortezomib and Chemotherapy in Treating Participants With Lymphoid Malignancies Undergoing Stem Cell Transplant(https://clinicaltrials.gov/show/NCT00439556)
 ,Velcade Dose Level 1,Velcade Dose Level 2,Gemcitabine Dose Level 3
 ,BEAM + Rituxan + ATG(MUD pts only) + Velcade 1.0mg/m2 + ALLO SCT,BEAM + Rituxan + ATG(MUD pts only) + Velcade 1.3mg/m2 + ALLO SCT,BEAM + Rituxan + ATG(MUD pts only) + Velcade 1.6mg/m2 + ALLO SCT
Total all-cause mortality,6/36 %16.67,2/3 %66.67,0/0 %0.0
Total serious adverse events,6/36 %16.67,2/3 %66.67,0/0 %0.0
Acute GvHD(graft vs Host Disease),2/36 %5.56,0/3 %0.0,0/0 %0.0
Infection,4/36 %11.11,2/3 %66.67,0/0 %0.0

R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma(https://clinicaltrials.gov/show/NCT00450801)
 ,R-MACLO Cycles,R-IVAM Cycles,Thalidomide Therapy
 ,Adverse Events occurring during the combination Rituximab Methotrexate Doxorubicin Cyclophosphamide and Vincristine (R-MACLO) treatment cycles.,Adverse Events occurring during the Rituximab Ifosfamide (and Mesna) Etoposide and Cytarabine (R-IVAM) treatment cycles.,Adverse Events occurring during Thalidomide maintenance therapy.
Total serious adverse events,21/22 %95.45,21/22 %95.45,19/20 %95.0
Thrombocytopenia (Grade 3-4),8/22 %36.36,21/22 %95.45,0/20 %0.0
Diarrhea (Grade 3-4),2/22 %9.09,1/22 %4.55,1/20 %5.0
Dizziness (Grade 3-4),0/22 %0.0,0/22 %0.0,1/20 %5.0
Neutropenia (Grade 3-4),12/22 %54.55,13/22 %59.09,7/20 %35.0
Febrile neutropenia (Grade 3-4),9/22 %40.91,20/22 %90.91,0/20 %0.0
Infection (Grade 3-4),5/22 %22.73,11/22 %50.0,2/20 %10.0
Bacteremia (Grade 3-4),2/22 %9.09,12/22 %54.55,0/20 %0.0
Mucositis (Grade 3-4),1/22 %4.55,0/22 %0.0,0/20 %0.0
Anemia (Grade 3-4),7/22 %31.82,19/22 %86.36,0/20 %0.0
Peripheral Neuropathy (Grade 3-4),0/22 %0.0,0/22 %0.0,8/20 %40.0
Dyspnea (Grade 3-4),1/22 %4.55,1/22 %4.55,0/20 %0.0
Pleural effusion (Grade 3-4),1/22 %4.55,1/22 %4.55,0/20 %0.0
Erectile Dysfunction (Grade 3-4),0/22 %0.0,0/22 %0.0,2/20 %10.0

Oxaliplatin  Fludarabine  Cytarabine  and Rituximab in Patients With Richter's Transformation and Leukemias(https://clinicaltrials.gov/show/NCT00472849)
 ,OFAR (Phase I),OFAR MTD (Phase II)
 ,Oxaliplatin 30 mg/m^2/day over 2 hours before on days 1-4 Fludarabine. Fludarabine 30 mg/m^2 daily IV over 30 minutes on days 2-3 2-4 or 2-5 until maximum tolerated dose reached. Cytarabine 500 mg/m^2 daily IV 2-hour infusion starting 4 hours after first fludarabine dose started on days 2-3 2-4 or 2-5 until maximum tolerated dose reached. Rituximab 375 mg/m^2 IV on day 3 course 1 (on day 1 subsequent courses).,Oxaliplatin 25 mg/m^2 IV per day MTD on days 1-4 before Fludarabine. Fludarabine 30 mg/m^2 daily IV over 30 minutes on days 2-4. Cytarabine 500 mg/m^2 daily IV 2-hour infusion starting 4 hours after fludarabine dose started on days 2-4. Rituximab 375 mg/m^2 IV on day 3 course 1 (on day 1 subsequent courses). Pegfilgrastim 6 mg subcutaneously once per chemotherapy cycle approximately 24 hours after last dose of chemotherapy.
Total serious adverse events,8/12 %66.67,15/78 %19.23
Hemolysis,0/12 %0.0,1/78 %1.28
Hemorrhage,0/12 %0.0,1/78 %1.28
Immune Hemolytic Anemia,1/12 %8.33,0/78 %0.0
Hypotension,0/12 %0.0,1/78 %1.28
Nausea/Vomiting,0/12 %0.0,1/78 %1.28
Abdominal Pain,0/12 %0.0,1/78 %1.28
Dehydration,1/12 %8.33,3/78 %3.85
Diarrhea,2/12 %16.67,1/78 %1.28
Death,1/12 %8.33,5/78 %6.41
Dyspnea,1/12 %8.33,1/78 %1.28
Infection,2/12 %16.67,3/78 %3.85
Neutropenic Fever,3/12 %25.0,0/78 %0.0
Hyponatremia,1/12 %8.33,0/78 %0.0
Secondary Malignancy,0/12 %0.0,2/78 %2.56
Renal Failure,0/12 %0.0,1/78 %1.28
Pleural Effusion,1/12 %8.33,0/78 %0.0

Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System(https://clinicaltrials.gov/show/NCT00520130)
 ,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,B - Cyclosporine (AC) Arm
 ,TMS Arm  Rituximab: Rituximab: 375 mg/m2 IV day 1 for patients with CD20-positive disease  Allogenic stem cell transplant (ASCT): Allogenic stem cell transplant  Conditioning Chemotherapy: Fludarabine:30 mg/m2 per day IV infusion over 30 minutes daily On days -6 -5 -4 and -3 Cyclophosphamide:1200 mg/m2 per day IV infusion over 2 hours on Days 6 -5 -4 -3 Mesna: 1200 mg/m2 per day IV infusion Daily on days 6 -5-4 and -3  TMS: Tacrolimus: 0.02 mg/kg  start day 3. Continue IV or PO. Taper will begin at day +63 if no acute GVHD then at day +119 and discontinue at day +180 as tolerated Methotrexate: 5 mg/m2 IV over 15 minutes on days 1 3 6 and 11. Sirolimus: 12 mg PO on days -3 to 63 followed by a taper if GVHD does not develop.  FLAG: Fludarabine:25 mg/m2 per day IV over 30 minutes Daily on days 1-5 Cytarabine: 2000 mg/m2 IV over 4 hourson Days 1 2 3 4 5 Filgrastim: 5 mcg/kg per day SC beginning 24 hours PRIOR to initiation of chemotherapy,AC Arm  Rituximab: Rituximab: 375 mg/m2 IV day 1 for patients with CD20-positive disease  Cyclosporine: Cyclosporine: IV over 2 hours or orally every 12 hours on days -1 to 100 followed by a taper if GVHD does not develop.  Allogenic stem cell transplant (ASCT): Allogenic stem cell transplant  Conditioning Chemotherapy: Fludarabine:30 mg/m2 per day IV infusion over 30 minutes daily On days -6 -5 -4 and -3 Cyclophosphamide:1200 mg/m2 per day IV infusion over 2 hours on Days 6 -5 -4 -3 Mesna: 1200 mg/m2 per day IV infusion Daily on days 6 -5-4 and -3  FLAG: Fludarabine:25 mg/m2 per day IV over 30 minutes Daily on days 1-5 Cytarabine: 2000 mg/m2 IV over 4 hourson Days 1 2 3 4 5 Filgrastim: 5 mcg/kg per day SC beginning 24 hours PRIOR to initiation of chemotherapy EPOCH-F: Fludarabine:25 mg/m2 per day IV infusion over 30 minutes daily on days 1-4 Etoposide :50 mg/m2 per day continuous IV infusion over 24 hours on days 1-4 Doxorubicin:10 mg/m2/d
Total all-cause mortality,8/44 %18.18,19/45 %42.22
Total serious adverse events,36/44 %81.82,41/45 %91.11
Edema: limb,1/44 %2.27,0/45 %0.0
Edema: viscera,1/44 %2.27,0/45 %0.0
Hemoglobin,3/44 %6.82,2/45 %4.44
Hemolysis (e.g. immune hemolytic anemia drug-related hemolysis),0/44 %0.0,1/45 %2.22
Iron overload,0/44 %0.0,1/45 %2.22
Leukocytes (total WBC),0/44 %0.0,2/45 %4.44
Lymphopenia,1/44 %2.27,2/45 %4.44
Neutrophils/granulocytes (ANC/AGC),3/44 %6.82,1/45 %2.22
PTT (Partial Thromboplastin Time),1/44 %2.27,0/45 %0.0
Platelets,1/44 %2.27,2/45 %4.44
Thrombotic microangiopathy,2/44 %4.55,1/45 %2.22
Cardiac ischemia/infarction,1/44 %2.27,0/45 %0.0
Cardiopulmonary arrest cause unknown (non-fatal),1/44 %2.27,0/45 %0.0
Hypertension,0/44 %0.0,5/45 %11.11
Hypotension,3/44 %6.82,5/45 %11.11
Left ventricular diastolic dysfunction,1/44 %2.27,1/45 %2.22
Left ventricular systolic dysfunction,2/44 %4.55,4/45 %8.89
Right ventricular dysfunction (cor pulmonale),0/44 %0.0,1/45 %2.22
Supraventricular and nodal arrhythmia::Atrial fibrillation,3/44 %6.82,0/45 %0.0
Supraventricular and nodal arrhythmia::Sinus tachycardia,0/44 %0.0,2/45 %4.44
Supraventricular and nodal arrhythmia::Supraventricular tachycardia,0/44 %0.0,1/45 %2.22
Ventricular arrhythmia::Ventricular tachycardia,0/44 %0.0,1/45 %2.22
Adrenal insufficiency,0/44 %0.0,1/45 %2.22
Pancreatic endocrine: glucose intolerance,2/44 %4.55,1/45 %2.22
Dry eye syndrome,3/44 %6.82,0/45 %0.0
Ocular/Visual - Other,0/44 %0.0,1/45 %2.22
Colitis,0/44 %0.0,1/45 %2.22
Colitis infectious (e.g. Clostridium difficile),5/44 %11.36,7/45 %15.56
Diarrhea,8/44 %18.18,8/45 %17.78
Dysphagia (difficulty swallowing),1/44 %2.27,2/45 %4.44
Esophagitis,0/44 %0.0,1/45 %2.22
Gastritis (including bile reflux gastritis),2/44 %4.55,0/45 %0.0
Heartburn/dyspepsia,0/44 %0.0,1/45 %2.22
Hemorrhage GI::Abdomen NOS,0/44 %0.0,1/45 %2.22
Hemorrhage GI::Duodenum,0/44 %0.0,1/45 %2.22
Hemorrhage GI::Lower GI NOS,0/44 %0.0,3/45 %6.67
Hemorrhage GI::Rectum,0/44 %0.0,1/45 %2.22
Hemorrhage GI::Upper GI NOS,0/44 %0.0,1/45 %2.22
Ileus GI (functional obstruction of bowel i.e. neuroconstipation),1/44 %2.27,1/45 %2.22
Mucositis/stomatitis (clinical exam)::Oral cavity,3/44 %6.82,0/45 %0.0
Mucositis/stomatitis (functional/symptomatic)::Oral cavity,1/44 %2.27,0/45 %0.0
Nausea,1/44 %2.27,2/45 %4.44
Pain::Abdomen NOS,1/44 %2.27,0/45 %0.0
Perforation GI::Small bowel NOS,1/44 %2.27,0/45 %0.0
Stricture/stenosis (including anastomotic) GI::Esophagus,1/44 %2.27,0/45 %0.0
Ulcer GI::Duodenum,1/44 %2.27,0/45 %0.0
Death not associated with CTCAE term::Death NOS,4/44 %9.09,7/45 %15.56
Death not associated with CTCAE term::Disease progression NOS,3/44 %6.82,10/45 %22.22
Death not associated with CTCAE term::Multi-organ failure,1/44 %2.27,2/45 %4.44
Fatigue (asthenia lethargy malaise),0/44 %0.0,1/45 %2.22
Fever (in the absence of neutropenia where neutropenia is defined as ANC <1.0 x 10e9/L),2/44 %4.55,1/45 %2.22
Tumor lysis syndrome,0/44 %0.0,1/45 %2.22
Weight gain,0/44 %0.0,1/45 %2.22
Cholecystitis,1/44 %2.27,1/45 %2.22
Liver dysfunction/failure (clinical),1/44 %2.27,0/45 %0.0
Allergic reaction/hypersensitivity (including drug fever),2/44 %4.55,0/45 %0.0
Cytokine release syndrome/acute infusion reaction,0/44 %0.0,1/45 %2.22
Febrile neutropenia,6/44 %13.64,6/45 %13.33
Infection:: Abdomen NOS,0/44 %0.0,1/45 %2.22
Infection ::Bladder (urinary),0/44 %0.0,1/45 %2.22
Infection ::Blood,3/44 %6.82,8/45 %17.78
Infection::Catheter-related,1/44 %2.27,4/45 %8.89
Infection ::Lip/perioral,0/44 %0.0,1/45 %2.22
Infection ::Lung (pneumonia),4/44 %9.09,3/45 %6.67
Infection::Meninges (meningitis),1/44 %2.27,0/45 %0.0
Infection ::Muscle (infection myositis),0/44 %0.0,1/45 %2.22
Infection::Nose,0/44 %0.0,1/45 %2.22
Infection::Rectum,1/44 %2.27,0/45 %0.0
Infection::Sinus,2/44 %4.55,2/45 %4.44
Infection ::Trachea,1/44 %2.27,0/45 %0.0
Infection::Upper airway NOS,0/44 %0.0,1/45 %2.22
Infection ::Urinary tract NOS,2/44 %4.55,1/45 %2.22
Infection - Other,1/44 %2.27,2/45 %4.44
Infection with normal ANC or Grade 1 or 2 neutrophils::Bladder (urinary),1/44 %2.27,1/45 %2.22
Infection with normal ANC or Grade 1 or 2 neutrophils::Blood,9/44 %20.45,21/45 %46.67
Infection with normal ANC or Grade 1 or 2 neutrophils::Brain (encephalitis infectious),3/44 %6.82,0/45 %0.0
Infection with normal ANC or Grade 1 or 2 neutrophils::Bronchus,2/44 %4.55,1/45 %2.22
Infection with normal ANC or Grade 1 or 2 neutrophils::Catheter-related,4/44 %9.09,12/45 %26.67
Infection with normal ANC or Grade 1 or 2 neutrophils::Colon,0/44 %0.0,1/45 %2.22
Infection with normal ANC or Grade 1 or 2 neutrophils::Esophagus,1/44 %2.27,0/45 %0.0
Infection with normal ANC or Grade 1 or 2 neutrophils::Heart (endocarditis),1/44 %2.27,0/45 %0.0
Infection with normal ANC or Grade 1 or 2 neutrophils::Liver,1/44 %2.27,1/45 %2.22
Infection with normal ANC or Grade 1 or 2 neutrophils::Lung (pneumonia),10/44 %22.73,13/45 %28.89
Infection with normal ANC or Grade 1 or 2 neutrophils::Meninges (meningitis),1/44 %2.27,0/45 %0.0
Infection with normal ANC or Grade 1 or 2 neutrophils::Paranasal,1/44 %2.27,0/45 %0.0
Infection with normal ANC or Grade 1 or 2 neutrophils::Pharynx,2/44 %4.55,1/45 %2.22
Infection with normal ANC or Grade 1 or 2 neutrophils::Sinus,4/44 %9.09,6/45 %13.33
Infection with normal ANC or Grade 1 or 2 neutrophils::Skin (cellulitis),2/44 %4.55,4/45 %8.89
Infection with normal ANC or Grade 1 or 2 neutrophils::Stomach,0/44 %0.0,1/45 %2.22
Infection with normal ANC or Grade 1 or 2 neutrophils::Upper airway NOS,0/44 %0.0,1/45 %2.22
Infection with normal ANC or Grade 1 or 2 neutrophils::Urinary tract NOS,1/44 %2.27,3/45 %6.67
Infection with normal ANC or Grade 1 or 2 neutrophils::Wound,1/44 %2.27,1/45 %2.22
Infection with unknown ANC::Blood,2/44 %4.55,2/45 %4.44
Infection with unknown ANC::Catheter-related,1/44 %2.27,0/45 %0.0
Infection with unknown ANC::Colon,1/44 %2.27,0/45 %0.0
Infection with unknown ANC::Lung (pneumonia),2/44 %4.55,1/45 %2.22
ALT SGPT (serum glutamic pyruvic transaminase),4/44 %9.09,1/45 %2.22
AST SGOT(serum glutamic oxaloacetic transaminase),4/44 %9.09,1/45 %2.22
Albumin serum-low (hypoalbuminemia),1/44 %2.27,1/45 %2.22
Alkaline phosphatase,1/44 %2.27,0/45 %0.0
Bilirubin (hyperbilirubinemia),3/44 %6.82,2/45 %4.44
Creatinine,3/44 %6.82,2/45 %4.44
Magnesium serum-low (hypomagnesemia),0/44 %0.0,1/45 %2.22
Phosphate serum-low (hypophosphatemia),1/44 %2.27,1/45 %2.22
Potassium serum-high (hyperkalemia),0/44 %0.0,1/45 %2.22
Potassium serum-low (hypokalemia),0/44 %0.0,1/45 %2.22
Sodium serum-low (hyponatremia),1/44 %2.27,0/45 %0.0
Uric acid serum-high (hyperuricemia),0/44 %0.0,1/45 %2.22
Arthritis (non-septic),1/44 %2.27,0/45 %0.0
Muscle weakness generalized or specific area (not due to neuropathy)::Right-sided,0/44 %0.0,1/45 %2.22
Musculoskeletal/Soft Tissue - Other,0/44 %0.0,1/45 %2.22
Myositis (inflammation/damage of muscle),0/44 %0.0,2/45 %4.44
Pain::Back,0/44 %0.0,1/45 %2.22
Secondary Malignancy - possibly related to cancer treatment (AML);,0/44 %0.0,4/45 %8.89
Secondary Malignancy - possibly related to cancer treatment (metastat. test cancer in lung),1/44 %2.27,0/45 %0.0
Ataxia (incoordination),0/44 %0.0,1/45 %2.22
CNS cerebrovascular ischemia,0/44 %0.0,1/45 %2.22
Cognitive disturbance,0/44 %0.0,1/45 %2.22
Confusion,1/44 %2.27,1/45 %2.22
Encephalopathy,0/44 %0.0,3/45 %6.67
Hemorrhage CNS,0/44 %0.0,2/45 %4.44
Leukoencephalopathy (radiographic findings),0/44 %0.0,1/45 %2.22
Seizure,0/44 %0.0,1/45 %2.22
Somnolence/depressed level of consciousness,0/44 %0.0,1/45 %2.22
Cystitis,1/44 %2.27,0/45 %0.0
Renal failure,10/44 %22.73,6/45 %13.33
Renal/Genitourinary - Other (AKI required CVVH),0/44 %0.0,1/45 %2.22
Adult Respiratory Distress Syndrome (ARDS),0/44 %0.0,5/45 %11.11
Carbon monoxide diffusion capacity (DL(co)),0/44 %0.0,1/45 %2.22
Dyspnea (shortness of breath),4/44 %9.09,3/45 %6.67
Hemorrhage pulmonary/upper respiratory::Lung,1/44 %2.27,1/45 %2.22
Hemorrhage pulmonary/upper respiratory::Nose,0/44 %0.0,1/45 %2.22
Hypoxia,7/44 %15.91,8/45 %17.78
Pericardial effusion (non-malignant),2/44 %4.55,0/45 %0.0
Pleural effusion (non-malignant),2/44 %4.55,2/45 %4.44
Pneumonitis/pulmonary infiltrates,2/44 %4.55,5/45 %11.11
Pulmonary/Upper Respiratory - Other (Specify respiratory failure),1/44 %2.27,0/45 %0.0
Pulmonary/Upper Respiratory - Other (pleural thickening),0/44 %0.0,1/45 %2.22
Dermatology/Skin - Other (Deep sclerosis per MRI GVHD possible),1/44 %2.27,0/45 %0.0
Rash/desquamation,4/44 %9.09,7/45 %15.56
Rash: hand-foot skin reaction,1/44 %2.27,0/45 %0.0
Thrombosis/embolism (vascular access-related),2/44 %4.55,0/45 %0.0
Thrombosis/thrombus/embolism,4/44 %9.09,1/45 %2.22

Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia(https://clinicaltrials.gov/show/NCT00557193)
 ,Induction (All Patients),Post Induction (Follow-up Only),Arm A (Standard Risk MLL-G),Arm B (IR/HR MLL-R Chemotherapy),Arm C (Safety/ Dose Level 1),Arm C (Safety/ Dose Level 2),Arm C (Efficacy/ Dose Level 2)
 ,All Patients for Induction (not assigned),Post-Induction patients that did not receive therapy,Population Description: Eligible patients with MLL-G (germline or non-rearranged)  Asparaginase: Given IV IM or PO  Cyclophosphamide: Given IV  Cytarabine: Given IV or IT  Daunorubicin Hydrochloride: Given IV  Dexamethasone: Given IV or PO  Etoposide: Given IV  Filgrastim: Given IV or SC  Laboratory Biomarker Analysis: Correlative studies  Leucovorin Calcium: Given IV  Mercaptopurine: Given PO  Methotrexate: Given IV IT or PO  Methylprednisolone: Given IV  Pegaspargase: Given IM  Pharmacological Study: Correlative studies  Prednisone: Given PO  Therapeutic Hydrocortisone: Given IT  Vincristine Sulfate: Given IV,Population Description: Eligible patients with MLL-R (rearranged). Considered Intermediate Risk (IR) if age >= 90 days at diagnosis and High Risk (HR) if age < 90 days at diagnosis.  Asparaginase: Given IV IM or PO  Cyclophosphamide: Given IV  Cytarabine: Given IV or IT  Daunorubicin Hydrochloride: Given IV  Dexamethasone: Given IV or PO  Etoposide: Given IV  Filgrastim: Given IV or SC  Laboratory Biomarker Analysis: Correlative studies  Leucovorin Calcium: Given IV  Mercaptopurine: Given PO  Methotrexate: Given IV IT or PO  Methylprednisolone: Given IV  Pegaspargase: Given IM  Pharmacological Study: Correlative studies  Prednisone: Given PO  Therapeutic Hydrocortisone: Given IT  Vincristine Sulfate: Given IV,Arm C IR/HR MLL-R chemotherapy and lestaurtinib at Dose Level 1 (DL1) (HR: 3.5 mg/kg/day; SR: 4 mg/kg/day),Arm C IR/HR MLL-R chemotherapy and lestaurtinib at Dose Level 2 (DL2) (HR: 4.25 mg/kg/day; SR: 5 mg/kg/day),Arm C IR/HR MLL-R chemotherapy and lestaurtinib at Dose Level 2 (DL2)-Efficacy (HR: 4.25 mg/kg/day; SR: 5 mg/kg/day)
Total all-cause mortality,6/210 %2.86,6/12 %50.0,3/60 %5.0,31/54 %57.41,6/11 %54.55,5/11 %45.45,28/56 %50.0
Total serious adverse events,9/210 %4.29,0/12 %0.0,2/60 %3.33,9/54 %16.67,8/11 %72.73,7/11 %63.64,41/56 %73.21
Anemia,0/210 %0.0,0/12 %0.0,0/60 %0.0,1/54 %1.85,0/11 %0.0,1/11 %9.09,2/56 %3.57
Blood and lymphatic system disorders - Other specify,0/210 %0.0,0/12 %0.0,1/60 %1.67,0/54 %0.0,0/11 %0.0,0/11 %0.0,0/56 %0.0
Febrile neutropenia,0/210 %0.0,0/12 %0.0,0/60 %0.0,0/54 %0.0,6/11 %54.55,1/11 %9.09,22/56 %39.29
Hemolytic uremic syndrome,0/210 %0.0,0/12 %0.0,0/60 %0.0,0/54 %0.0,0/11 %0.0,0/11 %0.0,1/56 %1.79
Thrombotic thrombocytopenic purpura,0/210 %0.0,0/12 %0.0,0/60 %0.0,0/54 %0.0,1/11 %9.09,0/11 %0.0,0/56 %0.0
Cardiac arrest,0/210 %0.0,0/12 %0.0,0/60 %0.0,0/54 %0.0,0/11 %0.0,1/11 %9.09,1/56 %1.79
Heart failure,0/210 %0.0,0/12 %0.0,0/60 %0.0,0/54 %0.0,0/11 %0.0,0/11 %0.0,1/56 %1.79
Left ventricular systolic dysfunction,0/210 %0.0,0/12 %0.0,0/60 %0.0,0/54 %0.0,1/11 %9.09,0/11 %0.0,2/56 %3.57
Myocarditis,0/210 %0.0,0/12 %0.0,0/60 %0.0,0/54 %0.0,0/11 %0.0,0/11 %0.0,1/56 %1.79
Sinus tachycardia,0/210 %0.0,0/12 %0.0,0/60 %0.0,0/54 %0.0,0/11 %0.0,0/11 %0.0,2/56 %3.57
Ascites,0/210 %0.0,0/12 %0.0,0/60 %0.0,1/54 %1.85,0/11 %0.0,1/11 %9.09,1/56 %1.79
Colitis,0/210 %0.0,0/12 %0.0,0/60 %0.0,0/54 %0.0,2/11 %18.18,0/11 %0.0,3/56 %5.36
Diarrhea,0/210 %0.0,0/12 %0.0,0/60 %0.0,0/54 %0.0,5/11 %45.45,3/11 %27.27,11/56 %19.64
Enterocolitis,0/210 %0.0,0/12 %0.0,0/60 %0.0,0/54 %0.0,0/11 %0.0,0/11 %0.0,1/56 %1.79
Gastric hemorrhage,0/210 %0.0,0/12 %0.0,0/60 %0.0,0/54 %0.0,0/11 %0.0,0/11 %0.0,1/56 %1.79
Gastrointestinal disorders - Other specify,1/210 %0.48,0/12 %0.0,0/60 %0.0,0/54 %0.0,0/11 %0.0,0/11 %0.0,5/56 %8.93
Gastrointestinal fistula,0/210 %0.0,0/12 %0.0,0/60 %0.0,0/54 %0.0,0/11 %0.0,1/11 %9.09,0/56 %0.0
Lower gastrointestinal hemorrhage,0/210 %0.0,0/12 %0.0,0/60 %0.0,0/54 %0.0,0/11 %0.0,0/11 %0.0,2/56 %3.57
Mucositis oral,0/210 %0.0,0/12 %0.0,1/60 %1.67,0/54 %0.0,1/11 %9.09,2/11 %18.18,9/56 %16.07
Oral pain,0/210 %0.0,0/12 %0.0,0/60 %0.0,0/54 %0.0,0/11 %0.0,0/11 %0.0,1/56 %1.79
Small intestinal perforation,0/210 %0.0,0/12 %0.0,0/60 %0.0,0/54 %0.0,0/11 %0.0,1/11 %9.09,0/56 %0.0
Typhlitis,0/210 %0.0,0/12 %0.0,0/60 %0.0,0/54 %0.0,0/11 %0.0,1/11 %9.09,0/56 %0.0
Vomiting,0/210 %0.0,0/12 %0.0,0/60 %0.0,0/54 %0.0,1/11 %9.09,0/11 %0.0,2/56 %3.57
Death NOS,1/210 %0.48,0/12 %0.0,0/60 %0.0,0/54 %0.0,0/11 %0.0,0/11 %0.0,3/56 %5.36
Fatigue,0/210 %0.0,0/12 %0.0,0/60 %0.0,0/54 %0.0,1/11 %9.09,0/11 %0.0,0/56 %0.0
Fever,0/210 %0.0,0/12 %0.0,0/60 %0.0,0/54 %0.0,1/11 %9.09,2/11 %18.18,3/56 %5.36
General disorders and administration site conditions - Other specify,0/210 %0.0,0/12 %0.0,0/60 %0.0,0/54 %0.0,0/11 %0.0,1/11 %9.09,0/56 %0.0
Irritability,0/210 %0.0,0/12 %0.0,0/60 %0.0,0/54 %0.0,0/11 %0.0,0/11 %0.0,1/56 %1.79
Multi-organ failure,0/210 %0.0,0/12 %0.0,0/60 %0.0,1/54 %1.85,0/11 %0.0,0/11 %0.0,0/56 %0.0
Anaphylaxis,0/210 %0.0,0/12 %0.0,0/60 %0.0,0/54 %0.0,0/11 %0.0,0/11 %0.0,1/56 %1.79
Immune system disorders - Other specify,0/210 %0.0,0/12 %0.0,0/60 %0.0,1/54 %1.85,0/11 %0.0,0/11 %0.0,0/56 %0.0
Abdominal infection,0/210 %0.0,0/12 %0.0,0/60 %0.0,0/54 %0.0,1/11 %9.09,0/11 %0.0,0/56 %0.0
Anorectal infection,0/210 %0.0,0/12 %0.0,0/60 %0.0,0/54 %0.0,1/11 %9.09,0/11 %0.0,1/56 %1.79
Bronchial infection,0/210 %0.0,0/12 %0.0,0/60 %0.0,1/54 %1.85,0/11 %0.0,0/11 %0.0,0/56 %0.0
Catheter related infection,0/210 %0.0,0/12 %0.0,0/60 %0.0,0/54 %0.0,2/11 %18.18,2/11 %18.18,6/56 %10.71
Endocarditis infective,0/210 %0.0,0/12 %0.0,0/60 %0.0,0/54 %0.0,0/11 %0.0,0/11 %0.0,1/56 %1.79
Enterocolitis infectious,0/210 %0.0,0/12 %0.0,0/60 %0.0,1/54 %1.85,0/11 %0.0,0/11 %0.0,3/56 %5.36
Hepatic infection,0/210 %0.0,0/12 %0.0,0/60 %0.0,1/54 %1.85,0/11 %0.0,0/11 %0.0,0/56 %0.0
Infections and infestations - Other specify,5/210 %2.38,0/12 %0.0,0/60 %0.0,2/54 %3.7,6/11 %54.55,5/11 %45.45,23/56 %41.07
Lung infection,0/210 %0.0,0/12 %0.0,0/60 %0.0,2/54 %3.7,3/11 %27.27,1/11 %9.09,1/56 %1.79
Mucosal infection,0/210 %0.0,0/12 %0.0,0/60 %0.0,0/54 %0.0,0/11 %0.0,0/11 %0.0,1/56 %1.79
Peritoneal infection,0/210 %0.0,0/12 %0.0,0/60 %0.0,0/54 %0.0,0/11 %0.0,1/11 %9.09,0/56 %0.0
Sepsis,0/210 %0.0,0/12 %0.0,0/60 %0.0,2/54 %3.7,1/11 %9.09,1/11 %9.09,11/56 %19.64
Skin infection,0/210 %0.0,0/12 %0.0,0/60 %0.0,0/54 %0.0,0/11 %0.0,0/11 %0.0,3/56 %5.36
Small intestine infection,0/210 %0.0,0/12 %0.0,0/60 %0.0,0/54 %0.0,0/11 %0.0,1/11 %9.09,2/56 %3.57
Soft tissue infection,0/210 %0.0,0/12 %0.0,0/60 %0.0,0/54 %0.0,0/11 %0.0,0/11 %0.0,2/56 %3.57
Tracheitis,0/210 %0.0,0/12 %0.0,0/60 %0.0,0/54 %0.0,0/11 %0.0,1/11 %9.09,0/56 %0.0
Upper respiratory infection,0/210 %0.0,0/12 %0.0,0/60 %0.0,0/54 %0.0,1/11 %9.09,0/11 %0.0,0/56 %0.0
Urinary tract infection,0/210 %0.0,0/12 %0.0,0/60 %0.0,0/54 %0.0,1/11 %9.09,2/11 %18.18,3/56 %5.36
Wound infection,0/210 %0.0,0/12 %0.0,0/60 %0.0,0/54 %0.0,1/11 %9.09,1/11 %9.09,0/56 %0.0
Injury poisoning and procedural complications - Other specify,0/210 %0.0,0/12 %0.0,0/60 %0.0,0/54 %0.0,0/11 %0.0,0/11 %0.0,2/56 %3.57
Vascular access complication,0/210 %0.0,0/12 %0.0,0/60 %0.0,0/54 %0.0,0/11 %0.0,0/11 %0.0,1/56 %1.79
Activated partial thromboplastin time prolonged,0/210 %0.0,0/12 %0.0,0/60 %0.0,1/54 %1.85,0/11 %0.0,0/11 %0.0,0/56 %0.0
Alanine aminotransferase increased,1/210 %0.48,0/12 %0.0,0/60 %0.0,1/54 %1.85,3/11 %27.27,1/11 %9.09,10/56 %17.86
Aspartate aminotransferase increased,0/210 %0.0,0/12 %0.0,0/60 %0.0,1/54 %1.85,1/11 %9.09,1/11 %9.09,8/56 %14.29
Blood bilirubin increased,1/210 %0.48,0/12 %0.0,0/60 %0.0,1/54 %1.85,0/11 %0.0,1/11 %9.09,2/56 %3.57
Creatinine increased,0/210 %0.0,0/12 %0.0,0/60 %0.0,1/54 %1.85,0/11 %0.0,0/11 %0.0,1/56 %1.79
Fibrinogen decreased,0/210 %0.0,0/12 %0.0,0/60 %0.0,0/54 %0.0,0/11 %0.0,0/11 %0.0,1/56 %1.79
GGT increased,0/210 %0.0,0/12 %0.0,0/60 %0.0,0/54 %0.0,1/11 %9.09,0/11 %0.0,1/56 %1.79
Investigations - Other specify,0/210 %0.0,0/12 %0.0,0/60 %0.0,0/54 %0.0,0/11 %0.0,0/11 %0.0,1/56 %1.79
Lipase increased,0/210 %0.0,0/12 %0.0,0/60 %0.0,0/54 %0.0,0/11 %0.0,1/11 %9.09,0/56 %0.0
Lymphocyte count decreased,0/210 %0.0,0/12 %0.0,0/60 %0.0,0/54 %0.0,1/11 %9.09,1/11 %9.09,1/56 %1.79
Neutrophil count decreased,0/210 %0.0,0/12 %0.0,0/60 %0.0,1/54 %1.85,1/11 %9.09,2/11 %18.18,7/56 %12.5
Platelet count decreased,0/210 %0.0,0/12 %0.0,0/60 %0.0,0/54 %0.0,0/11 %0.0,2/11 %18.18,3/56 %5.36
Weight loss,0/210 %0.0,0/12 %0.0,0/60 %0.0,0/54 %0.0,2/11 %18.18,0/11 %0.0,0/56 %0.0
White blood cell decreased,0/210 %0.0,0/12 %0.0,0/60 %0.0,1/54 %1.85,1/11 %9.09,2/11 %18.18,2/56 %3.57
Acidosis,0/210 %0.0,0/12 %0.0,0/60 %0.0,0/54 %0.0,0/11 %0.0,0/11 %0.0,1/56 %1.79
Anorexia,0/210 %0.0,0/12 %0.0,0/60 %0.0,0/54 %0.0,2/11 %18.18,1/11 %9.09,1/56 %1.79
Dehydration,0/210 %0.0,0/12 %0.0,0/60 %0.0,0/54 %0.0,2/11 %18.18,2/11 %18.18,6/56 %10.71
Hyperglycemia,0/210 %0.0,0/12 %0.0,0/60 %0.0,0/54 %0.0,1/11 %9.09,0/11 %0.0,0/56 %0.0
Hypernatremia,0/210 %0.0,0/12 %0.0,0/60 %0.0,0/54 %0.0,1/11 %9.09,2/11 %18.18,1/56 %1.79
Hypertriglyceridemia,1/210 %0.48,0/12 %0.0,0/60 %0.0,0/54 %0.0,0/11 %0.0,0/11 %0.0,1/56 %1.79
Hypoalbuminemia,0/210 %0.0,0/12 %0.0,0/60 %0.0,0/54 %0.0,0/11 %0.0,0/11 %0.0,5/56 %8.93
Hypocalcemia,0/210 %0.0,0/12 %0.0,0/60 %0.0,1/54 %1.85,0/11 %0.0,0/11 %0.0,1/56 %1.79
Hypoglycemia,0/210 %0.0,0/12 %0.0,0/60 %0.0,0/54 %0.0,0/11 %0.0,1/11 %9.09,3/56 %5.36
Hypokalemia,0/210 %0.0,0/12 %0.0,0/60 %0.0,1/54 %1.85,2/11 %18.18,1/11 %9.09,6/56 %10.71
Hyponatremia,0/210 %0.0,0/12 %0.0,0/60 %0.0,0/54 %0.0,0/11 %0.0,0/11 %0.0,1/56 %1.79
Hypophosphatemia,0/210 %0.0,0/12 %0.0,0/60 %0.0,0/54 %0.0,1/11 %9.09,0/11 %0.0,1/56 %1.79
Treatment related secondary malignancy,0/210 %0.0,0/12 %0.0,0/60 %0.0,1/54 %1.85,0/11 %0.0,0/11 %0.0,0/56 %0.0
Abducens nerve disorder,0/210 %0.0,0/12 %0.0,0/60 %0.0,0/54 %0.0,1/11 %9.09,0/11 %0.0,0/56 %0.0
Cognitive disturbance,0/210 %0.0,0/12 %0.0,0/60 %0.0,0/54 %0.0,0/11 %0.0,0/11 %0.0,2/56 %3.57
Depressed level of consciousness,0/210 %0.0,0/12 %0.0,0/60 %0.0,0/54 %0.0,1/11 %9.09,0/11 %0.0,0/56 %0.0
Encephalopathy,0/210 %0.0,0/12 %0.0,0/60 %0.0,1/54 %1.85,0/11 %0.0,1/11 %9.09,1/56 %1.79
Oculomotor nerve disorder,0/210 %0.0,0/12 %0.0,0/60 %0.0,0/54 %0.0,0/11 %0.0,0/11 %0.0,1/56 %1.79
Seizure,0/210 %0.0,0/12 %0.0,0/60 %0.0,0/54 %0.0,2/11 %18.18,1/11 %9.09,2/56 %3.57
Stroke,0/210 %0.0,0/12 %0.0,0/60 %0.0,0/54 %0.0,0/11 %0.0,0/11 %0.0,1/56 %1.79
Psychiatric disorders - Other specify,0/210 %0.0,0/12 %0.0,0/60 %0.0,0/54 %0.0,0/11 %0.0,0/11 %0.0,1/56 %1.79
Acute kidney injury,0/210 %0.0,0/12 %0.0,1/60 %1.67,0/54 %0.0,0/11 %0.0,0/11 %0.0,2/56 %3.57
Adult respiratory distress syndrome,0/210 %0.0,0/12 %0.0,0/60 %0.0,1/54 %1.85,0/11 %0.0,0/11 %0.0,0/56 %0.0
Apnea,0/210 %0.0,0/12 %0.0,0/60 %0.0,0/54 %0.0,1/11 %9.09,0/11 %0.0,0/56 %0.0
Aspiration,0/210 %0.0,0/12 %0.0,0/60 %0.0,0/54 %0.0,0/11 %0.0,0/11 %0.0,1/56 %1.79
Atelectasis,0/210 %0.0,0/12 %0.0,0/60 %0.0,1/54 %1.85,0/11 %0.0,0/11 %0.0,1/56 %1.79
Dyspnea,0/210 %0.0,0/12 %0.0,0/60 %0.0,0/54 %0.0,0/11 %0.0,0/11 %0.0,1/56 %1.79
Hypoxia,2/210 %0.95,0/12 %0.0,0/60 %0.0,1/54 %1.85,1/11 %9.09,2/11 %18.18,4/56 %7.14
Pneumonitis,1/210 %0.48,0/12 %0.0,0/60 %0.0,0/54 %0.0,0/11 %0.0,1/11 %9.09,0/56 %0.0
Respiratory failure,0/210 %0.0,0/12 %0.0,0/60 %0.0,1/54 %1.85,1/11 %9.09,0/11 %0.0,4/56 %7.14
Rash maculo-papular,0/210 %0.0,0/12 %0.0,0/60 %0.0,0/54 %0.0,2/11 %18.18,0/11 %0.0,0/56 %0.0
Skin and subcutaneous tissue disorders - Other specify,1/210 %0.48,0/12 %0.0,0/60 %0.0,0/54 %0.0,0/11 %0.0,0/11 %0.0,2/56 %3.57
Skin ulceration,0/210 %0.0,0/12 %0.0,0/60 %0.0,0/54 %0.0,1/11 %9.09,0/11 %0.0,3/56 %5.36
Surgical and medical procedures - Other specify,0/210 %0.0,0/12 %0.0,0/60 %0.0,0/54 %0.0,0/11 %0.0,1/11 %9.09,0/56 %0.0
Hypertension,0/210 %0.0,0/12 %0.0,0/60 %0.0,0/54 %0.0,1/11 %9.09,0/11 %0.0,1/56 %1.79
Hypotension,0/210 %0.0,0/12 %0.0,0/60 %0.0,1/54 %1.85,2/11 %18.18,1/11 %9.09,5/56 %8.93
Thromboembolic event,0/210 %0.0,0/12 %0.0,0/60 %0.0,0/54 %0.0,0/11 %0.0,0/11 %0.0,1/56 %1.79
Visceral arterial ischemia,0/210 %0.0,0/12 %0.0,0/60 %0.0,0/54 %0.0,0/11 %0.0,0/11 %0.0,1/56 %1.79

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia(https://clinicaltrials.gov/show/NCT00558519)
 ,Treatment (Pediatric Regimen)
 ,Patients received induction (Course I) consolidation (Course II) interim maintenance (Course III) delayed intensification (Course IV) and long-term maintenance therapy (Course V). Please see the "Detailed Description" section for more information.
Total all-cause mortality,105/295 %35.59
Total serious adverse events,134/295 %45.42
Blood disorder,4/295 %1.36
Disseminated intravascular coagulation,1/295 %0.34
Febrile neutropenia,67/295 %22.71
Hemoglobin decreased,128/295 %43.39
Lymph node pain,1/295 %0.34
Lymphatic disorder,3/295 %1.02
Arrhythmia,1/295 %0.34
Atrial fibrillation,3/295 %1.02
Atrial flutter,3/295 %1.02
Atrial tachycardia,2/295 %0.68
Cardiac disorder,1/295 %0.34
Cardiac pain,1/295 %0.34
Conduction disorder,1/295 %0.34
Left ventricular dysfunction,1/295 %0.34
Left ventricular failure,1/295 %0.34
Myocardial ischemia,1/295 %0.34
Palpitations,4/295 %1.36
Pericardial effusion,1/295 %0.34
Right ventricular dysfunction,1/295 %0.34
Sinus arrhythmia,2/295 %0.68
Sinus bradycardia,4/295 %1.36
Sinus tachycardia,30/295 %10.17
Supraventricular tachycardia,4/295 %1.36
Ventricular fibrillation,1/295 %0.34
Ventricular tachycardia,4/295 %1.36
Ear disorder,1/295 %0.34
Ear pain,6/295 %2.03
Hearing impaired,1/295 %0.34
Tinnitus,2/295 %0.68
Adrenal insufficiency,1/295 %0.34
Cushingoid,5/295 %1.69
Dry eye syndrome,2/295 %0.68
Extraocular muscle paresis,2/295 %0.68
Eye disorder,4/295 %1.36
Eye pain,4/295 %1.36
Flashing vision,2/295 %0.68
Optic nerve edema,1/295 %0.34
Photophobia,2/295 %0.68
Retinopathy,1/295 %0.34
Vision blurred,13/295 %4.41
Watering eyes,1/295 %0.34
Abdominal distension,7/295 %2.37
Abdominal pain,44/295 %14.92
Anal hemorrhage,1/295 %0.34
Anal pain,1/295 %0.34
Colitis,6/295 %2.03
Colonic hemorrhage,4/295 %1.36
Colonic perforation,1/295 %0.34
Constipation,39/295 %13.22
Diarrhea,49/295 %16.61
Duodenal ulcer,1/295 %0.34
Dyspepsia,20/295 %6.78
Dysphagia,6/295 %2.03
Esophageal mucositis (clin exam),1/295 %0.34
Esophageal mucositis (funct/sympt),1/295 %0.34
Esophageal pain,5/295 %1.69
Fecal incontinence,1/295 %0.34
Gastritis,4/295 %1.36
Gastrointestinal disorder,4/295 %1.36
Hemorrhoids,4/295 %1.36
Ileus,1/295 %0.34
Mucositis oral (clin exam),30/295 %10.17
Nausea,95/295 %32.2
Oral hemorrhage,2/295 %0.68
Oral pain,12/295 %4.07
Pancreatic necrosis,1/295 %0.34
Pancreatitis,13/295 %4.41
Rectal hemorrhage,3/295 %1.02
Rectal pain,4/295 %1.36
Stomach pain,1/295 %0.34
Tooth disorder,1/295 %0.34
Toothache,4/295 %1.36
Typhlitis,4/295 %1.36
Upper gastrointestinal hemorrhage,1/295 %0.34
Vomiting,64/295 %21.69
Chest pain,12/295 %4.07
Chills,30/295 %10.17
Disease progression,1/295 %0.34
Edema limbs,26/295 %8.81
Facial pain,1/295 %0.34
Fatigue,87/295 %29.49
Fever,28/295 %9.49
Flu-like symptoms,1/295 %0.34
Gait abnormal,4/295 %1.36
General symptom,6/295 %2.03
Ill-defined disorder,4/295 %1.36
Injection site reaction,2/295 %0.68
Localized edema,14/295 %4.75
Multi-organ failure,1/295 %0.34
Pain,29/295 %9.83
Bile duct stenosis,1/295 %0.34
Cholecystitis,1/295 %0.34
Hepatic failure,7/295 %2.37
Hepatobiliary disease,5/295 %1.69
Cytokine release syndrome,1/295 %0.34
Hypersensitivity,22/295 %7.46
Immune system disorder,2/295 %0.68
Colitis infectious,4/295 %1.36
Opportunistic infection,1/295 %0.34
Urinary tract infection(gr 0/1/2 ANC),63/295 %21.36
Aortic injury,1/295 %0.34
Bruising,9/295 %3.05
Dermatitis radiation,1/295 %0.34
Intraop. inj. - Appendix,1/295 %0.34
Postoperative hemorrhage,1/295 %0.34
Seroma,1/295 %0.34
Wound dehiscence,1/295 %0.34
Activated partial throm time prolonged,35/295 %11.86
Alanine aminotransferase increased,125/295 %42.37
Alkaline phosphatase increased,56/295 %18.98
Amylase increased,14/295 %4.75
Aspartate aminotransferase increased,116/295 %39.32
Blood bilirubin increased,99/295 %33.56
Blood prolactin abnormal,1/295 %0.34
Cardiac troponin I increased,1/295 %0.34
Coagulopathy,4/295 %1.36
Creatine phosphokinase increased,1/295 %0.34
Creatinine increased,33/295 %11.19
Electrocardiogram QTc interval prolonged,2/295 %0.68
Fibrinogen decreased,73/295 %24.75
Gamma-glutamyltransferase increased,9/295 %3.05
INR increased,19/295 %6.44
Laboratory test abnormal,16/295 %5.42
Leukocyte count decreased,66/295 %22.37
Lipase increased,20/295 %6.78
Lymphocyte count decreased,45/295 %15.25
Neutrophil count decreased,126/295 %42.71
Platelet count decreased,126/295 %42.71
Serum cholesterol increased,15/295 %5.08
Weight gain,7/295 %2.37
Weight loss,18/295 %6.1
Acidosis,3/295 %1.02
Anorexia,36/295 %12.2
Blood bicarbonate decreased,8/295 %2.71
Blood glucose increased,111/295 %37.63
Blood uric acid increased,4/295 %1.36
Dehydration,12/295 %4.07
Glucose intolerance,7/295 %2.37
Obesity,1/295 %0.34
Renal tubular disorder,1/295 %0.34
Serum albumin decreased,69/295 %23.39
Serum calcium decreased,61/295 %20.68
Serum calcium increased,7/295 %2.37
Serum glucose decreased,30/295 %10.17
Serum magnesium decreased,35/295 %11.86
Serum magnesium increased,27/295 %9.15
Serum phosphate decreased,20/295 %6.78
Serum potassium decreased,59/295 %20.0
Serum potassium increased,20/295 %6.78
Serum sodium decreased,62/295 %21.02
Serum sodium increased,11/295 %3.73
Serum triglycerides increased,24/295 %8.14
Tumor lysis syndrome,3/295 %1.02
Arthralgia,21/295 %7.12
Back pain,34/295 %11.53
Buttock pain,2/295 %0.68
Chest wall pain,10/295 %3.39
Joint disorder,3/295 %1.02
Muscle weakness,9/295 %3.05
Muscle weakness lower limb,12/295 %4.07
Muscle weakness right-sided,2/295 %0.68
Muscle weakness upper limb,4/295 %1.36
Myalgia,17/295 %5.76
Myositis,3/295 %1.02
Neck pain,9/295 %3.05
Osteonecrosis,17/295 %5.76
Osteoporosis,3/295 %1.02
Pain in extremity,35/295 %11.86
Soft tissue necrosis lower limb,1/295 %0.34
Superficial soft tissue fibrosis,1/295 %0.34
Treatment related secondary malignancy,1/295 %0.34
Accessory nerve disorder,1/295 %0.34
Arachnoiditis,2/295 %0.68
Ataxia,2/295 %0.68
Central nervous system necrosis,1/295 %0.34
Cerebrospinal fluid leakage,3/295 %1.02
Depressed level of consciousness,5/295 %1.69
Dizziness,36/295 %12.2
Dysgeusia,9/295 %3.05
Encephalopathy,2/295 %0.68
Extrapyramidal disorder,1/295 %0.34
Facial muscle weakness,1/295 %0.34
Headache,86/295 %29.15
Hypoglossal nerve disorder,2/295 %0.68
Intracranial hemorrhage,2/295 %0.68
Ischemia cerebrovascular,2/295 %0.68
Leukoencephalopathy,2/295 %0.68
Memory impairment,4/295 %1.36
Mini mental status examination abnormal,1/295 %0.34
Neuralgia,1/295 %0.34
Neurological disorder NOS,8/295 %2.71
Oculomotor nerve disorder,1/295 %0.34
Peripheral motor neuropathy,14/295 %4.75
Peripheral sensory neuropathy,68/295 %23.05
Seizure,10/295 %3.39
Speech disorder,7/295 %2.37
Syncope,4/295 %1.36
Tremor,5/295 %1.69
Trigeminal nerve disorder,1/295 %0.34
Agitation,4/295 %1.36
Anxiety,22/295 %7.46
Confusion,9/295 %3.05
Depression,26/295 %8.81
Euphoria,1/295 %0.34
Insomnia,41/295 %13.9
Libido decreased,1/295 %0.34
Psychosis,5/295 %1.69
Bladder spasm,1/295 %0.34
Cystitis,1/295 %0.34
Glomerular filtration rate decreased,1/295 %0.34
Hemorrhage urinary tract,1/295 %0.34
Kidney pain,1/295 %0.34
Renal failure,8/295 %2.71
Urethral pain,2/295 %0.68
Urinary frequency,4/295 %1.36
Urinary incontinence,3/295 %1.02
Urine discoloration,5/295 %1.69
Urogenital disorder,2/295 %0.68
Erectile dysfunction,1/295 %0.34
Pelvic pain,1/295 %0.34
Reproductive tract disorder,1/295 %0.34
Scrotal pain,1/295 %0.34
Vaginal hemorrhage,9/295 %3.05
Adult respiratory distress syndrome,2/295 %0.68
Allergic rhinitis,10/295 %3.39
Aspiration,1/295 %0.34
Atelectasis,3/295 %1.02
Bronchopulmonary hemorrhage,1/295 %0.34
Bronchospasm,1/295 %0.34
Cough,32/295 %10.85
Dyspnea,30/295 %10.17
Epistaxis,15/295 %5.08
Hiccups,10/295 %3.39
Hypoxia,12/295 %4.07
Laryngeal stenosis,1/295 %0.34
Nasal congestion,2/295 %0.68
Pharyngeal mucositis (clin exam),2/295 %0.68
Pharyngolaryngeal pain,18/295 %6.1
Pleural effusion,5/295 %1.69
Pleuritic pain,3/295 %1.02
Pneumonitis,7/295 %2.37
Pneumothorax,3/295 %1.02
Respiratory disorder,7/295 %2.37
Voice alteration,2/295 %0.68
Alopecia,20/295 %6.78
Decubitus ulcer,1/295 %0.34
Dry skin,3/295 %1.02
Erythema multiforme,3/295 %1.02
Hand-and-foot syndrome/reaction,1/295 %0.34
Nail disorder,1/295 %0.34
Petechiae,8/295 %2.71
Photosensitivity,1/295 %0.34
Pruritus,7/295 %2.37
Rash acneiform,6/295 %2.03
Rash desquamating,26/295 %8.81
Scalp pain,1/295 %0.34
Skin disorder,6/295 %2.03
Skin hyperpigmentation,1/295 %0.34
Skin hypopigmentation,1/295 %0.34
Skin induration,1/295 %0.34
Skin striae,1/295 %0.34
Skin ulceration,6/295 %2.03
Sweating,15/295 %5.08
Urticaria,4/295 %1.36
Flushing,1/295 %0.34
Hematoma,6/295 %2.03
Hemorrhage,3/295 %1.02
Hypertension,10/295 %3.39
Hypotension,21/295 %7.12
Thrombosis,23/295 %7.8
Vascular disorder,2/295 %0.68

Combination of GTI-2040 and Cytarabine in the Treatment of Refractory and Relapsed Acute Myeloid Leukemia (AML)(https://clinicaltrials.gov/show/NCT00565058)
 ,Pilot,Phase II Arm
 ,Pilot PD Study (Delayed GTI-2040) Group: In the Pilot PD Study Group addition of GTI-2040 is delayed until 24 hours after initiation of HiDAC.,Phase II PD Study (Early GTI-2040) Group: In the Phase II PD Study Group GTI-2040 is given 24 hours prior to addition of HiDAC.
Total serious adverse events,2/10 %20.0,2/15 %13.33
Febrile Neutropenia,1/10 %10.0,1/15 %6.67
Disease Progression,2/10 %20.0,0/15 %0.0
Pneumonia,2/10 %20.0,0/15 %0.0
Sepsis,0/10 %0.0,1/15 %6.67
Acute Respiratory Failure,1/10 %10.0,0/15 %0.0
Hypoxia,1/10 %10.0,0/15 %0.0
Pulmonary oedema,1/10 %10.0,0/15 %0.0

Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma(https://clinicaltrials.gov/show/NCT00594815)
 ,Immunocompetent Pts With Newly Diagnosed Primary CNS Lymphoma
 ,This is a single-armed pilot study designed to evaluate the safety and efficacy of combined immunochemotherapy followed by reduced dose radiation for participants with newly diagnosed PCNSL.
Total all-cause mortality,13/52 %25.0
Total serious adverse events,22/52 %42.31
Leukocytes,4/52 %7.69
Hypotension,2/52 %3.85
Vision-double vision,1/52 %1.92
Dehydration,1/52 %1.92
Duodenal ulcer,1/52 %1.92
Radiation mucositis,1/52 %1.92
Nausea,1/52 %1.92
Vomiting,1/52 %1.92
Fever,2/52 %3.85
Pain other,1/52 %1.92
Febrile neutropenia,3/52 %5.77
Infection without neutropenia,4/52 %7.69
Infection,1/52 %1.92
Wound infectious,3/52 %5.77
Neutrophils/granulocytes,4/52 %7.69
Platelets,4/52 %7.69
Arthralgia,1/52 %1.92
Ataxia,1/52 %1.92
Neurology other,2/52 %3.85
Hallucinations,1/52 %1.92
Mood alteration-anxiety,1/52 %1.92
Mood alteration - depression,1/52 %1.92
Personality/behavior,1/52 %1.92
Elevated Creatinine,1/52 %1.92
Renal failure,1/52 %1.92
Renal/GU other,1/52 %1.92
Cough,1/52 %1.92
Pulmonary other,1/52 %1.92
Thrombosis,1/52 %1.92

Cytosine Arabinoside and Mitoxantrone for Patients With Juvenile Myelomonocytic Leukemia Receiving Repeat Stem Cell Transplantation(https://clinicaltrials.gov/show/NCT00609739)
 ,Cytarabine + Mitoxantrone
 ,Patients receive administration of high dose cytosine arabinoside and mitoxantrone followed by hematopoietic cell transplant.
Total serious adverse events,1/1 %100.0
Death,1/1 %100.0

A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia(https://clinicaltrials.gov/show/NCT00620321)
 ,LY2181308,LY2181308 + Idarubicin + Cytarabine
 ,750 milligrams (mg) was administered as a 3-hour intravenous infusion on Days 1 2 3 8 15 22 of Cycle 1 and Days 1 8 15 22 of Cycle 2 and beyond. Cycle length: 28 days.,LY2181308: 750 mg was administered as a 3-hour intravenous infusion on Days 1 2 3 8 15 22 of Cycle 1 and Days 1 8 15 22 of Cycle 2 and beyond.  Idarubicin: 12 milligrams per square meter (mg/m) was administered as a 30-minute intravenous infusion on Days 3 4 5 of Cycle 1 and on Days 1 2 3 of Cycle 2 and beyond.  Cytarabine: 1.5 grams per square meter (g/m) was administered as a 4-hour intravenous infusion on Days 3 4 5 of Cycle 1 and Days 1 2 3 of Cycle 2 and beyond.  Cycle length: 28 days.
Total serious adverse events,6/8 %75.0,13/16 %81.25
Febrile neutropenia,1/8 %12.5,7/16 %43.75
Neutropenia,1/8 %12.5,0/16 %0.0
Thrombocytopenia,0/8 %0.0,1/16 %6.25
Sinus bradycardia,0/8 %0.0,1/16 %6.25
Sinus tachycardia,1/8 %12.5,0/16 %0.0
Adrenal insufficiency,0/8 %0.0,1/16 %6.25
Abdominal pain,1/8 %12.5,0/16 %0.0
Diarrhoea,0/8 %0.0,1/16 %6.25
Neutropenic colitis,0/8 %0.0,1/16 %6.25
Oesophagitis,0/8 %0.0,1/16 %6.25
Pyrexia,1/8 %12.5,0/16 %0.0
Hyperbilirubinaemia,0/8 %0.0,1/16 %6.25
Graft versus host disease,0/8 %0.0,1/16 %6.25
Clostridial infection,1/8 %12.5,1/16 %6.25
Pneumonia,1/8 %12.5,1/16 %6.25
Sepsis,4/8 %50.0,1/16 %6.25
Septic shock,0/8 %0.0,1/16 %6.25
Hyperkalaemia,0/8 %0.0,1/16 %6.25
Hypoglycaemia,0/8 %0.0,1/16 %6.25
Hypokalaemia,0/8 %0.0,1/16 %6.25
Haemorrhagic transformation stroke,0/8 %0.0,1/16 %6.25
Headache,0/8 %0.0,1/16 %6.25
Metabolic encephalopathy,0/8 %0.0,1/16 %6.25
Mental status changes,1/8 %12.5,0/16 %0.0
Renal failure acute,0/8 %0.0,1/16 %6.25
Dyspnoea,1/8 %12.5,0/16 %0.0
Hypoxia,1/8 %12.5,0/16 %0.0
Respiratory failure,0/8 %0.0,2/16 %12.5
Hypotension,1/8 %12.5,2/16 %12.5

BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment(https://clinicaltrials.gov/show/NCT00632749)
 ,5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A,15 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A,30 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A,60 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A,100 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A,120 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A,5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,40 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,80 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,160 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,240 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,300 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,360 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,420 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B
 ,5 mg of BI 811283 (preconcentrate for infusion after dilution) in combination with cytarabine (solution for injection);  Treatment Schedule A: BI 811283 on Days 1 + 15 in combination with cytarabine 20 mg twice daily on Days 1-10 (28-day cycle);  BI 811283: 24-hour continuous intravenous infusion Cytarabine: subcutaneous injection,15 mg of BI 811283 (preconcentrate for infusion after dilution) in combination with cytarabine (solution for injection);  Treatment Schedule A: BI 811283 on Days 1 + 15 in combination with cytarabine 20 mg twice daily on Days 1-10 (28-day cycle);  BI 811283: 24-hour continuous intravenous infusion Cytarabine: subcutaneous injection,30 mg of BI 811283 (preconcentrate for infusion after dilution) in combination with cytarabine (solution for injection);  Treatment Schedule A: BI 811283 on Days 1 + 15 in combination with cytarabine 20 mg twice daily on Days 1-10 (28-day cycle);  BI 811283: 24-hour continuous intravenous infusion Cytarabine: subcutaneous injection,60 mg of BI 811283 (preconcentrate for infusion after dilution) in combination with cytarabine (solution for injection);  Treatment Schedule A: BI 811283 on Days 1 + 15 in combination with cytarabine 20 mg twice daily on Days 1-10 (28-day cycle);  BI 811283: 24-hour continuous intravenous infusion Cytarabine: subcutaneous injection,100 mg of BI 811283 (preconcentrate for infusion after dilution) in combination with cytarabine (solution for injection);  Treatment Schedule A: BI 811283 on Days 1 + 15 in combination with cytarabine 20 mg twice daily on Days 1-10 (28-day cycle);  BI 811283: 24-hour continuous intravenous infusion Cytarabine: subcutaneous injection,120 mg of BI 811283 (preconcentrate for infusion after dilution) in combination with cytarabine (solution for injection);  Treatment Schedule A: BI 811283 on Days 1 + 15 in combination with cytarabine 20 mg twice daily on Days 1-10 (28-day cycle);  BI 811283: 24-hour continuous intravenous infusion Cytarabine: subcutaneous injection,5 mg of BI 811283 (preconcentrate for infusion after dilution) in combination with cytarabine (solution for injection);  Treatment schedule B: BI 811283 on Day 1 in combination with cytarabine 20 mg twice daily on Days 1-10 (28-day cycle);  BI 811283: 24-hour continuous intravenous infusion Cytarabine: subcutaneous injection,40 mg of BI 811283 (preconcentrate for infusion after dilution) in combination with cytarabine (solution for injection);  Treatment schedule B: BI 811283 on Day 1 in combination with cytarabine 20 mg twice daily on Days 1-10 (28-day cycle);  BI 811283: 24-hour continuous intravenous infusion Cytarabine: subcutaneous injection,80 mg of BI 811283 (preconcentrate for infusion after dilution) in combination with cytarabine (solution for injection);  Treatment schedule B: BI 811283 on Day 1 in combination with cytarabine 20 mg twice daily on Days 1-10 (28-day cycle);  BI 811283: 24-hour continuous intravenous infusion Cytarabine: subcutaneous injection,160 mg of BI 811283 (preconcentrate for infusion after dilution) in combination with cytarabine (solution for injection);  Treatment schedule B: BI 811283 on Day 1 in combination with cytarabine 20 mg twice daily on Days 1-10 (28-day cycle);  BI 811283: 24-hour continuous intravenous infusion Cytarabine: subcutaneous injection,240 mg of BI 811283 (preconcentrate for infusion after dilution) in combination with cytarabine (solution for injection);  Treatment schedule B: BI 811283 on Day 1 in combination with cytarabine 20 mg twice daily on Days 1-10 (28-day cycle);  BI 811283: 24-hour continuous intravenous infusion Cytarabine: subcutaneous injection,300 mg of BI 811283 (preconcentrate for infusion after dilution) in combination with cytarabine (solution for injection);  Treatment schedule B: BI 811283 on Day 1 in combination with cytarabine 20 mg twice daily on Days 1-10 (28-day cycle);  BI 811283: 24-hour continuous intravenous infusion Cytarabine: subcutaneous injection,360 mg of BI 811283 (preconcentrate for infusion after dilution) in combination with cytarabine (solution for injection);  Treatment schedule B: BI 811283 on Day 1 in combination with cytarabine 20 mg twice daily on Days 1-10 (28-day cycle);  BI 811283: 24-hour continuous intravenous infusion Cytarabine: subcutaneous injection,420 mg of BI 811283 (preconcentrate for infusion after dilution) in combination with cytarabine (solution for injection);  Treatment schedule B: BI 811283 on Day 1 in combination with cytarabine 20 mg twice daily on Days 1-10 (28-day cycle);  BI 811283: 24-hour continuous intravenous infusion Cytarabine: subcutaneous injection
Total serious adverse events,3/4 %75.0,2/3 %66.67,3/3 %100.0,4/4 %100.0,6/7 %85.71,6/7 %85.71,4/4 %100.0,3/4 %75.0,5/5 %100.0,3/3 %100.0,7/7 %100.0,3/4 %75.0,3/3 %100.0,5/6 %83.33
Disseminated intravascular coagulation,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/4 %0.0,0/7 %0.0,0/7 %0.0,0/4 %0.0,0/4 %0.0,1/5 %20.0,0/3 %0.0,0/7 %0.0,0/4 %0.0,0/3 %0.0,0/6 %0.0
Febrile neutropenia,0/4 %0.0,0/3 %0.0,1/3 %33.33,2/4 %50.0,2/7 %28.57,0/7 %0.0,3/4 %75.0,1/4 %25.0,1/5 %20.0,1/3 %33.33,2/7 %28.57,2/4 %50.0,2/3 %66.67,2/6 %33.33
Leukocytosis,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/4 %0.0,1/7 %14.29,0/7 %0.0,0/4 %0.0,0/4 %0.0,0/5 %0.0,1/3 %33.33,0/7 %0.0,0/4 %0.0,0/3 %0.0,0/6 %0.0
Acute myocardial infarction,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/4 %0.0,0/7 %0.0,0/7 %0.0,0/4 %0.0,0/4 %0.0,0/5 %0.0,1/3 %33.33,1/7 %14.29,0/4 %0.0,0/3 %0.0,0/6 %0.0
Atrial fibrillation,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/4 %0.0,0/7 %0.0,0/7 %0.0,0/4 %0.0,0/4 %0.0,0/5 %0.0,1/3 %33.33,0/7 %0.0,0/4 %0.0,0/3 %0.0,0/6 %0.0
Cardiac failure,0/4 %0.0,0/3 %0.0,0/3 %0.0,1/4 %25.0,1/7 %14.29,0/7 %0.0,0/4 %0.0,0/4 %0.0,0/5 %0.0,0/3 %0.0,0/7 %0.0,0/4 %0.0,0/3 %0.0,0/6 %0.0
Cardiac fibrillation,0/4 %0.0,0/3 %0.0,0/3 %0.0,1/4 %25.0,0/7 %0.0,0/7 %0.0,0/4 %0.0,0/4 %0.0,0/5 %0.0,0/3 %0.0,0/7 %0.0,0/4 %0.0,0/3 %0.0,0/6 %0.0
Tachycardia,0/4 %0.0,0/3 %0.0,0/3 %0.0,1/4 %25.0,0/7 %0.0,0/7 %0.0,0/4 %0.0,0/4 %0.0,0/5 %0.0,0/3 %0.0,0/7 %0.0,0/4 %0.0,0/3 %0.0,0/6 %0.0
Aplasia,1/4 %25.0,0/3 %0.0,0/3 %0.0,0/4 %0.0,0/7 %0.0,0/7 %0.0,0/4 %0.0,0/4 %0.0,0/5 %0.0,0/3 %0.0,0/7 %0.0,0/4 %0.0,0/3 %0.0,0/6 %0.0
Blindness,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/4 %0.0,0/7 %0.0,0/7 %0.0,0/4 %0.0,0/4 %0.0,1/5 %20.0,0/3 %0.0,0/7 %0.0,0/4 %0.0,0/3 %0.0,0/6 %0.0
Eye haemorrhage,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/4 %0.0,0/7 %0.0,0/7 %0.0,0/4 %0.0,0/4 %0.0,1/5 %20.0,0/3 %0.0,0/7 %0.0,0/4 %0.0,0/3 %0.0,0/6 %0.0
Diarrhoea,0/4 %0.0,0/3 %0.0,0/3 %0.0,1/4 %25.0,0/7 %0.0,0/7 %0.0,0/4 %0.0,0/4 %0.0,0/5 %0.0,0/3 %0.0,1/7 %14.29,0/4 %0.0,0/3 %0.0,0/6 %0.0
Gastrointestinal haemorrhage,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/4 %0.0,0/7 %0.0,0/7 %0.0,0/4 %0.0,0/4 %0.0,0/5 %0.0,1/3 %33.33,0/7 %0.0,0/4 %0.0,0/3 %0.0,0/6 %0.0
Nausea,0/4 %0.0,0/3 %0.0,0/3 %0.0,1/4 %25.0,0/7 %0.0,0/7 %0.0,0/4 %0.0,0/4 %0.0,0/5 %0.0,0/3 %0.0,1/7 %14.29,0/4 %0.0,0/3 %0.0,0/6 %0.0
Rectal haemorrhage,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/4 %0.0,0/7 %0.0,0/7 %0.0,0/4 %0.0,0/4 %0.0,0/5 %0.0,1/3 %33.33,0/7 %0.0,0/4 %0.0,0/3 %0.0,0/6 %0.0
Upper gastrointestinal haemorrhage,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/4 %0.0,0/7 %0.0,0/7 %0.0,0/4 %0.0,0/4 %0.0,0/5 %0.0,1/3 %33.33,0/7 %0.0,0/4 %0.0,0/3 %0.0,0/6 %0.0
Asthenia,0/4 %0.0,0/3 %0.0,0/3 %0.0,1/4 %25.0,0/7 %0.0,0/7 %0.0,0/4 %0.0,0/4 %0.0,0/5 %0.0,0/3 %0.0,0/7 %0.0,0/4 %0.0,0/3 %0.0,0/6 %0.0
Death,1/4 %25.0,0/3 %0.0,0/3 %0.0,0/4 %0.0,0/7 %0.0,0/7 %0.0,0/4 %0.0,0/4 %0.0,0/5 %0.0,0/3 %0.0,0/7 %0.0,0/4 %0.0,0/3 %0.0,0/6 %0.0
General physical health deterioration,0/4 %0.0,0/3 %0.0,0/3 %0.0,1/4 %25.0,0/7 %0.0,2/7 %28.57,0/4 %0.0,0/4 %0.0,1/5 %20.0,2/3 %66.67,3/7 %42.86,1/4 %25.0,0/3 %0.0,0/6 %0.0
Multi-organ failure,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/4 %0.0,0/7 %0.0,1/7 %14.29,0/4 %0.0,2/4 %50.0,0/5 %0.0,0/3 %0.0,0/7 %0.0,0/4 %0.0,0/3 %0.0,0/6 %0.0
Pyrexia,1/4 %25.0,2/3 %66.67,0/3 %0.0,1/4 %25.0,0/7 %0.0,0/7 %0.0,2/4 %50.0,1/4 %25.0,0/5 %0.0,1/3 %33.33,0/7 %0.0,0/4 %0.0,0/3 %0.0,0/6 %0.0
Cholecystitis,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/4 %0.0,0/7 %0.0,0/7 %0.0,0/4 %0.0,0/4 %0.0,0/5 %0.0,0/3 %0.0,1/7 %14.29,0/4 %0.0,0/3 %0.0,0/6 %0.0
Abscess,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/4 %0.0,0/7 %0.0,0/7 %0.0,1/4 %25.0,0/4 %0.0,0/5 %0.0,0/3 %0.0,0/7 %0.0,0/4 %0.0,0/3 %0.0,0/6 %0.0
Arthritis infective,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/4 %0.0,0/7 %0.0,0/7 %0.0,0/4 %0.0,0/4 %0.0,0/5 %0.0,1/3 %33.33,0/7 %0.0,0/4 %0.0,0/3 %0.0,0/6 %0.0
Bacterial sepsis,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/4 %0.0,0/7 %0.0,0/7 %0.0,0/4 %0.0,0/4 %0.0,0/5 %0.0,0/3 %0.0,0/7 %0.0,0/4 %0.0,0/3 %0.0,1/6 %16.67
Cellulitis,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/4 %0.0,0/7 %0.0,0/7 %0.0,0/4 %0.0,0/4 %0.0,1/5 %20.0,0/3 %0.0,0/7 %0.0,0/4 %0.0,0/3 %0.0,0/6 %0.0
Clostridium difficile infection,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/4 %0.0,0/7 %0.0,0/7 %0.0,0/4 %0.0,1/4 %25.0,0/5 %0.0,0/3 %0.0,0/7 %0.0,0/4 %0.0,0/3 %0.0,0/6 %0.0
Device related infection,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/4 %0.0,1/7 %14.29,0/7 %0.0,0/4 %0.0,1/4 %25.0,0/5 %0.0,0/3 %0.0,0/7 %0.0,0/4 %0.0,0/3 %0.0,0/6 %0.0
Diverticulitis,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/4 %0.0,1/7 %14.29,0/7 %0.0,0/4 %0.0,0/4 %0.0,0/5 %0.0,0/3 %0.0,0/7 %0.0,0/4 %0.0,0/3 %0.0,0/6 %0.0
Endocarditis,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/4 %0.0,0/7 %0.0,0/7 %0.0,0/4 %0.0,1/4 %25.0,0/5 %0.0,0/3 %0.0,0/7 %0.0,0/4 %0.0,0/3 %0.0,0/6 %0.0
Escherichia sepsis,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/4 %0.0,1/7 %14.29,0/7 %0.0,0/4 %0.0,0/4 %0.0,0/5 %0.0,0/3 %0.0,0/7 %0.0,0/4 %0.0,0/3 %0.0,0/6 %0.0
Folliculitis,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/4 %0.0,0/7 %0.0,0/7 %0.0,1/4 %25.0,0/4 %0.0,0/5 %0.0,0/3 %0.0,0/7 %0.0,0/4 %0.0,0/3 %0.0,0/6 %0.0
Gingivitis,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/4 %0.0,0/7 %0.0,0/7 %0.0,0/4 %0.0,0/4 %0.0,0/5 %0.0,0/3 %0.0,0/7 %0.0,1/4 %25.0,0/3 %0.0,0/6 %0.0
Groin abscess,0/4 %0.0,0/3 %0.0,1/3 %33.33,0/4 %0.0,0/7 %0.0,0/7 %0.0,0/4 %0.0,0/4 %0.0,0/5 %0.0,0/3 %0.0,0/7 %0.0,0/4 %0.0,0/3 %0.0,0/6 %0.0
Haematoma infection,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/4 %0.0,0/7 %0.0,1/7 %14.29,0/4 %0.0,0/4 %0.0,0/5 %0.0,0/3 %0.0,0/7 %0.0,0/4 %0.0,0/3 %0.0,0/6 %0.0
Infection,0/4 %0.0,1/3 %33.33,0/3 %0.0,0/4 %0.0,0/7 %0.0,0/7 %0.0,0/4 %0.0,0/4 %0.0,0/5 %0.0,0/3 %0.0,1/7 %14.29,0/4 %0.0,0/3 %0.0,0/6 %0.0
Neutropenic sepsis,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/4 %0.0,0/7 %0.0,1/7 %14.29,0/4 %0.0,0/4 %0.0,0/5 %0.0,0/3 %0.0,0/7 %0.0,0/4 %0.0,0/3 %0.0,0/6 %0.0
Osteomyelitis,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/4 %0.0,0/7 %0.0,0/7 %0.0,0/4 %0.0,0/4 %0.0,1/5 %20.0,0/3 %0.0,0/7 %0.0,0/4 %0.0,0/3 %0.0,0/6 %0.0
Pneumonia,2/4 %50.0,0/3 %0.0,0/3 %0.0,2/4 %50.0,2/7 %28.57,1/7 %14.29,1/4 %25.0,2/4 %50.0,2/5 %40.0,0/3 %0.0,2/7 %28.57,0/4 %0.0,1/3 %33.33,1/6 %16.67
Pneumonia fungal,0/4 %0.0,1/3 %33.33,0/3 %0.0,0/4 %0.0,0/7 %0.0,1/7 %14.29,0/4 %0.0,0/4 %0.0,0/5 %0.0,0/3 %0.0,0/7 %0.0,0/4 %0.0,0/3 %0.0,0/6 %0.0
Sepsis,1/4 %25.0,0/3 %0.0,0/3 %0.0,0/4 %0.0,0/7 %0.0,1/7 %14.29,0/4 %0.0,0/4 %0.0,0/5 %0.0,1/3 %33.33,1/7 %14.29,2/4 %50.0,0/3 %0.0,0/6 %0.0
Skin infection,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/4 %0.0,0/7 %0.0,0/7 %0.0,0/4 %0.0,1/4 %25.0,0/5 %0.0,0/3 %0.0,0/7 %0.0,0/4 %0.0,0/3 %0.0,0/6 %0.0
Staphylococcal infection,0/4 %0.0,0/3 %0.0,1/3 %33.33,0/4 %0.0,1/7 %14.29,0/7 %0.0,0/4 %0.0,0/4 %0.0,0/5 %0.0,0/3 %0.0,0/7 %0.0,0/4 %0.0,0/3 %0.0,0/6 %0.0
Tooth infection,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/4 %0.0,0/7 %0.0,0/7 %0.0,0/4 %0.0,0/4 %0.0,0/5 %0.0,0/3 %0.0,0/7 %0.0,1/4 %25.0,0/3 %0.0,0/6 %0.0
Fall,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/4 %0.0,0/7 %0.0,0/7 %0.0,1/4 %25.0,0/4 %0.0,0/5 %0.0,0/3 %0.0,0/7 %0.0,0/4 %0.0,0/3 %0.0,0/6 %0.0
Subdural haematoma,1/4 %25.0,0/3 %0.0,0/3 %0.0,0/4 %0.0,0/7 %0.0,0/7 %0.0,0/4 %0.0,0/4 %0.0,0/5 %0.0,0/3 %0.0,0/7 %0.0,0/4 %0.0,0/3 %0.0,0/6 %0.0
Urostomy complication,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/4 %0.0,1/7 %14.29,0/7 %0.0,0/4 %0.0,0/4 %0.0,0/5 %0.0,0/3 %0.0,0/7 %0.0,0/4 %0.0,0/3 %0.0,0/6 %0.0
Blood uric acid increased,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/4 %0.0,0/7 %0.0,0/7 %0.0,0/4 %0.0,0/4 %0.0,1/5 %20.0,0/3 %0.0,0/7 %0.0,0/4 %0.0,0/3 %0.0,0/6 %0.0
C-reactive protein increased,0/4 %0.0,0/3 %0.0,0/3 %0.0,1/4 %25.0,1/7 %14.29,1/7 %14.29,0/4 %0.0,0/4 %0.0,1/5 %20.0,2/3 %66.67,1/7 %14.29,0/4 %0.0,0/3 %0.0,0/6 %0.0
Transaminases increased,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/4 %0.0,0/7 %0.0,0/7 %0.0,0/4 %0.0,0/4 %0.0,0/5 %0.0,0/3 %0.0,1/7 %14.29,0/4 %0.0,0/3 %0.0,0/6 %0.0
Hyperuricaemia,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/4 %0.0,0/7 %0.0,0/7 %0.0,0/4 %0.0,0/4 %0.0,0/5 %0.0,0/3 %0.0,0/7 %0.0,0/4 %0.0,1/3 %33.33,0/6 %0.0
Tumour lysis syndrome,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/4 %0.0,0/7 %0.0,1/7 %14.29,0/4 %0.0,0/4 %0.0,0/5 %0.0,0/3 %0.0,0/7 %0.0,0/4 %0.0,0/3 %0.0,1/6 %16.67
Fasciitis,1/4 %25.0,0/3 %0.0,0/3 %0.0,0/4 %0.0,0/7 %0.0,0/7 %0.0,0/4 %0.0,0/4 %0.0,0/5 %0.0,0/3 %0.0,0/7 %0.0,0/4 %0.0,0/3 %0.0,0/6 %0.0
Malignant neoplasm progression,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/4 %0.0,0/7 %0.0,1/7 %14.29,1/4 %25.0,0/4 %0.0,1/5 %20.0,0/3 %0.0,1/7 %14.29,0/4 %0.0,0/3 %0.0,2/6 %33.33
Cerebral haemorrhage,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/4 %0.0,1/7 %14.29,0/7 %0.0,0/4 %0.0,0/4 %0.0,0/5 %0.0,0/3 %0.0,0/7 %0.0,0/4 %0.0,0/3 %0.0,0/6 %0.0
Cerebral ischaemia,0/4 %0.0,0/3 %0.0,1/3 %33.33,0/4 %0.0,0/7 %0.0,0/7 %0.0,0/4 %0.0,0/4 %0.0,0/5 %0.0,0/3 %0.0,0/7 %0.0,0/4 %0.0,0/3 %0.0,0/6 %0.0
Convulsion,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/4 %0.0,0/7 %0.0,0/7 %0.0,0/4 %0.0,0/4 %0.0,0/5 %0.0,0/3 %0.0,0/7 %0.0,0/4 %0.0,1/3 %33.33,0/6 %0.0
Dizziness,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/4 %0.0,0/7 %0.0,1/7 %14.29,0/4 %0.0,0/4 %0.0,0/5 %0.0,0/3 %0.0,0/7 %0.0,0/4 %0.0,0/3 %0.0,0/6 %0.0
Confusional state,0/4 %0.0,0/3 %0.0,0/3 %0.0,1/4 %25.0,0/7 %0.0,0/7 %0.0,0/4 %0.0,0/4 %0.0,0/5 %0.0,0/3 %0.0,0/7 %0.0,0/4 %0.0,0/3 %0.0,0/6 %0.0
Renal failure,1/4 %25.0,0/3 %0.0,0/3 %0.0,0/4 %0.0,0/7 %0.0,0/7 %0.0,0/4 %0.0,0/4 %0.0,0/5 %0.0,0/3 %0.0,0/7 %0.0,0/4 %0.0,0/3 %0.0,0/6 %0.0
Renal failure acute,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/4 %0.0,0/7 %0.0,1/7 %14.29,0/4 %0.0,0/4 %0.0,0/5 %0.0,0/3 %0.0,0/7 %0.0,0/4 %0.0,0/3 %0.0,0/6 %0.0
Dyspnoea,0/4 %0.0,0/3 %0.0,0/3 %0.0,1/4 %25.0,0/7 %0.0,0/7 %0.0,0/4 %0.0,0/4 %0.0,0/5 %0.0,0/3 %0.0,0/7 %0.0,0/4 %0.0,0/3 %0.0,0/6 %0.0
Epistaxis,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/4 %0.0,0/7 %0.0,0/7 %0.0,0/4 %0.0,0/4 %0.0,0/5 %0.0,0/3 %0.0,1/7 %14.29,0/4 %0.0,0/3 %0.0,0/6 %0.0
Lung infiltration,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/4 %0.0,0/7 %0.0,1/7 %14.29,0/4 %0.0,0/4 %0.0,0/5 %0.0,0/3 %0.0,0/7 %0.0,0/4 %0.0,0/3 %0.0,0/6 %0.0
Pleural effusion,0/4 %0.0,0/3 %0.0,0/3 %0.0,1/4 %25.0,0/7 %0.0,0/7 %0.0,0/4 %0.0,0/4 %0.0,0/5 %0.0,0/3 %0.0,0/7 %0.0,0/4 %0.0,0/3 %0.0,0/6 %0.0
Pulmonary embolism,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/4 %0.0,0/7 %0.0,0/7 %0.0,0/4 %0.0,0/4 %0.0,0/5 %0.0,0/3 %0.0,0/7 %0.0,0/4 %0.0,1/3 %33.33,0/6 %0.0
Respiratory failure,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/4 %0.0,0/7 %0.0,0/7 %0.0,0/4 %0.0,1/4 %25.0,0/5 %0.0,0/3 %0.0,0/7 %0.0,0/4 %0.0,1/3 %33.33,0/6 %0.0
Hypotension,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/4 %0.0,0/7 %0.0,0/7 %0.0,0/4 %0.0,0/4 %0.0,0/5 %0.0,0/3 %0.0,1/7 %14.29,0/4 %0.0,0/3 %0.0,0/6 %0.0

Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant(https://clinicaltrials.gov/show/NCT00691015)
 ,Conditioning Regimen
 ,Chemotherapy or chemotherapy + total body irradiation  Standard of care (SOC) chemotherapy or ( SOC) chemotherapy + total body irradiation (TBI) of one of the following regimens:  Regimen I: Patients receive fludarabine phosphate IV and busulfan IV.  Regimen II: Patients undergo total body irradiation (TBI) twice daily for 8 fractions and receive etoposide IV.  Regimen III: Patients undergo TBI once or twice daily for 11 fractions and receive cyclophosphamide IV.  Regimen IV: Patients undergo TBI and receive fludarabine phosphate IV and busulfan IV.  Regimen V: Patients receive carmustine IV etoposide IV cytarabine IV and melphalan IV. Some patients also receive rituximab IV.  Regimen VI: Patients receive fludarabine phosphate IV and melphalan IV. Some patients also undergo TBI.
Total serious adverse events,44/47 %93.62
Blood/Bone Marrow,1/47 %2.13
Disseminated intravascular coagulation,1/47 %2.13
Febrile neutropenia,1/47 %2.13
Leukocytes,12/47 %25.53
Lymphopenia,11/47 %23.4
Cardiac ischemia/infarction,3/47 %6.38
Cardiopulmonary arrest,2/47 %4.26
Left Ventricular diastolic dysfunction,1/47 %2.13
Left Ventricular systolic dysfunction,1/47 %2.13
Pain-Cardiovascular-cardiac/heart,1/47 %2.13
Pericardial effusion,1/47 %2.13
Supraventricular and nodal arrhythmia,2/47 %4.26
Tachycardia,1/47 %2.13
Ventricular arrhythmia-ventricular tachycardia,1/47 %2.13
Ascites,4/47 %8.51
Colitis,7/47 %14.89
Diarrhea,6/47 %12.77
Gastritis,2/47 %4.26
Hemorrhage GI-Liver,1/47 %2.13
Ileus,1/47 %2.13
Mucositis/stomatis-large bowel,2/47 %4.26
Mucositis/stomatis-Small bowel,1/47 %2.13
Nausea,7/47 %14.89
Pain-Gastrointestinal-Abdominal NOS,1/47 %2.13
Pain-Gastrointestinal-oral cavity,4/47 %8.51
Pain-gastrointestinal-stomach,1/47 %2.13
Vomiting,3/47 %6.38
Fatigue,1/47 %2.13
Fever,1/47 %2.13
Hemorrhage GI,4/47 %8.51
Rigors/chills,2/47 %4.26
Death-disease progression,2/47 %4.26
Death-disease progression NOS,1/47 %2.13
Death-GVHD,1/47 %2.13
Death SOS,1/47 %2.13
Death-cGVHD,3/47 %6.38
Death-aGVHD/infection,1/47 %2.13
Death-Multi organ failure,2/47 %4.26
Death-Multi organ failure/SOS,1/47 %2.13
Death-pancytopenia possible bleed,1/47 %2.13
Death-Disease progression (from 2nd BMT not associated with this protocol),1/47 %2.13
Death-aGVHD,1/47 %2.13
Hepatobiliary/Pancreas - Other (VOD/SOS),3/47 %6.38
Liver Dysfunction/Failure,1/47 %2.13
Cytokine release syndrome,1/47 %2.13
Infection,24/47 %51.06
Infection BK,6/47 %12.77
Infection CMV,6/47 %12.77
Infection EBV,4/47 %8.51
Infection HSV,2/47 %4.26
Infection VZV in CSF,1/47 %2.13
Infections aspergillus,2/47 %4.26
Infection Pulmonary,1/47 %2.13
infection with normal ANC,11/47 %23.4
Infection-Pulmonary/Upper Resp.,2/47 %4.26
Death-Multi organ failure/Sepsis,2/47 %4.26
Fracture,1/47 %2.13
Hemorrhage/bleeding associated with surgery intra-operative or postoperative,1/47 %2.13
alanine aminotransferase (ALT) increased,6/47 %12.77
alanine aminotransferase (ALT) SGPT,2/47 %4.26
aspartate aminotransferase (AST) increased,7/47 %14.89
aspartate aminotransferase (AST) increased SGOT,2/47 %4.26
Alkaline Phosphatase increased,2/47 %4.26
Bilirubin increased,9/47 %19.15
Cardiac troponin I increased,3/47 %6.38
Creatinine increased,7/47 %14.89
Hemoglobin,11/47 %23.4
Lipase,2/47 %4.26
Lymphocytes,3/47 %6.38
Neutrophils,11/47 %23.4
Platelets,12/47 %25.53
prolonged intubation,3/47 %6.38
Acidosis,4/47 %8.51
Anorexia,6/47 %12.77
Calcium serum - low,6/47 %12.77
Glucose,1/47 %2.13
Hyperglycemia,12/47 %25.53
Iron Overload,6/47 %12.77
Magnesium Serum high,2/47 %4.26
Magnesium Serum low,1/47 %2.13
Potassium Serum high,7/47 %14.89
Potassium serum low,4/47 %8.51
Sodium Serum-low,4/47 %8.51
Arthritis,1/47 %2.13
Pain-mid/back hip,1/47 %2.13
Pain-Musculoskeletal-Back,1/47 %2.13
Pain-Musculoskeletal-Bone,1/47 %2.13
pain-chest wall,1/47 %2.13
CNS cerebrovascular ischemia,1/47 %2.13
Encephalopathy,1/47 %2.13
Other-Right side facial droop,1/47 %2.13
Pain-Neurology-head/headache,2/47 %4.26
Pain-Neurology-headache,1/47 %2.13
Somnolence/depressed level of consciousness,4/47 %8.51
Confusion,5/47 %10.64
mood alteration,1/47 %2.13
pain-renal/genitourinary,1/47 %2.13
Renal-other-Acute Renal Failure,5/47 %10.64
Acute Respiratory distress,2/47 %4.26
Dyspnea,4/47 %8.51
Hemorrhage pulmonary/upper respiratory,2/47 %4.26
Hemorrhage pulmonary/upper respiratory/lung,3/47 %6.38
Hypoxia,11/47 %23.4
Pain Pulmonary/Respiratroy-throat/pharynx/larynx,1/47 %2.13
Pleural effusion,2/47 %4.26
Pneumonitis/pulmonary infiltrates,8/47 %17.02
Pulmonary Edema,2/47 %4.26
Pulmonary Hypertension,2/47 %4.26
Death-intersititial pneumonia,1/47 %2.13
Dermatology/Skin - palmar erythema,1/47 %2.13
Rash,1/47 %2.13
Rash/Desquamation,10/47 %21.28
Hypertension,4/47 %8.51
Hypotension,3/47 %6.38
Thrombosis/embolism (vascular access-related),2/47 %4.26
Thrombosis/embolism/thrombus,1/47 %2.13
Thrombosis/embolism (left lower extremity),1/47 %2.13
Thrombosis/embolism (pulmonary),1/47 %2.13
Thrombotic microangiopathy,4/47 %8.51

Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BEAM Followed By ASCT For Relapsed B-Cell Non-Hodgkin Lymphoma(https://clinicaltrials.gov/show/NCT00695409)
 ,Treatment (RIT ZBEAM ASCT)
 ,RADIOIMMUNOTHERAPY: Patients receive yttrium Y 90 ibritumomab tiuxetan IV following rituximab IV on day -14. HIGH-DOSE COMBINATION CHEMOTHERAPY: Patients receive carmustine IV on days -7 and -6; etoposide IV over 1 hour twice daily and cytarabine IV over 2 hours twice daily on days -5 to -2; and melphalan IV on day -1. STEM CELL TRANSPLANTATION: Patients undergo autologous peripheral blood stem cell transplant on day 0. Patients also receive rituximab on day 8*. NOTE: * Some patients may also receive rituximab on day -1. Treatment continues in the absence of disease progression or unacceptable toxicity.  rituximab: Given IV  carmustine: Given IV  cytarabine: Given IV  etoposide: Given IV  melphalan: Given IV  ASCT: Undergo autologous peripheral blood stem cell transplant  yttrium Y 90 ibritumomab tiuxetan: Given IV
Total all-cause mortality,25/122 %20.49
Total serious adverse events,2/122 %1.64
Secondary Malignancy,1/122 %0.82
Pneumonitis/pulmonary infiltrates,1/122 %0.82

Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia(https://clinicaltrials.gov/show/NCT00720109)
 ,Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy),Standard-risk,High-risk
 ,See Detailed Description  Asparaginase: Given IT  Cyclophosphamide: Given IV  Cytarabine: Given IT or IV  Dasatinib: Given PO  Daunorubicin Hydrochloride: Given IV  Dexamethasone: Given IV or PO  Etoposide: Given IV  Filgrastim: Given IV or SC  Hydrocortisone Sodium Succinate: Given IT  Ifosfamide: Given IV  Laboratory Biomarker Analysis: Correlative studies  Leucovorin Calcium: Given IV or PO  Mercaptopurine: Given PO  Methotrexate: Given IT PO or IV  Methylprednisolone: Given IV  Pegaspargase: Given IM  Prednisone: Given PO or IV  Radiation Therapy: Some patients undergo cranial RT  Vincristine Sulfate: Given IV,Based on Minimal Residual Disease less than 1%.,Based on Minimal Residual Disease great than or equal to 1%.
Total serious adverse events,36/60 %60.0,28/48 %58.33,7/9 %77.78
Anemia,3/60 %5.0,2/48 %4.17,1/9 %11.11
Febrile neutropenia,4/60 %6.67,3/48 %6.25,1/9 %11.11
Sinus tachycardia,1/60 %1.67,1/48 %2.08,0/9 %0.0
Blurred vision,1/60 %1.67,1/48 %2.08,0/9 %0.0
Abdominal distension,1/60 %1.67,0/48 %0.0,0/9 %0.0
Colitis,2/60 %3.33,2/48 %4.17,0/9 %0.0
Diarrhea,1/60 %1.67,1/48 %2.08,0/9 %0.0
Ileus,1/60 %1.67,1/48 %2.08,0/9 %0.0
Intra-abdominal hemorrhage,1/60 %1.67,1/48 %2.08,0/9 %0.0
Mucositis oral,2/60 %3.33,2/48 %4.17,0/9 %0.0
Nausea,1/60 %1.67,1/48 %2.08,0/9 %0.0
Oral pain,1/60 %1.67,1/48 %2.08,0/9 %0.0
Typhlitis,2/60 %3.33,2/48 %4.17,0/9 %0.0
Edema limbs,1/60 %1.67,1/48 %2.08,0/9 %0.0
Fever,1/60 %1.67,1/48 %2.08,0/9 %0.0
Infusion related reaction,1/60 %1.67,1/48 %2.08,0/9 %0.0
Pain,1/60 %1.67,1/48 %2.08,0/9 %0.0
Cholecystitis,1/60 %1.67,1/48 %2.08,0/9 %0.0
Allergic reaction,1/60 %1.67,0/48 %0.0,1/9 %11.11
Anaphylaxis,1/60 %1.67,1/48 %2.08,0/9 %0.0
Catheter related infection,1/60 %1.67,1/48 %2.08,0/9 %0.0
Enterocolitis infectious,2/60 %3.33,2/48 %4.17,0/9 %0.0
Infections and infestations - Other specify,7/60 %11.67,4/48 %8.33,2/9 %22.22
Periorbital infection,1/60 %1.67,1/48 %2.08,0/9 %0.0
Sepsis,2/60 %3.33,1/48 %2.08,1/9 %11.11
Upper respiratory infection,1/60 %1.67,0/48 %0.0,1/9 %11.11
Vascular access complication,1/60 %1.67,1/48 %2.08,0/9 %0.0
Activated partial thromboplastin time prolonged,1/60 %1.67,1/48 %2.08,0/9 %0.0
Alanine aminotransferase increased,16/60 %26.67,11/48 %22.92,5/9 %55.56
Alkaline phosphatase increased,1/60 %1.67,1/48 %2.08,0/9 %0.0
Aspartate aminotransferase increased,9/60 %15.0,6/48 %12.5,3/9 %33.33
Blood bilirubin increased,2/60 %3.33,2/48 %4.17,0/9 %0.0
Creatinine increased,2/60 %3.33,1/48 %2.08,1/9 %11.11
Electrocardiogram QT corrected interval prolonged,2/60 %3.33,2/48 %4.17,0/9 %0.0
GGT increased,2/60 %3.33,2/48 %4.17,0/9 %0.0
INR increased,1/60 %1.67,1/48 %2.08,0/9 %0.0
Lymphocyte count decreased,2/60 %3.33,1/48 %2.08,1/9 %11.11
Neutrophil count decreased,3/60 %5.0,2/48 %4.17,1/9 %11.11
Platelet count decreased,3/60 %5.0,2/48 %4.17,1/9 %11.11
White blood cell decreased,3/60 %5.0,2/48 %4.17,1/9 %11.11
Anorexia,3/60 %5.0,2/48 %4.17,0/9 %0.0
Dehydration,4/60 %6.67,4/48 %8.33,0/9 %0.0
Hyperglycemia,1/60 %1.67,0/48 %0.0,1/9 %11.11
Hypoalbuminemia,5/60 %8.33,3/48 %6.25,2/9 %22.22
Hypocalcemia,3/60 %5.0,2/48 %4.17,1/9 %11.11
Hypokalemia,9/60 %15.0,6/48 %12.5,3/9 %33.33
Hyponatremia,5/60 %8.33,4/48 %8.33,1/9 %11.11
Hypophosphatemia,2/60 %3.33,2/48 %4.17,0/9 %0.0
Back pain,1/60 %1.67,1/48 %2.08,0/9 %0.0
Pain in extremity,1/60 %1.67,1/48 %2.08,0/9 %0.0
Treatment related secondary malignancy,1/60 %1.67,1/48 %2.08,0/9 %0.0
Dizziness,1/60 %1.67,1/48 %2.08,0/9 %0.0
Dysphasia,1/60 %1.67,1/48 %2.08,0/9 %0.0
Encephalopathy,1/60 %1.67,1/48 %2.08,0/9 %0.0
Headache,3/60 %5.0,3/48 %6.25,0/9 %0.0
Nervous system disorders - Other specify,1/60 %1.67,1/48 %2.08,0/9 %0.0
Peripheral motor neuropathy,2/60 %3.33,1/48 %2.08,1/9 %11.11
Peripheral sensory neuropathy,2/60 %3.33,1/48 %2.08,1/9 %11.11
Seizure,2/60 %3.33,2/48 %4.17,0/9 %0.0
Agitation,2/60 %3.33,1/48 %2.08,1/9 %11.11
Anxiety,1/60 %1.67,1/48 %2.08,0/9 %0.0
Confusion,2/60 %3.33,1/48 %2.08,1/9 %11.11
Personality change,1/60 %1.67,1/48 %2.08,0/9 %0.0
Chronic kidney disease,1/60 %1.67,1/48 %2.08,0/9 %0.0
Renal and urinary disorders - Other specify,1/60 %1.67,1/48 %2.08,0/9 %0.0
Dyspnea,1/60 %1.67,0/48 %0.0,1/9 %11.11
Hypoxia,2/60 %3.33,1/48 %2.08,1/9 %11.11
Pneumonitis,1/60 %1.67,1/48 %2.08,0/9 %0.0
Erythema multiforme,1/60 %1.67,0/48 %0.0,0/9 %0.0
Palmar-plantar erythrodysesthesia syndrome,1/60 %1.67,1/48 %2.08,0/9 %0.0
Pruritus,1/60 %1.67,1/48 %2.08,0/9 %0.0
Rash acneiform,1/60 %1.67,1/48 %2.08,0/9 %0.0
Skin and subcutaneous tissue disorders - Other spec,1/60 %1.67,1/48 %2.08,0/9 %0.0
Hypertension,2/60 %3.33,2/48 %4.17,0/9 %0.0
Hypotension,4/60 %6.67,4/48 %8.33,0/9 %0.0
Superior vena cava syndrome,1/60 %1.67,1/48 %2.08,0/9 %0.0
Thromboembolic event,3/60 %5.0,3/48 %6.25,0/9 %0.0

Rituximab  Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Stage II  III  or IV Follicular NHL(https://clinicaltrials.gov/show/NCT00732498)
 ,ESHAP Followed by Zevalin and Rituximab
 ,Etoposide Methylprednisolone Cytarabine Cisplatin (ESHAP) infusion X 2 Cycles followed by Rituximab and In-Zevalin or Y-Zevalin.  Methylprednisolone: 250 mg/m2/day IV over 1 hour days 1234 every 28 days for 2 cycles. If bone marrow <25% involved and expected biodistribution after 2 cycles yttrium-90-ibritumomab tiuxetan (Zevalin) to be administered.  Etoposide: 40 mg/day IV over 1 hour days 1234 every 28 days for 2 cycles. If bone marrow <25% involved and expected biodistribution after 2 cycles yttrium-90-ibritumomab tiuxetan (Zevalin) to be administered.  Cytarabine: 2000 mg/m2 IV over 2 hours days 4 every 28 days for 2 cycles. If bone marrow <25% involved and expected biodistribution after 2 cycles yttrium-90-ibritumomab tiuxetan (Zevalin) to be administered.  Cisplatin: 25 mg/m2/day IV at 1mg/min days 1234 every 28 days for 2 cycles. If bone marrow <25% involved and expected biodistribution after 2 cycles yttrium-90-ibritumomab tiuxetan (Zevalin) to be admin
Total all-cause mortality,0/28 %0.0
Total serious adverse events,6/28 %21.43
Myelodysplastic syndrome,2/28 %7.14
Thrombocytopenia,1/28 %3.57
Perforated duodenal ulcer,1/28 %3.57
Nausea/Vomiting,1/28 %3.57
Metachronous colon carcinoma,1/28 %3.57

Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia(https://clinicaltrials.gov/show/NCT00742625)
 ,Bortezomib + Daunorubicin + Cytarabine
 ,Induction: 60 mg/sq m IV infusion Days 1-3 (Days 1-2 if 2nd induction)
Total serious adverse events,43/95 %45.26
DIC (disseminated intravascular coagulation),1/95 %1.05
Febrile neutropenia (fever of unknown origin without clinically or microbiologically documented infe,24/95 %25.26
Hemoglobin,43/95 %45.26
Hemolysis (e.g. immune hemolytic anemia drug-related hemolysis),1/95 %1.05
Lymphatics - Other (Specify __),1/95 %1.05
Cardiac Arrhythmia - Other (Specify __),13/95 %13.68
Cardiac ischemia/infarction,6/95 %6.32
Cardiopulmonary arrest cause unknown (non-fatal),1/95 %1.05
Left ventricular diastolic dysfunction,1/95 %1.05
Left ventricular systolic dysfunction,16/95 %16.84
Palpitations,2/95 %2.11
Supraventricular and nodal arrhythmia,8/95 %8.42
Endocrine - Other (Specify __),1/95 %1.05
Thyroid function high (hyperthyroidism thyrotoxicosis),1/95 %1.05
Ocular/Visual - Other (Specify __),1/95 %1.05
Colitis,1/95 %1.05
Constipation,9/95 %9.47
Diarrhea,36/95 %37.89
Distension/bloating abdominal,4/95 %4.21
Dry mouth/salivary gland (xerostomia),2/95 %2.11
Dysphagia (difficulty swallowing),5/95 %5.26
Enteritis (inflammation of the small bowel),2/95 %2.11
Esophagitis,1/95 %1.05
Heartburn/dyspepsia,1/95 %1.05
Hemorrhage GI,6/95 %6.32
Ileus GI (functional obstruction of bowel i.e. neuroconstipation),1/95 %1.05
Mucositis/stomatitis (clinical exam),4/95 %4.21
Mucositis/stomatitis (functional/symptomatic),1/95 %1.05
Nausea,30/95 %31.58
Typhlitis (cecal inflammation),2/95 %2.11
Ulcer GI,1/95 %1.05
Vomiting,17/95 %17.89
Constitutional Symptoms - Other (Specify __),1/95 %1.05
Death not associated with CTCAE term,2/95 %2.11
Edema: limb,8/95 %8.42
Edema: trunk/genital,3/95 %3.16
Edema:head and neck,1/95 %1.05
Fatigue (asthenia lethargy malaise),16/95 %16.84
Fever,1/95 %1.05
Rigors/chills,5/95 %5.26
Liver dysfunction/failure (clinical),1/95 %1.05
Allergic reaction/hypersensitivity (including drug fever),2/95 %2.11
Colitis infectious (e.g. Clostridium difficile),2/95 %2.11
Infection,29/95 %30.53
Infection - Other (Specify __),8/95 %8.42
Infection with normal ANC or Grade 1 or 2 neutrophils,10/95 %10.53
Infection with unknown ANC,5/95 %5.26
Opportunistic infection associated with >=Grade 2 Lymphopenia,2/95 %2.11
Bruising (in absence of Grade 3 or 4 thrombocytopenia),1/95 %1.05
Fracture,1/95 %1.05
ALT SGPT (serum glutamic pyruvic transaminase),26/95 %27.37
AST SGOT(serum glutamic oxaloacetic transaminase),29/95 %30.53
Alkaline phosphatase,10/95 %10.53
Bilirubin (hyperbilirubinemia),25/95 %26.32
Carbon monoxide diffusion capacity (DL(co)),5/95 %5.26
Cardiac troponin I (cTnI),1/95 %1.05
Creatinine,8/95 %8.42
GGT (gamma-Glutamyl transpeptidase),2/95 %2.11
INR (International Normalized Ratio of prothrombin time),3/95 %3.16
Leukocytes (total WBC),20/95 %21.05
Lymphopenia,16/95 %16.84
Metabolic/Laboratory - Other (Specify __),2/95 %2.11
Neutrophils/granulocytes (ANC/AGC),43/95 %45.26
PTT (Partial Thromboplastin Time),4/95 %4.21
Platelets,43/95 %45.26
Prolonged QTc interval,6/95 %6.32
Weight gain,1/95 %1.05
Weight loss,3/95 %3.16
Acidosis (metabolic or respiratory),3/95 %3.16
Albumin serum-low (hypoalbuminemia),19/95 %20.0
Alkalosis (metabolic or respiratory),4/95 %4.21
Anorexia,10/95 %10.53
Calcium serum-low (hypocalcemia),12/95 %12.63
Dehydration,4/95 %4.21
Glucose serum-high (hyperglycemia),13/95 %13.68
Glucose serum-low (hypoglycemia),1/95 %1.05
Magnesium serum-high (hypermagnesemia),4/95 %4.21
Magnesium serum-low (hypomagnesemia),4/95 %4.21
Phosphate serum-low (hypophosphatemia),14/95 %14.74
Potassium serum-high (hyperkalemia),5/95 %5.26
Potassium serum-low (hypokalemia),19/95 %20.0
Sodium serum-high (hypernatremia),2/95 %2.11
Sodium serum-low (hyponatremia),6/95 %6.32
Uric acid serum-high (hyperuricemia),5/95 %5.26
Muscle weakness generalized or specific area (not due to neuropathy),8/95 %8.42
CNS cerebrovascular ischemia,2/95 %2.11
Dizziness,6/95 %6.32
Hemorrhage CNS,1/95 %1.05
Neuropathy: cranial,1/95 %1.05
Neuropathy: motor,3/95 %3.16
Neuropathy: sensory,16/95 %16.84
Pain,12/95 %12.63
Somnolence/depressed level of consciousness,7/95 %7.37
Speech impairment (e.g. dysphasia or aphasia),1/95 %1.05
Syncope (fainting),3/95 %3.16
Taste alteration (dysgeusia),1/95 %1.05
Vasovagal episode,1/95 %1.05
Confusion,5/95 %5.26
Insomnia,5/95 %5.26
Mood alteration,6/95 %6.32
Personality/behavioral,1/95 %1.05
Psychosis (hallucinations/delusions),2/95 %2.11
Glomerular filtration rate,1/95 %1.05
Hemorrhage GU,1/95 %1.05
Renal failure,5/95 %5.26
Renal/Genitourinary - Other (Specify __),3/95 %3.16
Urinary retention (including neurogenic bladder),1/95 %1.05
Adult Respiratory Distress Syndrome (ARDS),7/95 %7.37
Allergic rhinitis (including sneezing nasal stuffiness postnasal drip),1/95 %1.05
Aspiration,1/95 %1.05
Cough,4/95 %4.21
Dyspnea (shortness of breath),19/95 %20.0
Edema larynx,2/95 %2.11
Hemorrhage pulmonary/upper respiratory,4/95 %4.21
Hypoxia,16/95 %16.84
Pleural effusion (non-malignant),5/95 %5.26
Pneumonitis/pulmonary infiltrates,1/95 %1.05
Pulmonary/Upper Respiratory - Other (Specify __),4/95 %4.21
Dermatology/Skin - Other (Specify __),2/95 %2.11
Hair loss/alopecia (scalp or body),1/95 %1.05
Petechiae/purpura (hemorrhage/bleeding into skin or mucosa),2/95 %2.11
Rash/desquamation,22/95 %23.16
Rash: erythema multiforme (e.g. Stevens-Johnson syndrome toxic epidermal necrolysis),1/95 %1.05
Sweating (diaphoresis),2/95 %2.11
Acute vascular leak syndrome,1/95 %1.05
Flushing,1/95 %1.05
Hematoma,2/95 %2.11
Hemorrhage/Bleeding - Other (Specify __),1/95 %1.05
Hypertension,6/95 %6.32
Hypotension,26/95 %27.37
Phlebitis (including superficial thrombosis),1/95 %1.05
Thrombosis/thrombus/embolism,1/95 %1.05
Visceral arterial ischemia (non-myocardial),1/95 %1.05

Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL)(https://clinicaltrials.gov/show/NCT00823719)
 ,Ofatumumab + DHAP,Ofatumumab + ICE,Total Ofatumumab + Chemotherapy
 ,Participants received 3 cycles (21 days per each cycle) of ofatumumab combined with salvage chemotherapy. Ofatumumab (1000 milligrams [mg]) was intravenously (IV) infused on Day 1 (or up to 3 days prior to Day 1) and Day 8 (+/-2 days) of Cycle 1 of the salvage chemotherapy and then on Day 1 only of Cycles 2 and 3. The DHAP (dexamethasone cytarabine cisplatin) regimen (salvage chemotherapy) contained: dexamethasone (40 mg/day) administered orally or IV on Days 1 2 3 or 4 of each cycle; cisplatin (100 mg/square meter [m^2]/day) as an IV continuous infusion on Day 1 of each cycle; and cytarabine 2 gram (g)/m^2 over 3 hours (hr) every 12 hr (2 doses) for each infusion on Day 2 of each cycle.,Participants received 3 cycles (21 days per each cycle) of ofatumumab combined with salvage chemotherapy. Ofatumumab (1000 mg) was IV infused on Day 1 (or up to 3 days prior to Day 1) and Day 8 (+/-2 days) of Cycle 1 of the salvage chemotherapy and then on Day 1 only of Cycles 2 and 3. The ICE (ifosfamide carboplatin etoposide) regimen (salvage chemotherapy) contained: etoposide (100 mg/m^2/day) administered IV on Days 1 2 and 3 of each cycle; carboplatin (up to 800 mg) on Day 2 of each cycle; and ifosfamide plus mesna both at 5 g/m^2/day as an IV continuous infusion on Day 2 of each cycle.,Participants received 3 cycles (21 days per each cycle) of ofatumumab combined with salvage chemotherapy (either DHAP or ICE). Ofatumumab (1000 mg) was IV infused on Day 1 (or up to 3 days prior to Day 1) and Day 8 (+/-2 days) of Cycle 1 of the salvage chemotherapy and then on Day 1 only of Cycles 2 and 3. DHAP contained: dexamethasone (40 mg/day) administered orally or IV on Days 1 2 3 or 4 of each cycle; cisplatin (100 mg/m^2/day) as an IV continuous infusion on Day 1 of each cycle; and cytarabine 2 g/m^2 over 3 hr every 12 hr (2 doses) for each infusion on Day 2 of each cycle. ICE contained: etoposide (100 mg/m^2/day) administered IV on Days 1 2 and 3 of each cycle; carboplatin (up to 800 mg) on Day 2 of each cycle; and ifosfamide plus mesna both at 5 g/m^2/day as an IV continuous infusion on Day 2 of each cycle.
Total serious adverse events,17/26 %65.38,7/35 %20.0,24/61 %39.34
Febrile neutropenia,8/26 %30.77,1/35 %2.86,9/61 %14.75
Thrombocytopenia,7/26 %26.92,2/35 %5.71,9/61 %14.75
Anaemia,2/26 %7.69,1/35 %2.86,3/61 %4.92
Arrhythmia supraventricular,1/26 %3.85,0/35 %0.0,1/61 %1.64
Tinnitus,1/26 %3.85,0/35 %0.0,1/61 %1.64
Vision blurred,1/26 %3.85,0/35 %0.0,1/61 %1.64
Nausea,2/26 %7.69,0/35 %0.0,2/61 %3.28
Vomiting,1/26 %3.85,1/35 %2.86,2/61 %3.28
Caecitis,1/26 %3.85,0/35 %0.0,1/61 %1.64
Fatigue,1/26 %3.85,0/35 %0.0,1/61 %1.64
Pyrexia,0/26 %0.0,1/35 %2.86,1/61 %1.64
Hypersensitivity,2/26 %7.69,0/35 %0.0,2/61 %3.28
Cellulitis,2/26 %7.69,0/35 %0.0,2/61 %3.28
Clostridium difficile colitis,1/26 %3.85,0/35 %0.0,1/61 %1.64
Device related sepsis,1/26 %3.85,0/35 %0.0,1/61 %1.64
Parainfluenzae virus infection,1/26 %3.85,0/35 %0.0,1/61 %1.64
Pneumonia,1/26 %3.85,0/35 %0.0,1/61 %1.64
Urinary tract infection staphylococcal,0/26 %0.0,1/35 %2.86,1/61 %1.64
Haemoglobin decreased,3/26 %11.54,0/35 %0.0,3/61 %4.92
Blood creatinine increased,2/26 %7.69,0/35 %0.0,2/61 %3.28
Blood creatinine,1/26 %3.85,0/35 %0.0,1/61 %1.64
Hypokalaemia,2/26 %7.69,0/35 %0.0,2/61 %3.28
Dehydration,1/26 %3.85,0/35 %0.0,1/61 %1.64
Failure to thrive,1/26 %3.85,0/35 %0.0,1/61 %1.64
Tumour lysis syndrome,1/26 %3.85,0/35 %0.0,1/61 %1.64
Muscular weakness,1/26 %3.85,0/35 %0.0,1/61 %1.64
Ataxia,1/26 %3.85,0/35 %0.0,1/61 %1.64
Dyskinesia,1/26 %3.85,0/35 %0.0,1/61 %1.64
Syncope,1/26 %3.85,0/35 %0.0,1/61 %1.64
Toxic encephalopathy,1/26 %3.85,0/35 %0.0,1/61 %1.64
Mental status changes,0/26 %0.0,2/35 %5.71,2/61 %3.28
Renal failure,2/26 %7.69,1/35 %2.86,3/61 %4.92
Renal failure acute,1/26 %3.85,0/35 %0.0,1/61 %1.64
Dyspnoea,1/26 %3.85,1/35 %2.86,2/61 %3.28
Pleural effusion,0/26 %0.0,1/35 %2.86,1/61 %1.64
Pulmonary embolism,1/26 %3.85,0/35 %0.0,1/61 %1.64
Respiratory distress,0/26 %0.0,1/35 %2.86,1/61 %1.64
Respiratory failure,0/26 %0.0,1/35 %2.86,1/61 %1.64
Hyperhidrosis,1/26 %3.85,0/35 %0.0,1/61 %1.64
Hypotension,1/26 %3.85,0/35 %0.0,1/61 %1.64

Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS)  Acute Myeloid Leukemia (AML)(https://clinicaltrials.gov/show/NCT00831766)
 ,Phase I: Dose Escalation,Phase II: Treatment at MTD
 ,Participants enrolled during Phase I.,Participants enrolled during Phase II.
Total serious adverse events,5/23 %21.74,13/28 %46.43
Neutrophils/granulocytes - low,0/23 %0.0,1/28 %3.57
Platelets - low,0/23 %0.0,2/28 %7.14
Cardiac Arrhythmia - Other atrial fibrilation with rapid ventricular response,0/23 %0.0,1/28 %3.57
Supraventricular and nodal arrhythmai - atrial fibirillation,0/23 %0.0,1/28 %3.57
Cardiac ischemia/infarction,1/23 %4.35,0/28 %0.0
Left ventricular systolic dysfunction,1/23 %4.35,0/28 %0.0
Anorexia,0/23 %0.0,1/28 %3.57
Dehydration,0/23 %0.0,1/28 %3.57
Diarrhea,0/23 %0.0,2/28 %7.14
Mucositis/stomatitis - Oral cavity,1/23 %4.35,0/28 %0.0
Fever (in the absence of neutropenia),1/23 %4.35,1/28 %3.57
Death - Disease progression NOS,1/23 %4.35,0/28 %0.0
Death - Multi-organ failure,1/23 %4.35,0/28 %0.0
Pain - Extremity limb,1/23 %4.35,0/28 %0.0
Febrile neutropenia,1/23 %4.35,9/28 %32.14
Infection with Grade 3 or 4 neutrophils - abdomen NOS,0/23 %0.0,1/28 %3.57
Infection with Grade 3 or 4 neutrophils - Blood,0/23 %0.0,5/28 %17.86
Infection with Grade 3 or 4 neutrophils - Lung (pneumonia),0/23 %0.0,1/28 %3.57
Infection with normal ANC or Grade 1 or 2 neutrophnils - Gallbladder (cholecystitis),0/23 %0.0,1/28 %3.57
Infection with Grade 3 or 4 Neutrophils - Urinary Tract,0/23 %0.0,1/28 %3.57
AST SGOT - high,1/23 %4.35,0/28 %0.0
Confusion,0/23 %0.0,1/28 %3.57
Renal/Genitourinary - Other acute kidney injury,0/23 %0.0,1/28 %3.57
Hypoxia,1/23 %4.35,0/28 %0.0
Thrombosis/embolism (vascular access-related),0/23 %0.0,1/28 %3.57

S0919 Idarubicin  Cytarabine  and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia(https://clinicaltrials.gov/show/NCT00840177)
 ,Initial Cohort: Relapsed AML With Previous Remission  3 Mnths,Poor-risk Cohort: MDS Transformed to AML,Poor-risk Cohort: Refractory/Relapsed AML < 6 Mths Remission
 ,Participants with previous morphologically confirmed acute myeloid leukemia (AML) and preceding remission lasting  3 months,Participants with acute myeloid leukemia (AML) who had a previous morphologically confirmed diagnosis of MDS/CMML and for which they may have received previous non-intensive therapy.,Participants with previous morphologically confirmed acute myeloid leukemia (AML) and preceding remission lasting < 6 months.
Total all-cause mortality,27/36 %75.0,20/29 %68.97,41/46 %89.13
Total serious adverse events,5/35 %14.29,8/29 %27.59,10/46 %21.74
Febrile neutropenia,0/35 %0.0,0/29 %0.0,1/46 %2.17
Cardiac General-Other,1/35 %2.86,1/29 %3.45,0/46 %0.0
Cardiac-ischemia/infarction,0/35 %0.0,1/29 %3.45,0/46 %0.0
Conduction abnormality - Asystole,1/35 %2.86,0/29 %0.0,0/46 %0.0
SVT and nodal arrhythmia - Atrial fibrillation,1/35 %2.86,1/29 %3.45,0/46 %0.0
SVT and nodal arrhythmia - Sinus tachycardia,0/35 %0.0,0/29 %0.0,1/46 %2.17
Ileus GI (functional obstruction of bowel),0/35 %0.0,1/29 %3.45,0/46 %0.0
Mucositis/stomatitis (functional/symp) - Oral cav,1/35 %2.86,0/29 %0.0,0/46 %0.0
Death not associated with CTCAE term - Death NOS,1/35 %2.86,0/29 %0.0,3/46 %6.52
Inf (clin/microbio) w/Gr 3-4 neuts - Blood,0/35 %0.0,1/29 %3.45,0/46 %0.0
Inf (clin/microbio) w/Gr 3-4 neuts - Lung,1/35 %2.86,0/29 %0.0,0/46 %0.0
Infection with unknown ANC - Blood,1/35 %2.86,2/29 %6.9,5/46 %10.87
Infection with unknown ANC - Lung (pneumonia),0/35 %0.0,1/29 %3.45,0/46 %0.0
Infection with unknown ANC - Small bowel NOS,0/35 %0.0,1/29 %3.45,0/46 %0.0
Carbon monoxide diffusion capacity (DL(co)),1/35 %2.86,4/29 %13.79,1/46 %2.17
Lymphopenia,1/35 %2.86,0/29 %0.0,0/46 %0.0
Neutrophils/granulocytes (ANC/AGC),1/35 %2.86,0/29 %0.0,0/46 %0.0
Musculoskeletal/Soft Tissue-Other,0/35 %0.0,1/29 %3.45,0/46 %0.0
Hemorrhage CNS,0/35 %0.0,0/29 %0.0,1/46 %2.17
Renal failure,0/35 %0.0,0/29 %0.0,1/46 %2.17
Carbon monoxide diffusion capacity (DL(co)),1/35 %2.86,4/29 %13.79,1/46 %2.17
Hemorrhage pulmo/upper resp- Bronchopulmonary NOS,0/35 %0.0,0/29 %0.0,1/46 %2.17
Hypoxia,1/35 %2.86,0/29 %0.0,0/46 %0.0
Hypotension,0/35 %0.0,2/29 %6.9,1/46 %2.17

Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma(https://clinicaltrials.gov/show/NCT00873093)
 ,Pre-B ALL Relapse < 36 Mths From Dx (Chemotherapy) Age >21 Yrs,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs,T-cell ALL (Chemotherapy),T-cell Lymphoblastic Lymphoma (LL) (Chemotherapy)
 ,Re-Induction Block 1 patients receive liposomal vincristine sulfate  Prednisone pegaspargase and Doxorubicin hydrochloride. Re-Induction Block 2 patients receive Cyclophosphamide Etoposide phosphate and Methotrexate. Re-Induction Block 3 patients receive Cytarabine and L-Asparaginase. Patients receive Bortezomib on days 1 4 8 & 11 of Block 1 and days 1 4 & 8 of Block 2.,Re-Induction Block 1 patients receive liposomal vincristine sulfate  Prednisone pegaspargase and Doxorubicin hydrochloride. Re-Induction Block 2 patients receive Cyclophosphamide Etoposide phosphate and Methotrexate. Re-Induction Block 3 patients receive Cytarabine and L-Asparaginase. Patients receive Bortezomib on days 1 4 8 & 11 of Block 1 and days 1 4 & 8 of Block 2.,Re-Induction Block 1 patients receive liposomal vincristine sulfate  Prednisone pegaspargase and Doxorubicin hydrochloride. Re-Induction Block 2 patients receive Cyclophosphamide Etoposide phosphate and Methotrexate. Re-Induction Block 3 patients receive Cytarabine and L-Asparaginase. Patients receive Bortezomib on days 1 4 8 & 11 of Block 1 and days 1 4 & 8 of Block 2.,Re-Induction Block 1 patients receive liposomal vincristine sulfate  Prednisone pegaspargase and Doxorubicin hydrochloride. Re-Induction Block 2 patients receive Cyclophosphamide Etoposide phosphate and Methotrexate. Re-Induction Block 3 patients receive Cytarabine and L-Asparaginase. Patients receive Bortezomib on days 1 4 8 & 11 of Block 1 and days 1 4 & 8 of Block 2.,Re-Induction Block 1 patients receive liposomal vincristine sulfate  Prednisone pegaspargase and Doxorubicin hydrochloride. Re-Induction Block 2 patients receive Cyclophosphamide Etoposide phosphate and Methotrexate. Re-Induction Block 3 patients receive Cytarabine and L-Asparaginase. Patients receive Bortezomib on days 1 4 8 & 11 of Block 1 and days 1 4 & 8 of Block 2.
Total serious adverse events,2/4 %50.0,47/61 %77.05,40/49 %81.63,18/22 %81.82,7/10 %70.0
Anemia,0/4 %0.0,0/61 %0.0,1/49 %2.04,0/22 %0.0,0/10 %0.0
Disseminated intravascular coagulation,0/4 %0.0,1/61 %1.64,0/49 %0.0,0/22 %0.0,0/10 %0.0
Febrile neutropenia,0/4 %0.0,3/61 %4.92,3/49 %6.12,2/22 %9.09,0/10 %0.0
Cardiac arrest,0/4 %0.0,2/61 %3.28,1/49 %2.04,0/22 %0.0,0/10 %0.0
Cardiac disorders - Other specify,0/4 %0.0,0/61 %0.0,2/49 %4.08,0/22 %0.0,0/10 %0.0
Heart failure,0/4 %0.0,1/61 %1.64,1/49 %2.04,0/22 %0.0,0/10 %0.0
Left ventricular systolic dysfunction,0/4 %0.0,1/61 %1.64,0/49 %0.0,0/22 %0.0,0/10 %0.0
Pericardial tamponade,0/4 %0.0,0/61 %0.0,0/49 %0.0,0/22 %0.0,1/10 %10.0
Sinus bradycardia,0/4 %0.0,0/61 %0.0,1/49 %2.04,0/22 %0.0,0/10 %0.0
Sinus tachycardia,0/4 %0.0,0/61 %0.0,1/49 %2.04,0/22 %0.0,0/10 %0.0
Ventricular tachycardia,0/4 %0.0,1/61 %1.64,0/49 %0.0,0/22 %0.0,0/10 %0.0
Eye pain,0/4 %0.0,1/61 %1.64,0/49 %0.0,0/22 %0.0,0/10 %0.0
Abdominal pain,0/4 %0.0,2/61 %3.28,1/49 %2.04,1/22 %4.55,1/10 %10.0
Anal pain,0/4 %0.0,1/61 %1.64,0/49 %0.0,0/22 %0.0,0/10 %0.0
Colitis,0/4 %0.0,1/61 %1.64,0/49 %0.0,0/22 %0.0,0/10 %0.0
Dental caries,0/4 %0.0,1/61 %1.64,0/49 %0.0,0/22 %0.0,0/10 %0.0
Diarrhea,0/4 %0.0,1/61 %1.64,1/49 %2.04,0/22 %0.0,0/10 %0.0
Enterocolitis,0/4 %0.0,1/61 %1.64,1/49 %2.04,0/22 %0.0,0/10 %0.0
Esophagitis,0/4 %0.0,1/61 %1.64,0/49 %0.0,0/22 %0.0,0/10 %0.0
Gastric hemorrhage,0/4 %0.0,1/61 %1.64,0/49 %0.0,0/22 %0.0,0/10 %0.0
Ileus,0/4 %0.0,0/61 %0.0,1/49 %2.04,1/22 %4.55,0/10 %0.0
Lower gastrointestinal hemorrhage,0/4 %0.0,1/61 %1.64,0/49 %0.0,0/22 %0.0,0/10 %0.0
Mucositis oral,0/4 %0.0,3/61 %4.92,1/49 %2.04,1/22 %4.55,0/10 %0.0
Nausea,0/4 %0.0,2/61 %3.28,1/49 %2.04,0/22 %0.0,0/10 %0.0
Oral pain,0/4 %0.0,1/61 %1.64,0/49 %0.0,0/22 %0.0,0/10 %0.0
Pancreatic necrosis,0/4 %0.0,0/61 %0.0,0/49 %0.0,0/22 %0.0,1/10 %10.0
Pancreatitis,0/4 %0.0,1/61 %1.64,3/49 %6.12,3/22 %13.64,1/10 %10.0
Peritoneal necrosis,0/4 %0.0,1/61 %1.64,0/49 %0.0,0/22 %0.0,0/10 %0.0
Rectal fistula,0/4 %0.0,1/61 %1.64,0/49 %0.0,0/22 %0.0,0/10 %0.0
Typhlitis,0/4 %0.0,4/61 %6.56,1/49 %2.04,2/22 %9.09,1/10 %10.0
Vomiting,0/4 %0.0,0/61 %0.0,1/49 %2.04,0/22 %0.0,0/10 %0.0
Chills,0/4 %0.0,0/61 %0.0,1/49 %2.04,1/22 %4.55,0/10 %0.0
Death NOS,2/4 %50.0,24/61 %39.34,24/49 %48.98,9/22 %40.91,5/10 %50.0
Fever,0/4 %0.0,1/61 %1.64,2/49 %4.08,0/22 %0.0,0/10 %0.0
Flu like symptoms,0/4 %0.0,0/61 %0.0,1/49 %2.04,0/22 %0.0,0/10 %0.0
Hypothermia,0/4 %0.0,0/61 %0.0,1/49 %2.04,0/22 %0.0,0/10 %0.0
Multi-organ failure,0/4 %0.0,3/61 %4.92,0/49 %0.0,0/22 %0.0,0/10 %0.0
Pain,0/4 %0.0,1/61 %1.64,0/49 %0.0,1/22 %4.55,0/10 %0.0
Hepatobiliary disorders - Other specify,0/4 %0.0,1/61 %1.64,0/49 %0.0,0/22 %0.0,0/10 %0.0
Allergic reaction,0/4 %0.0,2/61 %3.28,0/49 %0.0,0/22 %0.0,0/10 %0.0
Cytokine release syndrome,0/4 %0.0,1/61 %1.64,0/49 %0.0,0/22 %0.0,0/10 %0.0
Appendicitis,0/4 %0.0,0/61 %0.0,1/49 %2.04,0/22 %0.0,0/10 %0.0
Appendicitis perforated,0/4 %0.0,1/61 %1.64,0/49 %0.0,1/22 %4.55,0/10 %0.0
Catheter related infection,0/4 %0.0,3/61 %4.92,1/49 %2.04,0/22 %0.0,0/10 %0.0
Encephalitis infection,0/4 %0.0,0/61 %0.0,1/49 %2.04,0/22 %0.0,0/10 %0.0
Enterocolitis infectious,0/4 %0.0,1/61 %1.64,0/49 %0.0,0/22 %0.0,0/10 %0.0
Infections and infestations - Other specify,0/4 %0.0,5/61 %8.2,3/49 %6.12,2/22 %9.09,1/10 %10.0
Infective myositis,0/4 %0.0,1/61 %1.64,0/49 %0.0,0/22 %0.0,0/10 %0.0
Joint infection,0/4 %0.0,1/61 %1.64,0/49 %0.0,0/22 %0.0,0/10 %0.0
Lung infection,0/4 %0.0,2/61 %3.28,2/49 %4.08,0/22 %0.0,1/10 %10.0
Mucosal infection,0/4 %0.0,2/61 %3.28,1/49 %2.04,0/22 %0.0,0/10 %0.0
Papulopustular rash,0/4 %0.0,1/61 %1.64,0/49 %0.0,0/22 %0.0,0/10 %0.0
Pharyngitis,0/4 %0.0,1/61 %1.64,0/49 %0.0,0/22 %0.0,0/10 %0.0
Sepsis,0/4 %0.0,8/61 %13.11,8/49 %16.33,2/22 %9.09,1/10 %10.0
Sinusitis,0/4 %0.0,1/61 %1.64,0/49 %0.0,0/22 %0.0,0/10 %0.0
Soft tissue infection,0/4 %0.0,0/61 %0.0,1/49 %2.04,0/22 %0.0,0/10 %0.0
Urinary tract infection,0/4 %0.0,0/61 %0.0,0/49 %0.0,0/22 %0.0,1/10 %10.0
Alanine aminotransferase increased,0/4 %0.0,1/61 %1.64,0/49 %0.0,1/22 %4.55,0/10 %0.0
Aspartate aminotransferase increased,0/4 %0.0,1/61 %1.64,0/49 %0.0,0/22 %0.0,0/10 %0.0
Blood bilirubin increased,1/4 %25.0,0/61 %0.0,0/49 %0.0,2/22 %9.09,1/10 %10.0
Cholesterol high,0/4 %0.0,0/61 %0.0,0/49 %0.0,1/22 %4.55,0/10 %0.0
Creatinine increased,0/4 %0.0,0/61 %0.0,1/49 %2.04,0/22 %0.0,0/10 %0.0
Investigations - Other specify,0/4 %0.0,0/61 %0.0,0/49 %0.0,0/22 %0.0,1/10 %10.0
Lipase increased,0/4 %0.0,2/61 %3.28,0/49 %0.0,3/22 %13.64,1/10 %10.0
Neutrophil count decreased,0/4 %0.0,1/61 %1.64,0/49 %0.0,0/22 %0.0,0/10 %0.0
Platelet count decreased,0/4 %0.0,1/61 %1.64,2/49 %4.08,0/22 %0.0,0/10 %0.0
Serum amylase increased,0/4 %0.0,0/61 %0.0,0/49 %0.0,1/22 %4.55,1/10 %10.0
White blood cell decreased,0/4 %0.0,1/61 %1.64,2/49 %4.08,0/22 %0.0,0/10 %0.0
Acidosis,0/4 %0.0,2/61 %3.28,1/49 %2.04,0/22 %0.0,0/10 %0.0
Anorexia,0/4 %0.0,3/61 %4.92,0/49 %0.0,0/22 %0.0,0/10 %0.0
Dehydration,0/4 %0.0,1/61 %1.64,0/49 %0.0,0/22 %0.0,0/10 %0.0
Hyperglycemia,0/4 %0.0,1/61 %1.64,1/49 %2.04,1/22 %4.55,0/10 %0.0
Hyperkalemia,0/4 %0.0,1/61 %1.64,1/49 %2.04,0/22 %0.0,0/10 %0.0
Hypernatremia,0/4 %0.0,1/61 %1.64,0/49 %0.0,0/22 %0.0,0/10 %0.0
Hypertriglyceridemia,0/4 %0.0,1/61 %1.64,1/49 %2.04,1/22 %4.55,1/10 %10.0
Hypoalbuminemia,0/4 %0.0,1/61 %1.64,1/49 %2.04,2/22 %9.09,0/10 %0.0
Hypocalcemia,0/4 %0.0,0/61 %0.0,0/49 %0.0,2/22 %9.09,0/10 %0.0
Hypokalemia,0/4 %0.0,8/61 %13.11,1/49 %2.04,1/22 %4.55,0/10 %0.0
Hyponatremia,0/4 %0.0,4/61 %6.56,4/49 %8.16,1/22 %4.55,1/10 %10.0
Hypophosphatemia,0/4 %0.0,0/61 %0.0,0/49 %0.0,0/22 %0.0,1/10 %10.0
Tumor lysis syndrome,0/4 %0.0,0/61 %0.0,0/49 %0.0,1/22 %4.55,0/10 %0.0
Arthralgia,0/4 %0.0,1/61 %1.64,0/49 %0.0,0/22 %0.0,0/10 %0.0
Back pain,0/4 %0.0,2/61 %3.28,0/49 %0.0,0/22 %0.0,0/10 %0.0
Joint effusion,0/4 %0.0,1/61 %1.64,0/49 %0.0,0/22 %0.0,0/10 %0.0
Pain in extremity,0/4 %0.0,2/61 %3.28,0/49 %0.0,0/22 %0.0,0/10 %0.0
Neoplasms benign malignant and unspecified (incl cysts and polyps) - Other specify,0/4 %0.0,3/61 %4.92,4/49 %8.16,2/22 %9.09,0/10 %0.0
Akathisia,0/4 %0.0,0/61 %0.0,0/49 %0.0,1/22 %4.55,0/10 %0.0
Depressed level of consciousness,0/4 %0.0,1/61 %1.64,1/49 %2.04,0/22 %0.0,0/10 %0.0
Dysarthria,0/4 %0.0,1/61 %1.64,0/49 %0.0,0/22 %0.0,0/10 %0.0
Encephalopathy,0/4 %0.0,1/61 %1.64,0/49 %0.0,0/22 %0.0,0/10 %0.0
Headache,0/4 %0.0,2/61 %3.28,1/49 %2.04,0/22 %0.0,0/10 %0.0
Memory impairment,0/4 %0.0,0/61 %0.0,0/49 %0.0,1/22 %4.55,0/10 %0.0
Nervous system disorders - Other specify,0/4 %0.0,1/61 %1.64,0/49 %0.0,0/22 %0.0,0/10 %0.0
Neuralgia,0/4 %0.0,1/61 %1.64,0/49 %0.0,0/22 %0.0,0/10 %0.0
Paresthesia,0/4 %0.0,0/61 %0.0,0/49 %0.0,1/22 %4.55,0/10 %0.0
Peripheral sensory neuropathy,1/4 %25.0,0/61 %0.0,1/49 %2.04,1/22 %4.55,0/10 %0.0
Reversible posterior leukoencephalopathy syndrome,0/4 %0.0,0/61 %0.0,1/49 %2.04,0/22 %0.0,0/10 %0.0
Seizure,0/4 %0.0,2/61 %3.28,1/49 %2.04,0/22 %0.0,0/10 %0.0
Stroke,0/4 %0.0,0/61 %0.0,2/49 %4.08,0/22 %0.0,0/10 %0.0
Syncope,0/4 %0.0,1/61 %1.64,0/49 %0.0,0/22 %0.0,0/10 %0.0
Anxiety,0/4 %0.0,0/61 %0.0,0/49 %0.0,1/22 %4.55,0/10 %0.0
Confusion,0/4 %0.0,0/61 %0.0,0/49 %0.0,1/22 %4.55,0/10 %0.0
Psychiatric disorders - Other specify,0/4 %0.0,0/61 %0.0,0/49 %0.0,1/22 %4.55,0/10 %0.0
Acute kidney injury,0/4 %0.0,1/61 %1.64,0/49 %0.0,0/22 %0.0,0/10 %0.0
Urinary retention,0/4 %0.0,0/61 %0.0,1/49 %2.04,0/22 %0.0,0/10 %0.0
Adult respiratory distress syndrome,0/4 %0.0,2/61 %3.28,2/49 %4.08,0/22 %0.0,0/10 %0.0
Atelectasis,0/4 %0.0,0/61 %0.0,1/49 %2.04,0/22 %0.0,0/10 %0.0
Bronchopulmonary hemorrhage,0/4 %0.0,1/61 %1.64,0/49 %0.0,0/22 %0.0,0/10 %0.0
Dyspnea,0/4 %0.0,2/61 %3.28,3/49 %6.12,0/22 %0.0,0/10 %0.0
Epistaxis,0/4 %0.0,0/61 %0.0,2/49 %4.08,0/22 %0.0,0/10 %0.0
Hypoxia,0/4 %0.0,8/61 %13.11,3/49 %6.12,0/22 %0.0,0/10 %0.0
Pharyngolaryngeal pain,0/4 %0.0,1/61 %1.64,0/49 %0.0,0/22 %0.0,0/10 %0.0
Pleural effusion,0/4 %0.0,2/61 %3.28,0/49 %0.0,0/22 %0.0,0/10 %0.0
Pneumonitis,0/4 %0.0,2/61 %3.28,2/49 %4.08,0/22 %0.0,0/10 %0.0
Pneumothorax,0/4 %0.0,0/61 %0.0,1/49 %2.04,0/22 %0.0,0/10 %0.0
Pulmonary edema,0/4 %0.0,3/61 %4.92,1/49 %2.04,0/22 %0.0,0/10 %0.0
Respiratory failure,0/4 %0.0,5/61 %8.2,4/49 %8.16,1/22 %4.55,0/10 %0.0
Respiratory thoracic and mediastinal disorders - Other specify,0/4 %0.0,1/61 %1.64,1/49 %2.04,0/22 %0.0,0/10 %0.0
Stridor,0/4 %0.0,0/61 %0.0,1/49 %2.04,0/22 %0.0,0/10 %0.0
Wheezing,0/4 %0.0,0/61 %0.0,1/49 %2.04,0/22 %0.0,0/10 %0.0
Pruritus,0/4 %0.0,1/61 %1.64,0/49 %0.0,1/22 %4.55,0/10 %0.0
Rash maculo-papular,0/4 %0.0,1/61 %1.64,0/49 %0.0,0/22 %0.0,0/10 %0.0
Skin ulceration,0/4 %0.0,1/61 %1.64,1/49 %2.04,0/22 %0.0,0/10 %0.0
Toxic epidermal necrolysis,0/4 %0.0,1/61 %1.64,0/49 %0.0,0/22 %0.0,0/10 %0.0
Capillary leak syndrome,0/4 %0.0,0/61 %0.0,1/49 %2.04,0/22 %0.0,1/10 %10.0
Hypertension,0/4 %0.0,3/61 %4.92,2/49 %4.08,0/22 %0.0,0/10 %0.0
Hypotension,0/4 %0.0,8/61 %13.11,5/49 %10.2,3/22 %13.64,1/10 %10.0

A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)(https://clinicaltrials.gov/show/NCT00875667)
 ,Lenalidomide,Investigator's Choice
 ,Participants received lenalidomide 25 mg capsules orally every day for 21 days of each 28-day treatment cycle until disease progression or unacceptable toxicity. Participants with moderate renal insufficiency (creatinine clearance is  30 mL/min but < 60mL/min received 10 mg lenalidomide for 21 days of each 28-day cycle (Cycles 1 and 2). After Cycle 2 if the participant remained free of Grade 3 or Grade 4 toxicity the dose was increased to 15 mg lenalidomide for 21 days of each 28-day treatment cycle until disease progression or unacceptable toxicity.,Participants received a single agent investigators choice (IC) of chlorambucil 40 mg/m^2 PO every 28 days until progressive disease (PD) or toxicity OR rituximab 375 mg/m^2 by intravenous (IV) infusion on days 1 8 15 and 22 of each 56-day treatment cycle until PD or toxicity OR cytarabine 1-2 g/m^2 by IV infusion on days 1 and 2 of each 28 day treatment cycle; up to 6 cycles OR gemcitabine 1000 mg/m^2 by IV infusion on days 1 8 and 15 of each 28 day treatment cycle; up to 6 cycles OR oral fludarabine 40 mg/m^2 or IV fludarabine 25 mg/m^2 on days 1 through 5 of each 28-day cycle; up to 6 cycles. Participants were given the option to enter into the lenalidomide crossover phase if PD occurred and received lenalidomide 25 mg capsules daily on days 1 to 21 of each 28 day treatment cycle until PD or toxicity.
Total all-cause mortality,119/167 %71.26,59/83 %71.08
Total serious adverse events,75/167 %44.91,22/83 %26.51
ANAEMIA,6/167 %3.59,2/83 %2.41
AUTOIMMUNE HAEMOLYTIC ANAEMIA,0/167 %0.0,1/83 %1.2
FEBRILE NEUTROPENIA,6/167 %3.59,2/83 %2.41
LYMPH NODE PAIN,1/167 %0.6,1/83 %1.2
NEUTROPENIA,6/167 %3.59,0/83 %0.0
THROMBOCYTOPENIA,3/167 %1.8,2/83 %2.41
ACUTE CORONARY SYNDROME,1/167 %0.6,0/83 %0.0
ACUTE MYOCARDIAL INFARCTION,1/167 %0.6,0/83 %0.0
ATRIAL FIBRILLATION,1/167 %0.6,1/83 %1.2
ATRIOVENTRICULAR BLOCK COMPLETE,1/167 %0.6,0/83 %0.0
ATRIOVENTRICULAR BLOCK SECOND DEGREE,1/167 %0.6,0/83 %0.0
CARDIAC ARREST,2/167 %1.2,0/83 %0.0
CARDIAC FAILURE,2/167 %1.2,1/83 %1.2
CARDIAC FAILURE ACUTE,0/167 %0.0,1/83 %1.2
CARDIAC FAILURE CONGESTIVE,1/167 %0.6,0/83 %0.0
CORONARY ARTERY DISEASE,1/167 %0.6,0/83 %0.0
LEFT VENTRICULAR FAILURE,1/167 %0.6,0/83 %0.0
MYOCARDIAL INFARCTION,1/167 %0.6,0/83 %0.0
SUPRAVENTRICULAR TACHYCARDIA,1/167 %0.6,0/83 %0.0
TACHYCARDIA,1/167 %0.6,0/83 %0.0
DEAFNESS BILATERAL,1/167 %0.6,0/83 %0.0
VERTIGO,1/167 %0.6,0/83 %0.0
RETINAL ARTERY OCCLUSION,1/167 %0.6,0/83 %0.0
ABDOMINAL PAIN,1/167 %0.6,0/83 %0.0
ABDOMINAL WALL HAEMATOMA,0/167 %0.0,1/83 %1.2
DIARRHOEA,6/167 %3.59,0/83 %0.0
GASTROINTESTINAL HAEMORRHAGE,1/167 %0.6,0/83 %0.0
LARGE INTESTINE PERFORATION,1/167 %0.6,0/83 %0.0
NAUSEA,1/167 %0.6,0/83 %0.0
OESOPHAGEAL ULCER HAEMORRHAGE,1/167 %0.6,0/83 %0.0
RECTAL HAEMORRHAGE,1/167 %0.6,1/83 %1.2
SMALL INTESTINAL OBSTRUCTION,0/167 %0.0,1/83 %1.2
VOMITING,2/167 %1.2,0/83 %0.0
DEATH,1/167 %0.6,0/83 %0.0
FATIGUE,1/167 %0.6,0/83 %0.0
GENERAL PHYSICAL HEALTH DETERIORATION,3/167 %1.8,1/83 %1.2
MULTIPLE ORGAN DYSFUNCTION SYNDROME,2/167 %1.2,0/83 %0.0
OEDEMA PERIPHERAL,1/167 %0.6,0/83 %0.0
PYREXIA,5/167 %2.99,2/83 %2.41
SUDDEN DEATH,1/167 %0.6,0/83 %0.0
CHOLECYSTITIS,1/167 %0.6,0/83 %0.0
CHOLECYSTITIS ACUTE,1/167 %0.6,0/83 %0.0
HYPERBILIRUBINAEMIA,1/167 %0.6,0/83 %0.0
DRUG HYPERSENSITIVITY,0/167 %0.0,1/83 %1.2
ARTHRITIS INFECTIVE,1/167 %0.6,0/83 %0.0
ASPERGILLUS INFECTION,1/167 %0.6,0/83 %0.0
BRONCHITIS,2/167 %1.2,1/83 %1.2
BRONCHOPULMONARY ASPERGILLOSIS,0/167 %0.0,1/83 %1.2
CELLULITIS,1/167 %0.6,1/83 %1.2
LOWER RESPIRATORY TRACT INFECTION,3/167 %1.8,1/83 %1.2
LUNG INFECTION,2/167 %1.2,0/83 %0.0
MENINGITIS VIRAL,1/167 %0.6,0/83 %0.0
NEUTROPENIC SEPSIS,1/167 %0.6,0/83 %0.0
PNEUMONIA,6/167 %3.59,3/83 %3.61
PNEUMONIA MORAXELLA,0/167 %0.0,1/83 %1.2
PNEUMONIA STREPTOCOCCAL,1/167 %0.6,0/83 %0.0
PSEUDOMEMBRANOUS COLITIS,1/167 %0.6,0/83 %0.0
SEPTIC SHOCK,1/167 %0.6,0/83 %0.0
SINUSITIS,1/167 %0.6,0/83 %0.0
SKIN INFECTION,1/167 %0.6,0/83 %0.0
STAPHYLOCOCCAL BACTERAEMIA,1/167 %0.6,0/83 %0.0
STAPHYLOCOCCAL SEPSIS,1/167 %0.6,0/83 %0.0
UPPER RESPIRATORY TRACT INFECTION,1/167 %0.6,0/83 %0.0
URINARY TRACT INFECTION,2/167 %1.2,0/83 %0.0
UROSEPSIS,1/167 %0.6,0/83 %0.0
FACIAL BONES FRACTURE,1/167 %0.6,0/83 %0.0
TOXICITY TO VARIOUS AGENTS,0/167 %0.0,1/83 %1.2
WEIGHT DECREASED,1/167 %0.6,0/83 %0.0
CACHEXIA,1/167 %0.6,0/83 %0.0
DEHYDRATION,1/167 %0.6,0/83 %0.0
DIABETES MELLITUS,0/167 %0.0,1/83 %1.2
HYPERKALAEMIA,1/167 %0.6,0/83 %0.0
HYPOALBUMINAEMIA,1/167 %0.6,0/83 %0.0
HYPOPROTEINAEMIA,1/167 %0.6,0/83 %0.0
ARTHRITIS,1/167 %0.6,0/83 %0.0
OSTEONECROSIS,1/167 %0.6,1/83 %1.2
PAIN IN EXTREMITY,1/167 %0.6,0/83 %0.0
ACUTE LYMPHOCYTIC LEUKAEMIA,3/167 %1.8,0/83 %0.0
BASAL CELL CARCINOMA,2/167 %1.2,0/83 %0.0
CANCER PAIN,1/167 %0.6,0/83 %0.0
DIFFUSE LARGE B-CELL LYMPHOMA,0/167 %0.0,1/83 %1.2
LIPOSARCOMA,1/167 %0.6,0/83 %0.0
MANTLE CELL LYMPHOMA,1/167 %0.6,3/83 %3.61
MENINGIOMA BENIGN,0/167 %0.0,1/83 %1.2
METASTASES TO LUNG,1/167 %0.6,0/83 %0.0
METASTATIC SQUAMOUS CELL CARCINOMA,1/167 %0.6,0/83 %0.0
SQUAMOUS CELL CARCINOMA OF SKIN,2/167 %1.2,0/83 %0.0
TUMOUR FLARE,1/167 %0.6,0/83 %0.0
CEREBRAL HAEMORRHAGE,1/167 %0.6,0/83 %0.0
CEREBROVASCULAR ACCIDENT,1/167 %0.6,0/83 %0.0
HEMIANOPIA HETERONYMOUS,1/167 %0.6,0/83 %0.0
ISCHAEMIC STROKE,1/167 %0.6,0/83 %0.0
SEIZURE,1/167 %0.6,0/83 %0.0
TRANSIENT ISCHAEMIC ATTACK,1/167 %0.6,0/83 %0.0
ANURIA,0/167 %0.0,1/83 %1.2
CHRONIC KIDNEY DISEASE,1/167 %0.6,0/83 %0.0
CYSTITIS HAEMORRHAGIC,1/167 %0.6,0/83 %0.0
OLIGURIA,0/167 %0.0,1/83 %1.2
RENAL FAILURE,1/167 %0.6,0/83 %0.0
OEDEMA GENITAL,1/167 %0.6,0/83 %0.0
UTERINE POLYP,1/167 %0.6,0/83 %0.0
ASPIRATION,1/167 %0.6,0/83 %0.0
BRONCHITIS CHRONIC,1/167 %0.6,0/83 %0.0
COUGH,0/167 %0.0,1/83 %1.2
DYSPNOEA,3/167 %1.8,1/83 %1.2
INTERSTITIAL LUNG DISEASE,1/167 %0.6,0/83 %0.0
PHARYNGEAL INFLAMMATION,1/167 %0.6,0/83 %0.0
PLEURAL EFFUSION,2/167 %1.2,0/83 %0.0
PLEURISY,1/167 %0.6,0/83 %0.0
PULMONARY EMBOLISM,6/167 %3.59,0/83 %0.0
RESPIRATORY DISTRESS,1/167 %0.6,0/83 %0.0
RESPIRATORY FAILURE,1/167 %0.6,0/83 %0.0
VOCAL CORD DISORDER,1/167 %0.6,0/83 %0.0
DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS,1/167 %0.6,0/83 %0.0
HAEMORRHAGE,1/167 %0.6,0/83 %0.0
HYPERTENSION,1/167 %0.6,0/83 %0.0
HYPOTENSION,2/167 %1.2,0/83 %0.0
VENOUS THROMBOSIS LIMB,1/167 %0.6,0/83 %0.0

Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia(https://clinicaltrials.gov/show/NCT00906945)
 ,Dose Level 1,Dose Level 2,Dose Level 3,Dose Level 4,Dose Level 5,MTD - Phase II
 ,G-CSF 10 mcg/kg SQ on Days 1-8  Plerixafor 240 mcg/kg/d IV qd  Mitoxantrone 8 mg/m2/day IV once over 30 minutes daily on days 4-8  Etoposide 100 mg/m2/day IV once over 60 minutes daily on days 4-8  Cytarabine 1000 mg/m2/day IV once over 60 minutes daily on days 4-8,G-CSF 10 mcg/kg SQ on Days 1-8  Plerixafor 320 mcg/kg/d IV qd  Mitoxantrone 8 mg/m2/day IV once over 30 minutes daily on days 4-8  Etoposide 100 mg/m2/day IV once over 60 minutes daily on days 4-8  Cytarabine 1000 mg/m2/day IV once over 60 minutes daily on days 4-8,G-CSF 10 mcg/kg SQ on Days 1-8  Plerixafor 420 mcg/kg/d IV qd  Mitoxantrone 8 mg/m2/day IV once over 30 minutes daily on days 4-8  Etoposide 100 mg/m2/day IV once over 60 minutes daily on days 4-8  Cytarabine 1000 mg/m2/day IV once over 60 minutes daily on days 4-8,G-CSF 10 mcg/kg SQ on Days 1-8  Plerixafor 560 mcg/kg/d IV qd  Mitoxantrone 8 mg/m2/day IV once over 30 minutes daily on days 4-8  Etoposide 100 mg/m2/day IV once over 60 minutes daily on days 4-8  Cytarabine 1000 mg/m2/day IV once over 60 minutes daily on days 4-8,G-CSF 10 mcg/kg SQ on Days 1-8  Plerixafor 750 mcg/kg/d IV qd  Mitoxantrone 8 mg/m2/day IV once over 30 minutes daily on days 4-8  Etoposide 100 mg/m2/day IV once over 60 minutes daily on days 4-8  Cytarabine 1000 mg/m2/day IV once over 60 minutes daily on days 4-8,G-CSF MTD determined in Phase 1 SQ on Days 1-8  Plerixafor MTD determined in Phase 1 mcg/kg/d IV qd  Mitoxantrone 8 mg/m2/day IV once over 30 minutes daily on days 4-8  Etoposide 100 mg/m2/day IV once over 60 minutes daily on days 4-8  Cytarabine 1000 mg/m2/day IV once over 60 minutes daily on days 4-8
Total serious adverse events,0/3 %0.0,2/3 %66.67,0/3 %0.0,2/6 %33.33,2/6 %33.33,2/14 %14.29
Febrile neutropenia,0/3 %0.0,1/3 %33.33,0/3 %0.0,0/6 %0.0,0/6 %0.0,0/14 %0.0
Cardiac troponin increased,0/3 %0.0,1/3 %33.33,0/3 %0.0,0/6 %0.0,0/6 %0.0,0/14 %0.0
Lung infection,0/3 %0.0,1/3 %33.33,0/3 %0.0,1/6 %16.67,0/6 %0.0,0/14 %0.0
Sepsis,0/3 %0.0,0/3 %0.0,0/3 %0.0,2/6 %33.33,1/6 %16.67,1/14 %7.14
Body pain,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/6 %0.0,1/6 %16.67,0/14 %0.0
Bone pain,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/6 %0.0,1/6 %16.67,0/14 %0.0
Hypoxia,0/3 %0.0,0/3 %0.0,0/3 %0.0,1/6 %16.67,0/6 %0.0,0/14 %0.0
Hypotension,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/6 %0.0,1/6 %16.67,0/14 %0.0
Subdural hematoma,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/6 %0.0,0/6 %0.0,1/14 %7.14

Study of SCH 900776 (MK-8776) With and Without Cytarabine in Participants With Acute Leukemias (P05247)(https://clinicaltrials.gov/show/NCT00907517)
 ,MK-8776 10 mg/m^2 + Cytarabine 2 g/m^2,MK-8776 20 mg/m^2 + Cytarabine 2 g/m^2,MK-8776 40 mg/m^2 + Cytarabine 2 g/m^2,MK-8776 56 mg/m^2 + Cytarabine 2 g/m^2,MK-8776 140 mg + Cytarabine 2 g/m^2
 ,Participants received MK-8776 10 mg/m^2 IV on Days 2 and 3 and again on Days 11 and 12 PLUS cytarabine 2 g/m^2 IV via 72-hour CIV on Days 1 through 3 and repeated on Days 10 through 12 of a treatment cycle. The duration of one treatment cycle was to be approximately 4 to 6 weeks (until hospital discharge).,Participants received MK-8776 20 mg/m^2 IV on Days 2 and 3 and again on Days 11 and 12 PLUS cytarabine 2 g/m^2 IV via 72-hour CIV on Days 1 through 3 and repeated on Days 10 through 12 of a treatment cycle. The duration of one treatment cycle was to be approximately 4 to 6 weeks (until hospital discharge).,Participants received MK-8776 40 mg/m^2 IV on Days 2 and 3 and again on Days 11 and 12 PLUS cytarabine 2 g/m^2 IV via 72-hour CIV on Days 1 through 3 and repeated on Days 10 through 12 of a treatment cycle. The duration of one treatment cycle was to be approximately 4 to 6 weeks (until hospital discharge).,Participants received MK-8776 56 mg/m^2 IV on Days 2 and 3 and again on Days 11 and 12 PLUS cytarabine 2 g/m^2 IV via 72-hour CIV on Days 1 through 3 and repeated on Days 10 through 12 of a treatment cycle. The duration of one treatment cycle was to be approximately 4 to 6 weeks (until hospital discharge).,Participants received MK-8776 140 mg flat dose IV on Days 2 and 3 and again on Days 11 and 12 PLUS cytarabine 2 g/m^2 IV via 72-hour CIV on Days 1 through 3 and repeated on Days 10 through 12 of a treatment cycle. The duration of one treatment cycle was to be approximately 4 to 6 weeks (until hospital discharge).
Total serious adverse events,0/3 %0.0,0/3 %0.0,1/6 %16.67,2/6 %33.33,1/6 %16.67
FEBRILE NEUTROPENIA,0/3 %0.0,0/3 %0.0,0/6 %0.0,0/6 %0.0,1/6 %16.67
GASTRITIS,0/3 %0.0,0/3 %0.0,0/6 %0.0,0/6 %0.0,1/6 %16.67
NAUSEA,0/3 %0.0,0/3 %0.0,0/6 %0.0,1/6 %16.67,0/6 %0.0
VOMITING,0/3 %0.0,0/3 %0.0,0/6 %0.0,1/6 %16.67,0/6 %0.0
FUNGAL INFECTION,0/3 %0.0,0/3 %0.0,1/6 %16.67,0/6 %0.0,0/6 %0.0
PNEUMONIA,0/3 %0.0,0/3 %0.0,0/6 %0.0,1/6 %16.67,0/6 %0.0
PNEUMONIA FUNGAL,0/3 %0.0,0/3 %0.0,1/6 %16.67,0/6 %0.0,0/6 %0.0
SUBDURAL HAEMATOMA,0/3 %0.0,0/3 %0.0,0/6 %0.0,1/6 %16.67,0/6 %0.0
HEADACHE,0/3 %0.0,0/3 %0.0,0/6 %0.0,1/6 %16.67,0/6 %0.0
RENAL FAILURE ACUTE,0/3 %0.0,0/3 %0.0,0/6 %0.0,1/6 %16.67,0/6 %0.0
PULMONARY OEDEMA,0/3 %0.0,0/3 %0.0,0/6 %0.0,1/6 %16.67,0/6 %0.0
HYPERTENSION,0/3 %0.0,0/3 %0.0,0/6 %0.0,1/6 %16.67,0/6 %0.0

S0910 Epratuzumab  Cytarabine  and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia(https://clinicaltrials.gov/show/NCT00945815)
 ,Ara-C + Clofarabine + Epratuzumab
 ,Ara-C 1 g/m2/d IV Days 1-5 clofarabine 40 mg/m2/d IV Days 2-6 epratuzumab 360 mg/m2/d IV Days 7 14 21 28 acetaminophen 650 mg/d PO Days 7 14 21 28 dephenhydramine 50 mg/d IV Days 7 14 21 28 IT methotrexate 12 mg IT at least 1 wk apart during induction. 1 cycle=28 days. Maximum of one cycle.
Total serious adverse events,15/31 %48.39
Anemia,1/31 %3.23
Febrile neutropenia,6/31 %19.35
Cardiac arrest,2/31 %6.45
Abdominal pain,1/31 %3.23
Diarrhea,2/31 %6.45
Oral pain,1/31 %3.23
Typhlitis,1/31 %3.23
Death NOS,1/31 %3.23
Hepatic failure,1/31 %3.23
Catheter related infection,3/31 %9.68
Enterocolitis infectious,1/31 %3.23
Lung infection,3/31 %9.68
Sepsis,4/31 %12.9
Tooth infection,1/31 %3.23
Alanine aminotransferase increased,2/31 %6.45
Aspartate aminotransferase increased,2/31 %6.45
Investigations - Other specify,1/31 %3.23
Neutrophil count decreased,1/31 %3.23
Platelet count decreased,2/31 %6.45
Hypocalcemia,1/31 %3.23
Hypokalemia,1/31 %3.23
Hyponatremia,1/31 %3.23
Hypophosphatemia,1/31 %3.23
Encephalopathy,2/31 %6.45
Nervous system disorders - Other specify,1/31 %3.23
Transient ischemic attacks,1/31 %3.23
Acute kidney injury,1/31 %3.23
Hypoxia,1/31 %3.23
Respiratory failure,2/31 %6.45
Hypotension,1/31 %3.23

Ondansetron Versus Aprepitant Plus Ondansetron for Emesis(https://clinicaltrials.gov/show/NCT00954941)
 ,Group 1: Ondansetron,Group 2: Ondansetron + Aprepitant
 ,Ondansetron 8 mg bolus by vein from 30 minutes before receiving chemotherapy followed by 24 mg by vein continuous infusion daily while receiving chemotherapy until 12 hours after chemotherapy.,Ondansetron 8 mg bolus by vein from 30 minutes before receiving chemotherapy followed by 24 mg by vein continuous infusion daily while receiving chemotherapy until 12 hours after chemotherapy. Aprepitant 125 mg capsule by mouth every morning while receiving chemotherapy followed by 80 mg capsule by mouth daily while receiving chemotherapy continued till 1 day after last chemotherapy dose.
Total serious adverse events,3/46 %6.52,3/44 %6.82
Nausea,0/46 %0.0,1/44 %2.27
Nausea/Vomiting,1/46 %2.17,0/44 %0.0
Death,1/46 %2.17,0/44 %0.0
Headache,0/46 %0.0,2/44 %4.55
Syncope,1/46 %2.17,0/44 %0.0

Depocyt With Sorafenib in Neoplastic Meningitis(https://clinicaltrials.gov/show/NCT00964743)
 ,Intrathecal DepoCyt and Oral Sorafenib
 ,This is a single arm pilot study. Investigators planned to enroll approximately 10 patients to receive concurrent intrathecal DepoCyt and oral Sorafenib. DepoCyt: through a reservoir every 2 weeks for 5 doses then every 4 weeks for an additional 5 doses (a total of 10 DepoCyt treatments). Oral Sorafenib: at 400 mg twice a day throughout the treatment course until disease progression or death.
Total serious adverse events,2/2 %100.0
Death not associated with CTCAE term - Death not otherwise specified (NOS),1/2 %50.0
Death not associated with CTCAE term - Disease progression not otherwise specified (NOS),1/2 %50.0

RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia(https://clinicaltrials.gov/show/NCT00968253)
 ,Phase I: RAD001 5 mg + Combination Chemo,Phase I: RAD001 10 mg + Combination Chemo,Phase II: MTD RAD001 + Combination Chemo
 ,RAD001 oral dose 5 mg every other day before chemo + two different chemotherapy combinations during alternating cycles Hyper-CVAD on Odd Cycles and Methotrexate & Ara-C during Even Cycles.,RAD001 oral dose 10 mg every other day before chemo + two different chemotherapy combinations during alternating cycles Hyper-CVAD on Odd Cycles and Methotrexate & Ara-C during Even Cycles.,RAD001 MTD oral dose 5 mg every other day before chemo + two different chemotherapy combinations during alternating cycles Hyper-CVAD on Odd Cycles and Methotrexate & Ara-C during Even Cycles.
Total serious adverse events,1/3 %33.33,7/9 %77.78,11/12 %91.67
Febrile Neutropenia,0/3 %0.0,5/9 %55.56,1/12 %8.33
Neutropenic Fever,1/3 %33.33,0/9 %0.0,5/12 %41.67
Pancytopenia,0/3 %0.0,0/9 %0.0,1/12 %8.33
Hyponatremia,0/3 %0.0,0/9 %0.0,1/12 %8.33
Chest Pain,0/3 %0.0,0/9 %0.0,1/12 %8.33
Sinus Tachycardia,0/3 %0.0,1/9 %11.11,0/12 %0.0
Mucositis/Stomatitis,0/3 %0.0,4/9 %44.44,1/12 %8.33
Multi-Organ Failure,0/3 %0.0,0/9 %0.0,1/12 %8.33
Death,0/3 %0.0,2/9 %22.22,3/12 %25.0
Septic Shock,0/3 %0.0,0/9 %0.0,2/12 %16.67
Infection - E Coli Bacterium,0/3 %0.0,1/9 %11.11,1/12 %8.33
Pneumonia,0/3 %0.0,3/9 %33.33,2/12 %16.67
Alanine aminotransferase increased,0/3 %0.0,0/9 %0.0,1/12 %8.33
Aspartate aminotransferase increased,0/3 %0.0,0/9 %0.0,1/12 %8.33
Cystitis,0/3 %0.0,1/9 %11.11,0/12 %0.0
Pleural effusions,0/3 %0.0,0/9 %0.0,1/12 %8.33

Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma(https://clinicaltrials.gov/show/NCT00992446)
 ,Treatment (Chemotherapy ASCT Bortezomib Vorinostat))
 ,All patients receive carmustine IV over 3 hours on day -7; cytarabine IV BID over 3 hours and etoposide IV BID over 2 hours on days -6 to -3; and melphalan IV over 30 minutes on day -2. Only patients with history of CD20+ NHL receive additional rituximab IV on days -19 and -12. Patients undergo ASCT on day 0. Patients then receive bortezomib IV on days 2 and 8 and vorinostat PO QD on days 1-14. Treatment with bortezomib and vorinostat repeats for total of 12 courses in the absence of disease progression or unacceptable toxicity.  Autologous Hematopoietic Stem Cell Transplantation: Undergo ASCT  Bortezomib: Given IV  Carmustine: Given IV  Cytarabine: Given IV  Etoposide: Given IV  Melphalan: Given IV  Rituximab: Given IV  Vorinostat: Given PO
Total all-cause mortality,7/27 %25.93
Total serious adverse events,9/27 %33.33
Febrile neutropenia,2/27 %7.41
Atrial flutter/atrial fibrillation,2/27 %7.41
Abdominal pain/diarrhea,1/27 %3.7
Nausea vomiting and diarrhea requiring hospitalization,2/27 %7.41
Colitis,1/27 %3.7
Pneumonia,2/27 %7.41

Lenalidomide as Maintenance Therapy After Combination Chemotherapy With or Without Rituximab and Stem Cell Transplant in Treating Patients With Persistent or Recurrent Non-Hodgkin Lymphoma That Is Resistant to Chemotherapy(https://clinicaltrials.gov/show/NCT01035463)
 ,All Phase I Participants,All Phase II Participants
 ,Post AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION  MAINTENANCE THERAPY: Beginning approximately 100 days post-transplant patients receive lenalidomide PO on days 1-21. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.,Post AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION  MAINTENANCE THERAPY: Beginning approximately 100 days post-transplant patients receive lenalidomide PO on days 1-21. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.
Total all-cause mortality,4/19 %21.05,7/40 %17.5
Total serious adverse events,9/19 %47.37,6/40 %15.0
Febrile neutropenia,1/19 %5.26,0/40 %0.0
abdominal pain,1/19 %5.26,0/40 %0.0
rectal hemorrhage,1/19 %5.26,0/40 %0.0
Hepatobiliary disorders - Other,1/19 %5.26,0/40 %0.0
acute hepatitis,1/19 %5.26,0/40 %0.0
bronchial infection,1/19 %5.26,0/40 %0.0
Enterocolitis infectious,0/19 %0.0,1/40 %2.5
Infection and infestation Other,0/19 %0.0,1/40 %2.5
Neutrophil count decreased,0/19 %0.0,1/40 %2.5
dehydration,1/19 %5.26,0/40 %0.0
Transient ischemic attack,0/19 %0.0,1/40 %2.5
Respiratory throacic and mediastinal Other,0/19 %0.0,1/40 %2.5
skin and subcutaneous tissue disorder - Other,1/19 %5.26,1/40 %2.5
Surgical and medical procedures - Other,1/19 %5.26,0/40 %0.0

A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With Recurrent Glioblastoma(https://clinicaltrials.gov/show/NCT01044966)
 ,ITV DepoCyt + Temozolomide
 ,Patients will undergo an induction phase of intraventricular (ITV) DepoCyt using the dosage determined from the Phase I portionPatients with stable disease (clinically and radiographically) not exhibiting systemic toxicity will undergo a three month consolidation phase of ITV DepoCyt for one month (Cycles 3-6). Patients without progression or toxicity will undergo maintenance therapy using ITV DepoCyt every four weeks (+/- 3 days) for a maximum of 8 months (cycles 7-14) or until recurrence or toxicity ensues.  ITV DepoCyt + Temozolomide: Intrathecal liposomal Ara-C dosing will begin at 50 mg ITV every 2-4 weeks and de-escalated based on toxicity obtained from the Phase I portion of the trial. Metronomic dosing of temozolomide will be given at 75 mg/m2 for 21 days (continuous ora
Total all-cause mortality,12/12 %100.0
Total serious adverse events,1/12 %8.33
CSF leak,1/12 %8.33

Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML)(https://clinicaltrials.gov/show/NCT01074047)
 ,Azacitidine,BSC Only,Low-dose Cytarabine,Intensive Chemotherapy,Azacitidine-extension
 ,Azacitidine 75 mg/m^2/day by subcutaneous injection [SC] for 7 days every 28 days with a 21 day rest period (optimally for at least 6 cycles) plus best supportive care as needed including antibiotics and blood product transfusions growth factors per physician's discretion,Transfusion of blood products antibiotics antifungals and nutritional help,Low-dose cytarabine 20 mg subcutaneously twice a day (BID) for 10 days every 28 days plus BSC,Cytarabine 100-200 mg/m^2 as a continuous intravenous infusion (CIVI) for 7 days and daunorubicin 45 to 60 mg/m^ daily (QD) IV on Days 1 2 and 3 or Idarubicin 9-12 mg/m^ IV QD for 3 days. Consolidation Therapy (Cycle 2 and 3) = Cytarabine 100-200 mg/m^2 as a CIVI for 3 to 7 days and daunorubicin 45 to 60 mg/m^ QD or Idarubicin 9-12 mg/m^ IV QD on Days 1 and 2. The first consolidation therapy started between Day 28 and Day 70 from start of induction therapy upon recovery of absolute neutrophil count (ANC) above 1.0 x 10^9/L and platelets above 75 x 10^9/L. The second cycle started between Day 28 and Day 70 from start of first consolidation therapy. Best supportive care (BSC) of antibiotics and transfusions were given as needed,Azacitidine 75 mg/m^2/day by subcutaneous injection [SC] for 7 days every 28 days with a 21 day rest period (optimally for at least 6 cycles) plus best supportive care as needed including antibiotics and blood product transfusions growth factors per physician's discretion.
Total serious adverse events,188/236 %79.66,30/40 %75.0,118/153 %77.12,27/42 %64.29,10/22 %45.45
AGRANULOCYTOSIS,0/236 %0.0,0/40 %0.0,1/153 %0.65,0/42 %0.0,0/22 %0.0
ANAEMIA,10/236 %4.24,1/40 %2.5,11/153 %7.19,0/42 %0.0,1/22 %4.55
DISSEMINATED INTRAVASCULAR COAGULATION,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
FEBRILE BONE MARROW APLASIA,2/236 %0.85,0/40 %0.0,3/153 %1.96,0/42 %0.0,0/22 %0.0
FEBRILE NEUTROPENIA,59/236 %25.0,12/40 %30.0,38/153 %24.84,7/42 %16.67,4/22 %18.18
LEUKOCYTOSIS,4/236 %1.69,0/40 %0.0,1/153 %0.65,0/42 %0.0,0/22 %0.0
LEUKOPENIA,1/236 %0.42,0/40 %0.0,2/153 %1.31,0/42 %0.0,0/22 %0.0
LYMPHADENOPATHY,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
NEUTROPENIA,5/236 %2.12,1/40 %2.5,3/153 %1.96,1/42 %2.38,0/22 %0.0
PANCYTOPENIA,0/236 %0.0,0/40 %0.0,1/153 %0.65,0/42 %0.0,0/22 %0.0
THROMBOCYTOPENIA,6/236 %2.54,0/40 %0.0,14/153 %9.15,0/42 %0.0,0/22 %0.0
THROMBOTIC THROMBOCYTOPENIC PURPURA,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
ACUTE CORONARY SYNDROME,2/236 %0.85,0/40 %0.0,1/153 %0.65,0/42 %0.0,0/22 %0.0
ACUTE LEFT VENTRICULAR FAILURE,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
ACUTE MYOCARDIAL INFARCTION,3/236 %1.27,0/40 %0.0,0/153 %0.0,1/42 %2.38,0/22 %0.0
ANGINA PECTORIS,0/236 %0.0,0/40 %0.0,1/153 %0.65,0/42 %0.0,1/22 %4.55
ATRIAL FIBRILLATION,7/236 %2.97,1/40 %2.5,3/153 %1.96,2/42 %4.76,0/22 %0.0
CARDIAC ARREST,0/236 %0.0,0/40 %0.0,1/153 %0.65,0/42 %0.0,0/22 %0.0
CARDIAC FAILURE,2/236 %0.85,0/40 %0.0,1/153 %0.65,1/42 %2.38,0/22 %0.0
CARDIAC FAILURE ACUTE,0/236 %0.0,0/40 %0.0,0/153 %0.0,1/42 %2.38,0/22 %0.0
CARDIAC FAILURE CONGESTIVE,0/236 %0.0,1/40 %2.5,0/153 %0.0,0/42 %0.0,0/22 %0.0
CARDIO-RESPIRATORY ARREST,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
CARDIOVASCULAR INSUFFICIENCY,1/236 %0.42,0/40 %0.0,2/153 %1.31,1/42 %2.38,0/22 %0.0
ISCHAEMIC CARDIOMYOPATHY,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
LEFT VENTRICULAR FAILURE,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
MYOCARDIAL INFARCTION,0/236 %0.0,0/40 %0.0,1/153 %0.65,0/42 %0.0,1/22 %4.55
PERICARDIAL EFFUSION,1/236 %0.42,0/40 %0.0,0/153 %0.0,1/42 %2.38,0/22 %0.0
PERICARDITIS,1/236 %0.42,0/40 %0.0,1/153 %0.65,0/42 %0.0,0/22 %0.0
SUPRAVENTRICULAR TACHYCARDIA,0/236 %0.0,0/40 %0.0,1/153 %0.65,0/42 %0.0,0/22 %0.0
VENTRICULAR TACHYCARDIA,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
CATARACT,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
CONJUNCTIVAL HAEMORRHAGE,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
ABDOMINAL PAIN,1/236 %0.42,0/40 %0.0,1/153 %0.65,0/42 %0.0,1/22 %4.55
ABDOMINAL PAIN LOWER,0/236 %0.0,0/40 %0.0,2/153 %1.31,0/42 %0.0,0/22 %0.0
ANAL HAEMORRHAGE,0/236 %0.0,1/40 %2.5,1/153 %0.65,0/42 %0.0,0/22 %0.0
ASCITES,0/236 %0.0,0/40 %0.0,0/153 %0.0,1/42 %2.38,0/22 %0.0
COLITIS,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
CONSTIPATION,0/236 %0.0,0/40 %0.0,0/153 %0.0,0/42 %0.0,1/22 %4.55
DIARRHOEA,4/236 %1.69,0/40 %0.0,4/153 %2.61,0/42 %0.0,0/22 %0.0
DIVERTICULUM INTESTINAL,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
DUODENAL ULCER HAEMORRHAGE,0/236 %0.0,0/40 %0.0,0/153 %0.0,0/42 %0.0,1/22 %4.55
DYSPHAGIA,0/236 %0.0,0/40 %0.0,1/153 %0.65,0/42 %0.0,0/22 %0.0
ENTERITIS,0/236 %0.0,1/40 %2.5,0/153 %0.0,0/42 %0.0,0/22 %0.0
ENTEROCOLITIS,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
GASTRITIS,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
GASTROINTESTINAL HAEMORRHAGE,1/236 %0.42,1/40 %2.5,4/153 %2.61,0/42 %0.0,0/22 %0.0
HAEMATEMESIS,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
ILEUS,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
INTESTINAL ISCHAEMIA,0/236 %0.0,0/40 %0.0,0/153 %0.0,0/42 %0.0,1/22 %4.55
INTESTINAL OBSTRUCTION,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
MELAENA,1/236 %0.42,0/40 %0.0,1/153 %0.65,0/42 %0.0,0/22 %0.0
MOUTH HAEMORRHAGE,1/236 %0.42,1/40 %2.5,0/153 %0.0,0/42 %0.0,0/22 %0.0
NAUSEA,2/236 %0.85,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
RECTAL HAEMORRHAGE,1/236 %0.42,0/40 %0.0,1/153 %0.65,0/42 %0.0,0/22 %0.0
RECTAL ULCER,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
STOMATITIS,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,1/22 %4.55
UPPER GASTROINTESTINAL HAEMORRHAGE,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
VOMITING,2/236 %0.85,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
ASTHENIA,4/236 %1.69,1/40 %2.5,3/153 %1.96,0/42 %0.0,0/22 %0.0
CHEST PAIN,0/236 %0.0,0/40 %0.0,2/153 %1.31,1/42 %2.38,0/22 %0.0
CHILLS,1/236 %0.42,0/40 %0.0,1/153 %0.65,0/42 %0.0,0/22 %0.0
DEATH,3/236 %1.27,0/40 %0.0,2/153 %1.31,0/42 %0.0,0/22 %0.0
FATIGUE,3/236 %1.27,0/40 %0.0,1/153 %0.65,1/42 %2.38,0/22 %0.0
GENERAL PHYSICAL HEALTH DETERIORATION,1/236 %0.42,0/40 %0.0,1/153 %0.65,0/42 %0.0,0/22 %0.0
HYPERTHERMIA,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
INJECTION SITE EXTRAVASATION,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
INJECTION SITE REACTION,2/236 %0.85,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
MALAISE,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
MULTI-ORGAN FAILURE,1/236 %0.42,0/40 %0.0,2/153 %1.31,0/42 %0.0,0/22 %0.0
OEDEMA PERIPHERAL,0/236 %0.0,1/40 %2.5,0/153 %0.0,0/42 %0.0,0/22 %0.0
PAIN,1/236 %0.42,0/40 %0.0,1/153 %0.65,0/42 %0.0,0/22 %0.0
PYREXIA,25/236 %10.59,3/40 %7.5,16/153 %10.46,2/42 %4.76,0/22 %0.0
SUDDEN CARDIAC DEATH,1/236 %0.42,0/40 %0.0,1/153 %0.65,0/42 %0.0,0/22 %0.0
SUDDEN DEATH,2/236 %0.85,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
CHOLANGITIS,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
CHOLECYSTITIS,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
CHOLECYSTITIS ACUTE,1/236 %0.42,0/40 %0.0,1/153 %0.65,1/42 %2.38,0/22 %0.0
CHOLELITHIASIS,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
HEPATIC FAILURE,0/236 %0.0,0/40 %0.0,2/153 %1.31,0/42 %0.0,0/22 %0.0
HYPERBILIRUBINAEMIA,0/236 %0.0,0/40 %0.0,0/153 %0.0,0/42 %0.0,1/22 %4.55
ANAPHYLACTIC SHOCK,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
ABSCESS NECK,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
ABSCESS SOFT TISSUE,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
ACUTE SINUSITIS,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
AEROMONA INFECTION,0/236 %0.0,0/40 %0.0,1/153 %0.65,0/42 %0.0,0/22 %0.0
ANAL ABSCESS,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
APPENDICITIS,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
ARTHRITIS INFECTIVE,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
ASPERGILLUS INFECTION,0/236 %0.0,1/40 %2.5,0/153 %0.0,0/42 %0.0,0/22 %0.0
BACTERAEMIA,2/236 %0.85,0/40 %0.0,1/153 %0.65,0/42 %0.0,1/22 %4.55
BRONCHITIS,3/236 %1.27,0/40 %0.0,1/153 %0.65,0/42 %0.0,0/22 %0.0
BRONCHOPNEUMONIA,4/236 %1.69,1/40 %2.5,1/153 %0.65,0/42 %0.0,0/22 %0.0
BRONCHOPULMONARY ASPERGILLOSIS,3/236 %1.27,1/40 %2.5,0/153 %0.0,0/42 %0.0,1/22 %4.55
CANDIDA INFECTION,0/236 %0.0,0/40 %0.0,1/153 %0.65,0/42 %0.0,0/22 %0.0
CELLULITIS,5/236 %2.12,4/40 %10.0,3/153 %1.96,1/42 %2.38,0/22 %0.0
CELLULITIS ORBITAL,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
CLOSTRIDIUM DIFFICILE COLITIS,2/236 %0.85,0/40 %0.0,1/153 %0.65,0/42 %0.0,0/22 %0.0
CLOSTRIDIUM DIFFICILE INFECTION,1/236 %0.42,0/40 %0.0,1/153 %0.65,0/42 %0.0,0/22 %0.0
CORYNEBACTERIUM SEPSIS,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
CYSTITIS,0/236 %0.0,0/40 %0.0,1/153 %0.65,0/42 %0.0,0/22 %0.0
DEVICE RELATED INFECTION,0/236 %0.0,0/40 %0.0,1/153 %0.65,0/42 %0.0,0/22 %0.0
DEVICE RELATED SEPSIS,2/236 %0.85,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
DIVERTICULITIS,4/236 %1.69,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
ENTEROBACTER PNEUMONIA,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
ENTEROCOCCAL BACTERAEMIA,0/236 %0.0,1/40 %2.5,1/153 %0.65,0/42 %0.0,0/22 %0.0
ENTEROCOCCAL SEPSIS,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
EPIGLOTTITIS,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
ERYSIPELAS,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
ESCHERICHIA BACTERAEMIA,3/236 %1.27,0/40 %0.0,1/153 %0.65,0/42 %0.0,0/22 %0.0
ESCHERICHIA INFECTION,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
ESCHERICHIA SEPSIS,4/236 %1.69,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
FURUNCLE,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
GASTROENTERITIS,1/236 %0.42,0/40 %0.0,1/153 %0.65,0/42 %0.0,0/22 %0.0
GASTROENTERITIS CLOSTRIDIAL,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
GASTROINTESTINAL FUNGAL INFECTION,0/236 %0.0,0/40 %0.0,1/153 %0.65,0/42 %0.0,0/22 %0.0
GROIN ABSCESS,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
HERPES ZOSTER,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
INFECTED CYST,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
INFECTION,0/236 %0.0,0/40 %0.0,1/153 %0.65,0/42 %0.0,1/22 %4.55
INFECTIVE EXACERBATION OF CHRONIC OBSTRUCTIVE AIRWAYS DISEASE,0/236 %0.0,0/40 %0.0,1/153 %0.65,0/42 %0.0,0/22 %0.0
KLEBSIELLA BACTERAEMIA,0/236 %0.0,0/40 %0.0,1/153 %0.65,0/42 %0.0,0/22 %0.0
KLEBSIELLA SEPSIS,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
LIVER ABSCESS,0/236 %0.0,0/40 %0.0,0/153 %0.0,0/42 %0.0,1/22 %4.55
LOBAR PNEUMONIA,2/236 %0.85,0/40 %0.0,2/153 %1.31,0/42 %0.0,0/22 %0.0
LOWER RESPIRATORY TRACT INFECTION,1/236 %0.42,1/40 %2.5,1/153 %0.65,0/42 %0.0,0/22 %0.0
LUNG ABSCESS,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
LUNG INFECTION,2/236 %0.85,0/40 %0.0,1/153 %0.65,0/42 %0.0,0/22 %0.0
MUMPS,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
NASOPHARYNGITIS,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
NEUTROPENIC SEPSIS,7/236 %2.97,2/40 %5.0,4/153 %2.61,1/42 %2.38,0/22 %0.0
ORAL CANDIDIASIS,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
OROPHARYNGITIS FUNGAL,0/236 %0.0,0/40 %0.0,0/153 %0.0,1/42 %2.38,0/22 %0.0
PARAINFLUENZAE VIRUS INFECTION,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
PERIORBITAL CELLULITIS,0/236 %0.0,1/40 %2.5,0/153 %0.0,0/42 %0.0,0/22 %0.0
PERIRECTAL ABSCESS,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
PERITONITIS,0/236 %0.0,0/40 %0.0,1/153 %0.65,0/42 %0.0,0/22 %0.0
PHARYNGITIS,2/236 %0.85,0/40 %0.0,2/153 %1.31,0/42 %0.0,0/22 %0.0
PHARYNGOTONSILLITIS,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
PNEUMONIA,48/236 %20.34,3/40 %7.5,29/153 %18.95,3/42 %7.14,2/22 %9.09
PNEUMONIA FUNGAL,3/236 %1.27,0/40 %0.0,1/153 %0.65,0/42 %0.0,0/22 %0.0
PNEUMONIA KLEBSIELLA,0/236 %0.0,0/40 %0.0,1/153 %0.65,0/42 %0.0,0/22 %0.0
PNEUMONIA MYCOPLASMAL,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
PNEUMONIA PARAINFLUENZAE VIRAL,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
PNEUMONIA PSEUDOMONAS AERUGINOSA,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
PNEUMONIA STAPHYLOCOCCAL,0/236 %0.0,0/40 %0.0,1/153 %0.65,0/42 %0.0,0/22 %0.0
PNEUMONIA STREPTOCOCCAL,0/236 %0.0,0/40 %0.0,0/153 %0.0,1/42 %2.38,0/22 %0.0
PSEUDOMEMBRANOUS COLITIS,3/236 %1.27,0/40 %0.0,1/153 %0.65,0/42 %0.0,0/22 %0.0
PSEUDOMONAL BACTERAEMIA,0/236 %0.0,0/40 %0.0,1/153 %0.65,0/42 %0.0,1/22 %4.55
PSEUDOMONAL SEPSIS,3/236 %1.27,0/40 %0.0,2/153 %1.31,0/42 %0.0,0/22 %0.0
RESPIRATORY TRACT INFECTION,0/236 %0.0,2/40 %5.0,2/153 %1.31,0/42 %0.0,0/22 %0.0
SEPSIS,12/236 %5.08,1/40 %2.5,9/153 %5.88,2/42 %4.76,0/22 %0.0
SEPTIC SHOCK,4/236 %1.69,1/40 %2.5,4/153 %2.61,4/42 %9.52,0/22 %0.0
SINUSITIS,3/236 %1.27,0/40 %0.0,0/153 %0.0,0/42 %0.0,1/22 %4.55
SINUSITIS FUNGAL,0/236 %0.0,0/40 %0.0,0/153 %0.0,1/42 %2.38,0/22 %0.0
SOFT TISSUE INFECTION,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
STAPHYLOCOCCAL BACTERAEMIA,1/236 %0.42,0/40 %0.0,0/153 %0.0,1/42 %2.38,0/22 %0.0
STAPHYLOCOCCAL SEPSIS,0/236 %0.0,0/40 %0.0,0/153 %0.0,1/42 %2.38,0/22 %0.0
SYSTEMIC CANDIDA,0/236 %0.0,0/40 %0.0,0/153 %0.0,0/42 %0.0,1/22 %4.55
TONSILLITIS,0/236 %0.0,0/40 %0.0,2/153 %1.31,0/42 %0.0,0/22 %0.0
TOOTH INFECTION,2/236 %0.85,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
UPPER RESPIRATORY TRACT INFECTION,2/236 %0.85,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
URINARY TRACT INFECTION,7/236 %2.97,1/40 %2.5,3/153 %1.96,0/42 %0.0,0/22 %0.0
UROSEPSIS,2/236 %0.85,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
VAGINITIS GARDNERELLA,0/236 %0.0,0/40 %0.0,1/153 %0.65,0/42 %0.0,0/22 %0.0
VULVAL ABSCESS,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
ZYGOMYCOSIS,0/236 %0.0,0/40 %0.0,0/153 %0.0,1/42 %2.38,0/22 %0.0
ALLERGIC TRANSFUSION REACTION,0/236 %0.0,0/40 %0.0,1/153 %0.65,0/42 %0.0,0/22 %0.0
ANKLE FRACTURE,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
CONCUSSION,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
CRANIOCEREBRAL INJURY,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
FALL,2/236 %0.85,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
FEMUR FRACTURE,1/236 %0.42,0/40 %0.0,1/153 %0.65,0/42 %0.0,0/22 %0.0
HIP FRACTURE,0/236 %0.0,0/40 %0.0,1/153 %0.65,0/42 %0.0,0/22 %0.0
LIGAMENT SPRAIN,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
RIB FRACTURE,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
ROAD TRAFFIC ACCIDENT,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
SUBDURAL HAEMATOMA,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
TENDON RUPTURE,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
TRANSFUSION REACTION,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
TROPONIN INCREASED,0/236 %0.0,0/40 %0.0,0/153 %0.0,1/42 %2.38,0/22 %0.0
URINE OUTPUT DECREASED,0/236 %0.0,1/40 %2.5,0/153 %0.0,0/42 %0.0,0/22 %0.0
WEIGHT DECREASED,0/236 %0.0,0/40 %0.0,1/153 %0.65,0/42 %0.0,0/22 %0.0
CACHEXIA,1/236 %0.42,0/40 %0.0,2/153 %1.31,0/42 %0.0,0/22 %0.0
DECREASED APPETITE,0/236 %0.0,0/40 %0.0,0/153 %0.0,0/42 %0.0,1/22 %4.55
DEHYDRATION,3/236 %1.27,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
FAILURE TO THRIVE,0/236 %0.0,0/40 %0.0,1/153 %0.65,0/42 %0.0,0/22 %0.0
FLUID OVERLOAD,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
HYPERGLYCAEMIA,0/236 %0.0,1/40 %2.5,0/153 %0.0,0/42 %0.0,0/22 %0.0
HYPOKALAEMIA,2/236 %0.85,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
HYPONATRAEMIA,2/236 %0.85,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
TUMOUR LYSIS SYNDROME,0/236 %0.0,0/40 %0.0,1/153 %0.65,0/42 %0.0,0/22 %0.0
ARTHRALGIA,2/236 %0.85,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
ARTHRITIS,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
BACK PAIN,3/236 %1.27,0/40 %0.0,1/153 %0.65,0/42 %0.0,0/22 %0.0
BONE PAIN,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
HAEMARTHROSIS,0/236 %0.0,0/40 %0.0,1/153 %0.65,0/42 %0.0,0/22 %0.0
MUSCULAR WEAKNESS,2/236 %0.85,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
MYALGIA,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
OSTEOARTHRITIS,0/236 %0.0,0/40 %0.0,0/153 %0.0,0/42 %0.0,1/22 %4.55
PAIN IN EXTREMITY,0/236 %0.0,1/40 %2.5,0/153 %0.0,0/42 %0.0,0/22 %0.0
SPINAL OSTEOARTHRITIS,0/236 %0.0,0/40 %0.0,1/153 %0.65,0/42 %0.0,0/22 %0.0
ACUTE MYELOID LEUKAEMIA,26/236 %11.02,12/40 %30.0,17/153 %11.11,0/42 %0.0,1/22 %4.55
CHLOROMA,2/236 %0.85,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
LEUKAEMIC INFILTRATION BRAIN,0/236 %0.0,0/40 %0.0,1/153 %0.65,0/42 %0.0,0/22 %0.0
OVARIAN CANCER METASTATIC,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
TUMOUR FLARE,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
CEREBRAL HAEMORRHAGE,1/236 %0.42,2/40 %5.0,0/153 %0.0,1/42 %2.38,0/22 %0.0
CEREBRAL INFARCTION,2/236 %0.85,0/40 %0.0,0/153 %0.0,0/42 %0.0,1/22 %4.55
CEREBROVASCULAR ACCIDENT,1/236 %0.42,0/40 %0.0,2/153 %1.31,0/42 %0.0,0/22 %0.0
COGNITIVE DISORDER,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
CONVULSION,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
DIZZINESS,5/236 %2.12,0/40 %0.0,0/153 %0.0,0/42 %0.0,1/22 %4.55
FEBRILE CONVULSION,0/236 %0.0,1/40 %2.5,0/153 %0.0,0/42 %0.0,0/22 %0.0
HAEMORRHAGE INTRACRANIAL,2/236 %0.85,0/40 %0.0,0/153 %0.0,1/42 %2.38,0/22 %0.0
HEADACHE,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
LOSS OF CONSCIOUSNESS,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
ORTHOSTATIC INTOLERANCE,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
PRESYNCOPE,2/236 %0.85,1/40 %2.5,0/153 %0.0,0/42 %0.0,0/22 %0.0
SUBARACHNOID HAEMORRHAGE,2/236 %0.85,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
SYNCOPE,4/236 %1.69,0/40 %0.0,2/153 %1.31,1/42 %2.38,1/22 %4.55
TRANSIENT ISCHAEMIC ATTACK,0/236 %0.0,0/40 %0.0,1/153 %0.65,0/42 %0.0,0/22 %0.0
CONFUSIONAL STATE,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
BLADDER MASS,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
HAEMATURIA,0/236 %0.0,1/40 %2.5,0/153 %0.0,0/42 %0.0,1/22 %4.55
RENAL COLIC,0/236 %0.0,0/40 %0.0,1/153 %0.65,0/42 %0.0,0/22 %0.0
RENAL FAILURE,3/236 %1.27,0/40 %0.0,2/153 %1.31,0/42 %0.0,0/22 %0.0
RENAL FAILURE ACUTE,3/236 %1.27,0/40 %0.0,2/153 %1.31,1/42 %2.38,0/22 %0.0
RENAL FAILURE CHRONIC,0/236 %0.0,1/40 %2.5,0/153 %0.0,0/42 %0.0,0/22 %0.0
RENAL IMPAIRMENT,0/236 %0.0,1/40 %2.5,0/153 %0.0,0/42 %0.0,0/22 %0.0
RENAL TUBULAR NECROSIS,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
URINARY RETENTION,0/236 %0.0,0/40 %0.0,1/153 %0.65,0/42 %0.0,0/22 %0.0
ACUTE PULMONARY OEDEMA,1/236 %0.42,0/40 %0.0,1/153 %0.65,0/42 %0.0,0/22 %0.0
ACUTE RESPIRATORY DISTRESS SYNDROME,1/236 %0.42,0/40 %0.0,0/153 %0.0,1/42 %2.38,0/22 %0.0
ACUTE RESPIRATORY FAILURE,2/236 %0.85,0/40 %0.0,0/153 %0.0,1/42 %2.38,0/22 %0.0
ASTHMA,0/236 %0.0,1/40 %2.5,0/153 %0.0,0/42 %0.0,0/22 %0.0
CHRONIC OBSTRUCTIVE PULMONARY DISEASE,0/236 %0.0,0/40 %0.0,1/153 %0.65,0/42 %0.0,0/22 %0.0
DYSPNOEA,5/236 %2.12,1/40 %2.5,3/153 %1.96,1/42 %2.38,0/22 %0.0
EPISTAXIS,2/236 %0.85,0/40 %0.0,1/153 %0.65,0/42 %0.0,0/22 %0.0
LUNG DISORDER,1/236 %0.42,0/40 %0.0,2/153 %1.31,0/42 %0.0,0/22 %0.0
ORGANISING PNEUMONIA,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
OROPHARYNGEAL PAIN,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
PLEURAL EFFUSION,2/236 %0.85,0/40 %0.0,2/153 %1.31,1/42 %2.38,0/22 %0.0
PNEUMONIA ASPIRATION,0/236 %0.0,1/40 %2.5,0/153 %0.0,0/42 %0.0,0/22 %0.0
PNEUMONITIS,1/236 %0.42,0/40 %0.0,1/153 %0.65,0/42 %0.0,0/22 %0.0
PRODUCTIVE COUGH,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
PULMONARY ALVEOLAR HAEMORRHAGE,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
PULMONARY EMBOLISM,1/236 %0.42,0/40 %0.0,1/153 %0.65,0/42 %0.0,0/22 %0.0
PULMONARY HAEMORRHAGE,0/236 %0.0,1/40 %2.5,1/153 %0.65,0/42 %0.0,0/22 %0.0
PULMONARY OEDEMA,2/236 %0.85,0/40 %0.0,2/153 %1.31,0/42 %0.0,0/22 %0.0
RESPIRATORY FAILURE,3/236 %1.27,1/40 %2.5,6/153 %3.92,2/42 %4.76,0/22 %0.0
SKIN ULCER,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
DEEP VEIN THROMBOSIS,2/236 %0.85,1/40 %2.5,0/153 %0.0,0/42 %0.0,0/22 %0.0
HAEMATOMA,2/236 %0.85,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
HYPERTENSION,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
HYPOTENSION,4/236 %1.69,1/40 %2.5,0/153 %0.0,0/42 %0.0,0/22 %0.0
PERIPHERAL ISCHAEMIA,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
PHLEBITIS,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0
THROMBOPHLEBITIS SUPERFICIAL,1/236 %0.42,0/40 %0.0,0/153 %0.0,0/42 %0.0,0/22 %0.0

Autologous Transplant in HIV Patients (BMT CTN 0803)(https://clinicaltrials.gov/show/NCT01141712)
 ,Autologous Transplant
 ,Patients will receive BCNU 300 mg/m^2 Day -6 Etoposide 100 mg/m^2 BID Days -5 to -2 Cytarabine 100 mg/m^2 BID Days -5 to -2 and Melphalan 140 mg/m^2 Day -1 followed by autologous HCT.
Total serious adverse events,6/40 %15.0
Febrile neutropenia,1/40 %2.5
Angina pectoris,1/40 %2.5
Odynophagia,1/40 %2.5
Septic shock,1/40 %2.5
Deep vein thrombosis,2/40 %5.0

Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia(https://clinicaltrials.gov/show/NCT01158885)
 ,Single Arm
 ,Clofarabine Cytarabine Methotrexate  See detailed description in Interventions section.
Total all-cause mortality,0/2 %0.0
Total serious adverse events,1/2 %50.0
Febrile neutropenia,1/2 %50.0
Platelet count decreased,1/2 %50.0
Grade 4 Infection,1/2 %50.0

Alvocidib  Cytarabine  and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia(https://clinicaltrials.gov/show/NCT01349972)
 ,Arm I (Alvocidib Cytarabine Mitoxantrone Hydrochloride),Arm II (Cytarabine Daunorubicin Hydrochloride)
 ,Patients receive alvocidib IV over 1 hour on days 1-3 cytarabine IV over 72 hours on days 6-8 and mitoxantrone hydrochloride IV over 1-2 hours on day 9. Patients who achieve complete or partial response to the first course (completion of all doses) may receive a second course of treatment or high-dose cytarabine after 21-63 days following blood count recovery and/or undergo allogeneic bone marrow transplant.  alvocidib: Given IV  mitoxantrone hydrochloride: Given IV  cytarabine: Given IV,Patients receive cytarabine IV continuously on days 1-7 and daunorubicin hydrochloride IV on days 1-3. Patients who have residual disease on day 14 may receive additional cytarabine for 5 days and daunorubicin hydrochloride for 2 days.  daunorubicin hydrochloride: Given IV  cytarabine: Given IV
Total serious adverse events,53/114 %46.49,21/58 %36.21
bone marrow hypocellular,1/114 %0.88,0/58 %0.0
Disseminated Intravascular Coagulation,2/114 %1.75,1/58 %1.72
febrile neutropenia,1/114 %0.88,0/58 %0.0
atrial fibrillation,1/114 %0.88,2/58 %3.45
cardiac chest pain,1/114 %0.88,0/58 %0.0
heart failure,2/114 %1.75,0/58 %0.0
left ventricular systolic dysfunction,5/114 %4.39,0/58 %0.0
myocardial infarction,2/114 %1.75,0/58 %0.0
pericardial effusion,1/114 %0.88,0/58 %0.0
pericarditis,1/114 %0.88,1/58 %1.72
thyrotoxicosis,1/114 %0.88,0/58 %0.0
ileal perforation,1/114 %0.88,0/58 %0.0
peritoneal necrosis,1/114 %0.88,0/58 %0.0
small intestinal obstruction,1/114 %0.88,0/58 %0.0
gastrointestinal hemmorrhage,1/114 %0.88,1/58 %1.72
death,1/114 %0.88,0/58 %0.0
fever,2/114 %1.75,0/58 %0.0
cytokine release syndrome,3/114 %2.63,2/58 %3.45
sogt tissue infection,1/114 %0.88,0/58 %0.0
appendicitis,1/114 %0.88,0/58 %0.0
lung infection,2/114 %1.75,0/58 %0.0
sepsis,1/114 %0.88,0/58 %0.0
blood bilirubin increased,2/114 %1.75,0/58 %0.0
creatinine increased,1/114 %0.88,0/58 %0.0
QTc prolonged,1/114 %0.88,0/58 %0.0
alkaline phosphatase increased,0/114 %0.0,1/58 %1.72
dehydration,1/114 %0.88,0/58 %0.0
hyperglycemia,1/114 %0.88,1/58 %1.72
hypokalemia,0/114 %0.0,1/58 %1.72
hyponatremia,1/114 %0.88,1/58 %1.72
hypocalcemia,1/114 %0.88,0/58 %0.0
hypophosphatemia,2/114 %1.75,2/58 %3.45
tumor lysis syndrome,4/114 %3.51,1/58 %1.72
seizure,1/114 %0.88,0/58 %0.0
acute kidney injury,2/114 %1.75,2/58 %3.45
chronic kidney disease,0/114 %0.0,1/58 %1.72
renal insufficiency,1/114 %0.88,0/58 %0.0
necrotic bladder,1/114 %0.88,0/58 %0.0
adult respiratory distress syndrome,0/114 %0.0,1/58 %1.72
hypoxia,0/114 %0.0,1/58 %1.72
thrombotic event,1/114 %0.88,0/58 %0.0
capillary leak syndrome,0/114 %0.0,1/58 %1.72
hypertension,0/114 %0.0,1/58 %1.72

Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia(https://clinicaltrials.gov/show/NCT01371981)
 ,Arm A,Arm B,Arm C (Cohort 1),Arm C (Cohort 2),Arm C (Cohort 3),Arm D
 ,INDUCTION (IND) 1Pts receive intrathecal (IT) cytarabine on day 1 and ADE with IV cytarabine over 1-30 minutes on days 1-10; daunorubicin hydrochloride IV over 1-15 minutes days1 3 5; etoposide IV 1-2 hours days1-5.  IND IILow risk (LR) pts receive cytarabine IT and ADE chemotherapy as in INDI. High risk (HR) cytarabine IT day 1 MA chemo comprising high-dose cytarabine IV over 1-3 hours days1-4 mitoxantrone IV over 15-30 minutes days 3-6. INTENSIFICATION (INT) I: cytarabine IT day 1 AE chemo with high-dose cytarabine IV over 1-3 hours etoposide IV over 1-2 hours days 1-5. INT II: LR-cytarabine IT day 1; Induction II MA chemo. HR and no SCT donor - high-dose cytarabine IV over 3 hours days1 2 8 9; asparaginase intramuscularly (IM) days29.  SCT:  : pts receive fludarabine phosphate IV over 30 minutes once daily days -5 to -2 busulfan IV over 2 hours 4 times daily days -5 to -2.  Allogeneic SCT within 36 to 48 hours after last busulfan dose. Pts receive GVHD prophylaxis.,IND I: Pts receive cytarabine IT and ADE chemotherapy as in Induction I Arm A. Patients also receive bortezomib IV over 3-5 seconds on days 1 4 8.  IND II: LR pts receive cytarabine IT ADE chemotherapy bortezomib as in IND I. HR pts receive cytarabine IT MA as in IND II Arm A (HR patients) and bortezomib IV on days 1 4 8.  INT I: Pts receive cytarabine IT and AE in Arm A Intensification II and bortezomib IV on days 1 4 8. INT II: LR pts receive cytarabine IT on day 1 MA as in Arm A IND II (HR patients) and bortezomib IV on days 1 4 8. HR pts with no donor for SCT receive high-dose cytarabine IV over 3 hours on days 1 2 8 9 and asparaginase intramuscularly (IM) on days 2 and 9.  SCT - Pts receive fludarabine phosphate IV over 30 minutes once daily on days -5 to -2 and busulfan IV over 2 hours 4 times daily on days -5 to -2.Pts undergo allogeneic SCT within 36 to 48 hours after the last dose of busulfan. Pts receive GVHD prophylaxis.,IND II: Pts receive cytarabine IT on day 1 cytarabine IV over 1-30 minutes on days 1-8 daunorubicin hydrochloride IV over 1-15 minutes on days 1 3 and 5 etoposide IV over 1-2 hours on days 1-5 sorafenib tosylate PO on days 9-36.  INT I: Pts receive cytarabine IT and AE chemotherapy in Arm A Intensification II and sorafenib tosylate PO on daily on days 6-28.  INT II: Pts receive cytarabine IT on day 1 MA chemotherapy as in Arm A Induction II (HR patients) sorafenib tosylate PO on days 7-34.  SCT (HR patients with matched family [MFD] or unrelated donor):  Pts receive fludarabine phosphate IV over 30 minutes once daily on days -5 to -2 busulfan IV over 2 hours 4 times daily on days -5 to -2.  Patients undergo allogeneic SCT within 36 to 48 hours after the last dose of busulfan. Pts receive GVHD prophylaxis.  MAINTENANCE: Pts receive sorafenib tosylate PO starting day 40-100 after INT II or SCT for one year.,IND I: Pts receive cytarabine IT & ADE as in Arm A IND I & sorafenib tosylate PO at the time of known HR FLT3/ITD+ (including IND I & concurrently with chemo).  IND II: Pts receive cytarabine IT day (d) 1 cytarabine IV over 1-30 minutes on d 1-8 daunorubicin hydrochloride IV over 1-15 minutes days 1 3 5 etoposide IV over 1-2 hours d 1-5 sorafenib tosylate PO d 9-36.  INTE I: Pts receive cytarabine IT and AE in Arm A INT II and sorafenib tosylate PO on daily d 6-28.  INT II: Pts receive cytarabine IT on d 1 MA as in Arm A IND II (HR pts) sorafenib tosylate PO d 7-34.  SCT (HR patients with matched family [MFD] or unrelated donor):  Pts receive fludarabine phosphate IV over 30 minutes once daily on d -5 to -2 busulfan IV over 2 hours 4 times daily d -5 to -2.  Pts undergo allogeneic SCT within 36-48 hours after last busulfan dose. Pts receive GVHD prophylaxis. MAINTENANCE: Pts receive sorafenib tosylate PO starting d 40-100 after INT II or SCT for 1 year.,IND I: Pts receive cytarabine IT & ADE as in Arm A IND I & sorafenib tosylate PO days 11-28.  IND II: Pts receive cytarabine IT day 1 cytarabine IV over 1-30 minutes on days 1-8 daunorubicin hydrochloride IV over 1-15 minutes days 1 3 5 etoposide IV over 1-2 hours days 1-5 sorafenib tosylate PO days 9-36.  INT I: Pts receive cytarabine IT & AE cin Arm A INT II & sorafenib tosylate PO daily days 6-28.  INT II: Pts receive cytarabine IT day 1 MA as in Arm A IND II (HR patients) & sorafenib tosylate PO days 7-34.  SCT (HR patients with matched family [MFD] or unrelated donor):  Pts receive fludarabine phosphate IV over 30 minutes once daily on days -5 to -2 and busulfan IV over 2 hours 4 times daily days -5 to -2.  Pts undergo allogeneic SCT within 36 to 48 hours after last busulfan dose. Pts receive GVHD prophylaxis. MAINTENANCE: Pts receive sorafenib tosylate PO starting day 40-100 after INT II or SCT for 1 year.,INDUCTION I: Patients with unknown FLT3/ITD status prior to study enrollment receive cytarabine IT and ADE chemotherapy as in Arm A Induction I. If patients are determined to be HR FLT3/ITD+ no later than the end of Induction I they will be eligible to participate in Arm C.
Total all-cause mortality,198/559 %35.42,189/575 %32.87,7/12 %58.33,11/33 %33.33,16/47 %34.04,2/376 %0.53
Total serious adverse events,82/559 %14.67,305/575 %53.04,6/12 %50.0,16/33 %48.48,30/47 %63.83,2/376 %0.53
Anemia,0/559 %0.0,3/575 %0.52,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Blood and lymphatic system disorders - Other specify,1/559 %0.18,4/575 %0.7,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Bone marrow hypocellular,0/559 %0.0,2/575 %0.35,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Disseminated intravascular coagulation,3/559 %0.54,3/575 %0.52,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Febrile neutropenia,0/559 %0.0,21/575 %3.65,0/12 %0.0,1/33 %3.03,0/47 %0.0,0/376 %0.0
Hemolysis,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Hemolytic uremic syndrome,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Leukocytosis,0/559 %0.0,3/575 %0.52,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Asystole,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Atrial fibrillation,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Atrial flutter,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Cardiac arrest,3/559 %0.54,4/575 %0.7,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Cardiac disorders - Other specify,0/559 %0.0,7/575 %1.22,0/12 %0.0,1/33 %3.03,2/47 %4.26,0/376 %0.0
Chest pain - cardiac,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Heart failure,4/559 %0.72,15/575 %2.61,0/12 %0.0,1/33 %3.03,2/47 %4.26,0/376 %0.0
Left ventricular systolic dysfunction,3/559 %0.54,23/575 %4.0,0/12 %0.0,2/33 %6.06,4/47 %8.51,0/376 %0.0
Myocardial infarction,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Pericardial effusion,0/559 %0.0,2/575 %0.35,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Pericarditis,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Restrictive cardiomyopathy,0/559 %0.0,4/575 %0.7,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Right ventricular dysfunction,2/559 %0.36,2/575 %0.35,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Sinus bradycardia,1/559 %0.18,0/575 %0.0,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Sinus tachycardia,0/559 %0.0,10/575 %1.74,0/12 %0.0,0/33 %0.0,1/47 %2.13,0/376 %0.0
Supraventricular tachycardia,0/559 %0.0,2/575 %0.35,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Ventricular arrhythmia,0/559 %0.0,3/575 %0.52,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Ventricular fibrillation,1/559 %0.18,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Ventricular tachycardia,0/559 %0.0,2/575 %0.35,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Adrenal insufficiency,0/559 %0.0,3/575 %0.52,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Endocrine disorders - Other specify,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Hypothyroidism,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Eye disorders - Other specify,1/559 %0.18,2/575 %0.35,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Optic nerve disorder,0/559 %0.0,0/575 %0.0,0/12 %0.0,0/33 %0.0,1/47 %2.13,0/376 %0.0
Papilledema,0/559 %0.0,0/575 %0.0,0/12 %0.0,0/33 %0.0,1/47 %2.13,0/376 %0.0
Abdominal distension,0/559 %0.0,2/575 %0.35,0/12 %0.0,1/33 %3.03,0/47 %0.0,0/376 %0.0
Abdominal pain,0/559 %0.0,2/575 %0.35,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Anal pain,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Ascites,1/559 %0.18,0/575 %0.0,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Colitis,0/559 %0.0,9/575 %1.57,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Colonic perforation,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Diarrhea,0/559 %0.0,9/575 %1.57,0/12 %0.0,1/33 %3.03,0/47 %0.0,0/376 %0.0
Enterocolitis,0/559 %0.0,2/575 %0.35,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Esophagitis,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Gastric hemorrhage,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Gastritis,0/559 %0.0,2/575 %0.35,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Gastrointestinal disorders - Other specify,0/559 %0.0,3/575 %0.52,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Ileus,0/559 %0.0,1/575 %0.17,0/12 %0.0,1/33 %3.03,1/47 %2.13,0/376 %0.0
Lower gastrointestinal hemorrhage,0/559 %0.0,0/575 %0.0,0/12 %0.0,0/33 %0.0,1/47 %2.13,0/376 %0.0
Mucositis oral,0/559 %0.0,3/575 %0.52,1/12 %8.33,0/33 %0.0,0/47 %0.0,0/376 %0.0
Nausea,0/559 %0.0,1/575 %0.17,0/12 %0.0,1/33 %3.03,0/47 %0.0,0/376 %0.0
Oral pain,0/559 %0.0,2/575 %0.35,0/12 %0.0,1/33 %3.03,0/47 %0.0,0/376 %0.0
Pancreatitis,0/559 %0.0,8/575 %1.39,0/12 %0.0,0/33 %0.0,1/47 %2.13,0/376 %0.0
Small intestinal obstruction,0/559 %0.0,2/575 %0.35,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Typhlitis,2/559 %0.36,24/575 %4.17,0/12 %0.0,1/33 %3.03,1/47 %2.13,0/376 %0.0
Upper gastrointestinal hemorrhage,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Vomiting,0/559 %0.0,1/575 %0.17,0/12 %0.0,1/33 %3.03,0/47 %0.0,0/376 %0.0
Chills,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Death NOS,38/559 %6.8,35/575 %6.09,1/12 %8.33,5/33 %15.15,6/47 %12.77,0/376 %0.0
Edema face,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Fever,0/559 %0.0,13/575 %2.26,0/12 %0.0,0/33 %0.0,3/47 %6.38,0/376 %0.0
Gait disturbance,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Hypothermia,1/559 %0.18,0/575 %0.0,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Multi-organ failure,1/559 %0.18,8/575 %1.39,0/12 %0.0,0/33 %0.0,2/47 %4.26,0/376 %0.0
Non-cardiac chest pain,0/559 %0.0,2/575 %0.35,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Pain,0/559 %0.0,2/575 %0.35,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Bile duct stenosis,1/559 %0.18,0/575 %0.0,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Cholecystitis,0/559 %0.0,2/575 %0.35,0/12 %0.0,0/33 %0.0,1/47 %2.13,0/376 %0.0
Hepatic failure,2/559 %0.36,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Hepatobiliary disorders - Other specify,0/559 %0.0,4/575 %0.7,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Allergic reaction,1/559 %0.18,2/575 %0.35,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Anaphylaxis,0/559 %0.0,5/575 %0.87,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Immune system disorders - Other specify,1/559 %0.18,0/575 %0.0,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Anorectal infection,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Appendicitis,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Bladder infection,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Bronchial infection,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Catheter related infection,0/559 %0.0,5/575 %0.87,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Cecal infection,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Duodenal infection,1/559 %0.18,0/575 %0.0,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Encephalitis infection,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Enterocolitis infectious,1/559 %0.18,2/575 %0.35,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Esophageal infection,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,1/47 %2.13,0/376 %0.0
Infections and infestations - Other specify,2/559 %0.36,13/575 %2.26,0/12 %0.0,2/33 %6.06,0/47 %0.0,0/376 %0.0
Lung infection,1/559 %0.18,13/575 %2.26,1/12 %8.33,2/33 %6.06,0/47 %0.0,0/376 %0.0
Lymph gland infection,1/559 %0.18,0/575 %0.0,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Meningitis,1/559 %0.18,0/575 %0.0,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Mucosal infection,0/559 %0.0,3/575 %0.52,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Periorbital infection,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Sepsis,17/559 %3.04,50/575 %8.7,0/12 %0.0,1/33 %3.03,4/47 %8.51,0/376 %0.0
Skin infection,0/559 %0.0,3/575 %0.52,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Soft tissue infection,1/559 %0.18,0/575 %0.0,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Tracheitis,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Upper respiratory infection,1/559 %0.18,3/575 %0.52,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Urinary tract infection,1/559 %0.18,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Infusion related reaction,0/559 %0.0,2/575 %0.35,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Postoperative hemorrhage,1/559 %0.18,0/575 %0.0,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Vascular access complication,0/559 %0.0,3/575 %0.52,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Activated partial thromboplastin time prolonged,0/559 %0.0,4/575 %0.7,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Alanine aminotransferase increased,0/559 %0.0,16/575 %2.78,0/12 %0.0,0/33 %0.0,2/47 %4.26,0/376 %0.0
Aspartate aminotransferase increased,1/559 %0.18,10/575 %1.74,0/12 %0.0,0/33 %0.0,1/47 %2.13,0/376 %0.0
Blood bilirubin increased,2/559 %0.36,16/575 %2.78,0/12 %0.0,1/33 %3.03,1/47 %2.13,0/376 %0.0
Carbon monoxide diffusing capacity decreased,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Creatinine increased,0/559 %0.0,8/575 %1.39,0/12 %0.0,1/33 %3.03,0/47 %0.0,0/376 %0.0
Ejection fraction decreased,2/559 %0.36,18/575 %3.13,0/12 %0.0,2/33 %6.06,4/47 %8.51,0/376 %0.0
Electrocardiogram QT corrected interval prolonged,1/559 %0.18,3/575 %0.52,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Fibrinogen decreased,1/559 %0.18,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
GGT increased,0/559 %0.0,4/575 %0.7,0/12 %0.0,1/33 %3.03,0/47 %0.0,0/376 %0.0
Investigations - Other specify,0/559 %0.0,2/575 %0.35,0/12 %0.0,0/33 %0.0,1/47 %2.13,0/376 %0.0
Lipase increased,0/559 %0.0,4/575 %0.7,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Lymphocyte count decreased,0/559 %0.0,5/575 %0.87,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Neutrophil count decreased,0/559 %0.0,8/575 %1.39,0/12 %0.0,1/33 %3.03,0/47 %0.0,0/376 %0.0
Platelet count decreased,0/559 %0.0,7/575 %1.22,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Serum amylase increased,0/559 %0.0,3/575 %0.52,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Urine output decreased,1/559 %0.18,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Weight loss,0/559 %0.0,0/575 %0.0,0/12 %0.0,1/33 %3.03,1/47 %2.13,0/376 %0.0
White blood cell decreased,0/559 %0.0,5/575 %0.87,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Acidosis,0/559 %0.0,4/575 %0.7,0/12 %0.0,1/33 %3.03,0/47 %0.0,0/376 %0.0
Alkalosis,0/559 %0.0,1/575 %0.17,0/12 %0.0,1/33 %3.03,0/47 %0.0,0/376 %0.0
Anorexia,0/559 %0.0,1/575 %0.17,0/12 %0.0,1/33 %3.03,0/47 %0.0,0/376 %0.0
Dehydration,0/559 %0.0,3/575 %0.52,0/12 %0.0,1/33 %3.03,0/47 %0.0,0/376 %0.0
Hypercalcemia,0/559 %0.0,2/575 %0.35,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Hyperglycemia,1/559 %0.18,2/575 %0.35,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Hyperkalemia,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,1/47 %2.13,0/376 %0.0
Hypernatremia,2/559 %0.36,3/575 %0.52,0/12 %0.0,0/33 %0.0,1/47 %2.13,0/376 %0.0
Hypertriglyceridemia,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Hypoalbuminemia,0/559 %0.0,6/575 %1.04,0/12 %0.0,1/33 %3.03,0/47 %0.0,0/376 %0.0
Hypocalcemia,0/559 %0.0,8/575 %1.39,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Hypokalemia,1/559 %0.18,27/575 %4.7,0/12 %0.0,2/33 %6.06,1/47 %2.13,0/376 %0.0
Hypomagnesemia,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Hyponatremia,0/559 %0.0,10/575 %1.74,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Hypophosphatemia,1/559 %0.18,3/575 %0.52,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Metabolism and nutrition disorders - Other specify,2/559 %0.36,0/575 %0.0,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Tumor lysis syndrome,1/559 %0.18,3/575 %0.52,0/12 %0.0,1/33 %3.03,0/47 %0.0,0/376 %0.0
Arthralgia,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Back pain,0/559 %0.0,4/575 %0.7,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Neck pain,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Pain in extremity,0/559 %0.0,2/575 %0.35,0/12 %0.0,1/33 %3.03,0/47 %0.0,0/376 %0.0
Neoplasms benign malignant and unspecified (incl cysts and polyps) - Other specify,2/559 %0.36,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,1/376 %0.27
Ataxia,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Central nervous system necrosis,1/559 %0.18,0/575 %0.0,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Cerebrospinal fluid leakage,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Cognitive disturbance,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Depressed level of consciousness,0/559 %0.0,2/575 %0.35,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Dizziness,0/559 %0.0,2/575 %0.35,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Dysesthesia,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Edema cerebral,1/559 %0.18,4/575 %0.7,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Encephalopathy,1/559 %0.18,5/575 %0.87,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Headache,0/559 %0.0,4/575 %0.7,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Hydrocephalus,1/559 %0.18,0/575 %0.0,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Hypersomnia,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Intracranial hemorrhage,2/559 %0.36,3/575 %0.52,0/12 %0.0,0/33 %0.0,0/47 %0.0,1/376 %0.27
Leukoencephalopathy,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Nervous system disorders - Other specify,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Neuralgia,0/559 %0.0,1/575 %0.17,0/12 %0.0,1/33 %3.03,0/47 %0.0,0/376 %0.0
Paresthesia,0/559 %0.0,2/575 %0.35,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Peripheral sensory neuropathy,0/559 %0.0,14/575 %2.43,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Reversible posterior leukoencephalopathy syndrome,0/559 %0.0,4/575 %0.7,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Seizure,1/559 %0.18,3/575 %0.52,0/12 %0.0,0/33 %0.0,1/47 %2.13,0/376 %0.0
Somnolence,0/559 %0.0,4/575 %0.7,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Syncope,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Agitation,0/559 %0.0,2/575 %0.35,1/12 %8.33,0/33 %0.0,0/47 %0.0,0/376 %0.0
Anxiety,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Delirium,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Acute kidney injury,5/559 %0.89,15/575 %2.61,0/12 %0.0,3/33 %9.09,3/47 %6.38,0/376 %0.0
Cystitis noninfective,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Hematuria,0/559 %0.0,3/575 %0.52,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Proteinuria,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Renal and urinary disorders - Other specify,1/559 %0.18,3/575 %0.52,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Adult respiratory distress syndrome,3/559 %0.54,15/575 %2.61,0/12 %0.0,2/33 %6.06,0/47 %0.0,0/376 %0.0
Apnea,1/559 %0.18,0/575 %0.0,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Aspiration,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Atelectasis,0/559 %0.0,2/575 %0.35,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Bronchopulmonary hemorrhage,3/559 %0.54,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Bronchospasm,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Cough,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Dyspnea,1/559 %0.18,12/575 %2.09,0/12 %0.0,1/33 %3.03,0/47 %0.0,0/376 %0.0
Epistaxis,0/559 %0.0,7/575 %1.22,0/12 %0.0,1/33 %3.03,0/47 %0.0,0/376 %0.0
Hypoxia,3/559 %0.54,55/575 %9.57,1/12 %8.33,3/33 %9.09,3/47 %6.38,0/376 %0.0
Laryngeal edema,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Laryngeal mucositis,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Mediastinal hemorrhage,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Pharyngeal mucositis,0/559 %0.0,2/575 %0.35,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Pleural effusion,0/559 %0.0,8/575 %1.39,0/12 %0.0,1/33 %3.03,0/47 %0.0,0/376 %0.0
Pneumonitis,0/559 %0.0,9/575 %1.57,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Productive cough,0/559 %0.0,0/575 %0.0,0/12 %0.0,0/33 %0.0,1/47 %2.13,0/376 %0.0
Pulmonary edema,3/559 %0.54,12/575 %2.09,0/12 %0.0,0/33 %0.0,2/47 %4.26,0/376 %0.0
Pulmonary hypertension,1/559 %0.18,2/575 %0.35,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Respiratory failure,10/559 %1.79,22/575 %3.83,0/12 %0.0,2/33 %6.06,2/47 %4.26,0/376 %0.0
Respiratory thoracic and mediastinal disorders - Other specify,1/559 %0.18,6/575 %1.04,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Sore throat,0/559 %0.0,1/575 %0.17,1/12 %8.33,0/33 %0.0,0/47 %0.0,0/376 %0.0
Stridor,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Tracheal mucositis,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Wheezing,0/559 %0.0,3/575 %0.52,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Erythroderma,0/559 %0.0,0/575 %0.0,1/12 %8.33,0/33 %0.0,0/47 %0.0,0/376 %0.0
Pain of skin,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,1/47 %2.13,0/376 %0.0
Palmar-plantar erythrodysesthesia syndrome,0/559 %0.0,1/575 %0.17,1/12 %8.33,1/33 %3.03,1/47 %2.13,0/376 %0.0
Pruritus,0/559 %0.0,1/575 %0.17,1/12 %8.33,0/33 %0.0,0/47 %0.0,0/376 %0.0
Rash maculo-papular,0/559 %0.0,10/575 %1.74,1/12 %8.33,2/33 %6.06,3/47 %6.38,0/376 %0.0
Skin and subcutaneous tissue disorders - Other specify,0/559 %0.0,2/575 %0.35,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Toxic epidermal necrolysis,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Urticaria,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Capillary leak syndrome,0/559 %0.0,5/575 %0.87,0/12 %0.0,0/33 %0.0,1/47 %2.13,0/376 %0.0
Flushing,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Hypertension,0/559 %0.0,10/575 %1.74,0/12 %0.0,1/33 %3.03,1/47 %2.13,0/376 %0.0
Hypotension,7/559 %1.25,47/575 %8.17,1/12 %8.33,3/33 %9.09,3/47 %6.38,0/376 %0.0
Peripheral ischemia,1/559 %0.18,0/575 %0.0,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Thromboembolic event,3/559 %0.54,3/575 %0.52,0/12 %0.0,0/33 %0.0,1/47 %2.13,0/376 %0.0

S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma(https://clinicaltrials.gov/show/NCT01412879)
 ,R-HCVAD/MTX/Ara-C (Induction Therapy),R-Bendamustine (Induction Therapy),Stem Cell Transplant (Consolidation Therapy)
 ,The R-HCVAD/MTX/ARA-C combination are rituximab cyclophosphamide vincristine doxorubicin dexamethasone methotrexate and cytarabine. Cycle 1 and 3: Patients receive induction therapy comprising rituximab IV on day 1; cyclophosphamide IV over 3 hours every 12 hours on days 2-4; doxorubicin hydrochloride IV over 72 hours on days 5-7; vincristine sulfate IV on days 5 and 12; and dexamethasone IV or orally (PO) once daily (QD) on days 2-5 and 12-15. Patients with responsive disease after course 1 proceed to course 2. Cycle 2 and 4: Patients receive rituximab IV on day 1; methotrexate IV over 2-22 hours on day 2; cytarabine IV over 2 hours every 12 hours on days 3-4; and leucovorin calcium PO or IV on days 3-6. Patients undergo stem cell collection after completion of Cycle 2 (1 cycle = 21 days).,R-bendamustine combinations are rituximab and bendamustine. Patients receive rituximab IV on day 1 and bendamustine hydrochloride IV over 30 minutes on days 1-2. Treatment repeats every 28 days for 4 cycles (1 cycle = 28 days). Patients with responsive disease receive 2 additional cycles of treatment. Patients undergo stem cell collection after completion of 6 Cycles of treatment.,Patients receive stem cell transplant with non-TBI containing regimen (BCV or BEAM Chemotherapy) for patients 61 years or older or TBI-containing regimen (TBI/VP-16/Cyclophosphamide). BCV chemotherapy: Carmustine IV over 2 hours on days -6 to -4; etoposide IV over 4 hours on day -4; and cyclophosphamide IV over 1 hour on day -2. BEAM chemotherapy: Carmustine IV over 4 hours on days -7 and -6; etoposide IV over 1 hour twice daily and cytarabine IV over 2 hours twice daily on days -5 to -2 and melphalan IV on day -1.  TBI etoposide cyclophosphamide: Patients undergo total-body irradiation (TBI)** twice daily on days -8 to -5. Patients also receive etoposide IV on day -4 and cyclophosphamide IV over 1 hour on day -2. * *TBI may not be used for patients 61 years of age and older. Stem cell transplantation: Patients then undergo autologous peripheral blood stem cell transplantation on day 0.
Total serious adverse events,0/17 %0.0,0/35 %0.0,1/26 %3.85
Diarrhea,0/17 %0.0,0/35 %0.0,1/26 %3.85
Enterocolitis infectious,0/17 %0.0,0/35 %0.0,1/26 %3.85
Adult respiratory distress syndrome,0/17 %0.0,0/35 %0.0,1/26 %3.85

Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07649)(https://clinicaltrials.gov/show/NCT01451437)
 ,Pt 1 Arm A: MK-8242 30 mg QD,Pt 1 Arm A: MK-8242 60 mg QD,Pt 1 Arm A: MK-8242 120 mg QD,Pt 1 Arm A: MK-8242 250 mg QD,Pt 1 Arm A: MK-8242 120 mg BID,Pt 1 Arm A: MK-8242 170 mg BID,Pt 1 Arm A: MK-8242 210 mg BID,Pt 1 Arm A: MK-8242 250 mg BID,Pt 1 Arm A: MK-8242 300 mg BID
 ,Participants received MK-8242 30 mg QD monotherapy on Days 1-7 and Days 15-21 of each 28-day cycle in Part 1 Arm A.,Participants received MK-8242 60 mg QD monotherapy on Days 1-7 and Days 15-21 of each 28-day cycle in Part 1 Arm A.,Participants received MK-8242 120 mg QD monotherapy on Days 1-7 and Days 15-21 of each 28-day cycle in Part 1 Arm A.,Participants received MK-8242 250 mg QD monotherapy on Days 1-7 and Days 15-21 of each 28-day cycle in Part 1 Arm A.,Participants received MK-8242 120 mg BID monotherapy on Days 1-7 and Days 15-21 of each 28-day cycle (except Cycle 1 Day 7 on which MK-8242 120 mg was administered QD in the morning) in Part 1 Arm A.,Participants received MK-8242 170 mg BID monotherapy on Days 1-7 and Days 15-21 of each 28-day cycle (except Cycle 1 Day 7 on which MK-8242 170 mg was administered QD in the morning) in Part 1 Arm A.,Participants received MK-8242 210 mg BID monotherapy on Days 1-7 of each 21-day cycle (except Cycle 1 Day 7 on which MK-8242 210 mg was administered QD in the morning) in Part 1 Arm A.,Participants received MK-8242 250 mg BID monotherapy on Days 1-7 and Days 15-21 of each 28-day cycle (except Cycle 1 Day 7 on which MK-8242 250 mg was administered QD in the morning) in Part 1 Arm A.,Participants received MK-8242 300 mg BID monotherapy on Days 1-7 of each 21-day cycle (except Cycle 1 Day 7 on which MK-8242 300 mg was administered QD in the morning) in Part 1 Arm A.
Total serious adverse events,1/1 %100.0,0/1 %0.0,2/3 %66.67,1/1 %100.0,1/4 %25.0,1/3 %33.33,5/6 %83.33,3/3 %100.0,2/4 %50.0
Febrile neutropenia,0/1 %0.0,0/1 %0.0,0/3 %0.0,0/1 %0.0,1/4 %25.0,1/3 %33.33,2/6 %33.33,3/3 %100.0,0/4 %0.0
Acute coronary syndrome,0/1 %0.0,0/1 %0.0,0/3 %0.0,0/1 %0.0,0/4 %0.0,0/3 %0.0,1/6 %16.67,0/3 %0.0,0/4 %0.0
Atrial fibrillation,0/1 %0.0,0/1 %0.0,0/3 %0.0,0/1 %0.0,0/4 %0.0,0/3 %0.0,1/6 %16.67,0/3 %0.0,0/4 %0.0
Extrasystoles,1/1 %100.0,0/1 %0.0,0/3 %0.0,0/1 %0.0,0/4 %0.0,0/3 %0.0,0/6 %0.0,0/3 %0.0,0/4 %0.0
Mouth haemorrhage,0/1 %0.0,0/1 %0.0,0/3 %0.0,0/1 %0.0,0/4 %0.0,0/3 %0.0,1/6 %16.67,0/3 %0.0,0/4 %0.0
Upper gastrointestinal haemorrhage,0/1 %0.0,0/1 %0.0,0/3 %0.0,0/1 %0.0,0/4 %0.0,1/3 %33.33,0/6 %0.0,0/3 %0.0,0/4 %0.0
Pyrexia,0/1 %0.0,0/1 %0.0,0/3 %0.0,0/1 %0.0,0/4 %0.0,0/3 %0.0,0/6 %0.0,0/3 %0.0,1/4 %25.0
Cellulitis,0/1 %0.0,0/1 %0.0,0/3 %0.0,0/1 %0.0,0/4 %0.0,0/3 %0.0,1/6 %16.67,1/3 %33.33,0/4 %0.0
Escherichia infection,0/1 %0.0,0/1 %0.0,0/3 %0.0,0/1 %0.0,0/4 %0.0,0/3 %0.0,0/6 %0.0,1/3 %33.33,0/4 %0.0
Lung infection,0/1 %0.0,0/1 %0.0,0/3 %0.0,0/1 %0.0,0/4 %0.0,0/3 %0.0,1/6 %16.67,0/3 %0.0,0/4 %0.0
Pneumonia,1/1 %100.0,0/1 %0.0,1/3 %33.33,0/1 %0.0,1/4 %25.0,0/3 %0.0,0/6 %0.0,0/3 %0.0,0/4 %0.0
Pneumonia fungal,0/1 %0.0,0/1 %0.0,0/3 %0.0,0/1 %0.0,0/4 %0.0,0/3 %0.0,0/6 %0.0,2/3 %66.67,0/4 %0.0
Sepsis,0/1 %0.0,0/1 %0.0,0/3 %0.0,0/1 %0.0,0/4 %0.0,0/3 %0.0,1/6 %16.67,0/3 %0.0,0/4 %0.0
Sinusitis,0/1 %0.0,0/1 %0.0,0/3 %0.0,0/1 %0.0,0/4 %0.0,0/3 %0.0,0/6 %0.0,0/3 %0.0,1/4 %25.0
Fall,0/1 %0.0,0/1 %0.0,0/3 %0.0,0/1 %0.0,1/4 %25.0,0/3 %0.0,0/6 %0.0,0/3 %0.0,0/4 %0.0
Dehydration,0/1 %0.0,0/1 %0.0,0/3 %0.0,0/1 %0.0,0/4 %0.0,0/3 %0.0,1/6 %16.67,0/3 %0.0,0/4 %0.0
Neoplasm progression,0/1 %0.0,0/1 %0.0,0/3 %0.0,1/1 %100.0,1/4 %25.0,0/3 %0.0,0/6 %0.0,0/3 %0.0,0/4 %0.0
Renal cell carcinoma,0/1 %0.0,0/1 %0.0,1/3 %33.33,0/1 %0.0,0/4 %0.0,0/3 %0.0,0/6 %0.0,0/3 %0.0,0/4 %0.0
Neuralgia,0/1 %0.0,0/1 %0.0,0/3 %0.0,0/1 %0.0,0/4 %0.0,0/3 %0.0,0/6 %0.0,0/3 %0.0,1/4 %25.0
Confusional state,0/1 %0.0,0/1 %0.0,0/3 %0.0,0/1 %0.0,0/4 %0.0,0/3 %0.0,0/6 %0.0,1/3 %33.33,0/4 %0.0
Depression,0/1 %0.0,0/1 %0.0,0/3 %0.0,0/1 %0.0,0/4 %0.0,0/3 %0.0,1/6 %16.67,0/3 %0.0,0/4 %0.0
Suicide attempt,0/1 %0.0,0/1 %0.0,0/3 %0.0,0/1 %0.0,0/4 %0.0,0/3 %0.0,1/6 %16.67,0/3 %0.0,0/4 %0.0
Renal failure acute,0/1 %0.0,0/1 %0.0,0/3 %0.0,1/1 %100.0,0/4 %0.0,0/3 %0.0,1/6 %16.67,0/3 %0.0,0/4 %0.0
Benign prostatic hyperplasia,0/1 %0.0,0/1 %0.0,0/3 %0.0,1/1 %100.0,0/4 %0.0,0/3 %0.0,0/6 %0.0,0/3 %0.0,0/4 %0.0
Dyspnoea,0/1 %0.0,0/1 %0.0,1/3 %33.33,0/1 %0.0,0/4 %0.0,0/3 %0.0,0/6 %0.0,1/3 %33.33,0/4 %0.0
Respiratory failure,0/1 %0.0,0/1 %0.0,0/3 %0.0,0/1 %0.0,0/4 %0.0,0/3 %0.0,1/6 %16.67,0/3 %0.0,1/4 %25.0
Hypertension,0/1 %0.0,0/1 %0.0,0/3 %0.0,1/1 %100.0,0/4 %0.0,0/3 %0.0,0/6 %0.0,0/3 %0.0,0/4 %0.0

A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)(https://clinicaltrials.gov/show/NCT01453205)
 ,Rituximab+ ICE/DHAP,MEDI-551 2 mg/kg + ICE/DHAP,MEDI-551 4 mg/kg + ICE/DHAP
 ,Participants received Rituximab in combination with ifosfamide + carboplatin + etoposide (ICE) or dexamethasone + cisplatin + cytarabine (DHAP) for 3 cycles (21-day cycles) and were followed until end of the study (36 months after the date of randomization for last participant or date the sponsor stops the trial whichever occurs first). Rituximab (375 mg/m^2) was administered intravenous (IV) on 2 days before the start of Cycle 1 and on Day 1 of each cycle. After completion of rituximab IV infusion of ICE as: ifosfamide 5 g/ m^2 continuously for 24 hours with mesna on Day 2; carboplatin AUC=5 mg/mL x min (800 mg maximum) on Day 2; etoposide 100 mg/ m^2 on Days 1 2 and 3 in 21-day cycles. After completion of rituximab IV infusion of DHAP as: dexamethasone 40 mg on Days 1 2 3 and 4; cisplatin 100 mg/m^2 continuously for 24 hours on Day 1; cytarabine 2 g/m^2 in 3-hour infusion repeated after 12 hours (2 doses) on Day 2 in 21-day cycles.,Participants received MEDI-551 (2 mg/kg) in combination with ICE or DHAP for 3 cycles (21-day cycles) and were followed until end of the study (36 months after the date of randomization for last participant or date the sponsor stops the trial whichever occurs first). MEDI-551 (2 mg/kg) was administered IV on 7 days before the start of Cycle 1 and on Day 1 of each cycle. After completion of MEDI-551 IV infusion of ICE as: ifosfamide 5 g/ m^2 continuously for 24 hours with mesna on Day 2; carboplatin AUC=5 mg/mL x min (800 mg maximum) on Day 2; etoposide 100 mg/ m^2 on Days 1 2 and 3 in 21-day cycles. After completion of MEDI-551 IV infusion of DHAP as: dexamethasone 40 mg on Days 1 2 3 and 4; cisplatin 100 mg/m^2 continuously for 24 hours on Day 1; cytarabine 2 g/m^2 in 3-hour infusion repeated after 12 hours (2 doses) on Day 2 in 21-day cycles.,Participants received MEDI-551 (4 mg/kg) in combination with ICE or DHAP for 3 cycles (21-day cycles) and were followed until end of the study (36 months after the date of randomization for last participant or date the sponsor stops the trial whichever occurs first). MEDI-551 (4 mg/kg) was administered IV on 7 days before the start of Cycle 1 and on Day 1 of each cycle. After completion of MEDI-551 IV infusion of ICE as: ifosfamide 5 g/ m^2 continuously for 24 hours with mesna on Day 2; carboplatin AUC=5 mg/mL x min (800 mg maximum) on Day 2; etoposide 100 mg/ m^2 on Days 1 2 and 3 in 21-day cycles. After completion of MEDI-551 IV infusion of DHAP as: dexamethasone 40 mg on Days 1 2 3 and 4; cisplatin 100 mg/m^2 continuously for 24 hours on Day 1; cytarabine 2 g/m^2 in 3-hour infusion repeated after 12 hours (2 doses) on Day 2 in 21-day cycles.
Total serious adverse events,33/79 %41.77,25/52 %48.08,27/54 %50.0
Anaemia,0/79 %0.0,1/52 %1.92,0/54 %0.0
Disseminated intravascular coagulation,1/79 %1.27,0/52 %0.0,0/54 %0.0
Febrile bone marrow aplasia,0/79 %0.0,1/52 %1.92,0/54 %0.0
Febrile neutropenia,11/79 %13.92,8/52 %15.38,9/54 %16.67
Leukopenia,1/79 %1.27,0/52 %0.0,0/54 %0.0
Lymphadenopathy,0/79 %0.0,1/52 %1.92,0/54 %0.0
Neutropenia,4/79 %5.06,1/52 %1.92,3/54 %5.56
Pancytopenia,1/79 %1.27,0/52 %0.0,1/54 %1.85
Thrombocytopenia,5/79 %6.33,0/52 %0.0,1/54 %1.85
Thrombotic microangiopathy,0/79 %0.0,0/52 %0.0,1/54 %1.85
Acute myocardial infarction,0/79 %0.0,0/52 %0.0,1/54 %1.85
Angina pectoris,0/79 %0.0,0/52 %0.0,1/54 %1.85
Atrial fibrillation,0/79 %0.0,1/52 %1.92,0/54 %0.0
Cardiac failure,1/79 %1.27,0/52 %0.0,0/54 %0.0
Cardiac failure congestive,0/79 %0.0,0/52 %0.0,1/54 %1.85
Vertigo,1/79 %1.27,0/52 %0.0,0/54 %0.0
Gastritis,1/79 %1.27,0/52 %0.0,0/54 %0.0
Nausea,1/79 %1.27,1/52 %1.92,1/54 %1.85
Neutropenic colitis,1/79 %1.27,0/52 %0.0,0/54 %0.0
Obstruction gastric,1/79 %1.27,0/52 %0.0,0/54 %0.0
Vomiting,2/79 %2.53,1/52 %1.92,0/54 %0.0
Death,0/79 %0.0,1/52 %1.92,0/54 %0.0
Fatigue,0/79 %0.0,1/52 %1.92,0/54 %0.0
General physical health deterioration,1/79 %1.27,1/52 %1.92,0/54 %0.0
Multiple organ dysfunction syndrome,1/79 %1.27,0/52 %0.0,0/54 %0.0
Pyrexia,1/79 %1.27,2/52 %3.85,2/54 %3.7
Bacteraemia,0/79 %0.0,0/52 %0.0,1/54 %1.85
Bacterial sepsis,0/79 %0.0,1/52 %1.92,0/54 %0.0
Cellulitis,0/79 %0.0,1/52 %1.92,0/54 %0.0
Clostridium difficile colitis,0/79 %0.0,0/52 %0.0,1/54 %1.85
Cystitis viral,1/79 %1.27,0/52 %0.0,0/54 %0.0
Device related infection,1/79 %1.27,1/52 %1.92,1/54 %1.85
Enterobacter sepsis,1/79 %1.27,0/52 %0.0,0/54 %0.0
Escherichia sepsis,1/79 %1.27,0/52 %0.0,0/54 %0.0
Herpes zoster,0/79 %0.0,1/52 %1.92,0/54 %0.0
Pneumonia,3/79 %3.8,0/52 %0.0,1/54 %1.85
Respiratory tract infection,0/79 %0.0,1/52 %1.92,0/54 %0.0
Sepsis,3/79 %3.8,1/52 %1.92,4/54 %7.41
Septic shock,1/79 %1.27,1/52 %1.92,0/54 %0.0
Staphylococcal sepsis,0/79 %0.0,1/52 %1.92,0/54 %0.0
Urinary tract infection,0/79 %0.0,1/52 %1.92,0/54 %0.0
Overdose,0/79 %0.0,1/52 %1.92,0/54 %0.0
Spinal fracture,0/79 %0.0,1/52 %1.92,0/54 %0.0
Toxicity to various agents,1/79 %1.27,0/52 %0.0,1/54 %1.85
Blood creatinine increased,0/79 %0.0,1/52 %1.92,0/54 %0.0
Neutrophil count decreased,0/79 %0.0,1/52 %1.92,0/54 %0.0
White blood cell count decreased,0/79 %0.0,1/52 %1.92,0/54 %0.0
Decreased appetite,0/79 %0.0,1/52 %1.92,0/54 %0.0
Dehydration,0/79 %0.0,1/52 %1.92,1/54 %1.85
Hyperglycaemia,0/79 %0.0,1/52 %1.92,0/54 %0.0
Hypokalaemia,0/79 %0.0,1/52 %1.92,0/54 %0.0
Hyponatraemia,1/79 %1.27,0/52 %0.0,1/54 %1.85
Tumour lysis syndrome,0/79 %0.0,2/52 %3.85,1/54 %1.85
Back pain,0/79 %0.0,1/52 %1.92,0/54 %0.0
Bone pain,1/79 %1.27,0/52 %0.0,0/54 %0.0
Musculoskeletal chest pain,0/79 %0.0,0/52 %0.0,1/54 %1.85
Central nervous system lymphoma,1/79 %1.27,1/52 %1.92,0/54 %0.0
Tumour haemorrhage,1/79 %1.27,0/52 %0.0,0/54 %0.0
Coma hepatic,0/79 %0.0,1/52 %1.92,0/54 %0.0
Dizziness,1/79 %1.27,0/52 %0.0,0/54 %0.0
Encephalopathy,0/79 %0.0,0/52 %0.0,1/54 %1.85
Headache,1/79 %1.27,0/52 %0.0,1/54 %1.85
Memory impairment,0/79 %0.0,1/52 %1.92,0/54 %0.0
Seizure,0/79 %0.0,0/52 %0.0,1/54 %1.85
Somnolence,0/79 %0.0,1/52 %1.92,0/54 %0.0
Syncope,0/79 %0.0,2/52 %3.85,0/54 %0.0
Confusional state,0/79 %0.0,0/52 %0.0,1/54 %1.85
Depression,0/79 %0.0,1/52 %1.92,0/54 %0.0
Mental status changes,1/79 %1.27,0/52 %0.0,0/54 %0.0
Suicidal ideation,1/79 %1.27,0/52 %0.0,0/54 %0.0
Acute kidney injury,3/79 %3.8,3/52 %5.77,2/54 %3.7
Nephropathy toxic,1/79 %1.27,0/52 %0.0,0/54 %0.0
Renal failure,1/79 %1.27,1/52 %1.92,2/54 %3.7
Acute pulmonary oedema,1/79 %1.27,0/52 %0.0,0/54 %0.0
Acute respiratory failure,0/79 %0.0,0/52 %0.0,1/54 %1.85
Dyspnoea,0/79 %0.0,0/52 %0.0,1/54 %1.85
Laryngeal inflammation,1/79 %1.27,0/52 %0.0,0/54 %0.0
Pleural effusion,0/79 %0.0,2/52 %3.85,2/54 %3.7
Pleurisy,1/79 %1.27,0/52 %0.0,0/54 %0.0
Pneumonitis,0/79 %0.0,0/52 %0.0,1/54 %1.85
Pneumothorax,1/79 %1.27,0/52 %0.0,0/54 %0.0
Pulmonary embolism,0/79 %0.0,0/52 %0.0,1/54 %1.85
Pulmonary oedema,0/79 %0.0,1/52 %1.92,0/54 %0.0
Respiratory failure,1/79 %1.27,0/52 %0.0,1/54 %1.85
Hypotension,0/79 %0.0,1/52 %1.92,0/54 %0.0
Thrombophlebitis,0/79 %0.0,1/52 %1.92,0/54 %0.0

Yttrium-90-labeled Daclizumab With Chemotherapy and Stem Cell Transplant for Hodgkin's Lymphoma(https://clinicaltrials.gov/show/NCT01468311)
 ,Yttrium-90-labeled Daclizumab + Chemotherapy
 ,Yttrium-90-labeled Daclizumab + BCNU etoposide cytarabine and melphalan (BEAM) + Auto stem cell transplant (ASCT)  Auto stem cell transplant: Auto stem cell transplant (ASCT) is given after 90Y-daclizumab  BEAM: BCNU etoposide cytarabine and melphalan (BEAM) chemotherapy are given after 90Y-daclizumab  111In-daclizumab: 111In-daclizumab will be administered to patients with each therapeutic infusion of 90Y-daclizumab in order to define the distribution of radiolabeled daclizumab and to allow visualization by scans.  90Y-daclizumab: 90Y-daclizumab administered with a fixed dose of pentetate calcium trisodium (Ca-DTPA) followed by BEAM Chemo and Auto stem cell transplant
Total all-cause mortality,0/6 %0.0
Total serious adverse events,1/6 %16.67
Menopause,1/6 %16.67

Ofatumumab in Combination With Cyclophosphamide  Doxorubicin Hydrochloride  Vincristine Sulfate  and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma(https://clinicaltrials.gov/show/NCT01527149)
 ,Treatment (Monoclonal Antibody and Combination Chemotherapy)
 ,COURSES 1 3 and 5 (O-HyperCVAD): Patients receive ofatumumab IV on day 1 cyclophosphamide IV over 2 hours every 12 hours for 6 doses on days 3-5 doxorubicin hydrochloride IV continuously over 72 hours on days 6-8 vincristine sulfate IV on days 6 and 13 and dexamethasone IV or PO on days 3-6 and 13-16.  COURSES 2 4 and 6 (O-HD-MA): Patients receive ofatumumab IV on day 1 methotrexate IV continuously over 24 hours on day 3 and cytarabine IV over 2 hours every 12 hours on days 4-5.  All courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.  Eligible patients then undergo standard HDC-ASCT.  Autologous Hematopoietic Stem Cell Transplantation: Undergo autologous HDC-ASCT  Cyclophosphamide: Given IV  Cytarabine: Given IV  Dexamethasone: Given IV or PO  Doxorubicin Hydrochloride: Given IV  Laboratory Biomarker Analysis: Correlative studies  Methotrexate: Given IV  Ofatumumab: Given IV  Vincristine Sulfate: Given IV
Total all-cause mortality,16/37 %43.24
Total serious adverse events,19/37 %51.35
Acute coronary syndrome,1/37 %2.7
Periorbital oedema,1/37 %2.7
Diarrhoea,1/37 %2.7
Pyrexia,1/37 %2.7
Diverticulitis,1/37 %2.7
Enterocolitis infectious,1/37 %2.7
Infusion site infection,3/37 %8.11
Lung infection,2/37 %5.41
Neutropenic sepsis,1/37 %2.7
Parainfluenzae virus infection,1/37 %2.7
Pneumonia,1/37 %2.7
Sepsis,8/37 %21.62
Neutrophil count decreased,1/37 %2.7
Cytarabine syndrome,1/37 %2.7
Pain in extremity,1/37 %2.7
Leukaemia,1/37 %2.7
Malignant melanoma,1/37 %2.7
Arachnoiditis,1/37 %2.7
Headache,1/37 %2.7
Dyspnoea,1/37 %2.7
Pulmonary embolism,1/37 %2.7
Blister,1/37 %2.7
Hypotension,1/37 %2.7

A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome(https://clinicaltrials.gov/show/NCT01546038)
 ,Phase 1B: Glasdegib 100 mg + LDAC,Phase 1B: Glasdegib 200 mg + LDAC,Phase 1B: Glasdegib 100 mg + Decitabine,Phase 1B: Glasdegib 200 mg + Decitabine,Phase 1B: Glasdegib 100 mg + Cytarabine/Daunorubicin,Phase 1B: Glasdegib 200 mg + Cytarabine/Daunorubicin,Phase 2 Fit: Glasdegib 100 mg + Cytarabine/Daunorubicin,Phase 2 Unfit: Glasdegib 100 mg + LDAC,Phase 2 Unfit: LDAC Alone
 ,Participants received oral doses of glasdegib (PF-04449913) tablets 100 milligram (mg) starting on Day 3 of Cycle 1 for pharmacokinetic (PK) assessment purposes and thereafter once daily (QD) and continuously for 28-day cycles (starting on Day 1 for all other cycles). Low dose Ara-C (LDAC) was given at a dose of 20 mg subcutaneously twice daily (BID) on Days 1-10 of the 28-day cycles.,Participants received oral doses of glasdegib tablets 200 mg starting on Day 3 of Cycle 1 for PK assessment purposes and thereafter QD and continuously for 28-day cycles (starting on Day 1 for all other cycles). LDAC was given at a dose of 20 mg subcutaneously BID on Days 1-10 of the 28-day cycles. In March 2013 all active participants receiving glasdegib 200 mg were required to reduce dose to 100 mg. Participants who had glasdegib dose reduction were reported as the starting glasdegib dose level received. Two (2) participants in this cohort had dose reduction to 100 mg starting from Cycle 2/Day 1 and Cycle 2/Day 16 respectively.,Participants received oral doses of glasdegib tablets 100 mg starting on Day 2 of Cycle 1 for PK assessment purposes and thereafter QD and continuously for 28-day cycles (starting on Day 1 for all other cycles). Decitabine was given at a dose of 20 mg/m^2 as an intravenous (IV) infusion over 1 hour on Days 1-5 of the 28-day cycles.,Participants received oral doses of glasdegib tablets 200 mg starting on Day 2 of Cycle 1 for PK assessment purposes and thereafter QD and continuously for 28-day cycles (starting on Day 1 for all other cycles). Decitabine was given at a dose of 20 mg/m^2 as an IV infusion over 1 hour on Days 1-5 of the 28-day cycles.In March 2013 all active participants receiving glasdegib 200 mg were required to reduce dose to 100 mg. Participants who had glasdegib dose reduction were reported as the starting glasdegib dose level received. Two (2) participants in this cohort had dose reduction to 100 mg starting from Cycle 1/Day 24 and Cycle 5/Day 1 respectively.,Participants received 1-2 cycles of induction (glasdegib and daunorubicin/cytarabine) followed by 2-4 cycles of consolidation (glasdegib and high dose cytarabine) and a maximum of 6 cycles of maintenance (glasdegib alone). Daunorubicin was given on Days 1-3 QD at a dose of 60 mg/m^2/day by IV together with cytarabine on Days 1-7 at a dose of 100 mg/m^2/day by continuous IV infusion for each cycle of induction. Cytarabine was given on Days 1 3 and 5 at a dose of 1 g/m^2 administered as a 3-hour IV infusion every 12 hours (2 g/m^2/day) for each cycle of consolidation. Glasdegib tablets 100 mg QD was started on induction Cycle 1/Day -3 and administered continuously QD thereafter for the duration of the study. A cycle was defined as 28 days.,Participants received 1-2 cycles of induction (glasdegib and daunorubicin/cytarabine) followed by 2-4 cycles of consolidation (glasdegib and high dose cytarabine) and a maximum of 6 cycles of maintenance (glasdegib alone). Daunorubicin was given on Days 1-3 QD at a dose of 60 mg/m^2/day by IV together with cytarabine on Days 1-7 at a dose of 100 mg/m^2/day by continuous IV infusion for each cycle of induction. Cytarabine was given on Days 1 3 and 5 at a dose of 1 g/m^2 administered as a 3-hour IV infusion every 12 hours (2 g/m^2/day) for each cycle of consolidation. Glasdegib tablets 200 mg QD was started on induction Cycle 1/Day -3 and administered continuously QD thereafter for the duration of the study. A cycle was defined as 28 days.In March 2013 all active participants receiving glasdegib 200 mg were required to reduce dose to 100 mg.One (1) participant in this cohort had dose reduction to 100 mg starting from Consolidation Cycle 1/Day 21.,Participants received 1-2 cycles of induction (glasdegib and daunorubicin/cytarabine) followed by 2-4 cycles of consolidation (glasdegib and high dose cytarabine) and a maximum of 6 cycles of maintenance (glasdegib alone). Daunorubicin was given on Days 1-3 QD at a dose of 60 mg/m^2/day by IV together with cytarabine on Days 1-7 at a dose of 100 mg/m^2/day by continuous IV infusion for each cycle of induction. Cytarabine was given on Days 1 3 and 5 at a dose of 1 g/m^2 administered as a 3-hour IV infusion every 12 hours (2 g/m^2/day) for each cycle of consolidation. Glasdegib tablets 100 mg QD was started on induction Cycle 1/Day -3 and administered continuously QD thereafter for the duration of the study. A cycle was defined as 28 days.,Participants received oral doses of glasdegib tablets 100 mg QD in 28-day cycles on a continuous basis starting on Day 1 of Cycle 1. LDAC was given at a dose of 20 mg subcutaneously BID on Days 1-10 of the 28-day cycles.,Participants received LDAC subcutaneously at a dose of 20 mg BID on Days 1-10 of the 28-day cycles.
Total all-cause mortality,6/17 %35.29,1/6 %16.67,1/4 %25.0,0/3 %0.0,0/16 %0.0,1/6 %16.67,5/69 %7.25,26/84 %30.95,17/41 %41.46
Total serious adverse events,13/17 %76.47,5/6 %83.33,4/4 %100.0,2/3 %66.67,10/16 %62.5,3/6 %50.0,35/69 %50.72,68/84 %80.95,32/41 %78.05
Febrile neutropenia,3/17 %17.65,3/6 %50.0,0/4 %0.0,1/3 %33.33,1/16 %6.25,1/6 %16.67,14/69 %20.29,24/84 %28.57,7/41 %17.07
Neutropenia,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,2/69 %2.9,0/84 %0.0,0/41 %0.0
Pancytopenia,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,1/69 %1.45,0/84 %0.0,2/41 %4.88
Anaemia,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,6/84 %7.14,0/41 %0.0
Disseminated intravascular coagulation,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,0/84 %0.0,1/41 %2.44
Granulocytopenia,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,0/84 %0.0,1/41 %2.44
Leukocytosis,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,1/84 %1.19,1/41 %2.44
Lymphadenitis,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,1/84 %1.19,0/41 %0.0
Thrombocytosis,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,1/84 %1.19,0/41 %0.0
Acute myocardial infarction,1/17 %5.88,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,1/69 %1.45,0/84 %0.0,1/41 %2.44
Cardiac failure congestive,1/17 %5.88,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,0/84 %0.0,0/41 %0.0
Angina pectoris,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,1/84 %1.19,0/41 %0.0
Atrial fibrillation,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,1/84 %1.19,1/41 %2.44
Cardiac arrest,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,2/84 %2.38,0/41 %0.0
Cardiac failure,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,2/84 %2.38,0/41 %0.0
Cardiogenic shock,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,0/84 %0.0,1/41 %2.44
Myocardial infarction,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,2/84 %2.38,1/41 %2.44
Tachyarrhythmia,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,1/84 %1.19,0/41 %0.0
Ventricular fibrillation,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,1/84 %1.19,0/41 %0.0
Myocarditis,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,1/69 %1.45,0/84 %0.0,0/41 %0.0
Tachycardia,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,1/69 %1.45,0/84 %0.0,0/41 %0.0
Mydriasis,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,1/84 %1.19,0/41 %0.0
Gastrointestinal haemorrhage,0/17 %0.0,0/6 %0.0,1/4 %25.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,2/84 %2.38,0/41 %0.0
Impaired gastric emptying,1/17 %5.88,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,0/84 %0.0,0/41 %0.0
Nausea,0/17 %0.0,1/6 %16.67,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,1/84 %1.19,1/41 %2.44
Neutropenic colitis,1/17 %5.88,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,0/84 %0.0,0/41 %0.0
Vomiting,0/17 %0.0,1/6 %16.67,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,1/84 %1.19,1/41 %2.44
Abdominal pain,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,2/69 %2.9,0/84 %0.0,0/41 %0.0
Upper gastrointestinal haemorrhage,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,1/69 %1.45,0/84 %0.0,0/41 %0.0
Diarrhoea,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,1/69 %1.45,0/84 %0.0,1/41 %2.44
Colitis,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,1/84 %1.19,0/41 %0.0
Constipation,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,1/84 %1.19,0/41 %0.0
Gastrooesophageal reflux disease,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,1/84 %1.19,0/41 %0.0
Haematemesis,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,1/84 %1.19,0/41 %0.0
Lower gastrointestinal haemorrhage,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,0/84 %0.0,1/41 %2.44
Pancreatitis acute,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,1/84 %1.19,0/41 %0.0
Retroperitoneal haematoma,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,1/84 %1.19,0/41 %0.0
Disease progression,3/17 %17.65,1/6 %16.67,1/4 %25.0,0/3 %0.0,0/16 %0.0,1/6 %16.67,2/69 %2.9,10/84 %11.9,5/41 %12.2
Fatigue,1/17 %5.88,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,3/84 %3.57,0/41 %0.0
Multiple organ dysfunction syndrome,1/17 %5.88,0/6 %0.0,1/4 %25.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,0/84 %0.0,0/41 %0.0
Nodule,1/17 %5.88,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,0/84 %0.0,0/41 %0.0
Pyrexia,0/17 %0.0,1/6 %16.67,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,3/84 %3.57,1/41 %2.44
Asthenia,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,0/84 %0.0,1/41 %2.44
Death,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,1/84 %1.19,0/41 %0.0
General physical health deterioration,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,0/84 %0.0,1/41 %2.44
Mucosal inflammation,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,1/84 %1.19,0/41 %0.0
Oedema,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,1/84 %1.19,0/41 %0.0
Sudden death,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,2/84 %2.38,0/41 %0.0
Cholecystitis,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,2/69 %2.9,0/84 %0.0,0/41 %0.0
Appendicitis,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,1/16 %6.25,0/6 %0.0,0/69 %0.0,0/84 %0.0,0/41 %0.0
Bacteraemia,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,1/16 %6.25,0/6 %0.0,2/69 %2.9,1/84 %1.19,0/41 %0.0
Cellulitis,0/17 %0.0,0/6 %0.0,1/4 %25.0,0/3 %0.0,0/16 %0.0,1/6 %16.67,0/69 %0.0,1/84 %1.19,0/41 %0.0
Clostridium difficile infection,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,1/16 %6.25,0/6 %0.0,0/69 %0.0,0/84 %0.0,0/41 %0.0
Enterobacter sepsis,1/17 %5.88,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,0/84 %0.0,0/41 %0.0
Enterocolitis infectious,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,2/16 %12.5,0/6 %0.0,0/69 %0.0,0/84 %0.0,0/41 %0.0
Lower respiratory tract infection bacterial,1/17 %5.88,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,0/84 %0.0,0/41 %0.0
Neutropenic sepsis,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,1/16 %6.25,0/6 %0.0,0/69 %0.0,0/84 %0.0,0/41 %0.0
Pneumonia,2/17 %11.76,0/6 %0.0,2/4 %50.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,4/69 %5.8,19/84 %22.62,7/41 %17.07
Sepsis,1/17 %5.88,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,6/69 %8.7,3/84 %3.57,5/41 %12.2
Skin infection,0/17 %0.0,1/6 %16.67,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,1/84 %1.19,0/41 %0.0
Staphylococcal bacteraemia,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,1/6 %16.67,1/69 %1.45,0/84 %0.0,0/41 %0.0
Septic shock,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,1/69 %1.45,2/84 %2.38,1/41 %2.44
Abscess,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,1/84 %1.19,0/41 %0.0
Aspergillus infection,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,1/84 %1.19,0/41 %0.0
Clostridium difficile colitis,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,1/69 %1.45,1/84 %1.19,0/41 %0.0
Cystitis,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,0/84 %0.0,1/41 %2.44
Device related infection,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,1/84 %1.19,0/41 %0.0
Escherichia urinary tract infection,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,1/84 %1.19,0/41 %0.0
Herpes zoster,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,1/84 %1.19,0/41 %0.0
Infected dermal cyst,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,1/84 %1.19,0/41 %0.0
Influenza,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,1/84 %1.19,1/41 %2.44
Lung infection,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,1/84 %1.19,1/41 %2.44
Otitis media chronic,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,1/84 %1.19,0/41 %0.0
Pneumonia fungal,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,1/84 %1.19,0/41 %0.0
Pseudomembranous colitis,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,0/84 %0.0,1/41 %2.44
Respiratory tract infection,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,1/84 %1.19,0/41 %0.0
Septic encephalopathy,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,1/84 %1.19,0/41 %0.0
Urogenital infection bacterial,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,0/84 %0.0,1/41 %2.44
Adenovirus infection,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,1/69 %1.45,0/84 %0.0,0/41 %0.0
Arthritis bacterial,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,1/69 %1.45,0/84 %0.0,0/41 %0.0
Mycobacterium avium complex infection,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,1/69 %1.45,0/84 %0.0,0/41 %0.0
Pharyngitis,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,1/69 %1.45,0/84 %0.0,0/41 %0.0
Pneumocystis jirovecii pneumonia,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,1/69 %1.45,0/84 %0.0,0/41 %0.0
Pseudomonal sepsis,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,1/69 %1.45,0/84 %0.0,0/41 %0.0
Tooth abscess,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,1/69 %1.45,0/84 %0.0,0/41 %0.0
Abdominal infection,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,1/84 %1.19,0/41 %0.0
Clostridial sepsis,1/17 %5.88,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,0/84 %0.0,0/41 %0.0
Fall,0/17 %0.0,2/6 %33.33,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,2/84 %2.38,0/41 %0.0
Skin abrasion,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,1/16 %6.25,0/6 %0.0,0/69 %0.0,0/84 %0.0,0/41 %0.0
Infusion related reaction,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,1/69 %1.45,1/84 %1.19,0/41 %0.0
Subdural haematoma,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,2/69 %2.9,0/84 %0.0,0/41 %0.0
Femur fracture,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,1/84 %1.19,0/41 %0.0
Subarachnoid haemorrhage,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,0/84 %0.0,0/41 %0.0
Splenic rupture,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,0/84 %0.0,1/41 %2.44
Thoracic vertebral fracture,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,1/84 %1.19,0/41 %0.0
Lumbar puncture abnormal,0/17 %0.0,1/6 %16.67,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,0/84 %0.0,0/41 %0.0
Alanine aminotransferase increased,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,1/69 %1.45,0/84 %0.0,0/41 %0.0
Aspartate aminotransferase increased,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,1/69 %1.45,0/84 %0.0,0/41 %0.0
Laboratory test abnormal,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,0/84 %0.0,1/41 %2.44
Dehydration,0/17 %0.0,1/6 %16.67,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,0/84 %0.0,0/41 %0.0
Gout,1/17 %5.88,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,1/84 %1.19,0/41 %0.0
Hyperuricaemia,1/17 %5.88,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,0/84 %0.0,0/41 %0.0
Hyponatraemia,0/17 %0.0,0/6 %0.0,1/4 %25.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,1/69 %1.45,2/84 %2.38,0/41 %0.0
Tumour lysis syndrome,1/17 %5.88,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,0/84 %0.0,0/41 %0.0
Decreased appetite,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,1/84 %1.19,0/41 %0.0
Arthralgia,0/17 %0.0,1/6 %16.67,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,0/84 %0.0,0/41 %0.0
Myalgia,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,1/16 %6.25,0/6 %0.0,0/69 %0.0,1/84 %1.19,0/41 %0.0
Back pain,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,1/69 %1.45,1/84 %1.19,0/41 %0.0
Muscle spasms,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,1/84 %1.19,0/41 %0.0
Muscular weakness,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,2/84 %2.38,0/41 %0.0
Squamous cell carcinoma of skin,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,0/84 %0.0,1/41 %2.44
Autonomic nervous system imbalance,0/17 %0.0,1/6 %16.67,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,0/84 %0.0,0/41 %0.0
Dizziness,0/17 %0.0,0/6 %0.0,0/4 %0.0,1/3 %33.33,0/16 %0.0,0/6 %0.0,0/69 %0.0,0/84 %0.0,0/41 %0.0
Ischaemic stroke,0/17 %0.0,0/6 %0.0,1/4 %25.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,0/84 %0.0,0/41 %0.0
Neurotoxicity,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,1/16 %6.25,0/6 %0.0,0/69 %0.0,0/84 %0.0,0/41 %0.0
Polyneuropathy,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,1/16 %6.25,0/6 %0.0,0/69 %0.0,0/84 %0.0,0/41 %0.0
Subarachnoid haemorrhage,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,1/16 %6.25,0/6 %0.0,0/69 %0.0,1/84 %1.19,0/41 %0.0
Dyskinesia,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,1/69 %1.45,0/84 %0.0,0/41 %0.0
Presyncope,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,1/69 %1.45,1/84 %1.19,0/41 %0.0
Syncope,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,1/69 %1.45,4/84 %4.76,0/41 %0.0
Cerebral haemorrhage,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,1/84 %1.19,0/41 %0.0
Haemorrhage intracranial,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,3/84 %3.57,1/41 %2.44
Peripheral sensorimotor neuropathy,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,1/84 %1.19,0/41 %0.0
Transient ischaemic attack,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,1/84 %1.19,0/41 %0.0
Cerebrovascular accident,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,1/84 %1.19,0/41 %0.0
Bipolar II disorder,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,1/16 %6.25,0/6 %0.0,0/69 %0.0,0/84 %0.0,0/41 %0.0
Mental status changes,0/17 %0.0,1/6 %16.67,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,0/84 %0.0,0/41 %0.0
Confusional state,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,1/69 %1.45,0/84 %0.0,0/41 %0.0
Acute kidney injury,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,1/69 %1.45,3/84 %3.57,0/41 %0.0
Acute respiratory distress syndrome,1/17 %5.88,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,1/84 %1.19,0/41 %0.0
Respiratory failure,0/17 %0.0,0/6 %0.0,1/4 %25.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,0/84 %0.0,0/41 %0.0
Pleuritic pain,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,1/69 %1.45,0/84 %0.0,0/41 %0.0
Pneumonitis,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,1/69 %1.45,0/84 %0.0,0/41 %0.0
Cough,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,0/84 %0.0,1/41 %2.44
Dyspnoea,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,1/84 %1.19,0/41 %0.0
Pleural effusion,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,1/84 %1.19,1/41 %2.44
Pulmonary embolism,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,1/84 %1.19,0/41 %0.0
Respiratory arrest,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,0/84 %0.0,1/41 %2.44
Respiratory distress,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,1/84 %1.19,0/41 %0.0
Rash generalised,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,1/16 %6.25,0/6 %0.0,0/69 %0.0,0/84 %0.0,0/41 %0.0
Rash maculo-papular,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,1/16 %6.25,0/6 %0.0,0/69 %0.0,0/84 %0.0,0/41 %0.0
Rash,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,1/84 %1.19,0/41 %0.0
Skin toxicity,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,1/84 %1.19,0/41 %0.0
Hypotension,0/17 %0.0,1/6 %16.67,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,1/69 %1.45,0/84 %0.0,0/41 %0.0
Haemorrhage,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,1/84 %1.19,0/41 %0.0
Hypertension,0/17 %0.0,0/6 %0.0,0/4 %0.0,0/3 %0.0,0/16 %0.0,0/6 %0.0,0/69 %0.0,1/84 %1.19,0/41 %0.0

Study of Intensive Consolidation and Stem Cell Mobilization Therapy Followed by Autologous Stem Cell Transplantation in High-risk Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma(https://clinicaltrials.gov/show/NCT01555541)
 ,Treatment
 ,OVA Treatment:  Ofatumumab: 1000 mg IV days 0 7 14 21  Etoposide: 10 mg/Kg IV over 24 hours daily days 1-4  Cytarabine: 2000 mg/m2 IV twice daily days 1-4  ---------  After Day 42 assessment:  Autologous Transplantation:  Stem Cell Infusion on day 0  BCNU 15 mg/Kg day -6  Etoposide 60 mg/Kg day -4  Cyclophosphamide: 100 mg/Kg day -2
Total all-cause mortality,1/19 %5.26
Total serious adverse events,5/19 %26.32
Anal Pain,1/19 %5.26
Retroperitoneal hemorrhage,1/19 %5.26
Allergic reaction,1/19 %5.26
Sepsis,1/19 %5.26
Tremor,1/19 %5.26
Pneumonitis,1/19 %5.26

Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDS(https://clinicaltrials.gov/show/NCT01607645)
 ,Arm I (Decitabine Day -4 to Day 0) Idarubicin Cytarabine),Arm II (Decitabine (Day -9 to Day -5) Idarubicin Cytarabine)
 ,Patients receive decitabine IV over 1 hour on days -4 to 0 cytarabine IV continuously over 24 hours on days 1-7 and idarubicin IV over 10-15 minutes on days 1-3.  decitabine: Given IV  idarubicin: Given IV  cytarabine: Given IV,Patients receive decitabine IV over 1 hour on days -9 to -5 and cytarabine and idarubicin as in Arm I.  decitabine: Given IV  idarubicin: Given IV  cytarabine: Given IV
Total serious adverse events,0/4 %0.0,1/3 %33.33
Grade 4 Infection,0/4 %0.0,1/3 %33.33

Phase II Study of V-BEAM Conditioning Regimen Prior to Second Autologous Stem Cell Transplantation(https://clinicaltrials.gov/show/NCT01653418)
 ,V-BEAM + Stem Cell Infusion
 ,Bortezomib IV or SC (1.3mg/m2) on Days -6 -3 +1 and +4 Carmustine IV (300mg/m2) on Day -7 Etoposide IV twice daily (100 mg/m2) on Days -6 -5 -4 and -3 Cytarabine IV twice daily (100 mg/m2) on Days -6 -5 -4 and -3 Melphalan IV (140 mg/m2) on Day-2 Stem cell infusion on Day 0
Total serious adverse events,4/10 %40.0
Diarrhea,1/10 %10.0
Multi-organ failure,1/10 %10.0
Febrile neutropenia,1/10 %10.0
Sepsis (death),2/10 %20.0

Trial of Eltrombopag During Consolidation Therapy in Adults With AML in Complete Remission(https://clinicaltrials.gov/show/NCT01656252)
 ,Phase I- Cytarabine & Eltrombopag
 ,Cycle 1= Cytarabine twice daily on Days 1 3 and 5 and Eltrombopag (Open-Label) until platelet recovery or for 35 consecutive days whichever occurs first. Phase I will determine the dose and schedule of Eltrombopag to be used in Phase II.  Phase I- Cytarabine & Eltrombopag: Cycle 1= Cytarabine 3 g/m IV twice daily on Days 1 3 and 5 (Patients >60 years of age will receive cytarabine 1.5 g/m IV per dose). Day 1 must start in AM.  Eltrombopag (Open-Label) by mouth daily until platelet recovery or for 35 consecutive days whichever occurs first. Phase I will determine the dose and schedule of Eltrombopag to be used in Phase II.  One cycle of consolidation therapy with high-dose cytarabine and eltrombopag will be received on study. Additional chemotherapy may be administered at the investigators discretion without eltrombopag.
Total serious adverse events,0/14 %0.0

A Phase 1 Trial of TST of PD 0332991 Followed by Cytarabine and Mitoxantrone for Adults With Relapsed and Refractory Acute Leukemias and High-Risk Myelodysplasia(https://clinicaltrials.gov/show/NCT01701375)
 ,Arm 1
 ,PD 0332991 will be given orally days 123  Cytarabine (ara-C) will be given by continuous 72 hour intravenous infusion beginning on day 6  Mitoxantrone will be given over 2 hour infusion day 9 12 hours after the completion of the ara-C infusion. The mitoxantrone dose may be reduced by 25-50% for patients who have received previous anthracyclines as determined by total previous anthracycline dose
Total serious adverse events,1/2 %50.0
Bone marrow aplasia,1/2 %50.0
Hyperbilirubinemia,1/2 %50.0

Decitabine Followed by Mitoxantrone Hydrochloride  Etoposide  and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes(https://clinicaltrials.gov/show/NCT01729845)
 ,Dose Level 1: 5-Days of Decitabine-MEC,Dose Level 2: 7-Days of Decitabine-MEC,Dose Level 3: 10-days of Decitabine-MEC
 ,Patients receive decitabine IV days -9 to -5 (dose level 1).  INDUCTION THERAPY: Patients receive mitoxantrone hydrochloride IV on days 1-5 etoposide IV on days 1-5 and cytarabine IV on days 1-5. Patients achieving CR or CR with CRp may receive up to 2 courses of induction therapy and up to 2 courses of consolidation therapy.  Cytarabine: Given IV Decitabine: Given IV Etoposide: Given IV Mitoxantrone Hydrochloride: Given IV,Patients receive decitabine IV days -11 to -5 (dose level 2).  INDUCTION THERAPY: Patients receive mitoxantrone hydrochloride IV on days 1-5 etoposide IV on days 1-5 and cytarabine IV on days 1-5. Patients achieving CR or CR with CRp may receive up to 2 courses of induction therapy and up to 2 courses of consolidation therapy.  Cytarabine: Given IV Decitabine: Given IV Etoposide: Given IV Mitoxantrone Hydrochloride: Given IV,Patients receive decitabine IV days -14 to -5 (dose level 3).  INDUCTION THERAPY: Patients receive mitoxantrone hydrochloride IV on days 1-5 etoposide IV on days 1-5 and cytarabine IV on days 1-5. Patients achieving CR or CR with CRp may receive up to 2 courses of induction therapy and up to 2 courses of consolidation therapy.  Cytarabine: Given IV Decitabine: Given IV Etoposide: Given IV Mitoxantrone Hydrochloride: Given IV
Total all-cause mortality,2/6 %33.33,1/34 %2.94,0/12 %0.0
Total serious adverse events,0/6 %0.0,0/34 %0.0,0/12 %0.0

Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia(https://clinicaltrials.gov/show/NCT01769209)
 ,Bortezomib + Chemotherapy
 ,Patients receive bortezomib on Days 1 4 8 and 11; doxorubicin hydrochloride on Day 1; PEG-asparaginase on Days 5 and 22; vincristine sulfate on Days 1 8 15 and 22; dexamethasone daily on Days 1 to 14; cytarabine on Day 1 and methotrexate on Day 15.  Bortezomib: Administered subcutaneously (SC) at 1.3 mg/m on Days 1 4 8 and 11.  Doxorubicin hydrochloride (HCl): Administered intravenously (IV) over 15 min at 60mg/m on Day 1.  PEG-Asparaginase: Administered intravenously (IV) or intramuscularly (IM) 2500 U/m (maximum 3750 U) on Days 5 and 22.  Vincristine sulfate: Administered by intravenous (IV) push at 1.5 mg/m (maximum 2 mg) on Days 1 8 15 and 22.  Dexamethasone: Administered orally (PO) at 10 mg/m daily on Days 1 to 14.  Cytarabine: Administered intrathecally (IT) at 100 mg on Day 1  Methotrexate: Administered intrathecally (IT) at 15 mg on Day 15.
Total all-cause mortality,13/18 %72.22
Total serious adverse events,10/18 %55.56
Neutropenic fever (febrile neutropenia),1/18 %5.56
Disseminated intravascular coagulation (DIC),1/18 %5.56
Colon and caecum inflammation (typhilitis colitis),1/18 %5.56
Hepatobilliary Disorders-Other veno-occlusive disease,1/18 %5.56
Septic shock (sepsis),5/18 %27.78
Intracranial hemorrhage,1/18 %5.56

Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia(https://clinicaltrials.gov/show/NCT01802333)
 ,Arm I (Standard Dose Cytarabine Daunorubicin Hydrochloride),Arm II (High-dose Cytarabine Idarubicin),Arm III (Vorinostat High-dose Cytarabine Idarubicin)
 ,INDUCTION/RE-INDUCTION: Patients receive standard dose cytarabine IV continuously on days 1-7 and daunorubicin hydrochloride IV on days 1-3. Patients with residual blasts may receive re-induction treatment beginning on day 15. Patients achieving CR or CRi may proceed to allogeneic HSCT or to consolidation therapy.,INDUCTION/RE-INDUCTION: Patients receive high dose cytarabine IV continuously on days 1-4 and idarubicin IV over 15 minutes on days 1-3. Patients with residual blasts may receive re-induction treatment beginning on day 28. Patients achieving CR or CRi may proceed to allogeneic HSCT or to consolidation therapy.,INDUCTION/RE-INDUCTION: Patients receive vorinostat PO TID on days 1-3 high-dose cytarabine IV continuously on days 4-7 and idarubicin IV over 15 minutes on days 4-6. Patients with residual blasts may receive re-induction treatment beginning on day 28. Patients achieving CR or CRi may proceed to allogeneic HSCT or to consolidation therapy.
Total all-cause mortality,126/261 %48.28,114/259 %44.02,103/211 %48.82
Total serious adverse events,11/261 %4.21,27/259 %10.42,75/211 %35.55
Febrile neutropenia,1/261 %0.38,4/259 %1.54,13/211 %6.16
Leukocytosis,0/261 %0.0,0/259 %0.0,1/211 %0.47
Atrial fibrillation,0/261 %0.0,2/259 %0.77,1/211 %0.47
Atrial flutter,0/261 %0.0,0/259 %0.0,1/211 %0.47
Cardiac arrest,1/261 %0.38,4/259 %1.54,2/211 %0.95
Heart failure,0/261 %0.0,0/259 %0.0,1/211 %0.47
Pericardial effusion,0/261 %0.0,0/259 %0.0,3/211 %1.42
Pericardial tamponade,0/261 %0.0,0/259 %0.0,1/211 %0.47
Sinus tachycardia,0/261 %0.0,1/259 %0.39,3/211 %1.42
Supraventricular tachycardia,0/261 %0.0,0/259 %0.0,1/211 %0.47
Abdominal distension,0/261 %0.0,0/259 %0.0,1/211 %0.47
Abdominal pain,0/261 %0.0,0/259 %0.0,5/211 %2.37
Colitis,0/261 %0.0,0/259 %0.0,6/211 %2.84
Colonic hemorrhage,0/261 %0.0,0/259 %0.0,1/211 %0.47
Colonic perforation,0/261 %0.0,0/259 %0.0,1/211 %0.47
Diarrhea,0/261 %0.0,0/259 %0.0,6/211 %2.84
Enterocolitis,0/261 %0.0,2/259 %0.77,2/211 %0.95
Esophageal hemorrhage,0/261 %0.0,0/259 %0.0,1/211 %0.47
Esophagitis,0/261 %0.0,0/259 %0.0,1/211 %0.47
Fecal incontinence,0/261 %0.0,0/259 %0.0,1/211 %0.47
Gastric hemorrhage,0/261 %0.0,1/259 %0.39,1/211 %0.47
Gastritis,0/261 %0.0,0/259 %0.0,1/211 %0.47
Gastrointestinal disorders-Other,0/261 %0.0,1/259 %0.39,1/211 %0.47
Ileus,0/261 %0.0,0/259 %0.0,2/211 %0.95
Jejunal obstruction,0/261 %0.0,0/259 %0.0,1/211 %0.47
Lower gastrointestinal hemorrhage,0/261 %0.0,0/259 %0.0,1/211 %0.47
Mucositis oral,0/261 %0.0,0/259 %0.0,3/211 %1.42
Nausea,0/261 %0.0,0/259 %0.0,1/211 %0.47
Typhlitis,1/261 %0.38,0/259 %0.0,7/211 %3.32
Vomiting,1/261 %0.38,0/259 %0.0,1/211 %0.47
Death NOS,2/261 %0.77,1/259 %0.39,1/211 %0.47
Edema limbs,0/261 %0.0,0/259 %0.0,2/211 %0.95
Edema trunk,0/261 %0.0,0/259 %0.0,1/211 %0.47
Gait disturbance,0/261 %0.0,0/259 %0.0,1/211 %0.47
General disorders and admin site conditions - Other,0/261 %0.0,1/259 %0.39,0/211 %0.0
Multi-organ failure,1/261 %0.38,2/259 %0.77,4/211 %1.9
Neck edema,0/261 %0.0,0/259 %0.0,1/211 %0.47
Cholecystitis,0/261 %0.0,0/259 %0.0,1/211 %0.47
Hepatic failure,1/261 %0.38,0/259 %0.0,0/211 %0.0
Hepatobiliary disorders-Other,1/261 %0.38,0/259 %0.0,1/211 %0.47
Allergic reaction,0/261 %0.0,0/259 %0.0,1/211 %0.47
Enterocolitis infectious,0/261 %0.0,0/259 %0.0,1/211 %0.47
Infections and infestations-Other,0/261 %0.0,0/259 %0.0,5/211 %2.37
Lip infection,0/261 %0.0,0/259 %0.0,1/211 %0.47
Lung infection,0/261 %0.0,1/259 %0.39,4/211 %1.9
Sepsis,1/261 %0.38,11/259 %4.25,17/211 %8.06
Upper respiratory infection,0/261 %0.0,0/259 %0.0,1/211 %0.47
Urinary tract infection,0/261 %0.0,0/259 %0.0,1/211 %0.47
Activated partial thromboplastin time prolonged,0/261 %0.0,0/259 %0.0,1/211 %0.47
Alanine aminotransferase increased,0/261 %0.0,0/259 %0.0,6/211 %2.84
Alkaline phosphatase increased,0/261 %0.0,0/259 %0.0,2/211 %0.95
Aspartate aminotransferase increased,0/261 %0.0,0/259 %0.0,5/211 %2.37
Blood bilirubin increased,0/261 %0.0,1/259 %0.39,7/211 %3.32
Cardiac troponin I increased,0/261 %0.0,1/259 %0.39,0/211 %0.0
Creatinine increased,0/261 %0.0,0/259 %0.0,1/211 %0.47
Ejection fraction decreased,0/261 %0.0,0/259 %0.0,3/211 %1.42
Electrocardiogram QT corrected interval prolonged,0/261 %0.0,0/259 %0.0,1/211 %0.47
Fibrinogen decreased,0/261 %0.0,0/259 %0.0,1/211 %0.47
GGT increased,0/261 %0.0,0/259 %0.0,2/211 %0.95
INR increased,0/261 %0.0,0/259 %0.0,1/211 %0.47
Platelet count decreased,0/261 %0.0,0/259 %0.0,2/211 %0.95
Weight gain,0/261 %0.0,0/259 %0.0,1/211 %0.47
Weight loss,0/261 %0.0,0/259 %0.0,1/211 %0.47
Acidosis,0/261 %0.0,0/259 %0.0,2/211 %0.95
Alkalosis,0/261 %0.0,0/259 %0.0,1/211 %0.47
Anorexia,0/261 %0.0,0/259 %0.0,5/211 %2.37
Dehydration,0/261 %0.0,0/259 %0.0,1/211 %0.47
Hyperglycemia,0/261 %0.0,0/259 %0.0,3/211 %1.42
Hypernatremia,0/261 %0.0,0/259 %0.0,2/211 %0.95
Hypoalbuminemia,1/261 %0.38,0/259 %0.0,3/211 %1.42
Hypocalcemia,1/261 %0.38,0/259 %0.0,4/211 %1.9
Hypokalemia,1/261 %0.38,0/259 %0.0,6/211 %2.84
Hyponatremia,1/261 %0.38,0/259 %0.0,2/211 %0.95
Hypophosphatemia,0/261 %0.0,1/259 %0.39,2/211 %0.95
Tumor lysis syndrome,0/261 %0.0,1/259 %0.39,4/211 %1.9
Back pain,0/261 %0.0,0/259 %0.0,1/211 %0.47
Generalized muscle weakness,0/261 %0.0,0/259 %0.0,3/211 %1.42
Musculoskeletal and connective tiss disorder - Other,0/261 %0.0,0/259 %0.0,1/211 %0.47
Myalgia,0/261 %0.0,0/259 %0.0,1/211 %0.47
Pain in extremity,0/261 %0.0,0/259 %0.0,1/211 %0.47
Ataxia,0/261 %0.0,0/259 %0.0,1/211 %0.47
Edema cerebral,0/261 %0.0,0/259 %0.0,1/211 %0.47
Encephalopathy,0/261 %0.0,0/259 %0.0,1/211 %0.47
Headache,1/261 %0.38,0/259 %0.0,0/211 %0.0
Intracranial hemorrhage,0/261 %0.0,0/259 %0.0,2/211 %0.95
Ischemia cerebrovascular,0/261 %0.0,0/259 %0.0,1/211 %0.47
Nervous system disorders-Other,1/261 %0.38,1/259 %0.39,0/211 %0.0
Paresthesia,0/261 %0.0,0/259 %0.0,1/211 %0.47
Peripheral sensory neuropathy,0/261 %0.0,0/259 %0.0,1/211 %0.47
Reversible posterior leukoencephalopathy syndrome,0/261 %0.0,0/259 %0.0,1/211 %0.47
Seizure,1/261 %0.38,0/259 %0.0,2/211 %0.95
Somnolence,0/261 %0.0,0/259 %0.0,1/211 %0.47
Stroke,0/261 %0.0,0/259 %0.0,3/211 %1.42
Vasovagal reaction,0/261 %0.0,0/259 %0.0,1/211 %0.47
Acute kidney injury,2/261 %0.77,4/259 %1.54,9/211 %4.27
Urinary incontinence,0/261 %0.0,0/259 %0.0,1/211 %0.47
Genital edema,0/261 %0.0,0/259 %0.0,1/211 %0.47
Adult respiratory distress syndrome,1/261 %0.38,3/259 %1.16,4/211 %1.9
Bronchopulmonary hemorrhage,0/261 %0.0,0/259 %0.0,2/211 %0.95
Dyspnea,0/261 %0.0,1/259 %0.39,2/211 %0.95
Hypoxia,0/261 %0.0,2/259 %0.77,5/211 %2.37
Pleural effusion,0/261 %0.0,0/259 %0.0,2/211 %0.95
Pulmonary edema,0/261 %0.0,1/259 %0.39,5/211 %2.37
Resp thoracic and mediastinal disorders - Other,0/261 %0.0,1/259 %0.39,1/211 %0.47
Respiratory failure,3/261 %1.15,6/259 %2.32,15/211 %7.11
Erythroderma,0/261 %0.0,0/259 %0.0,1/211 %0.47
Rash maculo-papular,0/261 %0.0,0/259 %0.0,2/211 %0.95
Hematoma,0/261 %0.0,1/259 %0.39,0/211 %0.0
Hypertension,0/261 %0.0,0/259 %0.0,3/211 %1.42
Hypotension,0/261 %0.0,2/259 %0.77,8/211 %3.79
Thromboembolic event,0/261 %0.0,0/259 %0.0,3/211 %1.42

Daunorubicin Hydrochloride  Cytarabine  and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia(https://clinicaltrials.gov/show/NCT01806571)
 ,Treatment (Nilotinib Daunorubicin Hydrochloride Cytarabine)
 ,INDUCTION THERAPY: Patients receive daunorubicin hydrochloride IV over 10 minutes on days 1-3 cytarabine IV continuously on days 1-7 and nilotinib PO BID on days 4-14. Patients achieving CR or CRi proceed to consolidation therapy. Patients not achieving a significant decrease in bone marrow recovery or CR/CRi upon bone marrow recovery receive another course of induction therapy. CONSOLIDATION THERAPY: Patients receive cytarabine IV every 12 hours on days 1 3 and 5 and nilotinib PO BID on days 4-14. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients achieving CR or CRi proceed to maintenance therapy. MAINTENANCE THERAPY: Patients receive nilotinib PO BID on days 1-84. Treatment repeats every 84 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Cytarabine: Given IV Daunorubicin Hydrochloride: Given IV Laboratory Biomarker Analysis: Correlative studies Nilotinib: Given PO
Total all-cause mortality,1/34 %2.94
Total serious adverse events,31/34 %91.18
Febrile neutropenia,18/34 %52.94
Atrial fibrillation,1/34 %2.94
Atrial flutter,1/34 %2.94
Heart failure,1/34 %2.94
Sinus tachycardia,1/34 %2.94
Vertigo,1/34 %2.94
Gastrointestinal disorders - Other specify,1/34 %2.94
Jejunal hemorrhage,1/34 %2.94
Nausea,1/34 %2.94
Pancreatitis,1/34 %2.94
Rectal fistula,1/34 %2.94
Vomiting,1/34 %2.94
Hepatic failure,1/34 %2.94
Hepatobiliary disorders - Other specify,1/34 %2.94
Anorectal infection,2/34 %5.88
Appendicitis,1/34 %2.94
Catheter related infection,2/34 %5.88
Enterocolitis infectious,1/34 %2.94
Infections and infestations - Other specify,3/34 %8.82
Lung infection,4/34 %11.76
Sepsis,5/34 %14.71
Alanine aminotransferase increased,7/34 %20.59
Alkaline phosphatase increased,1/34 %2.94
Aspartate aminotransferase increased,5/34 %14.71
Blood bilirubin increased,5/34 %14.71
Ejection fraction decreased,1/34 %2.94
Electrocardiogram QT corrected interval prolonged,1/34 %2.94
Lipase increased,1/34 %2.94
Serum amylase increased,2/34 %5.88
Hyperglycemia,3/34 %8.82
Hyperkalemia,1/34 %2.94
Hyperuricemia,1/34 %2.94
Hypocalcemia,2/34 %5.88
Hypokalemia,2/34 %5.88
Hypophosphatemia,4/34 %11.76
Metabolism and nutrition disorders - Other specify,1/34 %2.94
Peripheral motor neuropathy,1/34 %2.94
Syncope,1/34 %2.94
Confusion,1/34 %2.94
Proteinuria,1/34 %2.94
Menorrhagia,1/34 %2.94
Aspiration,1/34 %2.94
Hypoxia,1/34 %2.94
Pneumonitis,1/34 %2.94
Pulmonary edema,1/34 %2.94
Respiratory failure,3/34 %8.82
Sore throat,1/34 %2.94
Rash maculo-papular,2/34 %5.88
Hypertension,5/34 %14.71
Hypotension,2/34 %5.88

Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)(https://clinicaltrials.gov/show/NCT01829503)
 ,Decitabine + Cytarabine
 ,Participants received decitabine 20mg/m^2 intravenously (IV) for five days followed by cytarabine 100mg/m^2 continuous IV infusion over 24 hours for five days
Total serious adverse events,30/44 %68.18
Anemia,3/44 %6.82
Blood and lymphatic system disorders,1/44 %2.27
Febrile neutropenia,5/44 %11.36
Chest pain - cardiac,1/44 %2.27
Sinus tachycardia,1/44 %2.27
Abdominal pain,1/44 %2.27
Constipation,1/44 %2.27
Diarrhea,1/44 %2.27
Small intestinal obstruction,1/44 %2.27
Death NOS,2/44 %4.55
Fever,2/44 %4.55
General disorders and administration site conditions,1/44 %2.27
Malaise,1/44 %2.27
Multi-organ failure,1/44 %2.27
Pain,1/44 %2.27
Infections and infestations,1/44 %2.27
Lung infection,1/44 %2.27
Sepsis,1/44 %2.27
Skin infection,1/44 %2.27
Fall,1/44 %2.27
Fracture,1/44 %2.27
Hip fracture,1/44 %2.27
Intraoperative venous injury,1/44 %2.27
Creatinine increased,2/44 %4.55
INR increased,1/44 %2.27
Lymphocyte count decreased,1/44 %2.27
Neutrophil count decreased,1/44 %2.27
Platelet count decreased,1/44 %2.27
White blood cell decreased,3/44 %6.82
Dehydration,1/44 %2.27
Hyperglycemia,1/44 %2.27
Hypoalbuminemia,2/44 %4.55
Hypokalemia,1/44 %2.27
Dizziness,1/44 %2.27
Encephalopathy,1/44 %2.27
Intracranial hemorrhage,1/44 %2.27
Stroke,1/44 %2.27
Syncope,1/44 %2.27
Acute kidney injury,1/44 %2.27
Renal and urinary disorders,1/44 %2.27
Hypoxia,2/44 %4.55
Respiratory failure,2/44 %4.55
Hypertension,2/44 %4.55
Hypotension,1/44 %2.27
Vascular disorders - Other specify,1/44 %2.27

Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML(https://clinicaltrials.gov/show/NCT01849276)
 ,Treatment (Enzyme Inhibitor and Chemotherapy)
 ,Patients receive metformin hydrochloride orally twice a day on days 1-15 and cytarabine IV over 3 hours twice on days 4-10.  metformin hydrochloride: Given orally  cytarabine: Given IV  laboratory biomarker analysis: Correlative studies
Total all-cause mortality,2/2 %100.0
Total serious adverse events,2/2 %100.0
Gastric perforation,1/2 %50.0
Other-Transminitis,1/2 %50.0
Sepsis,1/2 %50.0

A Study of Decitabine (DACOGEN) in Sequential Administration With Cytarabine in Children With Relapsed or Refractory Acute Myeloid Leukemia(https://clinicaltrials.gov/show/NCT01853228)
 ,Phase 1 (Cohort 1): Dacogen + Cytarabine,Phase 1 (Cohort 2) and Phase 2: Dacogen + Cytarabine
 ,Participants received decitabine 20 milligram per square meter (mg/m^2) by intravenous infusion over 1 hour once daily for 5 consecutive days (Day 1 to Day 5 of each 28-day cycle) in Phase 1. In addition participants received cytarabine 1 gram per square meter (g/m^2) and 2 g/m^2 dose levels administered by intravenous infusion over 4 hours daily for 5 consecutive days (Day 8 to Day 12 of each 28-day cycle) for the determination of the maximum tolerated dose in Phase 1.,Participants received decitabine 20 mg/m^2 by intravenous infusion over 1 hour once daily for 5 consecutive days (Day 1 to Day 5 of a 28-day cycle) in Phase 1 and Phase 2. In addition participants received cytarabine 2 g/m^2 dose levels administered by intravenous infusion over 4 hours daily for 5 consecutive days (Day 8 to Day 12 of a 28-day cycle) for the determination of the maximum tolerated dose in Cohort 2 of Phase 1 and continued to receive (2 g/m^2) in Phase 2.
Total all-cause mortality,8/9 %88.89,6/8 %75.0
Total serious adverse events,4/9 %44.44,4/8 %50.0
Anaemia,0/9 %0.0,1/8 %12.5
Febrile Neutropenia,3/9 %33.33,2/8 %25.0
Neutropenia,0/9 %0.0,1/8 %12.5
Thrombocytopenia,0/9 %0.0,1/8 %12.5
Keratitis,0/9 %0.0,1/8 %12.5
Complication Associated with Device,1/9 %11.11,0/8 %0.0
Pyrexia,1/9 %11.11,1/8 %12.5
Lung Infection,0/9 %0.0,1/8 %12.5
Sepsis,0/9 %0.0,2/8 %25.0
Skin Exfoliation,1/9 %11.11,0/8 %0.0
Skin Hyperpigmentation,1/9 %11.11,0/8 %0.0

Vincristine  Doxorubicin  And Dexamethasone + Ixazomib in Acute Lymphoblastic Leukemia (ALL)  Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia(https://clinicaltrials.gov/show/NCT01887587)
 ,(Modified VXLD) Plus MLN9708
 ,Vincristine-1.5 mg/m2 to a max dose of 2 mg IV on days 1 8 15 and 22  Dexamethasone- 10 mg/m2 orally or IV on days 1-14  Doxorubicin- 60 mg/m2 on day 1 by IV bolus.  For patients without CNS involvement:  Cytarabine 100 mg will be administered intrathecally on day 1 (+/-1 day) (cytarabine dose should be reduced to 50 mg if given through a central ommaya reservoir)  Methotrexate 12 mg will be administered intrathecally on day 8 (+/-1 day)  For patients with CNS involvement:  -Cytarabine 100 mg will be administered intrathecally on day 1 (+/-1 day) (cytarabine dose should be reduced to 50 mg if given through a central ommaya reservoir) Triple intrathecal chemotherapy with cytarabine 30 mg methotrexate 15 mg and hydrocortisone 15 mg on (Day 1 8 15 and 22 (+/-1 day)).  MLN9708  Vincristine  Doxorubicin  Dexamethasone
Total all-cause mortality,1/5 %20.0
Total serious adverse events,4/5 %80.0
Febrile neutropenia,1/5 %20.0
Sinus tachycardia,1/5 %20.0
Lactic acidosis,1/5 %20.0
Increased blood bilirubin,1/5 %20.0
Sepsis,3/5 %60.0
Methemoglobinemia,1/5 %20.0
Hypotension,1/5 %20.0

A Safety and Efficacy Study of Eltrombopag in Subjects With AML(https://clinicaltrials.gov/show/NCT01890746)
 ,Eltrombopag (ELQ) QD,Placebo QD
 ,Par. received IDN CTY consisting of DAU bolus IV INF on D 1-3 at a dose of 90 mg/m^2 for Par. 18-60 years old or 60 mg/m^2 for Par.>60 years old plus cytarabine 100 mg/m^2 continuous IV INF on D1-7. Par. received ELT as 200 mg (100 mg for East-Asian Heritage) QD oral dose starting on D4 of initial IDN CTY at least 20 hours after end of D3 DAU INF. If PT count was not >100 Gi/L after 7 days the dose was increased to 300 mg (150 mg East-Asian Heritage) QD until a PT count of at least 200 Gi/L was achieved until remission was assessed by bone marrow biopsy or for a maximum of 42 days from the start of the CTY IDN cycle. Par. who were not aplastic after first cycle of IDN CTY received re-IDN with a modified DAU dose of 45mg/m^2/day on D1-3 plus cytarabine 100 mg/m^2/day on D1-7. For re-IDN Par. ELT was held from D1-3 of re-IDN and resumed on D4 at the same dose and duration.,Participants received first line IDN CTY consisting of DAU bolus IV INF on Days 1-3 at a dose of 90 mg/m^2 for participants 18-60 years old or 60 mg/m^2 for participants >60 years of age plus cytarabine continuous IV INF on Days 1-7 at a dose of 100 mg/m^2. Participants received placebo QD oral dose starting on Day 4 of initial IDN CTY at least 20 hours after end of Day 3 DAU INF up to a maximum duration of 42 days.
Total all-cause mortality,11/74 %14.86,4/71 %5.63
Total serious adverse events,24/74 %32.43,14/71 %19.72
Febrile neutropenia,1/74 %1.35,0/71 %0.0
Atrial fibrillation,2/74 %2.7,0/71 %0.0
Cardiac failure,1/74 %1.35,1/71 %1.41
Cardiac failure congestive,0/74 %0.0,1/71 %1.41
Cardiomyopathy,0/74 %0.0,1/71 %1.41
Left ventricular dysfunction,1/74 %1.35,0/71 %0.0
Myocardial infarction,1/74 %1.35,0/71 %0.0
Hydrocele,1/74 %1.35,0/71 %0.0
Abdominal pain,1/74 %1.35,0/71 %0.0
Constipation,0/74 %0.0,1/71 %1.41
Neutropenic colitis,0/74 %0.0,1/71 %1.41
Generalised oedema,0/74 %0.0,1/71 %1.41
Pyrexia,1/74 %1.35,1/71 %1.41
Sudden death,0/74 %0.0,1/71 %1.41
Acinetobacter bacteraemia,0/74 %0.0,1/71 %1.41
Appendicitis,1/74 %1.35,0/71 %0.0
Bronchitis,1/74 %1.35,0/71 %0.0
Catheter site infection,0/74 %0.0,1/71 %1.41
Klebsiella sepsis,1/74 %1.35,0/71 %0.0
Neutropenic sepsis,0/74 %0.0,1/71 %1.41
Perirectal abscess,0/74 %0.0,1/71 %1.41
Pneumonia,0/74 %0.0,1/71 %1.41
Sepsis,1/74 %1.35,2/71 %2.82
Septic shock,2/74 %2.7,2/71 %2.82
Systemic candida,1/74 %1.35,0/71 %0.0
Alanine aminotransferase increased,0/74 %0.0,1/71 %1.41
Blood bilirubin increased,1/74 %1.35,0/71 %0.0
Ejection fraction decreased,0/74 %0.0,2/71 %2.82
Hypernatraemia,0/74 %0.0,1/71 %1.41
Pseudohyperkalaemia,1/74 %1.35,0/71 %0.0
Cerebral haemorrhage,1/74 %1.35,0/71 %0.0
Cerebrovascular accident,1/74 %1.35,0/71 %0.0
Cognitive disorder,1/74 %1.35,0/71 %0.0
Haemorrhage intracranial,2/74 %2.7,0/71 %0.0
Acute kidney injury,3/74 %4.05,1/71 %1.41
Renal failure,1/74 %1.35,0/71 %0.0
Pulmonary alveolar haemorrhage,1/74 %1.35,0/71 %0.0
Pulmonary embolism,1/74 %1.35,0/71 %0.0
Pulmonary haemorrhage,1/74 %1.35,0/71 %0.0
Respiratory failure,1/74 %1.35,0/71 %0.0

Study of Melphalan HCl for Injection (Propylene Glycol-free)  Carmustine  Etoposide  Cytarabine (BEAM Regimen) and Autologous Stem Cell Transplantation for Lymphoma(https://clinicaltrials.gov/show/NCT01969435)
 ,Melphalan Carmustine Etoposide Cytarabine (BEAM)
 ,Day -7 carmustine intravenous (IV) infusion  Days -6 -5 -4 and -3 etoposide and cytarabine (IV) infusions twice a day  Day -2 melphalan HCl (propylene glycol-free)(IV) infusion  Day 0 stem cell transplant.
Total serious adverse events,1/50 %2.0
Multi-organ failure due to sepsis,1/50 %2.0

Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)(https://clinicaltrials.gov/show/NCT02013167)
 ,Standard of Care Chemotherapy,Blinatumomab
 ,Participants received one of four prespecified investigator-chosen chemotherapy regimens for 2 induction cycles. Participants who achieved a bone marrow response CR/CRh*/CRi within 2 induction cycles of treatment could receive up to 3 additional consolidation cycles of SOC chemotherapy.  Participants who received 2 induction and up to 3 consolidation cycles of therapy and continued to have a bone marrow response or CR/CRh*/CRi could continue to receive SOC therapy for an additional 12 months.,Participants received blinatumomab by continuous intravenous infusion (CIVI) over 4 weeks followed by a 2 week treatment-free interval for 2 induction cycles. Participants who achieved a bone marrow response complete remission or complete remission with partial or incomplete hematologic recovery (CR/CRh*/CRi) within 2 induction cycles of treatment could receive up to 3 additional consolidation cycles of blinatumomab.  Participants who received 2 induction and up to 3 consolidation cycles of therapy and continued to have a bone marrow response or CR/CRh*/CRi could continue to receive blinatumomab for an additional 12 months (4 cycles) where 1 cycle consisted of 4 weeks of CIVI followed by an 8-week treatment-free period.  The initial dose of blinatumomab was 9 g/day for the first 7 days of treatment increased to 28 g/day starting on day 8 through day 29 and for all subsequent cycles.
Total serious adverse events,49/109 %44.95,165/267 %61.8
Agranulocytosis,1/109 %0.92,0/267 %0.0
Anaemia,0/109 %0.0,1/267 %0.37
Febrile bone marrow aplasia,0/109 %0.0,1/267 %0.37
Febrile neutropenia,12/109 %11.01,23/267 %8.61
Histiocytosis haematophagic,0/109 %0.0,3/267 %1.12
Leukocytosis,0/109 %0.0,3/267 %1.12
Leukopenia,1/109 %0.92,0/267 %0.0
Lymphadenopathy,0/109 %0.0,1/267 %0.37
Neutropenia,2/109 %1.83,2/267 %0.75
Pancytopenia,1/109 %0.92,3/267 %1.12
Thrombocytopenia,1/109 %0.92,0/267 %0.0
Acute myocardial infarction,0/109 %0.0,1/267 %0.37
Atrial fibrillation,0/109 %0.0,1/267 %0.37
Atrial flutter,0/109 %0.0,1/267 %0.37
Cardiac arrest,1/109 %0.92,1/267 %0.37
Cardiac failure congestive,0/109 %0.0,1/267 %0.37
Cardiac tamponade,1/109 %0.92,0/267 %0.0
Cardiopulmonary failure,0/109 %0.0,1/267 %0.37
Pericardial effusion,0/109 %0.0,1/267 %0.37
Supraventricular tachycardia,1/109 %0.92,0/267 %0.0
Aplasia,0/109 %0.0,1/267 %0.37
Abdominal pain,0/109 %0.0,2/267 %0.75
Gastric haemorrhage,0/109 %0.0,1/267 %0.37
Gastrointestinal inflammation,1/109 %0.92,0/267 %0.0
Gastrointestinal necrosis,0/109 %0.0,1/267 %0.37
Haematemesis,0/109 %0.0,1/267 %0.37
Mouth haemorrhage,1/109 %0.92,0/267 %0.0
Nausea,0/109 %0.0,1/267 %0.37
Pancreatitis,1/109 %0.92,0/267 %0.0
Stomatitis,0/109 %0.0,1/267 %0.37
Vomiting,0/109 %0.0,2/267 %0.75
Asthenia,0/109 %0.0,2/267 %0.75
Chest pain,0/109 %0.0,1/267 %0.37
Death,0/109 %0.0,1/267 %0.37
Discomfort,0/109 %0.0,1/267 %0.37
General physical health deterioration,0/109 %0.0,2/267 %0.75
Hyperthermia,0/109 %0.0,1/267 %0.37
Medical device complication,0/109 %0.0,1/267 %0.37
Multi-organ failure,1/109 %0.92,4/267 %1.5
Oedema peripheral,0/109 %0.0,1/267 %0.37
Pyrexia,1/109 %0.92,16/267 %5.99
Systemic inflammatory response syndrome,0/109 %0.0,1/267 %0.37
Acute hepatic failure,1/109 %0.92,0/267 %0.0
Cholelithiasis,0/109 %0.0,1/267 %0.37
Cholestasis,1/109 %0.92,0/267 %0.0
Hepatitis,0/109 %0.0,1/267 %0.37
Acute graft versus host disease in skin,0/109 %0.0,1/267 %0.37
Anaphylactic shock,0/109 %0.0,1/267 %0.37
Cytokine release syndrome,0/109 %0.0,7/267 %2.62
Graft versus host disease,0/109 %0.0,1/267 %0.37
Graft versus host disease in liver,0/109 %0.0,1/267 %0.37
Abscess fungal,1/109 %0.92,0/267 %0.0
Bacteraemia,3/109 %2.75,2/267 %0.75
Bacterial infection,0/109 %0.0,2/267 %0.75
Bacterial sepsis,2/109 %1.83,6/267 %2.25
Brain abscess,1/109 %0.92,0/267 %0.0
Bronchitis,0/109 %0.0,1/267 %0.37
Bronchopulmonary aspergillosis,1/109 %0.92,4/267 %1.5
Catheter site infection,0/109 %0.0,2/267 %0.75
Cellulitis,0/109 %0.0,1/267 %0.37
Central nervous system abscess,1/109 %0.92,0/267 %0.0
Citrobacter infection,0/109 %0.0,1/267 %0.37
Citrobacter sepsis,1/109 %0.92,0/267 %0.0
Device related infection,1/109 %0.92,6/267 %2.25
Device related sepsis,2/109 %1.83,1/267 %0.37
Encephalitis enteroviral,0/109 %0.0,1/267 %0.37
Enterococcal bacteraemia,1/109 %0.92,0/267 %0.0
Enterococcal infection,1/109 %0.92,0/267 %0.0
Escherichia infection,0/109 %0.0,2/267 %0.75
Fungaemia,0/109 %0.0,1/267 %0.37
Fungal infection,1/109 %0.92,0/267 %0.0
Fungal sepsis,0/109 %0.0,2/267 %0.75
Fusarium infection,1/109 %0.92,0/267 %0.0
Gastroenteritis,0/109 %0.0,2/267 %0.75
Hepatosplenic candidiasis,1/109 %0.92,0/267 %0.0
Infection,0/109 %0.0,1/267 %0.37
Infection in an immunocompromised host,0/109 %0.0,1/267 %0.37
Influenza,0/109 %0.0,1/267 %0.37
Lower respiratory tract infection,0/109 %0.0,1/267 %0.37
Lower respiratory tract infection fungal,0/109 %0.0,1/267 %0.37
Lung infection,1/109 %0.92,1/267 %0.37
Mastoiditis,0/109 %0.0,1/267 %0.37
Meningitis bacterial,0/109 %0.0,1/267 %0.37
Mucormycosis,0/109 %0.0,1/267 %0.37
Muscle abscess,0/109 %0.0,1/267 %0.37
Neutropenic sepsis,1/109 %0.92,3/267 %1.12
Osteomyelitis,0/109 %0.0,1/267 %0.37
Otitis media acute,0/109 %0.0,1/267 %0.37
Pneumonia,2/109 %1.83,10/267 %3.75
Pneumonia bacterial,0/109 %0.0,1/267 %0.37
Pneumonia fungal,2/109 %1.83,1/267 %0.37
Pneumonia pseudomonal,0/109 %0.0,1/267 %0.37
Pneumonia respiratory syncytial viral,0/109 %0.0,1/267 %0.37
Progressive multifocal leukoencephalopathy,0/109 %0.0,1/267 %0.37
Pseudomonal sepsis,1/109 %0.92,3/267 %1.12
Pseudomonas infection,1/109 %0.92,3/267 %1.12
Pulmonary mycosis,0/109 %0.0,1/267 %0.37
Respiratory syncytial virus bronchiolitis,0/109 %0.0,1/267 %0.37
Rhinovirus infection,1/109 %0.92,0/267 %0.0
Sepsis,7/109 %6.42,13/267 %4.87
Sepsis syndrome,0/109 %0.0,1/267 %0.37
Septic shock,3/109 %2.75,8/267 %3.0
Sinusitis,0/109 %0.0,1/267 %0.37
Skin infection,0/109 %0.0,1/267 %0.37
Soft tissue infection,1/109 %0.92,0/267 %0.0
Staphylococcal infection,1/109 %0.92,2/267 %0.75
Staphylococcal sepsis,0/109 %0.0,1/267 %0.37
Streptococcal sepsis,1/109 %0.92,0/267 %0.0
Systemic candida,1/109 %0.92,0/267 %0.0
Tooth infection,0/109 %0.0,1/267 %0.37
Accidental overdose,0/109 %0.0,3/267 %1.12
Ankle fracture,1/109 %0.92,0/267 %0.0
Fall,0/109 %0.0,1/267 %0.37
Medication error,0/109 %0.0,1/267 %0.37
Overdose,0/109 %0.0,8/267 %3.0
Subdural haematoma,0/109 %0.0,1/267 %0.37
Subdural haemorrhage,0/109 %0.0,1/267 %0.37
Blood bilirubin increased,0/109 %0.0,2/267 %0.75
Blood lactate dehydrogenase increased,0/109 %0.0,1/267 %0.37
CSF cell count abnormal,0/109 %0.0,1/267 %0.37
Platelet count decreased,0/109 %0.0,1/267 %0.37
Transaminases increased,0/109 %0.0,1/267 %0.37
Weight increased,0/109 %0.0,1/267 %0.37
White blood cell count decreased,0/109 %0.0,1/267 %0.37
White blood cell count increased,0/109 %0.0,1/267 %0.37
Hypercalcaemia,0/109 %0.0,1/267 %0.37
Hyperkalaemia,1/109 %0.92,0/267 %0.0
Hyperuricaemia,0/109 %0.0,2/267 %0.75
Hypoglycaemia,1/109 %0.92,0/267 %0.0
Hypokalaemia,0/109 %0.0,1/267 %0.37
Hypomagnesaemia,0/109 %0.0,1/267 %0.37
Hypophosphataemia,0/109 %0.0,2/267 %0.75
Lactic acidosis,1/109 %0.92,1/267 %0.37
Metabolic acidosis,1/109 %0.92,0/267 %0.0
Tumour lysis syndrome,0/109 %0.0,3/267 %1.12
Back pain,0/109 %0.0,2/267 %0.75
Bone pain,0/109 %0.0,3/267 %1.12
Osteitis,1/109 %0.92,0/267 %0.0
Acute lymphocytic leukaemia,0/109 %0.0,1/267 %0.37
Leukaemic infiltration extramedullary,0/109 %0.0,1/267 %0.37
Leukaemic infiltration pulmonary,0/109 %0.0,1/267 %0.37
Tumour associated fever,0/109 %0.0,1/267 %0.37
Aphasia,0/109 %0.0,3/267 %1.12
Cerebral haemorrhage,0/109 %0.0,1/267 %0.37
Cognitive disorder,0/109 %0.0,1/267 %0.37
Depressed level of consciousness,0/109 %0.0,1/267 %0.37
Encephalopathy,0/109 %0.0,4/267 %1.5
Generalised tonic-clonic seizure,1/109 %0.92,0/267 %0.0
Haemorrhage intracranial,2/109 %1.83,1/267 %0.37
Haemorrhagic stroke,0/109 %0.0,1/267 %0.37
Hemianopia,0/109 %0.0,1/267 %0.37
Hemiparesis,0/109 %0.0,1/267 %0.37
Hemiplegia,1/109 %0.92,0/267 %0.0
Hypoaesthesia,0/109 %0.0,1/267 %0.37
Intention tremor,0/109 %0.0,1/267 %0.37
Leukoencephalopathy,0/109 %0.0,1/267 %0.37
Neurological symptom,0/109 %0.0,1/267 %0.37
Paraesthesia,0/109 %0.0,1/267 %0.37
Seizure,1/109 %0.92,1/267 %0.37
Somnolence,0/109 %0.0,1/267 %0.37
Status epilepticus,0/109 %0.0,1/267 %0.37
Tremor,0/109 %0.0,1/267 %0.37
Completed suicide,0/109 %0.0,1/267 %0.37
Mental status changes,0/109 %0.0,1/267 %0.37
Acute kidney injury,2/109 %1.83,3/267 %1.12
Calculus ureteric,0/109 %0.0,1/267 %0.37
Urinary bladder haemorrhage,1/109 %0.92,0/267 %0.0
Acute respiratory failure,0/109 %0.0,2/267 %0.75
Dyspnoea,0/109 %0.0,2/267 %0.75
Epistaxis,0/109 %0.0,2/267 %0.75
Haemoptysis,0/109 %0.0,2/267 %0.75
Hypoxia,0/109 %0.0,1/267 %0.37
Lung infiltration,1/109 %0.92,1/267 %0.37
Pleural effusion,1/109 %0.92,1/267 %0.37
Pneumonitis,0/109 %0.0,1/267 %0.37
Pneumothorax,1/109 %0.92,0/267 %0.0
Pulmonary oedema,0/109 %0.0,1/267 %0.37
Respiratory arrest,0/109 %0.0,1/267 %0.37
Respiratory failure,2/109 %1.83,1/267 %0.37
Stridor,0/109 %0.0,1/267 %0.37
Alopecia,0/109 %0.0,1/267 %0.37
Skin ulcer,0/109 %0.0,1/267 %0.37
Catheter placement,0/109 %0.0,1/267 %0.37
Aortic occlusion,0/109 %0.0,1/267 %0.37
Hypotension,2/109 %1.83,0/267 %0.0
Peripheral artery thrombosis,1/109 %0.92,0/267 %0.0
Shock,1/109 %0.92,0/267 %0.0

CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome(https://clinicaltrials.gov/show/NCT02019069)
 ,Liposomal Cytarabine-daunorubicin CPX-351
 ,1st INDUCTION: Patients receive liposomal cytarabine-daunorubicin CPX-351 IV at a dose of 65 units/m2/day over 90 minutes on days 1 3 and 5.  2nd INDUCTION: Patients receive liposomal cytarabine-daunorubicin CPX-351 IV a dose of 65 units/m2/day over 90 minutes on days 1 and 3.  CONSOLIDATION: Beginning on day 28 patients receive liposomal cytarabine-daunorubicin CPX-351 IV a dose of 65 units/m2/day over 90 minutes on days 1 and 3.  liposomal cytarabine-daunorubicin CPX-351: Given IV
Total all-cause mortality,10/11 %90.91
Total serious adverse events,5/11 %45.45
Febrile neutropenia,4/11 %36.36
Anemia,1/11 %9.09
Cardio-pulmonary arrest,1/11 %9.09
Chills,1/11 %9.09
Neoplasms - Other Acute myelogenous leukemia,1/11 %9.09
Pneumonia,2/11 %18.18
Adult repiratory distress syndrome (ARDS),1/11 %9.09
Respiratory failure,1/11 %9.09

Omacetaxine Mepesuccinate  Cytarabine  and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia(https://clinicaltrials.gov/show/NCT02029417)
 ,Treatment (Cytarabine Omacetaxine Mepesuccinate Decitabine)
 ,INDUCTION CHEMOTHERAPY: Patients receive cytarabine SC BID and omacetaxine mepesuccinate SC BID on days 1-14. Treatment for induction therapy repeats every 28 days for up to 4 courses or until patients achieve CR in the absence of disease progression or unacceptable toxicity.  CONSOLIDATION THERAPY: Patients alternate courses between decitabine and OAG. Patients receive decitabine IV on days 1-5. Patients alternate with OAG courses comprising cytarabine SC BID on days 1-7 and omacetaxine mepesuccinate SC BID on days 1-7. Treatment repeats every 28 days for up to 24 months in the absence of disease progression or unacceptable toxicity.  cytarabine: Given SC  omacetaxine mepesuccinate: Given SC  decitabine: Given IV  laboratory biomarker analysis: Correlative studies
Total serious adverse events,2/2 %100.0
Sepsis,2/2 %100.0

Filgrastim  Cladribine  Cytarabine  and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes(https://clinicaltrials.gov/show/NCT02044796)
 ,Newly Diagnosed Group Mitoxantrone Hydrochloride 12 mg/m^2,Newly Diagnosed Group Mitoxantrone Hydrochloride 14 mg/m^2,Newly Diagnosed Group Mitoxantrone Hydrochloride 16 mg/m^2,Newly Diagnosed Group Mitoxantrone Hydrochloride 18 mg/m^2,Relapsed/Refractory Group Mitoxantrone Hydrochloride 12 mg/m^2,Relapsed/Refractory Group Mitoxantrone Hydrochloride 14 mg/m^2,Relapsed/Refractory Group Mitoxantrone Hydrochloride 16 mg/m^2,Relapsed/Refractory Group Mitoxantrone Hydrochloride 18 mg/m^2,Phase 2 Newly Diagnosed Group 18 mg/m^2,Phase 2 Relapsed/Refractory Group 16 mg/m^2
 ,INDUCTION CHEMOTHERAPY (G-CLAM): Patients receive G-CLAM chemotherapy comprising filgrastim SC daily on days 0-5 mitoxantrone hydrochloride IV over 60 minutes on days 1-3 cladribine IV over 2 hours daily on days 1-5 and cytarabine IV over 2 hours daily on days 1-5. Patients achieving CRi partial remission or persistent disease may receive a second course of induction chemotherapy. Patients achieving CR or CRp may continue on to Consolidation Chemotherapy.  CONSOLIDATION CHEMOTHERAPY (G-CLA): Beginning within 6 weeks of achieving CR/CRp/CRi patients receive G-CLA comprising filgrastim SC on days 0-5 cladribine IV over 2 hours daily on days 1-5 and cytarabine IV over 2 hours daily on days 1-5. Treatment continues for up to 4 courses in the absence of disease progression or unacceptable toxicity.  Cladribine: Given IV  Cytarabine: Given IV  Filgrastim: Given SC  Laboratory Biomarker Analysis: Correlative studies  Mitoxantrone Hydrochloride: Given IV,INDUCTION CHEMOTHERAPY (G-CLAM): Patients receive G-CLAM chemotherapy comprising filgrastim SC daily on days 0-5 mitoxantrone hydrochloride IV over 60 minutes on days 1-3 cladribine IV over 2 hours daily on days 1-5 and cytarabine IV over 2 hours daily on days 1-5. Patients achieving CRi partial remission or persistent disease may receive a second course of induction chemotherapy. Patients achieving CR or CRp may continue on to Consolidation Chemotherapy.  CONSOLIDATION CHEMOTHERAPY (G-CLA): Beginning within 6 weeks of achieving CR/CRp/CRi patients receive G-CLA comprising filgrastim SC on days 0-5 cladribine IV over 2 hours daily on days 1-5 and cytarabine IV over 2 hours daily on days 1-5. Treatment continues for up to 4 courses in the absence of disease progression or unacceptable toxicity.  Cladribine: Given IV  Cytarabine: Given IV  Filgrastim: Given SC  Laboratory Biomarker Analysis: Correlative studies  Mitoxantrone Hydrochloride: Given IV,INDUCTION CHEMOTHERAPY (G-CLAM): Patients receive G-CLAM chemotherapy comprising filgrastim SC daily on days 0-5 mitoxantrone hydrochloride IV over 60 minutes on days 1-3 cladribine IV over 2 hours daily on days 1-5 and cytarabine IV over 2 hours daily on days 1-5. Patients achieving CRi partial remission or persistent disease may receive a second course of induction chemotherapy. Patients achieving CR or CRp may continue on to Consolidation Chemotherapy.  CONSOLIDATION CHEMOTHERAPY (G-CLA): Beginning within 6 weeks of achieving CR/CRp/CRi patients receive G-CLA comprising filgrastim SC on days 0-5 cladribine IV over 2 hours daily on days 1-5 and cytarabine IV over 2 hours daily on days 1-5. Treatment continues for up to 4 courses in the absence of disease progression or unacceptable toxicity.  Cladribine: Given IV  Cytarabine: Given IV  Filgrastim: Given SC  Laboratory Biomarker Analysis: Correlative studies  Mitoxantrone Hydrochloride: Given IV,INDUCTION CHEMOTHERAPY (G-CLAM): Patients receive G-CLAM chemotherapy comprising filgrastim SC daily on days 0-5 mitoxantrone hydrochloride IV over 60 minutes on days 1-3 cladribine IV over 2 hours daily on days 1-5 and cytarabine IV over 2 hours daily on days 1-5. Patients achieving CRi partial remission or persistent disease may receive a second course of induction chemotherapy. Patients achieving CR or CRp may continue on to Consolidation Chemotherapy.  CONSOLIDATION CHEMOTHERAPY (G-CLA): Beginning within 6 weeks of achieving CR/CRp/CRi patients receive G-CLA comprising filgrastim SC on days 0-5 cladribine IV over 2 hours daily on days 1-5 and cytarabine IV over 2 hours daily on days 1-5. Treatment continues for up to 4 courses in the absence of disease progression or unacceptable toxicity.  Cladribine: Given IV  Cytarabine: Given IV  Filgrastim: Given SC  Laboratory Biomarker Analysis: Correlative studies  Mitoxantrone Hydrochloride: Given IV,INDUCTION CHEMOTHERAPY (G-CLAM): Patients receive G-CLAM chemotherapy comprising filgrastim SC daily on days 0-5 mitoxantrone hydrochloride IV over 60 minutes on days 1-3 cladribine IV over 2 hours daily on days 1-5 and cytarabine IV over 2 hours daily on days 1-5. Patients achieving CRi partial remission or persistent disease may receive a second course of induction chemotherapy. Patients achieving CR or CRp may continue on to Consolidation Chemotherapy.  CONSOLIDATION CHEMOTHERAPY (G-CLA): Beginning within 6 weeks of achieving CR/CRp/CRi patients receive G-CLA comprising filgrastim SC on days 0-5 cladribine IV over 2 hours daily on days 1-5 and cytarabine IV over 2 hours daily on days 1-5. Treatment continues for up to 4 courses in the absence of disease progression or unacceptable toxicity.  Cladribine: Given IV  Cytarabine: Given IV  Filgrastim: Given SC  Laboratory Biomarker Analysis: Correlative studies  Mitoxantrone Hydrochloride: Given IV,INDUCTION CHEMOTHERAPY (G-CLAM): Patients receive G-CLAM chemotherapy comprising filgrastim SC daily on days 0-5 mitoxantrone hydrochloride IV over 60 minutes on days 1-3 cladribine IV over 2 hours daily on days 1-5 and cytarabine IV over 2 hours daily on days 1-5. Patients achieving CRi partial remission or persistent disease may receive a second course of induction chemotherapy. Patients achieving CR or CRp may continue on to Consolidation Chemotherapy.  CONSOLIDATION CHEMOTHERAPY (G-CLA): Beginning within 6 weeks of achieving CR/CRp/CRi patients receive G-CLA comprising filgrastim SC on days 0-5 cladribine IV over 2 hours daily on days 1-5 and cytarabine IV over 2 hours daily on days 1-5. Treatment continues for up to 4 courses in the absence of disease progression or unacceptable toxicity.  Cladribine: Given IV  Cytarabine: Given IV  Filgrastim: Given SC  Laboratory Biomarker Analysis: Correlative studies  Mitoxantrone Hydrochloride: Given IV,INDUCTION CHEMOTHERAPY (G-CLAM): Patients receive G-CLAM chemotherapy comprising filgrastim SC daily on days 0-5 mitoxantrone hydrochloride IV over 60 minutes on days 1-3 cladribine IV over 2 hours daily on days 1-5 and cytarabine IV over 2 hours daily on days 1-5. Patients achieving CRi partial remission or persistent disease may receive a second course of induction chemotherapy. Patients achieving CR or CRp may continue on to Consolidation Chemotherapy.  CONSOLIDATION CHEMOTHERAPY (G-CLA): Beginning within 6 weeks of achieving CR/CRp/CRi patients receive G-CLA comprising filgrastim SC on days 0-5 cladribine IV over 2 hours daily on days 1-5 and cytarabine IV over 2 hours daily on days 1-5. Treatment continues for up to 4 courses in the absence of disease progression or unacceptable toxicity.  Cladribine: Given IV  Cytarabine: Given IV  Filgrastim: Given SC  Laboratory Biomarker Analysis: Correlative studies  Mitoxantrone Hydrochloride: Given IV,INDUCTION CHEMOTHERAPY (G-CLAM): Patients receive G-CLAM chemotherapy comprising filgrastim SC daily on days 0-5 mitoxantrone hydrochloride IV over 60 minutes on days 1-3 cladribine IV over 2 hours daily on days 1-5 and cytarabine IV over 2 hours daily on days 1-5. Patients achieving CRi partial remission or persistent disease may receive a second course of induction chemotherapy. Patients achieving CR or CRp may continue on to Consolidation Chemotherapy.  CONSOLIDATION CHEMOTHERAPY (G-CLA): Beginning within 6 weeks of achieving CR/CRp/CRi patients receive G-CLA comprising filgrastim SC on days 0-5 cladribine IV over 2 hours daily on days 1-5 and cytarabine IV over 2 hours daily on days 1-5. Treatment continues for up to 4 courses in the absence of disease progression or unacceptable toxicity.  Cladribine: Given IV  Cytarabine: Given IV  Filgrastim: Given SC  Laboratory Biomarker Analysis: Correlative studies  Mitoxantrone Hydrochloride: Given IV,INDUCTION CHEMOTHERAPY (G-CLAM): Patients receive G-CLAM chemotherapy comprising filgrastim SC daily on days 0-5 mitoxantrone hydrochloride IV over 60 minutes on days 1-3 cladribine IV over 2 hours daily on days 1-5 and cytarabine IV over 2 hours daily on days 1-5. Patients achieving CRi partial remission or persistent disease may receive a second course of induction chemotherapy. Patients achieving CR or CRp may continue on to Consolidation Chemotherapy.  CONSOLIDATION CHEMOTHERAPY (G-CLA): Beginning within 6 weeks of achieving CR/CRp/CRi patients receive G-CLA comprising filgrastim SC on days 0-5 cladribine IV over 2 hours daily on days 1-5 and cytarabine IV over 2 hours daily on days 1-5. Treatment continues for up to 4 courses in the absence of disease progression or unacceptable toxicity.  Cladribine: Given IV  Cytarabine: Given IV  Filgrastim: Given SC  Laboratory Biomarker Analysis: Correlative studies  Mitoxantrone Hydrochloride: Given IV,INDUCTION CHEMOTHERAPY (G-CLAM): Patients receive G-CLAM chemotherapy comprising filgrastim SC daily on days 0-5 mitoxantrone hydrochloride IV over 60 minutes on days 1-3 cladribine IV over 2 hours daily on days 1-5 and cytarabine IV over 2 hours daily on days 1-5. Patients achieving CRi partial remission or persistent disease may receive a second course of induction chemotherapy. Patients achieving CR or CRp may continue on to Consolidation Chemotherapy.  CONSOLIDATION CHEMOTHERAPY (G-CLA): Beginning within 6 weeks of achieving CR/CRp/CRi patients receive G-CLA comprising filgrastim SC on days 0-5 cladribine IV over 2 hours daily on days 1-5 and cytarabine IV over 2 hours daily on days 1-5. Treatment continues for up to 4 courses in the absence of disease progression or unacceptable toxicity.  Cladribine: Given IV  Cytarabine: Given IV  Filgrastim: Given SC  Laboratory Biomarker Analysis: Correlative studies  Mitoxantrone Hydrochloride: Given IV
Total all-cause mortality,0/9 %0.0,2/9 %22.22,2/9 %22.22,1/6 %16.67,6/10 %60.0,4/6 %66.67,4/6 %66.67,2/4 %50.0,40/106 %37.74,21/34 %61.76
Total serious adverse events,0/9 %0.0,0/9 %0.0,0/9 %0.0,0/6 %0.0,0/10 %0.0,0/6 %0.0,0/6 %0.0,0/4 %0.0,0/106 %0.0,0/34 %0.0

Adoptive Transfer of Haplo-identical DLI for AML and MDS(https://clinicaltrials.gov/show/NCT02046122)
 ,Idarubicin + Cytarabine + DLI
 ,Chemotherapy combined with adoptive transfer of HLA-haploidentical donor lymphocyte infusion (DLI)  Idarubicin: Eligible subjects will receive induction chemotherapy with idarubicin (12 mg/m2 intravenously for 3 days) and cytarabine (100 mg/m2 intravenously for 7 days) starting Day 1 and ending Day 7. Patients 80 years or older will only receive 2 and 5 days of idarubicin and cytarabine respectively starting Day 1 and ending Day 5.  Subjects who experience no remission or partial remission will receive a second course of the identical induction chemotherapy.  Cytarabine: Cytarabine (100 mg/m2 intravenously for 7 days) starting Day 1 and ending Day 7. Patients 80 years or older will only receive 2 and 5 days of idarubicin and cytarabine respectively starting Day 1 and ending Day 5.  Subjects who achieve a complete remission (CR) will receive 2 further courses of cytarabine postremission chemotherapy (consolidation) at 1.0 g/m2 for 6 dosages followed by HLA-mismatched DLI after
Total all-cause mortality,12/17 %70.59
Total serious adverse events,8/17 %47.06
Febrile neutropenia,1/17 %5.88
Atrial fibrillation,1/17 %5.88
Ileus,1/17 %5.88
Mucositis oral,1/17 %5.88
Multi-organ failure,1/17 %5.88
Hepatic failure,1/17 %5.88
Urinary tract infection,1/17 %5.88
Treatment related secondary malignancy,1/17 %5.88
Delirium,1/17 %5.88
Hypoxia,1/17 %5.88

AML Therapy With Irradiated Allogeneic Cells(https://clinicaltrials.gov/show/NCT02105116)
 ,Treatment (Combination Chemotherapy DLI)
 ,INDUCTION CHEMOTHERAPY: Patients receive fludarabine phosphate IV over 1 hour QD for 5 days and cytarabine IV over 4 hours for 5 days. G-CSF 5 mcg/kg will be started at day14 if day14 bone marrow does not have >5% leukemic blasts. Treatment may continue for 1 or 2 courses at the discretion of the treating physician.  ALLOGENEIC CELLULAR THERAPY: Patients undergo irradiated Donor Lymphocyte Infusion (DLI) of 3 x 10^8 CD3+ cells/kg at 8 weeks. Patients with stable disease may repeat irradiated DLI every 8-12 weeks in the absence of disease progression or unacceptable toxicity.  fludarabine phosphate: Given IV  cytarabine: Given IV  donor lymphocytes: Undergo infusion of donor lymphocytes  laboratory biomarker analysis: Correlative studies  G-CSF: Given IV
Total all-cause mortality,1/6 %16.67
Total serious adverse events,0/6 %0.0

Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)(https://clinicaltrials.gov/show/NCT02343939)
 ,Group A Phase 1b ENTO 200 mg + Cytarabine + Daunorubicin,Group A Phase 1b/2 ENTO 400 mg + Cytarabine + Daunorubicin,Group B Phase 1b ENTO 200 mg + Decitabine,Group B Phase 1b ENTO 400 mg + Decitabine,Group B Phase 2 ENTO 400 mg + Azacitidine (Safety Run-In),Group B Phase 2 ENTO 400 mg + Decitabine (Randomized),Group B Phase 2 ENTO 400 mg + Azacitidine (Randomized),Group C Phase 1b/2 ENTO 400 mg,Group C Phase 1b ENTO 800 mg
 ,Participants received ENTO 200 mg tablet orally every 12 hours on Days 1 to 14 (Cycle 0) (during monotherapy lead-in) followed by ENTO 200 mg tablet orally every 12 hours in combination with chemotherapy (cytarabine 100 mg/m^2 on Days 1-7 and daunorubicin 60 mg/m^2 on Days 1-3 intravenously) for up to two 14-day cycles (Cycles 1 and 2) (during induction chemotherapy).,Phase1b/2: Participants received ENTO 400 mg tablet orally every 12 hours on Days 1 to 14 (Cycle 0) (monotherapy lead-in) followed by ENTO 400 mg tablet orally every 12 hours in combination with chemotherapy (cytarabine 100 mg/m^2 on Days 1-7 and daunorubicin 60 mg/m^2 on Days 1-3 intravenously) for up to two 14-day cycles (Cycles 1 and 2) (induction chemotherapy).  Phase 2 only: Participants who achieved a CR/CRi and did not require or could not proceed to allogeneic stem cell transplantation (SCT) were offered post-remission chemotherapy (cytarabine 3 g/m^2 intravenously every 12 hours on Days 1 3 and 5 or 1 g/m^2 intravenously once daily on Days 1-5) in combination with ENTO 400 mg tablet orally every 12 hours on Days 1-28 of each 28-day cycle for at least 3 and up to 4 cycles. Participants who maintained a CR/CRi after 3 or 4 cycles were offered maintenance therapy with ENTO 400 mg tablet orally every 12 hours on Days 1-28 of each 28-day cycle for up to 12 cycles.,Participants received ENTO 200 mg tablet orally every 12 hours on Days 1-14 (Cycle 0) (during monotherapy lead-in) followed by ENTO 200 mg tablet orally every 12 hours in combination with decitabine 20 mg/m^2 intravenously on Days 1-10 of every 28-day cycle for 2 cycles (or up to 4 cycles for participants with persistent disease after Cycle 2 Day 28) (induction chemotherapy). Participants who achieved a CR/CRi received SCT (if eligible) per investigator's discretion; other participants were offered maintenance therapy with ENTO every 12 hours on Days 1-28 in combination with decitabine on Days 1-5 of every 28-day cycle for at least 2 cycles (maximum up to 12 cycles). Participants who were intolerant to decitabine were offered maintenance therapy with ENTO 200 mg as monotherapy after completing 2 maintenance cycles.,Participants received ENTO 400 mg tablet orally every 12 hours on Days 1-14 (Cycle 0) (during monotherapy lead-in) followed by ENTO 400 mg tablet orally every 12 hours in combination with decitabine 20 mg/m^2 intravenously on Days 1-10 of every 28-day cycle for 2 cycles (or up to 4 cycles for participants with persistent disease after Cycle 2 Day 28) (induction chemotherapy). Participants who achieved a CR/CRi received SCT (if eligible) per investigator's discretion; other participants were offered maintenance therapy with ENTO every 12 hours on Days 1-28 in combination with decitabine on Days 1-5 of every 28-day cycle for at least 2 cycles (maximum up to 12 cycles). Participants who were intolerant to decitabine were offered maintenance therapy with ENTO 400 mg as monotherapy after completing 2 maintenance cycles.,As part of the safety run-in participants received ENTO 400 mg tablet orally every 12 hours on Days 1-14 (Cycle 0) (during monotherapy lead-in) followed by ENTO 400 mg tablet orally every 12 hours in combination with azacitidine 75 mg/m^2 intravenously on Days 1-7 of a 28-day cycle (Cycle 1). Participants who were not eligible for SCT were offered maintenance therapy with ENTO every 12 hours on Days 1-28 in combination with azacitidine on Days 1-7 of every 28-day cycle for at least 2 cycles (maximum up to 12 cycles). Participants who were intolerant to azacitidine were offered maintenance therapy with ENTO 400 mg as monotherapy after completing 2 maintenance cycles.,Participants were randomized to receive ENTO 400 mg tablet orally every 12 hours on Days 1-5 (Cycle 0) (during monotherapy lead-in) followed by ENTO 400 mg tablet orally every 12 hours in combination with decitabine 20 mg/m^2 intravenously on Days 1-10 of every 28-day cycle for 2 cycles (or up to 4 cycles for participants with persistent disease after Cycle 2 Day 28). Participants who were not eligible for SCT were offered maintenance therapy with ENTO every 12 hours on Days 1-28 in combination with decitabine on Days 1-5 of every 28-day cycle for at least 2 cycles (maximum up to 12 cycles). Participants who were intolerant to decitabine were offered maintenance therapy with ENTO 400 mg as monotherapy after completing 2 maintenance cycles.,Participants were randomized to receive ENTO 400 mg tablet orally every 12 hours on Days 1-5 (Cycle 0) (during monotherapy lead-in) followed by ENTO 400 mg tablet orally every 12 hours in combination with azacitidine 75 mg/m^2 intravenously on Days 1-7 of every 28-day cycle for 2 cycles (or up to 4 cycles for participants with persistent disease after Cycle 2 Day 28). Participants who were not eligible for SCT were offered maintenance therapy with ENTO every 12 hours on Days 1-28 in combination with azacitidine on Days 1-7 of every 28-day cycle for at least 2 cycles (maximum up to 12 cycles). Participants who were intolerant to azacitidine were offered maintenance therapy with ENTO 400 mg as monotherapy after completing 2 maintenance cycles.,Participants received ENTO 400 mg tablet orally every 12 hours on Days 1-28 of every 28-day cycle until treatment failure start of new therapy unacceptable toxicity withdrawal of consent withdrawal from study by investigator or study termination by sponsor.,Participants received ENTO 800 mg tablet orally every 12 hours on Days 1-28 of every 28-day cycle until treatment failure start of new therapy unacceptable toxicity withdrawal of consent withdrawal from study by investigator or study termination by sponsor.
Total all-cause mortality,2/3 %66.67,21/50 %42.0,5/5 %100.0,4/6 %66.67,5/8 %62.5,12/17 %70.59,11/14 %78.57,30/35 %85.71,6/7 %85.71
Total serious adverse events,0/3 %0.0,23/50 %46.0,5/5 %100.0,5/6 %83.33,7/8 %87.5,11/17 %64.71,7/14 %50.0,19/35 %54.29,4/7 %57.14
Febrile neutropenia,0/3 %0.0,13/50 %26.0,4/5 %80.0,4/6 %66.67,3/8 %37.5,8/17 %47.06,0/14 %0.0,5/35 %14.29,0/7 %0.0
Angina pectoris,0/3 %0.0,0/50 %0.0,0/5 %0.0,0/6 %0.0,0/8 %0.0,1/17 %5.88,0/14 %0.0,0/35 %0.0,0/7 %0.0
Atrial fibrillation,0/3 %0.0,0/50 %0.0,1/5 %20.0,0/6 %0.0,0/8 %0.0,0/17 %0.0,0/14 %0.0,0/35 %0.0,0/7 %0.0
Cardiac arrest,0/3 %0.0,0/50 %0.0,0/5 %0.0,0/6 %0.0,0/8 %0.0,1/17 %5.88,0/14 %0.0,0/35 %0.0,0/7 %0.0
Cardiac failure chronic,0/3 %0.0,0/50 %0.0,0/5 %0.0,0/6 %0.0,0/8 %0.0,0/17 %0.0,1/14 %7.14,0/35 %0.0,0/7 %0.0
Cardiac failure congestive,0/3 %0.0,0/50 %0.0,0/5 %0.0,0/6 %0.0,0/8 %0.0,0/17 %0.0,0/14 %0.0,2/35 %5.71,0/7 %0.0
Sinus bradycardia,0/3 %0.0,0/50 %0.0,0/5 %0.0,0/6 %0.0,0/8 %0.0,0/17 %0.0,0/14 %0.0,1/35 %2.86,0/7 %0.0
Colitis,0/3 %0.0,0/50 %0.0,0/5 %0.0,1/6 %16.67,0/8 %0.0,0/17 %0.0,0/14 %0.0,0/35 %0.0,0/7 %0.0
Constipation,0/3 %0.0,0/50 %0.0,0/5 %0.0,0/6 %0.0,0/8 %0.0,0/17 %0.0,1/14 %7.14,0/35 %0.0,1/7 %14.29
Gastric haemorrhage,0/3 %0.0,1/50 %2.0,0/5 %0.0,0/6 %0.0,0/8 %0.0,0/17 %0.0,1/14 %7.14,0/35 %0.0,0/7 %0.0
Gastrointestinal haemorrhage,0/3 %0.0,0/50 %0.0,0/5 %0.0,0/6 %0.0,0/8 %0.0,1/17 %5.88,0/14 %0.0,1/35 %2.86,0/7 %0.0
Haematemesis,0/3 %0.0,2/50 %4.0,0/5 %0.0,0/6 %0.0,0/8 %0.0,0/17 %0.0,1/14 %7.14,0/35 %0.0,0/7 %0.0
Haematochezia,0/3 %0.0,0/50 %0.0,0/5 %0.0,0/6 %0.0,0/8 %0.0,0/17 %0.0,0/14 %0.0,1/35 %2.86,0/7 %0.0
Intestinal ischaemia,0/3 %0.0,0/50 %0.0,0/5 %0.0,0/6 %0.0,0/8 %0.0,1/17 %5.88,0/14 %0.0,0/35 %0.0,0/7 %0.0
Large intestine perforation,0/3 %0.0,1/50 %2.0,0/5 %0.0,0/6 %0.0,0/8 %0.0,0/17 %0.0,0/14 %0.0,0/35 %0.0,0/7 %0.0
Oesophagitis,0/3 %0.0,0/50 %0.0,0/5 %0.0,0/6 %0.0,0/8 %0.0,0/17 %0.0,0/14 %0.0,1/35 %2.86,0/7 %0.0
Proctalgia,0/3 %0.0,0/50 %0.0,0/5 %0.0,0/6 %0.0,0/8 %0.0,0/17 %0.0,0/14 %0.0,1/35 %2.86,0/7 %0.0
Stomatitis,0/3 %0.0,0/50 %0.0,0/5 %0.0,0/6 %0.0,0/8 %0.0,1/17 %5.88,0/14 %0.0,0/35 %0.0,0/7 %0.0
Vomiting,0/3 %0.0,0/50 %0.0,0/5 %0.0,0/6 %0.0,0/8 %0.0,0/17 %0.0,0/14 %0.0,1/35 %2.86,0/7 %0.0
Asthenia,0/3 %0.0,0/50 %0.0,0/5 %0.0,0/6 %0.0,1/8 %12.5,0/17 %0.0,0/14 %0.0,0/35 %0.0,0/7 %0.0
Catheter site haemorrhage,0/3 %0.0,1/50 %2.0,0/5 %0.0,0/6 %0.0,0/8 %0.0,0/17 %0.0,0/14 %0.0,0/35 %0.0,0/7 %0.0
Non-cardiac chest pain,0/3 %0.0,1/50 %2.0,0/5 %0.0,1/6 %16.67,0/8 %0.0,0/17 %0.0,0/14 %0.0,0/35 %0.0,0/7 %0.0
Pyrexia,0/3 %0.0,1/50 %2.0,1/5 %20.0,1/6 %16.67,1/8 %12.5,0/17 %0.0,0/14 %0.0,2/35 %5.71,0/7 %0.0
Anal abscess,0/3 %0.0,0/50 %0.0,0/5 %0.0,0/6 %0.0,0/8 %0.0,0/17 %0.0,0/14 %0.0,1/35 %2.86,0/7 %0.0
Bacteraemia,0/3 %0.0,1/50 %2.0,0/5 %0.0,0/6 %0.0,0/8 %0.0,1/17 %5.88,0/14 %0.0,0/35 %0.0,0/7 %0.0
Bacterial infection,0/3 %0.0,0/50 %0.0,0/5 %0.0,0/6 %0.0,0/8 %0.0,0/17 %0.0,1/14 %7.14,0/35 %0.0,0/7 %0.0
Cellulitis,0/3 %0.0,0/50 %0.0,0/5 %0.0,0/6 %0.0,0/8 %0.0,0/17 %0.0,0/14 %0.0,1/35 %2.86,0/7 %0.0
Cellulitis staphylococcal,0/3 %0.0,0/50 %0.0,0/5 %0.0,0/6 %0.0,1/8 %12.5,0/17 %0.0,0/14 %0.0,0/35 %0.0,0/7 %0.0
Clostridium difficile colitis,0/3 %0.0,0/50 %0.0,0/5 %0.0,0/6 %0.0,0/8 %0.0,0/17 %0.0,0/14 %0.0,1/35 %2.86,0/7 %0.0
Device related infection,0/3 %0.0,1/50 %2.0,0/5 %0.0,2/6 %33.33,0/8 %0.0,0/17 %0.0,0/14 %0.0,1/35 %2.86,0/7 %0.0
Enteritis infectious,0/3 %0.0,0/50 %0.0,0/5 %0.0,0/6 %0.0,1/8 %12.5,0/17 %0.0,0/14 %0.0,0/35 %0.0,0/7 %0.0
Escherichia sepsis,0/3 %0.0,0/50 %0.0,0/5 %0.0,0/6 %0.0,1/8 %12.5,0/17 %0.0,0/14 %0.0,0/35 %0.0,0/7 %0.0
Fungal infection,0/3 %0.0,0/50 %0.0,0/5 %0.0,0/6 %0.0,0/8 %0.0,1/17 %5.88,0/14 %0.0,1/35 %2.86,0/7 %0.0
Influenza,0/3 %0.0,0/50 %0.0,0/5 %0.0,0/6 %0.0,0/8 %0.0,0/17 %0.0,0/14 %0.0,1/35 %2.86,0/7 %0.0
Lung infection,0/3 %0.0,0/50 %0.0,2/5 %40.0,1/6 %16.67,0/8 %0.0,0/17 %0.0,0/14 %0.0,0/35 %0.0,2/7 %28.57
Mucosal infection,0/3 %0.0,0/50 %0.0,0/5 %0.0,0/6 %0.0,0/8 %0.0,0/17 %0.0,0/14 %0.0,1/35 %2.86,0/7 %0.0
Otitis media,0/3 %0.0,0/50 %0.0,0/5 %0.0,0/6 %0.0,0/8 %0.0,0/17 %0.0,0/14 %0.0,1/35 %2.86,0/7 %0.0
Pneumonia,0/3 %0.0,2/50 %4.0,0/5 %0.0,0/6 %0.0,0/8 %0.0,2/17 %11.76,2/14 %14.29,2/35 %5.71,0/7 %0.0
Sepsis,0/3 %0.0,2/50 %4.0,1/5 %20.0,0/6 %0.0,2/8 %25.0,1/17 %5.88,0/14 %0.0,0/35 %0.0,0/7 %0.0
Staphylococcal infection,0/3 %0.0,0/50 %0.0,0/5 %0.0,0/6 %0.0,0/8 %0.0,0/17 %0.0,1/14 %7.14,0/35 %0.0,0/7 %0.0
Staphylococcal sepsis,0/3 %0.0,1/50 %2.0,0/5 %0.0,0/6 %0.0,0/8 %0.0,0/17 %0.0,0/14 %0.0,0/35 %0.0,0/7 %0.0
Urinary tract infection,0/3 %0.0,1/50 %2.0,0/5 %0.0,0/6 %0.0,0/8 %0.0,0/17 %0.0,0/14 %0.0,0/35 %0.0,0/7 %0.0
Vascular device infection,0/3 %0.0,0/50 %0.0,0/5 %0.0,0/6 %0.0,0/8 %0.0,0/17 %0.0,1/14 %7.14,0/35 %0.0,0/7 %0.0
Fall,0/3 %0.0,0/50 %0.0,0/5 %0.0,0/6 %0.0,0/8 %0.0,1/17 %5.88,0/14 %0.0,0/35 %0.0,1/7 %14.29
Blood alkaline phosphatase increased,0/3 %0.0,0/50 %0.0,0/5 %0.0,0/6 %0.0,0/8 %0.0,0/17 %0.0,0/14 %0.0,1/35 %2.86,0/7 %0.0
Transaminases increased,0/3 %0.0,0/50 %0.0,0/5 %0.0,0/6 %0.0,1/8 %12.5,0/17 %0.0,0/14 %0.0,0/35 %0.0,0/7 %0.0
Troponin I increased,0/3 %0.0,0/50 %0.0,1/5 %20.0,0/6 %0.0,0/8 %0.0,0/17 %0.0,0/14 %0.0,0/35 %0.0,0/7 %0.0
Dehydration,0/3 %0.0,0/50 %0.0,0/5 %0.0,0/6 %0.0,0/8 %0.0,0/17 %0.0,0/14 %0.0,1/35 %2.86,1/7 %14.29
Gout,0/3 %0.0,1/50 %2.0,0/5 %0.0,0/6 %0.0,0/8 %0.0,0/17 %0.0,0/14 %0.0,0/35 %0.0,0/7 %0.0
Hyponatraemia,0/3 %0.0,0/50 %0.0,0/5 %0.0,0/6 %0.0,1/8 %12.5,0/17 %0.0,0/14 %0.0,0/35 %0.0,0/7 %0.0
Tumour lysis syndrome,0/3 %0.0,0/50 %0.0,0/5 %0.0,0/6 %0.0,1/8 %12.5,0/17 %0.0,0/14 %0.0,1/35 %2.86,0/7 %0.0
Muscular weakness,0/3 %0.0,0/50 %0.0,0/5 %0.0,0/6 %0.0,0/8 %0.0,0/17 %0.0,0/14 %0.0,0/35 %0.0,1/7 %14.29
Acute lymphocytic leukaemia recurrent,0/3 %0.0,0/50 %0.0,0/5 %0.0,0/6 %0.0,0/8 %0.0,0/17 %0.0,0/14 %0.0,1/35 %2.86,0/7 %0.0
Thyroid cancer,0/3 %0.0,1/50 %2.0,0/5 %0.0,0/6 %0.0,0/8 %0.0,0/17 %0.0,0/14 %0.0,0/35 %0.0,0/7 %0.0
Cerebrovascular accident,0/3 %0.0,1/50 %2.0,0/5 %0.0,0/6 %0.0,0/8 %0.0,0/17 %0.0,0/14 %0.0,0/35 %0.0,0/7 %0.0
Cognitive disorder,0/3 %0.0,1/50 %2.0,0/5 %0.0,0/6 %0.0,0/8 %0.0,0/17 %0.0,0/14 %0.0,0/35 %0.0,0/7 %0.0
Haemorrhage intracranial,0/3 %0.0,0/50 %0.0,1/5 %20.0,0/6 %0.0,0/8 %0.0,1/17 %5.88,0/14 %0.0,0/35 %0.0,0/7 %0.0
Neuromyopathy,0/3 %0.0,0/50 %0.0,1/5 %20.0,0/6 %0.0,0/8 %0.0,0/17 %0.0,0/14 %0.0,0/35 %0.0,0/7 %0.0
Transient ischaemic attack,0/3 %0.0,1/50 %2.0,0/5 %0.0,0/6 %0.0,0/8 %0.0,0/17 %0.0,0/14 %0.0,0/35 %0.0,0/7 %0.0
Acute kidney injury,0/3 %0.0,0/50 %0.0,0/5 %0.0,0/6 %0.0,0/8 %0.0,0/17 %0.0,0/14 %0.0,1/35 %2.86,0/7 %0.0
Dyspnoea,0/3 %0.0,1/50 %2.0,1/5 %20.0,0/6 %0.0,0/8 %0.0,1/17 %5.88,0/14 %0.0,0/35 %0.0,0/7 %0.0
Haemoptysis,0/3 %0.0,0/50 %0.0,0/5 %0.0,0/6 %0.0,0/8 %0.0,0/17 %0.0,0/14 %0.0,1/35 %2.86,0/7 %0.0
Hypoxia,0/3 %0.0,0/50 %0.0,0/5 %0.0,1/6 %16.67,0/8 %0.0,0/17 %0.0,0/14 %0.0,0/35 %0.0,0/7 %0.0
Lung consolidation,0/3 %0.0,0/50 %0.0,0/5 %0.0,0/6 %0.0,0/8 %0.0,0/17 %0.0,1/14 %7.14,0/35 %0.0,0/7 %0.0
Pleural effusion,0/3 %0.0,0/50 %0.0,0/5 %0.0,0/6 %0.0,0/8 %0.0,1/17 %5.88,0/14 %0.0,0/35 %0.0,0/7 %0.0
Pneumonitis,0/3 %0.0,1/50 %2.0,0/5 %0.0,0/6 %0.0,0/8 %0.0,0/17 %0.0,0/14 %0.0,0/35 %0.0,0/7 %0.0
Pneumothorax,0/3 %0.0,1/50 %2.0,0/5 %0.0,0/6 %0.0,0/8 %0.0,0/17 %0.0,0/14 %0.0,0/35 %0.0,0/7 %0.0
Respiratory failure,0/3 %0.0,1/50 %2.0,0/5 %0.0,1/6 %16.67,1/8 %12.5,0/17 %0.0,0/14 %0.0,0/35 %0.0,0/7 %0.0
Photosensitivity reaction,0/3 %0.0,0/50 %0.0,0/5 %0.0,0/6 %0.0,0/8 %0.0,1/17 %5.88,0/14 %0.0,0/35 %0.0,0/7 %0.0
Rash maculo-papular,0/3 %0.0,1/50 %2.0,0/5 %0.0,1/6 %16.67,0/8 %0.0,0/17 %0.0,0/14 %0.0,0/35 %0.0,0/7 %0.0
Skin haemorrhage,0/3 %0.0,0/50 %0.0,0/5 %0.0,0/6 %0.0,0/8 %0.0,0/17 %0.0,1/14 %7.14,0/35 %0.0,0/7 %0.0
Deep vein thrombosis,0/3 %0.0,0/50 %0.0,0/5 %0.0,0/6 %0.0,0/8 %0.0,0/17 %0.0,1/14 %7.14,0/35 %0.0,0/7 %0.0
Hypotension,0/3 %0.0,0/50 %0.0,0/5 %0.0,0/6 %0.0,1/8 %12.5,0/17 %0.0,0/14 %0.0,0/35 %0.0,0/7 %0.0
Thrombosis,0/3 %0.0,0/50 %0.0,0/5 %0.0,1/6 %16.67,0/8 %0.0,0/17 %0.0,0/14 %0.0,0/35 %0.0,0/7 %0.0

Study of Ibrutinib in Subjects With Acute Myeloid Leukemia(https://clinicaltrials.gov/show/NCT02351037)
 ,Ibrutinib Monotherapy Cohort,Ibrutinib + LD-AraC Combination Cohort,Ibrutinib+Azacitidine Combination Cohort
 ,Up to 33 response evaluable subjects will receive ibrutinib 560 mg once daily on a continuous basis.  Ibrutinib: Subjects will receive ibrutinib 560 mg once daily on a continuing basis.,Up to 25-28 additional response evaluable subjects (for a total of 34 subjects) will receive ibrutinib 560 mg once daily on a continuous basis starting 2 days prior to first cytarabine dose (20 mg BID sc) for 10 days of a 28-day cycle.  Ibrutinib + LD-AraC: Subjects will receive ibrutinib 560 mg once daily on a continuous basis starting 2 days prior to first cytarabine dose (20 mg BID sc) for 10 days of a 28-day cycle.,Up to 34 response evaluable subjects will receive ibrutinib 560 mg once daily on a continuous basis starting 1 day prior to first azacitidine dose + azacitidine 75mg/m2 IV once daily Days 1-7 of a 28-day cycle (with an option to increase to 100mg/m2 after 2 cycles).  Ibrutinib+Azacitidine: Subjects will receive ibrutinib 560 mg once daily on a continuous basis starting 1 day prior to first azacitidine dose + azacitidine 75 mg/m2 IV once daily on Days 1-7 of a 28-day cycle (with an option to increase to 100 mg/m2 after 2 cycles).
Total all-cause mortality,7/7 %100.0,21/21 %100.0,8/8 %100.0
Total serious adverse events,4/7 %57.14,21/21 %100.0,8/8 %100.0
Febrile neutropenia,1/7 %14.29,6/21 %28.57,4/8 %50.0
Anaemia,0/7 %0.0,1/21 %4.76,0/8 %0.0
Thrombocytopenia,0/7 %0.0,1/21 %4.76,0/8 %0.0
Leukocytosis,0/7 %0.0,2/21 %9.52,0/8 %0.0
Atrial flutter,0/7 %0.0,1/21 %4.76,0/8 %0.0
Cardiac arrest,0/7 %0.0,1/21 %4.76,0/8 %0.0
Atrial fibrillation,0/7 %0.0,1/21 %4.76,1/8 %12.5
Diarrhoea,0/7 %0.0,1/21 %4.76,0/8 %0.0
Abdominal pain,0/7 %0.0,1/21 %4.76,0/8 %0.0
Stomatitis,0/7 %0.0,0/21 %0.0,1/8 %12.5
Small intestine obstruction,0/7 %0.0,0/21 %0.0,1/8 %12.5
Haematemesis,0/7 %0.0,1/21 %4.76,0/8 %0.0
Fatigue,0/7 %0.0,1/21 %4.76,0/8 %0.0
Asthenia,0/7 %0.0,2/21 %9.52,1/8 %12.5
Multiple organ dysfunction syndrome,0/7 %0.0,1/21 %4.76,0/8 %0.0
Pyrexia,0/7 %0.0,1/21 %4.76,0/8 %0.0
Pneumonia,0/7 %0.0,8/21 %38.1,1/8 %12.5
Bacteraemia,1/7 %14.29,1/21 %4.76,0/8 %0.0
Pneumonia fungal,0/7 %0.0,3/21 %14.29,0/8 %0.0
Cellulitis,0/7 %0.0,2/21 %9.52,0/8 %0.0
Sepsis,0/7 %0.0,1/21 %4.76,0/8 %0.0
Cellulitis orbital,0/7 %0.0,1/21 %4.76,0/8 %0.0
Escherichia sepsis,0/7 %0.0,0/21 %0.0,1/8 %12.5
Influenza,0/7 %0.0,0/21 %0.0,1/8 %12.5
Septic embolus,0/7 %0.0,0/21 %0.0,1/8 %12.5
Pseudomonal sepsis,0/7 %0.0,1/21 %4.76,0/8 %0.0
Septic shock,0/7 %0.0,1/21 %4.76,0/8 %0.0
Vulvitis,1/7 %14.29,0/21 %0.0,0/8 %0.0
Escherichia bacteraemia,0/7 %0.0,0/21 %0.0,1/8 %12.5
Lung infection,1/7 %14.29,0/21 %0.0,0/8 %0.0
Fall,0/7 %0.0,1/21 %4.76,0/8 %0.0
Transfusion reaction,0/7 %0.0,1/21 %4.76,0/8 %0.0
Hyponatraemia,0/7 %0.0,1/21 %4.76,0/8 %0.0
Dehydration,0/7 %0.0,2/21 %9.52,1/8 %12.5
Failure to thrive,1/7 %14.29,0/21 %0.0,0/8 %0.0
Acute myeloid leukaemia,3/7 %42.86,9/21 %42.86,0/8 %0.0
Cerebrovascular accident,0/7 %0.0,0/21 %0.0,1/8 %12.5
Seizure,0/7 %0.0,1/21 %4.76,0/8 %0.0
Syncope,0/7 %0.0,1/21 %4.76,0/8 %0.0
Haemorrhage intracranial,0/7 %0.0,1/21 %4.76,0/8 %0.0
Confusional state,0/7 %0.0,2/21 %9.52,0/8 %0.0
Acute kidney injury,0/7 %0.0,2/21 %9.52,0/8 %0.0
Pleural effusion,0/7 %0.0,1/21 %4.76,0/8 %0.0
Respiratory failure,0/7 %0.0,3/21 %14.29,1/8 %12.5
Pulmonary alveolar haemorrhage,0/7 %0.0,1/21 %4.76,0/8 %0.0
Respiratory arrest,0/7 %0.0,1/21 %4.76,0/8 %0.0

Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia(https://clinicaltrials.gov/show/NCT02416908)
 ,Phase I Schedule A (Selinexor),Phase I Schedule B (Selinexor),Phase II (Selinexor),Selinexor Maintenance Phase (Optional)
 ,Selinexor will be dosed on Days 1 5 10 and 12 of the 28-day cycle. All doses will be 60 mg each PO.  Single agent selinexor maintenance may be given at 60 mg on Days 1 8 15 and 22 (4 doses per 28 day cycle).  Cladribine will be given 5 mg/m^2/day IV once daily on Days 4-8.  G-CSF will be given 300 mcg SC once daily on Days 3-8.  Cytarabine will be given 2000 mg/m^2/day IV once daily on Days 4-8.  Bone marrow biopsy will be performed at baseline Day 3 at time of hematopoietic recovery and as clinically indicated to assess treatment response.,Selinexor will be dosed on Days 1 5 10 12 17 and 19 of the 28-day cycle. All doses will be 60 mg each PO.  Single agent selinexor maintenance may be given at 60 mg on Days 1 8 15 and 22 (4 doses per 28 day cycle).  Cladribine will be given 5 mg/m^2/day IV once daily on Days 4-8.  G-CSF will be given 300 mcg SC once daily on Days 3-8.  Cytarabine will be given 2000 mg/m^2/day IV once daily on Days 4-8.  Bone marrow biopsy will be performed at baseline Day 3 at time of hematopoietic recovery and as clinically indicated to assess treatment response.,Selinexor will be given at the schedule as determined in Phase 1.  Single agent selinexor maintenance may be given at 60 mg on Days 1 8 15 and 22 (4 doses per 28 day cycle).  Cladribine will be given 5 mg/m^2/day IV once daily on Days 4-8.  G-CSF will be given 300 mcg SC once daily on Days 3-8.  Cytarabine will be given 2000 mg/m^2/day IV once daily on Days 4-8.  Bone marrow biopsy will be performed at baseline Day 3 at time of hematopoietic recovery and as clinically indicated to assess treatment response.,Available for patients who have achieved a CR or CRi based on post-treatment bone marrow assessment at the time of hematopoietic recovery and are either (1) transplant ineligible or (2) do not have a stem cell transplant donor available  60 mg selinexor on Days 1 8 15 and 22 of a 28-day cycle
Total all-cause mortality,5/6 %83.33,0/0 %0.0,25/34 %73.53,2/2 %100.0
Total serious adverse events,4/6 %66.67,0/0 %0.0,14/34 %41.18,1/2 %50.0
Febrile neutropenia,1/6 %16.67,0/34 %0.0,0/2 %0.0
Constrictive pericarditis,0/6 %0.0,1/34 %2.94,0/2 %0.0
Colitis,0/6 %0.0,1/34 %2.94,0/2 %0.0
Pancreatitis,0/6 %0.0,1/34 %2.94,0/2 %0.0
Fever,0/6 %0.0,1/34 %2.94,0/2 %0.0
Appendicitis perforated,0/6 %0.0,1/34 %2.94,0/2 %0.0
Bone infection,1/6 %16.67,0/34 %0.0,1/2 %50.0
Lung infection,1/6 %16.67,1/34 %2.94,0/2 %0.0
Sepsis,1/6 %16.67,7/34 %20.59,0/2 %0.0
Sinusitis,0/6 %0.0,1/34 %2.94,0/2 %0.0
Soft tissue infection,0/6 %0.0,0/34 %0.0,1/2 %50.0
Acidosis,0/6 %0.0,1/34 %2.94,0/2 %0.0
Seizure,0/6 %0.0,1/34 %2.94,0/2 %0.0
Pulmonary edema,1/6 %16.67,0/34 %0.0,0/2 %0.0
Respiratory failure,0/6 %0.0,1/34 %2.94,0/2 %0.0
Hypotension,0/6 %0.0,1/34 %2.94,0/2 %0.0

A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation(https://clinicaltrials.gov/show/NCT02421939)
 ,Gilteritinib,Salvage Chemotherapy
 ,Participants received 120 mg dose (3 tablets of 40 mg) orally once a day in continuous 28-day cycles at least 2 hours after or 1 hour before food. Gilteritinib treatment continued until participants met one of the treatment discontinuation criteria.,Participants received chemotherapy in 28-day cycles. Participants on Low-Dose Cytarabine (LoDAC) received 20 mg of cytarabine twice daily by subcutaneous (SC) or intravenous (IV) injection for 10 days. Participants on azacitidine received 75 mg/m^2 daily by SC or IV injection for 7 days. Participants on LoDAC or azacitidine treatment continued until they met discontinuation criteria. Participants on MEC chemotherapy received mitoxantrone 8 mg/m^2 daily by IV for 5 days etoposide 100 mg/m^2 daily by IV for 5 days and cytarabine 1000 mg/m^2 daily by IV for 5 days (days 1-5). Participants on FLAG-IDA chemotherapy received G-CSF 300 g/m^2 daily by SC/IV for 5 days (days 1-5) fludarabine 30 mg/m^2 daily by IV for 5 days (days 2-6) cytarabine 2000 mg/m^2 daily by IV for 5 days (days 2-6) and idarubicin 10 mg/m^2 daily by IV for 3 days (days 2-4). Participants receiving MEC or FLAG-IDA received 1 cycle of therapy and were assessed for response on or after day 15.
Total all-cause mortality,170/246 %69.11,81/109 %74.31
Total serious adverse events,205/246 %83.33,34/109 %31.19
Anaemia,8/246 %3.25,0/109 %0.0
Aplasia pure red cell,1/246 %0.41,0/109 %0.0
Autoimmune haemolytic anaemia,1/246 %0.41,0/109 %0.0
Bone marrow failure,1/246 %0.41,0/109 %0.0
Disseminated intravascular coagulation,2/246 %0.81,0/109 %0.0
Febrile neutropenia,76/246 %30.89,9/109 %8.26
Haemolytic anaemia,2/246 %0.81,0/109 %0.0
Leukocytosis,2/246 %0.81,1/109 %0.92
Neutropenia,3/246 %1.22,1/109 %0.92
Pancytopenia,4/246 %1.63,0/109 %0.0
Thrombocytopenia,4/246 %1.63,1/109 %0.92
Acute coronary syndrome,1/246 %0.41,0/109 %0.0
Angina pectoris,1/246 %0.41,0/109 %0.0
Atrial fibrillation,1/246 %0.41,0/109 %0.0
Cardiac arrest,4/246 %1.63,0/109 %0.0
Cardiac failure,3/246 %1.22,0/109 %0.0
Cardiac failure congestive,2/246 %0.81,0/109 %0.0
Cardio-respiratory arrest,1/246 %0.41,0/109 %0.0
Myocardial infarction,1/246 %0.41,0/109 %0.0
Myocarditis,2/246 %0.81,0/109 %0.0
Pericardial effusion,3/246 %1.22,0/109 %0.0
Pericardial haemorrhage,1/246 %0.41,0/109 %0.0
Pericarditis,3/246 %1.22,0/109 %0.0
Sinus tachycardia,1/246 %0.41,1/109 %0.92
Supraventricular tachycardia,2/246 %0.81,0/109 %0.0
Hamartoma,1/246 %0.41,0/109 %0.0
Ocular hyperaemia,1/246 %0.41,0/109 %0.0
Vision blurred,1/246 %0.41,0/109 %0.0
Abdominal pain,2/246 %0.81,0/109 %0.0
Anal fissure,1/246 %0.41,0/109 %0.0
Colitis,2/246 %0.81,0/109 %0.0
Diarrhoea,10/246 %4.07,0/109 %0.0
Diarrhoea haemorrhagic,1/246 %0.41,0/109 %0.0
Dysphagia,1/246 %0.41,0/109 %0.0
Enterocolitis,1/246 %0.41,0/109 %0.0
Gastritis,1/246 %0.41,0/109 %0.0
Gastrointestinal haemorrhage,1/246 %0.41,1/109 %0.92
Gastrooesophageal reflux disease,1/246 %0.41,0/109 %0.0
Haematemesis,1/246 %0.41,0/109 %0.0
Haematochezia,1/246 %0.41,0/109 %0.0
Haemorrhoids,2/246 %0.81,0/109 %0.0
Ileus,1/246 %0.41,0/109 %0.0
Intestinal ischaemia,1/246 %0.41,0/109 %0.0
Large intestine perforation,2/246 %0.81,0/109 %0.0
Lower gastrointestinal haemorrhage,1/246 %0.41,0/109 %0.0
Melaena,1/246 %0.41,1/109 %0.92
Mouth haemorrhage,2/246 %0.81,0/109 %0.0
Nausea,2/246 %0.81,0/109 %0.0
Pancreatitis,3/246 %1.22,0/109 %0.0
Proctalgia,1/246 %0.41,0/109 %0.0
Stomatitis,1/246 %0.41,1/109 %0.92
Stomatitis necrotising,1/246 %0.41,0/109 %0.0
Tongue haematoma,1/246 %0.41,0/109 %0.0
Vomiting,1/246 %0.41,0/109 %0.0
Asthenia,3/246 %1.22,0/109 %0.0
Chills,1/246 %0.41,0/109 %0.0
Death,1/246 %0.41,0/109 %0.0
Face oedema,2/246 %0.81,0/109 %0.0
Fatigue,4/246 %1.63,1/109 %0.92
Generalised oedema,1/246 %0.41,0/109 %0.0
Influenza like illness,1/246 %0.41,0/109 %0.0
Mucosal haemorrhage,1/246 %0.41,0/109 %0.0
Mucosal inflammation,1/246 %0.41,0/109 %0.0
Multiple organ dysfunction syndrome,1/246 %0.41,1/109 %0.92
Oedema,1/246 %0.41,0/109 %0.0
Pyrexia,32/246 %13.01,1/109 %0.92
Cholecystitis,2/246 %0.81,0/109 %0.0
Drug-induced liver injury,1/246 %0.41,0/109 %0.0
Hepatic function abnormal,1/246 %0.41,0/109 %0.0
Hepatotoxicity,1/246 %0.41,0/109 %0.0
Acute graft versus host disease in intestine,1/246 %0.41,0/109 %0.0
Anaphylactic reaction,3/246 %1.22,0/109 %0.0
Drug hypersensitivity,1/246 %0.41,0/109 %0.0
Graft versus host disease,1/246 %0.41,0/109 %0.0
Graft versus host disease in gastrointestinal tract,1/246 %0.41,0/109 %0.0
Abscess bacterial,1/246 %0.41,0/109 %0.0
Adenoviral upper respiratory infection,1/246 %0.41,0/109 %0.0
Anal abscess,0/246 %0.0,1/109 %0.92
Bacteraemia,10/246 %4.07,1/109 %0.92
Bacterial colitis,1/246 %0.41,0/109 %0.0
Bacterial infection,1/246 %0.41,0/109 %0.0
Bacterial sepsis,1/246 %0.41,0/109 %0.0
Bronchitis,4/246 %1.63,0/109 %0.0
Bronchopulmonary aspergillosis,2/246 %0.81,0/109 %0.0
Catheter site infection,1/246 %0.41,0/109 %0.0
Cellulitis,6/246 %2.44,0/109 %0.0
Clostridium difficile colitis,2/246 %0.81,0/109 %0.0
Clostridium difficile infection,4/246 %1.63,0/109 %0.0
Cytomegalovirus infection,1/246 %0.41,0/109 %0.0
Device related infection,4/246 %1.63,1/109 %0.92
Diarrhoea infectious,1/246 %0.41,0/109 %0.0
Endocarditis,1/246 %0.41,0/109 %0.0
Enterococcal bacteraemia,1/246 %0.41,0/109 %0.0
Enterococcal sepsis,1/246 %0.41,0/109 %0.0
Enterocolitis infectious,4/246 %1.63,0/109 %0.0
Epstein-Barr viraemia,1/246 %0.41,0/109 %0.0
Escherichia bacteraemia,2/246 %0.81,0/109 %0.0
Escherichia sepsis,1/246 %0.41,0/109 %0.0
Escherichia urinary tract infection,3/246 %1.22,1/109 %0.92
Eye infection,1/246 %0.41,0/109 %0.0
Eye infection bacterial,1/246 %0.41,0/109 %0.0
Haemophilus infection,0/246 %0.0,1/109 %0.92
Hepatic infection,1/246 %0.41,0/109 %0.0
Infection,1/246 %0.41,1/109 %0.92
Infectious colitis,1/246 %0.41,0/109 %0.0
Influenza,3/246 %1.22,1/109 %0.92
Klebsiella bacteraemia,0/246 %0.0,1/109 %0.92
Leptotrichia infection,1/246 %0.41,0/109 %0.0
Lower respiratory tract infection,2/246 %0.81,0/109 %0.0
Lower respiratory tract infection bacterial,1/246 %0.41,0/109 %0.0
Lower respiratory tract infection fungal,2/246 %0.81,0/109 %0.0
Lung infection,14/246 %5.69,5/109 %4.59
Oesophageal infection,1/246 %0.41,0/109 %0.0
Otitis externa,1/246 %0.41,0/109 %0.0
Parotitis,1/246 %0.41,0/109 %0.0
Periorbital infection,1/246 %0.41,0/109 %0.0
Pneumonia,26/246 %10.57,4/109 %3.67
Pneumonia fungal,2/246 %0.81,0/109 %0.0
Pneumonia respiratory syncytial viral,1/246 %0.41,0/109 %0.0
Pneumonia viral,1/246 %0.41,0/109 %0.0
Pseudomonal bacteraemia,2/246 %0.81,0/109 %0.0
Pseudomonal sepsis,1/246 %0.41,0/109 %0.0
Pulmonary mycosis,1/246 %0.41,0/109 %0.0
Respiratory syncytial virus infection,1/246 %0.41,0/109 %0.0
Respiratory tract infection,4/246 %1.63,0/109 %0.0
Scrotal infection,1/246 %0.41,0/109 %0.0
Sepsis,18/246 %7.32,7/109 %6.42
Septic shock,9/246 %3.66,1/109 %0.92
Sinusitis,3/246 %1.22,0/109 %0.0
Sinusitis fungal,1/246 %0.41,0/109 %0.0
Skin infection,4/246 %1.63,0/109 %0.0
Soft tissue infection,1/246 %0.41,0/109 %0.0
Staphylococcal bacteraemia,6/246 %2.44,0/109 %0.0
Staphylococcal infection,2/246 %0.81,0/109 %0.0
Streptococcal bacteraemia,3/246 %1.22,0/109 %0.0
Systemic bacterial infection,1/246 %0.41,0/109 %0.0
Systemic mycosis,1/246 %0.41,0/109 %0.0
Tooth abscess,0/246 %0.0,1/109 %0.92
Tooth infection,2/246 %0.81,0/109 %0.0
Upper respiratory tract infection,3/246 %1.22,0/109 %0.0
Urinary tract infection,2/246 %0.81,0/109 %0.0
Urinary tract infection bacterial,2/246 %0.81,1/109 %0.92
Urinary tract infection enterococcal,1/246 %0.41,0/109 %0.0
Viral upper respiratory tract infection,2/246 %0.81,0/109 %0.0
Vulval cellulitis,1/246 %0.41,0/109 %0.0
Wound infection,1/246 %0.41,0/109 %0.0
Accidental overdose,1/246 %0.41,0/109 %0.0
Anaphylactic transfusion reaction,1/246 %0.41,0/109 %0.0
Ankle fracture,1/246 %0.41,0/109 %0.0
Fall,8/246 %3.25,1/109 %0.92
Hip fracture,1/246 %0.41,0/109 %0.0
Infusion related reaction,2/246 %0.81,0/109 %0.0
Joint dislocation,1/246 %0.41,0/109 %0.0
Patella fracture,1/246 %0.41,0/109 %0.0
Subarachnoid haemorrhage,1/246 %0.41,0/109 %0.0
Subdural haematoma,2/246 %0.81,0/109 %0.0
Subdural haemorrhage,0/246 %0.0,1/109 %0.92
Toxicity to various agents,1/246 %0.41,0/109 %0.0
Alanine aminotransferase increased,13/246 %5.28,0/109 %0.0
Aspartate aminotransferase increased,10/246 %4.07,0/109 %0.0
Blood alkaline phosphatase increased,1/246 %0.41,0/109 %0.0
Blood bilirubin increased,2/246 %0.81,0/109 %0.0
Blood creatine phosphokinase increased,2/246 %0.81,0/109 %0.0
Blood creatinine increased,1/246 %0.41,0/109 %0.0
Blood fibrinogen decreased,1/246 %0.41,0/109 %0.0
Blood pressure decreased,0/246 %0.0,1/109 %0.92
Ejection fraction decreased,0/246 %0.0,1/109 %0.92
Electrocardiogram QT prolonged,2/246 %0.81,0/109 %0.0
Gamma-glutamyltransferase increased,1/246 %0.41,0/109 %0.0
General physical condition abnormal,1/246 %0.41,0/109 %0.0
Liver function test increased,1/246 %0.41,0/109 %0.0
Menstruation normal,1/246 %0.41,0/109 %0.0
Neutrophil count decreased,4/246 %1.63,0/109 %0.0
Norovirus test positive,1/246 %0.41,0/109 %0.0
Platelet count decreased,5/246 %2.03,0/109 %0.0
Transaminases increased,1/246 %0.41,0/109 %0.0
White blood cell count decreased,1/246 %0.41,0/109 %0.0
White blood cell count increased,1/246 %0.41,0/109 %0.0
Decreased appetite,2/246 %0.81,0/109 %0.0
Dehydration,2/246 %0.81,0/109 %0.0
Failure to thrive,1/246 %0.41,0/109 %0.0
Hyperglycaemia,0/246 %0.0,1/109 %0.92
Hyperphosphataemia,1/246 %0.41,0/109 %0.0
Hypoglycaemia,1/246 %0.41,0/109 %0.0
Hypokalaemia,0/246 %0.0,1/109 %0.92
Hyponatraemia,2/246 %0.81,0/109 %0.0
Hyponatraemic syndrome,1/246 %0.41,0/109 %0.0
Hypophosphataemia,1/246 %0.41,0/109 %0.0
Metabolic acidosis,1/246 %0.41,0/109 %0.0
Tumour lysis syndrome,1/246 %0.41,2/109 %1.83
Arthralgia,3/246 %1.22,0/109 %0.0
Arthritis,2/246 %0.81,0/109 %0.0
Back pain,1/246 %0.41,0/109 %0.0
Bone pain,1/246 %0.41,0/109 %0.0
Joint effusion,1/246 %0.41,0/109 %0.0
Joint swelling,1/246 %0.41,0/109 %0.0
Muscular weakness,1/246 %0.41,0/109 %0.0
Myositis,3/246 %1.22,0/109 %0.0
Osteoarthritis,1/246 %0.41,0/109 %0.0
Pain in extremity,0/246 %0.0,1/109 %0.92
Pain in jaw,1/246 %0.41,0/109 %0.0
Soft tissue necrosis,1/246 %0.41,0/109 %0.0
Acute myeloid leukaemia,33/246 %13.41,4/109 %3.67
Acute myeloid leukaemia recurrent,7/246 %2.85,0/109 %0.0
Cancer pain,1/246 %0.41,0/109 %0.0
Central nervous system leukaemia,2/246 %0.81,0/109 %0.0
Gastric cancer,1/246 %0.41,0/109 %0.0
Leukaemia cutis,2/246 %0.81,0/109 %0.0
Leukaemia recurrent,1/246 %0.41,1/109 %0.92
Malignant neoplasm progression,0/246 %0.0,1/109 %0.92
Neoplasm malignant,1/246 %0.41,0/109 %0.0
Oesophageal carcinoma,1/246 %0.41,0/109 %0.0
Soft tissue sarcoma,1/246 %0.41,0/109 %0.0
Squamous cell carcinoma,0/246 %0.0,1/109 %0.92
Amnesia,0/246 %0.0,1/109 %0.92
Brain oedema,2/246 %0.81,0/109 %0.0
Cerebellar haemorrhage,1/246 %0.41,0/109 %0.0
Cerebral haemorrhage,3/246 %1.22,0/109 %0.0
Cerebral infarction,0/246 %0.0,1/109 %0.92
Cerebrovascular accident,1/246 %0.41,0/109 %0.0
Cognitive disorder,1/246 %0.41,0/109 %0.0
Depressed level of consciousness,2/246 %0.81,0/109 %0.0
Dizziness,1/246 %0.41,0/109 %0.0
Haemorrhage intracranial,1/246 %0.41,0/109 %0.0
Haemorrhagic stroke,0/246 %0.0,1/109 %0.92
Headache,5/246 %2.03,0/109 %0.0
Hemiplegia,1/246 %0.41,0/109 %0.0
Hydrocephalus,1/246 %0.41,0/109 %0.0
Posterior reversible encephalopathy syndrome,1/246 %0.41,0/109 %0.0
Presyncope,1/246 %0.41,0/109 %0.0
Seizure,2/246 %0.81,0/109 %0.0
Somnolence,1/246 %0.41,0/109 %0.0
Syncope,7/246 %2.85,0/109 %0.0
Tremor,1/246 %0.41,0/109 %0.0
Confusional state,1/246 %0.41,0/109 %0.0
Depression,0/246 %0.0,1/109 %0.92
Hallucination,1/246 %0.41,0/109 %0.0
Mania,1/246 %0.41,0/109 %0.0
Mental status changes,1/246 %0.41,0/109 %0.0
Acute kidney injury,16/246 %6.5,4/109 %3.67
Haematuria,1/246 %0.41,0/109 %0.0
Renal impairment,1/246 %0.41,0/109 %0.0
Pelvic pain,1/246 %0.41,0/109 %0.0
Vaginal haemorrhage,1/246 %0.41,0/109 %0.0
Acute respiratory distress syndrome,4/246 %1.63,0/109 %0.0
Acute respiratory failure,2/246 %0.81,1/109 %0.92
Aspiration,1/246 %0.41,0/109 %0.0
Cough,2/246 %0.81,0/109 %0.0
Dyspnoea,10/246 %4.07,2/109 %1.83
Hypoxia,4/246 %1.63,2/109 %1.83
Interstitial lung disease,1/246 %0.41,0/109 %0.0
Lung disorder,1/246 %0.41,0/109 %0.0
Organising pneumonia,2/246 %0.81,0/109 %0.0
Oropharyngeal pain,1/246 %0.41,0/109 %0.0
Pleural effusion,2/246 %0.81,0/109 %0.0
Pneumomediastinum,1/246 %0.41,0/109 %0.0
Pneumonia aspiration,2/246 %0.81,0/109 %0.0
Pneumothorax,1/246 %0.41,0/109 %0.0
Productive cough,1/246 %0.41,0/109 %0.0
Pulmonary alveolar haemorrhage,0/246 %0.0,1/109 %0.92
Pulmonary embolism,2/246 %0.81,0/109 %0.0
Pulmonary haemorrhage,0/246 %0.0,1/109 %0.92
Pulmonary hypertension,2/246 %0.81,0/109 %0.0
Respiratory failure,7/246 %2.85,3/109 %2.75
Acute febrile neutrophilic dermatosis,1/246 %0.41,0/109 %0.0
Dermatitis bullous,1/246 %0.41,0/109 %0.0
Drug eruption,1/246 %0.41,0/109 %0.0
Petechiae,1/246 %0.41,0/109 %0.0
Psoriasis,1/246 %0.41,0/109 %0.0
Skin necrosis,1/246 %0.41,0/109 %0.0
Swelling face,1/246 %0.41,0/109 %0.0
Toxic skin eruption,1/246 %0.41,0/109 %0.0
Deep vein thrombosis,0/246 %0.0,1/109 %0.92
Embolism,3/246 %1.22,1/109 %0.92
Haematoma,3/246 %1.22,0/109 %0.0
Haemorrhage,1/246 %0.41,0/109 %0.0
Hypertension,1/246 %0.41,1/109 %0.92
Hypotension,6/246 %2.44,1/109 %0.92
Orthostatic hypotension,1/246 %0.41,0/109 %0.0
Venous thrombosis,1/246 %0.41,0/109 %0.0

Study of Vosaroxin and Cytarabine for the Treatment of Adults 60 Years of Age or Older With Previously Untreated AML(https://clinicaltrials.gov/show/NCT02485353)
 ,Vosaroxin and Cytarabine
 ,Each cycle will include vosaroxin treatment on days 1 and 4 (total of 2 days) and cytarabine treatment on days 1-5 (total of 5 days) followed by a variable interval required to achieve hematologic recovery defined as absolute neutrophil count (ANC) > 1000 cells/L
Total serious adverse events,2/2 %100.0
Infections and infestations - Other,1/2 %50.0
Sepsis,1/2 %50.0

Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults(https://clinicaltrials.gov/show/NCT02535806)
 ,Treatment Arm
 ,Velcade will be given IV push on days 148 and 11 at a dose of 1.3 mg/m2/dose. At least 72 hours must have relapsed between doses.  IT Methotrexate (CNS Negative patients only) on days 1 and 8; age based dosing IT Methotrexate/Hydrocortisone/AraC (CNS positive patients only) on days 1 8 15 and 22; age based dosing.  Dexamethasone: Days 1-5 and 15-19; 10mg/m2/dose PO BID. Mitoxantrone: Days 1 and 2; 10mg/m2/dose Vincristine: days 1 8 15 and 22 at 1.5 mg/m2 (Maximum dose 2 mg) PEG-asparaginase: Days 3 and 17 2500 IU/m2/dose  Velcade: 4 doses of study drug will be given.  Methotrexate: Intrathecal dose For CNS negative patients Day 1 and Day 8  Methotrexate / Hydrocortisone / Cytarabine: Intrathecal dose for CNS positive patients Day 1 8 15 22  Dexamethasone: Days 1-5 and 15-19  Mitoxantrone: Days 1 and 2  Vincristine: Days 1 8 15 22  Pegaspargase: Days 3 and 17
Total all-cause mortality,0/2 %0.0
Total serious adverse events,1/2 %50.0
Respiratory Failure,1/2 %50.0

Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML(https://clinicaltrials.gov/show/NCT02560025)
 ,Alisertib / MLN8237
 ,Participants will initially receive 7+3 induction chemotherapy consisting of cytarabine and concurrent idarubicin (or daunorubicin if appropriate). Oral alisertib at 30mg twice daily will begin on day 8 and will continue for 7 days. During induction patients with residual disease at day 14 may have re-induction with "5+2" chemotherapy but will not receive additional dosing of alisertib at that time. Following count recovery after induction if patients proceed to consolidative cycles of therapy with cytarabine they will receive alisertib at day 6 following conclusion of cytarabine administration. Upon count recovery following consolidation alisertib will be resumed for 7 days followed by 14 days off and will be continued as 21-day cycles of maintenance for up to 12 cycles.
Total all-cause mortality,20/39 %51.28
Total serious adverse events,27/39 %69.23
Anemia,11/39 %28.21
Febrile neutropenia,16/39 %41.03
Colitis,1/39 %2.56
Diarrhea,2/39 %5.13
Dysphagia,1/39 %2.56
Esophagitis,2/39 %5.13
Mucositis oral,4/39 %10.26
Nausea,3/39 %7.69
Alanine aminotransferase increased,3/39 %7.69
Aspartate aminotransferase increased,2/39 %5.13
Blood bilirubin increased,3/39 %7.69
Neutrophil count decreased,12/39 %30.77
Platelet count decreased,12/39 %30.77
Anorexia,9/39 %23.08
Hypophosphatemia,1/39 %2.56
Laryngeal mucositis,1/39 %2.56

Liposome-encapsulated Daunorubicin-Cytarabine  Fludarabine Phosphate  Cytarabine  and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia(https://clinicaltrials.gov/show/NCT02642965)
 ,Treatment (CPX-351 and FLAG)
 ,COURSE 1: Patients receive cytarabine IT on day 0 and at day 28-30 or up to 7 days prior to day 1 of course 2 and liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1 3 and 5. Patients with CNS1 receive no further CNS-directed therapy in course 1. Patients with CNS2 disease may receive additional 4-6 doses of cytarabine IT twice weekly starting 48 hours after the third dose of liposome-encapsulated daunorubicin-cytarabine until CNS is clear at the discretion of the investigator. Patients meeting criteria for CR CRp and CRi may proceed to course 2.  COURSE 2: Patients receive filgrastim on days 1-5 and then on day 15 until blood count recovery and fludarabine phosphate IV over 30 minutes and high-dose cytarabine IV over 1-3 hours QD on days 1-5.
Total all-cause mortality,14/38 %36.84
Total serious adverse events,21/38 %55.26
Febrile neutropenia,11/38 %28.95
Dysphagia,1/38 %2.63
Gastrointestinal disorders - Other specify,1/38 %2.63
Mucositis oral,1/38 %2.63
Typhlitis,2/38 %5.26
Death NOS,5/38 %13.16
Fever,2/38 %5.26
Anorectal infection,1/38 %2.63
Catheter related infection,1/38 %2.63
Infections and infestations - Other specify,6/38 %15.79
Kidney infection,1/38 %2.63
Lung infection,2/38 %5.26
Skin infection,1/38 %2.63
Small intestine infection,1/38 %2.63
Soft tissue infection,1/38 %2.63
Blood bilirubin increased,1/38 %2.63
Ejection fraction decreased,1/38 %2.63
Lymphocyte count decreased,1/38 %2.63
White blood cell decreased,1/38 %2.63
Anorexia,1/38 %2.63
Hyperglycemia,2/38 %5.26
Headache,1/38 %2.63
Nervous system disorders - Other specify,1/38 %2.63
Syncope,1/38 %2.63
Urinary frequency,1/38 %2.63
Reproductive system and breast disorders - Other specify,1/38 %2.63
Hypoxia,1/38 %2.63
Stridor,1/38 %2.63
Rash maculo-papular,6/38 %15.79

Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia(https://clinicaltrials.gov/show/NCT02658487)
 ,Treatment (Vosaroxin Cytarabine) Induction 1,Induction 2
 ,Patients receive vosaroxin IV on days 1 and 4 and cytarabine IV continuously on days 1-7 (Induction I).  Cytarabine: Given IV  Vosaroxin: Given IV,Patients with residual leukemia and for whom a second course is indicated in the judgment of the investigator may undergo a second course of treatment (Induction II) 14-57 days after day 1 of Induction I.
Total all-cause mortality,18/33 %54.55,4/9 %44.44
Total serious adverse events,10/33 %30.3,5/9 %55.56
Febrile Neutropenia,1/33 %3.03,1/9 %11.11
Chronic heart failure,0/33 %0.0,1/9 %11.11
Ventricular fibrillation,1/33 %3.03,0/9 %0.0
Acute sigmoid diverticulitis,1/33 %3.03,0/9 %0.0
Colitis,6/33 %18.18,1/9 %11.11
Typhlitis,1/33 %3.03,1/9 %11.11
Cholecystitis,1/33 %3.03,1/9 %11.11
Sepsis,2/33 %6.06,0/9 %0.0
Fungemia,1/33 %3.03,0/9 %0.0
Electrocardiogram QT corrected interval prolonged,3/33 %9.09,0/9 %0.0
Altered mental state,0/33 %0.0,1/9 %11.11
Hematuria,1/33 %3.03,0/9 %0.0
Acute kidney injury,1/33 %3.03,0/9 %0.0
Adult Respiratory Distress Syndrome,1/33 %3.03,0/9 %0.0
Respiratory failure,2/33 %6.06,0/9 %0.0
Dyspnea,0/33 %0.0,1/9 %11.11
Pleural effusion,0/33 %0.0,1/9 %11.11
Thromboembolic event - Related to Hickman line placement,0/33 %0.0,1/9 %11.11

WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome(https://clinicaltrials.gov/show/NCT02666950)
 ,Arm A + Arm C (AZD1775 Combined With AraC OR AZD1775 Only)
 ,Patients receive 20 mg cytarabine (AraC) SC twice daily and 200 mg WEE1 inhibitor (AZD1775) PO daily on days 1-5 and days 8-12 OR receive only 200 mg WEE inhibitor (AZD1775) PO daily on days 1-5 8-12 15-19 and 22-26.
Total all-cause mortality,3/3 %100.0
Total serious adverse events,3/3 %100.0
Febrile neutropenia,3/3 %100.0
Abdominal pain,1/3 %33.33
Gastrointestinal disorders - Other specify,1/3 %33.33
Fatigue,1/3 %33.33
Lung infection,2/3 %66.67
Sepsis,1/3 %33.33

Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma(https://clinicaltrials.gov/show/NCT02788201)
 ,Doxorubicin 75mg/m^2,Paclitaxel 100 mg/m^2 and Erlotinib 150 mg,Paclitaxel 135mg/m^2 and Doxorubicin 40mg/m^2,Sunitinib 50mg,Vorinostat 500mg and Etoposide 100mg/m^2 and 60mg/m^2,Participants Who Were Enrolled But Not Treated
 ,All participants that received Doxorubicin 75mg/m^2.,All participants that received Paclitaxel 100 mg/m^2 and Erlotinib 150 mg.,All participants that received Paclitaxel 135mg/m^2 and Doxorubicin 40mg/m^2.,All participants that received Sunitinib 50mg.,All participants that received Vorinostat 500mg and Etoposide 100mg/m^2 and 60mg/m^2.,3 participants were enrolled and signed consent to this study but never started treatment. Treatment was assigned on course initiation.
Total all-cause mortality,1/1 %100.0,1/1 %100.0,1/1 %100.0,1/1 %100.0,0/1 %0.0,1/1 %100.0
Total serious adverse events,1/1 %100.0,1/1 %100.0,1/1 %100.0,1/1 %100.0,1/1 %100.0,0/0 %0.0
Febrile neutropenia,0/1 %0.0,0/1 %0.0,0/1 %0.0,0/1 %0.0,1/1 %100.0,0/0 %0.0
Death NOS,1/1 %100.0,1/1 %100.0,1/1 %100.0,1/1 %100.0,0/1 %0.0,0/0 %0.0

Decitabine With GCLAM for Adults With Newly Diagnosed  Relapsed  or Refractory AML or High-Risk MDS(https://clinicaltrials.gov/show/NCT02921061)
 ,Treatment (Decitabine 20 mg/m2 and G-CLAM)
 ,Patients receive induction therapy comprising decitabine IV over 1 hour (20 mg/m2) on days 1-10 and G-CLAM (filgrastim SC on days 0-5 cladribine IV over 2 hours on days 1-5 cytarabine IV over 2-4 hours on days 1-5 and mitoxantrone IV over 60 minutes on days 1-3).  Patients who do not achieve MRDneg CR after first induction are eligible for re-induction with G-CLAM.  Beginning 6 weeks after achieving MRDneg CR or CR/CR with CRi after induction and/or re-induction patients are eligible to receive consolidation therapy comprising GLCA (filgrastim cladribine cytarabine) for up to 4 cycles. Subsequent consolidation cycles would be given after recovery from the previous cycle (roughly 4-6 weeks).
Total all-cause mortality,19/28 %67.86
Total serious adverse events,2/28 %7.14
Cardiogenic shock/heart failure,1/28 %3.57
Sepsis,1/28 %3.57

A Study Of PF-06747143  As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia(https://clinicaltrials.gov/show/NCT02954653)
 ,Part 1: PF-06747143 0.3 mg/kg,Part 1: PF-06747143 1 mg/kg
 ,PF-06747143 was administered as an intravenous infusion once weekly at 0.3 mg/kg in 28-day cycles.,PF-06747143 was administered as an intravenous infusion once weekly at 1 mg/kg in 28-day cycles.
Total all-cause mortality,3/3 %100.0,1/4 %25.0
Total serious adverse events,1/3 %33.33,3/4 %75.0
Pyrexia,0/3 %0.0,1/4 %25.0
Cellulitis,0/3 %0.0,1/4 %25.0
Pneumonia,0/3 %0.0,1/4 %25.0
Sepsis,1/3 %33.33,0/4 %0.0
Neoplasm progression,0/3 %0.0,1/4 %25.0
Hypoxia,1/3 %33.33,0/4 %0.0

Entospletinib (ENTO) as Monotherapy and in Combination With Chemotherapy in Japanese Adults(https://clinicaltrials.gov/show/NCT03135028)
 ,ENTO 400 mg
 ,Participants received ENTO 400 mg (2  200 mg tablets) orally twice daily in a fasted state on Days 1 through 28 of every 28-day cycle and continued on study treatment as long as the participant experienced benefit and did not meet the criteria for study treatment discontinuation.
Total all-cause mortality,6/9 %66.67
Total serious adverse events,4/9 %44.44
Anaemia,1/9 %11.11
Cataract,1/9 %11.11
Choroidal haemorrhage,1/9 %11.11
Pyrexia,1/9 %11.11
Hepatic function abnormal,1/9 %11.11
Clostridium difficile colitis,1/9 %11.11
Enterococcal infection,1/9 %11.11
Pneumonia,1/9 %11.11
Hyphaema,1/9 %11.11
Diabetes mellitus,1/9 %11.11
